<SEC-DOCUMENT>0001564590-20-021342.txt : 20200505
<SEC-HEADER>0001564590-20-021342.hdr.sgml : 20200505
<ACCEPTANCE-DATETIME>20200505172802
ACCESSION NUMBER:		0001564590-20-021342
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200505
DATE AS OF CHANGE:		20200505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		20850277

	BUSINESS ADDRESS:	
		STREET 1:		1220 CONCORD AVENUE
		STREET 2:		SUITE 600
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		1220 CONCORD AVENUE
		STREET 2:		SUITE 600
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cers-10q_20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-05T00:58:57.4376327+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cers="http://www.cerus.com/20200331" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
cers-10q_20200331.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001020214_20200101_20200331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003_2" name="dei:DocumentFiscalYearFocus" contextRef="C_0001020214_20200101_20200331">2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001020214_20200101_20200331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001020214_20200101_20200331">0001020214</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001020214_20200101_20200331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001020214_20200101_20200331">Large Accelerated Filer</ix:nonNumeric>
			<ix:nonNumeric id="F_000013" name="dei:EntityCurrentReportingStatus" contextRef="C_0001020214_20200101_20200331">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000019" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001020214_20200101_20200331">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000288" name="us-gaap:RevenuePracticalExpedientRemainingPerformanceObligation" contextRef="C_0001020214_20200101_20200331">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001020214_20200101_20200331">2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000318" name="cers:ProductWarrantyTerm" contextRef="C_0001020214_20200101_20200331">P1Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001020214_20200331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001020214_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="cers-20200331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001020214_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_20200421">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-21</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:OtherMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:OtherMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cersCustomer">
				<xbrli:measure>cers:Customer</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cersSegment">
				<xbrli:measure>cers:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cers:EmployeeStockPurchasePlanRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cers:EmployeeStockPurchasePlanRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cersTranche">
				<xbrli:measure>cers:Tranche</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-29</xbrli:startDate>
					<xbrli:endDate>2019-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheOneMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-29</xbrli:startDate>
					<xbrli:endDate>2019-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_20190329_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-29</xbrli:startDate>
					<xbrli:endDate>2019-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheTwoMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheThreeMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-29</xbrli:startDate>
					<xbrli:endDate>2019-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329_20190329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-29</xbrli:startDate>
					<xbrli:endDate>2019-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-08</xbrli:startDate>
					<xbrli:endDate>2018-01-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cersPeriod">
				<xbrli:measure>cers:Period</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cers:PerformanceUnitsAndCashBasedAwardsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cers:PerformanceUnitsAndCashBasedAwardsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20190605_20190605">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-05</xbrli:startDate>
					<xbrli:endDate>2019-06-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusEuropeBVMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusEuropeBVMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217EUR">
				<xbrli:measure>iso4217:EUR</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20160101_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20190801_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:EtablissementFrancaisDuSangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:EtablissementFrancaisDuSangMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:AmericanRedCrossMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001020214</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:AmericanRedCrossMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000511 F_000512 F_000513 F_000516 F_000517 F_000518"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000526 F_000527"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000528 F_000529 F_000530 F_000531"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000003" fromRefs="F_000534 F_000535"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000004" fromRefs="F_000536 F_000537"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001020214_20200101_20200331">10-Q</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:DocumentQuarterlyReport" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-size:11pt;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15 (d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001020214_20200101_20200331" format="ixt:datemonthdayyearen">March&#160;31, 2020</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">or</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:DocumentTransitionReport" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-size:11pt;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15 (d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from: <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000020" name="dei:EntityFileNumber" contextRef="C_0001020214_20200101_20200331">000-21937</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001020214_20200101_20200331">CERUS CORPORATION</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001020214_20200101_20200331">68-0262011</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="middle" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressAddressLine1" contextRef="C_0001020214_20200101_20200331">1220 Concord Avenue</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressAddressLine2" contextRef="C_0001020214_20200101_20200331">Suite 600</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressCityOrTown" contextRef="C_0001020214_20200101_20200331">Concord</ix:nonNumeric>, <ix:nonNumeric id="F_000026" name="dei:EntityAddressStateOrProvince" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="top" style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressPostalZipCode" contextRef="C_0001020214_20200101_20200331">94520</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000028" name="dei:CityAreaCode" contextRef="C_0001020214_20200101_20200331">925</ix:nonNumeric>) <ix:nonNumeric id="F_000029" name="dei:LocalPhoneNumber" contextRef="C_0001020214_20200101_20200331">288-6000</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33.34%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title of Each Class</span><span style="text-decoration:underline;font-weight:normal;">&#160;</span></p></td>
<td valign="top" style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Trading Symbol</span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.32%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of Each Exchange on Which Registered</span><span style="text-decoration:underline;font-weight:normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:Security12bTitle" contextRef="C_0001020214_20200101_20200331">Common Stock</ix:nonNumeric>, par value $0.001 per share</p></td>
<td valign="top" style="width:33.34%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001020214_20200101_20200331">CERS</ix:nonNumeric></p></td>
<td valign="top" style="width:33.32%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SecurityExchangeName" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15 (d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;YES&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;NO&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;YES&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;NO&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:18.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:56.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;<span style="font-family:Times New Roman;">&#160;</span></p></td>
<td valign="bottom" style="width:21.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" style="width:18.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:56.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:21.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:18.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom" style="width:56.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<span style="font-family:Times New Roman;">&#160;&#160;</span></p></td>
<td valign="bottom" style="width:21.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:18.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:56.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:21.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:18.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:56.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:21.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth&#160;company</p></td>
<td valign="bottom" style="width:3.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;YES&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;NO&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 21, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000012" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001020214_20200421" decimals="INF" format="ixt:numdotdecimal">163,987,805</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Quarterly Period Ended March&#160;31, 2020</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;I </p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION<span style="font-weight:normal;"> </span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements (unaudited)</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets &#8211; March&#160;31, 2020 and December&#160;31, 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:3.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations &#8211; Three months ended March&#160;31, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:3.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE"><span style="text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss &#8211; Three months ended March&#160;31, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:3.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.3%;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STOCKHOLDERS"><span style="text-decoration:underline;">Condensed Consolidated Statements of Stockholders&#8217; Equity &#8211; Three months ended March&#160;31, 2020 and 2019</span></a></p></td>
<td valign="bottom" style="width:3.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.3%;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows &#8211; Three months ended March&#160;31, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:3.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> OTHER INFORMATION<span style="font-weight:normal;"> </span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top" style="width:6.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="width:93.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:93.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">SIGNATURES</span></a><span style="text-decoration:none;"></span></p></td>
<td colspan="2" valign="bottom" style="width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I: FINANCIAL INFORMATION</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_FINANCIAL_STATEMENTS">FINANCIAL STATEMENTS</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">CONDENSED CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">33,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">99,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:InventoryNet" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:InventoryNet" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">178,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">128,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,898</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:Goodwill" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:Goodwill" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001020214_20200331" decimals="-3" scale="3">82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001020214_20191231" decimals="-3" scale="3">132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,473</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">215,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Assets" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">165,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:SecuredDebtCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:SecuredDebtCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities &#8211; current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,751</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred product revenue &#8211; current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001020214_20191231" decimals="-3" scale="3">570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">45,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:SecuredLongTermDebt" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">39,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:SecuredLongTermDebt" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities &#8211; non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001020214_20200331" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001020214_20191231" decimals="-3" scale="3">327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:Liabilities" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">102,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:Liabilities" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">108,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000076">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000077">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommonStockValue" contextRef="C_0001020214_20200331" decimals="-3" scale="3">164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommonStockValue" contextRef="C_0001020214_20191231" decimals="-3" scale="3">144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">978,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">906,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_20200331" decimals="-3" sign="-" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_20191231" decimals="-3" scale="3">114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001020214_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">866,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001020214_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">850,111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">112,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">215,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">165,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Condensed Consolidated Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UNAUDITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit on product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="cers:GrossProfitOnProductRevenue" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="cers:GrossProfitOnProductRevenue" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government contract revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,030</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OperatingExpenses" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">31,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OperatingExpenses" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">29,601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-operating expense, net:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" scale="3">223</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" scale="3">162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:InterestExpense" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:InterestExpense" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-operating expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000120" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001020214_20200101_20200331" decimals="2" sign="-">0.10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000121" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001020214_20190101_20190331" decimals="2" sign="-">0.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used for calculating net loss per share:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000122" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">157,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">137,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Condensed Consolidated Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_COMPRE">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UNAUDITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (losses) gains on available-for-sale investments, net of taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Condensed Consolidated Financial Statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STOCKHOLDERS">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UNAUDITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000130" name="us-gaap:SharesOutstanding" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">906,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">850,111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from public offerings, net of offering costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">67,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">67,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from exercise of stock options,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; vesting of restricted stock units, and ESPP purchases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" sign="-" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances as of March 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:SharesOutstanding" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">163,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">978,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331" decimals="-3" sign="-" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">866,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">112,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FF0000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances as of December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:SharesOutstanding" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">136,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">136</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">863,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">778,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from exercise of stock options,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; vesting of restricted stock units, and ESPP purchases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331" decimals="-3" scale="3">965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331" decimals="-3" scale="3">682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20190331" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:NetIncomeLoss" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances as of March 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000172" name="us-gaap:SharesOutstanding" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">137,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">867,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190331" decimals="-3" sign="-" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">797,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001020214_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">69,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Condensed Consolidated Financial Statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UNAUDITED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Month Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:ProfitLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:ProfitLoss" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">706</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:ShareBasedCompensation" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:ShareBasedCompensation" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash operating lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="cers:NonCashOperatingLeaseCost" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="cers:NonCashOperatingLeaseCost" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on sale of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="cers:NonCashInterestExpense" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="cers:NonCashInterestExpense" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,597</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and other non-current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and development obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="cers:IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">19,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001020214_20190101_20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital expenditures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">68,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities and sale of investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net proceeds from equity incentives</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net proceeds from public offerings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">67,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net payment on revolving line of credit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from loans</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">39,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of debt</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">31,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">68,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001020214_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001020214_20190101_20190331" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001020214_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001020214_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">31,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Condensed Consolidated Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UNAUDITED</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000226" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000226_dcnt_70f3b415-e9d2-489a-bd22-04cd30ae54c4">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1. Summary of Significant Accounting Policies</p><ix:nonNumeric id="F_000237" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation and Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (together with Cerus Corporation, hereinafter &#8220;Cerus&#8221; or the &#8220;Company&#8221;) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three months ended March&#160;31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, which were included in the Company&#8217;s 2019 Annual Report on Form 10-K, filed with the SEC on February 21, 2020. The accompanying condensed consolidated balance sheet as of December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements as of that date<span style="font-style:italic;">.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000238" name="us-gaap:UseOfEstimates" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (&#8220;SSP&#8221;) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p></ix:nonNumeric><ix:nonNumeric id="F_000239" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000239_dcnt_b90f3fdd-016c-4118-a749-554c7d634fbb">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer&#59; (2) identify the performance obligations in the contract&#59; (3) determine the transaction price&#59; (4) allocate the transaction price to the performance obligations in the contract&#59; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (&#8220;platelet and plasma systems&#8221; or &#8220;disposable kits&#8221;), UVA illumination devices (&#8220;illuminators&#8221;), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company&#8217;s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis, and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company estimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.</p>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000226_dcnt_70f3b415-e9d2-489a-bd22-04cd30ae54c4" continuedAt="F_000226_dcnt_4dd555d0-1aa8-4e60-8a7d-bee558cecee9"><ix:continuation id="F_000239_dcnt_b90f3fdd-016c-4118-a749-554c7d634fbb">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives reimbursement under its U.S. government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that supports research and development of defined projects. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Note 1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and License A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greements&#8212;Agreement with BARDA&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract generally provides for reimbursement of approved costs incurred under the terms of the contract. Revenue related to the cost reimbursement provisions under the Company&#8217;s U.S. government contract are recognized as the qualified direct and indirect costs on the projects are incurred. The Company invoices under its U.S. government contract using the provisional rates in the government contract and thus is subject to future audits at the discretion of government. These audits could result in an adjustment to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue previously reported, which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> potentially could be significant. The Company believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. Costs incurred related to services performed under the contract are included as a component of research and development or selling, general and administrative expenses in the Company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations. The Company&#8217;s use of estimates in recording accrued liabilities for government contract activities (see &#8220;Use of Estimates&#8221; above) affects the revenue recorded from development funding and under the government contract. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disaggregation of Product Revenue</p><ix:nonNumeric id="F_000257" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe, Middle East and Africa</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">12,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">12,653</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">North America</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20200101_20200331" decimals="-3" scale="3">314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20190101_20190331" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000282" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="C_0001020214_20200101_20200331">The Company invoices its customers based upon the terms in the contracts, which generally requires payment <ix:nonNumeric id="F_000283" name="cers:PaymentOfCustomerInvoiceContractPeriod" contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331" format="ixt-sec:durwordsen" continuedAt="C_060a0598-a33b-46a4-b807-d34c8babd6b9">30</ix:nonNumeric> to <ix:nonNumeric id="F_000284" name="cers:PaymentOfCustomerInvoiceContractPeriod" contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331" format="ixt-sec:durwordsen">60<ix:continuation id="C_060a0598-a33b-46a4-b807-d34c8babd6b9"> days</ix:continuation></ix:nonNumeric> from the date of invoice.</ix:nonNumeric> Accounts receivable are recorded when the Company&#8217;s right to the consideration are estimated to be unconditional. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001020214_20200331" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001020214_20191231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> contract assets at March&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities mainly consist of deferred product revenue related to maintenance services, unshipped products, and uninstalled illuminators. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the service period. The increase in the deferred product revenue balance for the three months ended March&#160;31, 2020 is primarily driven by performance obligations not satisfied but invoiced as of March&#160;31, 2020, offset by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001020214_20200101_20200331" decimals="-5" scale="6">0.3</ix:nonFraction> million of revenue recognized that were included in the deferred product revenue balance as of December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000240" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (&#8220;R&#38;D&#8221;) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company&#8217;s U.S. government contract. Research and development expenses include salaries and related expenses for scientific and regulatory personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&#38;D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s use of estimates in recording accrued liabilities for R&#38;D activities (see &#8220;Use of Estimates&#8221; above) affects the amounts of R&#38;D expenses recorded from development funding and under its U.S. government contract. Actual results may differ from those estimates under different assumptions or conditions.</p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000226_dcnt_4dd555d0-1aa8-4e60-8a7d-bee558cecee9" continuedAt="F_000226_dcnt_d8c690f7-e359-483a-9641-7edf00553d67"><ix:nonNumeric id="F_000241" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.</p></ix:nonNumeric><ix:nonNumeric id="F_000242" name="cers:AvailableForSaleSecuritiesPolicy" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities were recorded in &#8220;Unrealized gains (losses) on available-for-sale investments, net of taxes&#8221; on the Company&#8217;s condensed consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale&#160;investments, if any, were recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000243" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020,&#160;the Company&#8217;s &#8220;Restricted cash&#8221; primarily consisted of a&#160;letter of credit relating to the lease of the Company&#8217;s office building. As of March&#160;31, 2020 and December&#160;31, 2019, the Company also had certain non-U.S. dollar denominated deposits recorded as &#8220;Restricted cash&#8221; in compliance with certain foreign contractual requirements.</p></ix:nonNumeric><ix:nonNumeric id="F_000244" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s investment policy, substantially all of the Company&#8217;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#8217;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#160;31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#8217;s cash equivalents and short-term investments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_cersCustomer" id="F_000290" name="cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" contextRef="C_0001020214_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_cersCustomer" id="F_000289" name="cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" contextRef="C_0001020214_20200331" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></ix:nonFraction> customers that accounted for more than 10% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. These customers cumulatively represented approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000291" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331" decimals="2" scale="-2">58</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000292" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">56</ix:nonFraction>% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.</p></ix:nonNumeric><ix:nonNumeric id="F_000245" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000245_dcnt_0aa691e6-8e9a-410a-9e32-330207a98748">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020 and December&#160;31, 2019, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, illuminators, and certain replacement parts for the illuminators. Platelet and plasma systems&#8217; disposable kits generally have <ix:nonNumeric id="F_000293" name="cers:InventoryLifeFinishedGoodsPeriod" contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331" format="ixt-sec:durwordsen" continuedAt="C_1a1a15c7-0603-4f5d-a603-0ce1656fdacf">18</ix:nonNumeric> to <ix:nonNumeric id="F_000294" name="cers:InventoryLifeFinishedGoodsPeriod" contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331" format="ixt-sec:durwordsen">24<ix:continuation id="C_1a1a15c7-0603-4f5d-a603-0ce1656fdacf"> month</ix:continuation></ix:nonNumeric> shelf lives from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time before being sold to, and ultimately incorporated and assembled by Fresenius Kabi Deutschland GmbH or Fresenius, Inc. (with their affiliates, &#8220;Fresenius&#8221;) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be sold to Fresenius for </p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000226_dcnt_d8c690f7-e359-483a-9641-7edf00553d67" continuedAt="F_000226_dcnt_522ccb9e-6b0a-439c-8eb0-740882e9f433"><ix:continuation id="F_000245_dcnt_0aa691e6-8e9a-410a-9e32-330207a98748">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within the next twelve month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and evaluates its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company&#8217;s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its work-in-process and finished units to meet the Company&#8217;s forecasted demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000295" name="cers:WorkInProcessInventoryLifePeriod" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company classified its work-in-process inventory as a current asset on its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets based on its evaluation that the work-in-process inventory would be sold to Fresenius for finished disposable kit production within each respective subsequent twelve-month period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in &#8220;Cost of product revenue&#8221; on the Company&#8217;s condensed consolidated statements of operations. At March&#160;31, 2020 and December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:InventoryValuationReserves" contextRef="C_0001020214_20200331" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:InventoryValuationReserves" contextRef="C_0001020214_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively, recorded for potential obsolete, expiring or unsalable product.</p></ix:continuation><ix:nonNumeric id="F_000246" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally <ix:nonNumeric id="F_000298" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331" format="ixt-sec:durwordsen" continuedAt="C_2c40f11b-b6da-4a89-98c5-ecb48efe614b">three</ix:nonNumeric> to <ix:nonNumeric id="F_000299" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331" format="ixt-sec:durwordsen">five<ix:continuation id="C_2c40f11b-b6da-4a89-98c5-ecb48efe614b"> years</ix:continuation></ix:nonNumeric>). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the three months ended March&#160;31, 2020 and 2019, the Company had non-cash purchases of capital expenditures of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001020214_20200101_20200331" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001020214_20190101_20190331" decimals="-5" scale="6">2.9</ix:nonFraction> million, respectively.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000247" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratable amortization over the original estimated useful life of <ix:nonNumeric id="F_000304" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. Accumulated amortization of intangible assets as of March&#160;31, 2020 and December&#160;31, 2019, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001020214_20200331" decimals="-5" scale="6">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001020214_20191231" decimals="-5" scale="6">1.9</ix:nonFraction> million, respectively. Goodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August&#160;31 of each fiscal year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test&#59; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in <ix:nonFraction unitRef="U_cersSegment" id="F_000305" name="us-gaap:NumberOfReportableSegments" contextRef="C_0001020214_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> reporting unit and estimates the fair value of its <ix:nonFraction unitRef="U_cersSegment" id="F_000306" name="us-gaap:NumberOfReportableSegments" contextRef="C_0001020214_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit&#8217;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company&#8217;s <ix:nonFraction unitRef="U_cersSegment" id="F_000307" name="us-gaap:NumberOfReportableSegments" contextRef="C_0001020214_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> reporting unit.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an impairment test on its intangible assets if certain events or changes in circumstances occur which indicate that the carrying amounts of its intangible assets may not be recoverable. If the intangible assets are not recoverable, an impairment loss would be recognized by the Company based on the excess amount of the carrying value of the intangible assets over its fair value. During the three months ended March&#160;31, 2020 and 2019, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_0001020214_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_0001020214_20190101_20190331" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> impairment charges recognized related to the acquired intangible assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000248" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000248_dcnt_1ba35106-ada9-484b-ad10-f728fd21d18f">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the </p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000226_dcnt_522ccb9e-6b0a-439c-8eb0-740882e9f433" continuedAt="F_000226_dcnt_82a7ac30-6465-4f28-9e5c-196898191c81"><ix:continuation id="F_000248_dcnt_1ba35106-ada9-484b-ad10-f728fd21d18f">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></ix:continuation><ix:nonNumeric id="F_000249" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Remeasurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s foreign subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company&#8217;s condensed consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000250" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to non-employees, the Company recognizes stock-based compensation expense for the grant date fair value of the vested portion of the awards in its condensed consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 8 for further information regarding the Company&#8217;s stock-based compensation expenses.</p></ix:nonNumeric><ix:nonNumeric id="F_000251" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company&#8217;s U.S. federal tax returns for years 1999 through 2018, California tax returns for years through 2018, and Netherlands tax returns for years 2015 through 2018 remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000252" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000252_dcnt_eb7bb207-d757-4d1a-8af8-9b87c8f58ed7">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the three months ended March&#160;31, 2020 and 2019, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000258" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000258_dcnt_b2f08561-bc57-4da6-8b5f-e07ad160634a">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of anti-dilutive potential shares:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000310" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000311" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000312" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000314" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20200101_20200331" decimals="-3" scale="3">41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000315" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20190101_20190331" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000316" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000317" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001020214_20190101_20190331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
</ix:nonNumeric></ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000226_dcnt_82a7ac30-6465-4f28-9e5c-196898191c81"><ix:continuation id="F_000252_dcnt_eb7bb207-d757-4d1a-8af8-9b87c8f58ed7"><ix:continuation id="F_000258_dcnt_b2f08561-bc57-4da6-8b5f-e07ad160634a">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:continuation><ix:nonNumeric id="F_000253" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s condensed consolidated balance sheets. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have finance leases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term. </p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000254" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#8217;s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company&#8217;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a <span style="-sec-ix-hidden:F_000318">one-year</span> warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="C_0001020214_20200331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="C_0001020214_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March&#160;31, 2020 and December&#160;31, 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000255" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company&#8217;s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company&#8217;s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 for further information regarding the Company&#8217;s valuation of financial instruments.</p></ix:nonNumeric><ix:nonNumeric id="F_000256" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):</span> <span style="font-style:italic;">Measurement of Credit Losses on Financial Instruments,</span> which requires measurement and recognition of expected credit losses for financial assets held. The standard is effective for annual periods beginning after December 15, 2019, and interim periods thereafter, with early application permitted. The Company adopted the new accounting standard on January 1, 2020, using the modified retrospective transition method. The adoption of this ASU had no material impact on the Company&#8217;s condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" /><ix:nonNumeric id="F_000227" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000227_dcnt_842a5d51-c1d2-4925-b9d8-c9d9e183e9fb">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. Available-for-sale Securities and Fair Value on Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Available-for-sale Securities</p><ix:nonNumeric id="F_000259" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000259_cnt_1">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331" decimals="-3" scale="3">274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" scale="3">487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">110,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_20200331" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001020214_20200331" decimals="-3" scale="3">487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">110,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000259_cnt_1">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" scale="3">98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001020214_20191231" decimals="-3" scale="3">114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000260" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following by contractual maturity (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One year or less</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">54,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">54,565</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greater than one year and less than five years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,811</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">110,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">110,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000261" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000261_cnt_1">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):</p></ix:nonNumeric><ix:continuation id="F_000261_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 Months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months or Greater</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" scale="3">487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" scale="3">487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="C_0001020214_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t have any available-for-sale securities in an unrealized net loss position.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically invests in highly-rated securities, and its investment policy limits the amount of credit exposure to any one issuer. The policy generally requires investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for expected credit loss, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, and any changes thereto, changes in market interest rates, and the Company&#8217;s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment&#8217;s cost basis. The Company also regularly reviews its investments in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three months ended March&#160;31, 2020 and 2019, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_20200331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001020214_20190331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognize any credit losses. The Company has no current requirement or intent to sell the securities in an unrealized loss position. The Company expects to recover up to (or beyond) the initial cost of investment for securities held. The Company recorded gross realized gains of less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGains" contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331" decimals="INF" scale="6">0.1</ix:nonFraction> million and gross realized losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" contextRef="C_0001020214_20200101_20200331" decimals="-5" scale="6">0.3</ix:nonFraction> million during the three months ended March&#160;31, 2020. The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGains" contextRef="C_0001020214_20190101_20190331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses" contextRef="C_0001020214_20190101_20190331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record any gross realized gains or losses from the sale or maturity of available-for-sale investments during the three months ended March&#160;31, 2019. </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000227_dcnt_842a5d51-c1d2-4925-b9d8-c9d9e183e9fb">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value Disclosures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses certain assumptions that market participants would use to determine the fair value of an asset or liability in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 1: Quoted prices in active markets for identical instruments</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the fair value of Level 2 debt securities as of March&#160;31, 2020, the Company&#8217;s primary pricing service relies on inputs from multiple industry-recognized pricing sources to determine the price for each investment. Corporate debt and U.S. government agency securities are systematically priced by this service as of the close of business each business day. If the primary pricing service does not price a specific asset a secondary pricing service is utilized.</p><ix:nonNumeric id="F_000262" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000262_cnt_1">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">76,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">110,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">99,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000262_cnt_1">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any transfers among fair value measurement levels during the three months ended March&#160;31, 2020. </p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" /><ix:nonNumeric id="F_000228" name="us-gaap:InventoryDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3. Inventories</p><ix:nonNumeric id="F_000263" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:InventoryNet" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:InventoryNet" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000229" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Accrued Liabilities</p><ix:nonNumeric id="F_000264" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and related costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="cers:AccruedDevelopmentCostsCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="cers:AccruedDevelopmentCostsCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000230" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000230_dcnt_5c7d80d0-6c9d-4284-ada2-af5fb17651f0">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Debt</p><ix:nonNumeric id="F_000265" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at March&#160;31, 2020, consisted of the following (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Credit Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" scale="3">542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:SecuredDebt" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">39,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="cers:DebtInstrumentCarryingNonCurrent" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="cers:DebtInstrumentUnamortizedNoncurrent" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" scale="3">542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:SecuredLongTermDebt" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">39,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" scale="3">586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:SecuredDebt" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="cers:DebtInstrumentCarryingNonCurrent" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="cers:DebtInstrumentUnamortizedNoncurrent" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" scale="3">586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:SecuredLongTermDebt" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000266" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal, interest and fee payments on Term Loan Credit Agreement at March&#160;31, 2020, are expected to be as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest and Fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFees" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">50,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Loan Agreements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2019 (the &#8220;Closing Date&#8221;), the Company entered into a Credit, Security and Guaranty Agreement (Term Loan) (the &#8220;Term Loan Credit Agreement&#8221;) with MidCap Financial Trust (&#8220;MidCap&#8221;) to borrow up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329" decimals="INF" scale="6">70</ix:nonFraction> million in <ix:nonFraction unitRef="U_cersTranche" id="F_000435" name="cers:NumberOfEqualTranches" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> tranches (collectively &#8220;2019 Term Loan&#8221;), with a maturity date of <ix:nonNumeric id="F_000437" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" format="ixt:datemonthdayyearen">March 1, 2024</ix:nonNumeric>. The first advance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheOneMember_20190329" decimals="-5" scale="6">40.0</ix:nonFraction> million (&#8220;Tranche 1&#8221;) was drawn by the Company on March 29, 2019, with the proceeds used in part to repay in full the outstanding term loans and fees under a prior loan agreement. The Company repaid principal and interest in an aggregate amount equal to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="cers:RepaymentsPrincipalAndInterestAggregateAmount" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329" decimals="-5" scale="6">31.2</ix:nonFraction>&#160;million and prepayment fees in an aggregate amount equal to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="cers:DebtPrepaymentFee" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329_20190329" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million, and terminated all obligations under the prior loan agreement. As a result, the Company recorded a loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_20190329_20190329" decimals="-5" scale="6">2.1</ix:nonFraction> million on the extinguishment of the prior loan agreement in &#8220;Interest expense&#8221; on the Company's condensed consolidated statements of operations. The second advance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="cers:DebtInstrumentAvailableAmountUponCondition" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheTwoMember_20190329" decimals="-5" scale="6">15.0</ix:nonFraction>&#160;million (&#8220;Tranche 2&#8221;) will be available to the Company from January&#160;1, 2020 through December&#160;31, 2020, subject to the Company&#8217;s satisfaction of certain conditions described </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000230_dcnt_5c7d80d0-6c9d-4284-ada2-af5fb17651f0">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the Term Loan Credit Agreement, and (ii)&#160;the third advance of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="cers:DebtInstrumentAvailableAmountUponCondition" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheThreeMember_20190329" decimals="-5" scale="6">15.0</ix:nonFraction>&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million (&#8220;Tranche 3&#8221;) will be available to the Company starting April&#160;1, 2020, through March&#160;31, 2021, subject to the Company&#8217;s satisfaction of certain other conditions described in the Term Loan Credit Agreement. The</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> borrowings under the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019 Term Loan bears interest at the sum of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a fixed percentage spread and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greater of (i) </span><ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329" decimals="4" scale="-2">1.80</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% or (ii)&#160;one month LIBOR. The effective interest rate on the Term Loan at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was approximately </span><ix:nonFraction unitRef="U_xbrlipure" id="F_000444" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331" decimals="4" scale="-2">7.50</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%. All three tranches require interest only payments through </span><ix:nonNumeric id="F_000445" name="cers:DebtInstrumentInterestOnlyPaymentsDate" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" format="ixt:datemonthdayyearen"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1, 2022</span></ix:nonNumeric><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, followed by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000446" name="cers:DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" format="ixt-sec:durmonth">24</ix:nonNumeric> months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of payments with interest and equal payment of principal. The interest only payment period can be extended for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000447" name="cers:InterestOnlyPaymentPeriod" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon achievement of a specified trailing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000448" name="cers:TrailingNetRevenueTarget" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329" format="ixt-sec:durwordsen">twelve month</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> net revenue target. Prepayments of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erm </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oan under the Term Loan Credit Agreement, in whole or in part, will be subject to early termination fees which decline each year until the fourth anniversary</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the applicable funding date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, at which time there is no early termination fee. Upon the final payment, the Company must also pay an exit fee </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculated based on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a percentage </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the aggregate principal amount of all tranches advanced to the Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also entered into a Credit, Security and Guaranty Agreement (Revolving Loan) (the &#8220;Revolving Loan Credit Agreement&#8221;) with MidCap on March 29, 2019, to initially borrow up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329" decimals="INF" scale="6">5.0</ix:nonFraction> million. The amount borrowed under the Revolving Loan Credit Agreement can be increased, upon request by the Company by up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="cers:DebtInstrumentAvailableAmountUponCondition" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329" decimals="-5" scale="6">15.0</ix:nonFraction> million, subject to agent and lender approval and the satisfaction of certain conditions. The Revolving Loan Credit Agreement has a maturity date of <ix:nonNumeric id="F_000453" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329_20190329" format="ixt:datemonthdayyearen">March 1, 2024</ix:nonNumeric>. Amounts drawn under the Revolving Loan Credit Agreement bear interest at the sum of a fixed percentage spread and the greater of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000454" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329" decimals="4" scale="-2">1.80</ix:nonFraction>% or (ii) one month LIBOR. There are also fractional fees based on the amounts either drawn or undrawn. If the Revolving Loan Credit Agreement is terminated before maturity or the funding obligation is permanently reduced, there are termination fees which decline each anniversary until the third anniversary, at which time there is no termination fee. As of March&#160;31, 2020 and December&#160;31, 2019, the Company had borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20200331" decimals="-5" scale="6">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20191231" decimals="-5" scale="6">5.0</ix:nonFraction> million, respectively, under the Revolving Loan Credit Agreement, which is included in &#8220;Debt &#8211; current&#8221; in the Company&#8217;s condensed consolidated balance sheets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Credit Agreement and Revolving Loan Credit Agreement contain certain financial and non-financial covenants, with which the Company was in compliance at March&#160;31, 2020. Additionally, both agreements are secured by substantially all of the Company&#8217;s assets, with some exclusions.</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000231_dcnt_2fcb8b34-3ee5-490a-8132-224b6f433325">
<p style="text-align:justify;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Commitments and Contingencies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of <ix:nonNumeric id="F_000455" name="cers:MinimumTermOfNonCancelableOperatingLeases" contextRef="C_0001020214_20200101_20200331" format="ixt-sec:durwordsen">one year</ix:nonNumeric> that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through <ix:nonNumeric id="F_000456" name="cers:ExpirationOfNonCancelableOperatingLeasesMaximumYear" contextRef="C_0001020214_20200101_20200331">2030</ix:nonNumeric>, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early.&#160;The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company&#8217;s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000267" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases is as follows<span style="font-family:Arial;"> </span>(dollars in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Month Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payments for operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:OperatingLeasePayments" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001020214_20200101_20200331" decimals="-3" scale="3">265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000459" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001020214_20200331" format="ixt-sec:duryear">9.0</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000460" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001020214_20200331" decimals="3" scale="-2">8.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000268" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000268_dcnt_ff7e1196-4993-4911-9de7-5adffaf6cd3d">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000231_dcnt_2fcb8b34-3ee5-490a-8132-224b6f433325"><ix:continuation id="F_000268_dcnt_ff7e1196-4993-4911-9de7-5adffaf6cd3d">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum non-cancelable payments under</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leases as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as follows (in thousands):</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,788</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2020 and 2019, the Company recorded operating lease expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:OperatingLeaseCost" contextRef="C_0001020214_20200101_20200331" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:OperatingLeaseCost" contextRef="C_0001020214_20190101_20190331" decimals="-5" scale="6">0.5</ix:nonFraction> million, respectively. As of March&#160;31, 2020, <ix:nonNumeric id="F_000472" name="us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription" contextRef="C_0001020214_20200101_20200331">the Company had no leases that have not yet commenced.</ix:nonNumeric> </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Purchase Commitments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000232" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Stockholders&#8217; Equity</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Public Offering of Common Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000473" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131" decimals="INF" format="ixt:numdotdecimal">16,866,667</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000474" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131" decimals="INF">0.001</ix:nonFraction> per share, at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000475" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131" decimals="INF">3.75</ix:nonFraction> per share in an underwritten public offering. The total proceeds from this offering were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200101_20200131" decimals="-5" scale="6">62.7</ix:nonFraction> million, net of the underwriting discount and other issuance costs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales Agreement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 4, 2017, the Company entered into Amendment No. 3 to the Controlled Equity Offering <sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup> Sales Agreement with Cantor Fitzgerald &#38; Co. (as amended on August 4, 2017, the &#8220;Amended Cantor Agreement&#8221;). The Amended Cantor Agreement became effective on January 8, 2018, and provided for the issuance and sale of shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="cers:MaximumAmountAvailableUnderOffering" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108" decimals="INF" scale="6">70.0</ix:nonFraction> million through Cantor Fitzgerald &#38; Co. (&#8220;Cantor&#8221;), which amount included the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="cers:CommonStockSharesUnsoldValue" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108" decimals="-5" scale="6">31.4</ix:nonFraction> million of unsold shares of common stock available for sale immediately prior to the effectiveness of the Amended Cantor Agreement. Under the Amended Cantor Agreement, Cantor also acts as the Company&#8217;s sales agent and receives compensation based on an aggregate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000478" name="cers:PercentageOfProceedsPayableAsCompensationToUnderwriter" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108" decimals="2" scale="-2">2</ix:nonFraction>% of the gross proceeds on the sale price per share of its common stock. The issuance and sale of these shares by the Company pursuant to the Amended Cantor Agreement are deemed an &#8220;at-the-market&#8221; offering and are registered under the Securities Act of 1933, as amended.&#160;During the three months ended March&#160;31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000480" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331" decimals="-5" scale="6">1.0</ix:nonFraction> million shares of the Company&#8217;s common stock were sold under the Amended Cantor Agreement for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331" decimals="-5" scale="6">4.4</ix:nonFraction> million.&#160;At March&#160;31, 2020, the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="cers:CommonStockSharesAvailableForSaleValue" contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200331" decimals="-5" scale="6">9.6</ix:nonFraction> million of common stock available to be sold under the Amended Cantor Agreement.</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000233" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000233_dcnt_deff88a6-6c70-441e-a5c5-77e61a073bb4">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Stock-Based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Plans</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains an Employee Stock Purchase Plan (the &#8220;Purchase Plan&#8221;), which is intended to qualify as an employee stock purchase plan within the meaning of Section&#160;423(b) of the Internal Revenue Code. Under the Purchase Plan, the Company&#8217;s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. Under the Purchase Plan eligible employee participants may purchase shares of common stock of the Company at a purchase price equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000483" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value per share on the start date of the offering period or the fair market value per share on the purchase date. The Purchase Plan consists of a fixed offering period of <ix:nonNumeric id="F_000484" name="cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331" format="ixt-sec:durmonth">12</ix:nonNumeric> months with <ix:nonFraction unitRef="U_cersPeriod" id="F_000485" name="cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> purchase periods within each offering period. At March&#160;31, 2020, the Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000486" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200331" decimals="INF" scale="6">0.4</ix:nonFraction> million shares available for future issuance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2008 Equity Incentive Plan and Inducement Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors. The Company currently grants equity awards from one plan, the 2008 Equity Incentive Plan and its subsequent amendments (collectively, the &#8220;Amended 2008 Plan&#8221;). The Amended 2008 Plan allows for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. On June 5, 2019, the Company&#8217;s stockholders approved an </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000233_dcnt_deff88a6-6c70-441e-a5c5-77e61a073bb4">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amendment and restatement of the 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance under the 2008 Plan by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000495" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20190605_20190605" decimals="INF" format="ixt:numdotdecimal">11,800,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wards under the Amended 2008 Plan generally have a maximum term of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000487" name="cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" format="ixt-sec:duryear">10</ix:nonNumeric> years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from the date of the award. The Amended 2008 Plan generally requires options to be granted at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000488" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="INF" scale="-2">100</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the fair market value of the Company&#8217;s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" format="ixt-sec:durwordsen">four years</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. RSUs are measured based on the fair market value of the underlying stock on the date of grant</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. RSUs granted by the Company to employees</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> generally vest over</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" format="ixt-sec:durwordsen" continuedAt="C_07bd264a-0d5e-4223-a32d-66b332fb685c">three</ix:nonNumeric> to <ix:nonNumeric id="F_000491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" format="ixt-sec:durwordsen">four<ix:continuation id="C_07bd264a-0d5e-4223-a32d-66b332fb685c"> years</ix:continuation></ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based stock or cash awards granted under the Amended 2008 Plan are limited to either </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="INF" format="ixt:numdotdecimal">500,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock or $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-5" scale="6">1.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million per recipient per calendar year.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000494" name="cers:PerformanceBasedStockOptionsOutstanding" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="INF" format="ixt:numdotdecimal">40,000</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance-based stock </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were outstanding. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020, the Company had an aggregate of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000496" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-5" scale="6">28.1</ix:nonFraction> million shares of its common stock subject to outstanding options or unvested RSUs, or remaining available for future issuance under the Amended 2008 Plan, of which approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000497" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-5" scale="6">18.6</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000498" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-5" scale="6">5.6</ix:nonFraction> million shares were subject to outstanding options and unvested RSUs, respectively, and approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000499" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-5" scale="6">3.9</ix:nonFraction>&#160;million shares were available for future issuance under the Amended 2008 Plan. The Company&#8217;s policy is to issue new shares of common stock upon the exercise of options or vesting of RSUs.</p><ix:nonNumeric id="F_000269" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231" decimals="2">4.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000501" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,034</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000506" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">5.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000502" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000507" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">3.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000503" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000508" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">5.51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000504" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="2">4.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000270" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000510" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,098</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000515" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231" decimals="2">5.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000511" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">5.09</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000517" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">5.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000513" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000518" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331" decimals="2">6.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000519" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331" decimals="2">5.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000000" xml:lang="en-US">Includes shares issuable under performance-based restricted stock unit awards.</ix:footnote></p></td></tr></table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Valuation Assumptions for Stock-based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan rights. The Black-Scholes option pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding a number of complex and subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company&#8217;s expected stock price volatility, the risk-free interest rate and expected dividends. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000234" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded income tax expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20200101_20200331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20190101_20190331" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million for both the three months ended March&#160;31, 2020 and 2019, primarily related to the operating profit of the Company&#8217;s Cerus Europe B.V. subsidiary. </p></ix:nonNumeric><ix:nonNumeric id="F_000235" name="cers:DevelopmentAndLicenseAgreementsTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000235_dcnt_3e0066df-3112-435e-80dd-c958108eeec7">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Development and License Agreements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Fresenius</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fresenius Kabi AG (&#8220;Fresenius&#8221;) manufactures and supplies the platelet and plasma systems to the Company under a supply agreement (the &#8220;Supply Agreement&#8221;). Fresenius is obligated to sell, and the Company is obligated to purchase, finished disposable kits for the Company&#8217;s platelet and plasma systems and the Company&#8217;s red blood cell system product candidate (the &#8220;RBC Sets&#8221;). The Supply Agreement permits the Company to purchase platelet and plasma systems and RBC Sets from third parties to the extent necessary to maintain supply qualifications with such third parties or where local or regional manufacturing is needed to obtain product registrations or sales. Pricing terms per unit are initially fixed and decline at specified annual production levels, and are subject to certain adjustments after the initial pricing term. Under the Supply Agreement, the Company maintains the amounts due from the components sold to Fresenius as a current asset on its accompanying condensed consolidated balance sheets until such time as the Company purchases finished disposable kits using those components. The Supply Agreement also required the Company to make certain payments totaling &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000522" name="cers:ManufacturingAndDevelopmentPaymentLiability" contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20200101_20200331" decimals="-5" scale="6">8.6</ix:nonFraction> million (&#8220;Manufacturing and Development Payments&#8221;) to Fresenius. Because these payments represented unconditional payment obligations, the Company recognized its liability for these payments at their net present value at discount rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000523" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20161231" decimals="2">9.72</ix:nonFraction>% based on the Company&#8217;s effective borrowing rate at that time. The Manufacturing and Development Payments liability was accreted through interest expense based on the estimated timing of its ultimate settlement.&#160;In 2016, the Company paid &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000524" name="cers:PaymentsForManufacturingAndDevelopmentCost" contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20160101_20161231" decimals="-5" scale="6">3.1</ix:nonFraction> million to Fresenius.&#160;In August 2019, the Company paid the remaining &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000525" name="cers:PaymentsForManufacturingAndDevelopmentCost" contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20190801_20190831" decimals="-5" scale="6">5.5</ix:nonFraction> million to Fresenius.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supply Agreement also required the Company to make payments to support certain projects Fresenius has and will perform on behalf of the Company related to certain R&#38;D activities and manufacturing efficiency activities for which certain assets have been established in the Company&#8217;s condensed consolidated balance sheets. The manufacturing efficiency asset is expensed on a straight-line basis over the life of the Supply Agreement.&#160;The prepaid asset related to amounts paid up front for the R&#38;D activities to be conducted by Fresenius on behalf of the Company is expensed over the period which such activities occur. <ix:nonNumeric id="F_000271" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000271_cnt_1">The following table summarizes the amounts of prepaid R&#38;D asset and manufacturing efficiency asset at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).</ix:nonNumeric></p><ix:continuation id="F_000271_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&#38;D asset &#8211; current <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="cers:UnamortizedDeferredCostForDevelopmentActivities" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="cers:UnamortizedDeferredCostForDevelopmentActivities" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231" decimals="-3" scale="3">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&#38;D asset &#8211; non-current <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="cers:UnamortizedDeferredCostForDevelopmentActivities" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="cers:UnamortizedDeferredCostForDevelopmentActivities" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing efficiency asset <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="cers:ManufacturingEfficiencyAssets" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="cers:ManufacturingEfficiencyAssets" contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000001" xml:lang="en-US">Included in &#8220;Prepaid and other current assets&#8221; in the Company's condensed consolidated balance sheets.</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000002" xml:lang="en-US">Included in &#8220;Prepaid and other assets&#8221; in the Company's condensed consolidated balance sheets.</ix:footnote></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the Supply Agreement extends through July 1, 2025 (the &#8220;Initial Term&#8221;) and is automatically renewed thereafter for additional two year terms (each, a &#8220;Renewal Term&#8221;), subject to termination by either party upon (i) two years written notice prior to the expiration of the Initial Term or (ii) one year written notice prior to the expiration of any Renewal Term. Under the Supply Agreement, the Company has the right, but not the obligation, to purchase certain assets and assume certain liabilities from Fresenius.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments to Fresenius of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="cers:PaymentForManufacturingOfEntityProducts" contextRef="C_0001020214_20200101_20200331" decimals="-5" scale="6">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="cers:PaymentForManufacturingOfEntityProducts" contextRef="C_0001020214_20190101_20190331" decimals="-5" scale="6">7.8</ix:nonFraction> million relating to the manufacturing of the Company&#8217;s products during the three months ended March&#160;31, 2020 and 2019, respectively. <ix:nonNumeric id="F_000272" name="cers:SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true" continuedAt="F_000272_cnt_1">The following table summarizes the amounts of the Company&#8217;s payables to and receivables from Fresenius at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).</ix:nonNumeric></p><ix:continuation id="F_000272_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payables to Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="cers:AccrualForManufacturingOfEntityProducts" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="cers:AccrualForManufacturingOfEntityProducts" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables from Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:AccountsAndNotesReceivableNet" contextRef="C_0001020214_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,631</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:AccountsAndNotesReceivableNet" contextRef="C_0001020214_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000003" xml:lang="en-US">Included in &#8220;Accounts Payable&#8221; and &#8220;Accrued Liabilities&#8221; in the Company's condensed consolidated balance sheets.</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000004" xml:lang="en-US">Included in &#8220;Other current assets&#8221; in the Company's condensed consolidated balance sheets.</ix:footnote></p></td></tr></table></div></ix:continuation>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreement with BARDA</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company entered into an agreement with BARDA to support the Company&#8217;s development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000235_dcnt_3e0066df-3112-435e-80dd-c958108eeec7">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement with BARDA and its subsequent modifications include a base period (the &#8220;Base Period&#8221;) and options (each, an &#8220;Option Period&#8221;). As of March&#160;31, 2020, the agreement included committed funding&#160;of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="cers:BasePeriodMaximumFundingOfCollaborativeAgreement" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331" decimals="INF" scale="6">103.2</ix:nonFraction> million for clinical development of the INTERCEPT Blood System for red blood cells (the &#8220;red blood cell system&#8221;). In April 2020, BARDA committed an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="cers:BasePeriodAdditionalFundingOfCollaborativeAgreement" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430" decimals="-5" scale="6">13.8</ix:nonFraction> million raising the committed funding to up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="cers:BasePeriodMaximumFundingOfCollaborativeAgreement" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430" decimals="INF" scale="6">116.9</ix:nonFraction> million, and the potential for the exercise by BARDA of subsequent Option Periods that, if exercised by BARDA and completed, would bring the total funding opportunity to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="cers:OptionPeriodMaximumFundingOfCollaborativeAgreement" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331" decimals="INF" scale="6">213.9</ix:nonFraction> million&#160;through December 31, 2021. If exercised by BARDA, subsequent Option Periods would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of emerging pathogens, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. The Company is responsible for co-investment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="cers:CoInvestmentForCollaborativeAgreement" contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331" decimals="INF" scale="6">5.0</ix:nonFraction> million and would be responsible for an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="cers:AdditionalCoInvestmentForCollaborativeAgreement" contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331" decimals="INF" scale="6">9.6</ix:nonFraction> million, if certain Option Periods are exercised. Through March&#160;31, 2020, the Company has incurred approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="cers:CoInvestmentForCollaborativeAgreementIncurred" contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331" decimals="-5" scale="6">1.2</ix:nonFraction> million related to the co-investment. BARDA will make periodic assessments of the Company&#8217;s progress and the continuation of the agreement is based on the Company&#8217;s success in completing the required tasks under the Base Period and each exercised Option Period. BARDA has rights under certain contract clauses to terminate the agreement, including the ability to terminate the agreement for convenience at any time.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020 and December&#160;31, 2019, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:ReceivablesLongTermContractsOrPrograms" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331" decimals="-5" scale="6">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:ReceivablesLongTermContractsOrPrograms" contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20191231" decimals="-5" scale="6">4.2</ix:nonFraction> million, respectively, of billed and unbilled amounts were included in accounts receivable on the Company&#8217;s condensed consolidated balance sheets related to BARDA.</p></ix:continuation><ix:nonNumeric id="F_000236" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Segment, Customer and Geographic Information</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to operate in only <ix:nonFraction unitRef="U_cersSegment" id="F_000547" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001020214_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment, blood safety. The Company&#8217;s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company&#8217;s operations in the U.S. are responsible for the R&#38;D and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.</p><ix:nonNumeric id="F_000273" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" contextRef="C_0001020214_20200101_20200331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had the following significant customers that accounted for more than 10% of the Company&#8217;s total product revenue, during the three months ended March&#160;31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#201;tablissement Fran&#231;ais du Sang</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000548" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331" decimals="2" scale="-2">25</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000549" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331" decimals="2" scale="-2">29</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Red Cross</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000550" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331" decimals="2" scale="-2">19</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000551" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331" decimals="2" scale="-2">13</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160; Represents an amount less than 10% of product revenue.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. Operating results for the three months ended March&#160;31, 2020 are not necessarily indicative of results that may occur in future periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. The forward-looking statements are contained principally in this Item&#160;2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in Item&#160;1A, &#8220;Risk Factors.&#8221; These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These forward-looking statements may include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the impact of the COVID-19 pandemic on our business and operations as well as the business or operations of our customers, manufacturers, research partners, and other third parties with whom we conduct business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">future sales of and our ability to effectively commercialize and achieve market acceptance of the INTERCEPT Blood System, including our ability to comply with applicable United States, or U.S., and foreign laws, regulations and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to successfully complete development, receive regulatory approvals and commercialize extended</span><span style="font-family:Times New Roman;"> </span><span style="font-style:italic;font-family:Times New Roman;">storage cryoprecipitate or other plasma derived biological products using the INTERCEPT Blood System&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to manage the growth of our business and attendant cost increases, including in connection with the commercialization of the INTERCEPT Blood System in the U.S. and our international operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the timing or likelihood of regulatory submissions and approvals and other regulatory actions or interactions,</span><span style="font-family:Times New Roman;"> </span><span style="font-style:italic;font-family:Times New Roman;">including our anticipated approval of our CE Mark submission for the red blood cell system&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to obtain and maintain regulatory approvals of the INTERCEPT Blood System&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to obtain adequate clinical and commercial supplies of the INTERCEPT Blood System from our sole source suppliers for a particular product or component they manufacture&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the initiation, scope, rate of progress, results and timing of our ongoing and proposed preclinical and clinical trials of the INTERCEPT Blood System&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the successful completion of our research, development and clinical programs and our ability to manage cost increases associated with preclinical and clinical development of the INTERCEPT Blood System&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the amount and availability of funding we may receive under our agreement with the Biomedical Advanced Research and Development Authority, or BARDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to transition distribution of the INTERCEPT Blood System from third parties to a direct sales model in certain international markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">the ability of our products to inactivate the emerging viruses and other pathogens that we may target in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-style:italic;font-family:Times New Roman;">our estimates regarding the sufficiency of our cash resources, our ability to continue as a going concern and our need for additional funding.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; and similar expressions intended to identify such forward-looking statements. Forward-looking statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks and uncertainties. There can be no assurance that any of the events anticipated by forward-looking statements will occur or, if any of them do occur, what impact they will have on our business, results of operations and financial condition. Certain important factors could cause actual results to differ materially from those discussed in such statements, including the rate of customer adoption in the U.S. and our ability to achieve market acceptance of our products in the U.S. and international markets, whether our preclinical and clinical data or data from commercial use will be considered sufficient by regulatory authorities to grant marketing approvals for our products or for product extensions or additional claims for our products, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to obtain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and maintain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reimbursement approval</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for our products, our ability to complete the development and testing of additional configurations or redesigns of our products, our need for additional financing and our ability to access funding under our agreement with BARDA, the impacts of regulation of our products by domestic and foreign regulatory authorities, our limited experience in sales, marketing and regulatory support for the INTERCEPT Blood System, our reliance on Fresenius and third parties to manufacture </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or supply </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain components</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or compounds for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the INTERCEPT Blood System, incompatibility of our platelet system with some commercial platelet collection methods, our need to complete our red blood cell system&#8217;s commercial design, more effective product offerings by, or clinical setbacks of, our competitors, product liability, our use of hazardous materials in the development of our products, business interruption due to earthquake, our expectation of continuing losses, protection of our intellectual property rights, volatility in our stock price, on-going compliance with the requirements of the Sarbanes-Oxley Act of 2002 and other factors discussed below and under the caption &#8220;Risk Factors&#8221; in Item 1A of this Quarterly Report on Form 10-Q. We discuss many of these risks in this Quarterly Report on Form 10-Q in greater detail in the section entitled &#8220;Risk Factors&#8221; under Part II, Item&#160;1A below. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q and the documents that we incorporate by reference in and have filed as exhibits to this Quarterly Report on Form 10-Q completely. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update or revise any forward-looking statements to reflect new information or future events, even if new information becomes available in the future. You should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 1991, we have devoted substantially all of our efforts and resources to the research, development, clinical testing and commercialization of the INTERCEPT Blood System. The INTERCEPT Blood System is designed for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE Marks and U.S. Food and Drug Administration, or FDA, approval and are being marketed and sold in a number of countries around the world. We sell both the platelet and plasma systems using our direct sales force and through distributors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The platelet system is approved in the U.S. for <span style="font-style:italic;">ex vivo</span> preparation of pathogen-reduced apheresis platelet components collected and stored in 100% plasma or InterSol in order to reduce the risk of transfusion-transmitted infection, or TTI, including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease or TA-GVHD. As part of the FDA&#8217;s approval of the platelet system, we are required to successfully conduct and complete two post-approval studies - a haemovigilance study to evaluate the incidence of acute lung injury following transfusion of INTERCEPT-treated platelets&#59; and a recovery study of platelets treated with the platelet system that is currently being discussed with FDA. The plasma system is approved in the U.S. for <span style="font-style:italic;">ex vivo</span> preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of TTI when treating patients requiring therapeutic plasma transfusion, and as an alternative to gamma irradiation for prevention of TA-GVHD.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The INTERCEPT Blood System for red blood cells, or the red blood cell system, is currently in development and has not been commercialized anywhere in the world. We announced the successful completion of our European Phase 3 clinical trial of our red blood cell system for acute anemia patients in January 2015, and in January 2018, we reported that the primary efficacy and safety endpoints were successfully achieved in our European Phase 3 clinical trial for chronic anemia patients. Based on the results of those trials, we filed for CE Mark approval in the European Union in December 2018, though we now know that we will have to transition from the Medical Device Directive, or MDD, to the Medical Device Regulation, or MDR, and do not expect an approval decision until 2022, if ever. We do not yet know whether the data generated from our European Phase 3 clinical trials will be sufficient to receive CE Mark approval. In the U.S., we successfully completed a Phase 2 recovery and lifespan study in 2014. In 2017, we initiated a Phase 3 clinical, double-blind study, known as the RedeS study, to assess the safety and efficacy of INTERCEPT-treated red blood cells when compared to conventional, un-treated, red blood cells in regions impacted by the Zika virus epidemic. Also in 2017, we received investigational device exemption, or IDE, approval from the FDA to initiate a Phase 3 clinical trial, known as the ReCePI study that is designed to evaluate the efficacy and safety of INTERCEPT-treated red blood cells in patients requiring transfusion for acute blood loss during surgery. Due to the COVID-19 pandemic, many of the hospital sites conducting our RedeS and ReCePI studies have temporarily suspended enrollment to focus on their response to the pandemic. In addition to successfully conducting and completing the RedeS and ReCePI studies, we will need to successfully conduct and complete an additional Phase 3 clinical trial for chronic anemia patients, including sickle-cell anemia patients, in the U.S. before the FDA will consider our red blood cell system for approval. We also understand that one or more additional <span style="font-style:italic;">in vitro</span> studies will be required to be successfully completed and submitted to the FDA, prior to any initiation of a potential additional Phase 3 clinical trial. There can be no assurance that we will be able to successfully complete any such <span style="font-style:italic;">in vitro</span> studies, nor can there be any assurance that we and the FDA will agree to any trial protocol we propose or that we will otherwise obtain FDA clearance to initiate a potential additional Phase 3 clinical trial. In part, we will seek to introduce supplemental clinical data we obtained from European clinical trials, though we cannot assure you that we will be able to demonstrate comparability or that the FDA will allow supplemental clinical European data. In addition, given the need to phenotypically match donations and patients and the existing burden of managing the production and supply to sickle-cell anemia patients, donor recruitment in a potential additional Phase 3 clinical trial may be difficult or impractical, which could significantly </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay or preclude our ability to obtain any FDA approval of our red blood cell system. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filed for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> CE </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the MDD</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the red blood cell system, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">understand that we will need to submit additional data from qualified suppliers which we will not have prior to needing to refile under the MDR</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therefore,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we do not expect to receive any regulatory approvals of our red blood cell system </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if ever. We must demonstrate an ability to define, test and meet acceptable specifications for our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current Good Manufacturing Practice</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> manufactured compounds used to prepare </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTERCEPT-treated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> red blood cells before we can submit and seek regulatory approval of our red blood cell system. We understand that while the data generated from our European Phase 3 clinical trials may be sufficient to receive </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CE Mark</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approval, we may need to generate additional safety data from commercial use in order to achieve broad market acceptance. In addition, these trials may need to be supplemented by additional, successful Phase 3 clinical trials for approval in certain countries. If such additional Phase 3 clinical trials are required, they would likely need to demonstrate equivalency of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTERCEPT-treated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> red blood cells compared to conventional</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, un-treated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> red blood cells and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> significantly lower lifespan for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTERCEPT-treated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> red blood cells compared to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conventional, un-treated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red blood cells may limit our ability to obtain any regulatory approvals </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in certain countries</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the red blood cell system. As part of our development activities, we will need to successfully complete a number of </span><span style="font-style:italic;">in vitro</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> studies prior to receiving any regulatory approvals in Europe and certain additional activities, including </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully completing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RedeS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and ReCePI studies and an additional Phase 3 clinical trial for chronic anemia</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients, including sickle-cell anemia patients,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the U.S., prior to receiving any regulatory approvals in the U.S. Successful completion of these activities may require capital beyond that which we currently have or that may be available to us under our agreement with the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biomedical Advanced Research and Development Authority</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BARDA, and we may be required to obtain additional capital in order to complete the development of and obtain any regulatory approvals for the red blood cell system. In addition, if we are unable to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain from our suppliers</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sufficient </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quantities of the active compounds for our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red blood cell system</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> meeting defined quality and regulatory specifications</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if our suppliers are not able to maintain regulatory compliance</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or if we experience an extended delay in enrollment for the RedeS and ReCePI studies because of the COVID-19 pandemic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or any other reason</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we may experience delays in testing, conducting trials or obtaining approvals, and our product development costs would likely increase.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, we extended our agreement with BARDA, part of the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, through December 2021. The agreement provides funding from BARDA to support the development of our red blood cell system, including clinical and regulatory development programs in support of potential licensure, and development, manufacturing and scale-up activities, as well as activities related to broader implementation of all three INTERCEPT systems in areas of emerging pathogens. The RedeS and ReCePI and other studies are being funded as part of our agreement with BARDA. Under the contract, BARDA reimburses us for allowable direct contract costs, as such costs are incurred, and for allowable indirect costs. See the discussion under &#8220;BARDA&#8221; below for more information. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our near-term capital requirements are dependent on various factors, including operating costs and working capital investments associated with developing and commercializing the INTERCEPT Blood System, including continuing U.S. commercialization of our platelet and plasma systems, costs to develop different configurations of existing products and new products, including our illuminator, costs associated with planning, enrolling and completing ongoing studies, and the post-approval studies we are required to conduct in connection with the FDA approval of the platelet system, costs associated with pursuing potential regulatory approvals in other geographies where we do not currently sell our platelet and plasma systems, costs associated with conducting <span style="font-style:italic;">in vitro</span> studies and clinical development of our red blood cell system in Europe and the U.S., costs associated with performing the agreed-upon activities under our BARDA agreement, and costs related to creating, maintaining and defending our intellectual property. Our long-term capital requirements will also be dependent on the success of our sales efforts, competitive developments, the timing, costs and magnitude of our longer-term clinical trials and other development activities, required post-approval studies, market preparedness and product launch activities for any of our product candidates and products in geographies where we do not currently sell our products, and regulatory factors. Until we are able to generate a sufficient amount of product revenue and generate positive net cash flows from operations, which we may never do, meeting our long-term capital requirements is in large part reliant on continued access to funds under our BARDA agreement and the public and private equity and debt capital markets, as well as on collaborative arrangements with partners, augmented by cash generated from operations and interest income earned on the investment of our cash balances. While we believe that our available cash and cash equivalents and short-term investments, as well as cash received from product sales and under our agreement with BARDA, will be sufficient to meet our capital requirements for at least the next twelve months, if we are unable to generate sufficient product revenue, or access sufficient funds under our BARDA agreement or the public and private equity and debt capital markets, we may be unable to execute successfully on our operating plan. We have based our cash sufficiency estimate on assumptions that may prove to be incorrect. If our assumptions prove to be incorrect, we could consume our available capital resources sooner than we currently expect or in excess of amounts than we currently expect, which could adversely affect our commercialization and clinical development activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have borrowed and in the future may borrow additional capital from institutional and commercial banking sources to fund future growth, including pursuant to our term loan agreement and revolving loan agreement with MidCap Financial Trust, or MidCap, as described below, or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms that may include restrictive covenants, including covenants that restrict the operation of our business, liens on assets, high effective interest rates, financial performance covenants and repayment provisions that reduce cash resources and limit future access to capital markets. In addition, we expect to continue to opportunistically seek access to the equity capital markets to support our development efforts and operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of economic conditions, general global economic uncertainty, political change, and other factors, including uncertainty associated with the COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. Specifically, the COVID-19 pandemic has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. In addition, we may need to obtain additional funds to complete development activities for the red blood cell system necessary for potential regulatory approval in Europe, if costs are higher than anticipated or we encounter delays. We may need to obtain additional funding to conduct additional randomized controlled clinical trials for existing or new products, particularly if we are unable to access any additional portions of the funding contemplated by our BARDA agreement, and we may choose to defer such activities until we can obtain sufficient additional funding or, at such time our existing operations provide sufficient cash flow to conduct these trials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we received FDA approval of our platelet and plasma systems in December 2014, our U.S. commercial efforts continue to be largely focused on enabling blood centers that are using INTERCEPT to optimize production and increase the number of platelet and plasma units produced and made available to patients and continuing to develop awareness of INTERCEPT&#8217;s product profile relative to other platelet and plasma products, including conventional, un-treated components. Significant increase in product revenue from customers in the U.S. may not occur, if at all, until we have been able to successfully implement the platelet and plasma systems and demonstrate that they are economical, safe and efficacious for potential customers. In addition, to address the entire market in the U.S., we will need to develop, test and obtain FDA approval of additional configurations of the platelet system. In September 2019, the FDA issued a final guidance document, &#8220;Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion.&#8221; The guidance document requires all blood collection facilities to comply with the options available under the guidance document, which includes the INTERCEPT Blood System, for all platelet collections, no later than eighteen months from the issuance date. Blood centers may wait until later in the compliance grace period before beginning to take steps to implement INTERCEPT. Should a large number of blood centers wait, we may not have sufficient resources or product available to allow customers to timely and successfully implement INTERCEPT before the end of the compliance grace period. Should we be unable to manufacture INTERCEPT in sufficient quantities in a timely manner, or have adequate resources to assist customer with implementing the INTERCEPT Blood System, U.S. blood centers may be forced to use alternate options allowed by the guidance document, which could permanently impact our ability to convert those blood centers to INTERCEPT users. Also, if the COVID-19 crisis persists, customers may not be able to implement new technologies such as INTERCEPT and may instead choose to utilize other allowable methods with which they may have more familiarity. We also plan to perform&#160;<span style="font-style:italic;">in vitro</span>&#160;studies and seek a premarket approval, or PMA, supplement&#160;to use&#160;our plasma system to produce extended-storage cryoprecipitate and possibly other plasma derived biological products.&#160;We currently have agreements with certain blood center manufacturing partners and are actively working to identify additional partners to manufacture the extended-storage cryoprecipitate.&#160;We are also working on implementing the infrastructure we believe will be necessary to market an approved extended-storage cryoprecipitate product directly to hospitals subsequent to potential regulatory approval of any PMA supplement that we may propose to submit to the FDA. Even if we were to receive approval for a PMA supplement for extended storage cryoprecipitate, we may not receive label claims for all indications or for indications with the highest unmet need or market acceptance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside of the U.S., we recognize product revenues from the sale of our platelet and plasma systems in a number of countries around the world including those in Europe, the Commonwealth of Independent States, or CIS, and the Middle East. In July 2017, we entered into agreements with &#201;tablissement Fran&#231;ais du Sang, or EFS to supply illuminators and platelet and plasma disposable kits. The agreement for supply of illuminators and platelet disposable kits provided for a base term of two year, with two options for EFS to extend for one year each, the first of which, EFS exercised in 2019. In January 2020, we entered into a new agreement with EFS to supply plasma disposable kits and maintenance services for illuminators for a base term of two years, with two options for EFS to extend for one year each. We understand that EFS has adopted the platelet system across France, but cannot provide any assurance that national usage is sustainable, since no purchase volume commitments have been made by EFS, in our current contract or otherwise. In addition, significant product revenue from the French market may decline or not consistently occur quarter-over-quarter. We cannot assure that EFS will use the INTERCEPT Blood System for plasma at historical levels or at all. We also cannot provide any assurance that we will be able to secure any subsequent contracts with EFS or that the terms, including the pricing or committed volumes, if any, of any future contract will be equivalent or superior to the terms under our current contract.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to gain widespread commercial adoption in markets where our blood safety products are approved for commercialization, including the U.S., we will have difficulties achieving profitability. In order to commercialize all of our products and product candidates, we will be required to conduct significant research, development, preclinical and clinical evaluation, commercialization and regulatory compliance activities for our products and product candidates, which, together with anticipated </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">selling, general and administrative expenses, are expected to result in substantial losses. Accordingly, we may never achieve a profitable level of operations in the future</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the product revenues from sales of our platelet and plasma systems, we anticipate that we will continue to recognize revenue from our BARDA agreement. We recognize revenue associated with the BARDA agreement as qualified costs are incurred for reimbursement over the performance period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fresenius</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fresenius Kabi AG, or Fresenius, manufactures and supplies the platelet and plasma systems to us under a supply agreement, or the Supply Agreement. Fresenius is obligated to sell, and we are obligated to purchase, finished disposable kits for our platelet, plasma and red blood cell systems. The Supply Agreement permits us to purchase platelet, plasma and red blood cell systems from third parties to the extent necessary to maintain supply qualifications with such third parties or where local or regional manufacturing is needed to obtain product registrations or sales. Pricing terms are initially fixed and decline at specified annual production levels, and are subject to certain adjustments after the initial pricing term. In response to public health directives in France similar to local orders issued in the United States to respond to the COVID-19 pandemic, Fresenius has recently reconfigured production workflow to ensure employee safety and to comply with local requirements for social distancing. For a discussion of the risks presented to our supply chain by the COVID-19 pandemic, see &#8220;Item 1A&#8212;<span style="font-style:italic;">Risk Factors</span>&#8221; in Part II of this Quarterly Report on Form 10-Q.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the Supply Agreement extends through July 1, 2025, or the Initial Term, and is automatically renewed thereafter for additional two year terms, or Renewal Terms, subject to termination by either party upon (i) two years written notice prior to the expiration of the Initial Term or (ii) one year written notice prior to the expiration of any Renewal Term. Under the Supply Agreement, we have the right, but not the obligation, to purchase certain assets and assume certain liabilities from Fresenius. In the event that Fresenius refuses or is unable to continue operating under the Supply Agreement, we may be unable to maintain inventory levels or otherwise meet customer demand, and our business and operating results would be materially and adversely affected. Pricing under the agreement is established through 2020 at which time new pricing will need to be agreed upon by both parties or calibrated off of the pre-existing prices using a price index for the remainder of the initial term.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Likewise, if we conclude that supply of the INTERCEPT Blood System or components from Fresenius and others is uncertain, we may choose to build and maintain inventories of raw materials, work-in-process components, or finished goods, which would consume capital resources faster than we anticipate and may cause our supply chain to be less efficient. Like most regulated manufacturing processes, our ability to produce our products is dependent on our or our suppliers&#8217; ability to source components and raw materials which may at times be in short demand or obsolete. In such cases, we and/or Fresenius or other suppliers may need to source, qualify and obtain approval for replacement materials or components which would likely prove to be disruptive and consume capital resources sooner than we anticipate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 10, <span style="font-style:italic;">Development and License Agreements</span>, in Part I of this Quarterly Report on Form 10-Q for further information regarding the Supply Agreement with Fresenius. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BARDA</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, we entered into an agreement with BARDA to support our development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells, including access to funding that could potentially support various activities, including funding studies necessary to support a potential premarket approval application submission to the FDA for the red blood cell system, and acceleration of commercial scale up activities to facilitate potential adoption of the red blood cell system by U.S. blood centers.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement with BARDA provides for the reimbursement of certain amounts incurred by us in connection with our satisfaction of certain contractual milestones. Under the agreement, we are reimbursed and recognize revenue as qualified direct contract costs are incurred plus allowable indirect costs, based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses. As of March&#160;31, 2020, BARDA has committed to reimburse certain of our expenses related to the clinical development of the red blood cell system during a base period, or the Base Period, and under exercised option periods, or Option Periods, in an aggregate amount of up to $103.2 million. In April 2020, BARDA committed an additional $13.8 million raising the committed funding to up to $116.9 million. If we satisfy subsequent milestones and BARDA were to exercise additional Option Periods, the total funding opportunity under the BARDA agreement could reach up to $213.9 million through December 31, 2021. If exercised by BARDA in its sole discretion, each subsequent Option Period would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of emerging pathogens, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. We are currently responsible for co-investment of approximately $5.0 million, and would be responsible for an additional $9.6 million, if certain additional Option Periods are exercised </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by BARDA.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 10, </span><span style="font-style:italic;">Development and License Agreements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in Part I of this Quarterly Report on Form 10-Q for further information regarding the agreement with BARDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cantor</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 7, <span style="font-style:italic;">Stockholders&#8217; Equity</span>, in Part I of this Quarterly Report on Form 10-Q for further information regarding the sales agreement with Cantor Fitzgerald &#38; Co. for the issuance and sale of our common stock. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has affected and will continue to affect economies and business around the world. To date, various governmental authorities and private enterprises have implemented numerous measures to contain the pandemic, such as travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns, which have led to severe disruptions to the global and United States economies that may continue for a prolonged duration and trigger a recession or a period of economic slowdown. We do not yet know the full extent of potential impacts on our product revenues, business operations, clinical trials, or overall financial projections. The extent and duration of the pandemic is highly uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, which could also impact trends and expectations as described in more detail below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Management Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Three months ended March&#160;31, 2020 and 2019</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,611</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government contract revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,030</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,461</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,641</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,965</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,676</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue increased by $1.1 million during the three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019, primarily due to year-over-year sales volume growth in disposable kit sales in the U.S, the majority of which resulted from the increased adoption of the platelet system in the U.S., partially offset by product mix in France and a decrease in disposable kit sales in the Middle East due to the timing of purchases during the three months ended March&#160;31, 2020, as compared to the three months ended March&#160;31, 2019.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate product revenue for INTERCEPT disposable kits will increase in future periods driven by the expected expansion of U.S. sales as increased market acceptance of the INTERCEPT Blood System and adoption of the INTERCEPT Blood System in geographies where commercialization efforts are underway. However, a deterioration of the Euro relative to the U.S. dollar has in the past and could in the future have a material impact on our product revenues, as a significant portion of our product revenue is expected to come from Euro denominated markets over the near term. As a result of these and other factors, the historical results may not be indicative of INTERCEPT Blood System product revenue in the future.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized $6.0 million and $4.5 million of revenue from our BARDA agreement during the three months ended March&#160;31, 2020 and 2019,&#160;respectively, as a result of the direct and indirect contract costs incurred under the BARDA agreement. We anticipate that reported BARDA revenue may decrease over the next three to nine months as a result of the COVID-19 pandemic. It is impossible to predict the duration of the COVID-19 pandemic but we expect revenue from our BARDA agreement to increase once the crisis is over and as our RedeS and ReCePI studies begin to re-enroll patients and other qualified clinical and development activities potentially increase under exercised Option Periods.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Product Revenue</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cost of product revenue consists of the cost of the INTERCEPT Blood System sold, provisions for obsolete, slow-moving and unsaleable product, certain order fulfillment costs, to the extent applicable and costs for idle facilities. Inventory is accounted for on a first-in, first-out basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,320</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,432</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue decreased by $0.1 million during the&#160;three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019. The decrease was primarily due to volume tier discounts from a contract manufacturer and the impact of foreign exchange rates, partially offset by the increase of sales. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our gross margin on product sales was 55% during the three months ended March&#160;31, 2020, compared to 52% during the three months ended March&#160;31, 2019. The increase in gross margin on product sales was primarily due to economies of scale and lower per unit costs driven by increased manufacturing production to meet existing and expected growth in demand. Changes in our gross margin on product sales are affected by various factors, including the volume of product manufactured and the relative per unit pricing in our agreement with Fresenius, exchange rate of the Euro relative to the U.S. dollar, manufacturing and supply chain costs, the mix of product sold, and the mix of customers to which products are sold. We may encounter unforeseen manufacturing difficulties, including those related to the COVID-19 pandemic, which, at a minimum, may lead to higher than anticipated costs, scrap rates, delays in manufacturing products, or lower production levels of manufacturing than would be needed to meet demand. In addition, we may face competition which may limit our ability to maintain existing selling prices for our products which in turn would negatively affect our reported gross margins on product sales. Our gross margins on product sales may be impacted in the future based on all of these and other criteria.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to build inventory levels that will be sufficient to meet forecasted demand. While our suppliers have initiated business continuity plans with minimal disruption to our supply, we cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not impact our supply chain.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses include salaries and related expenses for our scientific personnel, non-cash stock based compensation, payments to consultants, costs to prepare and conduct preclinical and clinical trials, third-party costs for development activities, certain regulatory costs, costs associated with our facility related infrastructure, and laboratory chemicals and supplies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,810</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,440</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,370</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by $2.4 million during the three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019, primarily due to increased costs associated with product enhancements and initiatives for expanded platelet label claims and costs for our red blood cell program, inclusive of activities related to the BARDA agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur additional research and development costs associated with planning, enrolling and completing our required post-approval studies for the platelet system, pursuing potential regulatory approvals in other geographies where we do not currently sell our platelet and plasma systems, planning and conducting <span style="font-style:italic;">in vitro</span> studies and clinical development of our red blood cell system in Europe and the U.S., completing activities to support our CE Mark submission for our red blood cell system in Europe, new product development and product enhancements, including potential new label claims, and costs associated with performing the activities under our BARDA agreement. Due to the inherent uncertainties and risks associated with developing biomedical products, including, but not limited to, intense and changing government regulation, the impact of global pandemics and natural disasters, including the current COVID-19 pandemic, uncertainty of future preclinical studies and clinical trial results and uncertainty associated with manufacturing, it is not possible to reasonably estimate the costs to complete these research and development projects. We face numerous risks and uncertainties associated with the successful completion of our research and development projects, which risks and uncertainties are discussed in further detail under &#8220;Item 1A&#8212;<span style="font-style:italic;">Risk Factors</span>&#8221; in Part II of this Quarterly Report on Form 10-Q.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General, and Administrative Expenses</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general, and administrative expenses include salaries and related expenses for administrative personnel, non-cash stock based compensation, expenses for our commercialization efforts in a number of countries around the world including those in U.S., Europe, the CIS and the Middle East, Asia, Latin America, and expenses for accounting, tax, internal control, legal and facility and infrastructure related expenses, and insurance premiums.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,913</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,161</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(248</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general, and administrative expenses decreased by $0.2 million during the three months ended March&#160;31, 2020,&#160;compared to the three months ended March&#160;31, 2019, primarily due to lower marketing related expenses as well as travel, both driven partially by the current COVID-19 pandemic. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Operating Expense, Net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-operating expense, net consists of foreign exchange gains and losses, interest charges incurred on our debt, and other non-operating gains and losses, including interest earned from our short-term investment portfolio. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange (loss) gain</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(223</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(162</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(935</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,924</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(271</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-operating expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,007</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,664</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.42%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Exchange Loss</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange loss increased during the three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019, primarily due to decreased foreign exchange rates for the Euro.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Expense</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense decreased $2.0 million during the&#160;three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019,&#160;primarily due to the loss of $2.1 million on the extinguishment of a previous loan and security agreement in the three months ended March&#160;31, 2019. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net decreased $0.3 million during the three months ended March&#160;31, 2020, compared to the three months ended March&#160;31, 2019, primarily due to the loss from the sale of an investment in marketable securities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provision for Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For both the&#160;three months ended March&#160;31, 2020 and 2019, we recorded tax expense of $0.1 million. The tax expenses were primarily a result of our Cerus Europe B.V. subsidiary&#8217;s operating profit. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to our history of cumulative operating losses, management has concluded that, after considering all of the available objective evidence, it is not likely that all our net deferred tax assets as of March&#160;31, 2020 will be realized. Accordingly, substantially all of our U.S. deferred tax assets continue to be subject to a valuation allowance as of March&#160;31, 2020. As of March&#160;31, 2020, there have been no material changes to our total amount of unrecognized tax benefits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, our sources of capital have primarily consisted of public issuance of common stock, debt instruments, and to a lesser extent, cash from product sales and reimbursements under our BARDA agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020, we had cash, cash equivalents, and restricted cash of $36.1 million, of which $33.7 million was included in cash and cash equivalents, and $2.4 million was included as restricted cash. At December&#160;31, 2019, we had cash, cash equivalents, and restricted cash of $37.4 million, of which $35.0 million was included in cash and cash equivalents, and $2.4 million was included as restricted cash. Our cash equivalents primarily consist of money market instruments, which are classified for accounting purposes as </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available-for-sale. In addition, we had $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.4</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of short-term investments at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We also had total indebtedness </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit, Security and Guaranty Agreement (Term Loan), </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Credit Agreement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and our Credit, Security and Guaranty Agreement (Revolving Loan), or the Revolving Loan Credit Agreement,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">both with MidCap Financial Trus</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.4</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Excess cash is typically invested in highly liquid instruments of short-term investments with high-quality credit rated corporate and government agency fixed-income securities in accordance with our investment policy.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $19.8 million during the three months ended March&#160;31, 2020, compared to $22.2 million net cash used during the three months ended March&#160;31, 2019. The decrease in net cash used in operating activities was primarily related to increased product sales and revenue from our BARDA agreement, and the timing of payments and accounts receivable collections <span style="letter-spacing:-0.1pt;">during the three months ended March&#160;31, 2020, compared to the same period in 2019.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $50.2 million during the three months ended March&#160;31, 2020, compared to $13.2 million net cash provided by investing activities during the three months ended March&#160;31, 2019. The change period over period was primarily the result of higher purchases of investments during the three months ended March&#160;31, 2020, resulting from the proceeds from our January 2020 public offering of common stock.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $68.7 million during the three months ended March&#160;31, 2020, compared to $9.1 million net cash provided during the three months ended March&#160;31, 2019. The increase in net cash provided by financing activities was primarily due to the proceeds of approximately $62.7 million, net of the underwriting discounts and other issuance costs, received from our January 2020 public offering of common stock, and proceeds of approximately $4.4 million received from the shares sold under the Amended Cantor Agreement during the three months ended March&#160;31, 2020, as compared to the net principal proceeds of $7.8 million received <span style="letter-spacing:-0.1pt;">during the</span> three months ended March&#160;31, 2019, from the Term Loan Credit Agreement described in more detail in <span style="font-style:italic;">Note 5, Debt,</span> in Part I of this Quarterly Report on Form 10-Q<span style="letter-spacing:-0.1pt;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Working Capital</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital increased to $133.2 million at March&#160;31, 2020, from $77.8 million at December&#160;31, 2019, primarily due to the cash received from our January 2020 public offering of common stock. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Capital Requirements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our near-term capital requirements are dependent on various factors, including operating costs and working capital investments associated with developing and commercializing the INTERCEPT Blood System, including in connection with the continuing U.S. commercialization of our platelet and plasma systems, costs to develop different configurations of existing products and new products, including our illuminator, costs associated with planning, enrolling and completing ongoing studies, and the post-approval studies we are required to conduct in connection with the FDA approval of the platelet system, costs associated with pursuing potential regulatory approvals in other geographies where we do not currently sell our platelet and plasma systems, costs associated with conducting <span style="font-style:italic;">in vitro</span> studies and clinical development of our red blood cell system in Europe and the U.S., costs associated with performing the agreed-upon activities under our BARDA agreement, and costs related to creating, maintaining and defending our intellectual property. Our long-term capital requirements will also be dependent on the success of our sales efforts, competitive developments, the timing, costs and magnitude of our longer-term clinical trials and other development activities required post-approval studies, market preparedness and product launch activities for any of our product candidates and products in geographies where we do not currently sell our products, and regulatory factors. Until we are able to generate a sufficient amount of product revenue and generate positive net cash flows from operations, which we may never do, meeting our long-term capital requirements is in large part reliant on continued access to funds under our BARDA agreement and the public and private equity and debt capital markets, as well as on collaborative arrangements with partners, augmented by cash generated from operations and interest income earned on the investment of our cash balances. While we believe that our available cash and cash equivalents and short-term investments, as well as cash received from product sales and under our agreement with BARDA, will be sufficient to meet our capital requirements for at least the next twelve months, if we are unable to generate sufficient product revenue, or access sufficient funds under our BARDA agreement or the public and private equity and debt capital markets, we may be unable to execute successfully on our operating plan. We have based our cash sufficiency estimate on assumptions that may prove to be incorrect. If our assumptions prove to be incorrect, we could consume our available capital resources sooner than we currently expect or in excess of amounts than we currently expect, which could adversely affect our commercialization and clinical development activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have borrowed and in the future may borrow additional capital from institutional and commercial banking sources to fund future growth, including pursuant to the Term Loan Credit Agreement and Revolving Loan Credit Agreement, or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms that may include restrictive covenants, including covenants that </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict the operation of our business, liens on assets, high effective interest rates</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial performance covenants</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and repayment provisions that reduce cash resources and limit future access to capital markets. In addition, we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunistically seek</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> access to the equity capital markets to support our development efforts and operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect to receive significant funding under our agreement with BARDA, our ability to obtain the funding we expect to receive under the agreement is subject to various risks and uncertainties, including with respect to BARDA&#8217;s ability to terminate the agreement for convenience at any time and our ability to achieve the required milestones under the agreement, including with respect to the conduct of the RedeS and ReCePI studies, enrollment for which has been suspended at many of the hospital sites due to the COVID-19 pandemic. In addition, access to federal contracts is subject to the authorization of funds and approval of our research plans by various organizations within the federal government, including the U.S. Congress. The general economic environment and uncertainty associated with the COVID-19 pandemic, coupled with tight federal budgets, has led to a general decline in the amount available for government funding. If BARDA were to eliminate, reduce or delay funding under our agreement, this would have a significant negative impact on the programs associated with such funding and could have a significant negative impact on our revenues and cash flows. Furthermore, should we be unable to deploy personnel or derive a benefit from fixed study costs or generate data from clinical sites and studies reimbursed by BARDA, our cash flows would be negatively impacted or we may have to initiate furloughs and layoffs which would likely prove disruptive to our management and operations. This in turn would impair our ability to recommence and complete studies if and when the COVID-19 crisis subsides and we are able to restart many suspended or delayed activities. In addition, if we are unable to generate sufficient perquisite Phase 3 clinical data and/or reach agreement with the FDA on an additional Phase 3 clinical trial for chronic anemia in the U.S. for our red blood cell system, our agreement with BARDA will be severely limited in scope or could be terminated altogether, and our ability to complete the development activities required for licensure in the U.S. may require additional capital beyond which we currently have. If alternative sources of funding are not available, we may be forced to suspend or terminate development activities related to the red blood cell system in the U.S.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of economic conditions, general global economic uncertainty, political change, global pandemics, natural disasters, and other factors, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. Specifically, the COVID-19 pandemic has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may need to obtain additional funds to complete development activities for the red blood cell system necessary for potential regulatory approval in Europe, if costs are higher than anticipated or we encounter delays. We may need to obtain additional funding to conduct additional randomized controlled clinical trials for existing or new products, particularly if we are unable to access any additional portions of the funding contemplated by our BARDA agreement, and we may choose to defer such activities until we can obtain sufficient additional funding or, at such time, our existing operations provide sufficient cash flow to conduct these trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Off-Balance Sheet Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Off-balance Sheet Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any off-balance sheet arrangements as of March&#160;31, 2020.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contractual Commitments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes our contractual commitments at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Commitments</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2 - 3 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4 - 5 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">After 5 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,273</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,854</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,391</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,028</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,372</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,442</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,933</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,432</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum purchase requirements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,914</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,744</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,474</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">783</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,913</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other commitments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contractual obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,926</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,397</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,808</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,243</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,478</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Debt</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <span style="font-style:italic;">Note 5, Debt</span>, in Part I of this Quarterly Report on Form 10-Q for more information on the debt under our Term Loan Credit Agreement and the Revolving Loan Credit Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <span style="font-style:italic;">Note 6, Commitments and Contingencies</span>, in Part I of this Quarterly Report on Form 10-Q for more information on the operating leases. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Minimum Purchase Requirements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our minimum purchase commitments include certain components of our INTERCEPT Blood System which we purchase from third-party manufacturers, which are not recorded in our condensed consolidated balance sheets as of March&#160;31, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Commitments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other commitments primarily consist of obligations related to business insurance financing and certain other warehousing obligations. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our investment policy is to manage our marketable securities portfolio to preserve principal and liquidity while maximizing the return on the investment portfolio to assist us in funding our operations. We currently invest our cash and cash equivalents in money market funds and interest-bearing accounts with financial institutions. Our money market funds are classified as Level 1 in the fair value hierarchy, in which quoted prices are available in active markets, as the maturity of money market funds are relatively short and the carrying amount is a reasonable estimate of fair value. Our available-for-sale securities related to corporate debt and U.S. government agency securities are classified as Level 2 in the fair value hierarchy, which uses observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. We maintain portfolio liquidity by ensuring that the securities have active secondary or resale markets. We did not record any credit losses during the three months ended March&#160;31, 2020,&#160;or for the year ended December&#160;31, 2019. Adverse global economic conditions have had, and may continue to have, a negative impact on the market values of potential investments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <span style="font-style:italic;">Note 1, Summary of Significant Accounting Policies,</span> in Part I of this Quarterly Report on Form 10-Q for more information on new accounting pronouncements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2020, there were no material changes to our market risk disclosures as set forth under, &#8220;Item 7A &#8211; <span style="font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span>,&#8221; in Part II of our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_CONTROLS_PROCEDURES">CONTROLS AND PROCEDURES</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have carried out an evaluation under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on their evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2020.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting which occurred during our fiscal quarter ended March&#160;31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Limitations on the Effectiveness of Controls</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designed to provide reasonable assurance, not absolute assurance, that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, that based on their evaluation as of the end of the period covered by this </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our disclosure controls and procedures were effective to provide reasonable assurance that the objective of our disclosure control system were met</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II: OTHER INFORMATION</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_LEGAL_PROCEEDINGS">LEGAL PROCEEDINGS</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS"><span style="font-style:italic;">Risk Factors</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our business faces significant risks. If any of the events or circumstances described in the following risks actually occurs, our business may suffer, the trading price of our common stock could decline and our financial condition or results of operations could be harmed. These risks should be read in conjunction with the other information set forth in this report. The risks and uncertainties described below are not the only ones facing us. There may be additional risks faced by our business. Other events that we do not currently anticipate or that we currently deem immaterial also may adversely affect our financial condition or results of operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The effects of the COVID-19 pandemic have materially affected how we, our customers, and our suppliers are operating our businesses, and the duration and extent to which this will impact our future results of operations and overall financial performance remains uncertain. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel coronavirus disease, or COVID-19, was reported and in January 2020, the World Health Organization, or the WHO, declared it a Public Health Emergency of International Concern. On February 28, 2020, the WHO raised its assessment of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and on March 11, 2020, the WHO characterized COVID-19 as a pandemic. A significant outbreak of epidemic, pandemic, or contagious diseases in the human population could result in a widespread health crisis that could adversely affect the broader economies, financial markets, our ability to make meaningful progress with many of our development programs and disruption and impact on existing and prospective customers.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we are currently deemed to be a critical business by national, state and local governments, out of an abundance of caution for our employees and to minimize the spread of COVID-19, we have put restrictions on employee travel and working from our facilities in the United States and Europe. These restrictions are likely to negatively impact productivity and disrupt at least certain aspects of our business and delay our timelines. Further, restrictions on our ability to travel, stay-at-home orders and other similar restrictions on our business have limited our ability to support our global and domestic operations, including providing training and technical support, resulting in disruptions in our sales and marketing efforts. In addition, the pandemic has severely restricted the level of economic activity in affected areas and may adversely impact demand for, and sales of, our products. We have deferred certain of our customer events and many planned trade shows have been cancelled and we may further defer or cancel additional customer, employee or industry events, or our participation in such events, in the future. In addition, many new customers and prospective customers have been effected by the COVID-19 pandemic and their ability to implement new technologies, including INTERCEPT, has and may continue to be negatively impacted. Conversely, during this pandemic, certain existing, new and prospective customers have and may continue to ask for increased utilization of our products beyond what was forecast, and we may not be able to timely satisfy this increase in demand. Customers whose operations have been effected may have difficulty paying timely, may ask for price reductions or may delay or cancel public tenders. In addition, while our suppliers have initiated business continuity plans with minimal expected disruption to our supply, we cannot be certain that any prolonged, intensified or worsened effect from the crisis would not impact our supply chain. All of the aforementioned could adversely affect our sales, operating results and overall financial performance.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary manufacturing partner for our disposable kits is located in France where restrictive government and private enterprise measures have been implemented in response to the COVID-19 pandemic. To ensure employee safety and comply with local requirements for social distancing, we understand that Fresenius recently reconfigured production workflow and the facility continues to produce INTERCEPT disposable kits. However, employee absenteeism at the manufacturing site, is a potential risk that could negatively impact production, the magnitude of which depends, in part, on the length and severity of the restrictions and other limitations on their ability to conduct business in the ordinary course.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration and extent of the impact from the COVID-19 pandemic depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions and the impact of these and other factors on our operations, employees, customers, partners and vendors. If we are not able to respond to and manage the impact of such events effectively, our business will be harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. To the extent the COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic has negatively impacted our ability to perform many clinical trials, studies and activities, including those covered by our agreement with BARDA.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond the commercial impact that the COVID-19 pandemic may have on our operations, our clinical and development programs have been adversely effected. Our ongoing clinical trials, the post-approval platelet studies, RedeS and ReCePI, as well as studies to support label expansion for our platelet program in the U.S. have been delayed, as patient enrollment sites have focused on treating COVID-19 patients and have paused participation in our clinical trials and studies. Also, three out of our four U.S blood center partners that produce pathogen-reduced red blood cells for the red blood cell clinical trials have temporarily suspended production because of the need to conserve red blood cells to meet hospital demand during the pandemic. Should the crisis persist, our ability to commence and complete any contemplated studies may also be negatively impacted. Furthermore, should we be unable to deploy personnel or derive a benefit from fixed study costs or generate data from clinical sites and studies reimbursed under our BARDA contract, our cash flows would be negatively impacted and/or we may have to initiate furloughs and layoffs<span style="color:#000000;"> which would likely prove disruptive to our management and operations</span>. This in turn would impair our ability to recommence and complete studies if and when the COVID-19 crisis subsides and we are able to restart many suspended or delayed activities. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, access to federal contracts is subject to the authorization of funds and approval of our research plans by various organizations within the federal government, including the U.S. Congress. The general economic environment and uncertainty associated with the COVID-19 pandemic, coupled with tight federal budgets, has led to a general decline in the amount available for government funding. If BARDA were to eliminate, reduce or delay funding under our agreement, this would have a significant negative impact on the programs associated with such funding and could have a significant negative impact on our revenues and cash flows. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend substantially upon the commercial success of the INTERCEPT Blood System for platelets and plasma in the United States, or U.S., and our inability to successfully commercialize the INTERCEPT Blood System in the U.S. would have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested a significant portion of our efforts and financial resources on the development of the INTERCEPT Blood System for platelets and plasma for the U.S. market. As a result, our business is substantially dependent on our ability to successfully commercialize the INTERCEPT Blood System in the U.S. in a timely manner. In December 2014, we received U.S. regulatory approval of the INTERCEPT Blood System for platelets and plasma, with certain restrictions regarding usage, and although the INTERCEPT Blood System is now commercially available in the U.S., we have no prior experience commercializing any products in the U.S. and we may be unable to commercialize the INTERCEPT Blood System in the U.S. successfully or in a timely manner, or at all. The broad successful commercial adoption of any product, particularly involving novel technologies, is often dependent upon the seller earning a level of trust from and familiarity with customers, which can take time to develop. In addition, although we received the U.S. Food and Drug Administration, or FDA, approval of our platelet and plasma systems in December 2014, our U.S. commercial efforts in 2020 have been largely focused on enabling blood centers that are using INTERCEPT to optimize production and increase the number of platelet and plasma units produced and made available to patients and continuing to develop awareness of INTERCEPT&#8217;s product profile relative to other platelet and plasma products, including conventional, un-treated components. In September 2019, the FDA issued a final guidance document, &#8220;Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion.&#8221; The guidance document requires all blood collection facilities to comply with the options available under the guidance document, which includes the INTERCEPT Blood System, for all platelet collections, no later than eighteen months from the issuance date. Although the INTERCEPT Blood System is one of the options available to U.S. blood centers for compliance, we cannot predict when, if ever, U.S. customers will adopt INTERCEPT over other options or at what levels. Significant product revenue from customers in the U.S. may not occur timely, if at all, until we have been able to successfully implement the platelet and plasma systems and demonstrate that they are economical, safe and efficacious for potential customers. Similar to our experience in foreign jurisdictions, some potential customers in the U.S. have chosen to first validate our technology or conduct other pre-adoption activities prior to purchasing or deciding whether to adopt the INTERCEPT Blood System for commercial use, which may never occur. Further, the hospital customers of any of our new blood center customers will need to go through the administrative process of generating internal tracking codes to integrate INTERCEPT-treated products into their inventories, which may further delay customer adoption in the U.S. If the COVID-19 crisis persists, customers may not be able to implement new technologies such as INTERCEPT and may instead to utilize other allowable methods that they have more familiarity with. If we are not successful in achieving market adoption of the INTERCEPT Blood System in the U.S., we may never generate substantial product revenue, and our business, financial condition, results of operations and growth prospects would be materially and adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize the INTERCEPT Blood System for platelets and plasma in the U.S. will depend on our ability to:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adequately respond in the event of increased U.S. customer demand resulting from the issuance of the FDA final guidance document&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">achieve market acceptance and generate product sales through execution of sales agreements on commercially reasonable terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">enter into and maintain sufficient manufacturing arrangements for the U.S. market with our third-party suppliers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">create market demand for the INTERCEPT Blood System through our education, marketing and sales activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">hire, train, deploy, support and maintain a qualified U.S.-based commercial organization and field sales force&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">expand the labeled indications of use for the INTERCEPT Blood System and/or design, develop, test and obtain regulatory approval for new product configurations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">comply with requirements established by the FDA, including post-marketing requirements and label restrictions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">comply with other U.S. healthcare regulatory requirements.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the other risks described herein, our ability to successfully commercialize the INTERCEPT Blood System for platelets and plasma in the U.S. is subject to a number of risks and uncertainties, including those related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the COVID-19 pandemic and its effect on customers, hospitals, suppliers and our employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the highly concentrated U.S. blood collection market that is dominated by a small number of blood collection organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">availability of donors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">regulatory and licensing requirements, including the CBER licensing process that U.S.-based blood centers are required to follow in order to obtain and maintain the required site-specific licenses to engage in interstate transport of blood components processed using the INTERCEPT Blood System&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changed or increased regulatory restrictions or requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the amount available for reimbursement pursuant to codes we have obtained under the Healthcare Common Procedure Coding System, or HCPCS, and pricing for outpatient use of INTERCEPT-treated blood components&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">any supply or manufacturing problems or delays arising with any of our suppliers, many of whom are our sole suppliers for the particular product or component they manufacture, the ability of our suppliers to maintain FDA approval to manufacture the INTERCEPT Blood System and to comply with FDA-mandated current Good Manufacturing Practice, or cGMP, and Quality System Regulation, or QSR, requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">dependency upon any third-party manufacturer that supplies products required by blood centers to process and store blood components consistent with our approved specifications and claims, including but not limited to, apheresis collection devices, disposable blood bags and reagents, and platelet additive solution, or PAS&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">changes in healthcare laws and policy, including changes in requirements for blood product coverage by U.S. federal healthcare programs&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">acceptance of the INTERCEPT Blood System as safe, effective and economical from the broad constituencies involved in the healthcare system.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above, our ability to successfully commercialize the INTERCEPT Blood System in the U.S. is dependent on our ability to operate without infringing on the intellectual property rights of others. For example, we are aware of an expired U.S. patent that had been held by a third-party that covered methods to remove psoralen compounds from blood products. We have reviewed the patent and believe there exist substantial questions concerning its validity. We cannot be certain, however, that a court would hold the patent not infringed by our platelet or plasma systems. In this regard, whether or not we have infringed this patent will not be known with certainty unless and until a court interprets the patent in the context of litigation. In the event that we are found to have infringed any valid claim of this patent, we may, among other things, be required to pay damages.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and the other risks described below related to the commercialization of the INTERCEPT Blood System could have a material adverse effect on our ability to successfully commercialize the INTERCEPT Blood System for platelets and plasma in the U.S.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The INTERCEPT Blood System may not achieve broad market adoption.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to increase market adoption of the INTERCEPT Blood System and to increase market demand, we must address issues and concerns from broad constituencies involved in the healthcare system, from blood centers to patients, transfusing physicians, key opinion leaders, hospitals, private and public sector payors, regulatory bodies and public health authorities. We may be unable to demonstrate to these constituencies that the INTERCEPT Blood System is safe, effective and economical or that the benefits of using the INTERCEPT Blood System products justify their cost and outweigh their risks. During the COVID-19 pandemic, we may not be able to generate sufficient interest and mindshare of prospective customers, who may instead be focused on their and their customers&#8217; responses to the pandemic, which would limit our ability to increase market adoption.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of the platelet system results in some processing loss of platelets. If the loss of platelets leads to increased costs, or the perception of increased costs for our customers, or if the use of our product in any way constrains the availability of blood due to platelet loss, or our customers or prospective customers believe that the loss of platelets reduces the efficacy of the transfusable unit, or our process requires changes in blood center or clinical regimens, prospective customers may not adopt our platelet system. Additionally existing customers may not believe they can justify any perceived operational change or inefficiency by itself or in conjunction with a blood component availability shortage. Certain customers that attempt to optimize collection practices from individual donors in order to increase the volume of transfusable units that can be treated with INTERCEPT from those collections may experience a less optimized yield as a result of adopting INTERCEPT as compared to collecting conventional platelet products. Certain studies have indicated that transfusion of conventionally prepared platelets may yield higher post-transfusion platelet counts (according to a measurement called &#8220;corrected count increment&#8221;) and may be more effective than transfusion of INTERCEPT-treated platelets. Although certain other studies demonstrate that INTERCEPT-treated platelets retain therapeutic function comparable to conventional platelets, prospective customers may choose not to adopt our platelet system due to considerations relating to corrected count increment, efficacy or other factors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The INTERCEPT Blood System does not inactivate all known pathogens, and the inability of the INTERCEPT Blood System to inactivate certain pathogens may limit its market adoption. For example, our products have not been demonstrated to be effective in the reduction of certain non-lipid-enveloped viruses, including hepatitis A and E viruses, due to these viruses&#8217; biology. In addition, our products have not demonstrated a high level of reduction for human parvovirus B-19, which is also a non-lipid-enveloped virus. Although we have shown high levels of reduction of a broad spectrum of lipid-enveloped viruses, prospective customers may choose not to adopt our products based on considerations concerning inability to inactivate, or limited reduction, of certain non-lipid-enveloped viruses. Similarly, although our products have been demonstrated to effectively inactivate spore-forming bacteria, our products have not been shown to be effective in reducing bacterial spores once formed. In addition, our products do not inactivate prions since prions do not contain nucleic acid. While transmission of prions has not been a major problem in blood transfusions, and we are not aware of any competing products that inactivate prions, the inability to inactivate prions may limit market adoption of our products. In addition, while we have data supporting INTERCEPT&#8217;s ability to inactivate SARS-CoV-1 and MERS, both corona viruses, we do not yet have data supporting INTERCEPT&#8217;s efficacy in inactivating the SARS-CoV-2 virus (the virus that causes COVID-19). We recently announced an amended collaboration with BARDA to study INTERCEPT&#8217;s pathogen inactivation efficacy against the SARS-CoV-2 virus and have several other studies underway, though we cannot assure you that the results of these studies will be successful. Furthermore, due to limitations of detective tests, we cannot exclude that a sufficient quantity of pathogen or pathogens may still be present in active form, which could present a risk of infection to the transfused patient. Should INTERCEPT-treated components contain detectable levels of pathogens after treatment, the efficacy of INTERCEPT may be called into question, whether or not any remaining pathogens are the result of INTERCEPT&#8217;s efficacy or other factors. Such uncertainties may limit the market adoption of our products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted studies of our products in both <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo </span>environments using well-established tests that are accepted by regulatory bodies. When an <span style="font-style:italic;">in vitro</span> test was not generally available or not well-established, we conducted <span style="font-style:italic;">in vivo</span> studies in mammalian models to predict human responses. Although we have no reason to believe that the <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span> studies are not predictive of actual results in humans, we cannot be certain that the results of these <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span> studies accurately predict the actual results in humans in all cases. In addition, strains of infectious agents in living donors may be different from those strains commercially available or for which we have tested and for which we have received approval of the inactivation claims for our products. To the extent that actual results in human patients differ, commercially available or tested strains prove to be different, or customers or potential customers perceive that actual results differ from the results of our <span style="font-style:italic;">in vitro</span> or <span style="font-style:italic;">in vivo</span> testing, market acceptance of our products may be negatively impacted. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If customers experience operational or technical problems with the use of INTERCEPT Blood System products, market acceptance may be reduced or delayed. For example, if adverse events arise from incomplete reduction of pathogens, improper processing or user error, or if testing of INTERCEPT-treated blood samples fails to reliably confirm pathogen reduction, whether or not directly attributable to the INTERCEPT Blood System, customers may refrain from purchasing our products. Furthermore, should customers communicate operational problems or suspected product failure, we will need to investigate and report imputability to the relevant regulatory authorities in a timely manner. We or others may be required to file reports on such complaints or product failure before we </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have the ability to obtain conclusive data as to imputability which may cause concern with existing and prospective customers or regulators. In addition, the U.S. is currently experiencing a shortage of platelet components in many markets. Should customers feel that INTERCEPT treatment has a negative impact on the number of transfusable platelet units able to be manufactured from available donors, our ability to convince a blood center to treat increasing proportions of its platelet units may be negatively impacted. Moreover, there is a risk that further studies that we or others may conduct, including the post-approval studies we are required to conduct as a condition to the FDA approval of the platelet system, will show results inconsistent with previous studies. Should this happen, potential customers may delay or choose not to adopt our products and existing customers may cease use of our products. In addition, some hospitals may decide to purchase and transfuse both INTERCEPT-treated blood components and conventional blood components. Managing such a dual inventory of blood products may be challenging, and hospitals may need to amend their product labels and inventory management systems before being able to move forward with INTERCEPT. This may require coordination between hospital suppliers and blood centers, which in turn may cause delay in market adoption. Further, in certain markets, potential customers may require us to develop, sell, and support data management application software for their operations before they would consider adopting INTERCEPT. Such software development efforts may be costly or we may be unsuccessful in developing a data management application that would be broadly accepted. Developing, maintaining and supporting software can be time consuming, costly and may require resources and skill sets that we do not possess. Failure to do so may limit market adoption in geographies where we commercialize the INTERCEPT Blood System, including the U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, customers may require certain changes to our products for any number of reasons. Complying with such requests may prove costly, and may create complexities surrounding the manufacturing of the kits, compliance with regulatory authorities, blood center usage, or inventory management. Conversely, failure to comply with such requests from customers may result in damage to our relationship or the potential loss of customer business.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market adoption of our products is affected by blood center and healthcare facility budgets and the availability of reimbursement from governments, managed care payors, such as insurance companies, and/or other third parties. In many jurisdictions, due to the structure of the blood products industry, we have little control over budget and reimbursement discussions, which generally occur between blood centers, healthcare facilities such as hospitals, and national or regional ministries of health and private payors. Even if a particular blood center is prepared to adopt the INTERCEPT Blood System, its hospital customers may not accept or may not have the budget to purchase INTERCEPT-treated blood products. Since blood centers would likely not eliminate the practice of screening donors or testing blood for some pathogens prior to transfusion, even after implementing our products, some blood centers may not be able to identify enough cost offsets or hospital pricing increases to afford to purchase our products. Budgetary concerns may be further exacerbated by economic legislation in certain countries and by proposals by legislators at both the federal and, in some cases, state levels, regulators, healthcare facilities and third-party payors to keep healthcare costs down, which may limit the adoption of new technologies, including our products. In some jurisdictions, commercial use of our products may not be covered by governmental or commercial third-party payors for health care services and may never be covered. Even if we received national reimbursement for our products, we may not be able to convince blood center customers to change their operating practices and produce INTERCEPT-treated platelets and plasma. In the U.S., we obtained HCPCS reimbursement codes for INTERCEPT-treated platelets and plasma in the outpatient setting in 2015. The costs and expenses incurred by the blood center related to donor blood are typically included in the price that the blood center charges a hospital for a unit of blood.&#160;Even after blood components treated with our products are approved for reimbursement by governmental or commercial third-party payors, including under HCPCS codes, the costs and expenses related to use of the INTERCEPT Blood System will not be directly reimbursed, but instead may be incorporated within the reimbursement structure for medical procedures and/or products at the site of patient care. Governmental or third-party payors may change reimbursement rates, year over year, or in reaction to submitted claims for reimbursement of costs and expenses related to blood components treated with INTERCEPT. If the costs to the hospital for INTERCEPT processed blood products cannot be easily, readily, or fully incorporated into the existing reimbursement structure, or if reimbursement rates are decreased in any given year for blood components treated with INTERCEPT, hospital billing and/or reimbursement for these products could be impacted, thus negatively impacting hospitals&#8217; acceptance and uptake of our products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market for the INTERCEPT Blood System is highly concentrated with few customers, including often-dominant regional or national blood collection entities. Even where our products receive regulatory approval and reimbursement is available, failure to effectively market, promote, distribute, price or sell our products to any of these customers could significantly delay or even diminish potential product revenue in those geographies. Moreover, the market for pathogen reduction systems in the U.S. is highly concentrated and dominated by a small number of blood collection organizations. In the U.S., the American Red Cross represents the largest single portion of the blood collection market. We cannot guarantee the long-term volume or timing of commercial purchases that the American Red Cross may make, if any, under our agreement. Our ability to gain significant market penetration in the U.S. is largely dependent on utilization of INTERCEPT and distribution of INTERCEPT-treated blood components by the American Red Cross. The American Red Cross is a large organization and broad-based utilization of INTERCEPT and distribution of INTERCEPT-treated products may be concentrated in a limited number of centers or may occur slowly, if at all. Conversely, given the large relative size of the American Red Cross, should they deploy the technology rapidly, our resources may be inadequate to fulfill the American Red Cross&#8217; and other customers&#8217; demands, which could result in a loss of product revenues or customer contracts, or both. In September 2019, the FDA issued a final guidance document, &#8220;Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion.&#8221; The guidance document requires all </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">blood collection facilities to comply with the options available under the guidance document, which includes the INTERCEPT </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lood </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ystem, for all platelet collections, no later than eighteen months from the issuance date. Blood centers may wait until later in the compliance grace period before beginning to take steps to implement INTERCEPT. Should </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the American Red Cross or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a large number of blood centers wait, we may not have sufficient resources or product available to allow customers to timely and successfully implement INTERCEPT before the end of the compliance grace period. Should we be unable to manufacture INTERCEPT in sufficient quantities in a timely manner, or have adequate resources to assist customer with implementing the INTERCEPT </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lood </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ystem, U.S. blood centers may be forced to use alternate options allowed by the guidance document, which could permanently impact our ability to convert those blood centers to INTERCEPT users.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f the COVID-19 crisis persists, customers may not be able to implement new technologies such as INTERCEPT and may instead</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> choose</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to utilize other allowable methods </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with which</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> they have more familiarity.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In many countries in Western Europe and in Japan, various national blood transfusion services or Red Cross organizations collect, store and distribute virtually all of their respective nations&#8217; blood and blood components supply. In Europe, the largest markets for our products are in Germany, France, and England. In Germany, decisions on product adoption are made on a regional or even blood center-by-blood center basis, but depend on both local approvals and centralized regulatory approvals from the Paul Ehrlich Institute, or PEI. Obtaining these approvals requires support and coordination from local blood centers, and may take a significant period of time to obtain, if ever. Product specifications that receive marketing authorization from the PEI may differ from product specifications that have been adopted in other territories where we rely on CE Mark approval, thereby necessitating market specific modifications to the commercial product, which may not be economical or technically feasible for us. Following the inclusion of pathogen-inactivated platelets for national reimbursement by the German Institute for the Hospital Remuneration System as of January 1, 2018, German customers who do not currently have an approved marketing authorization application, or MAA, will first need to obtain one before using our product. The review period for a new MAA can be up to twelve months or longer following submission and we cannot assure that any of the potential German customers submitting a new MAA will obtain it. Without broad approvals of MAA applications obtained by potential German customers, our ability to successfully commercialize INTERCEPT in Germany will be negatively impacted, which may adversely affect our results of operations and financial results. In addition, the reimbursement awarded to INTERCEPT in Germany may not be considered by German blood centers as attractive enough to implement pathogen reduction or cover the entirety of their blood center platelet collections which may in turn limit the market acceptance in Germany. Similar to the U.S., German blood centers will need to successfully market and sell to their hospital customers and understand and assist with the steps that are needed at the hospital level in Germany to administer pathogen-reduced platelets. Should German blood centers not adequately market and sell or assist their hospital customers or if hospitals object, or are slow implementing the steps needed to procure and administer pathogen reduced platelets, our market in Germany many be limited or be slow to realize acceptance.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, we entered into new agreements with EFS to supply illuminators and platelet and plasma disposable kits. The agreement for supply of illuminators and platelet disposable kits provided for a base term of two years, with two options for EFS to extend for one year each, the first of which, EFS exercised in 2019. In January 2020, we entered into a new agreement with EFS to supply plasma disposable kits and maintenance services for illuminators for a base term of two years, with two options for EFS to extend for one year each. While EFS has standardized production of its platelets using the INTERCEPT Blood System, we cannot provide any assurance that the national deployment of INTERCEPT to treat platelets in France will be sustainable or that we will be able to secure any subsequent contracts with EFS or that the terms, including the pricing or committed volumes, if any, of any future contract will be equivalent or superior to the terms under our current contract. If we are unable to continue to successfully support EFS&#8217; national adoption of the INTERCEPT Blood System for Platelets, EFS&#8217; use of the INTERCEPT Blood System for Plasma or the final commercial terms of any subsequent contract for platelet or plasma disposable kits are less favorable than the terms under our existing contracts, our financial results may be adversely impacted. Our contracts with EFS do not contain purchase volume commitments and as such, we may see variability in purchase levels or an altogether cessation. While EFS has exercised the first one-year extension option under the supply agreement for illuminators and platelet disposable kits, we cannot assure that EFS will exercise its remaining option under such agreement or under the supply agreement for plasma disposable kits, enter into a new longer-term agreement, or that EFS continue to use the INTERCEPT Blood System at historical levels or at all.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we understand that EFS is inspecting and testing samples of each lot that they purchase from us prior to accepting the products shipped to fulfill orders. We have little insight into the time to test, testing conditions or ultimate results. Other customers may require similar conditions of purchase. Testing may have a negative impact on our ability to recognize product revenue either due to the time it takes to test and approve the release of a shipment or if the customer experiences problems with testing or if testing results are outside of the customer acceptance criteria.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, the Japanese Red Cross controls a significant majority of blood transfusions and exerts a high degree of influence on the adoption and use of blood safety measures in Japan. The Japanese Red Cross has been reviewing preclinical and clinical data on pathogen reduction of blood over a number of years and has yet to make a formal determination to adopt any pathogen reduction approach. We also understand that the Japanese Red Cross has begun formal evaluation of a competing technology. Before the Japanese Red Cross considers our products, we understand that we may need to commit to making certain product configuration changes, which are currently under development but may not be economically or technologically feasible for us to accomplish.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant increases in demand may occur given the concentrated nature of many of the largest potential customers and the potential for a mandate by public health agencies to adopt pathogen reduction technologies. Should those customers choose to adopt and standardize their production on the INTERCEPT Blood System or be required to adopt and standardize on the INTERCEPT Blood System, our ability to meet associated increases in demand may be constrained due to a variety of factors, including supply issues, manufacturing disruptions, availability of disposable kits manufactured from the obsolete plastic materials in jurisdictions that have not approved the use of alternate plastics for our disposable kits, or other obsolescence of parts, among others. If we encounter such disruptions</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or supply shortages, we may have to allocate available products to customers, which could negatively impact our business and reputation or cause those customers to look for alternatives to the INTERCEPT Blood System.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to continue to generate losses.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never achieve a profitable level of operations. Our cost of product sold, research and development and selling, general and administrative expenses have resulted in substantial losses since our inception. The platelet and plasma systems have been approved in the U.S. only since December 2014 and are not approved in many countries around the world. Similarly, our extended-storage cryoprecipitate PMA supplement is not yet approved in the U.S. or anywhere else in the world. The red blood cell system is in the development stage and may never emerge from the development stage as a marketed product. We may be required to reduce the sales price for our products in order to make our products economically attractive to our customers and to governmental and private payors, or to compete favorably with other blood safety interventions or other pathogen reduction technologies, which may reduce or altogether eliminate any gross profit on sales. At our present and expected 2020 sales levels of the platelet and plasma systems, our costs to manufacture, distribute, market, sell, support the systems and develop new products are and are expected to continue to be in excess of our product revenue. We expect our losses to continue at least until we are able to gain widespread commercial adoption, which may never occur. We expect to invest in research and development costs as we pursue a PMA supplement for extended-storage cryoprecipitate and hire employees and possibly retain contract resources to build a specialized commercial effort to sell that product directly to hospitals. Even if we were to receive approval for a PMA supplement for extended-storage cryoprecipitate, we may not receive approval of label claims for all indications or for indications with the highest unmet need or for optimal market acceptance. We expect to incur additional research and development costs associated with the development of different configurations of existing product candidates and products including extended-storage cryoprecipitate and our illuminator, development of new products, planning, enrolling and completing ongoing clinical and non-clinical studies, including the post-approval studies we are required to conduct in connection with the FDA approval of the platelet system, pursuing potential regulatory approvals in other geographies where we do not currently sell our platelet and plasma systems, planning and conducting <span style="font-style:italic;">in vitro</span> studies and clinical development of our red blood cell system in Europe and the U.S., and completing activities to support a potential CE Mark approval for our red blood cell system in Europe. These costs could be substantial and could extend the period during which we expect to operate at a loss, particularly if we experience any difficulties or delays in completing the activities. Presently, we anticipate that the stress of COVID-19 on healthcare systems around the globe will negatively impact our ability to conduct clinical trials in the near term due primarily to the lack of resources at clinical trial sites and the resulting inability to enroll patients in these trials. For example, several of the hospital clinical trial sites for our RedeS and ReCePI studies have temporarily suspended enrollment and three out of four of the red blood cell production partners for the studies have suspended production in order to conserve red blood cells to meet hospital demand during the pandemic. The timing of other planned clinical trials has also been delayed due to the pandemic. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain countries, governments have issued regulations relating to the pricing and profitability of medical products and medical product companies. Healthcare reform in the U.S. has also placed downward pressure on the pricing of medical products that could have a negative impact on our profit margins.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adverse market and economic conditions may exacerbate certain risks affecting our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products are dependent on purchasing decisions of and/or reimbursement from government health administration authorities, distribution partners and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including the COVID-19 pandemic, disruptions due to political instability or terrorist attacks, economies and currencies largely affected by declining commodity prices or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may delay payment for the INTERCEPT Blood System. In addition, newly contracted or prospective customers may be unable to on-board, train staff and implement new technologies such as INTERCEPT due to the COVID-19 pandemic which would limit our ability to grow our business.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sales of our products in Europe and the Commonwealth of Independent States, or CIS countries are denominated in Euros and other non-U.S. currencies. As a result, we are exposed to foreign exchange risk, and our results of operations have been and will continue to be impacted by fluctuations in the exchange rate between the U.S. dollar and other currencies, in particular the Euro. In addition, there have been concerns for the overall stability and suitability of the Euro as a single currency given the economic and political challenges facing individual Eurozone countries. Continuing deterioration in the creditworthiness of Eurozone countries, the withdrawal of, or the announcement of the withdrawal of, one or more member countries from the European Union, or E.U., following the United Kingdom&#8217;s, or U.K.&#8217;s, referendum in which voters approved an exit from the E.U., or the failure of the Euro as a common European currency or an otherwise diminished value of the Euro could materially and adversely affect our product revenue.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, a meaningful amount of our product revenue has come from sales to distributor</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Russia</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other CIS countries</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as well as Middle Eastern markets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Weakness and/or instability in worldwide oil prices and the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing civil, political and economic disturbances in Russia, Turkey and Ukraine, and their spillover effect on surrounding areas, along with the impact of sanctions imposed against Russia by certain European nations and the U.S., </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may significantly devalue the Russian Ruble and other CIS currencies and have had and may continue to have a negative impact on the Russian and other CIS countries&#8217; economies, particularly if sanctions continue to be levied against Russia or are strengthened from those currently in place from either the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.U.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, U.S. or both. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, the current unprecedented weakness in oil demand and prices may negatively </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our existing and future business opportunities in oil dependent countries and may cause collection difficulties, declining prices or all of the above.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our agreement with our Russian and other CIS distributors calls for sales, invoicing and collections to be denominated in Euros, if significant sanctions continue or are strengthened, if new sanctions are imposed, the Russian economy and value of the Ruble or other CIS currencies may weaken, and our business in Russia and other CIS countries may be negatively impacted further or never recover to historical levels.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the Trump administration has recently imposed tariffs on certain U.S. imports, and Canada, the E.U., China and other countries have responded with retaliatory tariffs on certain U.S. exports. We cannot predict what effects these and potential additional tariffs will have on our business, including in the context of escalating trade tensions. However, these tariffs and other trade restrictions could increase our operating costs, reduce our gross margins or otherwise negatively impact our financial results. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, terrorist attacks and civil unrests in some of the countries where we do business, and the resulting need for enhanced security measures may impact our ability to deliver services, threaten the safety of our employees, and increase our costs of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our products, blood products treated with the INTERCEPT Blood System and we are subject to extensive regulation by domestic and foreign authorities. We will have to refile and obtain CE Mark approval under the MDR for all of our products and product candidates. If our preclinical and clinical data are not considered sufficient by a country&#8217;s regulatory authorities to grant marketing approval, we will be unable to commercialize our products and generate product revenue in that country. Our investigational red blood cell system requires extensive additional testing and development.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products, both those sold commercially and those under development are subject to extensive and rigorous regulation by local, state and federal regulatory authorities in the U.S. and by foreign regulatory bodies. These regulations are wide-ranging and govern, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">manufacturing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">storage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product safety&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">pre-market clearance or approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">sales and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">use standards and documentation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">conformity assessment procedures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product traceability and record keeping procedures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">post-launch surveillance and post-approval studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">quality&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">advertising and promotion&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product import and export&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">reimbursement.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products must satisfy rigorous standards of safety and efficacy and we must adhere to quality standards regarding manufacturing and customer-facing business processes in order for the FDA and international regulatory authorities to approve them for commercial use. For our product candidates, we must provide the FDA and international regulatory authorities with preclinical, clinical and manufacturing data demonstrating that our products are safe, effective and in compliance with government regulations before the products can be approved for commercial sale. The process of obtaining required regulatory approvals is expensive, uncertain and typically takes a number of years. We may continue to encounter significant delays or excessive costs in our efforts to secure necessary approvals or licenses, or we may not be successful at all. In addition, our labeling claims may not be consistent across markets. We have developed our products with the aim to standardize the volume of platelets treatable by our system, wherever possible, which may not be accepted by all regulators or customers, may require additional data to support approval or may not produce optimal transfusable blood components. For example, jurisdictions differ in the definition of what constitutes a transfusable unit of platelets and in certain jurisdictions, our approved label claims and the definition of a viable platelet unit for transfusion may allow for a significantly lower or higher platelet count per volume than certain jurisdictions may allow. This variability in platelet count per volume may result in differences in platelet quality once processed and stored using INTERCEPT, and if customers experience sub-optimal platelet quality following INTERCEPT treatment, they may limit their adoption of INTERCEPT or consider adoption of competing blood safety technologies over INTERCEPT. In addition, our approved labels from the FDA limit our current approvals to certain platelet collection platforms and a particular storage solution for the particular collection platform. For instance, our FDA approved claims permit apheresis collection of platelets on the Fresenius Amicus device while stored in an additive solution or for apheresis collection of platelets collected on the Terumo Trima device and stored in 100% plasma. While we and the manufacturers are generating data to support expansion of the approved claims for INTERCEPT-treated platelets collected on and used with additional storage solutions, we cannot assure you that the data generated will be acceptable to the FDA. Such discrepant collection methodologies and storage solutions and conditions also exist for red blood cells. We may be required to provide the FDA with data for each permutation for which blood banking treatment practices exist which may be time consuming, costly and limit the potential size of the U.S. market that can use our products. In addition, in order to generate data that would be satisfactory to the FDA, we need to test our products with different blood center production configurations producing otherwise saleable products for the blood center. As such, we will generally need to purchase blood components which are expensive and may be limited during periods of low availability. For example, we continue to experience such availability constraints for platelets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and expect even more constraints on availability during the COVID-19 pandemic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Any such inability to procure blood components at a reasonable price, or at all, to conduct studies in order to generate data sufficient for label claim expansions may negatively impact our business opportunities.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical and Preclinical</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are particularly expensive and have a high risk of failure. Any of our trials may fail or may not achieve results sufficient to attain market acceptance, which could prevent us from achieving profitability. We do not know whether we will begin or complete clinical trials on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a study, delays in reaching agreement on acceptable clinical study agreement terms with prospective clinical sites, delays in obtaining institutional review board, ministry of health or ethics committee approval to conduct a study at a prospective clinical site, delays in recruiting subjects to participate in a study, delays in the conduct of the clinical trial by personnel at the clinical site or due to our inability to actively and timely monitor clinical trial sites because of travel restrictions, extreme weather or other natural forces, terrorist activity or general concerns over employee safety. In addition, during the current COVID-19 pandemic, several of the hospital clinical trial sites for our RedeS and ReCePI have temporarily suspended the studies and three out of four of the red blood cell production partners for the studies have suspended production in order to conserve red blood cells to meet hospital demand during the pandemic. We have restricted travel by our employees in states that are subject to mandatory stay-at-home orders and may again in the future need to restrict travel to certain clinical trial sites for monitoring site visits or to otherwise manage the trial. Significant delays in clinical testing could also materially impact our clinical trials. Some clinical sites for the RedeS study are located in areas that are also subject to disruption by severe weather such as flooding, hurricanes or other natural forces such as earthquakes, which have delayed enrollment and progress of the RedeS study in the past. We cannot be certain that further delays in the RedeS study or other clinical trials will not occur because of the pandemic or otherwise. Criteria for regulatory approval in blood safety indications are evolving, reflecting competitive advances in the standard of care against which new product candidates are judged, as well as changing market needs and reimbursement levels. Clinical trial design, including enrollment criteria, endpoints and anticipated label claims are thus subject to change, even if original objectives are being met. As a result, we do not know whether any clinical trial will result in marketable products. Typically, there is a high rate of failure for product candidates in preclinical studies and clinical trials and products emerging from any successful trial may not reach the market for several years.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment criteria for certain of our clinical trials may be quite narrow, further delaying the clinical trial process. For instance, clinical trials previously conducted using INTERCEPT-treated plasma for patients with thrombotic thrombocytopenic purpura lasted approximately four years due in part to the difficulties associated with enrolling qualified patients. In addition, enrollment criteria impacted the speed with which we were able to enroll patients in our European Phase 3 red blood cell system trial in chronic anemia patients, ReCePI trial, and may impact other studies. Consequently, we may be unable to recruit suitable patients into clinical trials on a timely basis, if at all, which may lead to higher costs or the inability to complete the clinical trials. We cannot rely on interim results of trials to predict their final results, and acceptable results in early trials might not be repeated in later trials. Any trial may fail to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produce results satisfactory to the FDA or foreign regulatory authorities. In addition, preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval. Negative or inconclusive results from a preclinical study or clinical trial, or adverse medical events during a clinical trial could cause a preclinical study or clinical trial to be repeated, require other studies to be performed or cause a program to be terminated, even if other studies or trials relating to a program are successful.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted many toxicology studies to demonstrate the safety of the platelet and plasma systems, and we have conducted and plan to conduct toxicology studies for the red blood cell system throughout the product development process. At any time, the FDA and other regulatory authorities may require further toxicology or other studies to further demonstrate our products&#8217; safety, which could delay or preclude regulatory approval and commercialization. In addition, the FDA or foreign regulatory authorities may alter guidance at any time as to what constitutes acceptable clinical trial endpoints or trial design, which may necessitate a redesign of our product or proposed clinical trials and cause us to incur substantial additional expense or time in attempting to gain regulatory approval. Regulatory agencies weigh the potential risks of using our pathogen reduction products against the incremental benefits, which may be difficult or impossible to quantify.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any additional product candidates receive approval for commercial sale in the U.S., or if we obtain approval for expanded label claims for the platelet system or plasma system, the FDA may require one or more post-approval clinical or <span style="font-style:italic;">in vitro</span> studies as a condition of approval, such as the post-approval clinical study we are conducting in connection with the approval of the platelet system and the additional post-approval study that we are required to conduct on recovery and survival of platelets suspended in 100% plasma in connection with the expanded label claim that we received for the platelet system. Each of these studies and any additional studies that the FDA may require could involve significant expense and may require us to secure adequate funding to complete. In addition, enrollment of post-marketing studies may be difficult to complete timely if customers of blood centers are reluctant to accept conventional, non-INTERCEPT-treated products once INTERCEPT products become available to them. Other regulatory authorities outside of the U.S. may also require post-marketing studies. Governments or regulatory authorities may impose new regulations or other changes or we may discover that we are subject to additional regulations that could further delay or preclude regulatory approval and subsequent adoption of our potential products. We cannot predict the adoption, implementation or impact of adverse governmental regulation that might arise from future legislative or administrative action. In September 2019, the FDA issued a final guidance document, &#8220;Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion,&#8221; requiring all blood collection facilities to comply with the options available under the guidance document for all platelet collections. Our INTERCEPT Blood System for platelets is an approved option for blood centers to meet the guidance document requirements. However, we do not yet have approved label claims for all platelet processing standards. Our inability to meet such operational or processing constraints may impair our potential results permanently or until we are able to obtain such claims, or customers may be forced to choose alternative options to comply with the guidance document by the end of the eighteen month compliance grace period, March 31, 2021. Should that occur, we may be unable to subsequently convert blood centers to INTERCEPT Blood System for platelets which would limit our market potential. In addition, we do not know what effect, if any, the COVID-19 pandemic will have on blood centers abilities to comply with the guidance document or if the FDA will continue to enforce the compliance date of March 2021. If the COVID-19 crisis persists, customers may not be able to implement new technologies such as INTERCEPT and may instead choose to utilize other allowable methods with which they have more familiarity.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., regulations vary by country, including the requirements for regulatory and marketing approvals or clearance, the time required for regulatory review and the sanctions imposed for violations. In addition to CE Mark documentation, countries outside the E.U. may require clinical data submissions, registration packages, import licenses or other documentation. Regulatory authorities in Japan, China, Taiwan, South Korea, Vietnam, Thailand, Singapore and elsewhere may require in-country clinical trial data, among other requirements, or that our products be widely adopted commercially in Europe and the U.S., or may delay such approval decisions until our products are more widely adopted. In addition to the regulatory requirements applicable to us and to our products, there are regulatory requirements in several countries around the world, including the U.S., Germany, Canada, Austria, Australia and other countries, applicable to prospective customers of INTERCEPT Blood System products and the blood centers that process and distribute blood and blood products. In those countries, blood centers and other customers are required to obtain approved license supplements from the appropriate regulatory authorities before making available blood products processed with our pathogen reduction systems to hospitals and transfusing physicians. Our customers may lack the resources or capability to obtain such regulatory approvals. In Germany, blood centers need to obtain marketing authorizations before they can submit for reimbursement or sell to hospitals. Significant product changes or changes in the way customers use our products may require amendments or supplemental approvals to licenses already obtained. Blood centers that do submit applications, supplements or amendments for manufacturing and sale may face disapproval or delays in approval that could further delay or deter them from using our products. The regulatory impact on potential customers could slow or limit the potential sales of our products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Red Blood Cell System</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we submitted for CE Mark approval of our red blood cell system, it has not been approved or commercialized anywhere in the world. Significant development and financial resources will be required to progress the red blood cell system into a commercially viable product and to obtain the necessary regulatory approvals for the product. Final development of the red blood cell system may </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never occur and failure can occur any time during the process. Any failure or delay in completing the development activities for the red blood cell system would prevent or delay its commercialization, which could materially and adversely affect our business, financial condition, results of operations, growth prospects and potential future market adoption of any of our products, including the red blood cell system. Many of the factors described above that can contribute to the failure or delay of a clinical trial could impact the trials we conduct for our red blood cell system. Even if we are successful in earlier clinical trials, the results of those early trials may not be predictive of results obtained in later and larger clinical trials of the red blood cell system or the results of routine use if we are able to commercialize the red blood cell system. In those cases, the FDA or foreign regulatory agencies may require us to conduct additional clinical trials or further studies or analysis which may be costly and time-consuming. Furthermore, regulators may require clinical data for our red blood cell system under each collection and processing method using various additive or storage solutions before they would grant approval for any such configuration. The clinical data we have generated thus far and submitted for CE Mark approval does not support multiple configurations of collection processes, storage solutions and kits. If we are required to and are ultimately unable to collect data under each configuration or if we limit our pursuit of certain configurations over others, our market opportunity may be limited. In some instances, we are relying on contract research organizations and other third parties to assist us in designing, managing, monitoring and otherwise carrying out our clinical trials and development activities for the red blood cell system. We do not control these third parties and, as a result, they may not treat our activities as their highest priority, or in the manner in which we would prefer, which could result in delays, inefficient use of our resources and could distract personnel from other activities. Additionally, if we, our contract research organizations, other third parties assisting us or our study sites fail to comply with applicable good clinical practices, the clinical data generated in our trials may be deemed unreliable and the FDA or foreign regulatory agencies may require us to perform additional clinical trials before approving the red blood cell system for commercialization. We cannot assure you that, upon inspection, regulatory agencies will determine that any of our clinical trials comply with good clinical practices. In addition, our clinical trials must be conducted with product produced under the FDA&#8217;s cGMP regulations and similar regulations outside of the U.S. Our failure or the failure of our product manufacturers to comply with these regulations may require us to repeat or redesign clinical trials, which would delay the regulatory approval process.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we understand that a source chemical produced by a supplier to our contract manufacturer which uses the source chemical to produce a reagent for our red blood cell system, potentially experienced discrepancies in its quality management system. If these discrepancies cannot be mitigated by other means, it could negatively impact the usability of data generated in our clinical and in vitro studies which used that reagent or limit our ability to timely complete ongoing clinical trials. We must be able to demonstrate stability of our active compounds manufactured under cGMP which meets release specifications. We have not been able to demonstrate that our product manufacturers or we are able to meet those requirements. If we are unable to demonstrate an ability to manufacture according to our specifications under cGMP with acceptable stability data, we may be unable to satisfy regulatory questions and requirements which could prevent or delay the potential approval of or our ability to commercialize the red blood cell system. In addition, existing lots of these red blood cell compounds manufactured under cGMP may be dispositioned by regulators or ourselves as unsuitable for either commercial or clinical use which would impact our ability to produce INTERCEPT-treated red blood cells for ongoing and future clinical trials and may require changes to the manufacturing process of our red blood cell compounds or new production of the compounds, all of which would be costly and time consuming and impact our ability to perform under our contract with the Biomedical Advanced Research and Development Authority, or BARDA. Following bankruptcy of one of our suppliers, we do not currently have a qualified manufacturer to produce a key reagent compound for our red blood cell system beyond our existing inventory levels, which are in insufficient quantity to complete our clinical trials or launch a product commercially. While we are in the process of identifying and qualifying manufacture</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s of our red blood cell reagent, qualification of any alternate supplier will be time consuming and may cause delay in obtaining regulatory approval or commercialization and will cause us to incur additional cost.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we are currently in the process of negotiating a commercial supply agreement with the manufacturer of the processing kits used in the red blood cell clinical trials. If we are unable to reach agreement on terms, our ability to complete the RedeS and ReCePI studies and any future Phase 3 clinical trials may be adversely impacted. There can be no guarantee that we will reach agreement or that, if an agreement is reached, that it will be on terms favorable to us.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also understand that stricter regulations are being considered for certain raw materials used in our red blood cell processing sets. Should such regulations be enacted we may need to qualify alternate plastics which comply with the stricter regulations which may be costly and time consuming.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2003, we terminated Phase 3 clinical trials evaluating a prior generation of the red blood cell system in acute and chronic anemia patients. The trials were terminated due to the detection of antibody reactivity to INTERCEPT-treated red blood cells in two patients in the 2003 chronic anemia trial. Although the antibody reactivity was not associated with any adverse events, we developed process changes designed to diminish the likelihood of antibody reactivity in red blood cells treated with our modified process. In a subsequent Phase 1 clinical trial that we initiated in the fourth quarter of 2008 to evaluate recovery and survival of treated red blood cells with the modified process, there were no adverse events reported. Based on the results from that trial, we obtained approval for and commenced two Phase 3 clinical trials in Europe using the modified process in patients with acute and chronic anemia, respectively. We successfully completed the European Phase 3 acute anemia clinical trial and the European Phase 3 chronic anemia clinical trial, with the INTERCEPT Blood System for red blood cells meeting its primary efficacy and safety endpoints in both trials. However, we cannot assure you that the adverse events observed in the terminated 2003 Phase 3 clinical trials of our earlier red blood cell system will not be observed in the future. In addition, although our completed European Phase 3 clinical trials in acute anemia patients and chronic anemia patients using our modified process met their primary endpoints, we cannot assure you that the same or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar results will be observed in current and potential future clinical trials using our modified process. We cannot assure that patients receiving INTERCEPT-treated red blood cells will not develop allergic reactions to the transfusion.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to successfully conduct and complete license enabling Phase 3 clinical trials in the U.S. and to define a pathway toward generating sufficient chronic anemia data with the FDA for licensure. Prior to the COVID-19 pandemic, we were enrolling patients in two Phase 3 clinical trials in the U.S. However, as a result of the pandemic, enrollment in those clinical trials has been temporarily suspended at many of our hospital clinical trial sites and many blood centers have stopped producing INTERCEPT-treated red blood cells. Even prior to the pandemic, our ReCePI study in complex cardiovascular surgery patients had been slower to enroll due to a variety of factors including low frequency of administering red blood cells to the patient population. If we are unable to enroll a sufficient number of patients from the ReCePI study to generate the data needed for licensure, we will need to reach agreement with the FDA on a new pathway to generate sufficient data, including the potential for additional Phase 3 clinical trials beyond what is currently contemplated with the RedeS and ReCePI studies and in chronic anemia patients. Given the need to phenotypically match donations and patients and the existing burden of managing the production and supply to sickle-cell anemia patients, donor recruitment in a potential additional Phase 3 clinical trial in chronic anemia patients may be difficult or impractical, which could significantly delay or preclude our ability to obtain any FDA approval of our red blood cell system. In any event, there can be no assurance that we will be able to successfully complete these perquisite Phase 3 clinical trials or otherwise generate sufficient Phase 3 clinical data, nor can there be any assurance that we and the FDA will agree to any trial protocol we propose or that we will otherwise obtain FDA clearance to initiate an additional Phase 3 clinical trial. In part, we will seek to introduce supplemental clinical data we obtained from European clinical trials, though we cannot assure you that we will be able to demonstrate comparability or that the FDA will allow supplemental clinical European data. The FDA has recently agreed to modify the criteria for a clinical pause in the RedeS study if we see three or more treatment emergent antibodies with amustaline specificity without evidence of hemolysis in patients receiving INTERCEPT-treated red blood cells in that study. We will now be allowed to continue study enrollment for the RedeS study while we investigate the clinical significance of the antibodies. If we determine that there is no clinical significance and no impact on patients, then there will be no impact on study enrollment. If treatment emergent antibody reactions associated with hemolysis are observed in any of our Phase 3 trials, the FDA will require us to place a clinical hold and we will need to investigate the underlying cause, which in many patient populations may be difficult for us to assess imputability which may lead to a complete halt of the clinical trial, may irreparably harm our red blood cell product&#8217;s reputation and <span style="color:#000000;">may force us to suspend or terminate development activities related to the red blood cell system in the U.S</span>., which would have a material adverse effect on our business and business prospects. Should we see events where antibodies to amustaline (S-303) are formed without evidence of hemolysis, the Data and Safety Monitoring Board, or DSMB, and we will need to assess the underlying information and either agree to continue the study or either delay completion of the study or permanently halt the study until we can demonstrate that the antibodies were not clinically significant. To date, two S-303 antibody events without evidence of hemolysis have been detected in the RedeS study. We do not yet know if the S-303 antibody events were in the control or test arm, however the events are not clinically significant. These events have been reviewed by the DSMB who did not express concerns with respect to patient safety. In addition, if we are unable to generate sufficient perquisite Phase 3 clinical data and/or reach agreement with the FDA on a Phase 3 clinical trial design for our red blood cell system, our agreement with BARDA will be severely limited in scope or could be terminated altogether, and our ability to complete the development activities required for licensure in the U.S. may require additional capital beyond that which we currently have. In addition, if the COVID-19 pandemic persists and does not allow us to make progress against the initiatives reimbursed by our BARDA contract, we will experience a negative impact to our planned cash flows and may be forced to furlough or lay off employees<span style="color:#000000;"> which would likely prove disruptive to our management and operations</span>. <span style="color:#000000;">If alternative sources of funding are not available, we may be forced to suspend or terminate development activities related to the red blood cell system in the U.S</span>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed our European Phase 3 clinical trials of our red blood cell system for acute anemia patients and separately for chronic anemia patients. We filed our application for CE Mark approval of the red blood cell system in December 2018 under the MDD, and understand that we will have to re-file under the new MDR from the existing MDD. Accordingly, we do not expect to receive any regulatory approvals of our red blood cell system prior to 2022, if ever. We do not yet know whether the data generated from our European Phase 3 clinical trials will be sufficient to receive CE Mark approval. Furthermore, we do not yet know if the clinical data we have generated will be sufficient to satisfy the stricter standards imposed by the MDR, when we transition to that standard. If such data is deemed insufficient, we may need to generate additional safety data in clinical trials to satisfy the MDR standards. We may also need to generate additional safety data from commercial use in order to achieve broad market acceptance. In addition, the European Phase 3 clinical trials in acute, and separately, chronic anemia patients, may need to be supplemented by additional, successful Phase 3 clinical trials for approval in certain countries. If such additional Phase 3 clinical trials are required, they would likely need to demonstrate equivalency of INTERCEPT-treated red blood cells compared to conventional, un-treated red blood cells and the significantly lower lifespan for INTERCEPT-treated red blood cells compared to conventional, un-treated red blood cells may limit our ability to obtain any regulatory approvals in certain countries for the red blood cell system. A number of trial design issues that could impact efficacy, regulatory approval and market acceptance will need to be resolved prior to the initiation of further clinical trials. In addition, if we are unable to secure the full amount of funding contemplated by the BARDA agreement for any reason, or if the costs to complete the activities are more than allowed for by our BARDA agreement, our ability to complete the development activities required for potential licensure in the U.S. may require additional capital beyond that which we currently have, and we may be required to obtain additional capital in order to complete the development of and obtain any regulatory approvals for the red blood </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cell system.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Further, </span><span style="letter-spacing:-0.1pt;">while we believe that our available cash and cash equivalents and short-term investments, as well as cash to be received from product sales and under our agreement with BARDA, will be sufficient to meet our capital requirements for at least the next twelve months,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if we are unable to generate sufficient product revenue, or access sufficient funds under our BARDA agreement or the public and private equity and debt capital markets, we may be unable to execute successfully on our operating plan. </span><span style="color:#000000;">If alternative sources of funding are not available, we may be forced to suspend or terminate development activities related to the red blood cell system in the </span><span style="color:#000000;">U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which would have a material adverse effect on our business and business prospects. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in advancing the red blood cell system through clinical trials, resolving process and product design issues or in obtaining subsequent regulatory approvals and acceptable reimbursement rates, we may never realize a return on our R&#38;D expenses incurred to date for the red blood cell system program. Regulatory delays can also materially impact our product development costs. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we experience delays in testing, conducting trials or approvals, our product development costs will increase</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which costs may not be reimbursable to us under the BARDA agreement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Even if we were to successfully complete and receive approval for our red blood cell system, potential blood center customers may object to working with a potent chemical, like amustaline, the active compound in the red blood cell system, or may require modifications to automate the process, which would result in additional development costs, any of which could limit any market acceptance of the red blood cell system. If the red blood cell system were to face such objections from potential customers, we may choose to pay for capital assets, specialized equipment or personnel for the blood center, which would have a negative impact on any potential contribution margin from red blood cell system sales.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the use of the red blood cell system may result in some processing loss of red blood cells. If the loss of red blood cells leads to increased costs, or the perception of increased costs for potential customers, or potential customers believe that the loss of red blood cells reduces the efficacy of the transfusion unit, or our process requires changes in blood center or clinical regimens, potential customers may not adopt our red blood cell system even if approved for commercial sale.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Platelet and Plasma Systems</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2007, we obtained a CE Mark approval from E.U. regulators for our platelet system under the MDD and have subsequently received periodic extensions in accordance with the five-year renewal schedule. In March 2020, we received an extension of the CE Mark approval to 2024, under the MDD. While we currently received an extension of registration under the MDD, we cannot assure you that our products will timely meet the requirements of the new MDR prior to the expiration of the MDD extension. We or our customers have received approval for the sale and/or use of INTERCEPT-treated platelets within Europe in France, Switzerland, Germany and Austria. We or our customers may also be required to conduct additional testing in order to obtain regulatory approval in countries that do not recognize the CE Mark as being adequate for commercializing the INTERCEPT Blood System in those countries. The level of additional product testing varies by country, but could be expensive or take a long time to complete. In addition, regulatory agencies are able to withdraw or suspend previously issued approvals due to changes in regulatory law, our inability to maintain compliance with regulations or other factors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, we obtained a CE Mark approval from E.U. regulators for our plasma system under the MDD and have subsequently received periodic extensions in accordance with the five-year renewal schedule. In March 2020, we received an extension of the CE Mark approval to 2024, under the MDD. While we currently received an extension of registration under the MDD, we cannot assure you that our products will timely meet the requirements of the new MDR prior to the expiration of the MDD extension. We or our customers have received approval for the sale and/or use INTERCEPT-treated plasma within Europe in France, Switzerland, Germany and Austria. In some countries, including several in Europe, we or our customers may be required to perform additional clinical studies or submit manufacturing and marketing applications in order to obtain regulatory approval. If we or our customers are unable to obtain or maintain regulatory approvals for the use and sale or continued sale and use of INTERCEPT-treated platelets or plasma, market adoption of our products will be negatively affected and our growth prospects would be materially and adversely impacted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has approved the platelet system for <span style="font-style:italic;">ex vivo</span> preparation of pathogen-reduced apheresis platelet components collected and stored in InterSol and 100% plasma in order to reduce the risk of transfusion-transmitted infection, or TTI, including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease, or TA-GVHD. Additionally, the FDA approved the plasma system for <span style="font-style:italic;">ex vivo</span> preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of TTI when treating patients requiring therapeutic plasma transfusion and as an alternative to gamma irradiation for prevention of TA-GVHD. We have conducted and are conducting additional <span style="font-style:italic;">in vitro</span> studies for our platelet system to potentially expand our label claims to include, among others, platelets collected from pooled random donors, storage of INTERCEPT-treated platelets for up to seven days rather than five days, and a new processing set for triple dose collections. Failure to obtain any of these label expansion claims may negatively affect market adoption and our growth prospects would be materially and adversely affected.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition to the initial FDA approval of the platelet system, we are required to conduct a post-approval clinical study of the platelet system. Successful enrollment and completion of this study requires that we maintain sufficient INTERCEPT production capabilities with U.S. blood center customers. Delays in supplying INTERCEPT products to blood centers that are providing INTERCEPT-treated platelets to hospitals involved in the study may lead to increased costs to us and may jeopardize our ability to complete the study in a timeframe acceptable to the FDA. Furthermore, blood centers&#8217; ability to produce INTERCEPT-treated platelets and supply hospitals enrolled in the study may be negatively impacted by a shortage of overall platelet availability, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constraints in producing platelets in compliance with our approved claims or operational inefficiencies experienced as a result of INTERCEPT treatment. In addition, we must engage with hospitals that have the desire and ability to participate and contribute to the study in a timely manner and who are willing to purchase INTERCEPT-treated platelets from our blood center customers. If we are unable to complete this study, in a timely manner or at all, or the results of this study reveal unacceptable safety risks, we could be required to perform additional studies, which may be costly, and even lose U.S. marketing approval of the platelet system. Further, we are required to conduct a post-approval recovery and survival clinical study in connection with the label expansion approval for the use of the platelet system to treat platelets suspended in 100% plasma. Successful enrollment and completion of this additional study will also require that we identify and contract with hospitals that have the desire and ability to participate and contribute to the study in a timely manner and who are willing to purchase INTERCEPT-treated platelets from our blood center customers. We have recently learned that there may be a shortage of the radiolabel used for platelet recovery and survival studies. If our study sites are not able to secure sufficient supply of the radiolabel, we will not be able to complete enrollment timely, if at all.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, most activities under this study have been suspended as a result of the current COVID-19 pandemic.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If we are unable to complete this study, in a timely manner or at all, or the results of this study reveal unacceptable safety risks, we could be required to perform additional studies, which may be costly. In addition to these studies, the FDA may also require us to commit to perform other lengthy post-marketing studies, for which we would have to expend significant additional resources, which could have an adverse effect on our operating results, financial condition and stock price. In addition, there is a risk that these studies will show results inconsistent with our previous studies. Should this happen, potential customers may delay or choose not to adopt the INTERCEPT Blood System and existing customers may cease use of the INTERCEPT Blood System.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Marketing Approval</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also required to continue to comply with applicable FDA and other regulatory requirements now that we have obtained approval for the INTERCEPT Blood System for platelets and plasma. These requirements relate to, among other things, labeling, packaging, storage, advertising, promotion, record-keeping and reporting of safety and other information. In addition, our manufacturers and their facilities are required to comply with extensive FDA and foreign regulatory agency requirements, including, in the U.S., ensuring that quality control and manufacturing procedures conform to cGMP and current QSR requirements. As such, we and our contract manufacturers are subject to continual review and periodic inspections. We understand that the manufacturing facility which produces our platelet and plasma systems will be audited by the FDA in the near term. We and our contract manufacturers will need to satisfactorily resolve and comply with adverse findings of the audit, if any. Complying with and resolving any audit findings may result in additional costs, changes to our manufacturers quality management systems or both. Failure to timely resolve and comply to audit findings, if any, may result in enforcement actions and may result in a disruption to the supply of our products. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We are required to report certain adverse events and production problems, if any, to the FDA and foreign regulatory authorities, when applicable, and must additionally comply with requirements concerning advertising and promotion for our products. For example, our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion of unapproved, or off-label, use. If the FDA determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an off-label use, or a violation or any other federal or state law that applies to us, such as laws prohibiting false claims for reimbursement. Any enforcement action brought by a federal, state or foreign authority could result in significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, administrative burdens, and diminished profits and future earnings. In addition, our reputation could be damaged and adoption of the products could be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. In addition, the off-label use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend, divert our management&#8217;s attention, result in substantial damage awards against us and harm our reputation. Regulatory authorities may also challenge the classification of our approvals for our products. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should a regulatory agency question a reported adverse event, we may not be able to rule out product failure as the cause, whether or not product failure is the cause of the reported adverse event. If a regulatory agency suspects or discovers problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility or the manufacturing process at the facility where the product is manufactured, or problems with the quality of product manufactured, or disagrees with the promotion, marketing, or labeling of a product, a regulatory agency may impose restrictions on use of that product, including requiring withdrawal of the product from the market. Our failure to comply with applicable regulatory requirements could result in enforcement action by regulatory agencies, which may include any of the following sanctions:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">repair, replacement, recall or seizure of our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">operating restrictions or partial suspension or total shutdown of production&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">delaying or refusing our requests for approval of new products, new intended uses or modifications to our existing products and regulatory strategies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal to grant export or import approval for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">withdrawing marketing approvals that have already been granted, resulting in prohibitions on sales of our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">criminal prosecution.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these actions, in combination or alone, could prevent us from selling our products and harm our business. In addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing or changing regulatory requirements may significantly and adversely affect our ability to successfully commercialize and generate additional product revenues from our platelet and plasma systems or any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to continue to generate product revenues from the sale of our platelet and plasma systems, our potential for achieving operating profitability will be diminished and the need for additional capital to fund our operations will be increased.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should we obtain approval of our red blood cell system, we will likely be required by regulators to collect additional data in patients receiving INTERCEPT-treated red blood cells. In addition, we may be required to develop a registry of patients receiving INTERCEPT-treated red blood cells for future data collection and evaluation. Should we become subject to such a requirement post-approval, we may incur significant costs to develop, create and implement such a registry. Further, introducing and implementing use of such a registry may face data collection challenges or resistance from transfusing physicians, hospitals or patients. We cannot ensure that the data collected in such a registry would support continued use of INTERCEPT-treated red blood cells.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, increased operation costs or lower than anticipated sales. For instance, we understand that we will have to re-register our CE Marked products under the new MDR, (as required by all manufacturers who sell in Europe under a CE Mark), while we anticipate this will be a formality, there is always a possibility of new requirements. Complying with the new MDR will require considerable time, attention and effort by our manufacturers and us and may limit or delay any contemplated changes to our products or expansion of label claims.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A significant portion of the funding for the development of the red blood cell system is expected to come from our BARDA agreement, and if BARDA were to eliminate, reduce or delay funding from our agreement, this could have a significant, negative impact on our revenues and cash flows, and we may be forced to suspend or terminate our U.S. red blood cell development program or obtain alternative sources of funding. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that a significant portion of the funding for the development of the red blood cell system will come from our agreement with <span style="Background-color:#FFFFFF;">BARDA</span>. The agreement, including its subsequent modifications, provide for reimbursement of certain expenses incurred by us for up to approximately $213.9 million to support the development of the red blood cell system. However, our agreement with BARDA only reimburses certain specified development and clinical activities that have been authorized by BARDA pursuant to the base period <span style="color:#000000;">and certain options </span>of the agreement and the potential exercise of subsequent option periods. To date, BARDA has committed approximately $116.9 million under the base period of the agreement<span style="color:#000000;"> and options exercised</span>. Accordingly, our ability to receive any of the additional $97.0 million in funding provided for under the BARDA agreement is dependent on BARDA exercising additional options under the agreement, which it may do or not do at its sole discretion. In addition, BARDA is entitled to terminate our BARDA agreement for convenience at any time, in whole or in part, and is not required to provide continued funding beyond reimbursement of amounts currently incurred and obligated by us as a result of contract performance. In addition, activities covered under the base period and exercised options may ultimately cost more than is covered by the BARDA contract or require a longer performance period to complete than is remaining on our agreement&#59; if we are unable to secure additional funding or allow for </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional time for completion, we would have to incur additional costs to complete the activities or terminate the activities before completion. Moreover, the continuation of our BARDA </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depends in large part on our ability to meet development milestones previously agreed to with BARDA and on our compliance with certain operating procedures and protocols. BARDA may suspend or terminate the agreement should we fail to achieve key milestones, or fail to comply with the operating procedures and processes approved by BARDA and its audit agency. There can be no assurance that we will be able to achieve these milestones or continue to comply with these procedures and protocols. For instance, our RedeS study, which is being funded as part of our agreement with BARDA, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has been</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporarily suspended at some of our hospital clinical sites and blood centers producing INTERCEPT-treated red blood cells as a result of the COVID-19 pandemic. The study is being </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted in areas</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that are also</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subject to disruption </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due to</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> severe weather such as flooding or hurricane. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The uncertainty regarding the duration of the COVID-19 pandemic, and its impact on participating blood centers, hospitals and their patients, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">severe weather</span><span style="color:#000000;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other natural disaster impact</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to sites enrolling our clinical trials may </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negatively impact our ability to complete our clinical trials. Our ability to meet the expectations of BARDA under our contract is largely dependent on our ability to attract, hire and retain personnel with competencies that are in short supply. In addition, in many instances we must identify third-party suppliers, negotiate terms acceptable to us and BARDA and ensure ongoing compliance by these suppliers with the obligations covered by our BARDA agreement. If we are unable to provide adequate supplier oversight or if suppliers are unable to comply with the requirements of the agreement, our ability to meet the anticipated milestones may be impaired. There can also be no assurance that our BARDA </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will not be terminated, that our BARDA </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be extended through the exercise of subsequent option periods, that any such extensions would be on terms favorable to us, or that we will otherwise obtain the funding that we anticipate to obtain under our agreement with BARDA. Moreover, changes in government budgets and agendas may result in a decreased and deprioritized emphasis on supporting the development of pathogen reduction technology. If our BARDA </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is terminated or suspended, if there is any reduction or delay in funding under our BARDA </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or if BARDA determines not to exercise some or all of the options provided for under the agreement, our revenues and cash flows </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be significantly and negatively impacted and we may be forced to seek alternative sources of funding, which may not be available on non-dilutive terms, terms favorable to us or at all. If alternative sources of funding are not available, we may be forced to suspend or terminate development activities related to the red blood cell system in the U.S. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, should we be unable to deploy personnel or derive a benefit from fixed study costs or generate data from clinical sites and studies reimbursed by BARDA, our cash flows would be negatively impacted or we may have to initiate furloughs and layoffs which would likely prove disruptive to our management and operations. This in turn would impair our ability to recommence and complete studies if and when the COVID-19 crisis subsides and we are able to restart many suspended or delayed activities.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, u<span style="color:#000000;">nder the BARDA agreement, BARDA will regularly review our development efforts and clinical activities. Under certain circumstances, BARDA may advise us to delay certain activities and invest additional time and resources before proceeding. If we follow such BARDA advice, overall red blood cell program delays and costs associated with additional resources for which we had not planned may result. Also, the costs associated with following such advice may or may not be reimbursed by BARDA under our agreement. Finally, we may decide not to follow the advice provided by BARDA and instead pursue activities that we believe are in the best interests of our red blood cell program and our business, even if BARDA would not reimburse us under our agreement. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unfavorable provisions in government contracts, including in our contract with BARDA, may harm our business, financial condition and operating results.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government contracts typically contain unfavorable provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. For example, under our agreement with BARDA, the U.S. government has the power to unilaterally:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">audit and object to any BARDA agreement-related costs and fees on grounds that they are not allowable under the Federal Acquisition Regulation, or FAR, and require us to reimburse all such costs and fees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">suspend or prevent us for a set period of time from receiving new contracts or grants or extending our existing agreement based on violations or suspected violations of laws or regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">claim nonexclusive, nontransferable rights to product manufactured and intellectual property developed under the BARDA agreement and may, under certain circumstances involving public health and safety, license such inventions to third parties without our consent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">cancel, terminate or suspend our BARDA agreement based on violations or suspected violations of laws or regulations&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">t</span><span style="font-family:Times New Roman;">erminate our BARDA agreement </span><span style="font-family:Times New Roman;">in whole or in part for the convenience of the government for any reason or no reason, including if funds become unavailable to the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">reduce the scope and value of our BARDA agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">decline to exercise an option to continue the BARDA agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">direct the course of the development of the red blood cell system in a manner not chosen by us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">require us to perform the option periods provided for under the BARDA agreement even if doing so may cause us to forego or delay the pursuit of other red blood cell program opportunities with greater commercial potential&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">take actions that result in a longer development timeline than expected&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for the red blood cell program even after it has been funded for an initial period&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">change certain terms and conditions in our BARDA agreement.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, government contracts, including our agreement with BARDA, contain provisions permitting unilateral termination or modification, in whole or in part, at the U.S. government&#8217;s convenience. Termination-for-convenience provisions generally enable us to recover only our costs incurred or committed (plus a portion of the agreed fee) and settlement expenses on the work completed prior to termination. Except for the amount of services received by the government, termination-for-default provisions do not permit recovery of fees. In addition, in the event of termination or upon expiration of our BARDA agreement, the U.S. government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. government for denying certain payments under our BARDA agreement, such a challenge could subject us to substantial additional expenses that we may or may not recover. Further, if our BARDA agreement is terminated for convenience, or if we default by failing to perform in accordance with the contract schedule and terms, a significant negative impact on our cash flows and operations could result. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, government contracts normally contain additional requirements that may increase our costs of doing business and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">specialized accounting systems unique to government contracts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">public disclosures of certain contract information, which may enable competitors to gain insights into our research program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">mandatory internal control systems and policies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to the termination of our BARDA agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we have entered into and will continue to enter into agreements and subcontracts with third parties, including suppliers, consultants and other third-party contractors, in order to satisfy our contractual obligations under our BARDA agreement. Negotiating and entering into such arrangements can be time-consuming and we may not be able to reach agreement with such third parties. Any such agreement must also be compliant with the terms of our BARDA agreement. Any delay or inability to enter into such arrangements or entering into such arrangements in a manner that is non-compliant with the terms of our contract, may result in violations of our BARDA agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the unfavorable provisions in our BARDA agreement, we must undertake significant compliance activities. The diversion of resources from our development and commercial programs to these compliance activities, as well as the exercise by the U.S. government of any rights under these provisions, could materially harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Laws and regulations affecting government contracts, including our BARDA </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">agreement</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, make it more costly and difficult for us to successfully conduct our business. Failure to comply with these laws and regulations could result in significant civil and criminal penalties and adversely affect our business.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must comply with numerous laws and regulations relating to the administration and performance of our BARDA agreement. Among the most significant government contracting regulations are:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the FAR and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Statute, the Procurement Integrity Act, the False Claims Act and the U.S. Foreign Corrupt Practices Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">export and import control laws and regulations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">laws, regulations and executive orders restricting the exportation of certain products and technical data.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a U.S. government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Based on the results of its audits, the U.S. government may adjust our BARDA agreement-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contract prospectively. In addition, in the event BARDA determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our BARDA agreement, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us, which could cause our stock price to decline. In addition, under U.S. government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our third-party suppliers fail to comply with the FDA&#8217;s or other regulatory agency&#8217;s good manufacturing practice regulations, it could impair our ability to market our products in a cost-effective and timely manner.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to be used in clinical studies or sold in the U.S., our products are required to be manufactured in FDA-approved facilities. If any of our suppliers fail to comply with FDA&#8217;s cGMP regulations or otherwise fail to maintain FDA approval, we may be required to identify an alternate supplier for our products or components. For example, we understand that a source chemical produced by a supplier to our contract manufacturer which uses the source chemical to produce a reagent for our red blood cell system, potentially experienced discrepancies in its quality management system. If these discrepancies cannot be mitigated by other means, it could negatively impact the usability of data generated in our clinical and in vitro studies which used that reagent or limit our ability to timely complete ongoing clinical trials. Our products are complex and difficult to manufacture. Finding alternate facilities and obtaining FDA approval for the manufacture of the INTERCEPT Blood System at such facilities would be costly and time-consuming and would negatively impact our ability to generate product revenue from the sale of our platelet or plasma system in the U.S. and achieve operating profitability. Our red blood cell system also needs to be manufactured in FDA-approved facilities, several of which, are not currently FDA-approved. Failure of our suppliers to meet cGMP regulations and failure to obtain or maintain FDA approval will negatively impact our ability to achieve FDA approval for our red blood cell system or may require that we identify, qualify and contract with alternative suppliers, if they are available, which would be time consuming, costly and result in further approval delays.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our third-party suppliers are also required to comply with the cGMP and QSR requirements, which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. The FDA and other regulatory agencies audit compliance with cGMP and QSR requirements through periodic announced and unannounced inspections of manufacturing and other facilities. These audits and inspections may be conducted at any time. We understand that the manufacturing facility which produces our platelet and plasma systems will be audited by the FDA in the near term. If we or our suppliers fail to adhere to cGMP and QSR requirements, have significant non-compliance issues or fail to timely and adequately respond to any adverse inspectional observations or product safety issues, or if any corrective action plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA or other regulatory agency could take enforcement action against us, which could delay production of our products and may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">unanticipated expenditures to address or defend such actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">operating restrictions or partial suspension or total shutdown of production&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusing or delaying our requests for premarket approval of new products or modified products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">withdrawing marketing approvals that have already been granted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal to grant export or import approval for our products&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">criminal prosecution.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing actions could have a material adverse effect on our reputation, business, financial condition and operating results. Furthermore, our key suppliers may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, before any additional products would be considered for marketing approval in the U.S. or elsewhere, our suppliers will have to pass an audit by the FDA or other regulatory agencies. We are dependent on our suppliers&#8217; cooperation and ability to pass such audits. Such audits and any audit remediation may be costly. Failure to pass such audits by any of our suppliers would affect our ability to obtain licensure in the U.S. or elsewhere.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we modify our FDA-approved products, we may need to seek additional approvals, which, if not granted, would prevent us from selling our modified products.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any modifications to the platelet and plasma systems that could significantly affect their safety or effectiveness, including significant design and manufacturing changes, or that would constitute a major change in their intended use, manufacture, design, components, or technology requires approval of a new premarket approval application, or PMA, or PMA supplement. However, certain changes to a PMA-approved device do not require submission and approval of a new PMA or PMA supplement and may only require notice to FDA in a PMA Annual Report. The FDA requires every supplier to make this determination in the first instance, but the FDA may review any supplier&#8217;s decision. The FDA may not agree with our decisions regarding whether new submissions or approvals are necessary. Our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective or that appropriate regulatory submissions were not made. If new regulatory approvals are required, this could delay or preclude our ability to market the modified system. For example, due to the obsolescence of certain parts, we have redesigned the illuminators used in the platelet and plasma systems and may need to further redesign the illuminator. We will need to obtain regulatory approval of any future redesign of the illuminator before it can be commercialized in the U.S. or under CE Mark. Further, certain plastics used to make INTERCEPT disposable kits are no longer available. We have received CE Mark and FDA approval for our platelet and plasma products using the alternate plastics though we still need to qualify, validate and obtain approval for those plastics in other jurisdictions that require local regulatory approval before we can utilize them in worldwide commercial manufacturing. We also understand that a solvent used to make the plastic beads in our compound adsorption devices is no longer available and that a new material will need to be validated and approved by regulatory agencies before we can manufacture and sell our products with that new material. In addition, in order to address the entire market in the U.S., we will need to obtain approval for additional configurations of the platelet system, including triple dose collections and random donor platelets. Our approved labels from the FDA limit our current approvals to certain platelet collection platforms and a particular storage solution for the particular collection platform. For instance, our approved claims permit apheresis collection of platelets on the Fresenius Amicus device while stored in an additive solution or for apheresis collection of platelets collected on the Terumo Trima device and stored in 100% plasma. Such discrepant collection methodologies and storage solutions and conditions also exist for red blood cells. We may be required to provide the FDA with data for each permutation for which blood banking treatment practices exist which may be time consuming, costly and limit the potential size of the U.S. market that can use our products. We have conducted and may conduct additional <span style="font-style:italic;">in vitro</span> studies for our platelet system to potentially expand our label claims to include, among others, platelets collected from pooled random donors, storage of INTERCEPT-treated platelets for up to seven days rather than five days, and a new processing set for triple dose collections. Our failure to obtain FDA and foreign regulatory approvals of new platelet and plasma product configurations could significantly limit product revenues from sales of the platelet and plasma systems. In any event, delays in receipt or failure to receive approvals, the loss of previously received approvals, or the failure to comply with any other existing or future regulatory requirements, could reduce our sales and negatively impact our profitability potential and future growth prospects. In addition, if the FDA or other regulatory or accrediting body were to mandate safety interventions, including the option of pathogen reduction technology, when we had not received approval for all operational configurations, the market to which we could sell our products may be limited until we obtain such approvals, if ever, or may be permanently impaired if competing options are more broadly available. In addition, we may seek to expand use of our products under new PMA approvals or PMA supplements. For instance, we plan to perform <span style="font-style:italic;">in vitro</span> studies and seek a PMA supplement to use our plasma system to produce extended-storage cryoprecipitate and possibly for other plasma-derived biological plasma products. Even if we were to receive approval for a PMA supplement for extended-storage cryoprecipitate, we may not receive label claims for all indications or for indications with the highest unmet need or market acceptance. The market dynamics may require or we may choose to pursue a change in business model whereby we are selling the finished component to hospitals rather than an illuminator and disposable kit to blood centers. <span style="color:#000000;">While we are working </span>on implementing the infrastructure we believe will be necessary to market an approved extended-storage cryoprecipitate product directly to hospitals subsequent to potential regulatory approval of any PMA supplement that we may propose to submit to the FDA, we have no experience selling to hospitals nor do we </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have experience or expertise complying with regulations governing finished biologics. If we are unable to successfully market such products to hospitals or comply with unique regulations, our ability to monetize and deliver such products will be negatively impacted.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We operate a complex global commercial organization, with limited experience in many countries, including the U.S. We have limited resources and experience complying with regulatory, legal, tax and political complexities as we expand into new and increasingly broad geographies.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible for worldwide sales, marketing, distribution, maintenance and regulatory support of the INTERCEPT Blood System. If we fail in our efforts to develop or maintain such internal competencies or establish acceptable relationships with third parties to support us in these areas on a timely basis, our ability to commercialize the INTERCEPT Blood System may be irreparably harmed.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a wholly-owned subsidiary, headquartered in the Netherlands, dedicated primarily to selling and marketing the platelet and plasma systems in Europe, the CIS and the Middle East. Our commercial activities for the U.S., Latin and South America and Asia are based out of our headquarters in Concord, California with certain support from our European headquarters in the Netherlands, with certain individuals servicing Latin and South America and Asia, domiciled outside of the U.S. Our commercial organization focused on the U.S. market has limited resources and is relatively inexperienced, and as a result, has limited to no experience selling and marketing our platelet and plasma systems. Given the relatively concentrated customer base in the U.S., coupled with the FDA guidance document on platelet safety requiring all blood centers to comply by March 2021 by using a relatively small number of options, including INTERCEPT Blood System for platelets, should blood centers deploy INTERCEPT Blood System for platelets rapidly, our resources may be inadequate to fulfill the demands, which could result in a loss of product revenues or customer contracts, or both. We will need to maintain and may need to increase our competence and size in a number of functions, including sales, deployment and product support, marketing, regulatory, inventory and logistics, customer service, credit and collections, risk management, and quality assurance systems in order to successfully support our commercialization activities in all of the jurisdictions we currently sell and market, or anticipate selling and marketing, our products. Many of these competencies require compliance with U.S., E.U., South American, Asian and local standards and practices, including regulatory, legal and tax requirements, some of which we have limited experience. In this regard, should we obtain regulatory approval in an increased number of geographies, we will need to ensure that we maintain a sufficient number of personnel or develop new business processes to ensure ongoing compliance with the multitude of regulatory requirements in those territories. Hiring, training and retaining new personnel is costly, time consuming and distracting to existing employees and management. We have limited experience operating on a global scale and we may be unsuccessful complying with the variety and complexity of laws and regulations in a timely manner, if at all. In addition, in some cases, the cost of obtaining approval and maintaining compliance with certain regulations and laws may exceed the product revenue that we recognize from such a territory, which would adversely affect our results of operations and could adversely affect our financial condition. Furthermore, we may choose to seek alternative ways to sell or treat blood components with our products. These may include new business models, which may include selling kits to blood centers, performing inactivation ourselves, staffing blood centers or selling services or other business model changes. We have no experience with these types of business models, or the regulatory requirements or licenses needed to pursue such new business models. Additionally, such business models may be viewed as a threat to existing customers. We cannot assure you that we will pursue such business models or if we do, that we will be successful or that our existing customers will not feel threatened.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the result of a referendum in 2016, the U.K. left the E.U. on January 31, 2020, commonly referred to as &#8220;Brexit.&#8221; We may face new regulatory costs and challenges as a result of Brexit that could have a material adverse effect on our operations. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Altered regulations could add time and expense to the process by which our product candidates receive regulatory approval in the E.U. Given the lack of comparable precedent, it is unclear what financial, regulatory, trade and legal implications the withdrawal of the U.K. from the E.U. will have and how such withdrawal will affect us.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to market, sell, distribute and maintain our products and to maintain customer relationships in certain countries.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into distribution agreements, generally on a geographically exclusive basis, with distributors in certain regions. We rely on these distributors to obtain and maintain any necessary in-country regulatory approvals, as well as market and sell the INTERCEPT Blood System, provide customer and technical product support, maintain inventories, and adhere to our quality system in all material respects, among other activities. Generally, our distribution agreements require distributors to purchase minimum quantities in a given year over the term of the agreement. Failure by our distributors to meet these minimum purchase obligations may impact our financial results. In addition, failure by our distributors to provide an accurate forecast impacts our ability to predict the timing of product revenue and our ability to accurately forecast our product supply needs. While our contracts generally require distributors to exercise diligence, these distributors may fail to commercialize the INTERCEPT Blood System in their respective territories. For example, our distributors may fail to sell product inventory they have purchased from us to end customers or may sell competing products ahead of or in conjunction with INTERCEPT. In addition, initial purchases of illuminators or INTERCEPT disposable kits by these third parties may not lead to follow-on purchases of platelet and plasma systems&#8217; disposable kits. Agreements </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with our distributors typically require the distributor to maintain quality standards that are compliant with standards generally accepted for medical devices. We may be unable to ensure that our distributors are compliant with such standards. Further, we have limited visibility into the identity and requirements of blood banking customers these distributors may have. Accordingly, we may be unable to ensure our distributors properly maintain illuminators sold or provide quality technical services to the blood banking customers to which they sell. In addition, although our agreements with our distributors generally require compliance with local anti-corruption laws, the U.S. Foreign Corrupt Practices Act, and other local and international regulations, we have limited ability to control the actions of our distributors to ensure they are in compliance. Noncompliance by a distributor could expose us to civil or criminal liability, fines and/or prohibitions on selling our products in certain countries.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, a fairly concentrated number of distributors make up a significant portion of our product revenue and we may have little recourse, short of termination, in the event that a distributor fails to execute according to our expectations and contractual provisions. In the past, we have experienced weaker than expected growth due to declining performance by certain of our distributors. Periodically, we transition certain territories to new distribution partners or our direct sales force where we believe we can improve performance relative to the distributor. Because new distribution partners or our direct sales force may have limited experience marketing and selling our products in certain territories, or at all, we cannot be certain that they will perform better than the predecessor distributor. In certain cases, our distributors hold the regulatory approval to sell INTERCEPT for their particular geography. Termination, loss of exclusivity or transitioning from these distributors may require us to negotiate a transfer of the applicable regulatory approvals to us or new distributors which may be difficult to do in a timely manner, or at all. We expect that our product revenue will be adversely impacted with the loss or transition of one or more of these distributors. If we choose to terminate distributor agreements, we would either need to reach agreement with, qualify, train and supply a replacement distributor or supply and service end-user customer accounts in those territories ourselves. Although our distribution agreements generally provide that the distributor will promptly and efficiently transfer its existing customer agreements to us, there can be no assurance that this will happen in a timely manner or at all or that the distributor will honor its outstanding commitments to us. In addition, terminated distributors may own illuminators placed at customer sites and may require us to repurchase those devices or require end-user customers to purchase new devices from us. Additionally, we may need terminated distributors to cooperate with us or a new distributor in transitioning sub-distributor relationships and contracts, hospital contracts, public tenders, or regulatory certificates or licenses held in their name. These factors may be disruptive for our customers and our reputation may be damaged as a result. Our distribution partners may have more established relationships with potential end user customers than a new distributor or we may have in particular territory, which could adversely impact our ability to successfully commercialize our products in these territories. In addition, it may take longer for us to be paid if payment timing and terms in these new arrangements are less favorable to us than those in our existing distributor arrangements. As we service end-user accounts directly rather than through distributors, we incur additional expense, our working capital is negatively impacted due to longer periods from cash collection from direct sales customers when compared to the timing of cash collection from our former distribution partners and we may be exposed to additional complexity including local statutory and tax compliance. Current or transitioning distributors may irreparably harm relationships with local existing and prospective customers and our standing with the blood banking community in general. In the event that we are unable to find alternative distributors or mobilize our own sales efforts in the territories in which a particular distributor operates, customer supply, our reputation and our operating results may be adversely affected. In addition, in territories where new distributors are responsible for servicing end-user accounts, there will be a period of transition in order to properly qualify and train these new distributors, which may disrupt the operations of our customers and adversely impact our reputation and operating results. Furthermore, there may be local or regional restrictions on travel due to the COVID-19 crisis, which could impact our distributors or our ability to service customers in the field should issues arise.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our products are a novel technology in the U.S. and blood centers and clinicians have little to no experience with pathogen reduction systems. Further, we have no prior experience commercializing products in the U.S.&#160;We may be unable to develop and maintain an effective and qualified U.S. based commercial organization or educate blood centers, clinicians and hospital personnel. As a result, we may not be able to successfully educate the market on the value of pathogen reduction or commercialize our products in the U.S.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate significant product revenue from our platelet and plasma systems depends in part on our ability to achieve market acceptance of, and to otherwise effectively market, our platelet and plasma systems in the U.S. Even if we are able to achieve market acceptance in the U.S. or newly commercialized markets, we have provided and may provide adoption incentives in the future which may negatively impact our reported sales. Successfully commercializing our products in the U.S. may take considerable time during which we will need to build and maintain relationships, additional routine-use data and trust from the industry. We need to attract, retain, train and support sales, marketing and scientific and hospital affairs personnel and other commercial talent. For example, we need to attract and retain hospital affairs professionals to help educate hospitals and physicians on our products, clinical trial history and publications. Hospital affairs professionals are highly educated and trained professionals and the hiring and employment market for hospital affairs professionals is highly competitive. As such, we need to commit significant additional management and other resources in order to maintain and potentially expand our hospital affairs team and sales and marketing functions. We may be unable to develop and maintain adequate hospital affairs, sales and marketing capabilities for the U.S. market and we also may not be able to devote sufficient resources to the advertising, promotion and sales efforts for the platelet and plasma </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">systems in the U.S. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the COVID-19 crisis, we may have difficulties recruiting, on-boarding and training new field-based personnel, or we may choose to defer recruiting for certain positions due to the ongoing pandemic. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to develop and maintain an effective and qualified U.S.-based commercial organization in a timely manner or at all, we may fail to realize the full sales potential of our platelet and plasma systems in the U.S. In addition, should we seek and obtain approval for unique biological products created by use of the INTERCEPT </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lood </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ystem, including extended-storage cryoprecipitate, we may choose to sell the treated end product directly to hospitals using our commercial organization. </span><span style="color:#000000;">While we are working </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on implementing the infrastructure we believe will be necessary to market an approved extended-storage cryoprecipitate product directly to hospitals subsequent to potential regulatory approval of any PMA supplement that we may propose to submit to the FDA, we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have no experience selling biological end products directly to hospitals which may cause a distraction for our commercial organization or we may be viewed as a competitive threat to our blood center customers. Even if we were to receive approval for a PMA supplement for extended-storage cryoprecipitate, we may not receive label claims for all indications or for indications with the highest unmet need or market acceptance.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our manufacturing supply chain exposes us to significant risks.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own our own manufacturing facilities, but rather manufacture our products using a number of third-party suppliers, many of whom are our sole suppliers for the particular product or component that we procure. We rely on various contracts and our relationships with these suppliers to ensure that the sourced products are manufactured in sufficient quantities, timely, to our exact specifications and at prices we agree upon with the supplier. The price that we pay to some of our suppliers is dependent on the volume of products or components that we order. If we are unable to meet the volume tiers that afford the most favorable pricing, our gross margins will be negatively impacted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, we amended and restated our manufacturing and supply agreement with Fresenius. Under the amended agreement, Fresenius is obligated to sell, and we are obligated to purchase finished disposable kits for the platelet, plasma and red blood cell kits from Fresenius with certain exceptions permitted. The initial term of the amended agreement extends through July 1, 2025, and is automatically renewed thereafter for additional two-year renewal terms, subject to termination by either party upon (i) two years written notice prior to the expiration of the initial term or (ii) one year written notice prior to the expiration of any renewal term. We and Fresenius each have normal and customary termination rights, including termination for material breach. Fresenius is our sole supplier for the manufacture of these products. Fresenius may fail to manufacture an adequate supply of INTERCEPT disposable kits which would harm our business. Disruptions to our supply chain as a result of any potential ensuing protests, strikes or other work-stoppages would be detrimental to our business and operating results. In the event Fresenius refuses or is unable to continue operating under the agreement, we may be unable to maintain inventory levels or otherwise meet customer demand, and our business and operating results would be materially and adversely affected.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have contracts with other third-party suppliers, including Ash Stevens for the manufacture of amotosalen, our proprietary compound for reducing pathogens that is used in our platelet and plasma systems&#59; Purolite, and separately, Porex, for the manufacture of components of the compound adsorption devices used in our platelet and plasma systems&#59; and Nova for the manufacture of illuminators and certain components of the INTERCEPT Blood System. These independent suppliers are currently our sole qualified suppliers for such components and products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing and supply agreement with Ash Stevens automatically extended at the end of 2019 and now continues until December&#160;31, 2021, and will continue to automatically renew thereafter for periods of two years each, but may be terminated by Ash Stevens provided that Ash Stevens notifies us in writing at least two years in advance. We have not been notified by Ash Stevens of their intention to terminate the agreement. Although we are not subject to minimum annual purchase requirements under the manufacturing and supply agreement with Ash Stevens, we may be required to pay a maintenance fee of up to $50,000 a year if specified quantities of amotosalen are not purchased in any year. We have incurred these maintenance fees in the past and may incur these maintenance fees in future periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, we entered into an amended and restated manufacturing and supply agreement with Porex for the continued supply of the compound adsorption devices. Porex is our sole supplier for certain components of and manufacturing of the compound adsorption devices. Under the amended and restated Porex agreement, we are no longer subject to a minimum annual purchase requirement&#59; however, Porex has the right to terminate the agreement, upon twelve months&#8217; prior written notice, if annual production falls below a mutually agreed threshold. The amended and restated Porex agreement was renewed as of January 1, 2020, for additional two years. In addition, we entered into an amended and restated supply agreement with Brotech Corporation d/b/a Purolite Company, or Purolite, for the supply of raw materials used to make the compound adsorption devices. The amended supply agreement expires in April 2021 and will automatically renew for an additional year unless either party has provided notice not to renew at least two years prior to the expiration. Under the terms of the amended agreement, pricing is volume based and is subject to annual, prospective adjustments based on a Producer Price Index subject to an annual cap. Our agreement with Nova, which manufacturers our illuminators, currently extends through September 2020 and is automatically renewable for one year terms, but may be terminated by Nova on at least twelve months&#8217; prior written notice. We have not been notified by Nova of their intention to terminate the agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities at which the INTERCEPT Blood System or its components are manufactured may cease operations for planned or unplanned reasons or may unilaterally change the formulations of certain commercially available reagents that we use, causing at least temporary interruptions in supply. In addition, given our recent rapid growth and potential for continued or even accelerated growth, we may need to identify, validate and qualify additional manufacturing capacity with existing or new suppliers. Further, customer demand for our platelet kits may fully utilize the production capacity of our third-party manufacturer(s), as a result we may need to allocate manufacturing resources such that our supply of platelet kits or plasma kits could be adversely impacted. Even a temporary failure to supply adequate numbers of INTERCEPT Blood System components may cause an irreparable loss of customer goodwill and potentially irreversible loss of momentum in the marketplace.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while our suppliers have initiated business continuity plans with minimal disruption to our supply, we cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not impact our supply chain. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we are actively evaluating alternate suppliers for certain components, we do not have qualified suppliers or capacity beyond those on which we currently rely, and we understand that Fresenius relies substantially on sole suppliers of certain materials for our products. In addition, suppliers from whom our contract manufacturers source components and raw materials may cease production or supply of those components to our contract manufacturers. For example, we understand that a compound adsorbent housing component is no longer available and an alternate housing will need to be qualified by Fresenius. Identification and qualification of alternate suppliers is time consuming and costly, and there can be no assurance that we will be able to demonstrate equivalency of alternate components or suppliers or that we will receive regulatory approval in the U.S. or other jurisdictions. If we conclude that supply of the INTERCEPT Blood System or components from suppliers is uncertain, we may choose to build and maintain inventories of raw materials, work-in-process components, or finished goods, which would consume capital resources faster than we anticipate and may cause our supply chain to be less efficient.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently Nova is manufacturing illuminators to meet customer demand and maintain our own inventory levels. Subject to obsolescence, we may be required to identify and qualify replacement components for illuminators and in doing so, we may be required to conduct additional studies, which could include clinical trials to demonstrate equivalency or validate any required design or component changes. We and our customers rely on the availability of spare parts to ensure that customer platelet and plasma production is not interrupted. If we are not able to supply spare parts for the maintenance of customer illuminators, our ability to keep existing customers, increase production for existing customers or sign up new customers may be negatively impacted. Due to the obsolescence of certain parts, we have redesigned the illuminators used in the platelet and plasma systems and may need to further redesign the illuminator. We will need to obtain regulatory approval of any future redesign of the illuminator before it can be commercialized in the U.S. or under CE Mark. Our failure to obtain regulatory approvals of a new illuminator could constrain our ability to penetrate our markets and may otherwise significantly limit product revenue from sales of the platelet and plasma systems. In any event, delays in receipt or failure to receive these approvals could reduce our sales and negatively impact our profitability potential and future growth prospects. Furthermore, we understand that components used in the illuminator are no longer commercially available beyond what we and Nova have stockpiled or to which we have access under final buy transactions or may become unavailable in the current specifications in the near-term. As with our disposable sets, if we conclude that supply of components or spare parts for the illuminators is uncertain, we may choose to purchase and maintain inventories of such components or spare parts, which would consume capital resources faster than we anticipate and may cause our supply chain to be less efficient. We are and will need to continue investing in subsequent versions of the illuminator to enhance functionality and manage obsolescence. In addition, our illuminators contain embedded proprietary software that runs on software code we have developed and that we own. Changes to certain components due to obsolescence, illuminator redesign or market demand, may require us to modify the existing software code or to develop new illuminator software. Our ability to develop new illuminator software, correct coding flaws and generally maintain the software code is reliant on third-party contractors who, in some cases, have sole knowledge of the software code. Our ability to develop and maintain the illuminator software may be impaired if we are not able to continue contracting with those key third-party contracted developers or if we are unable to source alternate employees or consultants to do so. Software development is inherently risky and may be time consuming and costly.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that alternate manufacturers are identified and qualified, we will need to transfer know-how relevant to the manufacture of the INTERCEPT Blood System to such alternate manufacturers&#59; however, certain of our supplier&#8217;s materials, manufacturing processes and methods are proprietary to them, which will impair our ability to establish alternate sources of supply, even if we are required to do so as a condition of regulatory approval. We may be unable to establish alternate suppliers without having to redesign certain elements of the platelet and plasma systems. Such redesign may be costly, time consuming and require further regulatory review and approvals. We may be unable to identify, select, and qualify such manufacturers or those third parties able to provide support for development and testing activities on a timely basis or enter into contracts with them on reasonable terms, if at all. Moreover, the inclusion of components manufactured by new suppliers could require us to seek new or updated approvals from regulatory authorities, which could result in delays in product delivery. We may not receive any such required regulatory approvals. We cannot assure you that any amendments to existing manufacturing agreements or any new manufacturing agreements that we may enter into will contain terms more favorable to us than those that we currently have with our manufacturers. Many of the existing agreements we have with suppliers contain provisions that we have been operating under for an extended period of time, including pricing. Should we enter into agreements or amend agreements with any manufacturer with less favorable terms, including pricing, our results of operations may be impacted, our recourse against such manufacturers may be limited, and the quality of our products may be impacted.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials, components or finished product may not meet specifications or may be subject to other nonconformities. In the past, non-conformities in certain component lots have caused delays in manufacturing of INTERCEPT disposable kits. Similarly, we have experienced non-conformities and out of specification results in certain component manufacturing needed for clinical use, commercial sale and regulatory submissions. Non-conformities can increase our expenses and reduce gross margins or result in delayed regulatory submissions or clinical trials. Should non-conformities occur in the future, we may be unable to manufacture products to support our red blood cell clinical trials, or to meet customer demand for our commercial products, which would result in delays for our clinical programs, or lost sales for our commercial products, and could cause irreparable damage to our customer relationships. Later discovery of problems with a product, manufacturer or facility may result in additional restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We are subject to risks and costs of product recall, which include not only potential out-of-pocket costs, but also potential interruption to our supply chain. In such an event, our customer relations could be harmed and we would incur unforeseen losses. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a failure by Fresenius or other manufacturers to perform their obligations to supply components of the INTERCEPT Blood System to us, damages recoverable by us may be insufficient to compensate us for the full loss of business opportunity. Many of our supply agreements contain limitations on incidental and consequential damages that we may recover. A supplier&#8217;s potential liability in the event of non-performance may not be sufficient to compel the supplier to continue to act in conformity with our agreements. Our product supply chain requires us to purchase certain components in minimum quantities and may result in a production cycle of more than one year. Significant disruptions to any of the steps in our supply chain process may result in longer productions cycles which could lead to inefficient use of cash or may impair our ability to supply customers with product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter unforeseen manufacturing difficulties which, at a minimum, may lead to higher than anticipated costs, scrap rates, or delays in manufacturing products. In addition, we may not receive timely or accurate demand information from distributors or direct customers, or may not accurately forecast demand ourselves for the INTERCEPT Blood System. Should actual demand for our products exceed our own forecasts or forecasts that customers provide, we may be unable to fulfill such orders timely, if at all. Should we be unable to fulfill demand, particularly if mandated by a public health authority or as included in the FDA platelet safety guidance document, our reputation and business prospects may be impaired. Further, certain distributors and customers require, and potential future distributors or customers may require, product with a minimum shelf life. If customers requiring minimum shelf-lives order smaller quantities or do not purchase product as we anticipate, or at all, we may have elevated inventory levels with relatively short shelf-lives which may lead to increased write-offs and inefficient use of our cash. Should we choose not to fulfill smaller orders with minimum shelf lives, our product sales may be harmed. We will need to destroy or consume outdated inventory in product demonstration activities, which may in turn lead to elevated product demonstration costs and/or reduced gross margins. In order to meet minimum shelf-life requirements, we may need to manufacture sufficient product to meet estimated forecasted demand. As a result, we may carry excess work-in-process or finished goods inventory, which would consume capital resources and may become obsolete, or our inventory may be inadequate to meet customer demand. Our platelet and plasma systems&#8217; disposable kits have 18 to 24 months shelf lives from the date of manufacture. Should we change or modify any of our product configurations or components, such future configurations of our products may not achieve the same shelf life that existing products have. We and our distributors may be unable to ship product to customers prior to the expiration of the product shelf life, a risk that is heightened if we elect to increase our inventory levels in order to mitigate supply disruptions. We have entered into certain public tenders, some of which call for us to maintain certain minimum levels of inventory. If our suppliers fail to produce components or our finished products satisfactorily, timely, at acceptable costs, and in sufficient quantities, we may incur delays, shortfalls and additional expenses, or non-compliance with certain public tenders which may in turn result in penalty fees, permanent harm to our customer relations or loss of customers. In addition, certain large national prospective customers, like those in the U.K. or Japan, may choose to convert all of their operation to INTERCEPT. Should we or our suppliers encounter any manufacturing issues, we may not be able to satisfy all of the global demand or may have to allocate available product to certain customers which may negatively impact our customers operations and consequently, our reputation. Conversely, we may choose to overstock inventory in order to mitigate any unforeseen potential disruption to manufacturing which could consume our cash resources faster than we anticipate and may cause our supply chain to be less efficient. Additionally, should we conclude that existing suppliers are not able to produce sufficient quantities to meet the demand for our products, we may choose to invest in manufacturing capacity at existing or new facilities with existing or new suppliers, which could be costly and disruptive to our management.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain regions that we sell into or may sell into in the future may give priority to those products that are manufactured locally in their jurisdiction. Our failure to meet these local manufacturing conditions may prevent us from successfully commercializing our product in those geographies. In addition, should we choose to manufacture locally in those jurisdictions, we would likely incur additional costs, may be unable to meet our quality system requirements or successfully manufacture products, and such activities will be a distraction from our current focus and operations. We have no experience manufacturing or working with manufacturers outside of our current manufacturing footprint.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obsolescence or shortage of raw materials, key components of and accessories to the INTERCEPT Blood System, may impact our ability to supply our customers, may negatively impact the operational costs of our customers and may increase the prices at which we sell our products, resulting in slower than anticipated growth or negative future financial performance.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture, supply and availability of key components of, and accessories to, our products are dependent upon a limited number of third parties and the commercial adoption and success of our products is dependent upon the continued availability of these components or accessories. For example, our customers rely on continued availability of third-party supplied plastics, saline and reagents for processing, storing and manufacturing blood components. If the blood product industry experiences shortages of these components or accessories, the availability and use of our products may be impaired. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the manufacture of our products, our third-party manufacturers source components and raw materials for the manufacture of the INTERCEPT processing sets. Certain of these components are no longer commercially available, are nearing end-of-life or are available only from a limited number of suppliers. We and our third-party manufacturers do not have guaranteed supply contracts with all of the raw material or component suppliers for our products, which magnify the risk of shortage and obsolescence and decreases our manufacturers&#8217; ability to negotiate pricing with their suppliers. For example, a solvent used in the manufacture of a raw material for our compound adsorption device is no longer available. Our contract manufacturer has produced a substantial amount of the raw material using its remaining inventory of the solvent as a last time purchase. However, the amount of material is finite and we and our contract manufacturer will need to qualify an alternate solvent used in the manufacture of the raw material. If we are unable to use all of the raw material produced during the final production run, or if the final material produces suboptimal results, we may require customers to modify their operating practices, or run out of material before an alternate material can be qualified. Customers may object to changes in operating practices or changes to the instructions for use, and a potential negative impact on their operations as a result of the use of this material, could impair our reputation or customer acceptance of our products. Any shortage or obsolescence of raw materials, components or accessories or our inability to control costs associated with raw materials, components or accessories, could increase our costs to manufacture our products. Further, if any supplier to our third-party manufacturers is unwilling or unable to provide high quality raw materials in required quantities and at acceptable prices, our manufacturers may be unable to find alternative sources or may fail to find alternative suppliers at commercially acceptable prices, on satisfactory terms, in a timely manner, or at all. Furthermore, we do not yet know whether or not certain components used by blood center operators or used in the production of INTERCEPT will be able to successfully comply with the new standards under the MDR. Failure to comply with the new standards timely may result in a disruption to blood center operations or the manufacture of the INTERCEPT Blood System. If any of these events were to occur, our product quality, competitive position, reputation and business could suffer, we could experience cancellations of customer orders, refusal by customers to accept deliveries or a reduction in our prices and margins to the detriment of our financial performance and results of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to federal, state and foreign laws governing our business practices which, if violated, could result in substantial penalties and harm our reputation and business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a number of laws that affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements we may have with hospitals, physicians, healthcare providers or other potential purchasers of our products. These laws are often broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances. For example, within the E.U., the control of unlawful marketing activities is a matter of national law in each of the member states. The member states of the E.U. closely monitor perceived unlawful marketing activity by companies. We could face civil, criminal and administrative sanctions if any member state determines that we have breached our obligations under its national laws. Industry associations also closely monitor the activities of member companies. If these organizations or authorities name us as having breached our obligations under their regulations, rules or standards, our reputation would suffer and our business and financial condition could be adversely affected. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are numerous U.S. federal, state and local healthcare regulatory laws, including, but not limited to, anti-kickback laws, false claims laws, privacy laws, and transparency laws. Our relationships with healthcare providers and entities, including but not limited to, hospitals, physicians, healthcare providers and our customers are subject to scrutiny under these laws. Violations of these laws can subject us to penalties, including, but not limited to, administrative, civil and criminal penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in federal and state healthcare programs, including the Medicare and Medicaid programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment of our operations. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. The laws that may affect our ability to operate include, but are not limited to:</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce, the referral of an individual for, the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">federal false claims laws, including the federal False Claims Act, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other federal payors that are false or fraudulent, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, and which may apply to entities that provide coding and billing advice to customers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented, a claim to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program, including private payors, or making false statements relating to healthcare matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their business associates that perform services for them that involve individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly applicable privacy and security standards and requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA, that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program, with specific exceptions, to track and annually report to the Centers for Medicare &#38; Medicaid Services, or CMS, payments and other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">foreign, or U.S. state or local law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers&#59; U.S. state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government or otherwise restrict payments that may be made to healthcare providers&#59; U.S. state and local laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures&#59; and U.S. state laws governing the privacy and security of certain health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to foreign laws and regulations covering data privacy and the protection of health-related and other personal information. In this regard, E.U. member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, effective May 25, 2018, the collection and use of personal health data in the E.U. is governed by the provisions of the E.U. General Data Protection Regulation, or the GDPR. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the control over personal data by individuals to whom the personal data relates, the information provided to the individuals, the documentation we must maintain, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U., provides an enforcement authority and authorizes the imposition of large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiary, including employee information. The GDPR has increased our responsibility and potential liability in relation to personal data that we process compared to prior E.U. law, including in clinical trials, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. However, despite our ongoing efforts to bring our practices into compliance with the GDPR, we may not be successful either due to various factors within our control or other factors outside our control. It is also possible that local data protection authorities may have different interpretations of the GDPR, leading to potential inconsistencies amongst various E.U. member states. Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. In addition, new regulation, legislative actions or changes in interpretation of existing laws or regulations regarding data privacy and security </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new laws, regulations and industry standards relating to privacy and data protection in the U.S., the E.U. and other jurisdictions, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such as the California Consumer Privacy Act of 2018 that will go into effect beginning January 1, 2020, which has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the U.S. because it mirrors a number of the key provisions in the GDPR, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we cannot determine the impact such new laws, regulations and standards may have on our business.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws with a significant anti-corruption intent in foreign countries. In general, there is a worldwide trend to strengthen anticorruption laws and their enforcement. Any violation of these laws by us or our agents or distributors could create a substantial liability for us, subject our officers and directors to personal liability and also cause a loss of reputation in the market. We currently operate in many countries where the public sector is perceived as being more or highly corrupt. Our strategic business plans include expanding our business in regions and countries that are rated as higher risk for corruption activity, such as China, India and Russia. Becoming familiar with and implementing the infrastructure necessary to comply with laws, rules and regulations applicable to new business activities and mitigate and protect against corruption risks could be quite costly. In addition, failure by us or our agents or distributors to comply with these laws, rules and regulations could delay our expansion into high-growth markets, could damage market perception of our business and could adversely affect our existing business operations. Increased business in higher risk countries could also subject us and our officers and directors to increased scrutiny and increased liability.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, among other things, amends the intent requirements of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity can now be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Moreover, while we do not submit claims and our customers make the ultimate decision on how to submit claims, from time-to-time, we may provide reimbursement guidance to our customers. If a government authority were to conclude that we provided improper advice to our customers or encouraged the submission of false claims for reimbursement, we could face action against us by government authorities. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations and financial condition.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our relationships with healthcare providers and entities, including, but not limited to, hospitals, physicians, healthcare providers and our distributors, and certain sales and marketing practices, including the provision of certain items and services to our customers, could be subject to challenge under one or more of such laws.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To enforce compliance with the healthcare regulatory laws, federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been a recent trend of increased U.S. federal, state and local regulation of payments and transfers of value provided to healthcare professionals or entities. Section 6002 of the ACA, known as the Physician Payments Sunshine Act, imposes annual reporting requirements on device manufacturers for payments and other transfers of value provided by them, directly or indirectly, to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in significant civil monetary penalties. Manufacturers must submit reports to CMS by the 90th day of each subsequent calendar year. Due to the difficulty in complying with the Physician Payments Sunshine Act, we cannot assure you that we will successfully report all payments and transfers of value provided by us, and any failure to comply could result in significant fines and penalties. Some states, such as California and Connecticut, also mandate implementation of commercial compliance programs, and other states, such as Massachusetts and Vermont, impose restrictions on device manufacturer marketing practices and tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities. The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and reporting requirements in multiple jurisdictions increase the possibility that we may fail to comply fully with one or more of these requirements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of these laws apply to not only the actions taken by us, but also actions taken by our distributors or other third-party agents. We have limited knowledge and control over the business practices of our distributors and agents, and we may face regulatory action against us as a result of their actions which could have a material adverse effect on our reputation, business, results of operations and financial condition.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. U.S. federal or state regulatory authorities might challenge our current or future activities under these laws. Any such challenge could have a material adverse effect on our reputation, business, results of operations and financial condition. Any U.S. federal or state or foreign regulatory review of us, regardless of the outcome, would be costly and time-consuming. Additionally, we cannot predict the impact of any changes in these laws, whether or not retroactive. Compliance with these and other changing regulations will increase our costs and may require increasing management attention.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legislative, regulatory, or other healthcare reforms may make it more difficult and costly for us to obtain regulatory approval of our products and to produce, market and distribute our products after approval is obtained.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory guidance and regulations are often revised or reinterpreted by the regulatory agencies in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our products. Delays in receipt of, or failure to receive, regulatory approvals for our new products or product configurations would have a material adverse effect on our business, results of operations and financial condition. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state governments in the U.S. have recently enacted legislation to overhaul the nation&#8217;s healthcare system. While the goal of healthcare reform is to expand coverage to more individuals, it also involves increased government price controls, additional regulatory mandates and other measures designed to constrain medical costs. The ACA significantly impacts the medical device industry. Among other things, the ACA:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">established a Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. </span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to numerous provisions of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including delaying imposition of the medical device excise tax on non-exempt medical devices through December 31, 2019. In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how this decision, subsequent decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business. Any repeal and replace legislation may have the effect of limiting the amounts that government agencies will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure, or may lead to significant deregulation, which could make the introduction of competing products and technologies much easier. Policy changes, including potential modification or repeal of all or parts of the ACA or the implementation of new health care legislation could result in significant changes to the health care system, which could have a material adverse effect on our business, results of operations and financial condition.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August&#160;2, 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2%&#160;per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will stay in </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect through 2027, unless additional congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, there has been heightened governmental scrutiny in the U.S. to control the rising cost of healthcare. For example, such scrutiny has resulted in several recent congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to pricing and reform government program reimbursement methodologies for pharmaceutical products, some of which are included in the Trump </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration&#8217;s &#8220;Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs&#8221; released in May 2018. State legislatures are also increasingly passing legislation and implementing regulations designed to control the cost of healthcare, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trump administration has publicly stated a core goal is to deregulate wherever possible. It is unclear if this contraction in regulation would also apply to issued guidance documents that would impact our industry. Should the administration remove such guidance documentation, market uptake for INTERCEPT platelets may be impaired. Conversely, any significant deregulation could make the introduction of competing products and technologies much easier than the burden faced by us in order to receive FDA approval. We expect that additional U.S federal and state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our platelet and plasma products and product candidates are not compatible with some collection, production and storage methods or combinations thereof. Further, blood centers using INTERCEPT must have access to those certain devices, blood bags, assays or platelet additive solutions that are compatible with our products.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The equipment and materials used to collect platelets vary by manufacturer and by geographic region. Platelets may be collected from a single donor by apheresis using an automated collection machine. Apheresis devices currently used in the U.S. and European markets differ, among other characteristics, in their ability to collect platelets in reduced volumes of plasma. Platelet collection device manufacturers may need to modify device collection parameters or software before a prospective customer could use INTERCEPT. If these manufacturers are not cooperative or are resistant to assist their customers or do not assist with making such modifications, the potential market for our products may be limited. Platelet concentrates may also be prepared from whole blood by pooling together platelets from multiple donors. There are two commonly used methods for preparing whole blood platelets: the buffy coat method, which is used extensively in Europe, and the pooled random donor method, which is used in the U.S. Our platelet system is designed to work with platelets collected and stored in storage solutions, called InterSol and SSP+, and for platelets suspended in 100% plasma. Fresenius is the exclusive manufacturer of InterSol and MacoPharma of SSP+, both widely-used PASs. Many of our customers and prospective customers use InterSol or SSP+ in connection with INTERCEPT treatment. Similarly, some of our customers combine multiple platelet or plasma components before treating the combined product with INTERCEPT. There are several third-party manufacturers of pooling sets to allow for such combination. Our customers&#8217; ability to use our INTERCEPT products may be impaired should manufacturers of those products not provide access to their products allowing for the combination of multiple components or if such manufacturers experience a shortage of their products or encounter defects with their products. In addition, we do not yet know what impact, if any, the new MDR regulation may have on these suppliers or their products. Should manufacturers of collection devices, compatible assays and blood bags, pooling sets or platelet additive solutions fail to obtain or maintain regulatory approval, including the MDR, experience unexpected production disruption, or decide to cease distribution of those respective products to customers and prospective customers, our ability to sell the INTERCEPT Blood System may be impaired and acceptance in the marketplace could be harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to address the entire market in the U.S., Japan, and potentially elsewhere, we will need to develop and test additional configurations of the platelet system. For example, in the U.S., we understand a significant number of platelet concentrates are derived from larger volumes collected from apheresis donors split into three therapeutic transfusable doses. Future configurations of the platelet system will be needed to treat platelet donations with such processing parameters. We estimate that the majority of platelets used in the U.S. are collected by apheresis, though a significant minority is prepared from pooled random donor platelets derived from whole blood collections. In addition, many blood centers may view pooled random donor platelets treated with INTERCEPT as an economically optimal approach. In order to gain regulatory approvals for a pathogen reduction system compatible with triple dose collections, and random donor platelets, we will need to perform additional product development and testing, including additional clinical trials. We have conducted and may conduct additional <span style="font-style:italic;">in vitro</span> studies for our platelet system to potentially expand our label claims to include, among others, platelets collected from pooled random donors, storage of INTERCEPT-treated platelets for up to seven days rather than five days, and a new processing set for triple dose collections. In the U.S, our approved labels for the platelet system from the FDA limit our current approvals to certain platelet collection platforms and a particular storage solution for the particular collection platform. For instance, our approved claims permit apheresis collection of platelets on the Fresenius Amicus device while stored in an additive solution or for apheresis collection of platelets collected on the Terumo Trima device and stored in 100% plasma. While we are seeking to generate acceptable data for Amicus collected platelets stored in 100% plasma and Trima platelets stored in PAS, we cannot assure you that the data will be acceptable to the FDA or that we will receive timely approval, if ever. We may be required to provide the FDA with data for each permutation for which blood banking treatment practices exist which may be time consuming, costly and limit the potential </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">size of the U.S. market that can use our products. Our failure to obtain FDA and foreign regulatory approvals of any new configurations could significantly limit product revenue from sales of the platelet system. In addition, given that there is some loss of platelets using our product, blood centers may need to increase collection volumes in order to use our product and maintain an adequate concentration for a triple therapeutic dose. In any event, delays in receipt or failure to receive approval could reduce our sales and negatively impact our profitability potential and future growth prospects. Similarly, to achieve market acceptance in certain geographies, we may be required to design, develop and test new product configurations for the platelet and plasma systems. In addition, if the FDA or other regulatory or accrediting body </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were to</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mandate safety interventions, including the option of pathogen reduction technology, when we had not received approval for all operational configurations, the market to which we </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sell our products may be limited until we obtain such approvals</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if ever,</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or may be permanently impaired if </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> options are more broadly available. </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has delayed certain product configuration activities, including extended storage platelets for the U.S. market and data generation for a platelet set used to treat and provide three therapeutic doses from a single platelet donor in the U.S. Should the pandemic persist and limit our ability to generate the aforementioned data needed for licensure, beyond the end of the compliance grace period covered by the FDA guidance document for platelet safety, customers and prospective customers may choose to implement other acceptable alternatives under the guidance document.</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will need to continue to generate acceptable data in order to conform with the evolving collection practices such as automated whole-blood collection. If we are unable to conform to evolving collection practices our ability to address those portions of the market may be compromised. These development activities will increase our costs significantly and may not be successful. We may need to demonstrate the safety and efficacy of our platelet system using a variety of configurations before our platelet system would be approved for such configurations. Delays in obtaining any future approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our product revenue and potential future profitability.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our competitors develop products superior to ours, market their products more effectively than we market our products, or receive regulatory approval before our products, our commercial opportunities could be reduced or eliminated.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our products will continue to encounter significant competition. The INTERCEPT Blood System products compete with other approaches to blood safety currently in use and may compete with future products that may be developed by others. Our success will depend in part on our ability to respond quickly to customer and prospective customer needs, successfully receive and maintain regulatory approvals, and adapt to medical and technological changes brought about by the development and introduction of new products. Competitors&#8217; products or technologies may make our products obsolete or non-competitive before we are able to generate any significant product revenue. In addition, competitors or potential competitors may have substantially greater financial and other resources than we have. They may also have greater experience in preclinical testing, human clinical trials and other regulatory approval procedures. If competitors&#8217; products experience significant problems, customers and potential customers may question the safety and efficacy of all pathogen reduction technologies, including the INTERCEPT Blood System. Such questions and concerns may impair our ability to market and sell the INTERCEPT Blood System.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several companies have, or are developing, technologies that are, or in the future may be, the basis for products that will directly compete with or reduce the market for our pathogen reduction systems. A number of companies are specifically focusing on alternative strategies for pathogen reduction in platelets and plasma.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These alternative strategies may be more effective in reducing certain types of pathogens from blood products, including certain non-lipid-enveloped viruses, such as hepatitis A and E viruses, which our products have not demonstrated an ability to inactivate, or human parvovirus B-19, which is also a non-lipid-enveloped virus, for which our products have not demonstrated a high level of inactivation. While studies have demonstrated that our products can effectively inactivate a broad spectrum of pathogens in blood components, market adoption of our products may be reduced if customers determine that competitors&#8217; products inactivate a broader range of pathogens that are of particular interest to the transfusion medicine community. In addition, customers and prospective customers may believe that our competitors&#8217; products are safer, more cost effective or easier to implement and incorporate into existing blood processing procedures than INTERCEPT Blood System products. In Europe, several companies, including Grifols S.A., Octapharma AG, MacoPharma International and Kedrion Biopharma, are developing or selling commercial pathogen reduction systems or services to treat fresh frozen plasma. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MacoPharma has received CE Mark for a UVC-based product for pathogen reduced platelets. MacoPharma has recently completed a Phase 3 clinical trial in Germany for expanded approvals. The data from this trial has not yet been made publicly available. In addition, Terumo BCT, a subsidiary of Terumo Corporation, has developed a pathogen reduction system for blood products and has been issued CE Marks for its system for both platelets and plasma. We further understand that Terumo BCT developed a pathogen reduction system for whole blood and received a Class II CE Mark. MacoPharma or Terumo BCT&#8217;s products may offer competitive advantages over our INTERCEPT Blood System. Terumo Corporation is a large Japanese-based, multinational corporation with more mature products and relationships than we have. Our ability to commercialize our products in certain markets, particularly in Japan, may be negatively affected by Terumo BCT&#8217;s resources and their pre-existing relationships with regulators and customers. Should Terumo BCT&#8217;s product be approved for use and commercialized in Japan, our products would likely directly compete with their products and we believe we would likely either need to establish operations in Japan or partner with a local Japanese company. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Octapharma AG received FDA approval in January 2013 to sell treated fresh frozen plasma for certain indications and is currently commercially available. Should Octapharma enter into exclusive agreements with key customers, our plasma system may encounter market resistance and we will have a more limited market into which we can sell.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we understand that Octapharma received approval to sell fresh frozen plasma in France. Octapharma&#8217;s entry into the French market may pose a competitive threat to other pathogen reduced plasmas, including INTERCEPT and may in turn limit the potential market available to us in France.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other companies developing competing products may also offer and sell other blood-banking products and services. As a result, competitors may have pre-existing long-term relationships with customers and may be able to offer synergies for both pathogen reduction and non-pathogen reduction products that we are unable to offer. Regulatory agencies may mandate use of competing products which would limit our ability to sell our products in those markets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New methods of testing whole blood for specific pathogens have been approved by the FDA and in Europe, as have tests for bacteria in platelets. Other companies are marketing rapid, point-of-care bacterial tests, and developing synthetic blood product substitutes and products to stimulate the growth of platelets. Development and commercialization of any of these or other related technologies could limit the potential market for our products as would a mandate of any competing technology other than INTERCEPT.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be liable and we may need to withdraw our products from the market if our products harm people. We may be liable if an accident occurs in our controlled use of hazardous materials. Our insurance coverage may be inadequate to offset losses we may incur.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to potential liability risks inherent in the testing and marketing of medical devices. We may be liable if any of our products cause injury, illness or death. Although we will have completed preclinical and clinical safety testing prior to marketing our products, there may be harmful effects caused by our products that we are unable to identify in preclinical or clinical testing. In particular, unforeseen, rare reactions or adverse side effects related to long-term use of our products may not be observed until the products are in widespread commercial use. Because of the limited duration and number of patients receiving blood components treated with the INTERCEPT Blood System products in clinical trials, it is possible that harmful effects of our products not observed in preclinical and clinical testing could be discovered after a marketing approval has been received. For example, in cases where we have obtained regulatory approval for our products, we have demonstrated pathogen reduction to specified levels based on well-established tests. However, there is no way to determine, after treatment by our products, whether our products have completely inactivated all of the pathogens that may be present in blood components. There is also no way to determine whether any residual amount of a pathogen remains in the blood component treated by our products and there is no way to exclude that such residual amount would be enough to cause disease in the transfused patient or was a result of a potential defect or lack of efficacy of our products. For ethical reasons, we cannot conduct human testing to determine whether an individual who receives a transfusion of a blood component containing a pathogen that was inactivated using the INTERCEPT Blood System might show positive results if tested for an antibody against that pathogen. While we believe, based on the clinical experience of our scientists, that the level of inactivated pathogens would likely be too small to induce a detectable antibody response in diagnostic tests, we cannot exclude that a transfused patient might show positive results if tested for an antibody against that pathogen. We could be subject to a claim from a patient that tests positive, even though that patient did not contract a disease. In addition, should personnel at clinical study sites or ultimately, potential customers, be harmed by amustaline, or believe they have been or could be harmed by amustaline, our insurance coverage may be insufficient to provide coverage for any related potential liabilities. Amustaline is considered a potent chemical and is the active compound of our red blood cell system.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain product liability insurance, but do not know whether the insurance will provide adequate coverage against potential liabilities. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of hazardous materials, including certain hazardous chemicals, radioactive materials and infectious pathogens, such as HIV and hepatitis viruses. Although we believe that our safety procedures for handling and disposing of hazardous materials are adequate and comply with regulatory requirements, we cannot eliminate the risk of accidental contamination or injury. If an accident occurs, we could be held liable for any damages that result.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact on us.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious injury or death. Manufacturers may also, under their own initiative, recall a product if any material deficiency in a device is found or withdraw a product to improve device performance or for other reasons. The FDA requires that certain </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">classifications of recalls be reported to the FDA within ten working days after the recall is initiated. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Regulatory agencies in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert management attention and financial resources and could cause the price of our stock to decline, expose us to product liability or other claims and harm our reputation with customers. Such events could impair our ability to supply our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA or similar foreign governmental authorities. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA or foreign governmental authorities. If the FDA or foreign governmental authorities disagree with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA or a foreign governmental authority could take enforcement action for failing to report the recalls when they were conducted.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the FDA&#8217;s medical device reporting regulations, we are required to report to the FDA any incident in which our products may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product recall. We are also required to follow detailed recordkeeping requirements for all firm-initiated medical device corrections and removals, and to report such corrective and removal actions to FDA if they are carried out in response to a risk to health and have not otherwise been reported under the medical device reporting regulations. If we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face significant adverse publicity or regulatory consequences, which could harm our business, including our ability to market our products in the future.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any adverse event involving our products, whether in the U.S. or abroad could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to obtain the capital necessary to fund our future operations or if we are unable to generate positive cash flows from our operations, we will need to curtail planned development or sales and commercialization activities.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our near-term capital requirements are dependent on various factors, including operating costs and working capital investments associated with commercializing the INTERCEPT Blood System, including in connection with the continuing U.S. commercial launch of our platelet and plasma systems, costs to develop different configurations of existing products and new products, including our illuminator, costs associated with planning, enrolling and completing ongoing studies, and the post-approval studies we are required to conduct in connection with the FDA approval of the platelet system, costs associated with pursuing potential regulatory approvals in other geographies where we do not currently sell our platelet and plasma systems, costs associated with conducting <span style="font-style:italic;">in vitro</span> studies and clinical development of our red blood cell system in Europe and the U.S., costs associated with performing the agreed-upon activities under our BARDA agreement, and costs related to creating, maintaining and defending our intellectual property. Our long-term capital requirements will also be dependent on the success of our sales efforts, competitive developments, the timing, costs and magnitude of our longer-term clinical trials and other development activities, required post-approval studies, market preparedness and product launch activities for any of our product candidates and products in geographies where we do not currently sell our products, and regulatory factors. Until we are able to generate a sufficient amount of product revenue and generate positive net cash flows from operations, which we may never do, meeting our long-term capital requirements is in large part reliant on continued access to funds under our BARDA agreement and the public and private equity and debt capital markets, as well as on collaborative arrangements with partners, augmented by cash generated from operations and interest income earned on the investment of our cash balances. While we believe that our available cash and cash equivalents and short-term investments, as well as cash received from product sales and under our agreement with BARDA, will be sufficient to meet our capital requirements for at least the next twelve months, if we are unable to generate sufficient product revenue, or access sufficient funds under our BARDA agreement or the public and private equity and debt capital markets, we may be unable to execute successfully on our operating plan. We have based our cash sufficiency estimate on assumptions that may prove to be incorrect. If our assumptions prove to be incorrect, we could consume our available capital resources sooner than we currently expect or in excess of amounts than we currently expect, which could adversely affect our commercialization and clinical development activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have borrowed and in the future may borrow additional capital from institutional and commercial banking sources to fund future growth, including pursuant to our Credit, Security and Guaranty Agreement (Term Loan), or the Term Loan Credit Agreement, and our Credit, Security and Guaranty Agreement (Revolving Loan), or the Revolving Loan Credit Agreement, both with MidCap Financial Trust, or MidCap, as described below, or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms that may include restrictive covenants, including covenants that restrict the operation of our business, liens on assets, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">high effective interest rates, financial performance covenants and repayment provisions that reduce cash resources and limit future access to capital markets. In addition, we e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xpect to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunistically seek</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> access to the equity capital markets to support our development efforts and operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect to receive significant funding under our five-year agreement with BARDA, our ability to obtain the funding we expect to receive under the agreement is subject to various risks and uncertainties, including with respect to BARDA&#8217;s ability to terminate the agreement for convenience at any time and our ability to achieve the required milestones under the agreement, including with respect to the conduct of the RedeS and ReCePI studies, enrollment for which has been suspended at many of the hospital sites due to the COVID-19 pandemic. In addition, access to federal contracts is subject to the authorization of funds and approval of our research plans by various organizations within the federal government, including the U.S. Congress. The general economic environment and uncertainty associated with the COVID-19 pandemic, coupled with tight federal budgets, has led to a general decline in the amount available for government funding. If BARDA were to eliminate, reduce or delay funding under our agreement, this would have a significant negative impact on the programs associated with such funding and could have a significant negative impact on our revenues and cash flows. Furthermore, should we be unable to deploy personnel or derive a benefit from fixed study costs or generate data from clinical sites and studies reimbursed by BARDA, our cash flows would be negatively impacted or we may have to initiate furloughs and layoffs. This in turn would impair our ability to recommence and complete studies if and when the COVID-19 crisis subsides and we are able to restart many suspended or delayed activities. In addition, if we are unable to generate sufficient perquisite Phase 3 clinical data and/or reach agreement with the FDA on an additional Phase 3 clinical trial for chronic anemia in the U.S. for our red blood cell system, our agreement with BARDA will be severely limited in scope or could be terminated altogether, and our ability to complete the development activities required for licensure in the U.S. may require additional capital beyond which we currently have. <span style="color:#000000;">If alternative sources of funding are not available, we may be forced to suspend or terminate development activities related to the red blood cell system in the U.S.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of economic conditions, general global economic uncertainty, political change, and other factors, including uncertainty associated with the COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. Specifically, the COVID-19 pandemic has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. In addition, we may need to obtain additional funds to complete development activities for the red blood cell system if additional studies are necessary for regulatory approval in Europe, which would increase our costs and potentially delay the approval. We may need to obtain additional funding to conduct additional randomized controlled clinical trials for existing or new products, particularly if we are unable to access any additional portions of the funding contemplated by our BARDA agreement, and we may choose to defer such activities until we can obtain sufficient additional funding or, at such time, our existing operations provide sufficient cash flow to conduct these trials. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Covenants in our Term Loan Credit Agreement and Revolving Loan Credit Agreement restrict our business and operations in many ways and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected. In addition, our operations may not provide sufficient cash to meet the repayment obligations of our debt incurred under the Term Loan Credit Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020, our total indebtedness under our Term Loan Credit Agreement and Revolving Loan Credit Agreement was approximately $44.3 million. All of our current and future assets, except for intellectual property and 35% of our investment in our subsidiary, Cerus Europe B.V., are secured for our borrowings under the Term Loan Credit Agreement and Revolving Loan Credit Agreement. The Term Loan Credit Agreement and Revolving Loan Credit Agreement require that we comply with certain covenants applicable to us and our subsidiary, including among other things, covenants restricting dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. In addition, receipt of a qualified audit opinion (other than as to going concern or a qualification resulting solely from the scheduled maturity of term loans occurring within one year from the date such opinion is delivered) would be a violation of an affirmative covenant under the Term Loan Credit Agreement. <span style="letter-spacing:-0.1pt;">While we believe that our available cash and cash equivalents and short-term investments, as well as cash to be received from product sales and under our agreement with BARDA, will be sufficient to meet our capital requirements for at least the next twelve months</span>, if we are unable to generate sufficient product revenue, or access sufficient funds under our BARDA agreement or the public and private equity and debt capital markets, we may be unable to execute successfully on our operating plan. Our failure to comply with any of the covenants could result in a default under the Term Loan Credit Agreement or the Revolving Loan Credit Agreement, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable, or to refuse to permit additional borrowings under the Term Loan Credit Agreement or the Revolving Loan Credit Agreement. If we are unable to repay those amounts, the lenders under the Term Loan Credit Agreement or the Revolving Loan Credit Agreement could proceed against the collateral granted to them to secure that debt, which would </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seriously harm our business. In addition, should we be unable to comply with these or certain other covenants or if we default on any portion of our outstanding borrowings, the lenders can also impose an exit fee of a percentage of the amount borrowed pursuant to the Term Loan Credit Agreement. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Virtually all of our research and development activities and the significant majority of our general and administrative activities are performed in or managed from a single site that may be subject to lengthy business interruption in the event of a severe earthquake. We also may suffer loss of computerized information and may be unable to make timely filings with regulatory agencies in the event of catastrophic failure of our data storage and backup systems.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Virtually all of our research and development activities and the significant portion of our general and administrative activities are performed in or managed from our facilities in Concord, California, which are within an active earthquake fault zone. Should a severe earthquake occur, we might be unable to occupy our facilities or conduct research and development and general and administrative activities in support of our business and products until such time as our facilities could be repaired and made operational. Our property and casualty and business interruption insurance in general does not cover losses caused by earthquakes. While we have taken certain measures to protect our scientific, technological and commercial assets, a lengthy or costly disruption due to an earthquake would have a material adverse effect on us. We have also taken measures to limit damage that may occur from the loss of computerized data due to power outage, system or component failure or corruption of data files. However, we may lose critical computerized data, which may be difficult or impossible to recreate, which may harm our business. We may be unable to make timely filings with regulatory agencies in the event of catastrophic failure of our data storage and backup systems, which may subject us to fines or adverse consequences, up to and including loss of our ability to conduct business.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is increasingly dependent on complex and interdependent information technology systems, including internet-based systems, databases and programs, to support our business processes as well as internal and external communications. As use of information technology systems has increased, deliberate attacks and attempts to gain unauthorized access to computer systems and networks have increased in frequency and sophistication. Our information technology, systems and networks are potentially vulnerable to breakdown, malicious intrusion and computer viruses which may result in the impairment of production and key business processes or loss of data or information. We are also potentially vulnerable to data security breaches&#8212;whether by employees or others&#8212;which may expose sensitive data to unauthorized persons. For example, we have in the past and may in the future be subject to &#8220;phishing&#8221; attacks in which third parties send emails purporting to be from reputable sources. Phishing attacks may attempt to obtain personal information, infiltrate our systems to initiate wire transfers or otherwise obtain proprietary or confidential information. Although we have not experienced any losses as a result of such attacks or any other breaches of data security, such breaches could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, distributors, customers and others. Breaches and other inappropriate access can be difficult to detect and any delay in identifying them could increase their harm. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Any such breaches of security and inappropriate access could disrupt our operations, harm our reputation or otherwise have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to attract, retain and motivate key personnel or to retain the members of our executive management team, our operations and our future growth may be adversely affected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent upon our executive management team and other critical personnel, including our specialized research and development, regulatory and operations personnel, many of whom have been employed with us for many years and have a significant amount of institutional knowledge about us and our products. We do not carry &#8220;key person&#8221; insurance. If one or more members of our executive management team or other key personnel were to retire or resign, our ability to achieve development, regulatory or operational milestones for commercialization of our products could be adversely affected if we are unable to replace them with employees of comparable knowledge and experience. In addition, we may not be able to retain or recruit other qualified individuals, and our efforts at knowledge transfer could be inadequate.&#160;If knowledge transfer, recruiting and retention efforts are inadequate, significant amounts of internal historical knowledge and expertise could become unavailable to us.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on our ability to attract, retain and motivate skilled and highly qualified personnel in order to grow our company. Competition for qualified personnel in the medical device and pharmaceutical industry is very intense. If we are unable to attract, retain and motivate quality individuals, our business, financial condition, ability to perform under our BARDA agreement, or results of operations and growth prospects could be adversely affected. Even if we are able to identify and hire qualified personnel commensurate with our growth objectives and opportunities, the process of integrating new employees is time consuming, costly and distracting to existing employees and management. Such disruptions may have an adverse impact on our operations, our ability to service existing markets and customers, or our ability to comply with regulations and laws.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the employees of our subsidiary, Cerus Europe B.V., are employed outside the U.S., including in France, where labor and employment laws are relatively stringent and, in many cases, grant significant job protection to certain employees, including rights on termination of employment. In addition, one of our manufacturing partners that we are dependent on is located in France and may </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have employees that are members of unions or represented by a works council as required by law. These more stringent labor and employment laws to the extent that they are applicable, coupled with the requirement to consult with the relevant unions or works&#8217; councils, could increase our operational costs with respect to our own employees and could result in passed through operational costs by our manufacturing partner. If the increased operational costs become significant, our business, financial condition and results of operations could be adversely impacted.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards and certain other tax attributes is uncertain and may be limited.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to use our federal and state net operating loss, or NOL, carryforwards to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income before the expiration dates of the NOL carryforwards, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOL carryforwards. Under the Tax Act, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the Tax Act. In addition, utilization of NOL carryforwards to offset potential future taxable income and reduce income taxes that would otherwise be due is subject to annual limitations under the &#8220;ownership change&#8221; provisions of Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state provisions, which may result in the expiration of NOL carryforwards before future utilization. In general, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research and development credit carryforwards) to offset its post-change taxable income or taxes may be limited. Our equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. Although we have completed studies to provide reasonable assurance that an ownership change limitation would not apply, we cannot be certain that a taxing authority would reach the same conclusion. If, after a review or audit, an ownership change limitation were to apply, utilization of our domestic NOL and tax credit carryforwards could be limited in future periods and a portion of the carryforwards could expire before being utilized to reduce future income tax liabilities. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property or operate our business without infringing intellectual property rights of others.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend, in part, on obtaining and maintaining patent protection on our products and successfully defending our products against third-party challenges. Our technology will be protected from unauthorized use only to the extent that it is covered by valid and enforceable patents or effectively maintained as trade secrets. As a result, our success depends in part on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">obtain patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">protect trade secrets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">operate without infringing upon the proprietary rights of others&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">prevent others from infringing on our proprietary rights.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that our patents or patents that we license from others will be enforceable and afford protection against competitors. Our patents or patent applications, if issued, may be challenged, invalidated or circumvented. Our patent rights may not provide us with proprietary protection or competitive advantages against competitors with similar technologies. Others may independently develop technologies similar to ours or independently duplicate our technologies. For example, we are aware of a recently expired U.S. patent issued to a third-party that covers methods to remove psoralen compounds from blood products. We have reviewed the patent and believe there exist substantial questions concerning its validity. We cannot be certain, however, that a court would hold the patent to be invalid or not infringed by our platelet or plasma systems. In this regard, whether or not we have infringed this patent will not be known with certainty unless and until a court interprets the patent in the context of litigation. In the event that we are found to have infringed any valid claim of this patent, we may, among other things, be required to pay damages. Our patents expire at various dates between 2019 and 2031. Recent patent applications will, if granted, result in patents with later expiration dates. In addition, we have a license from Fresenius to U.S. and foreign patents relating to the INTERCEPT Blood System, which expire at various dates between 2019 and 2024. Due to the extensive time required for development, testing and regulatory review of our potential products, our patents may expire or remain in existence for only a short period following commercialization. This would reduce or eliminate any advantage of the patents.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that we were the first to make the inventions covered by each of our issued patents or pending patent applications or that we were the first to file patent applications for such inventions. We may need to license the right to use third-party patents and intellectual property to continue development and commercialization of our products, including in connection with our planned commercialization of the platelet and plasma systems in the U.S. We may not be able to acquire such required licenses on </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acceptable terms, if at all. If we do not obtain such licenses, we may need to design around other parties&#8217; patents, or we may not be able to proceed with the development, manufacture or sale of our products.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patents do not cover all of the countries in which we are selling, and planning to sell, our products. We will not be able to prevent potential competitors from using our technology in countries where we do not have patent coverage. Further, the laws of some foreign countries may not protect intellectual property rights to the same extent as the laws of the U.S., including the CIS countries, China and India, jurisdictions where we are currently expanding our commercialization efforts through distributors. In certain countries, compulsory licensing laws exist that may be used to compel a patent owner to grant licenses to third parties, for reasons such as non-use of the patented subject matter within a certain period of time after patent grant or commercializing in a manner that is cost-prohibitive in the country. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license for INTERCEPT to a third-party, which could materially diminish the value of such patents. This could adversely impact our potential product revenue opportunities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may face litigation requiring us to defend against claims of infringement, assert claims of infringement, enforce our patents, protect our trade secrets or know-how or determine the scope and validity of others&#8217; proprietary rights. Patent litigation is costly. In addition, we may require interference proceedings before the U.S. Patent and Trademark Office to determine the priority of inventions relating to our patent applications. Litigation or interference proceedings could be expensive and time consuming, and we could be unsuccessful in our efforts to enforce our intellectual property rights. We may rely, in certain circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We protect our proprietary technology and processes, in part, by confidentiality agreements with employees, consultants and contractors. These agreements may be breached and we may not have adequate remedies for any breach or our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use intellectual property owned by others, disputes also may arise as to the rights in related or resulting know-how and inventions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As our international operations grow, we may be subject to adverse fluctuations in exchange rates between the U.S. dollar and foreign currencies, as well as to tariffs and other trade restrictions.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our international operations are subject to risks typical of an international business, including, among other factors: differing political, economic, and regulatory climates, different tax structures and foreign exchange volatility. We do not currently enter into any hedging contracts to normalize the impact of foreign exchange fluctuations. As a result, our future results could be materially affected by changes in these or other factors.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales of the INTERCEPT Blood System sold outside of the U.S. are typically invoiced to customers in Euros. In addition, we purchase finished INTERCEPT disposable kits for our platelet and plasma systems and incur certain operating expenses in Euros and other foreign currencies. Our exposure to foreign exchange rate volatility is a direct result of our product sales, cash collection and cash payments for expenses to support our international operations. Foreign exchange rate fluctuations are recorded as a component of other income, net on our consolidated statements of operations. Significant fluctuations in the volatility of foreign currencies relative to the U.S. dollar may materially affect our results of operations. For example, the announcement of Brexit caused severe volatility in global currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against foreign currencies in which we transact business. Should this foreign exchange volatility continue or increase, it could cause volatility in our results of operations. In addition, in a period where the U.S. dollar is strengthening/weakening as compared to Euros and other currencies we transact in, our product revenues and expenses denominated in Euros or other foreign currencies are translated into U.S. dollars at a lower/higher value than they would be in an otherwise constant currency exchange rate environment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently we do not have a formal hedging program to mitigate the effects of foreign currency volatility. As our commercial operations grow globally, our operations are exposed to more currencies and as a result our exposure to foreign exchange risk will grow.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Trump administration has called for substantial changes to foreign trade policy and has recently imposed tariffs on certain U.S. imports. Canada, the E.U., China and other countries have responded with retaliatory tariffs on certain U.S. exports. We also rely on various U.S. corporate tax provisions related to international commerce. If we are subject to new regulations, including those under the Tax Act, or if restrictions and tariffs increase our operating costs in the future, and we are not able to recapture those costs from our customers, or if such initiatives, regulations, restrictions or tariffs make it more difficult for us to compete in overseas markets, our business, financial condition and results of operations could be adversely impacted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the London Inter-Bank Offered Rate, or LIBOR, is discontinued, interest payments under our Term Loan Credit Agreement or Revolving Loan Credit Agreement may be calculated using another reference rate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the Chief Executive of the U.K. Financial Conduct Authority, or FCA, which regulates LIBOR, announced that the FCA intends to phase out the use of LIBOR by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIBOR with the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there have been certain issuances utilizing SOFR, it is unknown whether this or any other alternative reference rate will attain market acceptance as a replacement for LIBOR. U.S. dollar LIBOR is used as a benchmark rate in our Term Loan Credit Agreement and Revolving Loan Credit Agreement. There remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, and any potential effects of the transition away from LIBOR on us are not known. The transition process may involve, among other things, increased volatility and illiquidity in markets for instruments that currently rely on LIBOR and may result in increased borrowing costs, the effectiveness of related transactions such as hedges, uncertainty under applicable documentation, including our Term Loan Credit Agreement and Revolving Loan Credit Agreement, or difficult and costly processes to amend such documentation. As a result, our ability to refinance our Term Loan Credit Agreement, Revolving Loan Credit Agreement or other indebtedness or to hedge our exposure to floating rate instruments may be impaired, which would adversely affect the operations of our business.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have a limited trading volume, which results in higher price volatility for, and reduced liquidity of, our common stock.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares of common stock are currently quoted on the Nasdaq Global Market under the symbol &#8220;CERS.&#8221; The market for our common stock has been limited due to low trading volume and the small number of brokerage firms acting as market makers. Active trading markets generally result in lower price volatility and more efficient execution of buy and sell orders. The absence of an active trading market increases price volatility and reduces the liquidity of our common stock. As long as this condition continues, the sale of a significant number of shares of common stock at any particular time could be difficult to achieve at the market prices prevailing immediately before such shares are offered, which may limit our ability to effectively raise money. In addition, due to the limitations of our market and the volatility in the market price of our stock, investors may face difficulties in selling shares at attractive prices when they want to sell. As a result of this lack of trading activity, the quoted price for our common stock is not necessarily a reliable indicator of its fair market value.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are obligated to develop and maintain proper and effective internal control over financial reporting. In the future, we may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weakness identified by our management in our internal control over financial reporting, as well as a statement that our independent registered public accounting firm has issued an attestation report on the effectiveness of our internal control over financial reporting.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complying with Section 404 requires a rigorous compliance program as well as adequate time and resources. As a result of expanding our commercialization efforts, developing, improving and expanding our core information technology systems as well as implementing new systems to support our sales, supply chain activities and reporting capabilities, all of which require significant management time and support, we may not be able to complete our internal control evaluation, testing and any required remediation in a timely fashion. Additionally, if we identify one or more material weaknesses in our internal control over financial reporting, we will not be unable to assert that our internal controls are effective. <span style="Background-color:#FFFFFF;color:#000000;">Should </span>our internal controls be deemed ineffective, our ability to obtain additional financing, or obtain additional financing on favorable terms, could be materially and adversely affected which, in turn, could materially and adversely affect our business, our financial condition and the value of our common stock. If we are unable to assert that our internal control over financial reporting is effective in the future, or if our independent registered public accounting firm is unable to express an opinion or expresses an adverse opinion on the effectiveness of our internal controls in the future, investor confidence in the accuracy and completeness of our financial reports could be further eroded, which would have a material adverse effect on the price of our common stock.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions of our charter documents, our stockholder rights plan, our compensatory arrangements and Delaware law could make it more difficult for a third-party to acquire us, even if the offer may be considered beneficial by our stockholders.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of the Delaware General Corporation Law could discourage potential acquisition proposals and could delay, deter or prevent a change in control. The anti-takeover provisions of the Delaware General Corporation Law impose various impediments to the ability of a third-party to acquire control of us, even if a change in control would be beneficial to our existing stockholders. In addition, Section&#160;203 of the Delaware General Corporation Law, unless its application has been waived, provides certain default anti-takeover protections in connection with transactions between us and an &#8220;interested stockholder&#8221;. Generally, Section&#160;203 prohibits stockholders who, alone or together with their affiliates and associates, own more than 15% of the subject company from engaging in certain business combinations for a period of three years following the date that the stockholder became an interested stockholder of such subject company without approval of the board or the vote of two-thirds of the shares held by the independent stockholders. Our board of directors has also adopted a stockholder rights plan, or &#8220;poison pill,&#8221; which would significantly dilute the ownership of a hostile acquirer. Additionally, provisions of our amended and restated certificate of incorporation and bylaws could deter, delay or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent a third-party from acquiring us, even if doing so would benefit our stockholders, including without limitation, the authority of the board of directors to issue, without stockholder approval, preferred stock with such terms as the board of directors may determine. In addition, our executive employment agreements, change of control severance benefit plan and equity incentive plans and agreements thereunder provide for certain severance benefits in connection with a change of control of us, including single-trigger equity vesting acceleration benefits with respect to outstanding stock options, which could increase the costs to a third-party acquirer and/or deter such third-party from acquiring us.</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">DEFAULTS UPON SENIOR SECURITIES</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">MINE SAFETY DISCLOSURES</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;5.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_OR_INFORMATION">OTHER INFORMATION</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 6.</span></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_EXHIBITS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">E</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">XHIBITS</span></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7.5pt;">&#160;</p></td>
<td valign="bottom" style="width:88.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:10.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:88.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 (1)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:-5.6pt;;text-indent:5.6pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1020214/000119312512460653/d398575dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Cerus Corporation.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 (1)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1020214/000119312512460653/d398575dex32.htm"><span style="text-decoration:underline;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3 (4)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1020214/000119312514303221/d748617dex33.htm"><span style="text-decoration:underline;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation. </span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4 (2)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1020214/000119312508136741/dex32.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of Cerus Corporation.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.1 (3)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1020214/0000950149-97-000045-index.html"><span style="text-decoration:underline;">Specimen Stock Certificate (see Exhibit 4.2 to Form S-1 Registration Statement filed with the SEC on January 8, 1997).</span></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cers-ex101_169.htm">2019 and 2020 Executive Officer Compensation Arrangements.</a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2*</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<a href="cers-ex102_170.htm"><span style="text-decoration:underline;">Amended and Restated Non-Employee Director Compensation Policy, effective March 27, 2020.</span>
</a></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3<span style="color:#000000;">&#8224;</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cers-ex103_76.htm"><span style="text-decoration:underline;">Side Letter to Supply Agreement, dated January 14, 2020, by and between Cerus Corporation and Fresenius Kabi Deutschland GmbH.</span></a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;31.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cers-ex311_8.htm"><span style="text-decoration:underline;">Certification of the Principal Executive Officer of Cerus Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;31.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cers-ex312_6.htm"><span style="text-decoration:underline;">Certification of the Principal Financial Officer of Cerus Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;32.1 (5)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cers-ex321_7.htm"><span style="text-decoration:underline;">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF </p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB </p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE </p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104 </p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td>
</tr>
<tr style="height:9pt;">
<td valign="top" style="width:10.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Incorporated by reference to the like-described exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended September 30, 2012.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Incorporated by reference to the like-described exhibit to the Registrant&#8217;s Current Report on Form 8-K (File No. 000-21937), filed with the SEC on June&#160;19, 2008.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Incorporated by reference to the like-described exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-11341) and amendments thereto.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Incorporated by reference to the like-described exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended June&#160;30, 2014.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><span style="color:#000000;">Compensatory plan.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:8pt;">Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted as the Registrant has determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to the Registrant if publicly disclosed.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 5, 2020</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kevin D. Green</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin D. Green</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(on behalf of registrant and as Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cers-ex101_169.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex101_169.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_103"></a><a name="EXHIBIT_103"></a>Exhibit 10.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 and 2020 Executive Officer Compensation Arrangements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation for the executive officers of Cerus Corporation regarding annual base salaries and target bonus percentages were as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:46.5%;"></td>
<td style="width:11.46%;"></td>
<td style="width:14.29%;"></td>
<td style="width:13.91%;"></td>
<td style="width:13.84%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 1.5pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019<br />Annual&#160;Base<br />Salary as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 1</p></td>
<td valign="bottom"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019<br />Targeted&#160;Bonus<br />(paid in 2020)</p></td>
<td valign="bottom"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020<br />Annual&#160;Base<br />Salary as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 1</p></td>
<td valign="bottom"  style=" border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020<br />Targeted&#160;Bonus<font style="font-weight:normal;"><br /></font>(to be paid in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DAEEF3" style=" border-top:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Greenman</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3" style=" border-top:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$650,000</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3" style=" border-top:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3" style=" border-top:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$675,000</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3" style=" border-top:solid 1.5pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin D. Green</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">VP, Finance and Chief Financial Officer</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$409,336</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$429,803</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DAEEF3">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Benjamin </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$429,698</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$444,737</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurence M. Corash, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$441,537</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$445,953</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DAEEF3">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vivek Jayaraman</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Operating Officer</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$434,805</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50%</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$478,286</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50%</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chrystal N. Menard</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Legal Officer and General Counsel</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$402,436</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$416,522</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DAEEF3">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carol Moore</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Senior Vice President, Regulatory Affairs and Quality </p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$367,427</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$380,287</p></td>
<td valign="bottom"  BGCOLOR="#DAEEF3">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45%</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cers-ex102_170.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex102_170.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 10.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Cerus Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated Non-Employee Director Compensation Policy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Effective: January 1, 2012</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended by Compensation Committee: February 13, 2014</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approved by Board of Directors: February 14, 2014</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended by Board of Directors: April 19, 2017 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended by Board of Directors: March 2, 2018</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended by Board of Directors: March 27, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each member of the Board of Directors (the &#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221;) of Cerus Corporation (&#8220;<font style="font-weight:bold;font-style:italic;">Cerus</font>&#8221;) who is not also serving as an employee of Cerus or any of its affiliates (each such member, a &#8220;<font style="font-weight:bold;font-style:italic;">Director</font>&#8221;) will receive the compensation set forth in this Cerus Corporation Amended and Restated Non-Employee Director Compensation Policy (this &#8220;<font style="font-weight:bold;font-style:italic;">Policy</font>&#8221;) for his or her Board service, as applicable.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Cash Compensation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual cash compensation set forth below is payable to each Director, as applicable, in equal quarterly installments, payable in advance during the first 30 days of each quarter in which the service will occur.&nbsp;&nbsp;If a Director joins the Board, or becomes Chairman of the Board or a Chairman or other member of any of the committees of the Board set forth below, in each case at a time other than effective as of the first day of the calendar year, each applicable element of the annual cash compensation set forth below will be pro-rated based on days served in the applicable calendar year, with the pro-rated amount paid for the first quarter in which the Director provides the service (payable not later than 30 days after the Director commences such service), and regular full quarterly amounts paid thereafter.  The annual cash compensation is vested upon payment.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Annual Cash Retainer:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">Chairman of the Board: $</font>67,500</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">All other Directors: $</font>45,000</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Committee Chair Service Fee:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">Chairman of the Audit Committee: $26,000</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">Chairman of</font> the Compensation Committee: $15,000</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font><font style="letter-spacing:-0.2pt;">Chairman of the Nominating and Corporate Governance Committee: $10,000</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Committee Member (non-Chair) Service Fee:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">Audit Committee: $13,000</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">Compensation Committee: $8,000</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1</a>.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font><font style="margin-left:36pt;">Nominating and Corporate Governance Committee: $6,000</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The equity compensation set forth below will be granted under the Cerus Corporation Amended and Restated 2008 Equity Incentive Plan (the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;).&nbsp;&nbsp;All stock options granted pursuant to this Policy will be non-statutory stock options, with an exercise price per share equal to 100% of the &#8220;Fair Market Value&#8221; (as defined in the Plan) of the underlying Cerus common stock on the date of grant, and a term of not more than ten (10) years from the date of grant.&nbsp;&nbsp;All equity awards granted pursuant to this Policy will be made automatically in accordance with the terms of this Policy and the Plan, without the need for any additional corporate action by the Board or the Compensation Committee of the Board.&nbsp;&nbsp;All equity awards granted pursuant to this Policy will become fully vested immediately prior to a &#8220;Change in Control&#8221; (as defined in the Plan), subject to the Director&#8217;s &#8220;Continuous Service&#8221; (as defined in the Plan) through such time.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Annual Grant, Non-Chair:</font> On the date of each of Cerus&#8217; Annual Meetings of Stockholders (each, an &#8220;<font style="font-weight:bold;font-style:italic;">Annual Meeting</font>&#8221;), each Director, other than the Chairman of the Board, will be granted the following equity awards, provided that such individual: (i) is a Director on such date, (ii) has been a member of the Board for at least twelve (12) months prior to the date of the applicable Annual Meeting and (iii) will be continuing as a Director immediately following such date:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="margin-left:36pt;"></font>a stock option for the number of shares of Cerus common stock equal to (i) $75,000, divided by (ii) the Black-Scholes value of a stock option share, determined using the average daily closing sales price per share of Cerus common stock for the thirty (30) market trading days immediately prior to the grant date (the &#8220;<font style="font-weight:bold;font-style:italic;">Average 30-Day Price</font>&#8221;), with the resulting number rounded down to the nearest whole share, with such stock option vesting on the later of (x) the first anniversary of the date of grant or (y) the day prior to the next Annual Meeting, subject to the Director&#8217;s Continuous Service through the applicable vesting date; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="margin-left:36pt;"></font>a restricted stock unit award (&#8220;<font style="font-weight:bold;font-style:italic;">RSU</font>&#8221;) for the number of shares of Cerus common stock equal to (i) $75,000, divided by (ii) the Average 30-Day Price, with the resulting number rounded down to the nearest whole share, with 100% of the shares subject to such RSU vesting on the later of (x) the first anniversary of the date of grant or (y) the day prior to the next Annual Meeting, subject to the Director&#8217;s Continuous Service through the applicable vesting date.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Annual Grant, Chair: </font>On the date of each Annual Meeting, the Chairman of the Board will be granted the following equity awards, provided that such individual: (i) is a Director and the Chairman of the Board on such date, (ii) has been a member of the Board for at least twelve (12) months prior to the date of the applicable Annual Meeting and (iii) will be continuing as a Director and the Chairman of the Board immediately following such date:<font style="font-weight:bold;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(a) <font style="margin-left:36pt;"></font>a stock option for the number of shares of Cerus common stock equal to (i) $90,500, divided by (ii) the Black-Scholes value of a stock option share, determined using the Average 30-Day Price, with the resulting number rounded down to the nearest whole share, with such stock option vesting on the later of (x) the first anniversary of the date of grant or (y) the day </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to the next Annual Meeting</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject to the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s Continuous Service</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through the applicable vesting date; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="margin-left:36pt;">an RSU </font>for the number of shares of Cerus common stock equal to (i) $90,500, divided by (ii) the Average 30-Day Price, with the resulting number rounded down to the nearest whole share, with 100% of the shares subject to such RSU vesting on the later of (x) the first anniversary of the date of grant or (y) the day prior to the next Annual Meeting, subject to the Director&#8217;s Continuous Service through the applicable vesting date.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Initial Grant. </font><font style="Background-color:#FFFFFF;color:#000000;">On the date of the Director&#8217;s initial election to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Director will be granted the following equity awards:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="margin-left:36pt;"></font>a stock option for the number of shares of Cerus common stock equal to (i) $112,500, divided by (ii) the Black-Scholes value of a stock option share, determined using the average daily closing sales price per share of Cerus common stock for the thirty (30) market trading days immediately prior to the grant date (the &#8220;<font style="font-weight:bold;font-style:italic;">Average 30-Day Price</font>&#8221;), with the resulting number rounded down to the nearest whole share, with such stock option vesting in three (3) equal annual installments following the date of grant, subject to the Director&#8217;s Continuous Service through the applicable vesting date; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="margin-left:36pt;">a restricted stock unit award (&#8220;</font><font style="font-weight:bold;font-style:italic;">RSU</font>&#8221;) for the number of shares of Cerus common stock equal to (i) $112,500, divided by (ii) the Average 30-Day Price, with the resulting number rounded down to the nearest whole share, with such RSU vesting in three (3) annual installments following the date of grant, subject to the Director&#8217;s Continuous Service through the applicable vesting date, subject to the Director&#8217;s Continuous Service through the applicable vesting date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3</a>.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>cers-ex103_76.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex103_76.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***] = CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BECAUSE THE OMITTED PORTIONS ARE BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3_</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gq2jml0zqpqg000001.jpg" title="" alt="" style="width:153px;height:52px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14 January 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Via Electronic Mail</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fresenius Kabi Deutschland GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Else-Kr&#246;ner-Stra&#223;e 1 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61352 Bad Homburg </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Dr. Christian Hauer </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Re:&nbsp;&nbsp;Side Letter to Supply Agreement<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Mr. Hauer:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to the Amended and Restated Manufacturing and Supply Agreement between Fresenius Kabi Deutschland GmbH (&#8220;Fresenius Kabi&#8221;) and Cerus Corporation (&#8220;Cerus&#8221;), effective July 1, 2015, as amended from time to time (the &#8220;Agreement&#8221;). Capitalized terms used but not otherwise defined in this side letter agreement (the &#8220;Letter Agreement&#8221;) shall have the meanings ascribed to them in the Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Letter Agreement sets forth the understanding between Cerus and Fresenius regarding additional terms and conditions relating to the payment terms for production volumes from December 2019 through June 30, 2020 (the &#8220;Letter Term&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties hereby acknowledge and agree that, during the Letter Term, Cerus will pay for production volumes in excess of any firm purchase order set forth in the rolling forecast described in Section 2.4 of the Agreement (the &#8220;Excess Production Volume&#8221;) up to [***] within [***] after the date of Fresenius Kabi&#8217;s invoice related to the applicable Manufactured Product. The payment terms for Excess Production Volume above [***] shall be [***]; provided however, that during the Letter Term, Fresenius Kabi shall not [***] without Cerus&#8217; prior written consent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, this Letter Agreement and the Agreement constitute the entire agreement between Cerus and Fresenius Kabi with respect to the subject matter described herein. Except as otherwise set forth herein, the terms of the Agreement shall continue in full force and effect after the date hereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please indicate your acceptance of the terms and provisions of this Letter Agreement by signing below and returning the signed copy to my attention. This Letter Agreement may be executed in counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same instrument.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Best Regards,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERUS CORPORATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ William M. Greenman</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: William M. Greenman</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Chief Executive Officer and President</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Kevin D. Green</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Kevin D. Green</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Financial Officer and Vice President, Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gq2jml0zqpqg000001.jpg" title="" alt="" style="width:153px;height:52px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ACKNOWLEDGED AND AGREED:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FRESNIUS KABI DEUTSCHLAND GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Christian Hauer</font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="margin-left:36pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Christian Hauer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; President, Transfusion Medicine &amp; Cell Therapies Division</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;<font style="text-decoration:underline;">/s/ Dirk Roehner</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dirk Roehner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Financial Officer, Transfusion Medicine &amp; Cell Therapies Division</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc:<font style="margin-left:36pt;">Chrystal Menard, Chief Legal Officer and General Counsel, Cerus Corporation</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Marcel Kirsch, Director Finance &amp; Controlling, Global Operations Disposables &#8211; Transfusion Medicine &amp; Cell Therapies Division</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">Scott Day, Vice President and Chief IP Counsel, Transfusion Medicine &amp; Cell Therapies Division</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cerus Corporation<font style="font-weight:normal;margin-left:36pt;">1220 Concord Avenue, Concord, CA US 94520T 925 288 6000</font><font style="font-weight:normal;margin-left:117pt;">F 925 288 6001</font><font style="font-weight:normal;margin-left:315pt;">cerus.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***] = CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BECAUSE THE OMITTED PORTIONS ARE BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>cers-ex311_8.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex311_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, William M. Greenman, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Cerus Corporation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 5, 2020</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William M. Greenman&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Greenman</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>cers-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kevin D. Green, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form&#160;10-Q of Cerus Corporation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 5, 2020</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kevin D. Green&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin D. Green</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>cers-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cers-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), William M. Greenman, the Chief Executive Officer of Cerus Corporation (the &#8220;Company&#8221;) and Kevin D. Green, the Chief Financial Officer of the Company, hereby certify that, to the best of their knowledge:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The Company&#8217;s Quarterly Report on Form&#160;10-Q for the period ended March&#160;31, 2020, to which this Certification is attached as Exhibit&#160;32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange Act, and</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 5th day of May, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William M. Greenman&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Greenman</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer (Principal&#160;Executive Officer)</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kevin D. Green&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin D. Green</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Financial Officer (Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cerus Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gq2jml0zqpqg000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gq2jml0zqpqg000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[@ .061O8F4 9       _^$ 2D5X:68
M $U- "H    (  ,!&@ %     0   #(!&P %     0   #H!*  #     0 "
M         2P    !   !+     $  /_B\ !)0T-?4%)/1DE,10 !"@ (@'!!
M1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$
M0D4                       #VU@ !     -,M041"10
M                                                "F1E<V,   #\
M    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(
M  &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R
M03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O
M871E9" H4U=/4"D@=C(
M
M    =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N
M  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MFO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ. 8V.HGYN
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MQ(N YH&VOO-_^''"N9!_2F%*M&U^XE -KYY^Q#VMJU]^Y2E=J&9_,@^%J<.
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M@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F S(8C@4.
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MX@  AQF  ),JL+><^8/+K&::2W/4J#B7U6,OI$&5K5'.H)23Y3]FG5F2PRM
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MIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^ M4GVJTR
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MC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P  @ !]T)!
MG8UQ8X)(FQ!R47,\F,-S.F,FEJ-T(E'PE+9U##]EDRIUZ2K3DG5V>A XE/5U
M\@  @ "  (^8G"%YV8%UF;IZ$G)]EVUZ36)@E5-ZE5$]DVIZZ3[+D>%[0"I9
MD1Q[<1 &DR][)0  @ "  ([/FLR"/8"2F&Z!VW&$EBV!>6&0E!.!)E![DC>
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MNC&#?UTUMB."VE!6LA6"2T*TKBN!US04JK>!FB.4J(6!G@^IJ3"!K@  FFR
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MI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1O!*"F*V,@P  D">
M    @ "  &KPI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\EVJ6YQ*J
MEZF,G@ +CXJ "   @ "  &&SN'Q@B57TM7QB4DFALI!D&#QAK\-EPRV[K8QG
M)1R2K41GN A<KJ1G:P  DUARV   @ "  &$PMY%GVU7'M$]I DF2L15J.#QO
MK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@  @ "  &#JM@MN[%5WLK]O
MDDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@   @ "  &"J
MM&1UV%4EL1IV&4C]K=!V83P$JJMVNBVJJ"!W"QT7IS)W!@FHIWIW.   C[]_
M%@  @ "  &!HLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9I8Y\F0GJ
MI8A]&0  CL&     @ "  & NL=J#\53'KH&#ETBCJR2#*CN;I_&"P2UOI4B"
M@QTEI!""H HGH\R".0  C>.     @ "  %_]L/R+%%2UK8V*?4B8JA^)O#N+
MIN&)""U=I#&(MATKHMZ)( IEHDJ&B   C3.     @ "  %_9L%>21E2RK,N1
M?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R     @ "  %_!
MK]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*')@  C "
M    @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW<+ELT4;'
M<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)ORW)&;,]Q
M8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'9GUV\X5S
M:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN 7:FX8?6
M#Y=#9&Q_R(/N9L%_C6^7:0%_:5I2:QA_34//;+Y_*2I";.1^[0AV<;-^AKG,
M756+!*@@8!>)W)6R8J:(M8)I90R'EVY29V*&CEDU:9"%IT+G:SF$S2F):QF$
M&@@4<EF"/[AQ6\"5LZ;47I*3NY1P82V1M8$Q8Z*/MFTM9@.-U%@\:#>,'4(:
M:>.*H"CE:7Z)L0?!<N6%/K=<6GF@8Z7,75:=GI-J7_6:NH Q8G"7WFP]9-Z5
M,5=J9QJ2P$%Q:+N0KRA@:!>/R@=\<UF%$+:.67^K#J4%7&*G?)*<7OZCOG]?
M87:@"&MN8^><F5:M9BR9CT#69\F7)R?L9N*5(@=$<[B$ZK8*6-2UK*1^6[6Q
M/Y(#7D2LI7ZZ8+&H(6K/8QVD U8?96"@?D!-9O">'R=N9<B97P<8= .$S+,W
M;NQ?1Z*9<$]B,9$.<:=DZ7YH<O9G=VJT=#]I[57I=8%L33^\=J1N=R8"=UIO
M_ 0R>PEQ$K'";"QIJZ%[;<]KC)  ;U!M4'UK<+UN_VG#<B!PGU4.<WAR,C[X
M=*!SFB57=0]T> /A>7)UR; Q:;5S])_-:WYTWXY[;2!UN'OV;JUVC&AZ<#!W
M8%/M<:%X+CW^<LEXW"2'<N9Y)@.9>>MZ1JZ29X)^'YXF:69^+8S::R%^+GJ5
M;,=^*6<X;FE^,%+9;^Y^.ST<<1=^/"/2<.%^$ -;>E-^*ZT099^(1YRS9YB'
MBXML:6F&NGDN:R"%X683;-&%%5'7;FR$9SQ+;Y*#QR,P;P:#4P,F>JV!@JO6
M9!B2?9N 9A^0_(I!9_J/67@.:;^-KV4%:WJ,&E#V;1:*KSN4;CJ)B"*@;5V)
M'P+Z>OF" ZK<8MR<M9J)9.R:<HE+9LN7_G<?:)65A60E:ER3-5 V:_Z1)CK_
M;1*/CR(O:^J.W +5>S>!ZJHC8>RF[9G,8_ZCZ8B$9=F@J'969Y^=8F-@:6J:
M84^ :Q27T3IN;"&6%B'):JJ3D *W>VJ!UJFM846Q'YE&8U2M6X?H92*I376Q
M9MRE16+%:**AI$[Z:DJ>MCGK:TJ<^B%/:8J6A0*?>Y.!Q:6D=Q5>PY9Z=Z]A
MNH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP  @ !R8*1X
M='EHC95:=51JCH4!=B5L:7.+=O9N)V#N=\MOU4TB>*-Q;#?#>69RQQXH>=AS
M40  @ !W!:,V<A=R4)0"<Q]S;H/D= YT=')H=/AU9E_L=>!V4TQ&=L=W-C<1
M=X5W[1V==Y)X!P  @ ![&*'$;_5[]Y*-<1=\3X)8<A]\C'$9<QY\N5ZX="5\
MZ4L\=1Y]&#8U==5]-ASS=7=] P  @ !^HJ!L;B:%G)$X;UJ%.X$(<'6$MV_4
M<8.$'UVT<I2#D$I5<Y^#%S5\=$V"K1QJ<X6";P  @ "  )]0;*^/5I @;>^.
M/G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P  @ "  )YM
M:X"9$X\\;,B71W\4;>Z5/VWP;PN3)UON<"Z1-$C<<3>/B#19<<6.<1N0<%V-
M6   @ "  )W$:I:BTXZ*:^.@5WY8;06=D6TU;AV:O%LV;T*8*T@P<%*6&3/1
M<-25'QLZ;S61>@  @ "  )U4:?&LEXX(:SVI<GW!;%2E\FR7;5^B:UJE;GV?
M34>U;XJ= S-6;_^;>!K$;D>2&0  @ "  )A0?Y=>6HI)?W!A1GL8?WAC^&J6
M?YYF=EC8?]=HU47&@"YK#3#E@+YLWA:U@CUM-   @ !V7)=3?1MGF(E&?3EI
MI'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP  @ !Z9Y8Y
M>M=POH@!>R!R 7CE>V)S)VAX>[!T-U;Z? AU.D0O?'!V*2^7?-MVV!7%?4AV
MA0  @ !]\Y4%>,1YYX:\>2IZ<G>7>85ZVV=Y>>%[.580>DY[CD-Q>L![W"\)
M>QM\"A5F>QU[I@  @ "  )/3=P>##H6N=W^"\W:$=^J"L&9->%*"4E4?>,>!
M^T*6>4B!M"Y7>9*!=A3I>4V!4P  @ "  )+4=:2,2X2I=B:+AW6$=I>*D658
M=P:)@U0Z=WZ(@T'@=_:'KBW&>#"'+12!=\:&I@  @ "  )('=(*5B8/;=0R4
M(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@  @ "  )%J
M<Z">S(,W=#"<RG0+=)Z:>&/G=0B8$U+7=8:5\T"A=@"49BS:=@>3_A/U=7>-
M?@  @ "  )#]<OVH'(*Z<X^EBG-]<_2BDV-5=%&?CU)3=,:<_4 S=3F;:BQL
M=3.9C!.+=+2--P  @ "  (LLB'Y=\'X1AZU@QV_3AQUC:F!'AKAEVT]TAG%H
M)STKAF9J.RB\ANUKN0X&B/YK1P  @ !YTXI1AC1FK7TZA:1HM6[LA2UJFE]S
MA,YL8DZZA(IN#SR/A'QOCRA A-]PCPW7ADEO]0  @ !]6(E>A =O4WP=@Z1P
MHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P  @ "  (A/
M@A1WZ'KZ@<5XEVRX@7AY*EV$@3)YJ$T @0UZ'CLC@0=Z@2<L@3)ZJPUF@=%Z
M70  @ "  (=*@%: BWG]@!N HVO"?]^ EER+?Z: ;DQG?WN 23JH?WV +2;<
M?XZ $ U2?_Y_Z   @ "  (9H?P>)3WDV?MB(TVL"?IN((UO"?EZ'5DN-?C>&
MESG]?BR&"291?B2%V0T-?GJ$HP  @ "  (6Q??.2$7AY?<R1!FI'?8V/MUL-
M?4Z.4$K<?2F-#SEF?1:,+"7U?..,.@SJ?3*(E@  @ "  (4B?1V:U7?G?/N9
M1&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@  @ "  (2X
M?'^CL7=T?&"AK&DO?!.?.%GV>[R<L4G6>X>:K#AV>VN9X"4F>PR7(PR*>U^(
M>@  @ "  'Y#D?E=9G':D)%@&F1ICW%BIE6ZCH-E!T6^C<-G.30?C7)I&Q_2
MCE9J%P9.CIEJ%   @ !\RWU[C^AEJ'$JCK!GH&.RC9EI?U49C*1K0T4VB]QL
MY3.UBWUN11^.C"=NX 9JB_9N\   @ !_WGRNC==MT7 ZC,5O(V+DB[QP8E1.
MBM!QCD2+B@URHS,NB:ESAA\VBB-SS 9WB9]T*P  @ "  'O)B^UUZ6]$BNYV
MJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP  @ "  'KI
MBDI^!6YXB5A^1&$9B&M^9%*PAXY^:D-1ALM^;3(VAF=^=QZ=AHQ^8P:,A<9^
MKP  @ "  'HBB/J&1&VYB!:%^V!>ARJ%AU(+AD*$^$*ZA7R$<3'RA/>$(!YN
MA/F$.P:1A#R"VP  @ "  'F#A_2.C&TZAQJ-SE_CAB>,RE%WA3"+IT(9A&F*
MLC%@@]Z*,AXI@Z.*B0:+@O.$;   @ "  'D$ARJ6W6RYAE25L5]=A5F4)U#U
MA%62?$&:@X.1,3#4@OB0R!VX@IN/U@:)@>6$:P  @ "  'BBAI*?36Q2A;Z=
MRU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P  @ "  '&O
MF]A<LF7QF?=?0ED[F&!AM$M.EOQC^SP*E=IF!RKBE7UGGA8NEX5GQP  DPUI
MOP  @ !_2G#WF@YDC&5GF$=F;UBTEJ)H0$KAE2-I^#NVD^IK@RJODVYLJQ8P
ME1=LE  OD+YNM@  @ "  '!/F!-L0F2BEFIMCE@.E,MNS$H_DTUO^SLTDA%Q
M"2I6D8)QRA85DMQQA0!SCG!T,P  @ "  &^3EC%SXV/1E)9TK5<KDP=U94F-
MD8]V$CJ9D%MVJ"GEC\%W"17>D-EVK0"BC&MY1   @ "  &[7E)M[D&,7DPQ[
MXE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@  @ "  &XR
MDUN#6F)\D=:#/E7<D$B"^T@[CLJ"H3F$C8:"5BDPC+Z"-Q5VC62": #@B2>
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MF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR 5E=QG!:
M84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2     @ "  &(F
MG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%#0  A<Z
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MI]*+0TP3I3**_4"JHH.*9S0RG_Z)SR9=GB&)RA7_GA&)-@5-F:N#E@  @A:
M    @ "  %9BIS22?DP,I'J2(D"GH;J1530NGR.0I"9GG2^0F18FG/:-Y 5J
MF'"#J0  @8"     @ "  +4F85-9LJ/^8]%= Y(V9B]@-W^&:'%C3&O>:I]F
M1E<H;*YI)4$J;F)KSR?K;MIMW0:Y=*-NQ;,J7<YD8:)Q8)IFK)#48S9HYGY+
M9:YK$&JZ: UM*%8>:D!O+D U:_QQ!B<8;!)R7@9C=35S0;%.6K%O :"J7;-P
M2H]-8(-QC'S68R9RSFEN9:QT#53[9_YU0S\^:;MV5B91:65W"@87=;5X(J]T
M5^5Y@9[=6Q9YW(V,7@EZ.7M98-)ZEV@48W][ 5/49>I[:SY.9ZA[Q"679MU[
MZP75=B1\FJV^57B#\IU&6,Z#=8P$6^."]GG>7L6">6;B88R""%+(9!&!KSUV
M9<J!6"3R9(2!$06==H. ;:Q24W:.9IOW5NF-&(K,6A2+P'BX70V*:F7.7^2)
M*%'G8G"("CR^9"6'&21B8G6&G05N=M.#IJLM4<^8U9KJ55B6MHG06)&4@W?*
M6YB2663O7H"05%$D812.A3PI8KB-#"/P8,B,H@5&=Q:#D:I04(2C-IH>5!N@
M0XD*5UJ=-W<,6F2:.V0W7527@%!X7_&5'CN<88J35B..7VR1[ 4F=TR#>ZG!
M3YBM=9F24S2IH(AX5FREN79Y67"A^&.P7%Z>F5 $7OJ;Q3LH8'^:!2,B7D66
M'@4-=W>#:J@7:-M929AC:JE<KX?/;&M?YG8E;A]B\&-E;\IEW$]_<5]HISHB
M<J]K*B#H<O%LS %,?<]N\Z:!98AC=Y<T9Z5EY(:]:9IH,74M:W9J8V* ;4)L
M?4ZS;O%N?SET<#YP12!;< )Q3 $N?@%SQZ3>8HAMCI5_9-EO#H4W9OMP>'.X
M:/]QU&$X:N]S)DV6;+AT:3B!;?UU?!^=;2YU^0$4?BUX9:,T7]=WB)/58E!X
M,(.69)1XQW)?9KAY45_^:,UYW$R,:JIZ8S>K:^9ZSQ[Z:IUZX0#]?E1\9J&H
M77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@. 2QYK:'2
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M<   @ "  (<,:@*7N7G-:UB61&N5;'R4@5Q=;8F2J4PC;HZ1#SJJ;UN/]B>
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ME+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQD"UZS <[C?A[T0  @ "
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M^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3H0=G5@[1HN%G"@
MFMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]L
MD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TK
MG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V
M\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $US
MGQ-]54-_G8-]HCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "
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MU0-6>ER"0IWB1%^EAH\/2/"B27]530F?%6Z;4,Z<%ESK5%.9<DHU5S^72#9
M6&F6(![^6$22_P-->FN"/)V'8B93@(ZD9&576'[V9I5;!FXZ:+=>B%QA:L5A
MYDE1;*EE%S2S;@9G[1O7;8)IFP  @ !M\)O$7A!==(U>8+%@9'W:8R=C-6U"
M97YEYEN$9[=H=TB2:;9JY#07:P-M 1MG:DUN(   @ !RTYH+6EIG68N>74-I
M9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP  @ !W@YA2
M5OUQ)HGN6B)R7WJN70-SAVIX7[9TG5D(8D5UIT9U9'%VI#)A985W=AHK93MW
MM@  @ ![EI:X5 5Z[(AU5UU[7WE)6FI[O6D>73Y\"E@"7^I\5D6.8BA\I#&M
M8QM\Y1FP8T1\[@  @ !_$I5D48*$M8<\50&$9'@K6#&#^F@56R6#@E<,7>.#
M$D358"2"N3$:8/2"@1E(8:6"H0  @ "  )113VB.<X8_4P:-7W=#5D^,*V<_
M65J*\E9"7"N)U$0K7FZ(YC"I7Q2(4AC\8$V(20  @ "  ).!3;B8&H5[46V6
M1':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0  @ "  )+T
M3'>AEX3M4#>?!'7W4Y.<1&8'5JN9F54E68B724,L6\:5C2_)7!.4^QA97F:0
M=@  @ "  )%8::Q38H.>:TQ7+W3S;/!:S&4;;I!>-U00<"-A>$&L<9AD@"UU
M<J5G"1/1<\9GQP  @ !QY(_*9<-<OH)39\!?MW.V::%BB60#:V]E-U,9;2=G
MP$#8;JYJ&BS';Y)L A-A<.=L4@  @ !VE8Y+8BIF((#=9')H27*/9HQJ5V+H
M:(%L0U(I:E9N%T 6:^MOQ2PY;*5Q%1,2;EUQ#P  @ !ZLXRW7NAO;G]386AP
MUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#   @ !^1XM%
M7 QXN'WR7K5Y:6^M82!Y_&!@8UEZ=5 096QZYCY'9Q=[42K09VA[G1(T:GI[
M;P  @ "  (H16:"""'S27&J"!VZB7O*!WU]E84:!H$\G8V>!9#V=90N!.RI-
M922!+!'F:/>!.P  @ "  (D95YF+3WOG6GV*GFW%71B)O%Z67W^(R$YD8:Z'
M[3SZ8TN'0BGI8R>&_Q&S9["&0P  @ "  (A<5?:4@GLQ6.V3)VT16Y61CEWL
M7@*/ZDV_8#:.>SQ;8<Z-<2EO86Z-21&"9JJ*8@  @ "  (?95+J=F7JJ5[V;
MGVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP  @ "  (4P
M<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EEUPNZ>L1F
M @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA=")I)"4+
M=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK*4F8<$!L
M_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V< :K9PH5B5
M;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V@'-(9G-W
M8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90  @ "  'Z@
M8AU_67(W9#E_FF3<9AM_K59P9]!_HT;T:51_F#8&:E]_F"+W:<I_HPK?<!A_
MQP  @ "  'V\8"B()G%>8EJ'RF0/9$R'-%6N9@V&AD8]9YB%ZS5P:).%@B*D
M9Z2%B@K+;L^$0P  @ "  'T*7I&0Y7"S8-2/]F-D8M".NU4,9)2-:T6?9AZ,
M4#349PJ+I2(N9=B+Z0JS;>J'/   @ "  'R+75>9DG R7ZB8(&+;8:662E2$
M8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P  @ "  'C]>>Y2_FT$>F)6
MCV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0  @ !Y('>S
M=F!;2&OU=RA>+U\.=_)@[U#_>+ACA4&4>7UEYC!T>D=GZAR(>P5H\02;?BEI
ML@  @ !\P'9]<PUCEVJP=!=EU%W\=0EG\T_\=>IIZT"Y=K]KN"_%=WUM-1P0
M=\MMU@2<>\5NN0  @ !_[W5$< 5KWVES<3IM?5RZ<D]N_D\0<T5P8#_B="YQ
MFB\A=-]REANF=+IRX@2?>;%T*   @ "  '03;5=T-VA+;K!U.ENB;]YV'4X%
M<.=VWC\\<=9WC"Z9<GMX$AM8<>YX(@2M>!EYLP  @ "  ',.:QA\GF=O;(]]
M$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@  @ "  '(Z
M:3.$^6:A:KZ$Y%H6; J$D4QX;26$(CVZ;A"#Q"UN;G6#EQJ8;8B#W@2:>#B"
M@P  @ "  '&29Z>-1F8 :4.,L5EX:I:+S4OD:["*SCTH;).*!BS<;-^)NAHK
M:_:)S 29>#J#'   @ "  '$59G&5C66$:!J4CECW:7"3(DME:H.1GCR]:UB0
M@"R*:X607QG0:K2.B 1L>(>"_0  @ "  &S%@ME2>V&"@LU5YU5(@O19+$?+
M@SE</3C6@Z%? 2?9A'AA+!+TAKMAE0  @SIEK@  @ !\ VN6?X1:3F"0?\%=
M(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@  @ !_-FJ$
M?%-B(U]O?,MD7E-V?3)F?$8N?9!H;C>+??AJ)R;J?HIK9Q*4?XEK/P  @ !O
M>@  @ "  &EM>69I^%Y.>@1KH5)1>H5M+45+>O=NF#:_>VAOSB9,>]MPH1(Y
M?(]P2   @ !T_@  @ "  &AC=M5QTUU4=Y!R]5%=>"5S]411>*)TT38C>0MU
MC27(>6!V Q'U>?AUG@  @ !YX@  @ "  &=S=*!YQ5QP=7AZ8E"(=AYZU4.:
M=IU[)35_=O][9"5]=Q][DA'7=[E[8   @ !^"0  @ "  &:N<LB!LUO+<[V!
MVT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "     @ "  &82
M<4F)FELT<DV)54]B<P&(O4*"<W2(!31G<[N'BR1R<XF'FQ%+=&J&P0  @ "
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M>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB>=F+,@E,>RJ&20  @ "
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M>@  @ "  $='G^94_CWXGNQ7=S-XGAI9Q2>/G:];O!E%GJ%<V BGGW-=60
MCMQD?@  @ !U40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UA
MZ@B7F\YB4   C$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9
MF$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ
M*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%
ME9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "
M    @ "  $0[D\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP
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M3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F ?H=K0M2
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M9)-[>%-+9I5[\T@;:#-\.CO2:5]\8BXS:>A\BQYZ:1U\K O7;\)]/0  @ "
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M;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>** )P  @ "
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MZP  @ "  $B;?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5@,%J^ L[@6!J_0
M@ !P>0  @ !^O@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ?7UP(AK[?:9P
M; L3?H9PAP  @ !V50  @ "     @ "  $;X>3%T73V5>BUU'3-<>LMUIR?F
M>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "     @ "  $9/=M![;#SK> -[
MT#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "     @ "  $73
M=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "     @ "
M    @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2F;Y48
MA+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!69A%NF*%7
M+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>DCY: A\Z
MDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;_310CI]=
M]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6   @ "  #R:
MBQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T!   @ "
M    @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,
M@ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQ
MA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPN
MA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^
M3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "
M__\  /__  #__P  ;69T,@     $ PD   $                    !
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M*ZLLGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z]COM/.,]VS[3/\M
MQ$&]0K=#LD2L1:9&H4><2)=)E$J02XY,BTV*3HE/B%"(48E2B%.(5(A5B%:)
M5XI8BUF-6H];D5R3799>F%^;8)UAGV*@8Z%DHV6D9J9GIVBH::EJJFNJ;*MM
MJVZK;ZMPJ7&H<J5SHW2@=9UVF7>5>)%YC'J'>X)\?'UV?F]_:8!A@5J"48-(
MA#Z%-88KAR&(%XD,B@**]XOMC.*-V([-C\.0N9&ODJ63G)22E8F6@)=XF'"9
M:IICFUZ<69U5GE*?4*!/H4^B4*-2I%6E6:9?IV:H;JEXJH*KCJR<K:NNNZ_,
ML-^Q\[,)M""U.+91MVRXA[FDNL*[X;T!OB&_0\!EP8?"JL/.Q/'&%<<YR%[)
M@LJFR\K,[<X0SS+05-%TTI33LM3/U>O7!M@>V3;:3-MAW'3=A]Z8WZ?@L^&^
MXL?CS>31Y=+FT.?,Z,3INNJLZYOLA^UO[ECO7/!;\5;R3/,]]"KU$O7V]M;W
ML_B-^6+Z+_KT^['\9OT1_;/^3?[A_W'__P   =D#C04)!E0'?PB6":$*I N?
M#),-@@YP#U\03!$W$B$3"1/P%-85NQ:?%X,8@1E]&G0;9AQ5'4$>+!\7(  @
MZB'3(KTCIB20)7HF9"=.*#DI)2H0*OTKZBS7+<0NL2^>,(PQ>3)G,U4T1#4R
M-B(W$3@!./$YXCK3.\0\M3VF/I@_BD!]06]"8D-51$E%/$8P1R-(%TD+2?]*
M\TOH3-Q-T$[%3[E0K5&A4I53B%1Z56U67U=16$-9-5HF6QA<"5SZ7>M>W%_,
M8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G- ="EU
M$G7[=N1WS7BV>9YZAGMN?%9]/GXE?PU_](#;@<*"J(.-A'*%5X8[AR"(!8CJ
MB<^*LXN8C'V-8HY'CRV0$I#XD=Z2Q).JE)&5>)9@ET>8+YD8F@&:ZIO4G+^=
MJIZ6GX.@<:%?HD^C/Z0PI2*F%:<(I_VH\ZGJJN*KVZS5K="NRZ_'L,2QPK+!
ML\&TPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,) PU+$9L5ZQH_'ILB^R=;*
M\<P,S2K.1\]CT(#1G]*_T^#5 ]8GUTS8<]F;VL3;[]T:WD;?<^"AX<_C N1-
MY9GFY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"
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M,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N +J-<7BF
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M>$6U%']<::ZO#W\'6Q6H\W[\3*:BIW\L/KV<$W^ ,9.5%H ?)=R-G8$!E-G
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M,WR"!'YUX.&"CH*IS%R"%X'FMQ*!LX$_H2B!98#!BNF!*X!K=*"!"8 Y7G.
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M9ZJT4Y4%6Q.MSI(03JFG*X\U0J2@6HQD-V690XF7+3.2 8;=)*>*K(1<@)_
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MHHO51]MZ0XA?,GI\)(1>WD%P$ZI5R5EQ/Z77M )R;J%AGDYSK)T&B'!U!)C
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M&YD94%B<"93K1 R6_9#*.(.1SXRU+>*,FXBF),V';83A>1K ,&YE;7VZRV^
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M*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B IY B2%F
M5(R#.&^ .(BB*:6 ,(1WJ26#9*F F=N"E:6XB=2!PZ&*>4B!"9T<:)^ @YBJ
M6 R +I0H1_-_Z8^&.$%_THJ7*9Y_VX5EJ,2#!K(7F62"/*U]B46!8*A5>+.
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MVVAO6IB%4FM83$6$SVYI/EN$5W&F,.6#_74\)*6#RWE"CLN%R6@0@K*%+FI
M=;B$IFQ>:!:$+&Y[6?^#NG"J2]&#6'+Z/@^# W5L,-""T7@@)-:"PWLAC>F#
MP'!1@:R#5G' =-6"ZW,A9SR"C72!64V".W7Q2TN!_7=Y/;J!SWD:,+:!Q'KE
M)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L: P7O>/6F
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M@6^DH\Y?N7$!DW%BU7)<@E9EZW/%<--I&W4\7RML>G;(3=)P"GAL/.=S[7I
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M$G=9)J>"''GL']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E> RG5Z0-^ OG<
M-W. RWB>+KN YGI.)L6!('P9("J!;'WA91-^]7?R7$U_-7C64S-_3WFC2=E_
M6'IF0'M_:GLW-U)_E'P?+K=_W'T5)N& 17X6(&F O'\-9'9]9'Y]6[M]RW[2
M4K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V *X .8_M\
M*(3?6VI\M(2O4G%\^X0J23Y]'(-[0 A]58+A-P9]OX);+K1^/8'J)Q=^[X%K
M(,=_M8#E8YI[*HL%6P][RHI/4AU\(XD:2/E\48>L/]M\E895-O!]#H46+K%]
MIH/J)R1^>(*W(.A_5X&47N.3B%395IZ2%5B33@J0JEQF11V/)6!A/ 2-?F2.
M,Q2+R&CZ*LN*%FV8(TV(?W*%'2:'''>07@B0^UN#5?>/QEZW37>.=F(#1+&-
M!F5P.\B+>6D),PJ)ZFS8*O:(9'#2(ZJ&_G4,':^%RWE575B.9V(5546-9&3#
M3.N,/6>#1#J*[VIB.WV)C6UD,O"(+G"5*Q"&V7/G(_6%IW=L'B:$I7KR7+&+
M^VB25)N+(&JX3$.*'FSK0\B(^V\V.RN'R'&A,LR&FW0N*QV%>G;6)#"$>WFC
M'HV#J'QE7 V)VF\#5 *))G"B2[>(17)%0TN'07/Q.NN&-76^,JN%.'>G*R2$
M1GF@)&&#=WNP'N."T'VN6W6("W5A4WN'?G9\2T>&NG>(0N^%T'B5.J:$X'FV
M,I^#_WKV*S&#-WQ )(F"EWV0'RN"&W[,6O*&AWN-4PV&'WPG2NV%<WR80JF$
MFWS^.FZ#PWUW,H6"_GX(*T>"37ZG)+"!V'\\'V>!A7^_6H>%1H%P4J6$_8&!
M2H^$:(%40ER#HH$2.C2"W8#E,E""-X#**S^!DX#$)-N!,H"P'Y>!#("*6C.$
M2(=(4H&$)X;K2GF#IH8)0E^"SX3T.F*!^X0.,J"!6H--*WR WX*E)/V LH'J
M'[V K($O5-R<AE0C38N:6E?71?N8(%NO/A^5KE_ -B:2_F06+F"0-6BQ)T6-
M;6U\(.^*S'**&]*(?G>:5 2:/%IJ3-Z84UVG1566*F$*/:23N62>->F1#VAH
M+F&.76QL)X6+M7"5(6&)/W3W'&V'('E24WV7OV"43$R5_&-:1-F3_68]/3F1
MIVE2-:R/(6R-+EJ,F6_[)[>*'W.%(<*'W'<['/*%[WKA4PB54F:C2\F3KVCL
M1$Z1T&M1/-R/J&W:-7*-4'"++DZ*^G-?)]N(LW9*(A"&IGE5'62$Z7Q&4HF3
M*6RE2TZ1LVYT0^>/[G!3/(.-WG)%-4Z+LW1D+DF)BW:B)_>'=WCK(E"%FGM&
M'<6$"GV!4@V15'*C2N*0"W/X0Y:.8W5*/$V,:7:F-2^*5'@?+E>(27F]*!B&
M87MD(H6$M'T-'A:#4'Z24:&/RGAU2HB.K'E10U2-&WH0/!R+-'K/-0N)-GNJ
M+E"'1GRA*#N%<WVF(K6#\GZ@'EB"MW]Y44J.AWX92D&-C7YZ0Q^,$GZA._V*
M-7ZZ-/F(17[T+CB&=7]%*#B$NG^J(MV#4'__'HZ".H Y41&-?X.;2@V,H(-]
M0O2+/8, .^6):X)K-/V'?X'\+E&%O(&I*%2$&X%I(OV"T8$@'KF!UX#5HC56
MFT^JD^1:*50CA4)=OUB8=AUA>%T+9H=E:&&'5L9IFF8C1V9N"FKV.'=RVG M
M*L=W^W8$H"A1REF?DDU5VETP@^%9[&"Z=.Q>&&1#97UB?&?45>IG(VN%1KYL
M#6]G.!IQ6'.G*L]VZGALGDU-<6.+D)-1^68H@FU6=VC#<Y=;"VMB9%Y?U6X.
M509DZG#81AUJ1'/*-\AP '<+*M=U^'JQG'=)@VU5CN).?&\%@-936'"Z<E18
M2')R8TA=>70X5"]B\G8718QHLW@5-X!NU'I/*MYU(GS.FK1%_G;[C6!+8'?)
M?X)0G'B;<1I5X'EM8FU;9GI+4WUA/WL\11-G6WP_-T1MTWUJ*N-T:GZ]F2I"
M[H!VC!E(KX!E?GA.0(!4<#Q3UX!"8:A9IX T4OQ?R8 T1+=F-X \-Q5L^H!3
M*NASS8!YE^) 3(F]BPU&88C"?:1,/H?);Y%2&X;180]8,87<4H->E83J1'1E
M08/W-O-L0X+\*NQS2H'^EM\^'Y*SBCE$>I#&?/U*EH[@;P]0JXT#8*)6^HLK
M4A]=F8E,1"QD?8=B-MAKK85>*N]RWH-+EB@\=9LAB9Y# )@[?(%)1Y5J;K)/
MAI*R8&%5_I #4?1<QXU#1 1CUXIK-KMK-(=J*O)RB(1AEV1=94_^BAE@851I
M?&UC<UC1;CMFJ5TW7YQJ$&&K4-UMMF9%0HEQF6L8-+1UW'!6*"]Z9W8PE7I8
MQUEJB,=<25S_>UM?S6"/;5MC:V0>7N)G.V>U4$QK3FMN0B9OH6]8-(MT6'.H
M*$QY3WA]D[I4FF+,AQA8DF6#>>Y<?&@V; U@?6KJ7<QDLVVJ3W)I,7"*08]M
M\'.2-$9S#7;L*&5X5WJFD@A0TFP0A7]5,FWL>'-9=V_(:NE=T7&D7-)B:W.*
M3K5G2W6+011L;7>K-!!QYGH(*'MW?7RFD'9-=74WA!Q2,'8_=S-6SG=#:<%;
M>WA#7 A@:'E-3A-EI'IL0*QK'GN?,^9PZ'SY*(YVP7YYCR-*CGX\@O5/EWYQ
M=CA4@WZ::.A9?GZ]6TI>M7[E39ID.'\=0%UI_W]B,\1P$'^W*)YV(8 9C@](
M%(<+@@9-8X9H=6U2D(6R:#M7S83U6K%=1X0]329C"H.-0"1I#(+C,ZYO68(U
M**MUG8&$C3E&#(^+@4M+DXX0=,M0]HQY9[-69XK86CM<%HE 3+QB%(>K/]]H
M2H86,YQNPX1N*+5U,(*[C*)$>I>6@,%**Y5(=$Y/M)+/9TE52Y!.6>M;(8W;
M3(9A1XMF/Z]GJHCI,WQN3H91*+YTV8.\C+YD75!C@'!FR52W<[II5%D.9GYL
M 5UH6-YNV&'52R5QZ&9M/>!U,6L_,25XUW" )<!\O798BNQ?^%DR?Q=BY5S(
M<I%EVV!:98=HZ&/N6!!L)&>12H9OGFM;/79S4F]8,0%W7W.V)?%[FWB+B51;
M\6(-?:=?4V38<7UBJ6>@9)%F$6IH5T]IJ&T_2?IMA' V/21QG7-7,.MV"W;*
M)AQZG'J9A\)846K.?"]<%&S/<!-?P&[/8WIC?7#-5F!G=W+524AKLG3Z/+-P
M*'<_,,)TZWG!)D%YO'Q^AEA5&G-T>N19+72P;N==*W7C8FIA.G<15:IE@WA*
M2+AJ%WF8/%UNX'K\,*AS[7R))F%X_'XVA2I24WO\>==6K7QT;?Q:\GS889I?
M2GTR5/ACVGV22$IHL7X%/!MMPWZ(,)-S%'\=)GMX67^]A#9/]X1->/U4C(0"
M;3Q9#8.38/)=I(,45&1B=(*=1]UGB((R.^ULT('2,(ER6X%R)I%WT8$0@WE.
M!HQ4>%12S8M&;*!7?XH"8&M<18BG4^MA28=71W1FEH80.ZUL$(30,']QQ(.#
M)J-W8H(P@O1,@I/T=]=1<I(P;"=61I 67_Q;+XW=4Y5@5XNR1SIERXF0.WIK
M<H=P,%]Q485")K%W"H,?@AMKCE##=K9M;53^:NYO<%E#7JMQCUV44@YSSF'^
M165V/F:7.3QXWVMJ+:U[TG"O(WM^^'9[@&)G85D =7%IN%R2:=]L&V E7<YN
MDV._45UQ+V=N1.1T FM'..]W!V]3+:-Z67/ (\!]S'B6?N]CBV%(=!5F3F0C
M:,]I"F;^7-YKUVG<4*-NS&S.1&!Q_6_C.*9U8',C+9IY"7:Q(_Q\PWJ+?8A@
M#6F)<L)C+6NH9YIF.VW'7 YI5F_J3_MLI'(60_)P*W1@.'-SY';,+9MWWWEV
M)#%[W7Q6?#I<_'&Q<:E@9W,99I5CP'1Z6PQG)G763TEJP'<_0V1NG7C .!]R
MI'I8+8AVY'P9)%U[%GWU>R=:4WF[<*U=_7IP9;5AF'L.6D9E1'N@3J1I(7P\
M0P)M/'SM-^IQB7VO+7]V"'Z%)()Z;W]C>DA8#H&.;^5;\(&090-?PH%H6:EC
MJ($M3AQGP(#[0J)L%H#8-\=PE8#$+8!U3("T)*%YY("@>9M6+HD9;TE:0(AN
M9'%>/X=^62EB489P3:EFFX5N0CYK)X1Y-X]OU(.0+7UTLH*@)+IY<X&M>1Y4
MM)!*;M98[8[]8_Y=#HU%6+YA0(M@355EJXF)0@=J78?!-V!O-X8"+6-T0(0^
M),YY&(**=VQS!E$%;/%T5U4K8AQUS%ED5M5W55VQ2T)X\&(=/[)ZL6:]-*]\
MF&N8*E=^Q'#@(62!$W:9==AO&%B]:\]PU5Q,82YRGE_B5AMT<V.%2K9V8F=#
M/U9X?FLP-(9ZP6]/*FQ]1'/+(;U_VGB==(=K<6"":I1MDF-J8#1OK69654%Q
MT6E+2@YT$VQ8/N-VAF^,-$]Y(7+L*G5[\G:6(@I^R'I[<TQH'F@Y:6=JDFIU
M7Q=L^6RU5'QO9&[[26QQ_'%3/GMTPG/+-"%WKG9E*G]ZR7DX(DU]V7PO<A]E
M*6_C:%)GY7%S7B!JD', 4Z)M0G2+2/9P'G8I/BIS,G?A- 1V9GFP*I!YQ'NI
M(H5]#'VW<2%BG'=V9X)EEWAA77!H?WDW4OIK<'H$2%YNB7K>/=%QV'O2,]5U
M2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX'] 1]]M,7]7
M/7EPM7^",[IT5W^]*IEX*'_](MQ[T8 X;[!>F87E9C1A]X6-7$%E083O4?!H
MDX0S1WAL$8.$/2%OR8+G,XUSE8)9*J!WBH''(OQ[78$R;SE=)(RJ9<=@JHN_
M6]9D%HIE48YGB(C;1RYK)8=@//-O (7Y,V=R^(2?*HYW%X-&(Q5[ ('_;-)Z
MS5$58TI[AU4N66U\8EE@3RE]15VO1*1^+6(E.C!_+6;5,%6 2FN^)SB!FG$.
M'X"#!':R:VAW'UA58D1X/%OE6)5Y7E^#3H1Z@F,U1"][LV<).>Y]!&L/,$I^
M<F]')VB $G/6'^R!OWBB:D!SIU^@82UU'V*75[MVBV683<9W]&BH0Z5Y<&O6
M.9I[$F\O,#!\T'*R)XI^N79[($F H7IK:2AP>F;?8!UR/6DX5KMS[6N730UU
MGFX$0Q%W:'").3UY5W,Q, U[877Z)Z%]C7CX()E_JGP*:"1MI&X+7S-OJ6_&
M5>1QF7&"3$9SC'-#0J1UE748./-WSG<.+_9Z&WD9)[I\AGM((-Y^UWU\9SMK
M*G4F7E]M;79$52UOF7=42[=QQ'AA0C5T!WE].,UV<GJY+_)X^GP&)]1[H'UF
M(1=^)7[!9GQI!WP17<-KAWR85*MMYWSX2T9P07U+0<YRM7VP.(1U5'XN+^1X
M!7Z^)^=ZWG]/(49]DG_79>1G/8*Y73EI[H*L5"]L?()<2MYN_H'R079QG(&<
M.#IT:H%<+\!W0H$N)_5Z/X#[(6Q]&H#!97)ERXD<7-!HI(B#4\MK6(> 2H=M
M^X9303APMX4[.!=SI80[+ZEVI8-,)_%YR()?(8M\NH& 8H2"W%#A6?2"\53W
M412#(%DJ1].#2UV#/EN#;F(--0.#FV;6+$V#VVO8)&*$0W$U'=6$Q';'84-_
M:E>W60-_W5M/4$> 2E[[1S: JF+$/?2!"&:V--6!>VK?+%N" F\X)*J"L7/>
M'E*#<7BE8$-\'5Z06 Q\X6&>3X1]D&2Y1H]^+F?L/8!^T&M#-)A_C&[)+%J
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M?'45-KY^W';-+XA_37BG*/-_TGJ+(QR ='QT'G.!%WX[4\5ZLW9Y3)1[N'>
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M/96"KWJ?-U:"7GM8,2V!ZGPR*T6!BWT@)AJ!,GX6(82!&7[Y'=J!+'^T2?N
M?'ZE0Y>!4G[;/56!G7[F-S&!;'[Y,22!#W\P*U2 RG]\)BB EG_1(9J GH ;
M'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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MGXC:CY^(VH^?B-K_IS@R_Z-$2_ZC25_SJ49OZ*Y$@-VS0Y#3MDB?S+=1JLK
M7*R]N&RWL[)XP*VN@<:IJH;*HJB$SINEA-&4HX34C*&'UXRAA]>,H8?7C*&'
MUXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7
MC*&'UXRAA]?_IS<R_Z-$2_ZE1U[SJD1NZ;%!?]^X/H[6O4*;S\-*I,*^7*^V
MMVRYKK%XP:FN@<:EJX7)GJF$S)BG@\^1I832BJ.&U(JCAM2*HX;4BJ.&U(JC
MAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&
MU(JCAM3_J#<R_Z1$2_ZF1E[TK4)MZK0^?>&].XO:QCR6RL9(I+F\7+*OMFV[
MJ;%YP:6N@L6AK(3(FZJ#RY6I@\V/IX3/B::&T8FFAM&)IH;1B::&T8FFAM&)
MIH;1B::&T8FFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FF
MAM'_J#<R_Z1#2_^H0UWUKS]L[+@Z>N3#-X?=TS60P<1)I[&Z7K6IM6Z\I+%Z
MP**O@L2=K83'F*R$R9*JA,N-J87-B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.
MB*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHAL[_
MJ38R_Z5"2_^J05SVLCMJ[KTV=^C+,X#0TC.3N,-+J*JY8+:DM7"\H;)[P)ZP
M@\.:KH3%E:V$QY"LA,F+JX7*AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&
MS(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALS_J34R
M_Z5"2_^L/5KXMS=G\<0Q<=_7+'O%T#65L,).J:2X8[>?M7*\G;-\OYNQ@\&7
MKX3#DJZ$Q8ZMA<:*K(;(AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>L
MA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\G_JC0R_Z9
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M/GF&WDZ#@=A?BW_4:Y!ZT7"4=\]TEW7.=YASS7F:<LU[FW',?9MPRW^<;\N
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M0?^G0U#_KC]=][<\:?#".W/FT#]YT]D_BK[+49VOP&&LI;ENMJ"U>;R<LH'
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MH[1\O9JO@<.2K(7(BZF*S(2GDL^ IIS0@*.ESX"AILZ H:;.@*&FSH"AILZ
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MI6C%D:7_IRP:_[4E'^S)&AS0XADAO_ B.*_]*TV@^#5>D^Y!;(GF37>!X%B
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MA"@)_X0Y%_^(123_D4PP_Y51._^65D?_E5Q2_Y-B7/F/:F;SBG)P[85[>.F
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MAL&HB(;!J(B&P:C_BB<)_XPW%_^;/1__HCTG_Z@_+_^N0C;WM$<\[;I-0>3
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M9]F)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G_>2,&_WDT$/^
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M>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^ MV??@+=GWX"W9]^
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MBI=TV(K_<R $_WHJ"?^++P__ECD6_YT_'/^A0R/ZI$@J\:9.,>BG5#CAIUQ
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M>EVAY'E=H>1Y7:'D>5VAY'E=H>1Y7:'D>5VAY'G_?14"_Y 4 ?^A& 'VL10
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M:%2I\&A4J?!H5*GP:%2I\&C_@@X _Y0, -NE!@#.L0< Q;L' +W'!P"UT!
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M[#R_J@  L;,  *2_  "8R@$ C-@$ (3Z#@!\^QL"=/LF!6S\, IE_#@07OU
M%5C^1QE3_DT=3_]4($O_6B)(_V$E1?]G)D+_;2A _W4J/?]]*SK_ABTX_Y$N
M-O^;+S3_IC S_[(Q,O^^,C'_T#(Q_]8R,?_6,C'_UC(Q_]8R,?_6,C'_UC*R
MKP  I;H  )C&  "+T@  ?]\" 'G_$0%O_QD"9_\B!&#_+ =:_S0,5/\\#T__
M0Q-*_TD51_]/%T/_51E _UL;/O]A'#O_9AXY_VT?-O]T(#3_?2$Q_X8C+_^1
M)"W_FR4L_Z4F*_^O)BK_NR<I_[XG*?^^)RG_OB<I_[XG*?^^)RG_OB>FM@
MF,(  (O.  !^VP  =?D' &O_#P%B_Q8"6_\> U3_)@5._RX&2?\U"$7_/ M!
M_T,-/O](#CO_3A X_U,1-?]8$C/_7A,Q_V04+O]J%2S_<A8J_WH7)_^#&"7_
MCADD_Y@:(_^@&B+_JALA_ZT;(?^M&R'_K1LA_ZT;(?^M&R'_K1N:O@  B\H
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M O]\&@'_B!X!_Y$D O*9*P3GGC$%W: V"=&<017'ETTAOY%6+;>,7S>QAV=
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M8V2,]&-DC/1C9(ST8V2,]&/_<1 !_X(/ /^1#0#>GPD TZH) ,RS"0#$N!,
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M-D#DN#<_Y<LW/^7D-S_C\S8]XOLX/>+[.#WB^S@]XOLX/>+[.#WB^SC&H0
MMZL  *JT  ">O@  D\D" (C4!@!_[@X >>T; 7'M)P-J[C((9.X[#5[N0Q-8
M[DL74^Y2&E#O61Y,[V @2>]G(T?O;R5$\'<G0?" *3_PBBH]\94L._&A+3GR
MKBXX\KXO-_/0+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S+S;Q\R^YIP  J[
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M$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O   AL<  'G3  !KX
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M6(EK_5>':_U6AVO^5H=K_E:':_Y6AVO^5H=K_E;_7A<!_VP2 ?]X% '_@Q<
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MHA< QJ$I [V>-PNTFD,6K)9-(*225BJ=CEXREXME.9*(;$"-A7-%B(-Z2H2
M@4Z ?XI2?'V357A\G5AU>ZA;<WJV7'%ZQUQQ>N)<<7OS6G%[^UER>OQ8<GK\
M6')Z_%AR>OQ8<GK\6')Z_%C_9Q$!_W4/ /^##@#TC@T VYD* -2A"P#,I!4
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M2$JSN4A)M,Y(2;/I2$BQ]DE(L/]*2+#_2DBP_TI(L/]*2+#_2DBP_TKBA@
MSI0  ,*A  "VJ0  J[$  *&Z 0"8PP4 D,D0 (K)( &#R2\%>\@[#73'111N
MQDX;:,56(6/$72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S CSQ*P)L^1\"H/T;
MN$!%P,U 1<#H/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL
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M(S3NYB,TZ_4C-.OX(S3K^",TZ_@C-.OX(S3K^".SI0  IJT  )FW  "-P0
M@,L  '75 0!IX08 9/,1 %[S' %9]"8"5/0P!$_U. 9+]4 (1_9'"D3V3@Q!
M]U4./_=<#SSW8Q$Z^&H3-_AS%#7X?18S^8@7,?F4&"_ZH1DN^J\:+?N^&BS[
MSQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,
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M1YU;_T>;7/]&FES_1II<_T::7/]&FES_1II<_T;_51<!_V 2 ?]K% '_=!<
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M%P#=BQP T(LL \>(.PJ_A$<3N']1'+%[6B2L=V(KIW1J,:-Q<C:?;WD[FVV
M/YAKB$*5:9!%DFB92(]FHDJ,9JU,BF6Z38AES$Z'9N9.AF?V3(9G_TN%:/]+
MA&C_2H1H_TJ$:/]*A&C_2H1H_TK_7!(!_V@/ /]T$ #_?1  \X40 .2+$0#6
MCQ< RXXJ L*,. FZB$02LX1/&ZQ_6".G?& KH7AH,9UU;S:9<W8[E7%]/Y)O
MA4*.;8U%BVR62(AKH$N%:JI-@VFW3H%IR$^ :N-/@&OT3G]K_TQ_:_]+?VO_
M2W]K_TM_:_]+?VO_2W]K_TO_7A !_VL. /]V#@#[@ T ZH@- -N/# #0DA4
MQY(G KZ/-@BVC$(1KHA-&JB$5B*B@%XJG'UE,)=Z;#63=W,ZCW5[/HQS@D*(
M<HM&A7"328)OG4Q_;JA.?6ZU3WMMQE!Z;N!0>6_R3GEO_DUY;_],>6__2WEO
M_TMY;_]+>6__2WEO_TO_8 \ _VT- /]Y# #N@PL VXL) -21"@#,E1, PI4E
M KF3- >QCT$0JHQ+&:.(5"&=A%PIEX%C+Y)^:C6.?'$YBGIX/89X@$*#=HA%
M?W6127QSFTQY<J9.=G*S4'5RPU!S<MU0='/P3W1S_4UT<_],='/_3'1S_TQT
M<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$ OI@C ;66
M,@:MDS\/II!)&)^,4B"8B5HHDX9A+HZ#:#2)@6\YA7]V/8%]?D%]>X9%>GF/
M279XF4QS=Z1.<7>Q4&]VP5!N=]E0;G?O3VYW_$YN=_]-;W?_3&]W_TQO=_],
M;W?_3&]W_TS_9 T _W(* /!^!@#:B 4 T) ' ,J7" #"FQ  N9LA ;&:, :I
MEST.H91'%YJ14!^4C5@GCHM?+8F(9C.$AFTX@(1T/7N">T%X@(1%='^-2'%]
METMM?*).:WRO3VE[OE!H?-50:'SM3VE\^TYI?/]-:GO_3&I[_TQJ>_],:GO_
M3&I[_TS_9@H _W4( .&! @#4BP4 RY,& ,2:!@"]G@X M9\? :R>+@6DFSL,
MG9A%%9:53AZ/DU8EB9!=+(2.9#)_BVLW>HIR/':(>4!RAH%$;X6*1VN#E4IH
M@J!-98&L3F.!O$]B@=%/8H'K3F.!^4UC@?],9(#_2V2 _TMD@/]+9(#_2V2
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M2UB0N$Q7D,Q,5Y#G2U>/]TI7CO]*6([_25B._TE8CO])6([_25B._TG_<0$
MX(   ,^,  #$E@( NYX" +*D  "IJ@4 HJP5 )NL)@*4JS0'C*H_#X6H2!=^
MIE >>*18)7.B7BMNH64P:I]L-&6><SEAG7L\7IN$0%J:CD-7F9I%5)FG1U*9
MMDA1F<I(49CF2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4
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M-$*Y\S5!N/TW0+?_-T"W_S= M_\W0+?_-T"W_S?.BP  OY@  +*A  "GJ0
MG+   )&X  "&P ( >\@' '3+$@!PS"(!:\LP V;+/ =ART4,7,I.$5C*5A54
MRET94<ED'$[);!]+R70B2,A^)$7(B"=#R)4H0<BB*C_(L2L^R<0K/LGA*C['
M\BL]QOPM/,7_+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\  *FF  "=K@  DK<
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M$2?U\1$G]?$1)_7Q$2?U\1&CJ   EK(  (B[  ![Q0  ;\X  &+7  !6W@
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M/(]<_SR/7/\\CUS_/(]<_SS_51$ _U\- /]I#@#_<0X ]7<0 .9[$0#9?1@
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M0V9XN$1E>,Q%97CG1&5X]T-F>/]"9GC_069X_T!F>/] 9GC_0&9X_T#_9 ,
M[G$  -A\  #+A0( PXP# +N1 P"SE D K)88 *66* *=E#8'EI)!#I"/2A6*
MC5(<A(M:(G^)8"=[AV<L=X5N,'.#=31O@GTW;(&&.VE_D#YF?IM!8WZH0V%]
MMD1@?<E$7WWE0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_9P  XW0
M -)_  #'B $ OH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N52!2%DU :
M?Y%8('J/7R5VC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F05N$M$):
MA,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@  WG@  ,V#
M  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_F4X8>I=6
M'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+LD!4B\5
M5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP  ,B'  "]
MD0  M)@  *J<  "@H@  F:00 ).E( &,I"X#A:,Y"7^B0P]YH$P6=)]3&V^=
M6B!JG&$E9IIH*6.9;RU?F'<P6Y> -%B6BC=5E94Y4I6B.U"4L#U/E,,]3Y3?
M/$^3\CQ/DOT\3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=   SX$  ,*,  "XE@
MK9P  *.A  "8J   D*H- (NK&P"%JRH"?JHV!GBI00QRJ$D2;:=1&&FF6!QD
MI%\A8*-F)5VB;2E9H74L5J%^+U.@B#)/GY,U39^@-TN>KSA*GL$X29[=.$F=
M\#A)G/PX29O_.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<  +R2  "QF@  IJ
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M)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y  !UOP
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M!!;_Y 23K@  A;<  'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP
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M*Z=+_RNG2_\KITO_*Z=+_RO_21( _U . /]9$ #_7Q( _V,6 /)E'0#G924
MWF0Q =1B/P7-8$L*QUU6#\):8!6^6&D9NU9Q'+A4>1^V4X$BLU*()+%0D":O
M4)<HK4^?*:M.J"NI3K(LITZ^+:9.SBZC3N8NH4_U+I]/_RZ>3_\NG4__+IU0
M_RZ=4/\NG5#_+IU0_R[_3!  _U0- /]=#@#_8P\ ^6<1 .MI%0#?:AP TVHL
M <MH.P3%94<)OV)2#[I@7!6V7649LEMM':]9=2&L6'PCJE:#)J=5BRBE5),J
MHU.;+*%3HRZ?4JTOG5*Y,)M2R3&94N(QEU/R,993_S&55/\QE%3_,)14_S"4
M5/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8 S&\H <1M
M-P2]:T0)MVA/#[)E6!6N8F$:JF!I'J=><"&D77@EH5M_)Y]:ARJ<68XLFEB7
M+IA7H#"55JHRDU:U,Y%6Q3205MTTCE?P-(U7_3.,6/\SC%C_,HQ8_S&,6/\Q
MC%C_,8Q8_S'_40P _UL) /]C" #K:@< W6X( -AQ"@#/<A, QG,E ;YR- .W
M<$$(L6U,#JQJ512G9UX9HV5E'J!C;2*<870EFF![*)=>@RN478LMDER3,(];
MG#*-6J8TBUJR-8E:P3:'6M8VAEOM-H5;^S6%7/\TA%S_,X1<_S.$7/\SA%S_
M,X1<_S/_4PH _UT& /5F! #?;0, U7(& -!U"0#)=A$ P'<B +AV,0.Q=#X'
MJW%)#J9N4A2A;%L9G6EB'9EG:B*69G$EDV1X*)!C?RN-88<NBF"0,(A?F3.%
M7Z,U@UZO-H%>OCB 7M$X?U_J-WY?^C9^8/\U?F#_-'Y@_S1^8/\T?F#_-'Y@
M_S3_50@ _V $ .AI  #:< , T'4% ,IX!P##>@\ NWL? +-Z+P*L>#P'IG5&
M#:%S4!.<<%@8EVY@'9-K9R&0:FXEC6AU*(IG?"N'9H0NA&2-,8%CEC1_8Z$V
M?&*M-WIBNSEY8LXY>&/H.'AC^#=X9/\V>&3_-7AD_S5X9/\U>&3_-7AD_S7_
M5P4 _V(! .%L  #4<P( RW@$ ,5[!0"^?0T MGX= *]^+ *H?#D&H7E$#)QW
M3A*7=%88DG)='(YP9""*;FLDAVQR*(1K>BN!:H(N?FF*,7MHE#1X9Y\V=F:J
M.'1FN3ES9LLZ<F;F.7)G]SAR9_\W<FC_-G)H_S5R:/\U<FC_-7)H_S7_60(
M]F4  -UN  #/=@$ QWL# ,!_! "Y@ P L8(: *J"*@*C@#<%G7U""Y=[2Q&2
M>%07C79;&XET8B"%<FDD@7%P)WYO=RM[;G\N>&V(,79LDC1S:YPV<&JH.&YJ
MMSIM:LDZ;&KD.FUK]3AM:_\W;6O_-FUK_S9M:_\V;6O_-FUK_S;_6P  ZV<
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M.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9   W'   ,IZ  # @P
MMHD  *Z-  "DCP  G9$0 )>2( "1D2X#BI Y!X2.0PQ_C4P2>HM3%W6)6AMQ
MB&$@;H9H(VJ%;R=GA'<K8X-_+F""B3%=@90S6X"A-EE_KS=7?\ X5W_:-U=_
M\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[AP  LHT
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M+D:6_RY&EO\N1I;_+D:6_R[1=P  P80  +:.  "JE0  H)L  )6?  "*I
M?:D  '>K$ !SJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:J5@35ZA?%E.G9AE0
MIVX<3:9V'TJE@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&CZB= HO@H0*'_*4"@
M_RE H/\I0*#_*4"@_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;
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M$B['_Q*NEP  H9X  )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @
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M 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[Z0*/JP
M@;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X* "'_$  ?
M_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8 "_]B  G_
M;P (_W\!!_^0 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T
M &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0  &O\% !?_#  5_Q
M$O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0  _T8  /]1  #_70
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M*X56NBR#5LPL@E?F+(%7]RN 6/\J@%C_*H!8_RF 6/\I@%C_*8!8_RG_3P(
M_5D  .)@  #59P  S&H# ,9L!0# ; X MVT= +!N+ &J;#D$I6I$"*!H3@V;
M9E<1EV1>%91B91F18&P<CE]S'HM>>R&)78(DAER+)H1;E"B!6YXJ?UJJ+'U:
MMRU\6LDN>EKC+GI;]2UZ7/\L>5S_*WI<_RIZ7/\J>ES_*GI<_RK_40  \EL
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M,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,  ,]L  #$<P
MNW@  +-Z  "K>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'=TT.@W55$G]S7!9[
M<F(:>'!I'75O<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9KKR]D:K\P8VO8,&-K
M[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  # =@  MWL
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MA@  E(@, (Z)&0")B2@!@XDT WZ'/@=YAD<+=(5/#W"$5A-M@ET7:8%C&F:
M:AUC?W(@8'YZ(UU]A"9:?(\I6'N<*U9[J2Q4>[DM4WO.+51ZZBU4>ODL5'G_
M*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@  JX<  *&*  "5BP
MC8T) (>.%@""CR0!?8\Q GB..P5SC40);XQ,#6N*5!%GB5H59(AA&&&':!M>
MAG >6X5X(5B$@B15A(TF4H.:*5""IRI/@K<K3H+,*TZ"Z"M.@?@J3X#_*D^
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M(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L! !?K1$
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M!BW%F@<KQ:H(*L6^""K%V@@JQ/ (*<+["2C!_PHHP?\+*,'_"RC!_PNHE0
MG9L  )&B  "$J0  >*\  &NU  !?NP  5+\  $G#   _R 0 -LT) #/.$0 R
MSQP ,<\G ##0,0 OT#H +M%# "W13  KTE4 *M)? 2C3:0$GTW8!)=.$ B34
ME (BU*8"(=6Y B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(
M (>I  !YL0  ;;@  &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA(
M(]X< "+?)0 AX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7
MY9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ
M  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7
M !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H
M"_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !B
MP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\
M%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)
M  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#  !6RP
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M&IQ%OQJ:1=$;F$7I&Y9&^!R51O\;E$;_&Y-&_QN31_\;DT?_&Y-'_QO_0@4
M_TH! /)0  #A5 $ V58% --5"0#,51( PU8B +Q7,@&W5C\"LE1*!:U35 BJ
M45T+IU!D#J1.;!"B37,2GTQZ%)U,@1:;2XD7F4J1&9=*F1J52:,;DTFN'9))
MNQZ02<P>CDKE'HU*]AZ+2_\>BTO_'8I+_QV*2_\=BDO_'8I+_QW_10  _TT
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M)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?  #(9
MOV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*C&)7#8AA7A"%
M7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q6K\E<%K5)6];
M[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$9P  NVL
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M(V!F_R-A9O\B86;_(F%F_R+H6   TV,  ,1K  "Y<0  L'4  *=W  ">=0
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M;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@  BG\' (2
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M($M[_R#09P  P'(  +1[  "J@@  H(8  )6(  "'B   ?(H  ':,#@!RC1H
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M$SR:FQ0ZFJL5.9J]%3F:V14YF.\6.9?\%CB6_Q<XE?\7.)7_%SB5_Q>[>@
MKX4  *2,  "8D0  C94  (&:  !UG0  :*   %ND  !6I0P 4Z87 %&G(P!/
MIR\ 3*<X 4JG00%(ITD"1J=0!$.G6 5!IU\&/Z9H"#VF<@HZIGT+.*:*#3:E
MF0XTI:D/,Z6[#S.EU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P
M )V2  "2EP  AIP  'FA  !MI0  8:D  %6L  !+KP4 1[ 0 $6P' !$L2<
M0K$R $&R.P _LD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4SLGD&,;*'!R^QE@@N
MLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP  H)(  )68
M  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P WO!X -;PI
M #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_D0,FOZ(#
M)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@  (R>  "
MI0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!, )\D= ";)
M)P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;S9P &<ZN
M 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0
M:+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5
MV2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@
MN  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P
M %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D
M#.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP
MZ[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)
M   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88
M  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<
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M![HOQP>X,-T'M3#N";(P^PJP,/\+KC#_"ZXP_PNM,/\+K3#_"ZTP_PO_,PP
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M%HA&\!:&1OT6AD;_%H5'_Q6%1_\5A4?_%85'_Q7_/P  [$@  -U/  #/4P
MQE4  ,!3 P"[40P LU(9 *U3*0"H4S8!HU)" I]12P2<4%0&F4]<")9.8PJ4
M36H,D4QQ#H]+> ^-2W\1BTJ'$HE*D!2'29H5A4FE%X-)L1B"2< 8@4K6&7]*
M[1A^2_P8?DO_%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP  -93  #)6   P%D
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M&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@  LV4  *ME  "C8@
MG&(. )9C' "19"D C&,U 8AB/P.$84@%@&!0!WU?5PEZ7ET+=UUD#75<:Q!S
M7'(2<%M[%&Y;A!=L6H\8:EJ:&FA:IQQF6K8=95K('65:Y!UE6O8<95K_&V5:
M_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">90  EV8-
M )%G&0",:"< AV<R 8-F/0)_948$>V1-!GAC5 EU8EL+<F%A#7!A:0]M8' 2
M:U]Y%&E?@A9G7HT995Z8&F->I1QA7K0=8%[''6!>XQU@7O4<8%[_&V!>_QIA
M7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0  DFH+ (QJ
M%@"':R0 @FLP 7YJ.@)Z:4,$=FA+!G-G4@AP9UD*;69@#6ME9@]H9&X19F1V
M%&1C@!9B8XL88&*7&EYBI!Q<8K(=6V+%'5MBX1U;8O0<6V+_&UQB_QI<8O\:
M7&+_&EQB_QK@50  RU\  +UG  "R;   J7   )]O  "4;   C&T( (9N$P""
M;R$ ?6\M 7EO. )U;D$#<FU)!6YL4 =K:U<*:6M>#&9J90YD:6P186ET$U]H
M?A9=9XD86V>5&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI79O\:5V;_
M&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R$0!\<QX
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M%DEYG!=(>*L81GB]&49XU1E&=^\81W;\&$=V_QA'=?\71W7_%T=U_Q?)90
MNF\  *YW  "D?0  F'\  (M_  !^?P  <X$  &R#"0!HA!, 984@ &*&+ !?
MAC8!7(8_ EF%1@-7A4X%5(55!U*$7 E/@V,+38-K#4N"= ](@G\11H&,$T2!
MFA5"@*D608"Z%D" TA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74
M *I]  "?@@  DH,  (6$  !YA0  :HD  &2* P!@C!  78T; %N.)P!8CC(
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M""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@   HXD  )>.  "-DP
M?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  ZJA\ .:HI #BK,@ W
MJSL -:M# #2L2P RK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJLC@,HK)X$)ZRP!":L
MQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X
M &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC(
M*;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<
MN-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K
M  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O
M !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0
M$,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+
MN   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1
M*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<
M  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P
M-,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(
MWB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #E
MU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P
M !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T
M .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP
M],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<
M   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08
M  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[
M /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_
M &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D
MLP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_
M .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0
M_P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q
M ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&
M_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ
M /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8
MZ G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_
M'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0
M;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^
M -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A(
M_R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D
M%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7
MR0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+
M /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>90#5'FT
MTA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W <$@Q '
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M!J$P\P>?,/\(GC'_")TQ_PB<,?\(G#'_")PQ_PC_,   _S4  .\X  #B.@
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M$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P  N%0  +%2  "K3@4
MI$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&3&$&A$MH"()+;@F
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M$F%6_Q+@30  RU8  +U=  "R80  J&,  )UA  "570  C5X) (=>$P"#7R
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M$E1BG!-38JH54F*[%5%BTA518>T54F'[%%)A_Q-38?\24V'_$E-A_Q+15@
MP%\  +-F  "I:P  G&L  )!J  "%9P  ?6D  '=J#0!S:Q< ;VLD &QL+P!I
M;#@!9FM! F-K20-A:U $7FI7!EQJ70=::64)6&EM"U5H=@U3:($/46>-$4]G
MFA).9ZD436>Y%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,
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M#CQ[R X\>N8./'GW#CQX_PX\>/\./7?_#CUW_PZ\:   KW(  *1Y  "6>@
MB'H  'QZ  !P?   8W\  %R"  !7A L 4X44 %&&( !/ABH 3H<T $R'/ %*
MAT0!2(=+ D:'4P)$AEH#0H9B!$"&; 8^A78'.X6#"#F%D0HXA* +-H2Q"S:$
MQ@LV@^0+-H+V"S:!_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\
M '>   !K@@  7H<  %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$
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M 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8  !7G0
M3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q !ZP.@ =
ML4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX $['K !.O
M^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P
M #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3<
M$+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (
MO?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X
M   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV
M  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\
M ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =
MQ   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9
M-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B
M  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP
M#=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P
MZ#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #N
MQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X
M  #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",
M /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_
M$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\
M=P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"]
M /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP
M_Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z
M 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@
MQ@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4
M /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '<
M[P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#=
M -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2
M#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z
M .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\
MS@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_
M&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-
M? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F
M , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT
M_QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'
M%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9
M\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$,
M .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?<0"Z'W@
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M!8TQ_P6,,?\%C#'_!8PQ_P7_+0  ZC4  -PZ  #./0  QCP  , W @"[,PT
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M"FM&_PKE0   STD  ,%/  "U4@  JU(  *%/  ";2@  E$H, (]+%P"+3"0
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M"UY0FPU=4*D.6U&Y#EM1S@]:4>H.6U'Z#5M1_PQ;4?\,6U'_"UM1_PO62@
MPU,  +99  "K7   GEH  )-9  "+5   A%8# 'Y6$ !Z5QH =E<F '-8,0!P
M5SH ;5=" 6I720)H5E "9E97 V167@1B564%8%5M!UY5=@A=58$*6U6-"UE4
MF@U85*<.5E6X#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8
M +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;+@!K6S<
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M#4=BQPU'8N0-2&'V#$AA_PQ(8/\+26#_"TE@_PO$6   M6   *IF  ";9@
MC68  ()E  !V9   ;F4  &AF!0!C9Q  8&@: %UI)0!;:B\ 66HX %=J0 %5
M:D<!4VI. E%J50-/:5T$36ED!4MI;09):'@'1VB$"49HD@I$9Z$+0V>Q#$)G
MQ0Q"9^(,0F;U#$-F_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D
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M<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T 08!% #^
M3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P?MH&,'WP
M!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW  !C>0
M5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E  #>)2  V
MB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#*8;N RF%
M_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4
M $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH
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M  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@
M(ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &
MMT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U
M]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@
M !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0
M ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&
MF   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%
M   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$
M  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H
M;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0
MU    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G
M0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\
M %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=    X0
M .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P
M]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\
M&0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P""
M /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$
MZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_
M !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /(
MA #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B
M -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4
M_P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G
M (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$
M[0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9
M /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($
MV0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@##
M /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*
M'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6"
M ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@
MM0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H
M#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.
M@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_
M *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A<
MSQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O
M%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;
M_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@
M +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X
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M WPQ_P/M+P  VS<  ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H
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M.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$ A4 M ()
M-P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N/X0$;#^0
M!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65 _P7</@
MQT8  +E+  "L3   H$H  )='  "10P  BT,( (9#$@""1!X ?D0I 'M%- !Y
M13T =D5% '1$3 %R1%,!<$19 6Y$8 )L0V<":T-O VE#=P1G0X$%9D.-!F1#
MF09B0Z<'842V"&!$R@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD
M +9.  "G3P  FTT  ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H
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M"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P  N5,  *M7  "<5@
MCU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B5#$ 8%0Y %Y400!<
M5$@!6E1/ 5E45@%75%T"5E1E U14;@125'@%452$!D]4D0=.5* (3%2O"$Q4
MP@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@
M (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9/P!7648
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M!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80  ?V$  '1A  !I80
M7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(:3X 1FI% $5J3 !#
M:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=HN@4W:=,%-VCN!3=G
M_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D9@  66@
M %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!<#H 0'%" #]Q20 ]<5$
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M B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P
M,X8  "V)"@ JBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @
MC5X 'XUK !V->0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(
M_P&==P  C'8  'UV  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9
M "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@
M%)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5
M?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=
M   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<
M  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P
M?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1
MJP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P
M80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H
M &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@
M!;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@
MOF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:
M  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0
M  #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD
M ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.
MK@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@   -    #1
M    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<
M  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0
M-;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\   #?
MX0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U
M7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C
M /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@
M]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F
M /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\
M*P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"*
M .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D
MU@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\
M #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X
MBP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_
M ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P
M[  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#,
M (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L
M_P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R
M -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (<
MO@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M
M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#
M-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:)
M + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\
MH0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\
M#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/
MC0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_
M )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4
MK!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8
M%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<
M_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ
M )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@A ",((T
MBB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_ 7\D_P'L
M)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H EB8U ),F
M/P"1)D< CR9/ (TF5@"+)UP B2=B (@G:0"&)V\ A2=W (,G?P"!)XD!@"B3
M 7XHG@%]*:L!>RFY 7HIS0%X*N@!=ROY 78K_P%V*_\!=2O_ 74J_P'E+
MT#0  ,$X  "S.   J#4  *(Q  "=+0  F2H. )0K& "0+"0 C2TP (HM.@"'
M+4, A2U* (,M40"!+E@ @"Y> 'XN9 !]+FL >RYS 7DN>P%X+H4!=BZ/ 70O
MFP%S+Z@"<2^V G PR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D
M +L^  "L/0  H3H  )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX
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M!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P  O$8  *M(  "<1P
MD48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J03, :$$[ &9"0P!D
M0DH 8T%0 &%!5P!@0EX!7D)E 5U";@);0G@"6D*$ UA"D -70IX$5D.M!%5#
MOP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D
M (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%/P!?14<
M745- %M%5 !:1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K!%!'O01/
M1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53   B4L  ']*
M  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9240 5TE*
M %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+O 1*2],%
M2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X  'M-  !S
M20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$ 4TY( %).
M3P!03E<!3TY? 4Y.9P%,3G("2TY] DE.BP-(3ID$1T^H!$9/N@1&3]$$1D_M
M!$9._ 1&3O\#1T[_ T=._P.]3   KE(  )Q1  "-40  @5$  '=0  !N3
M9TX  &)/  !=4 T 6E 4 %=1'@!542< 4U$P %%2. !04C\ 3E)& $U230!,
M4U4 2E-= 4E390%(4V\"1E-[ D53B0-#4Y<#0E.G!$%3N 1!4\\$05/L!$%2
M^P-"4O\#0E+_ T)1_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(
M %Q3  !85 H 5%42 %)5&P!/5B0 3E8M $Q7-0!+5SP 2E=$ $A72P!'6%(
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M C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90
M068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q
M:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG
M_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX%
M #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$
M*7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A
M90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX
M"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH
M !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0
MB&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B
M@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&
M<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T
M '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08
M%8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +
MD7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S
M  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(
M  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(
M )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<
M?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G
M#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ
M  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0
M28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(   "S!P
MLPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X
M@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP
M #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^    OP8
M , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0
MR8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P
M   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*    S    ,T#
M  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P
M ."1  #@I   X+(  ."^  #@PP!FGP  6:8  /_B\ !)0T-?4%)/1DE,10 $
M"DRM   _M   ,K@  "2\   8OP  $,,   C'    R@   ,T   #1    U0
M -@   #9    VP   -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P
M\#4  /%&  #R6   \VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\
M$0#_ !4 _P ? /\ + #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X
M /4 ?@#T (0 \@") /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4
MY0#; ., [0#B /L X@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_
M !( _P ; /\ * #_ #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H
M>@#I '\ YP"% .8 B@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0
M -, Z #2 /< T0#_ -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \
M_P 6 /L (@#W "\ ]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#<
M 'H V@"  -@ A0#5 (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4
MX@#$ /( PP#^ ,( _P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1
M /$ '0#K "D YP V ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4
MR0![ ,@ @ #& (8 Q0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V
M .T M #Z +0 _P"T /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4
M%@#> "( UP O -$ .P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U
M +H >P"Y ($ MP"' +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@
MJ #W *< _P"G /\ I@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #-
M !L QP G ,, ,P"_ #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T
M=@"L 'P J@"" *D B0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T
M )L$_P":!?\ F@7_ )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !,
MO (? +<#+ "S!#< L 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@
M"'< GPA^ )T(A0";"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\.
M_P".#O\ C@[_ (T._P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7
M *P-) "H#C  I0X[ *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'(
MDQ!Y )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#
M%?\ @A7_ ((5_P#M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4
M'@"<%2H F14U )86/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T
M (88? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\
M>!W_ '@=_P#E(@  T"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1
M'20 CAXO (P>.0")'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@
M> !Z(($ >2&, '<AEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_
M &XD_P#=*0  R#   +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\
MA"4J ((E- " )CT ?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q
M)WT ;RB( &XHE !L**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J
M_P'4+P  PC8  *\V  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE
M 'DK+P!W+#@ =2Q  ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H
M9RZ% &4ND0%D+IX!8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'-
M-   O#L  *DZ  ";.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q
M*P!O,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S."
M 5XSC@%=-)P!6S2J 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.
MMSX  *0^  "6/0  BSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H
M-C  9C8X &0V/P!C-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<X
MC %6.9D!53FH E0YN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$
M *!   "20   AC\  'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP
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M D5&M )$1LD"1$;G D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2
M>T<  ')&  !J0@  8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,
M1SH 2T=! $I'20!)2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)
MLP(_2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH
M &Y)  !E10  7D<  %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@
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M 3!6] $Q5O\!,57_ 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P
M3U0  $E6  !$5P  0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T
M7$8 ,UU. #%=5P P76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<
M\@$J6_X!*UO_ 2M:_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D
M $5;   _70  .E\$ #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T(
M+&-* "ID4P I9%T *&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C
M8OT!)&'_ 21A_P&<6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@
M   Z8P  -&8  "]H"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M&
M "-K3P B;%D (&QE !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P
M'&C_ !QH_P"57   @UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U
M:@  +VT  "AP!  C<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT
M2@ 9=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_
M !-Q_P".8   ?6   &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0
M*74  ")X   <>P< %WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0
M?TX #W]:  Y_:  -?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ
M_P"&90  =V4  &IE  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX
M !R!   5A   $(<(  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@
M!8E4  2)80 "B7$  8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^
M:@  <6H  &=K  !;;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,
M   0CP  #)(&  :3#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,
M  "660  EFD  )5Z  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<
M;7   &!R  !4=0  27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *
MF@  !)T#  ">"0  GPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C
M4   HU\  *-Q  "CA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<
M %E[  !-@   0H4  #B+   ND   ))4  !N:   4G@  #J$   FD   "IP
M *H   "K!   JPH  *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@
MLE4  +)F  "R>0  LHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'
M  !&C0  .Y,  #"9   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<
M  "X    N0(  +D(  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD
M ,-:  ##;   Q((  ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _
MFP  ,Z(  "BH   =K0  %+$   VV   &N0   +P   "_    PP   ,0   #%
M    Q@   ,<   #)!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-
M  #97P  VG,  -J*  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@
M++$  ""W   5NP  #;X   3"    Q0   ,D   #-    T    -(   #2
MU0   -8   #9    VP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M
M40  [F4  .]Z  #OCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P =
M /\ *0#_ #4 _P!! /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\
M\ "$ .X B0#M (\ ZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#?
M /D W0#_ -T _P#= /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\
M) #^ #$ ^P ] /@ 2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_
M .( A0#@ (H W@"0 -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0
MRP#_ ,L _P#+ /\ RP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R
M "L [P W .L 0@#G $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -
M@ #/ (4 S0"+ ,L D@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\
M +P _P"\ /\ O #_ +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4
MWP Q -L / #7 $< T@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#
M (  O@"& +P C0"Z )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X
M_P"M /\ K0#_ *T _P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K
M ,@ -@#% $  P@!* +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H
ML "! *X B "M (\ JP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@
M /\ H #_ *  _P#_    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D
M+P"V #H M !# +$ 3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![
M *$ @@"@ (H G@"3 )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\
MDP#_ )( _P#Y!0  Z@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J
M #, IP ] *0 10"B $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4
M?@"3 (8 D@&/ ) !F0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_
M (8(_P#O#P  WA0  ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP
MG @V )D(/P"7"4< E0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"(
M"X( APN, (4,EP"##*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0
M_P#F%P  T1X  +T=  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O
M (\0.0",$$$ BA!( (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X
M?!*( 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<
M'P  QB4  +,E  "E(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6
M,P"!%SP @!=# 'X72@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$
M &\:D !N&IT ;!NK &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@
MO2H  *LJ  "=*@  DR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W
M'C8 =AX^ '0>10!R'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8A
MC0!E(IH 8R*H &(CN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\
M *0O  "6+P  C"T  (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#(
M;20Z &LE00!J)4< :"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=
M*)< 6RFE %HIM0!:*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS
M  "0,P  AC(  '\O  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU
M &,J/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4
M5"ZC %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+
M-@  @34  'DS  !S,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO
M.0!;+T  62]& %@O30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A
M $TSL0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0
M?#D  '0W  !N-   :3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5
M-#P 4S1# %(T2@!1-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@X
ML %'.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P
M ' Z  !J-P  9#8  & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D
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M 3E$\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0
M5D   %%"  !-0@( 24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \
M1D< .T9/ #I&5P Y1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(
M\  T1_T -$?_ #5&_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440
M $Q&  !(1P  1$<* $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0
M-DM, #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O
M3/T +TO_ #!+_P"A1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*
M  !"2P  /TP& #M-#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!*
M "]14@ N45P +5%G "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P
M*E#_ "I/_P"<2@  B4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]
M4   .5(" #53#  S5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E6
M3P H5UD )U=D "97<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_
M "15_P"630  A$X  '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@
M,U@  "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A
M758 (%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;
M_P"040  ?E$  '!1  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX
M "A@ P D8@P (F,1 "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$
M&&5= !=E:@ 697H %66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")
M5   >%4  &M5  !@5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G
M   =:@< &6P. !AL$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8
M  ]N90 .;G4 #6Z'  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60
M<ED  &99  !<6@  5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7
M<@  $G4)  ]W#P .=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W
M7P %=V\ !'>   -WE  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T
M &)>  !97@  3F   $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?
M#7\&  F!#  %@1$  X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60
M@F@  ()Y  ""C0  @:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB
M  !39   26<  #]K   V<   +70  "5X   >?   %X   !&#   -A@  "(D$
M  *+"@  BPX  (L3  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF
M (YQ  ".A0  CID  (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-
M;   0G$  #AV   O>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6
M!P  EPP  )</  "8$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH
M  "<>P  G)   )NE  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P
M.WP  #&"   GAP  'HP  !:1   0E0  "ID   2<    H    *(   "C 0
MHP8  *0+  "E#@  IA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L
M<   K(4  *R;  "KKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H
M "F0   ?E@  %IL  !"?   )HP   :<   "J    K@   +    "P    L0
M +(#  "T"   M0T  +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9
MOGD  +Z0  "]I   O;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?
M   7I   $*D   FN    L@   +8   "Y    O0   +\   "_    P    ,$
M  ##    Q 4  ,8*  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL
M -."  #3EP  TZD  -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1
MM   ";D   "]    P0   ,0   #(    RP   ,T   #-    SP   -    #2
M    U    -@   #:!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR
M  #KB   ZYL  .RH  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #(
M_P ] /\ 2 #[ %( ^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I
M (H Z "0 .8 E@#D )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@
M_P#7 /\ UP#_ -0 _P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X
M /0 0P#P $T [0!5 .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4
MV0"+ -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#&
M /\ Q@#_ ,< _P#_    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8
M/0#B $< W0!0 -D 6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"%
M ,4 C ## )0 P0"< +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\
MM@#_ +8 _P#_    _P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#.
M $$ R@!* ,< 4@#$ %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8
MAP"T (X L@"7 +  H "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_
M *8 _P#_    _@   /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L
MN@!$ +< 3 "T %, L@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F
M (D I "1 *( FP"@ *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@
M_P#]    \    .$   #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^
M *@ 1@"F $T I !4 *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (,
ME@", )4 E@"3 *$ D0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S
M @  X@<  ,P'  "_!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P
M0 ": $< F !. )8 5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"(
M (@ D@"& )T A0"I (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0
MT!   +X0  "Q#@  J T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0".
M 4$ C %( (H"3@") E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%
MC@![!9H >0:G '@&M0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<
M +$7  "E%@  G!,  )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL
M@0M" ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P
M#9D ;PZF &T.M0!L#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>
M  ";'0  DAL  (L9  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$]
M '811 !T$4H <Q%0 '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8
M912C &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2
M(P  B2(  ((@  !^'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7
M/P!K%T4 :1A+ &@840!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA
M %L<L !:',, 61W@ %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*
M@B<  'LE  !V(P  <R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B
M'D$ 8!Y' %\>30!>'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,B
MK@!2(\  42/= %$D\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P
M '0J  !O*   :R4  &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST
M621# %<D2@!6)%  5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+
M*;X 2RG: $HI\0!**?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N
M  !J*P  92H  &,G 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE
M % I1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP
M12[6 $4N[P!%+OX 12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E
M+P  8"T  %TL  !9+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM
M0P!)+4H 2"Y1 $<N60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3
M #\R[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@
M7#   %<P  !4, 8 43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#
M,D< 0C)/ $$S5P! ,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV
M[0 [-OP .S;_ #LV_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,
M %,T  !/- , 2S0, $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0
M/3=, #PW50 [.%X .CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V
M.OL -CG_ #<Y_P"B.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW
M  !*.   1C@* $0Y$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M*
M #<[4P V/%P -3QG #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH
M,CW_ #(]_P">.P  BSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%
M/   03T' #X]#@ \/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #)
M4  Q0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_
M "U!_P"9/0  ASX  '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0
M/$$$ #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L
M15@ *T9C "I&;P I1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%
M_P"50   @D$  '-"  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8
M #1'"@ Q2!  +T@6 "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4
M)4M@ "1+;0 C2WP (DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"0
M0P  ?D0  &]$  !D10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-
M!P K3@X *4X3 "=/&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%=
M !Y1:@ =47D '%&* !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@
M>4<  &M'  !@2   5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D
M5 L (E40 "!5%@ ?5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=8
M9@ 56'4 %%B' !18F@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H
M &9+  !<2P  4TL  $M,  !$30  /$\  #51   O5   *58  "19   >6P<
M&ET- !A=$@ 771D %EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /
M7W$ #E^#  U?E@ -7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).
M  !83P  3T\  $A0  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4)
M !%F#P 09A0 #V8;  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP
M!F=]  5GD  $9J,  F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !4
M4@  3%,  $-5   [6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP
M#  (<!$ !W 6  5P'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V
M  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  !15P
M1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !
M> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z
M@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F
M #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  """   @PT
M (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P
MAY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M
M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!   C@D  (\-
M  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@
M )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A
M?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (  )T'  ">
M"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4
M  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0
M$9(   N7   $G    *    "C    I@   *@   "I    J@   *P   "M!
MK@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "X
MG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(
M  .G    JP   *X   "R    M@   +@   "X    N@   +L   "]    O@
M , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0
MS:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K    [$   "V
M    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-    S@   -
M  #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8
M .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y
M $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ .,
MD0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_
M ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@
MZ !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #.
M ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X
M_P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+
M -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X
MNP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_
M    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\
M30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1
M *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_
M]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L
M $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L
ME0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP
M -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *  0 "> $<
MG !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+
M )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!
M  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!(
M (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8
M?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F
M"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" ((
M2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"?
M '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0
MD1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U
M!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)
MK !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8
M ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0
M:PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;
M$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;
M  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%%
M & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH
M41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L
M'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@8
M1P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/
M $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P
M8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/
M'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,C
MZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4
M %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8
M1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]
M*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F
M  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+
M #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@
M."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,
M*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL
M4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_
M #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@
M1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T
M,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S
M_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(%
M #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4
M+C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2
M-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W
M"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M>
M "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@
M?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O
M/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ")
M:  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H
M &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P
M)T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;
M170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^
M  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/
M "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$
M%$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !7
M0@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0
M$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^
M  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310
M2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 0
M6!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98
MC  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@
M $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!
M"6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@
M7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.
M   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3
M  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90
M &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P
M5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q
M%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C
M  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8
M(F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0
M?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_
ML@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\
M !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")#0  BA
M (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP
MC<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!
M   (A0   (D   "-    D    )(   "3    E    )8#  "7"   F P  )H/
M  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<
M )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0
ME    )@   "<    GP   *$   "B    I    *4   "G    J 0  *H)  "L
M#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_
M  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?    I
M *@   "L    KP   +$   "Q    LP   +4   "V    N    +H   "\!@
MO@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(
MO !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O    LP   +<
M  "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-    SP,
M -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_
M  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /
M5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"<
M -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_
M_P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#=
M %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0
MH #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P
M /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %,
MQ0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q
M *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X
M  #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3
M +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\
MGP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+
M    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$
M4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F
M (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z
ML    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1
M %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (
MKP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@
M )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T
M@@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R
M +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X
M  "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!,
M '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8
M9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^
M!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H
M30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /'
M %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@
M<@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?
M!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,
MY !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$
M &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L
M5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)
M$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4
M 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A).
M $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8
M0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5
M%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $48
M4@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_
M #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' (
M31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]
M'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A
M_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R )
M $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4
M-B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1
M)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D
M#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"==
M "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*
M?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W
M*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL
M9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T
M &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X
M,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D
M,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P
M  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1
M "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$
M'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9
M-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W
M%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_
M !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@
M338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =
M/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !)
MCP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD
M $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4
M%40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -
M19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \
M   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8
M  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH
M!$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W
M/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1
M&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I
M  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P
M+44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P
M61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69   %FE  !8
MN@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P
M ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D
M &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@
M8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7
M   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;
M  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@
M &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   0
M9   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X
M'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??
M  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P
M!7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0
MB!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&
MZ !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($
M  "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5$   EQ4
M )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+
M7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C    )$   "5
M    F    )H   ";    G0   )\   "@    H@   *0%  "F"@  J X  *H4
M  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@
M.6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$   "E
MJ    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_
M$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@
M ">    <B   $I    J7    G0   *,   "H    K0   +(   "V    N0
M +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%  #1#0
MUA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\
M  #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!?
M .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P
MR@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^
M  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X
M7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T
M +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M
MY0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z
M %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8
MO@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP &
M ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@
MI@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5
M ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!    MP " *\
M"P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7
M )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,(
MA0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@   )X !P":
M  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8
M5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3
M '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )   @"+  L
MB  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W
M %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D
MZ !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_  8 >P -
M 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %
M:@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!>
M /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\
M#P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2
M %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\
M5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D
M !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"
M5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y
M $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T
M6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+
M"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-
M_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT.
M %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E<
M0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3
M&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0
M$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q->
M #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P
M?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!
M%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,9
M9@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"
M &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$
M.1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L
M'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D
M  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3
M #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\
M)2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9
M)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB
M%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=]
M !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0
M32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E
M)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HL
MC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP
M $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@
M'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4
M,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N
M   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(<
M !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P
M$#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X
M,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X
M'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL
M  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P
M,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  .
M/B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^
MO  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4
M "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"
M!T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0
M1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[
M   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC
M  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX
M $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <
M0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3
M)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G
M  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@
M$DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0
M7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9
M\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8
M  I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,
M &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/
M1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C
M    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F
M  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@
M14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L   !O
M<@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$
M*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U
M #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]    @0
M (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06  "6(
MEBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=
M   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-    D0   ),
M  "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H%P  J2,
M *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =
M<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@   *0   "E
M    IP   *D   "K    K0   +    "R    M0(  +<)  "[$   OA@  +XF
M  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@
M#8@   6/    E@   )P   "B    IP   *P   "P    LP   +8   "W
MN0   +L   "]    OP   ,(   #%    R    ,H   #."   TA   -4;  #5
M+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P .
M /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &,
MW !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #
M .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T
M$@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C
M ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N .,
MK@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#-
M !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +
M8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R
M )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H # "V !(
ML@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"<
M &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L
M_0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A  X GP 5
M )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H
MB@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\
M /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P C0 1 (L
M& ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!:
M 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X
M;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ . 'P % ![
M !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P
M6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_
M &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8
M;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!?
M %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8
M_P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8
M &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@
M4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"=
M"0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %<
M&0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!=
M $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0
M@P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!.
M 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %
M9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(
M &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8
M10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X
M#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7
M  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8
M #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X
M+Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9
M&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0
M&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[
M "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@
M31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O
M%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9
MB@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B
M $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H
M)Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <
M'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B
M   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T=
M "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID
M%B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y
M)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB
M(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K
M !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@
M,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6
M)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJ
MO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@
M "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2,
M$"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (
M+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ
M   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G
M  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T
M S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B
M+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X
M+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF
M   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0
M&C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*
M/C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]
M\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@
M !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T
M $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5
M-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!
M   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR
M  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.
M1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '
M2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7
M.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP
M #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51    5
M %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0
M8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_
M   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;    7@   &$
M  !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8
M &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K
M1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P   &T   !O
M    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]
M  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4
M'%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P   !^
M?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "2
M1   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(
M  YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".    D
M )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@
MI4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W
M    ?@   (0   "*    CP   )0   "8    FP   )X   "?    H@   *0
M  "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[,   NT,
M +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8    "(
MCP   )8   ";    H0   *8   "J    K@   +    "Q    M    +8   "X
M    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.
M  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L
M]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0
M &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@
M_P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @
M -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &<
MN0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C
M /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !( PP ; ,
M) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G
M *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\
MD #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H
M "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$
M9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_
M ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$
MD@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_
M &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0
M_P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "! !L @  C
M '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$
M;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X
M    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8 <  = '
M) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C
M &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H
ME0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B
M "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0
M: !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0
M 'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "
M5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!)
M &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*
M  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @
M $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L
M/@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?
M#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $,
M(0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U
M #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0
M41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z
M R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'
M@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0
M $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\
M,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F
M#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6
M   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA
M "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8
M'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z
M&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40
M)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G
M !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P
M,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >
M%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8
MN@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP
M "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0
M&!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .
M'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=
M   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI
M !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H
M"R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C
M'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC
M+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C
M  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0
M'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )
M*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G
M\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0
M !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3
M BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:
M)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I
M   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V
M   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P
M2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /
M,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y
M/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP
M #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0
M"3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@
M0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO
M   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X
M  !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$
M $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P
M,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1    $8   !(
M @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*
M  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-
M)S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\   !1
M4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<
M5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP
M !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<    70
M %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30
M:5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)
M   030  "E$   15    6@   %T   !@    8P   &8   !H    :@   &L
M  !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D
M 'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *
M60   EX   !C    9P   &L   !O    <@   '4   !W    >0   'L   !]
M    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC
M  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P
M &T   !R    =P   'L   !_    @P   (8   "(    B@   (T   "/
MD0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@
M<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P    =P   'T
M  "#    B    (T   "1    E0   )@   ":    G    )\   "A    HP
M *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90
MMGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6
M    FP   *    "D    J    *L   "L    KP   +(   "T    M@   +D
M  "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,
M ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K
M #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8
M=0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_
M )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T
MS  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O
M '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\
M_P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O
M *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\
MF@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G
M    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L
M, "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P
M (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6
MP    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"%
M #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4
M<P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP
M )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H
M<P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D
M '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H
M  !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J
M &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '(
M50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q
M    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %<
M*@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z
M $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '    !F
M7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!,
M "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\
MA0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508
M % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4
M00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U
M ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+
M  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E
M #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\
M+ "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^
M#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #
M)P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"?
M "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$
M-@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H
M!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'
ML  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$
M "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28
M(0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6
M#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2
M   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ
M !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D
M$ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D
M$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41
M,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A
M  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06   A%@
M'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0
M%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5
M[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<
M !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3,
M#!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<
M&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8
M 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY
M  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@
M2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3
M&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B
M0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\
M #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P(
M#B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0
M)TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB
M   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /(P  #24#
M  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48
M "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P
M)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L
M!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0
M   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P
M*"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !  (R!
M- <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z
M7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@
M "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y @  .P4
M #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P
M0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K
M   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!    0P(  $4%
M  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0
M $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5
M-   $#<   TZ   (/0   D    !#    1@   $@   !*    3    $X!  !/
M!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S
M  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/
M#$    =$    1P   $H   !-    4    %,   !5    5P   %D   !:
M7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !B
MA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH
M  !/    4P   %8   !9    7    %\   !A    9    &4   !G    :0
M &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P
M<I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<
M    8    &0   !H    :P   &X   !Q    <P   '4   !W    >@   'P
M  !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L
M (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8   !K
M;P   '0   !Y    ?0   (    "#    A0   (<   "*    C    (\   "2
M    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9
M  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]    @@
M (8   "+    CP   ),   "5    EP   )H   "=    H    *,   "F
MJ@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "O
MI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0    E0   )H
M  "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z    O0
M ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\
M    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X X@ V -X
M/@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "!
M +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T
M[    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\
M #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4
MA0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP
M -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@
MI  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/
M (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L
M  "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W
M (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ ((
M>@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9
M    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H
M-@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"*
M &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )    "%
M?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H
M #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D
MDP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;
M &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\
M60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !,
M )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G    7P   %H
M  !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N
M $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@
M0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50   $\   !,
M    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $(
M+0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G
M #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0
M00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W
M "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T
MN  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4
M #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D
M+@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E
M ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (
M   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K
M "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,<
M'@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H
M"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\
M+@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A
M !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0
M(@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8
M!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#
M[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X"
M !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$
M$@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<
M#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/
M!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[
M  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0
M2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3
M$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H1
M00 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210
M #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0<
M$!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $
M%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7
M   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((
M  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<
M !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P
M&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6
M"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2
M   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P
M)AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '
M' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B
M7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T
M " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@
M "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+   G7
M)VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=
M   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(
M   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H
M "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :
M'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00  "\&   P
M"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\
M   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0
M$R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$   X!@
M.@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [
MD0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@
M  TK   )+@  !3     S    -0   #@    Z    /    #X!  !  P  0@<
M $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP
M0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS
M   #-@   #D    \    /@   $$   !#    1@   $@   !*    3 ,  $X&
M  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX
M $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D   (]
M0    $,   !&    20   $P   !.    40   %,   !5    5P   %D!  !<
M!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP
M  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(    3
M $\   !2    50   %@   !;    70   &    !B    9    &8   !I
M;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !J
MP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5    60   %T
M  !A    90   &@   !K    ;0   &\   !R    =    '<   !Z    ?@
M (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I
M.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0   &X   !R
M    =@   'H   !]    @    ((   "%    B    (L   ".    D@   )8
M  "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P
M&4@  !%.   )50   %P   !C    :@   '$   !V    >P   (    "&
MB@   (X   "1    DP   )8   "9    G    *    "C    IP   *L   "P
M    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0
M  M<   !9    &P   !T    ?    (,   ")    CP   )0   ":    GP
M *(   "D    IP   *H   "N    L0   +0   "X    O    ,$   #'
MS0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
M         0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R
M,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK
M;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.D
MIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>
MW^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________
M____________________________                      $#! 4&" D*
M"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$
M149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]
M?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6V
MN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P
M\?+T]?;W^?K[_/[_____________________________________________
M_________P                     ! P0%!@@)"@L-#@\1$A,4%A<8&AL<
M'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U15
M5UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/
MD)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(
MR<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____
M__________________________________________________\  0(#! 4&
M!P@)"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3(S
M-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@
M86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-
MCH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZ
MN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;G
MZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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MYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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M<<"+K'' BZQQP(NL_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MC*:%T(FFAM&&I8?2A*6*TH&EC=* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MILZ<A:;._[04"/^T'QW_L2PZ_ZTX6>NF17O5G5><QYMGLL2>;K;"H'>ZOZ&
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MEUQIZY=@?-^6:8W5DW*=S))\JL62A;3$DHRVPH^/N<&+DKO AY6]OH.8O[V
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MQ9.'KL.2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MF)_1>)RBT'>?I,YUHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ''
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MFW&CRIA[K<65A;3"DHVZOHJ2O[J!F\6W?*G)JWRKQZ1]KL.@?K# G7^RO9N
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M;ZNING*EM;IWG;6Y>IFVMWV6M[9^D[FT?Y&ZLH"0N[& D+NQ@)"[L8"0N[&
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MP*IMHL"J_Y4- /^:'@7_HBP0_ZTH%?N[(QCHS2 7U=\E'<CH,#&\[SE$L.Q
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M;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=LW:\  ,6\! "UR@0
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MR)^,@<B?C('(GXR!R)^,@<B?_X(1 ?^!&@/_ABT-_Y8T%?^@.1W_ICPF_ZM
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M?U+&WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!_Y(, /^@#0#;MP8
MRL,' ,#2"0"U]! &J?L?%)_\+".4_#<QBOQ!/8']24=X_5%0;OU75V7Z7EQ@
M]F9A6_1O95;Q>&A3[X)K4.Z,;4[LEV],ZZ-Q2NJP<DGJP7)(ZMAR2^/D<D[8
MYG-.U>=T3M7G=$[5YW1.U>=T3M7G=$[5YW1.U>=T_Y8* -ZL @#+N@4 O<<&
M ++8" &G_Q((G/\A%I+_+B.)_SDO@/]".7?_2D)M_U!)9?]63E__7E-:_F56
M5?QM6E+Z=5Q/^'Y?3/>'84KUD6)(])QD1O.F947RLV9$\L%G0_+49T7NYV=&
MZ^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0 K\T$ *3>
M!P&:_Q4)D/\D%8?_,"!^_SLJ=/]",FO_2#EC_TX_7?]50UC_74=3_V1*4/]K
M34W_<D]*_WE11_^"4T7_BU1#_I160?V>5T#]J%@__+-9/OR_6C[[T5H]^]M:
M/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:TJT  +VX @"NQ0( H=4" );W"P*-
M_Q@(A/\F$7S_,1IQ_S@B:/\^*6#_12]:_TPS5/]3-U#_6CI,_V \2?]F/D;_
M;4!$_W1"0?][0S__@T4]_XQ&._^51SK_GDDY_Z=*./^Q2C?_ODLW_\)+-__"
M2S?_PDLW_\)+-__"2S?_PDLW_\)+O[,  *Z^  "@S0  DMX  (G_#0&!_QH%
M=_\C#&W_*A-D_S$97/\X'E7_0")0_T@F3/]/*4C_52M$_ULM0O]A+S__9S$]
M_VTR._]S,SG_>C4W_X(V-?^+-S/_E#@R_YPY,?^D.C#_KSLP_[([,/^R.S#_
MLCLP_[([,/^R.S#_LCLP_[([L+@  *#'  "1V   A.\  'S_#0%O_Q$#9O\9
M!E[_(0I6_RD/4/\R$TO_.A9&_T$90O](&S__3AT\_U,>.?]9(#?_7B$U_V0B
M,_]I(S'_<"0O_W<E+?]^)BS_AR<J_X\H*?^7*2C_H"HH_Z,J*/^C*BC_HRHH
M_Z,J*/^C*BC_HRHH_Z,JH<(  )'1  ""X0  >/\  &S_" %@_PT"5_\1 T__
M& 5(_R &0_\I"#__,0H[_S@,./\^#C7_1 \R_TD0,/].$2[_4Q(L_U@3*O]=
M%"G_8Q4G_VD6)?]O%R3_=Q<B_WX8(?^%&1__CQH?_Y$:'_^1&A__D1H?_Y$:
M'_^1&A__D1H?_Y$:_V@9 O]D(P3_7R\&_UY $/]C2QK_9U0E_VA=+_]F9SG_
M9')!_V)]2/]@AT[_79!2_UN85O]:GEG_6*1;_U>J7?Y6L%_]5;5@_%2\8?Q4
MQ&+[4\UC^5+<8_92YF/Q4^IC[%3M8^96[V+@5_!CX%?P8^!7\&/@5_!CX%?P
M8^!7\&/@5_!C_VD8 O]E(P3_8"X&_U] $/]F21K_:E,E_VM<,/]I93K_9W!"
M_V1[2?]BA4__7XY4_UV66/];G5O_6J-=_5BI7_Q7KV'[5K5B^E6\9/I5Q&7Y
M5,YE]U/=9O-3YF;N5>IFYU;M9>%8[F7;6>]FVUGO9MM9[V;;6>]FVUGO9MM9
M[V;;6>]F_VH8 O]F(@3_82X'_V _$/]I2!O_;5$F_VY;,/]L9#K_:6Y#_V=Y
M2_]D@U'_88Q6_U^56O]=G%W]6Z)@^UJI8OI9KV3Y6+5E^5>\9_A6Q6CW5<]H
M]53@:?!5YFGI5^IHXEGL:-M:[6G36^YITUON:=-;[FG36^YITUON:=-;[FG3
M6^YI_VH8 O]G(@3_8BX'_V,^$/]L1AO_<5 F_W)9,?]P8CO_;&M$_VEV3/]G
M@5+_9(M8_V&37/U?FV#[7:%B^ENH9?E:KF?X6;5H]UB\:?97QFKU5M%K\E7A
M;.Q7YVSD6>EKW%OK:]1<[&S-7>ULS5WM;,U=[6S-7>ULS5WM;,U=[6S-7>UL
M_VL7 O]H(0/_8RT'_V<\$/]P11O_=$XF_W97,?]T8#O_<&E%_VUS3?]J?E3_
M9HA:_F.17OMAF6+Y7Z!E^%VG:/9<K6KU6K1L]%F];?18QV[R5]1O[E?B;^99
MYF_=7.ENTUWJ;\U>ZW#'7^MPQU_K<,=?ZW#'7^MPQU_K<,=?ZW#'7^MP_VP7
M O]I(0/_92T'_VLZ$/]T0QO_>4PF_WI5,?]Y73S_=69%_W!P3O]M>U;_:H5<
M_&:/8?IDEV7W89]H]E^F:_1=K6WS7+1O\EJ]<?%9R7+O6-ISZ%KC<]Y=YG+3
M7NASRU_H=,9@Z'3!8>ATP6'H=,%AZ'3!8>ATP6'H=,%AZ'3!8>AT_VT6 O]J
M( /_9BT'_V\X$/]X01K_?4HE_W]2,?]^6SS_>V-&_W9L3_]Q=U?^;8)>^VJ,
M8_AFE6CU9)UL\V&D;_)?K''P7;1S[UR_=>Y;RW;J6]UWX%WC=M-@Y7?*8>5X
MQ&+E>+YCY7BZ9.5XNF3E>+IDY7BZ9.5XNF3E>+IDY7BZ9.5X_VX6 O]K( /_
M:"P'_W,V$/]]/QK_@D<E_X10,/^$6#O_@6!%_WQI3_]V<E?^<7U?^6V(9?9J
MDFKS9IMO\6.C<N]AJW7M7[5X[%W!>>Q<T'KC7=][U&'B>\IBXGS"9.%]O&7A
M?;=FXGRS9^)\LV?B?+-GXGRS9^)\LV?B?+-GXGRS9^)\_W 5 ?]L'P/_:2P'
M_W<T#_^!/!G_AT4D_XI-+_^)53K_AUU%_X)E3_]\;EC]=GA@^'*$9_5MCFWQ
M:9AR[V:A=NQCJWGK8+9\Z5[$?N=>V'_88=]^RF/?@,%EWH&Y9]Z!M&C>@;!I
MWX"L:=]_K&G??ZQIWW^L:=]_K&G??ZQIWW^L:=]__W$5 ?]M'P/_:RL'_WLR
M#_^&.AC_C$,B_X]++?^/4SC_C5I#_XEB3?^#:5?]?')@^'9_9_1QBF[P;)5T
M[6B?>>IDJGWH8;> YE_(@MUAVX/,9-R$P&;<A;AHVX6Q:MN%K6O<A*ELW8.F
M;-V"IFS=@J9LW8*F;-V"IFS=@J9LW8*F;-V"_W(4 ?]O'@/_;RD'_W\P#O^*
M.!?_D4$A_Y1*+/^543;_DUA!_Y!@2_N+9U7UA&]?\'UZ9^MWA6_G<I!VXVV;
M?-YHIH':9;.$U6/$AL]DVH?!9]F(MVG8B:]KV(FJ;=F(IF[:AZ-NVH:@;]N%
MH&_;A:!OVX6@;]N%H&_;A:!OVX6@;]N%_W(4 ?]P'@/_<B@'_X(N#?^.-A;_
ME4 ?_YE(*?^93S3_F%4^^I9<2?229%/MC&M=YX5V9N%_@6_;>(QWTW*6?LUM
MH83):JV)Q6B[B\%HT(RV:]6-KFW5C:=OUHRC<-:+GW'8BIUQV8F;<MJ'FW+:
MAYMRVH>;<MJ'FW+:AYMRVH>;<MJ'_W,4 ?]P'0/_=28&_X8L#?^1-A7_F4 =
M_YQ&)_^=3#'\G5([])Q91>V98$_FE&A9WXYS8]6&?6[-?X=XQGB1@,!SFX>[
M;Z>,MFVTC[-LR)&L;M*1I7#3D*!RU(^<<]6-F736C)=TV(J6==F)EG79B99U
MV8F6==F)EG79B99UV8F6==F)_W03 ?]Q'0/_>"0&_XDK#/^5-1/_G#X;_Z!#
M)/^B22[WHU W[Z)60>>A74K?G6=4U)5O8LN->&[#A8)YNW^,@K5YEHFO=:&.
MJG*ODJ9QP92A<]"4G'31DIAVTI&6=]./E'?5C9)WUHR1>-B*D7C8BI%XV(J1
M>-B*D7C8BI%XV(J1>-B*_W43 ?]R' /_>R,&_XPI"_^8-!+_GSP9_Z-!(ONF
M1BKRJ$TSZJE4/.*I6T37HV-3S)IL8L*3=6ZZBWYYLH6'@ZI_D8JD>YR0GGBJ
ME)IVNY:7=\^6E'G0E)%ZT9*/>M.0CGK4CXUZU8V,>M>+C'K7BXQZUXN,>M>+
MC'K7BXQZUXN,>M>+_W43 ?]S' /_?2$%_XXI"O^;-!#_HCD7_Z8^'_>J1";N
MKDHNY;%2-=RO64'/J&%2Q:!I8;N8<FZQD7IYJ8N#@Z&%C8N:@9B1E'ZEEI!\
MMIB-?<V7C'[/E8I^T).*?M*1B7[3CXE]U8V(?=:+B'W6BXA]UHN(?=:+B'W6
MBXA]UHN(?=:+_W82 ?]T' /_@" %_Y$H"?^>,P__I#<5_JH[&_.O02+JM$@H
MXKE0+M2T5D#)K5]1OJ5G8+2>;VVJEW=XH9& @IF,BHN1AY61BX2BEH:#LIF#
MA,N8A(/.EH2#T)2$@M*2A('3D(2!U(Z$@-:,A(#6C(2 UHR$@-:,A(#6C(2
MUHR$@-:,_W<2 ?]T&P/_@AX$_Y0G"/^@,@W_IS03^JXX&.^U/1SFO$8AW+],
M+,ZY5#_#L5U0MZIE7ZVD;&RCG71WF9A\@9&3AHJ)CY*1@HR?EGV*KYAZB\>8
M?(G.EGV(T)1^AM*2?X73D'^$U(Z @]:,@(/6C("#UHR @]:,@(/6C("#UHR
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MAV&AVX9CG=N%8YW;A6.=VX5CG=N%8YW;A6.=VX5CG=N%_WX0 ?^'$0'_FA$
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M_VH5 ?]K&P+_>Q<"_XH< O^8)@7_HC (]:@S#.NN.1#BLT$4UK%'(\JK4C3
MI%Q#MIYD4:V8;%REDG1FG8U];Y:(AG:/A9%]BH*<@H6 JH6!?[R&@(#;A8"
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M<%FCZW!9H^MP6:/K<%FCZW!9H^MP_W</ ?^-" #>H ( SZX% ,2Y!0"[Q08
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MA X5_Y(/%/^@$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X
M (;,  !WVP  :><  %S]  !4_P  2_\% $/_# $]_Q$"-_\7 C+_'@,N_R0#
M*O\J!"7_+P0B_S4%'_\Z!1W_/P4:_T4&&/]+!A;_4@84_UH'$O]B!Q#_; </
M_W<(#?^$" S_D @,_YP(#/^B" S_H@@,_Z((#/^B" S_H@@,_Z((_U @ O]+
M*@/_1#8%_T<Z!O]*/PC_3DD/_T]4%_]/8![_36PD_TIY*O](A2[_1I R_T2:
M-/]#HC?_0JHX_T&Q.O] N3O_0,$\_S_+/?\^W#[_/N@^_SWS/O\]^S__/O\^
M_T#_/OI#_SWT1/\^[D;_/^Y&_S_N1O\_[D;_/^Y&_S_N1O\__U @ O]+*@/_
M134%_THX!O]-/0C_44@/_U)2%_]17A[_3VHE_TUW*_]*@R__2(XS_T:8-O]$
MH3C_0ZDZ_T*P//]"N#W_0<$^_T#+/_] W$#_/^E _S_T0/\^_4'_0/] _4+_
M0/9%_T#P1O]!Z4C_0>E(_T'I2/]!Z4C_0>E(_T'I2/]!_U$? O],*0/_1S0%
M_TTV!O]1.PC_5480_U90&/]57!__4F@F_U!T+/]-@#'_2HPU_TB7./]&H#O_
M1:@\_T2P/O]#N#__0\%!_T+,0?]!WD+_0>M#_T#U0_] _4/_0_]#^$;_0O!(
M_T/J2?]$XTK_1>-*_T7C2O]%XTK_1>-*_T7C2O]%_U(? O]-*0/_2C($_U S
M!O]5.0C_64,0_UI-&/]96"#_5F0G_U-Q+?]0?3/_38DW_TN4.O])GCW_1Z8_
M_T:N0?]%MT+_1,%$_T3,1?]#WT7_0NU&_T+W1O]#_4;Y1O]&\$G_1NE+_T?B
M3/](VTW_2-M-_TC;3?](VTW_2-M-_TC;3?](_U,> O].* /_3B\$_U0P!O]:
M-@C_7D 0_V!*&/]>52#_6V H_UAM+_]4>33_484Y_TZ1/?],FT#_2J1"_TFM
M1/](MD;_1\%'_T;-2/]%X4G_1.]*_T7X2OM'_4KQ2O])Z$W_2]]._TS73_],
MSU'_3,]1_TS/4?],SU'_3,]1_TS/4?],_U0= O]0)P/_4BP$_UDM!?]?,@C_
M9#P0_V9'&/]D4B#_85PH_UUH,/]:=3;_5H$[_U*-/_]/F$/_3:)%_TRK2/]*
MM4G_2;]+_TC,3/](X4W_2.Y-_$CY3O)+_$WG3OU/W5#]4-)2_E#,4_]1QE3_
M4<94_U'&5/]1QE3_4<94_U'&5/]1_U4= O]1)P/_5BD$_UXJ!?]D+PC_:CH/
M_VQ%%_]L3R#_:%DH_V1C,/]@<#?_7'P]_UB(0O]5DT;_4YU)_U&F2_]/L$W_
M3KI/_4W&4/I-V5'V3.I1\DWW4>=0^E+;4OM4SE3\5<=6_57!5_Y5O%C^5;Q8
M_E6\6/Y5O%C^5;Q8_E6\6/Y5_U<< O]2)@/_6B8$_V(F!/]J+ ?_<3<._W-"
M%O]S3!__<%8H_VM@,/]F:SC_8W<^_E^#1/M;CDCY6)A,]U:A3_55JU'S4[53
M\5+!5.]1T%7K4>=5YE+V5MI4^5C,5OI9PUC[6KQ:^UJW6_M9LUS[6;-<^UFS
M7/M9LUS[6;-<^UFS7/M9_U@; O]3)0/_7B,#_V<C!/]P*@;_=S4-_WI %?]Z
M2AW_>%,F_W-<+_QN9C?X:7(_]&5^1?%AB4KN7I-.ZUR=4NA9IE7F6+!7Y%>\
M6.)6S%G>5N19V%;T6\I8]UW 6OA>N%SX7K-=^%ZN7OA=JU_Y7*M?^5RK7_E<
MJU_Y7*M?^5RK7_E<_UD; O]6(P/_8B #_VP@ _]U* 7_?3,+_X ]$_^!1QO_
M?U D^7M9+?1V8C;N<6T^ZFQY1>9HA$OB9(Y1WF&85=M>HEG67*Q;TUNX7M!:
MQE_-6M]@R%KR8;Y<]6*U7O1BKF#U8JIA]6&F8O9AHV/W7Z-C]U^C8_=?HV/W
M7Z-C]U^C8_=?_UH: O]9(0+_9AT"_W > _]Z)@3_@C$)_X8[$/^(1!GYADTA
M\H-6*^M^7C3E>6D]X'1T1=IO?TS3:HE3SV:26,MCG%W'8:9@Q%^Q8\%>OV2^
M7M)ENE_L9K)@\F:K8O)FI63R9:%E\V2?9?1CG&;U8IQF]6*<9O5BG&;U8IQF
M]6*<9O5B_UL: O]<'P+_:1L"_W4< O]^) /_ARX(_XPX#ON.0A;RCDH>ZXM2
M)^2'6S#=@68ZTWIP1<UU>D[(<(-5PVR-6[YIEF"Z9J!DMV2K9[1CN&FQ8LIJ
MKF/F:JAD[VJB9N]IG6?P:)IH\6>8:?)FEFGS9)9I\V26:?-DEFGS9)9I\V26
M:?-D_UL9 O]?' +_;!@"_WD; O^#(0/_C"P&_Y$V"_64/Q+LE4<9Y)-/(MR.
M6"W2AV(ZRH%L1<-[=4Z^=G]6N'*(7;1ND6*O:YMFJVFF:JAGLVRE9\-NHF?@
M;IYI[6V9:NYLEFOO:I-L\&F2;/%GD&SR9I!L\F:0;/)FD&SR9I!L\F:0;/)F
M_UP9 ?]B&@+_<!8"_WP9 O^&'P+_D"D$^I8S"?":/ [GFT05WYI+'=.452S*
MC5\YPH=I1;N!<4^U?'M7KWB$7JITC6.E<9=HH6ZB;)ULKF^:;+YPF&S9<95M
MZV^1;NQNCV_M;(UO[VJ,;_!IBV_Q9XMO\6>+;_%GBV_Q9XMO\6>+;_%G_UT9
M ?]D&0+_<A0!_W\8 ?^*'0'_E"8#]ILP!NN?. KBHC\0V)]'',V94BO$DETY
MNXQF1+2';DZM@G=7IWV 7J)YB62==I-IF'.>;91QJG&0<;IRCG'1<XQRZG&*
M<^MOB'/M;8=S[FN'<^]JAG+P:(9R\&B&<O!HAG+P:(9R\&B&<O!H_UX8 ?]G
M%P'_=1,!_X,6 ?^.&@'^F","\9\L!.>E,P?=J#D,T:-%&\>=4"J^EUHXM9)C
M1*V,;$ZFAW17H(-\7II_AF25?(]JD'F:;HMWIG*(=K9TA7;,=(1WZ7*#=^IP
M@G?L;H)V[6R"=N]J@7;P:8%V\&F!=O!I@7;P:8%V\&F!=O!I_UX8 ?]I%0'_
M>!(!_X84 ?^1& 'ZG!\![:0G N*J+ 36K#0+RZ=#&L&B3BFXG%@VKY=A0Z>1
M:4V@C7%6F8AY7I.%@F2-@8QJB'^7;X-]I')_?+-T?7S(=7Q]Z'-\?.IQ?'OL
M;WUZ[6U]>>YK?7GP:7UY\&E]>?!I?7GP:7UY\&E]>?!I_U\8 ?]K$P'_>Q$!
M_XD3 /^5%0#UH!H!Z*D@ =VP) '0L#(*QJQ!&+RF3">SH58UJIQ?0:*79TR:
MDF]5DXYW78R+@&2&B(II@865;GR#H7)W@K!T=8+%=72#YW-U@>IQ=G_K;W=^
M[6UX?>YK>'SP:7A\\&EX?/!I>'SP:7A\\&EX?/!I_V 7 ?]N$@'_?A  _XP1
M /^9$0#QI!, XZX6 -:V' '+M# (P; _%[>K2R6MIE0SI*%=0)R=94J4F&Q3
MC)5T6X:1?6)_CH=H>8R2;72*GG%PB*UT;8C!=&V)Y'-OA^IQ<(3L;W*#[6US
M@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X _Y . /6=
M#0#CJ0P V;4, ,^Y&@#%N"X'N[0]%;&P22.GJU(QGJ=;/I:C8TB.GVI1AIMR
M67^8>F!XE81F<I./;&V1G&]ID*IR9I"^<V61X7)HCNMP:HKL;FR([6QMAN]K
M;H3P:6Z$\&ENA/!I;H3P:6Z$\&ENA/!I_V,5 ?]U#@'_A@T ^)0+ -RB" #4
MK0D S[@* ,F]%P"_O"L&M;D[$ZNV1R&AL5 OF*U9.X^J84:'IFA/?Z-P5WB@
M>%YRGH%D:YN,:6::F6UBF:AO7YF\<%Z9WV]@ENQN8Y'M;6:.[FMGB^]J:8GP
M:&F)\&AIB?!H:8GP:&F)\&AIB?!H_V<2 ?]Y# #_B@H WYH$ -.F!P#,L0@
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M0.FR/C_JRSX^Z.\^/>;_/SW@_T(_U_]$0,[_1D#._T9 SO]&0,[_1D#._T9
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ML"@N_\@I+?_J*BS__RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8
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M&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,  )"_  "
MS   <MH  &3D  !8]0  4?\! $K_"P!$_Q !/O\7 3G_'@(T_R4",/\L RS_
M,@0H_S@$)?\^!2+_1 4?_TH%'/]1!AK_6087_V,'%/]N!Q+_? @0_XP(#_^<
M" [_K D._[L)#?_3"0W_TPD-_],)#?_3"0W_TPD-_],)D;P  (')  !RUP
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M6W5Y^UIU>?M:=7G[6G5Y^UIU>?M:_UT3 ?]L#0#_>PL ]H@) -R3!@#5G0D
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MQCM#T.HZ0,W]/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@
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M'2K\^ATJ^O\=*O?_'"KW_QTJ]_\=*O?_'2KW_QTJ]_\=LZ,  *2K  "7M@
MB<$  'O+  !OU@  8]\  %OU!@!5_Q  4/\9 4O_(P)&_RP#0O\T!#[_/ 4Z
M_T,&-_]+!S3_4P@Q_UL)+O]D"BO_;PPH_WP-)O^+#B3_G! B_ZX1(?_%$B#_
MZ1,?__P3'O__$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H
M &[5  !@WP  5.<  $[_! !)_PX 0_\4 #__'0$Z_R4"-O\L C+_,P,O_SH#
M*_]!!"C_2 0E_T\%(O]7!2#_8 8=_VP'&O]Y!QC_B@@6_YL(%?^M"13_PPD3
M_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R   ;=0  %_@
M  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B_R\"'_\U
M AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_J 4(_[D%
M!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^   %#G  !"
M[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!$_\H 1#_
M+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0, _YT# /^L
M P#_M0, _[4# /^U P#_M0, _[4#_SDG O\S,@+_-30#_S@V _\X.P3_-D,%
M_S-.!_\Q6PG_+V@-_RUV$?\KA!3_*9$6_RF;&/\HI!G_**T:_RBU&_\GOAS_
M)\@<_R?4'?\GY!W_)^\>_R?Y'O\G_Q[_)_\>_R?_'?\H_QW_*_\>_RW_'_PO
M_Q_\+_\?_"__'_PO_Q_\+_\?_SHG O\T,0+_.#$#_SLT _\[.03_.D$%_S=+
M!_\U6 K_,V4._S%S$O\O@17_+8X7_RV8&?\LH1O_+*H<_RNR'?\KNQ[_*\0?
M_RO0'_\JX2#_*NT@_RKW(/\J_R#_*_\@_RO_'_\L_Q__+_\A_#'_(O<S_R+W
M,_\B]S/_(O<S_R+W,_\B_SLF O\U, +_.R\"_SXQ _\_-@3_/CT%_SQ(!_\[
M50O_.6(/_S=O$_\U?1?_,XH9_S*5&_\QGAW_,*<>_S"O'_\PMR#_+\ A_R_+
M(O\OW"+_+^HC_R_U(_\O_B/_+_\B_S#_(O\P_R/[,_\E]37_)? W_R;P-_\F
M\#?_)O W_R;P-_\F_SPF O\Y+0+_/RP"_T,M _]$,@3_0SD%_T-%!_]"4@O_
M0%\0_SYK%?\[>!C_.84;_S>0'O\WFB#_-J,A_S6K(O\ULR/_-+PD_S3&)?\T
MU"7_-.8F_S3Q)O\T^R;_-?\E_C7_)OHV_RCS./\I[#K_*>8\_RKF//\JYCS_
M*N8\_RKF//\J_STE O\]*@+_0R@"_T<I _])+03_2C8%_TI!!_])30S_1UH1
M_T5G%O]"=!K_0( =_SZ,(/\]E2+_/)XD_SNF)O\[KB?_.K<H_SK!*/\ZS2G_
M.N$I_CKN*?LZ^2GW._\I]CK_*_ [_RWH/?\NX3__+MM!_R[;0?\NVT'_+MM!
M_R[;0?\N_SXE O]!)@+_2"0"_TPE O]/*0/_4C,%_U$^!_]120S_3U82_TQB
M%_]*;QS_1WL@_T6&(_]#D27_0IHG_T&B*?]!JBK]0+(K_$"\+/L_R"WX/]LM
M]$#K+?! ]RWM0/\OZS__,>1!_S+;0_\ST43_,\M&_S/+1O\SRT;_,\M&_S/+
M1O\S_T D O]%(P+_3" "_U(A O]6)@/_62\$_UDZ!_]91@S_5E$2_U1=&/]1
M:AW^3G4A_$R!)?E*BRCW294K]4>=+/-'IB[R1JXO\$6X,.]%Q#'M1=,QZ$;H
M,>5&]C+B1?\UWT3_-M-'_S?*2/\XQ$K_.+]+_S>_2_\WOTO_-[]+_S>_2_\W
M_T$C ?])'P'_41P!_U<< O]<(P+_8"P#_V V!O]@00O_7DT1_5M8&/A89!WT
M57 C\5-\)^Y0ABOK3Y NZ4V9,.=,H3+E3*HSXTNT-.)+P#7@2\\UVTOF-M5*
M]#C12O\ZSDK_/,1,_SR]3?\\N$__/+1/_SNT3_\[M$__.[1/_SNT3_\[_T(B
M ?],' '_51@!_UP9 ?]C( +_9B@#_V@R!?]H/0GZ9D@0]&-3%^Y@7QWJ76LC
MYEIV*.)7@2W?58LPW%.4,]E1G3;54*8XTT^O.M!/NSO.3LD\RT_A/<=/\C[#
M3_] P$__0;=1_T&Q4O] K5/_0*I4_S^J5/\_JE3_/ZI4_S^J5/\__T8? ?]0
M&0'_614!_V(7 ?]H'0'_;"0"_V\N _EO. ?Q;D0.ZVM.%>5H6QS?9&<CVF!Q
M*M1=>R_06X4TS%B..,E7ESO'5: ]Q%2I/\)3M$&_4\)"O5/60[E3[42V4_U%
MLU3_1:Q6_T2G5_]$I%C_0Z%8_T*A6/]"H5C_0J%8_T*A6/]"_T@= ?]3%@'_
M71(!_V84 ?]M&0'_<B$!^W4I O)V,P7I=CX+XG-*$MMO5QK2:V(CS6=L*\AD
M=C'$87\WP%Z).[U<DCZZ6YI!MUFD1+58KD:R5[M'L%?-2*U8Z$BJ6/I)IUG_
M2*%:_TB=6_]'FUS_1IE<_T697/]%F5S_19E<_T697/]%_TL: ?]7$P'_81
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M3(!K_TJ :_]*@&O_2H!K_TJ :_]*_U02 ?]A# #_;@H _7@) .B"" #<B0D
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MNDI.HME)3J#U24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX
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M,#W$_S,[P_\U/+[_-CVX_S<]N/\W/;C_-SVX_S<]N/\WT88  ,"5  "RGP
MI:<  )JO  ".MP  @[\  'C' P!NSP< 9=<- &/8'0!@V"T"6]@Z!%?81@E3
MV% -3]A9$4O78A5'UVP81-=W&T'7A!X^V),@/-BC(3O9MR(ZVM4B.M;R(S?4
M_R<VTO\I--'_*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T
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M"1G__PD9__\)&?__"1G__PD9__\)HJ<  ).Q  "%NP  =L8  &G0  !;V@
M3N   $/E   ^^P$ .O\, #;_$P R_QL +_\C "O_*@$H_S$!)/\W 2'_/P(?
M_T8"'/]. AG_6 ,6_V,#$_]P Q+_@001_Y,$$/^G! __O04._^ %#O_V!0[_
M_P4.__\%#O__!0[__P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<
M #?S   R_P  +O\' "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!
M$/]  0[_2 $,_U(!"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ ,
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M.X];_SJ/6_\ZCUO_.H];_SJ/6_\Z_TP2 /]6#0#_8 D _V@* /IO# #S<PX
MY7<1 -IY&P#/>2X"QW<^";]T2Q&Y<%8:LVU@(:]J:2BJ9W(MIV5Z,J-C@S:@
M88PYG6"5/)I>GS^77:I!E5VX0I-=RT.07>A#CU[\08Y?_T"+7_\^BE__/8A?
M_SR(7_\[B%__.XA?_SN(7_\[_TX1 /]8"@#_8P< ^FP& .=S!@#=> @ VGL+
M -%^%P#(?BL"P'P["+EY2!&R=E,9K')=(:=O9BBC;6XNGVIW,YMH?S>89H@[
ME661/I%CFT&.8J=#C&&T18EAQT6(8N5%AF+Z0X9C_T*$8_] @V/_/H)C_SV"
M8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? < T8 ) ,J"
M% #"@R@"NH$Y![-^1A"L>U$9IG=:(:%T8RB<<FLNF&]S,Y1M?#>1:X0[C6J.
M/XIHF$*&9Z-$A&:Q1H%FPT=_9N%'?V?X17YH_T-^:/]!?6?_/WQG_SY\9_\]
M?&?_/7QG_SU\9_\]_U(. /]= P#]:0  X7(  -9Z @#.?P4 RH,( ,6&$@"\
MAR8!M88V!JZ#0P^G@$X8H7Q8()MY8">6=VDMDG1P,XYR>3>*<($\AFZ+/X-M
ME4-_;*%%?&NN1WIKOTAX:]U(>&SV1GAL_T1W;/]"=VO_0'=J_S]W:O\^=VK_
M/G=J_SYW:O\^_U0, /]?  #R;   W78  -!] @#)@P0 Q(<& +^*$ "WC",!
ML(HT!:F(00ZBA4P7G(%5'Y9_7B:1?&8MC'EN,HAW=C>$=7\[@'2(/WQRDD-X
M<9Y&=7"L2'-OO4EQ<-E)<7#T1W%Q_T1R</]"<F__07)N_S]R;O\^<F[_/G)N
M_SYR;O\^_U8* /]B  #F;P  UWD  ,R! 0#%AP, OXL$ +F.#@"RD" !JX\Q
M!:2,/PV=BDH6EH=3'I&$7"6+@60LAG]K,8)]<S9^>WP[>GF&/W9WD$)R=IQ%
M;W6I2&QUNDEK==1):W7R1VMU_T5L=?]#;7/_06UR_S]M<O\_;7+_/VUR_S]M
M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T II,O!)Z1
M/ N8CT@4D8Q1'(N)6B2&AV(J@85I,'R"<35X@7HZ='^#/G!]CD)L?)I%:7NG
M1V9ZN$AD>]!(9'OP1V5[_T1F>O]#9WC_06AV_S]H=O\_:';_/VAV_S]H=O\_
M_UL$ /=I  #==@  S8   ,.(  "[C@  M),! *V7"0"GF!H H)@L YF6.@J2
ME$42C))/&H:/5R* C5\H>XMG+G:);S-RAW<X;86!/&F$BT!F@I=#8H&E1F"!
MMD=>@<U'7H'O1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX
M .EM  #6>0  R(0  +Z,  "VDP  KI<  *:;! "@G1< FITI I.<-PB,FD,0
MAIA-&("651]ZE%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?BI5!7(FC1%J)M$58
MB<M%6(CM1%B(_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV _SY=@/\^_V(  .1Q
M  #/?@  PX@  +F1  "PEP  IYL  )ZA  "8HQ, DZ,E 8VB- :&H4 -@)]*
M%7F=4QQTFUHC;YEB*&J8:BYFEG(R895\-UV4ACI9DI,^5I*A0%.1LD%2DLE"
M4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<  -UV  #)
M@P  O8T  +.5  "IFP  H*   ):G  "/J0\ BZHA 86I, 1_J#P*>*='$G.E
M4!AMHU@>:*)@)&2A9RE?H' N6YYY,E>=A#93G)$Y4)R?.TZ;L#U,G,<]3)OJ
M/$R9_SQ,F/\\397_/$^1_SM0C_\[4(__.U"/_SM0C_\[ZVT  --\  ##B0
MMY,  *R:  "BGP  F:4  (ZK  "%L L @;$; 'RQ*P)WL#@'<:]##6NN311F
MK5498:Q='EVK92-9JFXG5:EW*U&H@B]-IX\R2J>>-4BGKS9'I\8V1J;I-D6D
M_C=%H_\W1J#_-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@
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M'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0  EJD  (JP  !]N
M<;\  &;&  !;S ( 4-(' $?:# !&W!@ 1=PG $3=-0%!W4 "/]Y+ SW>500Z
MWU\&.-]I!S7?=@DSX(0+,>"4#"_AI@TNX;P.+>+@#BW>^ \KW?\2*MS_%"G:
M_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !QP   9<@
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M @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0  .^(  ##G   G[@
M(_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -_RX "O\V  ?_/@ $
M_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_
M\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\
M !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<
M /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@  _\,  /_#  #_PP
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M)ZI'_R:G2/\FITC_)J=(_R:G2/\F_T 4 /](#@#_3@L _U4. /]9$0#_7!8
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MM#QN:\D\;6OI.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,
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M.EM\^CA<>_\W77O_-5YY_S1?=_\S7W?_,U]W_S-?=_\S_EP  .%J  #-=0
MP'X  +:&  "NBP  I8X  )N1  "5DQ$ D)0B 8N3,0.%DCT)?Y%(#WJ/419U
MC5D;<8Q@(&R*:"5HB7 I9(=Y+6&&@S%=A8\T6H2<-E>#K#A5@[\Y58/A.%6"
M^3=6@O\U5H'_-%A__S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,
M +*+  "HD   GY,  )26  "-F0X B9H> (2:+@)^F3H'>9=%#7263A-OE588
M:I->'6:292%BD6TF7H]V*EN.@2U7C8TP5(R:,U&,JC5/C+TU3XS>-4^+]S1/
MBO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P  MH@  *R0
M  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]HG5,49)Q;
M&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4]C!)D_\P
M29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\  *:4  ";
MF0  D9T  (:B  !ZI@, =J<3 '.H) !NJ#(#:J@]!F6G1PMAIE /7:58%%FD
M8!A5HV@<4J-Q'TZB?"-+H8@F2*&6*$6@IBI$H;HK0Z':*D.?]2M"G?\K0IS_
M+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC   JI0  )^9  "4G@
MB:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99L$P*5:]4#E*O71%.
MKF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK]2,\J?\E.Z?_)CNF
M_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",I   @*H
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M#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP  8,(  %3&  !(RP
M/M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P FY4H ).95 "/F80$A
MYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%&./_!1CC
M_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \TP  ,MH
M "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U4@ 3]E\
M$O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_ 0WS_P$-
M\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@  )N(  !_J
M   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )_TX !O]<
M  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\
MC:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2
M_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_
M5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4
M '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P
M"/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V  #_0P
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M$-$L_Q#/+/\0SBW_$,XM_Q#.+?\0_S(9 /\W% #_.A$ _SP2 /\_&0#_0"(
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M'II'_QZ:1_\>_T - /]&! #_3   ^%(" .A5! #A50@ XE4- -55&0#,5RP
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MM"U_6<<N?5GF+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD
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M,&EG]2YI9_\L:6?_*FIG_REJ9O\H:F;_)VIF_R=J9O\G_U   .=;  #39@
MQ6X  +MS  "S=P  JWD  *1X P"=>A0 F'LE 9-[- ..>D 'B7A*#81V4Q*
M=5L7?'-B&WAR:A]U<7(B<F][)F]NA2EL;9 L:6R<+F9LJC!D;+PQ8VS9,&-L
M]"]C;/\M9&S_*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$
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M*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  # =@  M'X  *N%  "AB0
MEXL  (F-  "#CP@ ?I 7 'N1)P%VD30#<I _!FV/20MICE$/98U9$V*,8!=>
MBV@;6XIQ'E>)>R%4B(8D48>4)T^&HBE-AK0J2X;,*DN%[BE,A/\I3(/_*$R#
M_R=-@?\F3H'_)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0  *:*  ";C@  D9$
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M'#>?_QPWG_\<Q'@  +6%  "ICP  G94  )*:  "&GP  >J,  &ZH  !BK
M5;   %"R#@!.LAL 3;,H $NS-0!)LS\!1K-) D2S4@1!LUL&/[-D"#RS;PHZ
MLWL,-[.*#C6RF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M_Q4OK/\6+ZS_%B^L
M_Q8OK/\6NX$  *Z.  "AE0  EIH  (F@  !]I@  <:L  &6O  !9M   3K<
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MA0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH
M )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35   <VP
M%=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (
M\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I
M  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !
M  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74
M /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !J
MNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_
M P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U
M  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\  !=Q@
M3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\   #_
M_P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH  /]=  #_
M<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_&2@ _Q4K
M /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\ E '_ )P
M_P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#] /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4 _QDG /\3
M+ #_#C0 _PM  ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_ I@!_P*?
M ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$ _P#\ /P!_P#\ O\
M_ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_("$ _QXC /\8)P#_
M$S  _Q$\ ?\.2@'_#5<!_PMC ?\*;P'_"GH!_PJ$ ?\*C0'_"I0!_PJ; ?\*
MH@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\ ]PKZ /4+_P'U#/\!] W_
M ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_)!P _R(= /\>(@#_'"P
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M#+LL_PR[+/\,_S$1 /\U# #_-@< _SH+ /\\$ #_.Q4 ^#D? .\W*P#G-CD
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M(W=5\B)V5O\@=E;_'W96_QUV5O\<=E;_&W96_QMV5O\;_T4  .Q.  #:6
MR5X  +]B  "W9   L6,  *MA" "D8Q< GV0H )IE-P*69$,%D6--"(YA50R*
M8%T0AU]E$X1>;!:!7709?EQ]''Q;AAYY6I$@=UJ=(G19JB1R6;HE<5G2)7!:
M\"-O6O\B;UK_('!:_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(
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M(5]F_Q]@9O\>8&;_'F!F_QY@9O\>[T\  -I<  #&90  NFT  +!R  "G=0
MG70  )1S  "-= T B78< (5W*P&!=S@#?'9#!GAU3 ET=%0-<7-;$6YR8Q1K
M<6L7:'!S&F5O?!UB;H<@7VV4(EULHB1:;+(E66S')5ALZ"59;/TC66O_(5IK
M_Q];:_\>6VK_'EMJ_QY;:O\>ZU,  --@  #":0  MG$  *QV  "C>0  F7D
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M'$E\_QQ)?/\<UF$  ,)N  "T>   JH   )^%  "4AP  B(<  'N)  !PC
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M_Q(SF?\3,YG_$S.9_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP
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M Q;!_P,6P?\#HY$  )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0
M-,   "K$   BR   &<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -
MU58 #=5E  S6>  ,UHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2
M_P$+TO\!FI@  (Z?  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D
M !_-   7T0  $=8   S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<
M .16  #D9P  Y7L  .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P
MZ/\ D9\  (*G  !TKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39
M   .W0  ">$   +E    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%
M  #R5@  \V@  /-^  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\
MA:<  ':P  !FN   6,$  $K(   [S   +M$  "/6   9W   $>    SC   $
MYP   .H   #U    ]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_
M0P  _U4  /]I  #_@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+
M &BZ  !9PP  2\L  #O1   MV   (=T  !;B   .Y@  ".H   #M    \
M /@   #_    _P   /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,
M_T   /]3  #_:0  _X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3
M)0#_$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"(
M /\ D #_ )< _P"= /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P
M_P#X /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_
M%"$ _Q C /\** #_ #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\
MC #_ ), _P": /\ H #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V
M /D _P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T
M_Q,> /\.(@#_"BP _P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_
M (\ _P"6 /\ G0#_ *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$
M_P#P /\ [P#_ .\ _P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8
M /\3'@#_$2@ _PXT /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL
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M \,<_P/#'/\#PQS_ \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1<
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M#9$\_PV1//\-_S4  /\Y  #J00  W48  -!'  #)1@  QD$% ,! $0"Y0B$
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MIAET4+4:<U#)&G%0Z!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4
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M'%]=X1Q?7?@:7UW_&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@
MMF4  *QI  "B:0  F&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S
M:%$(<&=9"FUG8 UK9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EB
MWQQ98O<:6F+_&5IA_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@
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M%TIQ_Q9*</\52W#_%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>
MA'@  '=Y  !O?   :GT- &=^&0!D?R8 8H R 5^ /0)<@$8#6G].!5=_50=4
M?ET)4GUE#$]];PY,?'D12GR&$T=[E!5%>Z061'NW%D-[TA9#>O(60WG_%4-X
M_Q1$=_\41';_$T1V_Q-$=O\3S5\  +MK  "N=   I'P  )=^  "*?0  ?WX
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M"RV2_PLMDO\+MG4  *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0
M29T  $"@   ZH@T .*,7 #>C(@ VI"T -:0W #2D00 SI4L ,:54 3"E7@$N
MI6H!+*5X BJEB ,HI9H#)Z6M!":EQ@,FI.L$):+_!26@_P8DG_\&))[_!R2>
M_P<DGO\'KWX  *.(  "7C@  C9,  'Z5  !PF   8YL  %>?  !,H@  0J8
M #BI   OK , *JX. "FN&  HKR, )Z\M ":P-P EL$$ )+!+ ".Q5@ BL6,
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M:@ "S'X  <R4  #,JP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8
M (J<  !\HP  ;JH  &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@
M#<T   C1   !U D  -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P
MWFX  -Z$  #?FP  W[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E
M  !PK   8;,  %.Z  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H
M  #>    X $  .$)  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET
M .YQ  #OB0  \*(  /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !C
MM0  5+T  $;$   WR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I
M    Z@   .P   #N!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>
M  #_=   _XT  /^F  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P
M1\@  #C-   JT@  '=@  !/=   ,X@   ^8   #I    [    /    #S
M]    /8   #X    ^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_
M7@  _W8  /^/  #_I@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D
M /\ *0#_ #( _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )(
M_P"9 /\ GP#_ *4 _P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^
M /\ _P#_ /X _P#^ /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\
M(P#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5
M /\ FP#_ *$ _P"G /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\
M]0#_ /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_
M "D _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D
MEP#X )T ]P"C /4 J@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_
M .H _P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0
M_P(P /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N
M )D [ "@ .L I@#I *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T
M_P#= /\ W0#_ -T _P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK
M /\). #_!D4 ^P-1 /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4
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M JX=_P*N'?\"_R8& /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT
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MJ0J).[<+B#O*"X4\Z N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,
M .PZ  #:0P  RD<  +])  "W1P  L4(  *T^"@"F0!< HD(G )Y#-0":1$(!
MET1, 91$50*10UT#CT-D!8U#:P:+0G,'B4)["(="A J%08X+@T&9#(%!I0U_
M0;,.?D'&#GQ!Y YZ0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9
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M$FQ+W!)K3/41:DS_#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4
MNE4  +!8  "E5@  G%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\
M5%,$>E-:!GA38@AU4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50
MV!-D4/,29%#_$&10_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED
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M$55<_Q!57/\.55O_#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39
MB6,  ']A  !Y8@, =601 ')E'@!O9BL ;&<W 6IG0 )G9DD#9691!&)E6 9@
M96 (761G"EMD< Q98WL.5F.&$%1BE!)28J,34&*T$T]BS!-/8NT23V'_$4]A
M_Q!08/\.4&#_#E!@_PU08/\-V4\  ,-:  "T8P  J6D  )MH  "/9P  A&<
M 'EE  !S9P  ;VD. &QJ&P!I:R@ 9VPT &1L/0%B;$8"7VM.!%UK5@5::ET'
M6&IE"59I;@M3:7@-46B$#TYHDA!,9Z$22V>R$DEGR1))9^L226;_$$IF_P]*
M9?\.2V7_#4MD_PU+9/\-T50  +Y>  "Q9P  IFT  )=L  "*:P  ?VL  '-K
M  !M;0  :&X, &5P%P!B<20 8'$P %YQ.@%<<4,"67%+ U=Q4P15<%H&4G!B
M!U!P:PE.;W4+2V^"#4ENCP]';I\016ZP$41NQQ%#;>H01&S_#T1K_PY%:_\-
M16K_#45J_PU%:O\-RU@  +IC  "M;   H7$  ))P  "%;P  >F\  &YP  !E
M<P  8'4' %UV$@!;=Q\ 67@K %=X-@!5>#\!4WA( E%X3P-/=U<$3'=?!4IW
M: =(=G,)179_"T-UC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_
M##]P_PP_</\,Q5X  +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0
M6'P! %1]#@!2?AH 47\F $]_,0!-@#L 3(!# 4J 2P)(?U0"1G]<!$-_905!
M?W &/WY\"#Q^B@DZ?IH*.7ZL"S=^PPLW?>8+-WO\"S=Z_PLW>?\*.'C_"CAX
M_PHX>/\*OF0  +!O  "E>   EGD  (=Y  ![>0  <'H  &1\  !8@   4(,
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M?@$BGI !()ZC 1^>N0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT
M )Z%  "3BP  A8H  '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP
M(J8) !^G$0 >IQH ':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5
MJHD %*J> !.KM  2J], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,
M  "-D0  ?9(  &V5  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$
M !*S!P /M1  #K47  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\
M![:4  :VJ@ %ML4 !K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$
MF   =)P  &6@  !7I   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^
M @ &P L  L 1  '!&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'
M  #$G0  Q+4  ,3:  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH
M:J8  %RL  !/L0  0;4  #6W   IN@  '[T  !;    0PP  "L8   /*
MS 4  ,P,  #-$0  SA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5
MCP  U:<  -;"  #6Z0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K
M %"V  !"N@  -+T  "C!   =Q   %,<   W+   &S@   -(   #7    V0
M -H%  #<"P  W1   -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@
MZ9<  .JO  #JS@  Z^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+
M   TPP  )\<  !O+   2SP  "],   +8    W0   .$   #D    Y0   .<
M  #I    ZP<  .T-  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0
M /N=  #\M@  _-(  /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   F
MS0  &M(  !#8   (W0   .$   #E    Z    .P   #O    \0   /,   #U
M    ]P   /D!  #["   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'
M  #_H   _[8  /_*  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X
M_P [ /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_
M *  _P"F /\ K0#_ +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T
M_P#] /\ _ #_ /D _P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W
M /\ 10#_ %$ _P!> /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P
M_@"B /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S
M /\ \P#_ /, _P#S /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\
M0 #_ $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P">
M /( I #P *P [@"T .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\
MY0#_ .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_
M $< ^@!3 /< 7@#T &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4
MH #C *< X0"P -\ N@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_
M -, _P#3 /\ _Q40 /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $
M[P!- .L 6 #H &$ Y0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2
M *, T "L ,X M@#, ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!
M_P#$ ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!&
M -X!40#: EL U0)D -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:
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MK@"F'+P I!W/ *$>Z@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(
M /\A  #L)P  X"H  -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D
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M4P"3-5L!D35B 8\U:0*--7$"C#5Y XHU@@.(-8L$AC66!(0UH@6"-:\%@37
M!G\VW 9]-O0&>S;_!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P
MPD,  +=$  "M0   ISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*
M/%<!B#Q> H8\90*$/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\
MU0AT//$(<SS_!W(\_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@
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M"EY+_PE>2O\(7DK_!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@
MC5   (=,  "!30@ ?4\3 'I0(0!W42X =%(Y ')20@%O4DL!;5)2 FM160-I
M46$$9U%H!F50<0=C4'L(85"&"E]/DPM=3Z$,6T^R#5E/QPU93^@,6$_]"UA/
M_PE93_\(64[_!UE._P=93O\'WT,  ,=-  "X5   K%D  )U7  "150  B%0
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M"$I:_P=*6O\'SDX  +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P
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M@@0U>),%,W>D!3)WN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,
M *IM  "<<0  BW   'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X
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M !>7K@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0
M>X   &R"  !?A   5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4
MH1( %*$; !.A)0 2H2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RC
MIP *HL  "Z+F  R@_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@
M &6+  !8C@  3)(  $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P
M!ZT2  :M&P %K20 !*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0
MKK0  *[5  "M]   K?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6
M  !0F@  1)\  #FC   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.
M  "Y%   N1P  +HE  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D
M +S$  "\ZP  N_X  +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'
MJ   .ZT  #"Q   EM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%
M#@  QA0  ,<;  #()   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU
M  #.V@  SO8  ,W_  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@
M,+D  "2\   9OP  $<(   K%   "R0   ,P   #0    T0   -(!  #3"
MU0T  -<1  #:&   W"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #E
MP   Y>8  .7X  #E_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,
M !?'   /R@  !\X   #1    U@   -P   #?    X    .(   #D    Y@,
M .@)  #I#@  [!4  .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0
M^<8  /GD  #Y\P  ^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2
M   $V    -T   #A    Y    .@   #K    [0   .\   #Q    \P   /8
M  #X P  ^@L  /T1  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\
M /_#  #_U@  _]8 _P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_
M %, _P!> /\ :0#_ '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\
MJ #_ *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_
M /  _P#P /\ _P<8 /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X
M_P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X
M *L ]P"T /4 OP#T ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H
M_P#J /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4
M /X 7P#[ &@ ^0!P /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8
MZ@"N .@ N0#G ,< Y0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A
M /\ _PT0 /\)#0#_ 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /(
M60#O &( [ !K .H <@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J
M -@ M #5 ,  T@#3 -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\
M_Q , /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A
M %P W@!E -L ; #7 ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8
MKP#$ +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$%
M /\.  #_"@  _P@! /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8
MRP!? ,D 9@#& &X Q !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V
M +< M #' +( X "Q ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0
M  #_#P  \@T  .H*  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019
M +L%80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4
MJ K% *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O
M&   Y!D  -L6  #2$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\0
M6P"M$&, JQ!J *D1<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/#
M )L4W@"7%O0 E1;_ )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P
MU24  ,HD  #"'0  OA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@
M&ET GAME )T;; ";'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?
MV ",(/$!B2#_ 8@@_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC
M +XN  "U*   L"(  *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D
MDR5@ )(E9P"0)FX CB9V (TF?P"+)H@!BB>3 8@GG@&&)ZL!A">[ 8,HT0&
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M VLV_P-K-O\":C;_ FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@
ME3H  ) V  ",-0T B#<8 (0X)0"!.C$ ?SL\ 'P[10!Z/$T >#Q5 7<\7 %U
M/&,!<SQJ G$\<P)P/'P#;CN' VP[E 1J.Z$$:#NQ!6<\Q05E/.4%9#SZ!&0\
M_P-C._\#8SO_ V,[_P)C._\"Y34  ,T_  "]1@  KD<  )]%  "50P  CD
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M U)(_P-32/\#U$$  ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@
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M@P1"79(%0%VC!C]=M@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5
M +%:  "A70  D%P  ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081<
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M BMQKP(J<<@"*G#K BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:
M@&<  '1G  !I9P  7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R
M>"4 ,7DN #!Y-P O>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-Z
MK $B>L4!(GGI 2)W_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP
M &]L  !E;   6FX  %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX
M)8(G "2"+P C@S@ (H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8
MA,$ &(/F !B!_0 9@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ
M  !><P  5'8  $EY   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T>
M !B.)P 7CC  %HXY !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L
M#8_@  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8
M>P  37X  $*"   YA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:
M'0 +FB8 "YHP  J:.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/
M  *9\  "F/\ !)?_  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0
M18D  #N-   QD@  *)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@
MIA\  *8H  "F,@  IST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "E
MZ0  I?P  *7_  "D_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98
M #*:   HG@  'Z(  !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<
M +,?  "S*   M#(  +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW
MM/<  +3_  "T_P  M/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH
M   @K   %K    ^T   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6
M  #"'0  PR<  ,4R  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P
M ,?^  #'_P  Q_\ @Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6
MN@  #KT   ;     PP   ,<   #)    R@   ,P   #- P  S@D  - .  #2
M$P  U!L  -@E  #;,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S
M  #?_P  W_\ =Y\  &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@
M \D   #,    T    -4   #9    V@   -P   #>    X    .(%  #D"P
MYQ   .H8  #M)   \#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T
M\P  ]/0 :J@  %NO  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<
M  #<    X    .4   #G    Z0   .L   #M    [P   /$   #S    ]@<
M /D.  #\%@  _R(  /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V
M_]L _P 8 /\ %@#_ !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\
M9 #_ &T _P!U /\ ?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T
M /X OP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\
M_P 4 /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_
M &@ _P!P /\ > #] 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /(
MN0#Q ,< [P#@ .X \@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0
M /\ #@#_  T _P - /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &,
M]0!K /, <@#Q 'D [P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A
M ,  X #3 -X ZP#< /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\
M"0#_  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E
M .0 ; #B ', X !Z -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D
MRP#) ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_
M    _P $ /\ "P#T !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$
M9P#. &T S !T ,H >@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#"
M +D VP"W /  M0#_ +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_
M_@   /8  P#H  T X  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^
M &< O !N +H = "Y 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H
MT "H .L IP#[ *8 _P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D
M .($  #:  < SP 1 ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &(
MK@!H *P ;P"K '4 J0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<
M!.@ F@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1
M  #&#0  P@0+ +P % "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC
M * *:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH
MCA#\ (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W
M%P  LQ$  +(+#0"K#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )43
M90"3$VP DA-S ) 4? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[
M ( 9_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@
MI1P  *05" "@%!, FQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "(
M'6< AAYO (4>=P"#'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B
M_P!U(O\ ="'_ '0A_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8
M )@A 0"5'A  D" ; (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F,
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M 5PU_P%<-/\!W#,  ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0
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M@@)+29$#2DFA TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,
M +9,  "B3   D4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL
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M CA7K0(W5\0"-U?G C=6_0(W5?\"-U3_ C=3_P(X4_\"ND\  *E6  "550
MA50  'A4  !M5   9%0  %A4  !25@  3E<  $I9"0!'6A$ 1EH; $1;)0!#
M6RX 0EPV $%</@ _7$8 /EU/ #U=5P [76$ .EUL 3A=>0$V78@!-%V9 C-=
MJP(Q7<(",5SE C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@
M '-7  !I5P  8%@  %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD
M.F(R #EB.@ X8T( -V-+ #9C5  T8UT ,V-H #%C=@$O8X4!+F.6 2QCJ0$K
M8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7   >UL  &];
M  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S:20 ,FDM
M #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1KIP C:[T
M(FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\  &I?  !A
M8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X *'$F "=R
M+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :<[D &7/<
M !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9
M4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :
M>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![
M]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T
M $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@
M#H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  '
MA/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY
M   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I
M  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H
M (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   K
MB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?
M*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_
M  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@
M&IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@
MKBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M
M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@
M  RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[&   O2$
M +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P
MP/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[
M    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?
M  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\
M<)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(
MRP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T  .43  #H
M'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8
M %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6    W
M .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*  #X$0
M_!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\
M$@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P
M /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@
M^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_
M  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P
M<P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6
M .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @
M_P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L
M '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -<
MY@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P #
M /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T
MV0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #!
M /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8
M" #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M
M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H
MKP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>
M  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +(
M;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V
M )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8
MPP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B
M &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$
M_P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP *
M +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD
ME )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#
M"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'
M#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL
M (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\
M=Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8
M#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6
M;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_
M &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP
MB!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q
M('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B
M_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2
M 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$
M9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<
M*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I
M&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X
M %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\
MT#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I
M,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U
M@@!5-9 !5#6? 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8
M +@]  "C/   DCP  (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX
M8#<H %XW,0!=.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@ 4SIS %$Z?P%/
M.HT!3CJ= 4PZK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX_P%*./\!QSH  +-
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M 4)#JP% 0\ !/T/A 3]#^0$_0O\!/T'_ 4!!_P% 0/\!OT$  *I%  "610
MAD4  'E$  !O1   9T(  & _  !;00  5T(  %1##0!11!4 3T4? $Y%* !,
M1C$ 2T8Y $I'00!)1T@ 2$=0 $9'6 !%1V$ 0TAL $)(> % 2(<!/DB7 3Q(
MJ0$[2+X!.DC? 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<
M '9'  !K1P  8T8  %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX
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M "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4
M6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O
M7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<
M\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4
M $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8
M)F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;
M8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;
M   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY
M !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\
M$VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y
M9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U
M.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_
M  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH   S;
M*V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %
M?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![
M_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D
M !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<
M (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P
MA_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(
M   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY
M  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\
M>W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )
MF0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H
M/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL
M &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D    J
M *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0
MND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&
M  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T    MP   +L
M  "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,
M ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)
MF@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-
M    S@   -    #1    U    -8   #: @  W D  -\/  #C%P  YB0  .<V
M  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP
M-+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L   #?
MX    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18  /PE  #]
M.0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1
M /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H
M_P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T
M /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\
M$0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z
M /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L
MXP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_
M !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0
M>@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_
M ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !,
M\0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#,
M 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@
M_P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8
M -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ',
MMP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F
M /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H R  2 ,(
M'0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S
M *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\
MEP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  . +, %@"O
M "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )<
M=0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_
M (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H
MG@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "(
M '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$
M_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP >
M ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0
M? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O
M#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,
M(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[
M ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\
MWQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y
M%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89
M@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24
M +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'",
M;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<
M(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N
M  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I
M &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H
M4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<
M,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK
M+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7
M $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0
MAS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5
M,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4T
MI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@
M '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C
M3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^
M.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[
M  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU
M $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8
M.#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F
M/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $)
M.@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+.
M #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0
M6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [
M13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&
M[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,
M %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL
M-$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G
M2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'
M  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]
M "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\
M(D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  !
M3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "56
M10 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_
M !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/   \40
M-E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;
M74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:
M_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED
M "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940
M$650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -
M8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B
M   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*
M  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\
MA5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9
M;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X
M4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\
M &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT   2=P
M#7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2
MA%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED
M  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<
M  "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX
M ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8
M:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8
M    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5
M  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0
M1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0   "G
MJ    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U
M70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<
M "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W    N
M +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4
MRF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?
M   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(    R0   ,L
M  #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<
M .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3
MM@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP   -X   #@
M    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?
M  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X
M_P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#]
M (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\
M_P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E
M /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($
M[@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4
M /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H
M*P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"!
M -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\
MNP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP : .< )0#D
M #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$
M@0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_
M *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H
MQP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L
M (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T
M_P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U ", LP N
M +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L
MF@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/
M /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T H@ G *
M,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^
M (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\
M] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/
M #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P
MA ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T
M ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X
M@0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O
M HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7
M  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P
M '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L
M9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D
M'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0
M,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7
M %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P
MC2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A
M%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;
MI !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@
M 'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C,
M6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!(
M(K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K
M  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W
M % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+(
M0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H
M+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK
M.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW(
M #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@
M73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#
M,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0R
MZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630
M %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T
M/35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O
M-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V
M  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I"
M #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT
M*CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&
M.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_
M1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_
M "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0
M/#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J
M1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"
M_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^00  .$,
M #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH
M(DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :
M1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)
M   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1
M !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\
MCT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F
M4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%7
M60 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D
M '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@
M&UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (
M7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.
M  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6
M !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP
M &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=
M4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK
M 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F
M  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P
M458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(   1V
M> 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]
M<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT
M $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""    @P$
M (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0
MBX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI
M   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0    D@   )(
M  "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8
M )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E
M?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0   *(   "D
M    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%
M  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C
M$Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,   "T
MM@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%
MDP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,
M  .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&    R
M ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A
MX:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z
M    OP   ,0   #(    S@   -$   #4    U0   -@   #:    W0   -\
M  #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9
M /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_
M #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D
MCP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_
M ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@
M_P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G
M )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L
M_P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \
M .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H
MRP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K
M /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -,
M/P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+
M +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\
M_P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X
M $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$
MC@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P
M /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H
MH@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP".
M ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4
M  #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \
M )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T
M?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[
M @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V ((
M/0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6
M &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#
MG@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T
M #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0
MH0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(
M (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD
M:0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9
M![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7
M  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\
M %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$
M3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O
M'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2
M/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7%
M $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0
M8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.
M&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<
MY0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720
M %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX
M1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W
M(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F
M  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5#
M #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D
M,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,
M*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ
M2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_
M "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+
M12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S
M+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O
M_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\
M #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P
M+#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C
M,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T
M   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3
M "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\
MDS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O
M.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^
M7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<
M 'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0
M)D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 7
M1&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\
M  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48#
M !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0
M#TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B
M0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.
M!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O
M  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1
M4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .
M5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8
M?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<
M $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U; @ )7@D
M!%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@
M8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+
M   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "9@<  &<,
M  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4
M &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U
M4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q
M#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7
M  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P
M)E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#  !^"
M?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$
MJ0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL
M !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "- 0  C@8
M ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@
ME,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_
M   'A    (D   ".    D@   )8   "8    F@   )L   "=    GP   *$#
M  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4
M *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH   >0
ME@   )H   "?    HP   *<   "J    JP   *T   "O    L0   +,   "U
M    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)
M  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP
M *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8   #(
MR@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;
MV0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T    N0   +X
M  #"    R    ,L   #.    SP   -(   #4    U@   -H   #=    WP
M .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP
M]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\
M30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P";
M /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\
M_P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X
M $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P
MGP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P
M /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D
MWP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #
M *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\
M  #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !*
M ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P
MJ "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O
M    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L
M20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B
M )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9
MQP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6
M $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": ((
MJ@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP
M *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $,
MA !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R
M +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<
M  "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!#
M '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\
M90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  ""
M P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D
M1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_
M %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0
M<0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!=
M $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!
MVP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q
M &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T(
M5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%
M"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3
M  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y%
M $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8
M/1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3
M%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $03
M20!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_
M #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P
M3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \
M&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;
M_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT
M $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP
M-"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K
M(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A
M   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53
M "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\
ME"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W
M)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J
M7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@
M 'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P,
M,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A
M+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M
M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S *
M "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0
M&C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E
M,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V
M#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ
M !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-
M530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;
M/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^
M@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<
M $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT
M$D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &
M1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z
M   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/
M  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL
M $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \
M/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1
M$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=
M  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0
M,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$
M6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9
ML0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<
M "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@#0  81
M &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0
M8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2
M   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@  :PT  &T1
M  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8
M &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   1
M8   #&0   9H    :P   &\   !R    =    '4   !W!   > D  'H-  !\
M$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI
M  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0
M W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'  "+#
MC1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",
M^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "?0   ((
M  "&    BP   (X   "1    DP   )4   "7    F0   )L   "=!   GPH
M *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0
MG_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@   ),   "8
M    G0   *$   "D    I0   *<   "I    JP   *T   "P    L@   +4(
M  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P
M1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8   "K
ML    +,   "W    MP   +H   "\    OP   ,$   #$    QP   ,H   #-
M!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD
M #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]    P@
M ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\   #C
MYP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\
M  #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8
M /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\
MZ #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_
M    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X
M6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V
M ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_
M_P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0
M %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4
MP0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@
M .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$
MM0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"=
M -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8
M  "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/
M )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,,
MB0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O    +    "G
M    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L
M3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8
M '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X   "6
MCP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y
M $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@
M[0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&    @0
M 'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@
M:@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !<
M /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X    =    '
M! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!)
M %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4
M40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C
M  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %,
M2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_
M $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0(
M600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !)
M D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&
M_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P%
M % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT
M0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V
M#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.
M!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4
M #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\
MEQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!
M$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$4
M7  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H
M 'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P<
M.18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J
M&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?
M  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P-
M #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0
M(A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E
M(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA
M$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P
M !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@
M5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E
M)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I
M@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD
M $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$
M'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0
M+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L
M   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3
M !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX
M"C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \
M+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W
M%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?
M  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0
M-#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +
M/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]
ML@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,
M "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8
M D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP
M0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW
M   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9
M  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH
M $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?
M/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4
M&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M
M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@
M$TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@
M7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:
M_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(
M  I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H$0  :A<
M &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P
M9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A
M    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8
M  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\
M3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H   !O
M<@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P  (L1  ".
M&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$
M $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_    @P
M (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,  "@$0
MHQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<
M   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2    E@   )H
M  "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T"P  N!$
M +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E
M;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@   *X   "Q
M    L@   +4   "W    N@   +P   "_    PP   ,8   #)    S@H  -(3
M  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@
M$8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(   #%
MQ@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0   .H+  #K
M%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P '
M /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &
M^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #?
M /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\
M!@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!?
M ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T
MP #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P
M  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4
M70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\
M *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0
MR@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J
M %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0
M_P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T    KP *
M *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4
MDP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"
M /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=    EP % )0
M#0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4
M 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\
M;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0   (( "0!_
M  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X
M4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_
M &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '( !0!P  P
M;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!?
M %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4
M_P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C  D 80 .
M &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %
M4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!*
M /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8
M$ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4
M $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\
MH @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!,
M !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X
M6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T
M (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X
M1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V
M!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1
M  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0
M #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$
M+0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G
M%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.
M$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O
M "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0
M5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O
M$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5
M?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT
M $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q,
M*!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7
M&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@
M   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6
M "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT
M$1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \
M(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA
M&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?
M  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)
M-"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5
M)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <G
ML0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28
M "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L
M$"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@
M+,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH
M   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>
M  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<
M ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E
M*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W
M(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J
M   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0
M'2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@
M/B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \
M_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30
M !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(
M $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@
M0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]
M   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E
M  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\
M4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '
M2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9
M*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT
M $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.    40
M %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@
M9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!
M   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:    70   &
M  !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8
M '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U
M1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P   &\   !R
M    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK
M  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P
M(U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($   "$
MAP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10  * A  "@
M,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V
M !%G   );0   '0   ![    @0   (8   "+    D    )0   "7    F0
M )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@
MMCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX
M    @    (<   ".    E0   )H   "?    I    *@   "L    K0   +
M  "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1&P  T"X
M ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+
MDP   )L   "B    J    *X   "T    N    +T   #     P@   ,4   #(
M    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ
M  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !
M_P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V
M &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,
M_P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^  L _P 1
M /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4
MV !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D
M /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4 YP . .(
M%0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D
M +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\
MCP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\
M !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\
M8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_
M 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *( #0"A !,
MH  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"(
M &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '
M_P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@") !  B  5
M (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L
M<P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C
M /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P =0 1 '0
M& !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!=
M &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\
MN0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C
M !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0
M8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@
M )0   ""    =0   &L   !D    8    %T   !:  4 6  , %< $ !6 !4
M5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!(
M &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D
M  !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7
M $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$
M/0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O
M"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$
M& !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J
M #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0
M7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y
M !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L
M=P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$
M $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!<
M,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C
M!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3
M  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9
M "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@
M&@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]
M%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/
M'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!">
M !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0
M-!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >
M$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4
ML0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH
M "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT
M&!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )
M&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<
M   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB
M !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(
M QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D
M'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB
M)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E
M   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(
M'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ (
M)BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E
M^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$
M !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<
M "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@
M*?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E
M   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L
M   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\
M6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1
M+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."   #@H   X
M,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H
M $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0
M"C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@
M0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O
M   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   ).   !3L
M   ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0
M $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V
M,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00   $,   !&
M    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\
M  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@
M+S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T   !0
M4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A
M10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH
M "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<    7P
M &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0
M<$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&
M   22@  #$\   14    6    %T   !A    90   &@   !K    ;@   '$
M  !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8
M ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,
M5P   UT   !C    :    &T   !Q    =@   'H   !^    @0   (,   "&
M    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2
M  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P
M &X   !T    >@   (    "$    B@   (X   "2    E0   )<   ":
MG0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q
M8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q    >0   ($
M  "(    CP   )0   ":    GP   *0   "H    J0   *P   "O    LP
M +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [  #-5
MRG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0   )4   "=
M    HP   *D   "O    M    +D   "\    O@   ,(   #%    R    ,P
M  #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J20  Z&4
M .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_
M "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /
M=@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_
M )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T %@#[ "
M]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#,
M '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T
M_P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#: !H VP C
M -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X
MK@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^
M /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0 M  = +,
M)0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N
M ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\
MX    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4
M "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X
M<0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S
M +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\ & "  "
M?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H
M '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D
M  "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @
M &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T
M5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&
M    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4 6P ; %H
M(0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T
M $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X
M;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !,
M "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X
M?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N    80
M %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T
M0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S
M (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '
M  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P >
M #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P <P K (<
M*@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !"
M"P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\
M'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7
M "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@
M. T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G
M "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H
MJ@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q
M "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\
M( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3
M!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1
M   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB
M !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X
M#0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E
M$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40
M*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?
M  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0
M'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0
M$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2
M]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18
M !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD
M"Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0
M%O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7
M   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO
M  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\
M7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4
M&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A
M-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL
M $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'
M$!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@
M)CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@
M   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$
M  PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H
M "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X
M)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H
M   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#
M   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P
M+28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP   ,O
M,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [
M3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD
M "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V    .
M #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2
M1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J
M   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _    00   $0
M  !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4
M $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9
M,0  $C,   XW   ).@   CT   !     1    $<   !)    3    $\   !1
M    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC
M  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0
M#CT   A!    10   $D   !,    4    %,   !6    60   %L   !=
M8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J
M=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  /_B\ !)0T-?4%)/
M1DE,10 '"A4_   .1   !TD   !-    4@   %8   !:    7@   &(   !E
M    :    &L   !M    <    ',   !V    >0   'T$  "!"P  A1$  (0=
M  ""+   @#X  'Y4  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00
M%T8   ]+   '40   %<   !<    8@   &8   !K    ;P   '0   !X
M>P   'X   "     @P   (8   "*    C0   )$   "6 P  FPP  )T3  ";
M(0  FC,  )=)  "48@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,
M  A:    80   &@   !N    =    'D   !_    A    (D   "-    D0
M ),   "6    F0   )T   "@    I    *@   "L    L@,  +<-  "W%P
MM2@  +(^  "P5@  K',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J
M    <P   'L   ""    B0   (X   "4    F@   )\   "D    I@   *D
M  "M    L    +,   "W    NP   ,    #%    RP   -$$  #5#@  TQT
M - R  #-2P  RF8  ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]
MAP   )    "7    G@   *0   "K    L0   +8   "Z    O    ,    #$
M    R    ,L   #/    U    -H   #@    Y@   .L   #Q!@  \!,  .XG
M  #L/P  ZEL  .=Z  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P
M^@ 1 /\ &0#_ "( _P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S
M &0 \0!J .X <@#L 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T
M_P"> /\ E@#_ )  _P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ ,
M /@ $@#W !L ]0 E /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P
MS0!B ,H :@#( '( Q0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0
M /\ B #_ (, _P"  /\ \    .4   #>    V@   -L   #<    V  ' -$
M#@#1 !4 T@ > ,L )P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !;
M *X 80"L &D J0!S *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\
M>P#_ '8 _P!T /\ X@   -,   #*    QP   +P   "V    L  ! *\ "P"L
M !$ K0 8 *T ( "H "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ),
M60"1 &$ CP!J (P =0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_
M &H _P!H /\ SP   ,$   "Y    K0   *    "8    E    )$ !@"0  T
MD  2 (\ &0". "$ BP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z
M %D > !B '8 ; !T 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X
M_P!< /\ O@   +$   "@    D@   (D   ""    ?    'H  0!X  D =P .
M '@ % !W !H =  A '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$
M9 !: &, 9 !A '  7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1
M /\ L    )\   "-    ?P   '0   !N    :@   &8   !E  0 8P + &,
M$ !C !4 8P ; &$ (0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3
M %, 7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\
MH@   (T   !\    ;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3
M !$ 5  6 %( &P!1 "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8
M5@!$ &$ 0P!P $( @0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E
M '\   !O    8P   %D   !1    30   $H   !(    1P $ $< "@!&  X
M1@ 1 $< %@!% !P 1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y
M %L . !I #< >@ V (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0
M  !E    6    $\   !(    0P   #\    ]    /  " #P !P [  P .P /
M #L $@ Z !< .0 < #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8
M+@!C "T <P L (@ + "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   !=
M 0  40(  $@#  !  P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$
M$  Q !, ,  8 "\ '0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!>
M "4 ;@ D (( (P"9 ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@
M2P<  $((   Z"   -0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I
M !$ *  5 "< &0 F !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X
M:0 = 'P ' "3 !L K  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L
M #T+   U"P  , L  "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \
M(0 2 "  %@ ? !L '@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6
M '@ %0"/ !4 I@ 4 ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-
M   Q#0  + T  "<-   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00
M !L$%  9!!@ &00> !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4
M$ ** ! !H@ / +P #P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N
M#P  * \  "0.   @#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)
M$@ 5"18 % D; !,)(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(
M  L(GP *![< "@;;  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0
M)1   "$0   =$   &@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1
M#!0 $ P9 ! ,'P /#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-
MG0 $#+0  PS2  (,\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(
M !X1   ;$0  &!$  !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q(
M#0\7  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G
M#[0   [4   .\P  #O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3
M   9$@  %A(  !01 P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5
M  D2&@ ($B$ !A,I  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0
M !'7   1]0  $?\ 6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7
M%   %!,! !,2!  1$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06
M&  #%A\  A8G   7,   %SL  !=(   76   %VH  !:    6F0  %;0  !79
M   4]P  $_\ 510  $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0
M$Q0# !(3!@ 0$P< #Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@
M&QP  !LD   ;+0  &S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8
M^0  %_\ 418  $,8   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4%
M !$5!  /%00 #18$  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D
M " A   A*@  (34  "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@
M'/\ 31D  #\;   T'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8
M 0 -&0$ "QH"  @< P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>
M   G)P  )S(  "<_   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\
M2!T  #P>   Q'P  *!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +
M'0  "!\   0A   !(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N
M(P  +BX  "X[   N2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"
M #@A   N(0  )B$  " @   <'@  &!T  !0=   0'@  #A\   LA   '(P
M R4    G    *0   "P!   N P  , 8  #,*   U#0  -A$  #87   V'P
M-BD  #8V   V10  -5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D
M   K)   )",  !\A   ;(   %B   !$A   .(P  "B4   8H   "*@   "T
M   O    ,@   #0    W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4
M $ Q  ! 0   /U(  #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I
M)P  (R4  !\C   8)   $B4   XH   **@  !2T    P    ,P   #8    X
M    .P   #X   !     0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK
M  !+.@  2DP  $EA  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0
M(R<  !LH   4*@  #BT   HP   $,P   #<    Z    /0   $    !#
M1@   $@   !+    30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9
M-   6$8  %=:  !5=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT
M !8O   0,@  "C8   ,Z    /P   $(   !&    20   $P   !/    4@
M %4   !8    6@   %T   !@    8P   &<&  !K#   ;!(  &L>  !K+
M:3T  &=2  !F:@  9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y
M   */0   D(   !'    3    %    !4    6    %L   !?    8@   &4
M  !H    :P   &X   !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4
M 'Q)  ![80  >'\  ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "
M2P   %$   !6    6P   &    !E    :0   &X   !R    =@   'D   !\
M    ?@   ((   "%    B0   (X   "3    F 8  )P.  ";&@  F"L  )9
M  "260  D7,  (V5  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P
M &$   !H    ;@   ',   !Y    ?@   (,   "(    C    (\   "2
ME0   )D   "=    H0   *4   "J    L    +<'  "X$0  M2$  +(U  "O
M30  JFD  *B(  "FJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4
M  !\    @P   (D   "/    E0   )L   "@    HP   *8   "I    K0
M +$   "U    N0   +X   #$    R@   -(   #:"@  UA8  -(I  #.00
MREP  ,5\  #"G0  P;T '%4  !%<   '90   &X   !W    ?P   (@   "0
M    F    )\   "E    K0   +,   "X    N@   +X   #"    Q@   ,H
M  #.    TP   -H   #@    YP   .T   #S    ] X  /(>  #O-@  [%$
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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M%O^X0B'^Q$HP]\Y21/#66%KGX%YRUMIDB,3-:9JTPVRHJ+MOLIZV<+J6LG+
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M$?^I/!C_LD4D_[M-,_^_5D;]P5Y:\\%F;^:_;8/9MG.7S:UWJ,2E>[>^H8/
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MZM-<8M[/8GC-QVB+O[YNF[*W<ZBGL'FRGJM^NI6GA,".HXO$B*&2QX.?FLF
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MQ'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;#
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MQ+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PI_^8%P+_GB $_Z\F!?C
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M)3O_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)JO!  "=T
MC^$  (;_#@)Z_Q4#;O\<!F3_(PE<_RL,5?\S#T__.Q%)_T(31O])%$+_3Q9
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M1DK_T$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1]&N  "_N0,
MLL4# *?5!0"<_0\"E/\B!HG_*PQ^_S(2=?\Z&&S_0AUE_TDB7_]1)5K_6BA7
M_V,K5/]K+5+_<B]0_WDP3_^ ,4W_B#)+_Y T2O^8-4C_H35'_ZHV1O^S-T3_
MOSA$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.,&S  "RO@( I<P!
M )G= P"0_Q("AO\?!7O_)PIQ_RX.:/\V$V'_/A=:_T8:5?]-'5'_51]._UT@
M2_]D(DG_:R-'_W$D1O]X)43_?R9#_X8G0?^.*$#_EB@__YXI/?^G*3S_L"H\
M_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@  E]4  (OO
M! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%_U880O]<
M&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_H!\R_Z0?
M,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X  '__!P%T
M_Q ":?\5 U__' 57_R0(4/\L"DK_,PQ%_SL.0?]!#SW_1Q Z_TT1./]2$3;_
M5Q(T_UP3,O]A$S'_9A0O_VL4+O]Q%2W_=Q4L_WT5*O^#%BG_BQ8I_XX6*?^.
M%BG_CA8I_XX6*?^.%BG_CA8I_XX6*?^.%O]F( /_82H%_V$S"/]I-@O_;CT/
M_W%&%?]S41S_<UXC_W!M*?]N?##_:XDU_VF6.?]GH3W_9JI _V2R0O]CN43_
M8<)&_V#(1_]>S4C_7-1*_UO>2_M9Y$SW6.I,]%?O3?!6\TWL5?A-[%7X3>Q5
M^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3?]F( /_82H%_V$S"/]I-@O_;CT/_W%&
M%?]S41S_<UXC_W!M*?]N?##_:XDU_VF6.?]GH3W_9JI _V2R0O]CN43_8<)&
M_V#(1_]>S4C_7-1*_UO>2_M9Y$SW6.I,]%?O3?!6\TWL5?A-[%7X3>Q5^$WL
M5?A-[%7X3>Q5^$WL5?A-[%7X3?]F( /_8BH%_V,Q"/]K-0O_<#P/_W-%%?]U
M3QS_=ETC_W-L*O]P>C'_;8<V_VN4._]IGS__:*A"_V:P1?]DN$?_8\!)_V''
M2O]?S$S_7=--_%S>3OE:Y$_U6>I0\5CO4>U7]%'I5_E0Z5?Y4.E7^5#I5_E0
MZ5?Y4.E7^5#I5_E0Z5?Y4/]G'P/_8RH%_V4P"/]N,PO_=#H/_W=#%?]Y3AS_
M>EHD_W=H*_]T=C/_<80Y_VZ0/_]LFT/_:J5'_VBM2O]GMDS_9;Y._V/%4/]A
MRU+]7])4^5W=5?1;Y%;P6NI7ZUCP6.=8]5?C6?I4XUGZ5.-9^E3C6?I4XUGZ
M5.-9^E3C6?I4XUGZ5/]H'P/_8RD%_V@N!_]Q,@K_=S@/_WM"%?]]3!S_?E@D
M_WMF+?]W<S7_=( \_W&,0O]OET?_;*%+_VJJ3_]HLE+_9[M4_V7$5OYBRECY
M8-%:]5[<7/!<Y%WJ6NM>YEGQ7^):]5O<6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;
M^5?<6_E7W%OY5_]I'@/_9"D%_VLM!_]T, K_>S<._W]!%?^!2AS_@E4E_W]C
M+O][<#;_>'P^_W6)1?]QE$O_;YY0_VRF5/]JKEC]:+=;_&; 7?IDR6#U8=!B
M\%[<8^I<Y67E6^QFWEKP8]A;]&#17?A;T5WX6]%=^%O17?A;T5WX6]%=^%O1
M7?A;T5WX6_]I'@/_92@%_VXK!_]X+@K_?S8._X,_%/^%2!S_AU,E_X1@+_^
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MN[^ 5;S9?U:XXWI8LN=U6++G=%BRYW18LN=T6++G=%BRYW18LN=T6++G=/^
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M;$W8[&I.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9_^/"P#II 0
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M@*" A'^K@H%_N(-_?\J$@8'A?8&!YG:!@.MO@(#O:H" [VJ @.]J@(#O:H"
M[VJ @.]J@(#O:O]H' +_>!<"_X<8 O^4'0+_GR,#^*DJ!.RQ,0?BMSD-U;="
M',FP3BV^JE<]M*-?2JN>9U6CF&Y?G)1U9I:0?&V0C8-SBXJ+>(:(E'R!AIZ
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M>5JKZ'-<I^QN7:3O:EVD[VI=I.]J7:3O:EVD[VI=I.]J7:3O:O]Y$0'_C X
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M3TCA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3^&9  #-J0  OK," +.^ P"HRP4
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M!/]K* ;_<3 (_W0Y#?]U0Q/_=4T9_W59(?]Q9RG_;70P_6J -OIFBCSX8Y1
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M6U:M^UI6K?M:5JW[6E:M^UI6K?M:5JW[6O]^"0#RD0( UJ$" ,JM!0# MP4
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M4<]9L%/-6+I4RUC&5<E7VE;%5^Q5PUOY3\)>_TK 7_]&O6#_0KI@_T"Z8/]
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M5V>1_U)GD?]29Y'_4F>1_U)GD?]29Y'_4O]N#@#_?PD \8X% -F;!0#/I@<
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MH?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00 N;8# ++
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M24ZY_TE.N?])3KG_2>^%  #4E0  QZ,  +JL 0"PM   I[\# )[)!@"5U L
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M"1;_E D5_Y\*%/^J"A3_LPH4_[,*%/^S"A3_LPH4_[,*%/^S"I.[  "$QP
M==,  &?A  !8Z   3OL  $C_  !!_PH ._\0 3;_%0$Q_QP!+?\B BG_* (E
M_RT"(O\R Q__. ,<_ST#&O]" Q?_2 05_TX$$_]5!!'_704/_V<%#?]R!0S_
M?04*_XD&"O^3!@G_G 8)_YP&"?^<!@G_G 8)_YP&"?^<!O\_*@+_/S #_T0P
M _](,P3_23D&_TA""/]&30O_15L._T-I$?]!=Q/_0(45_S^1%O\^FQC_/J08
M_SVK&?\]LQK_/;H:_SW#&O\\S!O_/-L;_SSG&_\\\!O_//@;_SW_&_\]_QO_
M/?\;_SW_&O\]_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#_T<N _]*
M,03_3#<&_TM "/]*2PO_2%D/_T9G$?]$=13_0X(6_T*/&/]!F1G_0:(:_T"I
M&_] L1O_/[@<_S_ '/\_R1W_/]8=_S_E'?\_[QW_/_<>_S_^'?\__QW_/_\=
M_T#_'/Y _QO^0/\;_D#_&_Y _QO^0/\;_D#_&_] *@+_0RP#_TDL _]-+P3_
M3S4&_U ^"/].20S_3%8/_TID$O](<A7_1W\8_T:+&?]%EAO_1)\<_T2G'?]#
MKA[_0[4?_T*]'_]"QB#_0M$@_T+B(?]"[2'_0O4A_T+](?U"_R'[0_\@^D/_
M'_E#_Q[Y0_\>^4/_'OE#_Q[Y0_\>^4/_'O]!*0+_1BH#_TPI _]1+ 3_4S(&
M_U0\"/]41PS_45(/_T]@$_]-;Q?_3'P9_TJ('/])DA[_2)L?_T>C(?]'JR+_
M1K(C_T:Z(_]&PR3_1<TE_T7>)?]%ZB;\1?0F^47\)O9%_R;U1O\D]$;_(_-'
M_R'S1_\A\T?_(?-'_R'S1_\A\T?_(?]"* +_22<"_U F _]5* 3_6"\%_UHY
M"/]:1 S_5T\0_U5<%/]3:AC_47<;_T^#'_].CB'_39<C_TR?)?]+IR;_2JXG
M_TJV*?Y)OBK]2<DJ^DC9*_=(YRST2/(L\4C[+.])_RKM2O\H[$K_)^M+_R7K
M3/\EZTS_)>M,_R7K3/\EZTS_)?]#* +_320"_U0C _]:)0/_7BP%_V V!_]@
M00O_7DP0_UM7%?]99AG_5W(>_U5^(OY3B27\49,H^E";*OE/HRSW3JHN]DVR
M+_1,NC#S3,0R\DO1,^Y+Y#3J2O TYTOZ,^5-_S#D3O\MXD__*^%0_RGA4/\I
MX5#_*>%0_RGA4/\IX5#_*?]&)0+_4"$"_U@@ O]?(0/_9"H$_V8S!_]F/0O_
M94@0_V)3%?]@81O\76T@^%IY)?58A"GS5HTM\%26,.Y2GC/M4:4UZU"M-^E.
MM3GG3K\[YDW,/.-,X#W?3>X\W$_Y.=E1_S764O\RU%/_,--4_RW35?\MTU7_
M+=-5_RW35?\MTU7_+?]*(P+_5!X"_UP< O]D'P+_:2<$_VPP!O]M.@K_;$0/
M_6I/%?AG7!SS8V@B[V!T*.M=?B[H6H@SY5>1-^-5F3K@4Z ^WE*H0-Q1L4'9
M4+M"UE#(0]-0W$3/4.Q#S%+X/\M5_SO)5_\WR%C_-,=9_S+&6?\QQEG_,<99
M_S'&6?\QQEG_,?]-( +_5QL"_V 9 O]I'0+_;R4#_W(M!?]T-PC]<T$.]G%+
M%/!N6!SJ:F0DY65N*^!A>3/<7H(XV%R+/--:E#_06)Q"SE>C1,M5K$;)5;5'
MQU3 2<54T$G"4^9)P%;U1;Y9_T"]6_\\O%S_.;M=_S6Z7?\UNEW_-;I=_S6Z
M7?\UNEW_-?]0'@+_6QD!_V06 ?]M&P+_="("_W@J!/]Z,P?V>CT,[WA'$^=U
M5!OA<%\EVFMJ+=-G=#3.9'TZRF&&/\=?CD+$799%P5N>2+]:IDJ\6:],NEBZ
M3;A8R$ZV6-].M%GP2[-<_46R7_] LF#_/+!A_SFP8?\XL&'_.+!A_SBP8?\X
ML&'_./]2&P'_7A8!_V@4 ?]R&0'_>1\"_WXG _F , 7P@3D*YX!#$>!\4!K6
M=ULDSW)F+LEM;S7$:G@[P&>!0+QDB42Y8I%(MF"92K-?H4VQ7:I/KERT4:Q<
MP5*J7-12J%WK4*A@^DFH8_]$J&3_0*9E_SRF9?\[IF7_.Z9E_SNF9?\[IF7_
M._]5&0'_810!_VP2 ?]V%P'_?1P!_X,C O2&+ 3JB#4'X8= #M:"3!G-?5@D
MQG=B+<!S:S6[;W0\MVQ\0;-IA$:O9XQ)K&643*ECG$^F8J51I&&O4Z)@O%6@
M8,U5GF#F5)YD]TV?9_]'GVG_0YYI_S^=:?\]G6G_/9UI_SV=:?\]G6G_/?]7
M%P'_8Q(!_V\1 ?]Y% '_@1D!^X<@ >^,)P+DCC %VHT]#,^'2AC'@E4COWU?
M+;EX:#6S=' \KW%X0JMN@$:G;(A*I&F03J!HF%&=9J%3FV6K59ADN%>69,A8
ME&3A6)5H]%"6:_]*EVS_199M_T&6;?] EFW_0)9M_T"6;?] EFW_0/]9%0'_
M9A !_W(0 /]]$@#_A18 ]HP; >J1(@'?E"L#TY$Z"\F,1Q? AU,BN8)<++)]
M936M>6T\J'5U0J-S?4>@<(1+G&Z,3IELE5*5:YY4DFFH5Y!IM%F.:,-9C&C<
M6HUL\E./;O],D'#_1X]Q_T./<?]!CW'_08]Q_T&/<?]!CW'_0?];% '_: \
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M6V6&XUEHB/92:XK_36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0
MY8<  -:2 P#-G 4 QJ0& ,&K!@"YK1< L*PK!*>I.@Z?ID49EJ)/(X^?5RV(
MG%\U@IEF.WV7;$%XE7-&<Y-[2VZ1@T]JCXU29HZ756.-HUA@C;%97XW#6EZ-
MX%ABC_529)#_36:0_TAFC_]'9H__1V:/_T=FC_]'9H__1_]L" #^?   WHH
M -"6 @#(GP0 P*<$ +FN P"RLA0 JK$H Z&O-PR9K$,7D:A-(8FE52J"HUPR
M?*!C.7>>:CYRG'%$;9IY2&B9@4QDEXM08):54UV6HE5:E;!7697!5UB5WE9;
MEO-079?_3%^7_T=@EO]&8);_1F"6_T9@EO]&8);_1O]P P#K@0  UH\  ,J:
M 0#!HP, N:H" +&R 0"JMQ$ H[<D INU- J3LD 4BJ]*'H.M4R=\JUHN=JAA
M-7"G:#MKI6] 9Z-W1&*B?TA>H8E,6J"43U>?H%%4GZY34Y_ 4U*?W5)5G_-.
M5Z#_2EF@_T99G_]%69__15F?_T59G_]%69__1?]U  #@A@  SY,  ,2? 0"Z
MIP$ L:X  *FV  "AO0T F[T@ 92\,0>+NCT0@[=(&GRU4")ULU@J;[)?,&JP
M9C9EKVT[8*UU/URL?D-8JX='5:J32E&JGTQ/JJY-3:K 34VJW$U.JO))4*K^
M1E*I_T-2J?]"4JG_0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP
MJ;(  *"[ @"7Q D DL4; (O$+ 2#PCH,>\%$%72_3AUNO58D:+Q=*F.[9#!?
MNFPT6KET.5:X?#Q3MX<_3[>20DRVGT1*MJU&2+; 1DBWW45)MO)#2K7_04NU
M_SY+M/\]2[3_/4NT_SU+M/\]2[3_/>*#  #-D@  P9\  +2G  "JKP  H+@
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M)#GB_R0YXO\D.>+_)+^>  "OI@  HZX  )>X  "*P@  ?LP  '/6 @!IY0D
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M!HZZ  !_Q0  <-$  &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0
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M4'1RXT]V=?9'>'?_0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0
M]7D" -Z# @#3BP4 S9(' ,F7" # F1D MY@L Z^5.PRGD4<6GXU0'YF)62>3
MAF$NCH-H-(F!;SF%?W8]@7U^07U[AD5Y>H])=GB93'-WI4YP=[)0;G?$4&UW
MX$]P>?5(<GO_0W1\_SYU??\[=7W_.W5]_SMU??\[=7W_._]A"@#_;P( Z'P
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M0V*+_S]CC/\\8XS_/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$
MN)\! +"E  "HJ0X HJDA 9JH,0:3I3X/BZ-(&(2@42!^GEDG>)Q@+7.:9S)O
MF&XW:I9U/&:5?3]BE(=#7Y*11EN2G4E9D:M*5Y&[2U:1TTM7DN]'6I+]0ER3
M_SY=D_\[79/_.UV3_SM=D_\[79/_._]N  #@?@  SHL  ,25  "ZG0  L:,
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M,TBO_S-(K_\S2*__,]N"  #'D   NYP  *ZC  "DJ@  F;$  (^Y  "$P ,
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M$*VB  "@J0  D[,  (:]  !YQ@  ;,\  &#8  !5W@  3O,* $KW$P!&^!T
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M PO_BP,*_YH#"O^H PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP
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M&ZYL82&I:FDGIF=Q*Z)E>"^?9( SG&*(-IEAD#B67YD[E%ZB/9%>K3^/7;M
MC5W-08Q>Z#^-8?DXC6+_,XYD_S".9/\LCF7_+(YE_RR.9?\LCF7_+/]5#@#_
M7P8 _VD& /1R!@#B> 8 VWP) -E_# #-@1T Q'\P [M\/PJT>$L2K755&JAQ
M7B&C;F8FGVQN*YMJ=2^8:'TSE6>$-I)EC#F/9)4\C&.?/HEBJD"'8;="A6')
M0H1BY$&%9/<[AF;_-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800
M_FP# .1U 0#;>P4 TX ( -"#"@#'A1H OH0M [:!/ FO?4@2J'E2&:)V6R"=
M<V,FF7!K*Y5N<B^1;7DSCFN!-HMIB3J(:)(\A6></X)FIT& 9K1#?F;%1'QF
MX4-^:/4\?VK_-X!K_S.!;/\O@6S_+X%L_R^!;/\O@6S_+_]9"P#_8P$ ]&\
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M.F]W_S9Q>/\R<7C_,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $
MP(T# +F1 P"RDQ$ JY,C :.1,P:<CD -E8M*%8^(4QR)AELBA(-B*("!:2U\
M?W Q>'YW-71\@#AQ>XD\;GJ3/VMYGD)H>*M$9GB[161XT45F>>Y :'O].FI[
M_S9K?/\R:WS_,FM\_S)K?/\R:WS_,O]A  #J;P  V7H  ,R$  ##BP  NY$!
M +25 0"LEPX I9<A 9Z6,067DSX,D)!(%(J.41N$BUDA?XE@)WN'9RMWA6XP
M<X1U-&^"?3=K@8<[:("1/F5_G$%B?JE#8'ZY1%]^ST1@?^Q 8H#\.F2 _S9E
M@?\S9H'_,F:!_S)F@?\R9H'_,O]D  #E<@  TWX  ,>'  "^CP  MI4  *Z9
M  "FFPP H)P> )F;+@22F3L*BY9&$H643QE_D5<?>H]>)76.92IQC&PN;8IS
M,FF)>S9FB(0Y8H://5^%FC]<A:A!6H6W0EF%S$):A>H_7(;[.EZ&_S9?A_\R
M7X?_,E^'_S)?A_\R7X?_,OUH  #@=@  S8(  ,*,  "YDP  L)D  *B=  "?
MH D F:$: ).@*P.,GS@(A9U#$'^:3!=YF%0==)=<(G"58R=KDVHL9Y)Q,&21
M>3-@CX(W7(Z-.EF-F3U7C:8_5(VV0%.-RT!4C>D]5HWZ.5>-_S59CO\R68[_
M,5F._S%9CO\Q68[_,>UM  #9>P  R(<  +V0  "TF   JIT  *&A  "7I@0
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M(\>(  "YE0  K)T  *&D  "6JP  BK(  '^Y  !SOP$ :,8% &#*#@!>RAT
M6\HL 5?*. -4RD,%4,I,"$W)50M*R5T.1\EF$43);Q1!R7D6/\B%&#S(DQHZ
MR*(;.<FS'#C)R1PXR.@<-\?Y'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1
M  "PFP  I*,  )BJ  ",L@  @+D  '3   !HQP  7<T% %/3"@!/UQ( 3=@B
M $O8, !)V#P"1MA& T393P1!V5@&/]EA"#S9:PHZV78,-]F"#C7:D \TVJ 0
M,MJQ$3';QQ$QVN<1,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "F
MH0  FJD  (VQ  " N@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F
M*@ ^YC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG
M"BCJN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP
MC[   (*Y  !TP@  :,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T
M]"X ,?0W 2[U/P$L]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SY
MJP4;^L %&OK>!1KY\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D
M '7"  !GRP  6M,  $W:  !"WP  ..4  #7[!P Q_P\ +O\6 "O_'P I_R8
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M,)M1ZB^:4_HJFE7_)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508
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M+WMF_RM\9_\H?&?_)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $
MQ7L# ,!]!0"Y?A( L7XE :I]-02C>D$*G7=,$9=T51>2<ET<CG!D((IN:R2'
M;'(HA&MZ*X%J@BY^:8LQ>V>5-'AGH#9V9JPX=&:\.7-FT3IS9^TV=&G],'5J
M_RQV:_\I=VO_)W=K_R=W:_\G=VO_)_]7  #V8P  WVT  -%U  #(>P  P7\"
M +N  P"T@1  K((C :6!,@2>?C\)F'M*$))Y4Q:-=EL;B71B((5R:22!<7 G
M?F]W*WMN?RYX;8@Q=6R2-'-KGC=P:JHY;FJY.FUJSCIM:^LW;VW\,7!N_RUQ
M;O\J<6__*'%O_RAQ;_\H<6__*/]9  #K90  VW   ,UX  #$?@  O((! +:$
M 0"NA0X IX8@ *"%, .:@CT(DX!(#XY]416)>UD:A'E@'X!W9R-\=6XG>71U
M*G9S?2YS<H8Q<'&0-&UPG#=J;Z@Y:&^W.F=ORSIG<.DW:7'Z,FMR_RUL<_\J
M;'/_*&QS_RAL<_\H;'/_*/]<  #G:   U7,  ,E[  # @@  N(8  +&(  "I
MB0T HHH= )R)+@*5ASL'CX5%#HF"3Q2$@%<9?WY>'GM\92)X>VPF='ES*G%X
M>RUN=X0P:W:.,VAUFC9E=*8X8W2U.6%TR3IA=.<X8W;Y,F5V_RYF=_\K9W?_
M*6=W_REG=_\I9W?_*?]?  #C;   T'8  ,5_  "\A0  M(H  *R,  "CC@H
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M'#JUP!TYM=\<.;/T'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP
MIYH  )R@  "1IP  A:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-
MQ#L"2L1% T?$3@5%Q%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#
MP!,SP^ 3,\'U$S+ _Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ
M ).G  "'K@  >[0  &Z[  !CP   6,4! $W*!0!$SPP 0] 7 $+0)0! T#(
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M A/T[P(2\OP"$O#_ A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP
M5LX  $G3   ]V@  ,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7
M_C$ %?\Y !/_00 1_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_
MU $'_^L!!O_V 0;_]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@
M #O=   PX@  )N8  !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0
M"_\K  G_,@ &_SL  _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M
M_\8  /_6  #_U@  _]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E
M   CZ0  &NT  !7]   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>
M  #_)   _RL  /\S  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@
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M&+H^\A>W/_\6M4#_%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P
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M(HM5_QZ+5O\<BU;_&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$
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M'W%F_Q]Q9O\?<6;_'_]4  #H7P  UVD  ,IP  # =0  N7@  +)X  "K> T
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M)DB-NR='C=0G1XSP)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P
MMX4  *R-  "BD@  EY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1A
MGD4'79U-"EJ<5 U7FUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7
MNB)!E],B09;O($*5_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P
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M#"VZ_@TLN?\-++C_#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@
M=K   &JU  !>N@  4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 S
MRT< ,<M1 3#+6P$NS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)
M_ 8CR/\'(\?_!R/'_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@
M %^^  !2P@  1\8  #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL
M(]M% "+<4  AW5L (-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8
MV_\"%]K_ A?:_P(7VO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&
M  !&R@  .\X  #'3   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY
M !7K0P 4[$X $NQ: !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P
M#.O_  SK_P ,Z_\ #.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   Y
MTP  +]@  "7=   =X0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ
M-0 )^S\ !_M*  3\5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\
M  #\_0  _/T  /S] (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0
M(N$  !GE   3Z@  $/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P
M_S   /\Z  #_10  _U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_
MY0  _^4  /_E '^T  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH
M !#M   ,^@  "?\   ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$
M /\I  #_-   _T   /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0
M_[D  /^Y /\@*0'_(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*
M;0+_"7D"_PF$ O\)C@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC(
M ?\(U@'_".8!_PCQ ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!
M_PG_ ?\C)@'_)20 _R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_
M#G8"_PZ  O\.B@+_#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-
MT0'_#>,!_PWO ?X-^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_
M ?\F(P#_*"  _R@@ /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"
M_Q-\ O\3A@+_$XX"_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']
M$M\!^1/M ?43^ 'S$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J
M'P#_+!P _RP; /\K'0#_*20 _R@O ?\E.P'_(D@!_Q]4 O\=80+_&VT"_QIW
M O\:@0+_&HH"_QJ2 O\:F0+]&I\"_!JF OL:K +Y&K0"^!J] O8:R +S&ML"
M[QKJ NP;]P+I&_\"Z!O_ ^<<_P/F'/\#Y1S_ ^4;_P/E&_\#Y1O_ _\M&P#_
M,!< _S$5 /\P%@#_,2  _S J /\N-@'_*T,!_RA/ O\F7 +_)&<"_"-R _DC
M? /W(H4#]2*- _,BE0/R(IL#\"*B ^\BJ0/M(K$#["*Y ^HBQ0/H(M4#Y"/I
M ^ C]@3>(_\$VR3_!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!(
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M2PT ^4H1 .U)&@#C1B8 VD8V -%&10'+15$#QD1<!<)"9@B_0F\*O$%W"[I
M?PVX/X8.MC^.$+0^E1&R/IT2L#ZF$Z\^L!2M/KT4JS[-%:D^YA6F/_<3I$#_
M$J- _Q"B0/\/HD#_#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8
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M%GY5_Q5^5?\5?E7_%?]*  #N4@  WEL  ,]A  #&9   OV4  +IC @"S8@\
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M)%5QN254<= E5''N(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0
MOW,  +1Z  "K?P  HH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N
M?TD(:GY0"V=]5PYD?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!W
MMR-/=\XC3W?L(5!W_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<
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M&#V0^A<^C_\6/H__%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP
MBY8  '^9  !SG   9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*
MH%,%2*!:!T6?8PE#GVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;
M^A(VFO\2-IG_$3>9_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P
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M QS!_P0<P?\$','_!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0
M0L   #C#   OQP  )LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6
MU%  %=5= !35:P 3UGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1
M_P$0T?\!$-'_ 9R:  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@
M "W,   DT   '-4  !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD(
M"N9/  GG70 (YVT !N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P
MYO\  .;_ ).A  "%J0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6
M   9VP  $M\   WC   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_
M  #R3   \EP  /)M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L
M /3[ (>I  !YL@  :KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /
MY   "N@   7S   #_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]
M/   _DD  /Y:  #^;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D
M 'NR  !LNP  7<0  $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0
M /0   #_    _P   /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P
M_S<  /]&  #_6   _VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;
M)@#_'"0 _QHD /\5)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"!
M /\ B@#_ )( _P": /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\
M_P#L /\ ^ #_ /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_
M'R$ _QXA /\9(P#_$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#
MAP'_ X\ _P*6 /\"G #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J
M /P ]@#X /\ ]P+_ /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP
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M \0D_P/#)/\#PB3_ \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A(
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M"Y)!_PN20?\+DD'_"_\]  #_0P  Z4D  -Y.  #33P  S4X# ,I)" #"210
MNTHF +5+-@"O2T,"JTI. Z=)5P6D2& 'H4=G"9Y&;PJ<1G8,FD5]#IA%A0^6
M1(X0E$27$I)#H1.00ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&
M_PV(1O\-B$;_#?]   #R1P  XT\  -13  #+50  Q%0  ,!0! "Y3Q$ LE B
M *Q1,@"G43\"HE!* YY/4P6;3EP(F$UC"I5,:@R32W$-D4IY#XY*@!&,28D2
MBDF2%(A(G!6&2*@6A4BU%X-(QQB!2.08@4KW%8!*_Q* 2_\0@$O_#X!+_PZ
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M'&%>N!U?7LX=7U[L&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47
MQ&0  +EJ  "P;@  IW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V
M:4H&<VA2"'!G60IM9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MB
MMAU:8LP=6F+J'%MC_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@
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M&DMR^1=,<O\53'+_$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P
MEX$  (R!  !Z?@  <W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99
M?E<(5WU>"U1\9@U1?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y
M^!9&>?\41GC_$D=X_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8
M (:&  !WA@  :X8  &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&
M4(9;"$Z%8PI+A&P,281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_
M@?\20(#_$4" _Q! @/\00(#_$,9K  "W=@  K'\  **%  "7B0  C(L  (&-
M  !SC@  98\  %V/"0!:D!0 6) A %:1+0!3D#@!49!! DZ020-,D% $2H]8
M!4>/8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-K!$YC<$1.(WA$#B+]A XBO\/
M.8G_#SF)_PXYB?\..8G_#K]R  "R?0  IX8  )R*  "1C@  AI$  'J3  !M
ME0  7Y<  %29 0!/F0\ 3IH: $R:)P!*FC( 2)H\ 4::1 %$FDP"0II4 T"9
M7 0^F68%.YEP!SF8? @WF(H*-9B:"S.8JPLRF+\,,IC?"S&6]0LQE?\+,93_
M"S&3_PLQD_\+,9/_"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0
M6J   $ZB  !%I D 0J03 $"D'P _I"H /J4T #RE/@ [I4<!.:5/ 3>E6 (U
MI6$",Z5L S&E>00OI(<%+:27!BRDJ08KI+T&*J3>!BJB]0<IH?\'*:#_""F?
M_P@IG_\(*9__"+&"  "EBP  FI$  )"6  "#F@  =I\  &JB  !>I@  4JD
M $:K   \K0  -:\, #.P%0 RL"$ ,; K "^P-0 NL3X +;%( "RQ40 KL5L
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M )B8  "-G@  ?Z4  '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@
M%\T  !'1   ,U@4 "-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@
MWF(  -YS  #>B   WYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?
M  "!I@  <ZX  &6U  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD
M  G=   #X0   .,'  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(
M .QB  #M=@  [HP  .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !U
MKP  9[<  %F_  !+Q@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G
M    ZP   .L   #M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1
M  #[8P  _'<  /V-  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0
M6L$  $S*   \SP  +M0  "+:   7W@  $.(   GF    Z0   .P   #P
M]@   /8   #W    ^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_
M3P  _V(  /]W  #_C0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A
M /\.) #_!BH _P S /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\
M_P"6 /\ G #_ *( _P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^
M /X _0#_ /P _P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0
M( #_"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P
M] #_ /0 _P#S /\ \P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_
M#B$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\
ME #^ )L _ "A /H IP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_
M .H _P#J ?\ Z0'_ .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT
M_Q,H /\0- #_#4$ _PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V
M!I8 \P:= /$&HP#O!JH [0:R .H&NP#H!L@ Y@;< .0&[ #B"/H X K_ -X+
M_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_'A@ _QPC
M /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I(
MYPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_ ,T2_P',
M$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1, _R,< /\@
M* #['#4 ]1I" .\83P#J%UH YA9E .,6;@#@%G< WA9_ -P6AP#9%HX UA:5
M -06G #2%Z, T!>K ,X8M0#,&,$ RQC2 ,<:Z '#&_@!P!O_ ;X<_P&]'/\"
MO!S_ KP;_P*\&_\"O!O_ O\K# #_*P4 _RL# /\M"0#_+ X _RD5 /<F( #N
M(RT YR$Z .$?2 #;'U0 U2!? -$@: #.('$ S"%Y ,HA@0'((8@!QB&/ <0A
ME@'#(9X!P2*F ;\BKP&](KL"O"/* KDCXP*U)/0"LR3_ [$D_P.O)/\#KR3_
M ZXD_P.N)/\#KB3_ _\O!@#_+P  _S(  /\S @#Y,@@ ]R\. .LK%@#A)R(
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M"/\\  #K0P  W$H  ,Q/  ##4   O$X  +=) 0"Q1@X JD@< *1)+ "@23H
MFTE% 9A(3@*41U<#DD=>!8]&90:-1FP'BT5S"8E%>PJ'1(,+A42-#(-$EPZ!
M0Z(/?T.O$'Y#P!!\1-H1>T3Q#WI%_PUZ1O\+>D;_"GI&_PEZ1O\)>D;_"?4^
M  #F2   TT\  ,=4  "]50  ME0  +!0  "I3 L HDT8 )U.* "83C8 E$Y!
M 9!-2P*-35,$BDQ:!8=+80:%2V@(@TIO"8!*=PM^27\,?$F)#GI(DP]X2)\0
M=TBL$G5(O!)T2=(3<TGN$7)*_P]R2O\-<DK_"W)*_PMR2O\*<DK_"O)"  #@
M3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S( C5,^ 8E2
M1P*&45 $@U%7!8!07@9^3V4(>T]L"7E.<PMW3GL-=4V%#G--D!!Q39P2;TVI
M$VY-N11L3<X4;$WK$VQ._1!L3_\.;$__#&Q/_PML3_\+;$__"^Y%  #<4
MR5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7(0"+6"\ AU<[ 8-61 )_
M5DT#?%54!7I46P9W5&((=5-H"7-3< MQ4G@-;U*"#VU1C1%K49D2:5&F%&=1
MMA5F4<L595+I%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H
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M%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(70  NV0  +!J  "F;0
MG6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG.0%K9T(":&9* V5F4@5C
M95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?$U)BKA518L(54&+A%5%B
M]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN  "C<0  FG,
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M#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P  C($  (&!  !R@
M97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-@$X"2W]5 TE_705&
M?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\\0TZ>_\,.GO_"SIZ
M_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !NAP  8(<
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M!*R!  "@B   E8X  (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@
M+J@% "FI#P HJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >
MJWD ':N+ !NKG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)
M  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,
M !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$
M$+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2
ME0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7
M   0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W
M  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G
M>Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (
MS@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6
M?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL
M &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75    VP
M -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P
MZ8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\
M  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C    Y0   .<
M  #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T
M /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   Y
MRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P   /$   #S
M    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N
M  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "<
M_P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_
M )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L
M_P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M
M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H
M_@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q
M /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\
M-@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"<
M /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\
MY0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_
M 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D
MG@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_
M -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@
M_0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;
M!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,
M_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^
M .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT
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M O\L  #_+0  [3(  .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D,
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M!X(YO B!.=,(?SKN"'TZ_@=\._\&?#O_!7P[_P5\._\%?#O_!?0W  #E0
MTD<  ,5*  "\2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.
M05$!BT!9 HE 8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^
MN IW/\T*=3_J"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P
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M#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;  "J70
MH5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!<%-, FU24P)K
M4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;4< .6E'>#UI1
M]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F80  G6$
M )1>  "(5P  @%8* 'I7%0!V5R( <U@N '!7.0!M5T$!:E=) FA64 )F5E<#
M9%9>!&)5905@56T'7E5W"%Q5@@I:58X,656<#5=5JPY65;X/557;#U55\PU5
M5?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90  FF4  )!C
M  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A6E4#7UI<
M!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9\@U16?\+
M45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD  (QG  !]
M8   =5\# &]?$ !K7QP :& H &9@,P!C8#P!86!$ 5]?3 )<7U,#6U]:!%E?
M80577FD&55YS"%->?@E178H+3UV9#$U=J U,7KH.2U[4#DM>\0Q,7O\+3%W_
M"DQ=_PE,7?\(3%W_",]4  "^7@  L64  *=J  "=;0  E&T  (EL  !X90
M;V0  &ED#@!E9!D 8F0E &!E, !>93H 7&5" 5IE2@)89%$"5F18 U1D7P12
M9&<%4&-Q!TYC>PE,8X@*2F.7"TACI@Q'8[@-1F/1#49C[PQ&8O\*1V+_"4=B
M_PE'8O\(1V+_",I8  "Z8@  KFD  *-N  ":<0  D'(  (1Q  !T:P  :6D
M &-I"P!?:14 7&HA %IJ+0!8:S8 5FL_ 55K1P%3:DX"46I5 T]J701-:F4%
M2FEN!DAI>0=&:88)1&F5"D-HI0M!:;<,0&G/#$!H[@M!:/\*06?_"4%G_PA"
M9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@  97$  %QP
M!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'<6($17!L
M!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM_P<[;?\'
M.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@  %9W 0!0
M=PX 3G@8 $QX) !+>2X 27DW $AY0 !&>4@!1'E/ 4)Y5P)!>6 "/WAI SQX
M= 0Z>((%.'B1!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U_P8U=/\&-73_
M!KEH  "M<0  HGD  )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H
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M !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_  "<A@
MD8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$  "&C"@ ?
MHQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7  %*6! !.E
ME  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$
M '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D
M$+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %
ML:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=
M  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,
M  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4
M +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<
MJP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)
M#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=
M  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0
M0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4   #6!@
MV P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #D
MI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(
M "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D    Y0,
M .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP
M]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0
M   1U0  "ML   #?    X@   .4   #I    [    .T   #P    \0   /,
M  #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8
M /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_
M $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\
MI@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_
M /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4
M_P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[
M *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\
M_P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!-
M /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *,
M[@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@
M /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D
M4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F
M -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\
MS@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I
M %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T
MJ@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_
M /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$
MU@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]
M!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>
M  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5
M ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T
MKQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_
M(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +47
M5P"S&&  L!AG *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT
M )\<Q0">'-\ FAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P
MYBT  -HO  #/+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F
M(EH HR-B *$C:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(E
MOP&1)=8!CB;O 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38
M ,TX  #$-P  OC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4
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M!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@  Q$@  +E+  "O2P
MITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^/T@ ?#]/ 7H_5@%X
M/UT!=CYD G0^:P)R/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^K@9I/\ '9S_>!V<_
M]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J4   HD\
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M!E5,_P553/\%54S_!=5(  #"40  M5<  *I;  "@7   EUP  (U9  "!4P
M=T\$ '%/$ !N4!P :E H &A0,@!E4#L 8U!# &%02@%?4%$!75!8 EQ07P):
M4&<#6%!Q!%=0>P554(@&4U"6!U)0I0A04+<)4%#."4]0[0A04/\'4%#_!E!0
M_P504/\%4%#_!=!+  "_5   LEH  *=>  "=8   E&   (E=  !\5P  <E0
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M!<-6  "T7P  J&8  )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A
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M S%RF@,O<JP#+G+! RYRXP,N<?@#+G#_ RYO_P,N;_\#+F__ [-F  "G;P
MG78  )-Z  "(?   ?GT  ')]  !D?   5WL  $QZ  !">0, /'D. #IZ%P Y
M>B$ .'HJ #=[,P V>SL -'M$ #-[3  R>U4 ,'M? "][:@$M>W<!*WN' 2I[
MF (H>ZH")WN_ B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P
M (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H
M+80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @
MAJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%
M  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I <
M "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0
M%)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !W
MCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=
M&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR
M  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@
M8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P '
MJAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "I
MP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(
M $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4
M +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@
MM],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO
M   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P  PQ   ,05
M  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,
M ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   E
MN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D  -$.  #3
M$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+
M  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0
M$,@   G,    SP   -,   #9    W    -T   #?    X0   .(%  #D"P
MYA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #S
MR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4
M  #:    W@   .(   #F    Z0   .H   #L    [@   /    #R    ] 8
M /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP
M_\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\
M7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O
M /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\
M\0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_
M &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8
MLP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_
M /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &
M^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G
M +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/
M#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C
M .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +(
MT@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_
M#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T
M90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X
M ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P
M_PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#'
M &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$
MP@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(
M .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F
MMP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C
M#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>
M  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A
M *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3O "7%-
ME!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@  - J  #'
M)P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50 G!I< )H:
M8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T C1VI (L=MP"*'LH B!_G
M (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E+   TS$  ,8S  "\,0
MMBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B1P"3(T\ D2-6 (\C70"-
M)&0 BR1K (DD<@"()'H AB2# (0EC0"#)9@!@26D 8 FL@%^)L4!?2?B 7LG
M]P%Y*/\!>"C_ 7@H_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38
M *8O  "A* < FR<3 )8H( "1*2T CBHX (LK0@"(*TH ABM2 (0K6 ""+%\
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M E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3   FTH  ))%  ")/P
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M \A)  "X40  K%<  *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!,
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M CU8F0,\6*H#.UF_ SI9X ,Z6/<#.EC_ SM7_P,[5_\#.U?_ [Q4  "N7
MHV,  )EG  "0:0  A6D  'EG  !K8@  8&   %5=  !.6PP 2UL4 $E<'P!'
M7"@ 1ETQ $5=.0!#74$ 0EU( $%>4 ! 7E@ /EYA 3Q>; $[7G@".5Z' C=>
MEP(V7JD#-5Z] S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<
M )9L  ",;@  @6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0
M/V,M #YC-0 ]9#T /&1% #MD30 Y9%4 .&1? #9D:0$U9'8!,V2% 3%EE0(P
M9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@  G&T  )-Q
M  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y:B  .&HH
M #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2ILDP$I;*4!
M*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,  (YV  "$
M>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH +W,C "YS
M*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A=:( ('6W
M !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@
M='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B
M?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_
MS@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88
M &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8
M%HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,
MB>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/
M  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F
M  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.
M )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$
MF@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C
M)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P
M  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP
M+:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(
ML2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O
M]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX
M !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^%@  OQX
M , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P
MPOH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[
M   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <
M  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?
M -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0   7'
MR@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P  .,1  #F
M&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D
M &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4    V0
M -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()  #U#P
M^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\
M%0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O
M /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\
M_0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_
M !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\
M<@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #&
M .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T
M_P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S
M '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\
MT #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P #
M /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X
MX@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#(
M .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\
M P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N
M ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0
MM0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T
M  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P
M;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F
M *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0
MV@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K
M &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&
M] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ
M ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD
MG MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")
M$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04
M 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I
M (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\
M?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C
M%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<
M:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_
M '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P(
MDAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V
M)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I
M_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<,
M (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH
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M <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1<
M93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH %4\<P%3
M/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!33W_ <E
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M 49%F )%1JD"1$:] D-&W )#1O4"0T;_ D-&_P%#1?\!0T7_ <%'  "R3P
MIE0  )Q7  "26   B%@  'Y5  !Q3P  9DH  %Q&!0!71@\ 5$88 %%&(@!/
M1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(2%@ 1TAA $5); !$27@!0DF& 4%)
ME@% 2J<"/TJ[ CY+V (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@
M )E;  "070  AEP  'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@
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M 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I  "':@
M?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF #5=+@ T
M738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z  *%^S 2=?
MS  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\
M &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$
M+&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?
M9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET
M  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT
M ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND
M%VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7
M>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW
M-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z
M  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@
M1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -
M@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6
M_P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P
M #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(
M ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P
MB_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6
M   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU
M  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\
M )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5
MH@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L
M-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_
M (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@
M!K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P
MO#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5
M  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P
M  "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL
M - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !D
MHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-
M    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J
M  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K
M2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D   #=
MX    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[
M*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1
M /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H
M_P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X
M /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\
M#@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![
M /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P
MZ #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_
M !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P
M? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V
M -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T
M^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8
M 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\
M_@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1
M .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4
MP0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L
M /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8
M%0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U
M *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\
MG #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #
M !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$
M=0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_
M (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !(
MK@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1
M!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,
M_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6
M )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$
M@PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T
M$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0
M&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T
M '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\
M:AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!
M&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>
M>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_
M -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T
M="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A
M)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R
M  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C
M &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T
M6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z
M/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N
M* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&(
M % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@
MJ48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8
M,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HW
ME0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH
M )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH
M4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N# $0[DP!#
M/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20  HTX  )E0
M  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-.R< 2SLO
M $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_D0 ^0*(
M/4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$  )=4  "-
M50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0 1D L $1
M,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y1*  .$6S
M 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18  "+60
M@%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I #]%,0 ^
M13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X ,TFQ #))
MR0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET
M '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4
M.$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L
M3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?
M  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z
M #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^<
M)E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@
M80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7
M/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ
M "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:
M464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A
M7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>
M_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P
M $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX
M%V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 1
M9?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS
M   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"
M  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\
M"6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J
M?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\
M2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_
M )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP
M&H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@
MB$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^
M  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,
M  V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8
M )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#
MB@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@
M    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+
M  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0
M:I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L   "M
MKP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W
M4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT
M %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z    O
M +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P
MRU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K
M   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(    RP   ,L
M  #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@
M .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   H
MN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W    -T   #?
M    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-
M  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8
M_P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_
M (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /,
M_P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P >
M /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (,
M] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B
M /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\
M)0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "#
M .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\
MR@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M
M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P
M@P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_
M +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$ &0#; "4
MU0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X
M (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0
M_P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#' !\ P@ J
M +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P
MI0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5
M /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\
M+@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!]
M )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\
MA@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@">
M #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8
M@ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_
M .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD
MC0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X
M"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<
M  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL
M 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$((
M:Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##
M*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4
M, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+
M %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0
MKS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G
M&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@
ME@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH
M * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\
M72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.
M)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!
M  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R
M %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$
M1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/
M10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM
M-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q
M #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20
M@T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&
M,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HW
MQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P
M '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38
M/S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T
M.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--
M  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[
M #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0
M+S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D
M3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_
M0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y
M "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@
M5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M
M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'
M_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554
M $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T,
M)DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?
M3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8
M   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%)
M !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\
M&5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X
M7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !99
M4  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_
M )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90
M*6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .
M85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF
M  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P
M !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U,
M!&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-
M<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V
M   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<
M  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@
M@'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *
M@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!
M90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0
M &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.   "CP
M ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070
MCW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-
M  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";    G0   )T
M  "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8
M )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+
MF0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@   *H   "J
M    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O
M  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP
M,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<   "X
MN0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&
M>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\
M !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(    R0
M ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P
MX84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\
M   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:    W    -\
M  #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0
M /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_
M #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T
MD #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_
M -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #,
M_P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M
M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P
M_P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y
M /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L
MV "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X
M /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$
M/@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@",
M ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\
MJ0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#&
M $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T
MC0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_
M /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H
ML0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@":
M )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@
M  #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \
M )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H
MB0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<
M#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )
M/@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/
M 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P
MOQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"
M #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#
MF !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,
M *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@
M<@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@
M#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K
M  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y
M &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z(
M51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5
M,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5
M.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP
M $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P
MAS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2
M'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0A
MQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH
M 'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH
M22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ]
M)^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[
M  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8]
M $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.
M-RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H
M.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK
M00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W
M #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0
M6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U
M,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU
M_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$
M $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40
M+S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H
M./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"
M  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI*
M "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\
M(SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  !
M1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "-
M4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_
M *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@
M,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <
M1EH &T9H !E&>  81XH %T>> !9'LP#_XO  24-#7U!23T9)3$4 "0H42,X
M%4?O !9'_P 71O\ %T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !9
M6@  3U@  $14   Y40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+
M,  92S@ %TM" !9,3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN
M !!-_P 13/\ $4S_ )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680
M2EX  #];   U6   *U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  1
M4C0 $5(^ !!32  /4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3
M^P +4O\ "U+_ )M=  "19   B&@  'YK  !T;   :VP  %]J  !29P  160
M #IB   P8   )EX  !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S
M"ELZ  E;10 '6U$ !EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !
M6O\  EG_ )=D  ".:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K
M   J:0  (6<  !AF   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U
M  !D0   9$P  &1:  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\
M &'_ )-L  ")<0  @'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C
M<@  &G$  !)Q   -<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O
M.P  ;T<  &]4  !O9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_
M (YS  "%>   ?7L  '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?
M$WP   U\   &?0   'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-
M>T   'M.  ![7@  >V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ
M  "!?P  >((  &N#  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@
M  :)    B@   (H   ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@
M (I&  ")5@  B6@  (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]
MA@  ;X@  &&+  !3C0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6
M    EP   )@   "7    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]
M  "930  F5X  )ES  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC
M9(\  %:3  !(E@  .ID  "R:   ?FP  %)P   R>   #GP   *$   "C
MI0   *4   "E    I0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K
M00  K%,  *QG  "K@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@
M $J<   \GP  +:(  ""C   3I0  "Z<   &I    JP   *X   "Q    L@
M +(   "S    M    +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0
MP$<  ,!;  # <@  P(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE
M   OJ0  (:L  !.M   +L    +,   "U    N    +P   "_    P0   ,$
M  ##    Q    ,8   #'    R0   ,L   #."   T0\  -48  #8)P  V3D
M -I-  #;9   VWX  -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   B
ML@  %+4   JX    NP   +\   ##    Q@   ,L   #.    T0   -$   #4
M    U@   -D   #;    W@   .    #D    YP8  .L.  #O&0  \"H  /(_
M  #S50  ]&T  /2(  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$
M_P < /\ * #_ #0 _P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\
M 'X ^P"$ /H BP#Y )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T
M_P#L /\ X0#_ -( _P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7
M /\ (P#_ "\ _P [ /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@
M[ !^ .H A0#I (P YP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6
M /\ SP#_ ,0 _P"] /\ N0#_ /\   #_    _P   /\   #_  L _  3 /<
M'@#T "H \@ U .X 0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X
M -0 ?@#2 (4 T "- ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\
MO@#_ +8 _P"P /\ K0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A
M "0 W@ O -H .0#3 $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\
M=P"] 'X NP"& +D C@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_
M *@ _P"C /\ H #_ /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X
MQ@ I ,( ,P"_ #T NP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K
M '< J0!_ *< AP"E )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8
M_P"6 /\ DP#_ /T   #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B
M +  + "M #8 J0 ^ *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '
MF !W )8 @ "4 (H D0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"&
M /\ A@#_ /,   #C    T0   ,4   "]    M@   *X "P"H !( I  < *
M)@"< "\ F@ W )< /P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q
M (8 >0"$ (, @@"/ '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\
M=P#_ .<'  #1#   PPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P".
M "@ BP Q (@ .0"& $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@
M<P!V 'T = "( '$ E0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_
M -H0  #&%   N!8  *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$
M?@ J 'L ,@!Y #D =P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I
M '< 9P"# &4 D0!C )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8
M  "]'0  L"   *4?  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C
M &\ *P!M 3, :P$Z &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7,
M7 9_ %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V
M)0  J2@  )XH  "4)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*
M)0!B"BT 8 LT %X+.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[
M % .B@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P
MI"\  )DO  "/+0  ABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8
M$"< 5A N %00-0!3$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3
MAP!&$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0
M )4U  "+-   @3$  '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2,
M3A4J $P5,0!+%C< 218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _
M&I0 /1JF #P;NP [&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[
M  "'.@  ?C<  ',R  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF
M $4;+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y(
M-R"D #8@N  U(=8 -2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%
M/P  >SP  ' X  !G,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@
M*0 ](#  .R V #HA/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B
M "\EM@ O)M( +R;R "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P
M>$$  &X]  !C.   6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V
M)"P -24S #0E.@ S)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJ
MM  I*L\ *2OP "HK_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4
M &Q"  !A/0  5S@  $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D
M+RDP "\J-P N*C\ +2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D
M+\T )"_N "4O_P E+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'
M  !>0@  5#T  $LY  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN
M "DN-0 I+ST *"]& "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L
M'C/M !\S_P @,_\ (3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<
M1@  4D,  $D_   _.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S
M,@ C-#H (C1# "$U30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK
M !HX_P ;-_\ &S?_ *-'  "830  CE$  (13  ![5   <5,  &90  !:3
M4$D  $=%   ]00  ,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >
M.3@ '3E! !PZ2P :.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\
M_0 5//\ %CO_ *!+  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\
M $5+   Z1P  ,$,  "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4
M%C\^ !4_2  40%, $T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  0
M0?\ $$#_ )U0  "35@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1
M   V3@  +$L  "-(   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[
M !!&10 /1E  #D=>  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\
M"T;_ )I5  "06P  AV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R
M50  *%(  !]0   73@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-
M0@ )34T !TY:  9.:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_
M )9;  "-8@  A&8  'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7
M(UH  !I8   25P$ #58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@
M54H  %97  !690  57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B
M  "*:   @&P  '=N  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,
M !5B   .80  "6 (  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4
M %]3  !?80  7G(  %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&
M;P  ?7(  '5T  !J=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L
M   *;    FL&  !K"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.
M  !I7   :6T  &B"  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@
M>GD  '![  !B>P  57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #
M=P   '<"  !W"   =@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U
M5@  =6@  '1\  !TD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\
M &B!  !:@@  3((  #^#   RA   )8,  !J#   1@P  "H,   *#    A
M (4   "$ P  @P@  (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P
M@V   ()U  ""C   @:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(
M  !0B@  0HL  #6-   GC0  &XT  !&.   *C@   (\   "1    D@   )(
M  "2    D@$  )('  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<
M )-K  "3@@  DIP  )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%
MDP  -Y4  "F6   <EP  $9@   F9    FP   )P   ">    H    *    "@
M    H    *$   "A!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@
M  "E>   I9(  *2L  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG
M*IX  !V@   1H0  "*,   "E    IP   *D   "L    K@   *X   "N
MKP   +    "Q    L@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[
M:@  NH4  +FA  "YNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@
M !&J   'K    *\   "Q    M    +@   "[    O    +P   "^    OP
M ,    #"    Q    ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370
MU'8  -22  #5JP  U<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U
M    N    +L   "^    P@   ,<   #*    S    ,P   #.    T    -(
M  #5    V    -L   #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<
M /""  #PG   \+(  /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_
M #  _P \ /\ 1P#_ %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8
MA0#U (P \P"4 /( G0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_
M ,L _P#" /\ O0#_ /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L
M_@ W /H 0@#V $L \@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C
M (8 X0". -\ E@#= *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T
M_P"V /\ L@#_ /\   #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q
M .@ .P#C $4 X !- -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\
MR0"' ,< D #% )H PP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I
M /\ I0#_ /\   #_    _@   /4   #L  , Y0 - -\ %0#: "  U  J -
M-0#+ #X R !' ,4 3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"
M +, B "Q )( K@"> *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\
MF #_ /\   #[    \    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W
M #@ M !  +$ 2 "N $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *
M@0"> (L G "6 )D HP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_
M /D   #K    W0   ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$
MH@ Y )\ 00"= $@ FP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@",
M (, B@"/ (@ G "& *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P
M  #:    R0   +X   "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R
M )  .@"- $$ BP!' (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T
M>P"( '@ E0!V *, =0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*
M"@  O L  +$)  "H!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($
M,P!_ #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; ""
M &H CP!I )T 9P"N &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@
MLA,  *<2  "=$   E0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q
M #0 ;P Z &X 0 !L $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X
MB0!< )@ 6P"I %D O !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT
M )\<  "5&0  C10  (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X
M9  T &( .P!@ $  7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2
M )0 4 &E $\!N !. M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE
M  "/(@  A1T  'T8  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O
M %<%-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9(
M1PJC $4*M@!$"]  1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "*
M*@  @"8  '<A  !N&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,
M+P!,##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B
M #P0M@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0
M?"T  '(H  !I(P  81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#
M$3$ 0A$W $$1/@! $44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45
MLP T%<T ,Q;N #06_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0
M &XN  !E*@  7"0  %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T
M.Q4T #D6.@ X%D( -Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M
M&\H +1OL "T<_P N&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT
M  !B+P  62H  % E  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP
M #,:-P R&SX ,1M' "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,<
M)B#J "<@_@ H(/\ *"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?
M-0  5C   $TK  !$)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?
M-  L(#L *R!$ "HA3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H
M "(E_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@
M4S8  $HQ  !!+   ."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F
M)#D )25! "0E2P C)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI
M^P =*?\ 'BC_ *,^  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L
M $<W   ^,@  -2T  "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38
M("D_ !\J20 >*E0 '2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8
M+?\ &2W_ *%!  "51P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]
M   ].   ,S0  "HO!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\
M !HO1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\
M$S'_ )Y%  "32P  B4\  (!1  !V4@  ;5   &).  !620  348  $1#   [
M/P  ,3H  "<V P ?,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T
M1  3-$\ $C5< !$U:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_
M )M)  "13P  AU,  'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10
M+D$  "0]   <.@@ %C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 .
M.DP #3M9  T[:  +.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.
M  ".5   A5@  'Q;  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<
M "%$   80@, $D + ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H
M!T%6  9!90 $078  T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",
M60  @UX  'E@  !P8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,
M   42@  #D@(  M'#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3
M  !(8@  2',  $B&  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8
M@&,  '=E  !N9@  968  %ED  !,8   0%T  #5;   J60  (%<  !=5   0
M4P  "U('  51#0 !4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !0
M7@  4&\  %"#  !/F   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D
M '1L  !L;0  86L  %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7
M!EP&  !;"P  6@\  %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@
M66L  %A^  !8E   5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R
M  !G<@  6G$  $QP   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#
M  !F"0  90T  &41  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8
M &-Z  !BD   8:<  &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@
M>   4G<  $5W   X=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q
M!0  <0H  '$.  !P$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT
M  !NBP  ;:(  &R\  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P
M27\  #Q_   O@   (G\  !=^   /?@  !WX   !_    ?P   '\   !^
M?@4  'X*  !^#0  ?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\
MA   >YP  'JV  !YV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@
M #*)   DB0  &(D   ^)   'B@   (L   ",    C0   (T   ",    C
M (P#  ","   C0T  (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P
MC)4  (NN  "*S0  B>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2
M   9DP  #I0   :5    E@   )@   ":    FP   )L   ";    FP   )L
M  "<    G04  )T+  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH
M )ZE  ">P@  G>@  )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /
MG0  !9\   "A    HP   *4   "H    J0   *D   "I    J@   *L   "L
M    K0   *X!  "P"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:
M  "SM   L]4  +/P &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J
M *L   "M    L    +0   "V    N    +@   "Y    N@   +P   "]
MOP   ,    ##    Q0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,
MJ   S,(  ,SB %B;  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<
M  "Z    O@   ,,   #&    R    ,@   #*    RP   ,T   #/    T@
M -4   #9    W0   .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP
M[*X  .S" /\   #_    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\
M0P#_ $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/
M .T EP#K *$ Z0"M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\
MM@#_ /\   #_    _P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q
M $8 [0!/ .L 5@#H %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@
MD0#4 )L T@"F ,\ M #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_
M /\   #_    _P   /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $
MV !) -, 4 #0 %8 S@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^
M )0 O "? +D K "V +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\
M  #_    ^0   .\   #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !"
M +T 2@"[ %  N !6 +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P
MIP"8 *4 I0"C +0 H #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V
M    Z@   -T   #/    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H
M0P"G $D I0!/ *, 50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0
M )( G0"0 *P C@"_ (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D
MU    ,@   "_    M0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6
M $, E !) )( 3@"0 %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($
ME0!_ *0 ?0"U 'L SP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP
M +@   "O    J    *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P
MA !" (( 1P"  $T ?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O
M )T ;0"N &P Q !J .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&
M  "B    FP   )0   "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [
M '0 00!R $< < !, &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )<
M8 "G %X NP!= -P 7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7
M#0  CP@  (@   ""  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &<
M.P!E $$ 8P!& &( 3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B
M %, M0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@
MAQ$  '\-  !W!@  <0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9
M #L 6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@
ML !' ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H
M '<5  !O$   : L  &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4
M3@ [ $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]
M!,0 / 7E #P'^  \!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>
M  !I&   81(  %H- P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V
M $,(/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,(
M,PSD #,-^0 S#?\ - W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D
M(   7!H  %04  !,#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-
M.  X#3\ -PY' #8.4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E
M "P1^@ L$?\ +1'_ *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P
M6"$  $\;  !'%@  0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q
M$3L ,!%# "X230 M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46
M^@ F%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@
M $PB  !#'0  .Q<% #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@
M*19  "@62@ G%U0 )A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @
M&O\ (!K_ *,T  "8.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH
M  ! (P  .!X! # 9"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^
M "(;1P A&U( (!Q> !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\
M&Q[_ *$X  "5/0  BT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]
M*0  -20  "T@!P G'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?
M10 <($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_
M )X\  "300  B40  ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,
M,RL  "HF P C(@L ("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6
M)4T %259 !0F:  3)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q
M  "110  AT@  'U*  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(
M "@M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L
M$2I7 ! J9@ .*W< #BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/
M20  A4P  'Q.  !S3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T
M   =, 4 %BT, !0L$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5
M  PP8P *,'0 "3"(  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30
M@U$  'I3  !Q5   9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :
M-P$ $C0)  \S#@ .,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V
M8  $-G$  C:$   VF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58
M 'A8  !O60  95@  %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P
M$#P'  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@
M/&X  #R!   \EP  /*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=
M  !M7@  8UT  %I<  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&
M  =##  #0Q   $,5  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL
M $-^  !#E   0JH  $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K
M9   8F,  %=A  !)70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-
M"P  3 X  $P3  !+&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[
M  !*D   2:<  $G   !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@
M7FD  %!F  !#9   -V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0
M5@T  %40  !5%0  5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3
MC0  4J0  %&]  !0X@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX
M $IL   ]:P  ,&D  "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L
M & .  !?$@  7Q<  %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B
M7*   %NY  !:WP  6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S
M   U<P  *'(  !UP   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+
M  !K#@  :Q(  &H9  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL
M &:U  !EV   9/4  &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L
M?   'WL  !1Z   ->@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X
M"P  > X  '@3  !X&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O
M  !SS@  <O$  ''_ 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0
M%84   V%   #A0   (8   "'    B    (@   "'    AP   (<   "'!
MAPD  (<.  "($P  B!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$
MQ0  @^P  (+^ 'B$  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9
M  *1    D@   ),   "5    E@   )8   "6    E@   )8   "7    EP
M )<'  "8#0  F1,  )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@
ME^(  );X &V*  !?C0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=
M    GP   *$   "D    I0   *0   "E    I0   *8   "G    J    *D
M  "J!   K P  *X3  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T
M *SO &&1  !3E0  1)@  #6<   FGP  %Z$   VC    I0   *<   "J
MK    +    "R    M    +,   "T    M0   +<   "X    N0   +L   "]
M    OP$  ,,+  #%%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;>
M %69  !'G0  .*(  "FF   9J   #:L   "M    L0   +0   "W    N@
M +\   #!    Q    ,,   #%    Q@   ,@   #*    S0   ,\   #2
MU@   -L   #@#   X1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\
M  #_    _P   /\  0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0
M /< 5P#U %T ] !C /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P
MY "H .( MP#? ,T W #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_
M    _P   /\   #_  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4
M40#B %@ X != -X 8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A
M ,@ KP#% ,$ P@#C ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_
M_P   /L   #S  $ [0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#)
M %$ Q@!7 ,0 70#" &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +(
MIP"O +< K0#0 *L \@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]
M .D   #@    U0 ( ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L
ML0!1 *\ 5@"N %L K !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"<
M *X F0## )< YP"6 /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0
M  #(    OP # +D #0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!*
M )T 4 "; %4 F0!: )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8
MAP"X (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X
M    K@   *< "0"B !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L
M20") $X B !3 (8 60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O
M ', QP!R .P <0#_ '  _P!P /\ ;@#_ -T   #)    O    +$   "I
MH0   )D  P"3  P C@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y
M $@ > !- '8 4@!T %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4
MO !C .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E
M (T   "&  @ @0 . 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$
M:0!' &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6
M -  50#R %4 _P!4 /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((
M  ![  ( =0 + '  $ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!!
M %L 1@!: $P 6 !3 %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8
M2@#J $D _@!) /\ 20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q
M P  :P & &4 #0!A !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %
M00!. $< 30!. $L 5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B
M #\ ^  ^ /\ /P#_ +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@
M8@@  %P!" !7  X 4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$
M $( 0P!) $$ 40 _ %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4
M]  U /\ -0#_ *P@  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!
M %0, 0!.!@H 2@(/ $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX
M.0)% #@#30 V U8 -01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L
M"/\ + C_ *@E  ";*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2
M  !(#@0 00H+ #X'$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E!
M "\)20 N"E, + I> "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\
M)0W_ *0J  "8+P  C3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#
M$P  /! & #4-#  S#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.
M1@ F#E  ) Y< ",/:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_
M *$O  "5,P  BC8  ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@
M.!4  # 1"  L$ X *A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @
M$DX 'A): !T3:  ;$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS
M  "3-P  B#H  'X[  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P
M "T7!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL
M&197 !<790 6%W8 %!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1
M.P  ACX  'P_  !S/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H>
M 0 B&0D 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5
M !(;8P 1''0 $!R'  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P
MA$(  'M$  !Q0P  :$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @
M( 8 &AT, !<<$  5'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@
M80 -(7$ #"&%  LBF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8
M 'E(  !P2   9T8  %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P,
M%B,* !(A#@ 1(1, $"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ )
M)F\ !R:"  8FE@ $)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,
M  !O3   94L  %M(  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'
M  \H#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP
M 2M_   KE   *ZD  "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M
M40  8U   %I-  !/2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO
M#  )+A  !RX5  8O&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\
M   QD0  ,:<  #"_   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@
M8E4  %A3  !.4   14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $
M-@\  383   V&0  -B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   W
MCP  -J4  #:]   VX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L
M %=9  !,5@  0%(  #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX
M #X1   ^%@  /AT  #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C
M/:,  #R[   \W@  ._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>
M  !'6P  .E<  "]5   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0
M  !'%   1AH  $8B  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*
M $2X  !#W   0O4  $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!
M80  -%X  "E<   ?6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0
M$0  3Q8  $\>  !/)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU
M  !+V   2O4  $K_ (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P
M+64  ")D   88@  $&    E?    7@   %X   != P  7 @  %L,  !:#P
M6A,  %D9  !9(@  62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5
MT@  5/0  %/_ (%L  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X
M !IL   1:P  "6H   !J    :0   &D   !H    9P,  &8(  !F#   9@\
M &44  !E'   92<  &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0
M7_$  %[_ 'UT  !W=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V
M   *=0   '4   !U    =@   '4   !T    =    ',"  !S!P  <PP  '(0
M  !R%0  <B   '(L  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T
M &O_ 'M[  !R?@  9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!
M@0   ((   "#    @P   (,   ""    @@   ((   ""    @@4  ((*  ""
M#P  @A<  ((C  "",@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\
M ':"  !H@P  684  $N'   \B0  +HH  ""+   3BP  "HL   ",    C0
M (\   "1    D@   )$   "1    D0   )$   "1    D@   )("  "3"0
ME \  )09  "4)P  E#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(
M  !<B@  38T  #^0   PD@  (90  !25   *E@   )<   "9    FP   )T
M  "?    H    *    "@    H    *$   "B    HP   *0   "E    I@<
M *@0  "H'   J"T  *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0
MD@  098  #.9   CG   %)T   J?    H0   *,   "F    J    *P   "N
M    KP   *\   "P    L    +(   "S    M    +8   "W    N@   +T'
M  "_$   OQ\  , S  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP
M-9\  ":C   6I0  "Z<   "J    K0   +    "S    M@   +L   "]
MP    +\   #!    P@   ,0   #&    R    ,H   #,    SP   -,   #:
M!P  VQ,  -TE  #>.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P
M /\   #_  < _P 0 /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D
M[P!> .T 9 #K &D Z0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5
M ,4 T@#H -  _P#/ /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\
M  #_  ( ^P - /< %0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8
M -0 7@#2 &, T !I ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H
MNP#9 +D ]P"X /\ M #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N
M    YP * .$ $0#< !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T
M6 "[ %T N0!B +@ : "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#(
M *0 [0"B /\ H@#_ )L _P"5 /\ D0#_ /\   #\    [@   .,   #8
MS0 % ,8 #@#! !4 O0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G
M %8 I0!; *, 80"A &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )
MWP". /L C@#_ (L _P"& /\ @P#_ /@   #I    W    ,P   #!    N
M +( "@"L !$ J  8 *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %
MD@!5 )  6@"/ &  C0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\
M /$ >P#_ 'H _P!W /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$
M!0";  T EP 3 ), &P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!.
M '\ 4P!] %D >P!@ 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8
M:@#_ &D _P!I /\ 9P#_ -,   ##    M0   *L   "C    FP   )(   ",
M  H AP 0 (, %@!_ !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\
M30!M %, ; !9 &H 80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W
M %L _P!: /\ 6@#_ ,4   "V @  J0(  )\   "6    C@   (<   "   4
M>@ , '4 $0!Q !@ ;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!?
M $T 7@!3 %P 6P!: &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X
M_P!. /\ 30#_ +L*  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ (
M &D #@!E !, 8@ 9 %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $<
M40!. %  50!. %X 3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !"
M /\ 0@#_ +(1  "E%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\
M"P!;  \ 5P 4 %0 &@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!(
M $4 4 !# %D 00!C #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\
M. #_ *P7  "?&P  DQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1
M  P 30 0 $H %0!' !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L
M2P Y %0 -P!? #8 :P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_
M *<>  ":(@  CR0  (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@
M10 - $$ $0 ^ !8 /  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P
M %  +@!; "T 9P K '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C
M  "6*   BRH  ($J  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<)
M #D##@ V 1( ,P$7 #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T
M)@58 "4%90 C!G0 (@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3
M+0  B"\  'XO  !T+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+
M"@ N" X *P<2 "D'%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5
M !T+8@ ;#'( &@R% !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0
MAC0  'PT  !R,P  :#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F
M#0L ) P/ "(,$P A#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.
M80 4#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@
M 'HY  !P.   9S8  %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0<
M'1 - !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0
M$F\ #A."  X3E@ -$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]
M  !O/0  93H  %LW  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10*
M !42#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP
M"Q=_  D8DP (&*@ !AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M
M00  9#\  %H\  !0.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7
M#0 0%Q$ #Q<6  X8'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\
M  0=D0 "':8  1V\  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10
M8T0  %E!  !//0  1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -
M'1  #!T4  L=&@ *'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   A
MC@  (:0  "&Z   AVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD
M %A&  !.0@  13\  #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX
M!B,2  4C&0 $)"   B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC
M)J(  ":Y   FV0  )?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+
M  !-2   1$4  #Q"   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1
M   J%@  *AX  "HF   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z
M "NW   KU@  *O(  "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,
M3@  0TL  #='   M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q
M%   ,1L  #$C   Q+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U
M   PU   ,/(  "__ (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P
M/D\  #),   H2   'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@
M.1@  #D@   Y*0  .30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   W
MT@  -O(  #7_ (=5  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4
M "U2   B3P  &$P  !!*   *2    T8!  !%!@  1 H  $,-  !"$   014
M $$=  !!)@  03$  $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T
M/?(  #S_ (1<  !\8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99
M   <5@  $E0   Q2   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9
M  !*(@  2BP  $HY  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$
M $3_ (%C  !Y9P  <FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   5
M7@  #5T   9;    6@   %D   !8    5P0  %8(  !6#   51   %04  !4
M'0  5"<  %0T  !40@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_
M 'YJ  !W;@  <'$  &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P
M!F8   !E    90   &4   !C    8@   &($  !A"   80T  & 0  !@%P
M8"$  %\N  !?/   7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR
M  !U=@  :W<  %UV  !/=@  074  #-U   F=   &7,  !!R   '<0   '$
M  !Q    <0   '$   !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H
M &TF  !L-0  ;$8  &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P
M?   87P  %-]  !$?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^
M    ?P   'X   !]    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=
M  !\+   ?#P  'Q/  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0
M5H,  $B$   YA@  *X<  !V'   1AP  !X@   "(    B0   (H   ",
MC0   (T   ",    C    (P   ",    C    (T   "-!   C@P  (X3  "/
M(0  CC(  (Y&  ".6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL
M #R-   MCP  'I   !&1   'D@   ),   "5    EP   )D   ";    G
M )L   ";    G    )P   "=    G@   )X   "?    H0,  *(,  "B%@
MHR8  *,Z  "C3P  HV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6
M   AF0  $IH   >;    G0   *    "B    I    *@   "J    JP   *H
M  "K    K    *T   "N    KP   +$   "R    M    +<!  "Y#0  N1H
M +HM  "Z0P  NEL  +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3
MH@  "*0   "G    J@   *P   "O    L@   +<   "Y    NP   +H   "\
M    O0   +\   #     P@   ,0   #&    R0   ,T   #2 0  U \  -4?
M  #7-0  V$T  -AI  #7A@  UZ,  -:] /\   #_    _P   /\   #_  ,
M_P - /\ %0#_ "  _  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E
M &0 XP!J .$ < #? '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D
M^P#' /\ O0#_ +$ _P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ +
M /$ $0#M !L Z0 E .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X
MR0!C ,< :0#% &\ PP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P
M /\ K #_ *, _P"< /\ EP#_ /\   #_    ^@   /$   #H    X  & -D
M#@#2 !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!=
M +  8@"N &D K !O *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\
MF@#_ )0 _P". /\ B@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z
M !$ M@ : +( (@"N "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P
M7 ": &( F0!H )< < "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_
M (0 _P!_ /\ ? #_ /(   #C    T@   ,4   "Z    L0   *L !P"E  X
MH0 4 )X ' ": "4 EP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"(
M %L A@!A (0 :0"" '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ',
M_P!P /\ ;@#_ -\   #,    OP   +0   "K    H0   )H  @"4  L D  0
M (P %P"( !X A0 F (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0
M= !: ', 8@!P &L ;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B
M /\ 8 #_ ,P   "\    KP   *4   "=    E    (P   "&  < @0 - 'P
M$@!X !D =0 ? ', )@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4
M &, 6P!A &0 7P!N %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\
M5 #_ +X   "P    I    )D   "0    B    ($   !Y  ( <P * &\ #P!K
M !0 9P : &4 ( !C "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8
M50!4 %X 4@!H %  = !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_
M +0)  "F"P  FPP  ) *  "&!0  ?@   '8   !O    :  % &, # !? !
M6P 5 %@ &@!6 "$ 5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !(
M %@ 1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0
M  "?$@  E!(  (D1  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1
M $X %@!+ !L 20 A $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %,
M.P!= #D :0 W '@ -@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":
M&0  CAH  (0:  !Z%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0
M$@!! !8 /P ; #T (0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9
M "\ 90 N ', + "% "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(
MBB$  '\A  !U'P  ;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X
M !( -@ 7 #0 '  S "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8
M80 E '  ) "! "( E0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@
M 'PG  !R)0  :2(  %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !
M+@ 3 "P &  J !T *0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ =
M &T ' !^ !H D@ 9 *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM
M  !P*P  9B@  %TD  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0
M "0!$P B AD (0(> " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH
M% =\ !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N
M,0  9"X  %LJ  !1)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'
M$  ;!Q4 &0@: !@((  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[
M  X,D  -#*4 # V[  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0
M8S,  %DO  !0*P  1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4
M#!$ $PP6 !(,'  1#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0
MC0 '$*( !A"X  40U  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@
M %@U  !.,   12P  #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X
M#@\3  T0&0 -$"  #! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !
M%*   !.V   3T0  $^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y
M  !--@  1#$  #PN   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2
M  D4%P (%!\ !Q4F  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\
M !BU   7T   %^T  !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,
M.P  0S<  #LT   S,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09
M%@ "&1T  1HD   :+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS
M   <S@  &^T  !O\ (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0
M0ST  #LZ   S-P  *C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%
M'QL  " B   @*P  (38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   A
MS0  (.T  !_\ (I#  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,
M #I    O.P  )3<  !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD
M "8A   F*0  )C,  "<_   G30  )UP  "=M   G@@  )YD  ":P   ES
M)>X  "3] (A(  !_3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$
M   K0   (3P  !<Y   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>
M   M)P  +3$  "T]   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX
M "K^ (5-  !]4@  =54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E
M1@  '$,  !,_   -/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T
M)   -"X  #0Z   T1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_
M (-3  ![6   <UL  &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3
M%DD   Y'   (1    $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0
M/"L  #PW   \1   /%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:
M  !Y7@  <6$  &EC  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$
M  I/   !30   $P   !*    200  $@(  !'#   1@\  $84  !%'   12<
M $4S  !%0   15   $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V
M90  ;V@  &AJ  !=:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8
M    5@   %8   !4    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N
M  !//   3TL  $Y=  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;
M;F\  &1O  !5;0  1VP  #EJ   L:0  (&<  !1E   -9    V(   !B
M80   &    !?    7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:
M-@  6D8  %E8  !9;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74
M %MT  !,<P  /G,  #!R   C<0  %F\   UN   $;0   &T   !M    ;0
M &P   !K    :@   &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P
M9S\  &92  !F9@  97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z
M  !">@  ,WL  "5[   8>@  #GD   1Y    >0   'D   !Z    >@   'H
M  !X    >    '<   !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8
M '9)  !U7P  =7<  '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V
M@P  *(0  !J$   .@P  !(0   "$    A0   (8   "(    B0   (@   "'
M    AP   (<   "'    AP   (@   "(    B <  (D0  ")'   B2P  (@_
M  "(50  B&T  (>)  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC
M&XT   ^-   $C@   )    "1    DP   )4   "7    F    )8   "7
MEP   )<   "8    F    )D   ":    FP   )T'  "=$0  G2$  )TS  "=
M20  G&(  )Q_  "<G   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8
M  28    F@   )P   ">    H0   *0   "F    IP   *8   "G    IP
M *@   "I    J@   *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0
MM54  +5P  "TC@  M*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C
M    I@   *D   "L    KP   +,   "U    MP   +8   "W    N    +H
M  "[    O0   +\   #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@
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M____________________________________________
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M^_S]_O]M9G0Q      ,!(0   0                    $
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M________X(,\       NA^W_____________________________K%,0
M   7;=;____________________________[@#$        )8<S_________
M___________________26@(         7<S_________________________
M__^H-0          7-/___________________________]]#0
M5-;__________________________^Y]10          1-3_____________
M______________RJ9"\"   $(C=)6,[____________________________I
MI&M!*#]C?Y6GNMK______________________________]6RK++,Y/K_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^6[EW=BR/______________________
M___________;GF<V"@ "C/_______________________________\A_/P4
M    7L______________________________V8$Y        /*K_________
M____________________GDP         (Y#_________________________
M___<;QH         $'WY__________________________^O2
M &_N__________________________^$$P           &3F____________
M_____________^Q1             %?>_________________________[@5
M             $C6_________________________W04             #C/
M________________________^:):$P           "/%________________
M_________]^;7"P           VZ___________________________OL7U5
M.2(1!P$"$2*R_______________________________?OZ69F)J@K+W:____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________C
MOIV ?/O________________________________RMX17, X ':S_________
M_____________________]**3!4      '+S________________________
M____UG\V         $O)___________________________ZD3X
M "^K___________________________ 6@           !J5____________
M______________^-)             B$_________________________^=>
M              !W_________________________[0E              !J
M_________________________WT               !;]/______________
M_________2L               !,Z_______________________I0
M           \X?______________________, P                MV?__
M__________________^9BF$G               GU___________________
M____[;Z)52<            EW/_________________________^RIUV74H\
M,BTL,#E'WO_______________________________>;=UM+0T]GD________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^_4N];_________________________
M________Y[B/:DLO%6_______________________________^2A9S0'
M #S)____________________________UH([         !*7____________
M_______________MA3$           !O__________________________^F
M0@            !0X?_______________________^QI               W
MR?_______________________[,O               BMO______________
M_________WD                0I_______________________\C0
M            F?______________________J0                  C/__
M____________________1@                  ?___________________
M___?                    =/____________________^7
M        :O_____________________.                    8_______
M________________*2(!                8?______________________
MN:. 5S<7            :/__________________________^M.NE(9\=7%P
M<G>!E/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________;NIV":6G3____________
M___________________(DV4]&0   !V>____________________________
MVXY,$P        !N___________________________;?"P           !%
MU_________________________^+*@             BM/______________
M_________\)$               #E________________________WT!
M            ?_______________________YS8                 :O__
M____________________G0                  6/__________________
M____1@                  1_C____________________I
M        ->G___________________^6                    )=O_____
M______________^\                    &,[____________________K
M                    #\+_____________________
M    "KG_____________________)P                  "K7_________
M____________<                   #;G_____________________X)R,
M<%5",R8;% \-#A(:)K_____________________________YY-C2SLS+S,_6
MX/S_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________KT[SC________________________________TJF%94@L$@&%
M____________________________\:MQ/ \       !/X/______________
M___________5?S4            ?LO_______________________^-U'0
M            B?_______________________Y C                9___
M____________________U4,                 2/;_________________
M____B@                  +MW_____________________.
M        %\C___________________^^                    !+;_____
M______________^<                     *7___________________^Z
M                     )/____________________<
M     (+_____________________                     '3_________
M____________$P                   &C_____________________0@
M                 &#_____________________>@
M %W_____________________T0                   &'_____________
M_________R0                  &;______________________\FLF8E]
M=G%L:6=F9VMP>HS_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________BQ:J1>6%W_____________________________]VF
M=U L#      QQ/_________________________@DDX3            C___
M_____________________])P'0              8/__________________
M____[F\/                -^+_____________________EAP
M        %,#_____________________0                    */_____
M______________^N                     (G___________________^>
M                     '+___________________^\
M     %_____________________:                     $W_________
M___________Z                     #O_____________________#@
M                 "KY____________________,P
M !OI____________________7@                    _;____________
M________CP                    ;0____________________T
M              #*_____________________RL                   #(
M_____________________X                    #+________________
M______<6 04% P$       $&#1C+_______________________\Z^'8S\S-
MS]#2U-?<XNK_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________\=K&____
M___________________________QQJ.$:$TR&  5J___________________
M________N7Q&&           <?_______________________]=\+P
M        .^/_____________________WV0)                #+7_____
M________________= ,                  (W____________________%
M%0                   &K___________________^9
M     $O___________________^V                     ##]________
M___________7                     !GG___________________V
M                  73____________________#@
M  #!____________________+P                    "O____________
M________4@                    ">____________________>0
M              ".____________________I0                    "
M____________________V                     !T________________
M_____S8                   !M_____________________WP
M          !I_____________________]<-                  !H____
M__________________]P                  !A____________________
M____4#Q&3E1976%D:&QP=GZ)____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________O
MU;NCBW-:E?__________________________^+^.9$$A!0      4OS_____
M__________________>=5A@             %\'_____________________
MY6P6                 (W_____________________8P
M     %[___________________^=                     #7\________
M__________^A                     !'9___________________*
M                  "[___________________N
M  "A____________________#                     "*____________
M________+0                    !V____________________30
M              !D____________________;P                    !2
M____________________E                     ! ________________
M____O                      P____________________Z@X
M           B_____________________T0                    5____
M_________________X$                    +]?__________________
M_\@+                   "[/____________________]>
M        Y?_____________________)'                   VO______
M________________G0$             !PX7Q?______________________
M_]6YO,''SM7;X>;M]/O_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________C?S_______________________
M_______LQJ6(;50[(0< ,M[________________________7DEDI
M     *#______________________XDV                 &?_________
M____________9@                   #+V__________________^5
M                  /(__________________^G
M  "@___________________7                      !\____________
M________                      !>____________________)0
M              !#____________________2                      L
M____________________:@                     8________________
M____BP                     %\___________________KP
M            X?__________________U0                      S___
M_________________R0                     OO__________________
M_U0                     KO___________________XL
M        G____________________\L.                    DO______
M______________]7                    AO____________________^J
M"@                  >?______________________;0
M    9O______________________]U4                 1?__________
M______________]J(RLU/TI58&IU?H>1G/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Z,^VG8-I3KG_________
M________________[+*#7#H= @       'O______________________\5M
M*0               $#_____________________@QL
M  ?+__________________^2                      "8____________
M______^D                      !J___________________=
M              !!____________________#@                     =
M____________________.0                      Z/______________
M____8                       SO__________________A0
M            M___________________J                       H___
M________________RP                      D/__________________
M[Q8                     ??___________________SX
M        ;/___________________VD                     6O______
M_____________YD                     2?___________________](6
M                    .?____________________]8
M    *?____________________^B                    &?__________
M___________U5@                  !/______________________NR\
M                 /C______________________ZLI
M ,_________________________)1P     '$R N/E)HA.W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________TU<G____________________________ZTK"2=UU"* P
M $K________________________%?447             !'8____________
M________Q%                    "?__________________^B#
M              !H__________________^4                       V
M___________________:                       '[/______________
M____%0                      Q/__________________2
M            HO__________________=0                      @___
M________________G0                      :?__________________
MPP                      4O__________________YP\
M        /O___________________S,                     *_______
M_____________U@                     &/___________________X$
M                    !?___________________ZP
M     /___________________]XB                     /+_________
M__________]<                     -____________________^?
M                 ,S____________________H2@
M +?_____________________H!8                  )S_____________
M_________WH"                 '?_______________________]Z"P
M            !4S_________________________HE=H=("-G*N\T.?_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[>/__________________________]*C
M>E@Z*2,<%@X&  "?_____________________ZQ2#@                !I
M___________________D0P                     T________________
M__]Y                        X__________________-
M            LO__________________$P                      A?__
M________________3P                      7?__________________
M@P                      .O__________________L@
M        '/__________________VP,                      O______
M_____________RH                      /O__________________T\
M                     .?__________________W0
M     -3__________________YL                      ,#_________
M_________\0'                     *W___________________ S
M                 )K___________________]G
M (;___________________^C                     '+_____________
M_______C1                    %S_____________________D08
M             $'_____________________ZU\                  !W_
M_____________________\I+                  #_________________
M_______+5P  #!@D,3].8'2+I\?__________________________]?G\O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^O4S<?"OKJWL["MJ:BE____________________W7Y3/S C&1$)
M @          V_________________]V                        I___
M______________^Z                        =?__________________
M!P                      1O__________________3@
M        &O__________________C                        /W_____
M____________P0                       -O_________________\1D
M                     +[__________________T0
M     *3__________________VL                      (W_________
M_________Y$                      'G__________________[<
M                 &;__________________]XA
M %/___________________]*                     #______________
M______]W                     "O___________________^L"@
M             !;____________________G10                    #_
M____________________B@                    #_________________
M____UDT                   #]_____________________Z<N
M          #5______________________^8*@          !A@M16#@____
M____________________J&-T@8^<J[O-XOK_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M        ,?__________________                         _______
M____________0@                       -S_________________C@
M                     ++_________________S@
M     (W__________________RD                      &O_________
M_________UH                      $[__________________X8
M                 #3__________________ZX
M ![__________________]07                      K_____________
M______H]                      #___________________]E
M              #___________________^.                      #_
M__________________^\&0                    #O________________
M___Q3@                    #8____________________BP
M          "_____________________S$,                   "A____
M_________________Y$9                  !Z____________________
M__)T"@               !%?_______________________H=!,?+#A%4V)R
MA9NTTO7__________________________]?H]/______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________^_?S\>[LZ^OL\?__________________V;*9
MAWEM9%U644M&03PX,BTH(\3_________________2R4+
M     )+_________________B                        &;_________
M________UP                       #W__________________S,
M                 !C__________________VP
M  #__________________YT                       #_____________
M_____\D,                      #V__________________$U
M              #?__________________];                      #+
M__________________^"                      "W________________
M__^I!@                    "C___________________3+P
M          "-____________________7@                    !W____
M________________DP<                   !>____________________
MS4,                   ! _____________________X<0
M       <_____________________]A>                    ________
M______________^_3@      #APL/E)JAJ7(________________________
MPGR,FJ>VQ=;H_?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[N'7S\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ
M-R\H(AP6$ L$     !3_________________UP4
M  #__________________S0                       #V____________
M_____W8                       #2_________________[
M              "R_________________^$D                      "6
M__________________]1                      !\________________
M__]Y                      !F__________________^@
M          !1___________________'(P                     \____
M_______________N2P                     G____________________
M=                      0____________________HQ8
M        ____________________V$P                     ________
M_____________X@/                    _____________________\M3
M                    ______________________^E.           "1TT
M3FN,________________________F3E#45]N?8Z@M<OE________________
M_____________^OY____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%,B,8#@8
M              ">_________________WX                       !U
M_________________\,                       !2________________
M__LW                       R__________________]J
M           6__________________^6                        ____
M______________^_&P                      ___________________F
M0@                      ____________________:0
M        ____________________D (                     ________
M____________N2P                     ]/__________________Z%P
M                    V?___________________Y$8
M    O/___________________\I3                    G?__________
M__________^8+@             0*49FQ/_____________________N?QT,
M&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________]]?#KYN+?V]C4TM'0TM?@________________
M_\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M            __________________]"                        ____
M______________]]                        __________________^P
M"P                      ]O_________________=.0
M        W/__________________8@                      Q?______
M____________B0                      K___________________KR(
M                    F?__________________UD@
M    @O___________________W(                     :?__________
M_________Z$H                    3O___________________]-<
M                ,_____________________^6+@              %3)2
M=______________________@<A,   $/'R]"6'"+J,CL________________
M________RF]N?HZ>L,/8[_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________YX-+(P+JUL*RHI:*?G9N;G*"G__________________^"
M9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M        K?_________________,'@                      B_______
M___________[4@                      ;?__________________@
M                    4?__________________J1L
M    .O__________________T$(                     (___________
M________]6@                     #/___________________X\4
M                 /___________________[@^
M /___________________^5M P                   /______________
M______^?-P              $"]0=/_____________________=<A0
M!A<J05IUE+;:________________________O%A$5&1UAIJOR./_________
M_____________________]+-X?'_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________S[^OO]____________
M___________NN:B=EH^*AH)_>WAV=')S=7A_D/_________________K3SHP
M*"$;%1 +!P(         (___________________:0
M     /__________________FPH                      /__________
M________R#D                      /__________________\&,
M                 /___________________XH.
M /___________________[ T                     /______________
M_____]5;                     /____________________^%&@
M             ^S___________________^Q20              &#E=@?__
M___________________E>QX       PA.%)OC[/9____________________
M____NU@I.4E:;("7L,WM_____________________________[.>M,77Z___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________KOY^'<V=;4TM#0T-'3V>#K]___________
M________N(I^=W%L:&1A7EM96%=765YE<?__________________OS$?%A *
M!0               /__________________[58
M .C__________________X($                     ,S_____________
M_____ZLO                     +/__________________])7
M             )O___________________=\$                    (7_
M__________________^B-P                 %*Y3_________________
M___+80(            ,+%!VGM'____________________UC3        TC
M.U=VF;[E________________________PV,8*CM,7W2-I\;G____________
M_________________ZA_EJB[T.?_________________________________
M___]________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________B$1!)
M0T-?4%)/1DE,10 *"O__________________________________________
M____________________________________________________________
M_____________________________________________]W.Q;^\N;:TL[&R
MLK6YP,G5X____________________Y=L9%Y955%/3$I(1T9(2U!99J'_____
M_____________Z<F#@<"                 %;__________________\Y0
M                     #K___________________1Y"P
M     "'___________________^?,@                    [_________
M___________$6                 @Q6H3____________________I?Q\
M          8G2W&:PNG_____________________ITD      A<O2FB*KM7\
M________________________TW4>)CA*7G6/J\OO____________________
M_________ZYRA9BLPMOV___________________________________?[___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________^_LJJFHZ&@GY^AHZ:L
MM,#-W>S___________________^*6E-/2TA&1$-"04)#1TY9:7W_________
M__________^>+@8                   #____________________#5@
M                %4'____________________G>QH             "31@
MB[3_____________________GS\         !"5*<9G"Z_______________
M________QF8/    $RI$8H.GS?7_________________________ZXXU*SY1
M:(&=O-[______________________________[YV?Y2IP=SY____________
M_______________________2V//_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________;R
M\._O[_'S^/W____________________________XL)^:EY:6EIB;GZ2LML+1
MX>[____________________^CE!*1T5$1$1%1D=+45IH@ZG_____________
M________ID$!           '-F./NN'_____________________QF4*
M   $)TQSG,3L________________________Y8@O   3*D1B@J;,]/______
M_____________________ZM0-DIA>Y:TUOK_________________________
M_____]*'?)BQR^G____________________________________4SNW_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^WEX^/D
MYNCM\?G______________________________;&4DI*5F9VCJ;*\T.W_____
M_____________________YU31TE-459@<XJOUOS_____________________
M_____[)6 !HU4&V+KM+W_____________________________\UO/E][F;?7
M^?_______________________________^Z?@Z;"X?__________________
M___________________CSNO_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________\
M
M
M     /______________________________________________________
M____________________________________________________________
M________________________________________________________
M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! @(" @(" @(" @(# P,# P,# P,#_\  % @ O0(D! $1  (1  ,1  01
M /_$ !X  0 " @,! 0$            *"P@)!08'! (#_\0 5!   00" @$#
M P $!PL%#0D   (#! 4!!@<("1$2"B$3%#%!(A51(W:V-[=X83)"%M87&#A8
MF#DS)#0E&G&!H;%28F.$U496=Y>1P=%#4V6U)BC_V@ .! $  @ #  0  #\
MG\$_@G\$_@
M
M
M
M
M
M
M
M                                      '4[_?=&U2ZT_6]IW34]:V+
MD.VFT&@4%_L=/3W6\WM;43=@L:73ZJQF1IVS6T"AK9$UZ-";?>:B,./*3AM"
ME8Z?L7(6@ZA>Z7J^V;QI^K[+R3<3M>X[UW8MEI:6]WZ_K*:=L=E1Z74V4V-/
MVFXKM>K),]^-!;?>9AQW7UIPVVM6 .V'<
M
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MKY:JZ^,I^]HF$H:F-(<LJUO$?$R'6@2A"5T
M
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M93][1,)0U,:0Y95K>(^)D.M E"$KH
M
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MI82G96Q:[%:3&KZOEJKKXRG[VB82AJ8TARRK6\1\3(=:!*$)70
M
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MI*FOR/\ D9["^33L)<<[<[6_XL"+^93\7<65$R2YI'$>D.2</QM9UF,_AO\
M*GROMMNVMJZVF7;2T_<<]C2(\=BH#\F/DQ['>4OL=<\_<_7/XE?$_-IN)^)Z
M:;*<T3AO1')6'XVK:M&?PW^782_MMNV]NZVF9;S$_<<^VTW'CQ_#MIS+MY"I
M$G.<X1C*66<9S]MAOU]?:WC_ ,K/I^UG]*L_][!^*N'(_)P^VO+32/HO/I_R
MN/UM>F?HK&?X?U?IQ]3.+PO^"SFGRJ[->[O=W5OPEU4TS]YU5]S0NB1:S]JW
M9$%68&D<:TT]^#$V2=7RWF'[F4IY$2MB?L*7F4\PTK/?PC> KF_RY;+L&\7]
MW<<%=2-)_>E1L'."]?1;6&V;VB O-=HW%])82*^'L]A6S'V)%W*4\B'60_XM
M3F93\=E7\=!URWS=MVT20Y @1E91+<]/5,]&?3*X"6U?LN)7Z8RI6?\ D_IG
M'[7H=J,$>_\ T [!^.'L'L/7[L#KWXTZ-]VUT7>JIJ2YI/*FDN276*S=-+LW
MVF_R8,G[?VY45SVRZV6E<:2A#J,XSKH\BGCK['>,GL=L?7/L9KGXMA%^];Z!
MO]0S*<T3EO1')3L>JWG1K60TW^57ROM_;E17/;,K)B7(LIM#J,XS[^#;QX'/
M/'MWCFVZLZ\=A[.\W+I+N5XK*T83+N-@Z[[!<2\KF;MI,-&'ID_1I\QY3]_0
M,)4K*E+L*]'YOY,:RW,_'S^09N7C.W*KZV=D[2^W?HEN]\I2T)3,N]CZU['=
MS,N3M[T2"WA^;8Z#8S7U2-BUV.E2\K4NQKD?G?E1;0"S=TO=-1Y'U'6M^T'9
M:/<M(W*CK=EU/;-:LHEQK^Q:_<1&IU5<4]K!=>ASZZ?#>0XTZVM25)5C.,EJ
M-H^\:;R;INK\B<=[10[OHF[T-7M&G[AJ]I#N]<V77+N&U85%W26]>Z_"L:VQ
MA/H=:=:6I"T*QG&0"(1\@_X^#'89C<>\G1O3F8W/T9F9L?.?!FN0T,L<XL,H
M7)L]^T&LC(2VUS$TVE3MA7M)PG:4XRZUC][^Y-I#(^1Y\<./V1C[MWXZ#Z2S
M%[$169NS<^\!:S"0Q'Y[CL(7*M>1..ZJ*A+;/-;+:5.V5:TG"=M3C+S./WU[
MDVX%?+0WVU:!M51LNM6]]INZZ;?0KFBO::;/H=EU?9:&>W+K[.LL(CD6RI[J
MGLHJ7&G6U-O,/-XSC*5)*XS7MAV[CO;J;:=6N=@TG>=)V"!=T%_23[#7MHU3
M:->L&YM;:U5E"<B6E+>4MI$0ZR\TMM^.^WA2<I4GZ 67/@(\]5)Y!==J.K79
MRTK==[I:C0O+I[O#4>KHNR&M4$%3\_9J2*PAF#5<FT]=&5(O:=E*&93*'+&O
M0F/B7%KK2#X[OR$Z'R-ZU3]3>U-K5ZUWETW7WETU[AF-54'9W5]>@+D6&TT,
M2.AB!4<J4M9%7)OZ5E+;$IEMRSKD)C8F1*T"3\2M
M                #2]Y.O.WT9\7K4O4.2MHG\K]AE0&)E7UUXH<K[7=8:)\
M3,JKL.0KB7)9UWC.DEH<9=];!Y5J_$?3(AU\QOU !"2[5?+D\G7-EA80N FN
M*^H>F.N/MU\?2M3J>4N0_P!WOI4A4:\WKE:JO:&3+2A><)E56NTCS>?12/:O
M&%  U#;?YB/*QO%EFUNO(IW)A2E*<5EK4.P?)?'M;ZN8:2KTIM!V'6J=*<89
MQ[<88QA&<JRGTRI7J /SJGF&\J^F3%3JCR*=RYCRG&'<HVOL-R;OD/"HV'L-
MX37;QL6Q5Z&U?D*^XC#6$.^B??A7L1[0!MNZM?+<\H?"=I6QN<Y'%O;?2V5)
M9LJ_?=-I^.-Z5 2I*L(I-[XIK=<K8=CA*/9^3:4=W[D*5E;:UYPM( GB^)GR
MS\+^6WA3;>5N*=!W_C"ZXUV6LTSDG2=[_<TY%3LEI3INXJM7V:CFNQ]HUYZ(
MK.$2GHE9*^XVK#D1O'LRL ;5@   :YO(MY4.GOB_XVB;YV:WQYG8=B9F9X[X
M=TMB%L'+O)<B#CTE?XKZL_85K$:FA.92B5;V<F!4175H:<DX?=9:< $#/N1\
MO'R'<V6EM4=6*#CSI]Q\ZI;%9,KJ6HY?Y??B*4IMY5MN7(%+)TB*J7'QCV)K
M=9ARH:EJ]DMQ>&W4@#2SMOF#\JVZ6B[>X\BO<V'+<4XI36I=B.4-!J\9=5A:
ML(I-%V37*9I.,X_9PF/C",?1/ICZ  [IQ?YP/+EQ#8Q+35/(/V9MI,*1^2RU
MRAR#,YNKEN>N<^V74<T-;_4SX_JK_DGV'&O3Z>WTQ@ $D+Q_?,<Y'J;VGT7R
M.<0T&W:A)<9A+YWX%IW->W2CPK[;?[SW'BZ=:2-:VR/EU:EONTC](Y'83_%0
M);G[*@!.]X/YTX?[*\6ZAS9P-R'K/*?%>^5C=MJVZ:G/3.JK&,K.6WX[R5):
MFU=O6R4+CS8$QIB= E-N,266GFUMI 'K    *UOR4?([\L/7#O\ =P^!>)^<
MM+H^,^(>PG)N@:+3S>$>);N76:QK6RSJVHA2;>VU.79V3S$1E*5//NN.N9QZ
MJ5G( ,(_^U2^:/\ VA]!_P!WWA7_ "+ !,&\MGR0N)/'!JNK</\ &%!2=A^Z
MNP\?:QLE[JS]CF'QCPX[L.OP+.#8\MRZ*2Q;2;ZVQ,3+B:O6KB3'("L/R9=<
MT]"5+ $&#L'Y_O+MV-NY]IL'=CEOC.NE2/N0=7Z^7"N!*2DCX=:>:@0)?&/^
M+VTS8[2VL8^Y8V4Z4M&5)<>6E6<9 'D?'_F<\L/&EPQ>:YY#^V]E-CR&I+;'
M('->Z<LTZG&4K2A+^O<J6>Y4$F/G#F?>TY&6TYGTRI.<IQZ "YU !%L^3EY/
M>XGC2T7J%>=1=_HM#L>6]MYAJMX=O-"TW>D64+4*?CZ91-QVMOI[=NN5&?OY
M65*8PVIW"\85G.$I] !$2_[5+YH_]H?0?]WWA7_(L $T3XTWD3[5>2'JESQR
MGVSW>FWG<]%["/:!K=C2:5JFCQXFL(XWT?8DPG:_4JJIA2WL6MW(7]YU"G?:
MO"?=[4XQ@ 2/      55>_?*/\RU#O6Z4=;V"T-FNIMMV.JKVE\ \,/+:A5U
MQ,AQ6U.NZ8IQU2&&4XRI6<J5G'KG/J #UCJ1\F7R^<L=K>L?%F[\]:/9:9R7
MV$X7T#;JZ/P3P_72)^L;ER1K>NW\)BP@Z@Q-@O2JJQ=0EYE:'6E*PI"L*QC(
M +/P   &*O<;NMUJZ$<+7//?:/DNJXXT*L>Q6UJ7T/6.S;GLK\>1)KM.T76(
M*7K?:=HLVXKBD1X[>4L,-N29*V(K+[[8 @7]X?F+=JN1KNVUSHAQ7J?7/CYM
M3\>JY$Y1J:CE#FFT1_&ICV_[@EKF\4:8I2'$Y57.1-FPAQO&?S5H5EO  T(\
MB^:SRT\I3UV.S>0OM562%O(?RWQURQL7#\#"T?E>U**OB21I%8VSG\Q?JVEG
M#:O1'JG/VF_8 .ETGEO\INOSL6$#R-=WGW\-J:PW=]H.9ME@^U2T+SG-9L>X
MVM:ISU;QZ+RU[\8]<8SZ*SC( V)=>_E'>8/@NPB9V'G/4NQ&LQE-^[4N>>,]
M5N&7$X<QE]2MOT*+Q]R0Z\\WCVXR]=/--_I2WZY5[@!,J\-/R/\ C+RD<GPN
ML^Z<";5PCV-5IM[M[+M#>0=XX@VBMU*/$<V"1 NY::';=5LW<2L/,5LFOGL)
M:2I.;%QS"<. "3     #I7)/(ND\0\?;MRKR3L5=J/'_ !SJM]NVZ[1;._9K
M:#6-9K)-O=6LQ>,*7]F%7Q'%Y2G"EKSCVIQE6<8ST;D_DO1>&>.-[Y<Y/V6M
MTWCGC/4=@WO>=KN'?LUFO:IJU7*N;VWFN8PI?V8-=#<<RE"5+7G'M2E2LXQD
M?AQ'OQZ?P?H*BKR[>3KDORC=J]CY:OY-M2<-:@_9:GUWXMDO^R#HW';4S/VK
M6? 8==AKW_>5,-V%],]SSBG\M0T.JA08;;5-7YE?*MREY8>W>S<Q[#+N*'A'
M3)%GI_6SB:5(]D#0>-6IO\3;6-='>=@N<B;\J.W9;#-]SSJG\M0FWE08$%MK
MXIL;\A'\/MQGTQ_W?TYQ_=R?#^)]Q7[7T3C/U_AS_<Q_^)E'X/?"!R'Y1^2_
M\X?(?[ZT#ICQKL+,/D??XB?P[OD:]AHBSWN*.,GGVW&U74B'):5:VF4.1Z2(
M^E6<.2G8[#F6_@6\#_)/EBY1_P Y/)&+SCOI#Q?LC,+DWD.(G\.]Y+V"$B+8
MO\0\5OR&G&UWDF')95;VWL<C44.0E6<.2GHT=SJ^->3,?_CO5$=.?XS./HI?
M_F(_@SG]>?U8.02E*$X2G&$I3CTQC'Z,8+23B;B;C;@KC;3.'^'],H>/.,N/
M*&'K6F:9K4-,&FHJ:"G/VH\=KU6Z^^^ZM;TB0\MR3+DN./ON./.+6JV.X@X@
MXQX!XQTCACAC2-?XWXLXWU^%J^DZ3J\),"EH*6 G.&HT9K&5O/R'WEK?DR7U
MNRIDIUQ]]QQYQQQ7<&66H[3;##:6FFDX0VVC'HE*<?JQC^'/Z\_ISDXBQM<0
M\X;:2EUWW)RYC.<X2A'TSE.<X_\ S%)_1_!^G^YF&5\L3R.]/K+C6+T$J-%T
M[G3M#2[%4;;9[TN0[EOJAC"X<J9%A7E1)CRY7)&]TC:8LFB4ZJ#'KG42K%I3
MR(#2H1_R^/)7TNN>+HOCQJ=!TOGOM91[)3[A9\@*D.J1U!_;A2YD6#?4TF/,
ME\F;_1MIB2M?4\J!'K'D2[)I3R*]I7G>Z[^G7%MPZUAJ?88<;7+0XI6&([&%
M84MI2F\X5^4\CZ)Q]<(]?<K&?HG/WQ93,QE+S*O7&?HI.?[Y"OUI5C]6<?\
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MF1*F2.+H]4_HLN2^ZZ]+DS)'$>Q:[F4^]G+LB9AYS.<^[UR -\0 *8KS._\
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MAO$38=UX_H+[8H'M2E",*KKR;(8S[,?;SEO.49RGTSD#)@RE
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M<5[+3HRTWAM/X6O<J\@4%<G*<9SZN)KZQK"U?X:\95^L W$&ZH
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M[B>HX)U^=(:3F-.VSDS::7=[W-:YE&<YGZYK_&\9$C.%)RAF[;Q]<.?3<_\
M"7ZR7-[V/[<=P+"O<1JO''#]-U_UR?)93F+/W#E/;*/>]@S6.J0K.;#6-<XQ
MBMR<I4G+;%ZWCT5AW]D"<%W+YFB==>I/9GG>9+3#3Q'P1RKO\5W,A^*MVUUG
M2KFSI(4=^,ZQ*;FV5PPQ'8^TM#N7G4X1G"LXR3SN[G-\/K5TY[3=@9LM,)/#
M?7[ESD6([F0_$6[;ZMHMY:T4&-(BNL2FYUG=1X\:/]I:'<ONHPA6%9QD I.R
MBH +C/P[\9RN(O%MT.TF?$;@6#?6CC/:K*$AAN,J)9<B4C7(EC&DM--M)Q/9
MF[4M,G.<94N1A:E*4K.59NNO"MQ;+X:\37CYT2PAMU]DWU;XMVVS@(CMQE0[
M3DJA9Y)LHLIEIII.+!B=MKB9.<XRI<C"U*4I6<JR!LE-GP
M             !"[^:;QE97/4?IYR]&:E.UO'W87;-"LU,^BH\=?*?'DB[@2
M);>&%N(3]SBE;2'?N(;2MW",X4IQ'M %<V "R,^&5S]4[=TB[']<I$[[NV<+
M=AL<@,PW)*/5G0N9M*H8E*F+$4K+WVV=PXUOG'EIQ]O"I3>/3"LYRH 3'
M       8F]]] G<L=%^Z/%E6EY=GR5U-[&:!7(C_ /2%3MRX?W'78B6/XF1_
M'*D6*<)_BU_M>G[*OT9 %(2 #?+\:^RX9=\M7!?'G/&A<><B:%S3JW*/%R*7
MD_3M5WC5F=KFZ78[;IKZJC;:NWA,VMALFGQJV&^PVF3B1/2W[\-..XR +0S_
M $ >B'^Q1U(_W;^'/\C0 /\ 0!Z(?[%'4C_=OX<_R-  _P! 'HA_L4=2/]V_
MAS_(T #_ $ >B'^Q1U(_W;^'/\C0 /\ 0!Z(?[%'4C_=OX<_R- !ZMQ=UXX
MX.?N97"O!O#W#\K8F84?8)/%W&>E<?OWK%:N2Y7,7+VITE2Y9LP')CRF4OY6
MEI3J\IQC*E>H ]A !3%>9W_BQ>0_^UOS7_/2S !K, !>U\5?T7\;_P @M/\
MYO5P .^@     @T_-G_HN\?'\ONP_P#-WB0 %?: "R,^%U_J']I_[7$C^IOC
M$ $QP     %$KRM_2CR3_+[<?YQ6( />N@'^OATG_M<=;OZY-, !=X
MPZ[9^/SI?WHU].O=KNN7&G,:6(3M=5['>TV:WD#7H;V'_?'U;DO7'Z;D#5F<
MKDK7E%?9QDY<]%YQE6,9P (N_:[X9'6?<_WA>].NS')/!]LMN3)CZ+R]3U_,
M.BO2_P"-S%JZW8JI[2-VU>LSZH2J1,5LLA'M5GVK]V,) $5_O/\ 'J\GG0RF
MO=YWKAB+S!Q!KR7Y%IR_UZM9').LU5=';4^_;;'K>:RFY,U2FAQT^Z3865%&
MK6,^N,R<_3.0!I$ !G=XVN]_)GCB[?\ $_:'CF58/Q=5NXU7R;IL24IB+R5Q
M)<3(C6^Z)/;4\U$=<M*EK+U>Z_A;<&WCQ)?M4J.G  +IK4MIH=YU76=VU6Q9
MM]8W'7Z;:=<MH_N_'M*'8:V-;4]BQ[\)7]F;7RVW4^N,9]JL>H .P   KO\
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MV;DJ=M.*.68=;$?V;5);;V?RI%*\\]^733U8PFQJGF7<X0]]YEH ;$P
M      4Q7F=_XL7D/_M;\U_STLP :S  7M?%7]%_&_\ (+3_ .;U< #OH
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MR9'J&9/XK"94V0[+M[+$=G,Z9)6TVI( P7 !EQT _P!?#I/_ &N.MW]<FF
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MK3G"L8SCT !QP /TA"W%I;;2I:UJ2A"$)RI:UJSA*4I2G&<J4K.?3&,?7.0
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MQ4J),O2.$-8M8S;=KIW&SUC'B2K78+E.5-7&PNQX[K\?_F4-IB+F4Y8 "2>
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M$1:ZHI*6K8BUU76P8S:6VF&6T-MHQC"<8P <^=B
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M'T_CK3*A*T5.HZ)K5+J.L5:'%>Y::ZAU^%7U4)*U?7.&FDXSD '<
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MOHNIU#>6:G5]-H*K6-=K&LY]V6JZDI(D&MA-Y5]?:VTG'J =D.T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
-              __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cers-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-04T01:24:33.0744239+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:cers="http://www.cerus.com/20200331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cerus.com/20200331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.cerus.com/20200331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cers-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cers-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cers-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cers-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments" id="Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments">
        <link:definition>100070 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories" id="Role_DisclosureInventories">
        <link:definition>100080 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100090 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100120 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements" id="Role_DisclosureDevelopmentAndLicenseAgreements">
        <link:definition>100150 - Disclosure - Development and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation" id="Role_DisclosureSegmentCustomerAndGeographicInformation">
        <link:definition>100160 - Disclosure - Segment, Customer and Geographic Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables" id="Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables">
        <link:definition>100190 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables" id="Role_DisclosureInventoriesTables">
        <link:definition>100200 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100210 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100220 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100230 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables" id="Role_DisclosureDevelopmentAndLicenseAgreementsTables">
        <link:definition>100250 - Disclosure - Development and License Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables" id="Role_DisclosureSegmentCustomerAndGeographicInformationTables">
        <link:definition>100260 - Disclosure - Segment, Customer and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail" id="Role_DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail">
        <link:definition>100290 - Disclosure - Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail" id="Role_DisclosureSummaryOfAvailableForSaleSecuritiesDetail">
        <link:definition>100300 - Disclosure - Summary of Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail" id="Role_DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail">
        <link:definition>100310 - Disclosure - Available-for-Sale Debt Securities by Original Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" id="Role_DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail">
        <link:definition>100320 - Disclosure - Available-for-Sale Marketable Securities in Unrealized Position (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail" id="Role_DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail">
        <link:definition>100340 - Disclosure - Fair Values on Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail" id="Role_DisclosureInventoriesDetail">
        <link:definition>100350 - Disclosure - Inventories (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail" id="Role_DisclosureAccruedLiabilitiesDetail">
        <link:definition>100360 - Disclosure - Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail" id="Role_DisclosureDebtDetail">
        <link:definition>100370 - Disclosure - Debt (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" id="Role_DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail">
        <link:definition>100380 - Disclosure - Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail" id="Role_DisclosureDebtAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail">
        <link:definition>100410 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2" id="Role_DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2">
        <link:definition>100430 - Disclosure - Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail" id="Role_DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail">
        <link:definition>100460 - Disclosure - Activity Under Equity Incentive Plans Related to Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail" id="Role_DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail">
        <link:definition>100470 - Disclosure - Activity Under Equity Incentive Plans Related to RSUs (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Development and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail" id="Role_DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail">
        <link:definition>100500 - Disclosure - Development and License Agreements - Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail" id="Role_DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail">
        <link:definition>100510 - Disclosure - Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail" id="Role_DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail">
        <link:definition>100520 - Disclosure - Segment, Customer and Geographic Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail" id="Role_DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail">
        <link:definition>100530 - Disclosure - Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cers_DebtInstrumentCarryingCurrent" name="DebtInstrumentCarryingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_DebtInstrumentUnamortizedCurrent" name="DebtInstrumentUnamortizedCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_DebtInstrumentCarryingNonCurrent" name="DebtInstrumentCarryingNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_DebtInstrumentUnamortizedNoncurrent" name="DebtInstrumentUnamortizedNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_GrossProfitOnProductRevenue" name="GrossProfitOnProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" name="IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" name="IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_NonCashOperatingLeaseCost" name="NonCashOperatingLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" name="IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_DevelopmentAndLicenseAgreementsTextBlock" name="DevelopmentAndLicenseAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_DevelopmentAndLicenseAgreementsAbstract" name="DevelopmentAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_AvailableForSaleSecuritiesPolicy" name="AvailableForSaleSecuritiesPolicy" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_TwoThousandEightEquityIncentivePlanMember" name="TwoThousandEightEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" name="SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_EuropeMiddleEastAndAfricaMember" name="EuropeMiddleEastAndAfricaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_OtherMember" name="OtherMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_PaymentOfCustomerInvoiceContractPeriod" name="PaymentOfCustomerInvoiceContractPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" name="CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cers_InventoryLifeFinishedGoodsPeriod" name="InventoryLifeFinishedGoodsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_WorkInProcessInventoryLifePeriod" name="WorkInProcessInventoryLifePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_EmployeeStockPurchasePlanRightsMember" name="EmployeeStockPurchasePlanRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_ProductWarrantyTerm" name="ProductWarrantyTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_AccruedDevelopmentCostsCurrent" name="AccruedDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_TermLoanCreditAgreementMember" name="TermLoanCreditAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" name="LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_RepaymentsPrincipalAndInterestAggregateAmount" name="RepaymentsPrincipalAndInterestAggregateAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_DebtPrepaymentFee" name="DebtPrepaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_DebtInstrumentAvailableAmountUponCondition" name="DebtInstrumentAvailableAmountUponCondition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" name="DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_InterestOnlyPaymentPeriod" name="InterestOnlyPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_TrailingNetRevenueTarget" name="TrailingNetRevenueTarget" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_NumberOfEqualTranches" name="NumberOfEqualTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_DebtInstrumentInterestOnlyPaymentsDate" name="DebtInstrumentInterestOnlyPaymentsDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_OxfordTermLoanAgreementMember" name="OxfordTermLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_TrancheOneMember" name="TrancheOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_TrancheTwoMember" name="TrancheTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_TrancheThreeMember" name="TrancheThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_TwoThousandSeventeenTermLoanMember" name="TwoThousandSeventeenTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_TwoThousandNineteenTermLoanMember" name="TwoThousandNineteenTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_MinimumTermOfNonCancelableOperatingLeases" name="MinimumTermOfNonCancelableOperatingLeases" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" name="ExpirationOfNonCancelableOperatingLeasesMaximumYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_MaximumAmountAvailableUnderOffering" name="MaximumAmountAvailableUnderOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" name="PercentageOfProceedsPayableAsCompensationToUnderwriter" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_CommonStockSharesUnsoldValue" name="CommonStockSharesUnsoldValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_CommonStockSharesAvailableForSaleValue" name="CommonStockSharesAvailableForSaleValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_UncategorizedAbstract" name="UncategorizedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_StockholdersEquityNoteLineItems" name="StockholdersEquityNoteLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_StockholdersEquityNoteTable" name="StockholdersEquityNoteTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_CantorFitzgeraldCoMember" name="CantorFitzgeraldCoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_SalesAmendmentThreeMember" name="SalesAmendmentThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_SalesAgreementMember" name="SalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_PerformanceUnitsAndCashBasedAwardsMember" name="PerformanceUnitsAndCashBasedAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cers_PerformanceBasedStockOptionsOutstanding" name="PerformanceBasedStockOptionsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cers_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_CerusEuropeBVMember" name="CerusEuropeBVMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_ManufacturingAndDevelopmentPaymentLiability" name="ManufacturingAndDevelopmentPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_PaymentsForManufacturingAndDevelopmentCost" name="PaymentsForManufacturingAndDevelopmentCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_LicensesAgreementsLineItems" name="LicensesAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_LicensesAgreementsTable" name="LicensesAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_ManufacturingAndSupplyAgreementsMember" name="ManufacturingAndSupplyAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_FreseniusKabiAGMember" name="FreseniusKabiAGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_CerusCorporationMember" name="CerusCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_UnamortizedDeferredCostForDevelopmentActivities" name="UnamortizedDeferredCostForDevelopmentActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_ManufacturingEfficiencyAssets" name="ManufacturingEfficiencyAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" name="DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" name="DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_PaymentForManufacturingOfEntityProducts" name="PaymentForManufacturingOfEntityProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_AccrualForManufacturingOfEntityProducts" name="AccrualForManufacturingOfEntityProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" name="BasePeriodMaximumFundingOfCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" name="OptionPeriodMaximumFundingOfCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_CoInvestmentForCollaborativeAgreement" name="CoInvestmentForCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_AdditionalCoInvestmentForCollaborativeAgreement" name="AdditionalCoInvestmentForCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_CoInvestmentForCollaborativeAgreementIncurred" name="CoInvestmentForCollaborativeAgreementIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" name="BasePeriodAdditionalFundingOfCollaborativeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cers_EtablissementFrancaisDuSangMember" name="EtablissementFrancaisDuSangMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cers_AmericanRedCrossMember" name="AmericanRedCrossMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cers-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-04T01:24:33.0744239+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cers-20200331.xsd#TemplateLink" roleURI="http://www.cerus.com/20200331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SecuredLongTermDebt" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_SecuredDebtCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cers-20200331.xsd#cers_GrossProfitOnProductRevenue" xlink:type="locator" xlink:label="cers_GrossProfitOnProductRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="cers_GrossProfitOnProductRevenue" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_GrossProfitOnProductRevenue" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_GrossProfitOnProductRevenue" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10140.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashInterestExpense" xlink:type="locator" xlink:label="cers_NonCashInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashOperatingLeaseCost" xlink:type="locator" xlink:label="cers_NonCashOperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cers_NonCashOperatingLeaseCost" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cers_NonCashInterestExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureInventoriesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AccruedDevelopmentCostsCurrent" xlink:type="locator" xlink:label="cers_AccruedDevelopmentCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cers_AccruedDevelopmentCostsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedNoncurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingNonCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="cers_DebtInstrumentCarryingNonCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="cers_DebtInstrumentUnamortizedNoncurrent" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredDebtCurrent" xlink:to="cers_DebtInstrumentCarryingCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredDebtCurrent" xlink:to="cers_DebtInstrumentUnamortizedCurrent" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10060.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cers-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-04T01:24:33.0744239+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="cers-20200331.xsd#TemplateLink" roleURI="http://www.cerus.com/20200331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="cers-20200331.xsd#cers_GrossProfitOnProductRevenue" xlink:type="locator" xlink:label="cers_GrossProfitOnProductRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentContractMember" xlink:type="locator" xlink:label="us-gaap_GovernmentContractMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10150.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_GrossProfitOnProductRevenue" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11040.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cers-20200331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OtherMember" xlink:type="locator" xlink:label="cers_OtherMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NorthAmericaMember" xlink:type="locator" xlink:label="srt_NorthAmericaMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EuropeMiddleEastAndAfricaMember" xlink:type="locator" xlink:label="cers_EuropeMiddleEastAndAfricaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cers_EuropeMiddleEastAndAfricaMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cers_OtherMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ProductWarrantyTerm" xlink:type="locator" xlink:label="cers_ProductWarrantyTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:loc xlink:href="cers-20200331.xsd#cers_WorkInProcessInventoryLifePeriod" xlink:type="locator" xlink:label="cers_WorkInProcessInventoryLifePeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_InventoryLifeFinishedGoodsPeriod" xlink:type="locator" xlink:label="cers_InventoryLifeFinishedGoodsPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" xlink:type="locator" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentOfCustomerInvoiceContractPeriod" xlink:type="locator" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_PaymentOfCustomerInvoiceContractPeriod" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_InventoryLifeFinishedGoodsPeriod" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_WorkInProcessInventoryLifePeriod" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_ProductWarrantyTerm" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent" order="11510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail" xlink:href="cers-20200331.xsd#Role_DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanRightsMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanRightsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cers_EmployeeStockPurchasePlanRightsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedNoncurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingNonCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentCarryingCurrent" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentUnamortizedCurrent" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebtCurrent" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentCarryingNonCurrent" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentUnamortizedNoncurrent" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredLongTermDebt" order="11340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10160.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_TrailingNetRevenueTarget" xlink:type="locator" xlink:label="cers_TrailingNetRevenueTarget" />
    <link:loc xlink:href="cers-20200331.xsd#cers_InterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="cers_InterestOnlyPaymentPeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" xlink:type="locator" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentInterestOnlyPaymentsDate" xlink:type="locator" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentAvailableAmountUponCondition" xlink:type="locator" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtPrepaymentFee" xlink:type="locator" xlink:label="cers_DebtPrepaymentFee" />
    <link:loc xlink:href="cers-20200331.xsd#cers_RepaymentsPrincipalAndInterestAggregateAmount" xlink:type="locator" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NumberOfEqualTranches" xlink:type="locator" xlink:label="cers_NumberOfEqualTranches" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandNineteenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandNineteenTermLoanMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandSeventeenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandSeventeenTermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheThreeMember" xlink:type="locator" xlink:label="cers_TrancheThreeMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheTwoMember" xlink:type="locator" xlink:label="cers_TrancheTwoMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheOneMember" xlink:type="locator" xlink:label="cers_TrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OxfordTermLoanAgreementMember" xlink:type="locator" xlink:label="cers_OxfordTermLoanAgreementMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_OxfordTermLoanAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheOneMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheTwoMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheThreeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cers_TwoThousandSeventeenTermLoanMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cers_TwoThousandNineteenTermLoanMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_NumberOfEqualTranches" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_RepaymentsPrincipalAndInterestAggregateAmount" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtPrepaymentFee" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentAvailableAmountUponCondition" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentInterestOnlyPaymentsDate" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_InterestOnlyPaymentPeriod" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_TrailingNetRevenueTarget" order="11240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesAvailableForSaleValue" xlink:type="locator" xlink:label="cers_CommonStockSharesAvailableForSaleValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesUnsoldValue" xlink:type="locator" xlink:label="cers_CommonStockSharesUnsoldValue" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:type="locator" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" />
    <link:loc xlink:href="cers-20200331.xsd#cers_MaximumAmountAvailableUnderOffering" xlink:type="locator" xlink:label="cers_MaximumAmountAvailableUnderOffering" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="cers_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAgreementMember" xlink:type="locator" xlink:label="cers_SalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAmendmentThreeMember" xlink:type="locator" xlink:label="cers_SalesAmendmentThreeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CantorFitzgeraldCoMember" xlink:type="locator" xlink:label="cers_CantorFitzgeraldCoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteTable" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteLineItems" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_StockholdersEquityNoteTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cers_CantorFitzgeraldCoMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cers_SalesAmendmentThreeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cers_SalesAgreementMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cers_UnderwrittenPublicOfferingMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_MaximumAmountAvailableUnderOffering" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_CommonStockSharesUnsoldValue" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_CommonStockSharesAvailableForSaleValue" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceBasedStockOptionsOutstanding" xlink:type="locator" xlink:label="cers_PerformanceBasedStockOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceUnitsAndCashBasedAwardsMember" xlink:type="locator" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_EmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cers_PerformanceUnitsAndCashBasedAwardsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_PerformanceBasedStockOptionsOutstanding" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail" xlink:href="cers-20200331.xsd#Role_DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10930.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail" xlink:href="cers-20200331.xsd#Role_DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusEuropeBVMember" xlink:type="locator" xlink:label="cers_CerusEuropeBVMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cers_IncomeTaxDisclosureLineItems" xlink:to="cers_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cers_CerusEuropeBVMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:type="locator" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreementIncurred" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AdditionalCoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentForManufacturingOfEntityProducts" xlink:type="locator" xlink:label="cers_PaymentForManufacturingOfEntityProducts" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentsForManufacturingAndDevelopmentCost" xlink:type="locator" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusCorporationMember" xlink:type="locator" xlink:label="cers_CerusCorporationMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_FreseniusKabiAGMember" xlink:type="locator" xlink:label="cers_FreseniusKabiAGMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndSupplyAgreementsMember" xlink:type="locator" xlink:label="cers_ManufacturingAndSupplyAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsTable" xlink:type="locator" xlink:label="cers_LicensesAgreementsTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsLineItems" xlink:type="locator" xlink:label="cers_LicensesAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_LicensesAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cers_ManufacturingAndSupplyAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_LicensesAgreementsTable" xlink:to="dei_LegalEntityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cers_FreseniusKabiAGMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cers_CerusCorporationMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_ManufacturingAndDevelopmentPaymentLiability" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_PaymentsForManufacturingAndDevelopmentCost" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_PaymentForManufacturingOfEntityProducts" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_CoInvestmentForCollaborativeAgreement" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_AdditionalCoInvestmentForCollaborativeAgreement" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_CoInvestmentForCollaborativeAgreementIncurred" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="11010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingEfficiencyAssets" xlink:type="locator" xlink:label="cers_ManufacturingEfficiencyAssets" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UnamortizedDeferredCostForDevelopmentActivities" xlink:type="locator" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_UnamortizedDeferredCostForDevelopmentActivities" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_ManufacturingEfficiencyAssets" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AmericanRedCrossMember" xlink:type="locator" xlink:label="cers_AmericanRedCrossMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EtablissementFrancaisDuSangMember" xlink:type="locator" xlink:label="cers_EtablissementFrancaisDuSangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_MajorCustomersAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cers_EtablissementFrancaisDuSangMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cers_AmericanRedCrossMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cers-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-04T01:24:33.0744239+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingCurrent" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion carrying value of the debt instrument before deducting unamortized discounts (if any).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentCarryingCurrent" xlink:to="cers_DebtInstrumentCarryingCurrent_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedCurrent" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of the unamortized discounts on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentUnamortizedCurrent" xlink:to="cers_DebtInstrumentUnamortizedCurrent_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingNonCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-current portion carrying value of the debt instrument before deducting unamortized discounts (if any).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentCarryingNonCurrent" xlink:to="cers_DebtInstrumentCarryingNonCurrent_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedNoncurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-current portion of the unamortized discounts on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentUnamortizedNoncurrent" xlink:to="cers_DebtInstrumentUnamortizedNoncurrent_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt &#8211; current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities &#8211; current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred product revenue &#8211; current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt &#8211; non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities &#8211; non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_GrossProfitOnProductRevenue" xlink:type="locator" xlink:label="cers_GrossProfitOnProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="cers_GrossProfitOnProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross profit on product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_GrossProfitOnProductRevenue" xlink:to="cers_GrossProfitOnProductRevenue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentContractMember" xlink:type="locator" xlink:label="us-gaap_GovernmentContractMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GovernmentContractMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractMember" xlink:to="us-gaap_GovernmentContractMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GovernmentContractMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_GrossProfitOnProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_GrossProfitOnProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit On Product Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-operating expense, net:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used for calculating net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (losses) gains on available-for-sale investments, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" />
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" />
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from public offerings, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from public offering, net of offering costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashOperatingLeaseCost" xlink:type="locator" xlink:label="cers_NonCashOperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="cers_NonCashOperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_NonCashOperatingLeaseCost" xlink:to="cers_NonCashOperatingLeaseCost_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashInterestExpense" xlink:type="locator" xlink:label="cers_NonCashInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="cers_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_NonCashInterestExpense" xlink:to="cers_NonCashInterestExpense_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued liabilities and other non-current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" xlink:to="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" />
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in manufacturing and development payment liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" xlink:to="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NonCashOperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NonCashOperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Manufacturing And Development Payment Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities and sale of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from equity incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from public offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net payment on revolving line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Lines Of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities and Fair Value on Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cers_DevelopmentAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DevelopmentAndLicenseAgreementsTextBlock" xlink:to="cers_DevelopmentAndLicenseAgreementsTextBlock_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DevelopmentAndLicenseAgreementsAbstract" xlink:to="cers_DevelopmentAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DevelopmentAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DevelopmentAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And License Agreements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment, Customer and Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_AvailableForSaleSecuritiesPolicy" xlink:type="locator" xlink:label="cers_AvailableForSaleSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="cers_AvailableForSaleSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_AvailableForSaleSecuritiesPolicy" xlink:to="cers_AvailableForSaleSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_AvailableForSaleSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AvailableForSaleSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Remeasurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantee and Indemnification Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees Indemnifications And Warranties Policies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Product Revenue by Geographical Locations of Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Effect of Common Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Debt Securities by Original Contractual Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Marketable Securities in Unrealized Position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrealized Loss On Investments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Values of Financial Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information Related to Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Non-Cancelable Lease Payments Under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eight equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TwoThousandEightEquityIncentivePlanMember" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2008 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eight Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Activity Under Equity Incentive Plans Related to Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Activity Under Equity Incentive Plans Related to RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" xlink:type="locator" xlink:label="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of amounts payable and receivable under agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" xlink:to="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amounts Payable and Amounts Receivable from Fresenius</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Amounts Payable And Receivable Under Agreement Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer that Accounted for More Than Ten Percent of Total Product Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_EuropeMiddleEastAndAfricaMember" xlink:type="locator" xlink:label="cers_EuropeMiddleEastAndAfricaMember" />
    <link:label xml:lang="en-US" xlink:label="cers_EuropeMiddleEastAndAfricaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Europe, middle east and africa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_EuropeMiddleEastAndAfricaMember" xlink:to="cers_EuropeMiddleEastAndAfricaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_EuropeMiddleEastAndAfricaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe, Middle East and Africa</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_EuropeMiddleEastAndAfricaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Europe Middle East And Africa [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NorthAmericaMember" xlink:type="locator" xlink:label="srt_NorthAmericaMember" />
    <link:label xml:lang="en-US" xlink:label="srt_NorthAmericaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NorthAmericaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">North America [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_OtherMember" xlink:type="locator" xlink:label="cers_OtherMember" />
    <link:label xml:lang="en-US" xlink:label="cers_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_OtherMember" xlink:to="cers_OtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total product revenue</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentOfCustomerInvoiceContractPeriod" xlink:type="locator" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of customer invoice contract period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PaymentOfCustomerInvoiceContractPeriod" xlink:to="cers_PaymentOfCustomerInvoiceContractPeriod_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cers_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment of customer invoice contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Performance Obligation Description Of Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of customer invoice contract period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Customer Invoice Contract Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized, that were included in deferred product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Application of an optional exemption not to disclose the value of unsatisfied performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Practical Expedient Remaining Performance Obligation</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" xlink:type="locator" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" />
    <link:label xml:lang="en-US" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customers whose outstanding trade receivables by a single customer accounts for 10 percent or more of an entity&apos;s trade receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" xlink:to="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of major customers representing outstanding trade receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Outstanding Trade Receivables Number Of Major Customers</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_InventoryLifeFinishedGoodsPeriod" xlink:type="locator" xlink:label="cers_InventoryLifeFinishedGoodsPeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_InventoryLifeFinishedGoodsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory life finished goods period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_InventoryLifeFinishedGoodsPeriod" xlink:to="cers_InventoryLifeFinishedGoodsPeriod_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_WorkInProcessInventoryLifePeriod" xlink:type="locator" xlink:label="cers_WorkInProcessInventoryLifePeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_WorkInProcessInventoryLifePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Work in process inventory life, period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_WorkInProcessInventoryLifePeriod" xlink:to="cers_WorkInProcessInventoryLifePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_InventoryLifeFinishedGoodsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shelf lives of inventory</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_InventoryLifeFinishedGoodsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Life Finished Goods Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_WorkInProcessInventoryLifePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Protracted length of inventory</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_WorkInProcessInventoryLifePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Work In Process Inventory Life Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory valuation reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash purchases of capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite Lived Intangible Assets Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment charges acquired intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanRightsMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanRightsMember" />
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_EmployeeStockPurchasePlanRightsMember" xlink:to="cers_EmployeeStockPurchasePlanRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of anti-dilutive potential shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_ProductWarrantyTerm" xlink:type="locator" xlink:label="cers_ProductWarrantyTerm" />
    <link:label xml:lang="en-US" xlink:label="cers_ProductWarrantyTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product warranty term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ProductWarrantyTerm" xlink:to="cers_ProductWarrantyTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_ProductWarrantyTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of warranty</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ProductWarrantyTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Warranty Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warranty claim liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Warranty Accrual Classified Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States government agency securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Credit Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One year or less, amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Greater than one year and less than five years, amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One year or less, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Greater than one year and less than five years, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total available-for-sale securities fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 Months, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 Months, Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 Months or Longer, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 Months or Longer, Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities in unrealized net loss position</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit losses recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross realized gains from the sale or maturity of available-for-sale investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross realized losses from the sale or maturity of available-for-sale investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial assets and liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total financial assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process Net Of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods Net Of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_AccruedDevelopmentCostsCurrent" xlink:type="locator" xlink:label="cers_AccruedDevelopmentCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="cers_AccruedDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued development costs, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_AccruedDevelopmentCostsCurrent" xlink:to="cers_AccruedDevelopmentCostsCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AccruedDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AccruedDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Development Costs Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TermLoanCreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan credit agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TermLoanCreditAgreementMember" xlink:to="cers_TermLoanCreditAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TermLoanCreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Credit Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TermLoanCreditAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Credit Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total debt, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: debt - current, Principal</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: debt - current, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Less: debt-current</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt - non-current, Principal</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentCarryingNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Non Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt - non-current, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt-non-current</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in remainder of fiscal year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees in remainder of fiscal year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees in year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees in year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees in year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" />
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of interest and fees in year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 (remainder), Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024, Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Principal</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 (remainder), Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees In Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021, Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022, Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023, Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024, Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees In Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Interest and Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Interest And Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 (remainder), Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021, Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022, Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023, Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024, Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_RepaymentsPrincipalAndInterestAggregateAmount" xlink:type="locator" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount" />
    <link:label xml:lang="en-US" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments principal and interest aggregate amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_RepaymentsPrincipalAndInterestAggregateAmount" xlink:to="cers_RepaymentsPrincipalAndInterestAggregateAmount_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtPrepaymentFee" xlink:type="locator" xlink:label="cers_DebtPrepaymentFee" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtPrepaymentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt prepayment fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtPrepaymentFee" xlink:to="cers_DebtPrepaymentFee_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentAvailableAmountUponCondition" xlink:type="locator" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, available amount upon condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentAvailableAmountUponCondition" xlink:to="cers_DebtInstrumentAvailableAmountUponCondition_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" xlink:type="locator" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument principal and declining interest payments additional period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" xlink:to="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_InterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="cers_InterestOnlyPaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_InterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest only payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_InterestOnlyPaymentPeriod" xlink:to="cers_InterestOnlyPaymentPeriod_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrailingNetRevenueTarget" xlink:type="locator" xlink:label="cers_TrailingNetRevenueTarget" />
    <link:label xml:lang="en-US" xlink:label="cers_TrailingNetRevenueTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Trailing net revenue target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TrailingNetRevenueTarget" xlink:to="cers_TrailingNetRevenueTarget_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NumberOfEqualTranches" xlink:type="locator" xlink:label="cers_NumberOfEqualTranches" />
    <link:label xml:lang="en-US" xlink:label="cers_NumberOfEqualTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equal tranches.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_NumberOfEqualTranches" xlink:to="cers_NumberOfEqualTranches_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentInterestOnlyPaymentsDate" xlink:type="locator" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate" />
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest only payments date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DebtInstrumentInterestOnlyPaymentsDate" xlink:to="cers_DebtInstrumentInterestOnlyPaymentsDate_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OxfordTermLoanAgreementMember" xlink:type="locator" xlink:label="cers_OxfordTermLoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cers_OxfordTermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford term loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_OxfordTermLoanAgreementMember" xlink:to="cers_OxfordTermLoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_OxfordTermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prior Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_OxfordTermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Term Loan Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheOneMember" xlink:type="locator" xlink:label="cers_TrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TrancheOneMember" xlink:to="cers_TrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 1</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheTwoMember" xlink:type="locator" xlink:label="cers_TrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TrancheTwoMember" xlink:to="cers_TrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 2</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheThreeMember" xlink:type="locator" xlink:label="cers_TrancheThreeMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TrancheThreeMember" xlink:to="cers_TrancheThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 3</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandSeventeenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandSeventeenTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandSeventeenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TwoThousandSeventeenTermLoanMember" xlink:to="cers_TwoThousandSeventeenTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandSeventeenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Term Loans</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandSeventeenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Term Loan [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandNineteenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandNineteenTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandNineteenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_TwoThousandNineteenTermLoanMember" xlink:to="cers_TwoThousandNineteenTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandNineteenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Nineteen Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TwoThousandNineteenTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Term Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Loan Credit Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NumberOfEqualTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of loan tranches</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_NumberOfEqualTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equal Tranches</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments principal and interest aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Principal And Interest Aggregate Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtPrepaymentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fees in aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtPrepaymentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Prepayment Fee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment loss recorded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and security agreement available upon revenue achievement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Available Amount Upon Condition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument floating interest rate percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Percentage Bearing Variable Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-only payments date</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Payments Date</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal plus declining interest payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal And Declining Interest Payments Additional Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_InterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest only payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_InterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Only Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TrailingNetRevenueTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trailing net revenue target period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_TrailingNetRevenueTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trailing Net Revenue Target</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_MinimumTermOfNonCancelableOperatingLeases" xlink:type="locator" xlink:label="cers_MinimumTermOfNonCancelableOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="cers_MinimumTermOfNonCancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum term of non-cancelable operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_MinimumTermOfNonCancelableOperatingLeases" xlink:to="cers_MinimumTermOfNonCancelableOperatingLeases_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" xlink:type="locator" xlink:label="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" />
    <link:label xml:lang="en-US" xlink:label="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Latest period of expiration of non-cancelable operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" xlink:to="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_MinimumTermOfNonCancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum term of non-cancellable operating leases</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_MinimumTermOfNonCancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Term Of Non Cancelable Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration of non-cancellable operating leases maximum year</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expiration Of Non Cancelable Operating Leases Maximum Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 (remainder)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease not yet commenced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Lease Not Yet Commenced Description</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_MaximumAmountAvailableUnderOffering" xlink:type="locator" xlink:label="cers_MaximumAmountAvailableUnderOffering" />
    <link:label xml:lang="en-US" xlink:label="cers_MaximumAmountAvailableUnderOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount available under ATM offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_MaximumAmountAvailableUnderOffering" xlink:to="cers_MaximumAmountAvailableUnderOffering_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:type="locator" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" />
    <link:label xml:lang="en-US" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of proceeds payable as compensation to underwriter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:to="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesUnsoldValue" xlink:type="locator" xlink:label="cers_CommonStockSharesUnsoldValue" />
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesUnsoldValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares unsold value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CommonStockSharesUnsoldValue" xlink:to="cers_CommonStockSharesUnsoldValue_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesAvailableForSaleValue" xlink:type="locator" xlink:label="cers_CommonStockSharesAvailableForSaleValue" />
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesAvailableForSaleValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, shares available for sale, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CommonStockSharesAvailableForSaleValue" xlink:to="cers_CommonStockSharesAvailableForSaleValue_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UncategorizedAbstract" xlink:type="locator" xlink:label="cers_UncategorizedAbstract" />
    <link:label xml:lang="en-US" xlink:label="cers_UncategorizedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncategorized [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_UncategorizedAbstract" xlink:to="cers_UncategorizedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_UncategorizedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Uncategorized [Abstract]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteLineItems" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteLineItems" />
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_StockholdersEquityNoteLineItems_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteTable" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteTable" />
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="cers_StockholdersEquityNoteTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Note [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_CantorFitzgeraldCoMember" xlink:type="locator" xlink:label="cers_CantorFitzgeraldCoMember" />
    <link:label xml:lang="en-US" xlink:label="cers_CantorFitzgeraldCoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cantor fitzgerald &amp; co.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CantorFitzgeraldCoMember" xlink:to="cers_CantorFitzgeraldCoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_CantorFitzgeraldCoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cantor Fitzgerald &amp; Co</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CantorFitzgeraldCoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cantor Fitzgerald Co [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAmendmentThreeMember" xlink:type="locator" xlink:label="cers_SalesAmendmentThreeMember" />
    <link:label xml:lang="en-US" xlink:label="cers_SalesAmendmentThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales amendment three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_SalesAmendmentThreeMember" xlink:to="cers_SalesAmendmentThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_SalesAmendmentThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment No. 3</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SalesAmendmentThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Amendment Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAgreementMember" xlink:type="locator" xlink:label="cers_SalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cers_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_SalesAgreementMember" xlink:to="cers_SalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="cers_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="cers_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_UnderwrittenPublicOfferingMember" xlink:to="cers_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Note [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_StockholdersEquityNoteLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_MaximumAmountAvailableUnderOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum common stock offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_MaximumAmountAvailableUnderOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Available Under Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of proceeds payable as compensation to underwriter</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Proceeds Payable As Compensation To Underwriter</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesUnsoldValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsold shares of common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesUnsoldValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Unsold Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesAvailableForSaleValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock registered for sale</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CommonStockSharesAvailableForSaleValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Available For Sale Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued and sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, sale of stock, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" />
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award employee stock purchase plan offering term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" />
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of purchase period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_EmployeeStockPurchasePlanMember" xlink:to="cers_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceUnitsAndCashBasedAwardsMember" xlink:type="locator" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance units and cash-based awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PerformanceUnitsAndCashBasedAwardsMember" xlink:to="cers_PerformanceUnitsAndCashBasedAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Stock or Cash Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Units And Cash Based Awards [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, option to be granted at percentage of fair value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan, offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Employee Stock Purchase Plan Offering Term</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of purchase periods within each offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Purchase Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceBasedStockOptionsOutstanding" xlink:type="locator" xlink:label="cers_PerformanceBasedStockOptionsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceBasedStockOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance-based stock options outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PerformanceBasedStockOptionsOutstanding" xlink:to="cers_PerformanceBasedStockOptionsOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, award term</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan, authorized shares for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option plan granted on cash award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Cash Flow Effect Cash Used To Settle Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceBasedStockOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based stock options, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PerformanceBasedStockOptionsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares of common stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options and other stock based awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of unvested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Activity under the Company&apos;s equity incentive plans related to stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Number of Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Number of Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited/canceled, Number of Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited/canceled, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Activity under the Company&apos;s equity incentive plans related to restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Restricted Stock Units Unvested, Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Number of Restricted Stock Units Unvested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Number of Restricted Stock Units Unvested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Number of Restricted Stock Units Unvested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Restricted Stock Units Unvested, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Exercise Price per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Ending Balance</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IncomeTaxDisclosureLineItems" xlink:to="cers_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_IncomeTaxDisclosureTable" xlink:to="cers_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusEuropeBVMember" xlink:type="locator" xlink:label="cers_CerusEuropeBVMember" />
    <link:label xml:lang="en-US" xlink:label="cers_CerusEuropeBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cerus Europe B. V.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CerusEuropeBVMember" xlink:to="cers_CerusEuropeBVMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_CerusEuropeBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cerus Europe B.V.</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CerusEuropeBVMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cerus Europe B V [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability" />
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing and development payment liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ManufacturingAndDevelopmentPaymentLiability" xlink:to="cers_ManufacturingAndDevelopmentPaymentLiability_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentsForManufacturingAndDevelopmentCost" xlink:type="locator" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost" />
    <link:label xml:lang="en-US" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for manufacturing and development cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PaymentsForManufacturingAndDevelopmentCost" xlink:to="cers_PaymentsForManufacturingAndDevelopmentCost_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsLineItems" xlink:type="locator" xlink:label="cers_LicensesAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_LicensesAgreementsLineItems_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsTable" xlink:type="locator" xlink:label="cers_LicensesAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses Agreements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_LicensesAgreementsTable" xlink:to="cers_LicensesAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licenses Agreements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndSupplyAgreementsMember" xlink:type="locator" xlink:label="cers_ManufacturingAndSupplyAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndSupplyAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing and supply agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ManufacturingAndSupplyAgreementsMember" xlink:to="cers_ManufacturingAndSupplyAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndSupplyAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndSupplyAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing And Supply Agreements [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_FreseniusKabiAGMember" xlink:type="locator" xlink:label="cers_FreseniusKabiAGMember" />
    <link:label xml:lang="en-US" xlink:label="cers_FreseniusKabiAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fresenius Kabi AG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_FreseniusKabiAGMember" xlink:to="cers_FreseniusKabiAGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_FreseniusKabiAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fresenius</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_FreseniusKabiAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fresenius Kabi A G [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProjectMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Project [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:label xml:lang="en-US" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biomedical advanced research and development authority.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BARDA Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusCorporationMember" xlink:type="locator" xlink:label="cers_CerusCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="cers_CerusCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cerus corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CerusCorporationMember" xlink:to="cers_CerusCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_CerusCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cerus Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CerusCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cerus Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_LicensesAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licenses Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments made based on the successful achievement of production volumes</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing And Development Payment Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and development obligations, discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and development payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Manufacturing And Development Cost</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_UnamortizedDeferredCostForDevelopmentActivities" xlink:type="locator" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities" />
    <link:label xml:lang="en-US" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unamortized deferred cost for development activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_UnamortizedDeferredCostForDevelopmentActivities" xlink:to="cers_UnamortizedDeferredCostForDevelopmentActivities_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingEfficiencyAssets" xlink:type="locator" xlink:label="cers_ManufacturingEfficiencyAssets" />
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingEfficiencyAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing efficiency assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_ManufacturingEfficiencyAssets" xlink:to="cers_ManufacturingEfficiencyAssets_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred costs capitalized prepaid and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred costs capitalized prepaid and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:to="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Costs Capitalized Prepaid And Other Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Costs Capitalized Prepaid And Other Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid R&amp;D asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Deferred Cost For Development Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingEfficiencyAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing efficiency asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_ManufacturingEfficiencyAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Efficiency Assets</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentForManufacturingOfEntityProducts" xlink:type="locator" xlink:label="cers_PaymentForManufacturingOfEntityProducts" />
    <link:label xml:lang="en-US" xlink:label="cers_PaymentForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for manufacturing of entity products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_PaymentForManufacturingOfEntityProducts" xlink:to="cers_PaymentForManufacturingOfEntityProducts_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_PaymentForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments made relating to the manufacturing of the products</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_PaymentForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Manufacturing Of Entity Products</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_AccrualForManufacturingOfEntityProducts" xlink:type="locator" xlink:label="cers_AccrualForManufacturingOfEntityProducts" />
    <link:label xml:lang="en-US" xlink:label="cers_AccrualForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrual for manufacturing of entity products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_AccrualForManufacturingOfEntityProducts" xlink:to="cers_AccrualForManufacturingOfEntityProducts_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_AccrualForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payables to Fresenius</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AccrualForManufacturingOfEntityProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrual For Manufacturing Of Entity Products</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsAndNotesReceivableNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from Fresenius</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNotesReceivableNet" xlink:to="us-gaap_AccountsAndNotesReceivableNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts And Notes Receivable Net</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" />
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base period maximum funding of collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" xlink:to="cers_BasePeriodMaximumFundingOfCollaborativeAgreement_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" />
    <link:label xml:lang="en-US" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option period maximum funding of collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" xlink:to="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreement" />
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-investment for collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CoInvestmentForCollaborativeAgreement" xlink:to="cers_CoInvestmentForCollaborativeAgreement_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AdditionalCoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement" />
    <link:label xml:lang="en-US" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional co-investment for collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_AdditionalCoInvestmentForCollaborativeAgreement" xlink:to="cers_AdditionalCoInvestmentForCollaborativeAgreement_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreementIncurred" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred" />
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co investment for collaborative agreement incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_CoInvestmentForCollaborativeAgreementIncurred" xlink:to="cers_CoInvestmentForCollaborativeAgreementIncurred_lbl" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" />
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base period additional funding of collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" xlink:to="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed fund receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Period Maximum Funding Of Collaborative Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional committed fund receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Period Additional Funding Of Collaborative Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed fund receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Period Maximum Funding Of Collaborative Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-investment by the company</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Investment For Collaborative Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional co-investment by the company</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Co Investment For Collaborative Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-investment incurred by the company</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Investment For Collaborative Agreement Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:type="locator" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable of billed and unbilled amounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Long Term Contracts Or Programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Revenue, Goods, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Product Line [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_EtablissementFrancaisDuSangMember" xlink:type="locator" xlink:label="cers_EtablissementFrancaisDuSangMember" />
    <link:label xml:lang="en-US" xlink:label="cers_EtablissementFrancaisDuSangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Etablissement Francais du Sang.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_EtablissementFrancaisDuSangMember" xlink:to="cers_EtablissementFrancaisDuSangMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_EtablissementFrancaisDuSangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Etablissement Francais du Sang</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_EtablissementFrancaisDuSangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Etablissement Francais Du Sang [Member]</link:label>
    <link:loc xlink:href="cers-20200331.xsd#cers_AmericanRedCrossMember" xlink:type="locator" xlink:label="cers_AmericanRedCrossMember" />
    <link:label xml:lang="en-US" xlink:label="cers_AmericanRedCrossMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">American red cross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cers_AmericanRedCrossMember" xlink:to="cers_AmericanRedCrossMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cers_AmericanRedCrossMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Red Cross</link:label>
    <link:label xml:lang="en-US" xlink:label="cers_AmericanRedCrossMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">American Red Cross [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Major Customer [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Wide Revenue Major Customer [Line Items]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cers-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-05-04T01:24:33.0744239+00:00 -->
<!-- Version            : 5.0.1.385 -->
<!-- Package ID         : fc0cf329203843ebb56481a822aed7d4 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cerus.com/20200331/role/TemplateLink" xlink:href="cers-20200331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cers-20200331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_SecuredDebtCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SecuredLongTermDebt" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="cers-20200331.xsd#cers_GrossProfitOnProductRevenue" xlink:type="locator" xlink:label="cers_GrossProfitOnProductRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentContractMember" xlink:type="locator" xlink:label="us-gaap_GovernmentContractMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_GrossProfitOnProductRevenue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" xlink:type="locator" xlink:label="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="cers-20200331.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashInterestExpense" xlink:type="locator" xlink:label="cers_NonCashInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NonCashOperatingLeaseCost" xlink:type="locator" xlink:label="cers_NonCashOperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cers_NonCashOperatingLeaseCost" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cers_NonCashInterestExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories" xlink:href="cers-20200331.xsd#Role_DisclosureInventories" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities" xlink:href="cers-20200331.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt" xlink:href="cers-20200331.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity" xlink:href="cers-20200331.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="cers-20200331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="cers-20200331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements">
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsTextBlock" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DevelopmentAndLicenseAgreementsAbstract" xlink:to="cers_DevelopmentAndLicenseAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation" xlink:href="cers-20200331.xsd#Role_DisclosureSegmentCustomerAndGeographicInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AvailableForSaleSecuritiesPolicy" xlink:type="locator" xlink:label="cers_AvailableForSaleSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cers_AvailableForSaleSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables" xlink:href="cers-20200331.xsd#Role_DisclosureInventoriesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="cers-20200331.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables" xlink:href="cers-20200331.xsd#Role_DisclosureDebtTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cers-20200331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables">
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" xlink:type="locator" xlink:label="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DevelopmentAndLicenseAgreementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DevelopmentAndLicenseAgreementsAbstract" xlink:to="cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables" xlink:href="cers-20200331.xsd#Role_DisclosureSegmentCustomerAndGeographicInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OtherMember" xlink:type="locator" xlink:label="cers_OtherMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NorthAmericaMember" xlink:type="locator" xlink:label="srt_NorthAmericaMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EuropeMiddleEastAndAfricaMember" xlink:type="locator" xlink:label="cers_EuropeMiddleEastAndAfricaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cers_EuropeMiddleEastAndAfricaMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cers_OtherMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ProductWarrantyTerm" xlink:type="locator" xlink:label="cers_ProductWarrantyTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" />
    <link:loc xlink:href="cers-20200331.xsd#cers_WorkInProcessInventoryLifePeriod" xlink:type="locator" xlink:label="cers_WorkInProcessInventoryLifePeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_InventoryLifeFinishedGoodsPeriod" xlink:type="locator" xlink:label="cers_InventoryLifeFinishedGoodsPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" xlink:type="locator" xlink:label="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentOfCustomerInvoiceContractPeriod" xlink:type="locator" xlink:label="cers_PaymentOfCustomerInvoiceContractPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cers_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cers_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cers_SummaryOfSignificantAccountingPoliciesLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_PaymentOfCustomerInvoiceContractPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_InventoryLifeFinishedGoodsPeriod" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_WorkInProcessInventoryLifePeriod" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cers_ProductWarrantyTerm" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail" xlink:href="cers-20200331.xsd#Role_DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanRightsMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanRightsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cers_EmployeeStockPurchasePlanRightsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSummaryOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureInventoriesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AccruedDevelopmentCostsCurrent" xlink:type="locator" xlink:label="cers_AccruedDevelopmentCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cers_AccruedDevelopmentCostsCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:type="locator" xlink:label="us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedNoncurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedNoncurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingNonCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:type="locator" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentUnamortizedCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentUnamortizedCurrent" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentCarryingCurrent" xlink:type="locator" xlink:label="cers_DebtInstrumentCarryingCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentCarryingCurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentUnamortizedCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebtCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentCarryingNonCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentUnamortizedNoncurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredLongTermDebt" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" xlink:type="locator" xlink:label="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDebtAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_TrailingNetRevenueTarget" xlink:type="locator" xlink:label="cers_TrailingNetRevenueTarget" />
    <link:loc xlink:href="cers-20200331.xsd#cers_InterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="cers_InterestOnlyPaymentPeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" xlink:type="locator" xlink:label="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentInterestOnlyPaymentsDate" xlink:type="locator" xlink:label="cers_DebtInstrumentInterestOnlyPaymentsDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtInstrumentAvailableAmountUponCondition" xlink:type="locator" xlink:label="cers_DebtInstrumentAvailableAmountUponCondition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DebtPrepaymentFee" xlink:type="locator" xlink:label="cers_DebtPrepaymentFee" />
    <link:loc xlink:href="cers-20200331.xsd#cers_RepaymentsPrincipalAndInterestAggregateAmount" xlink:type="locator" xlink:label="cers_RepaymentsPrincipalAndInterestAggregateAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="cers-20200331.xsd#cers_NumberOfEqualTranches" xlink:type="locator" xlink:label="cers_NumberOfEqualTranches" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandNineteenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandNineteenTermLoanMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandSeventeenTermLoanMember" xlink:type="locator" xlink:label="cers_TwoThousandSeventeenTermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheThreeMember" xlink:type="locator" xlink:label="cers_TrancheThreeMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheTwoMember" xlink:type="locator" xlink:label="cers_TrancheTwoMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TrancheOneMember" xlink:type="locator" xlink:label="cers_TrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OxfordTermLoanAgreementMember" xlink:type="locator" xlink:label="cers_OxfordTermLoanAgreementMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TermLoanCreditAgreementMember" xlink:type="locator" xlink:label="cers_TermLoanCreditAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_TermLoanCreditAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cers_OxfordTermLoanAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheOneMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheTwoMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cers_TrancheThreeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cers_TwoThousandSeventeenTermLoanMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cers_TwoThousandNineteenTermLoanMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_NumberOfEqualTranches" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_RepaymentsPrincipalAndInterestAggregateAmount" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtPrepaymentFee" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentAvailableAmountUponCondition" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentInterestOnlyPaymentsDate" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_InterestOnlyPaymentPeriod" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cers_TrailingNetRevenueTarget" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" xlink:type="locator" xlink:label="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" />
    <link:loc xlink:href="cers-20200331.xsd#cers_MinimumTermOfNonCancelableOperatingLeases" xlink:type="locator" xlink:label="cers_MinimumTermOfNonCancelableOperatingLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cers_MinimumTermOfNonCancelableOperatingLeases" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail" xlink:href="cers-20200331.xsd#Role_DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesAvailableForSaleValue" xlink:type="locator" xlink:label="cers_CommonStockSharesAvailableForSaleValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CommonStockSharesUnsoldValue" xlink:type="locator" xlink:label="cers_CommonStockSharesUnsoldValue" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:type="locator" xlink:label="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" />
    <link:loc xlink:href="cers-20200331.xsd#cers_MaximumAmountAvailableUnderOffering" xlink:type="locator" xlink:label="cers_MaximumAmountAvailableUnderOffering" />
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteLineItems" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="cers_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAgreementMember" xlink:type="locator" xlink:label="cers_SalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_SalesAmendmentThreeMember" xlink:type="locator" xlink:label="cers_SalesAmendmentThreeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CantorFitzgeraldCoMember" xlink:type="locator" xlink:label="cers_CantorFitzgeraldCoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_StockholdersEquityNoteTable" xlink:type="locator" xlink:label="cers_StockholdersEquityNoteTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UncategorizedAbstract" xlink:type="locator" xlink:label="cers_UncategorizedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_UncategorizedAbstract" xlink:to="cers_StockholdersEquityNoteTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cers_CantorFitzgeraldCoMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cers_SalesAmendmentThreeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cers_SalesAgreementMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cers_UnderwrittenPublicOfferingMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteTable" xlink:to="cers_StockholdersEquityNoteLineItems" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_MaximumAmountAvailableUnderOffering" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_PercentageOfProceedsPayableAsCompensationToUnderwriter" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_CommonStockSharesUnsoldValue" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="cers_CommonStockSharesAvailableForSaleValue" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceBasedStockOptionsOutstanding" xlink:type="locator" xlink:label="cers_PerformanceBasedStockOptionsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" xlink:type="locator" xlink:label="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PerformanceUnitsAndCashBasedAwardsMember" xlink:type="locator" xlink:label="cers_PerformanceUnitsAndCashBasedAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cers_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_EmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cers_PerformanceUnitsAndCashBasedAwardsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cers_PerformanceBasedStockOptionsOutstanding" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail" xlink:href="cers-20200331.xsd#Role_DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail" xlink:href="cers-20200331.xsd#Role_DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_TwoThousandEightEquityIncentivePlanMember" xlink:type="locator" xlink:label="cers_TwoThousandEightEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cers_TwoThousandEightEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusEuropeBVMember" xlink:type="locator" xlink:label="cers_CerusEuropeBVMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="cers_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cers_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cers_CerusEuropeBVMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_IncomeTaxDisclosureTable" xlink:to="cers_IncomeTaxDisclosureLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:type="locator" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreementIncurred" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreementIncurred" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AdditionalCoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_AdditionalCoInvestmentForCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CoInvestmentForCollaborativeAgreement" xlink:type="locator" xlink:label="cers_CoInvestmentForCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BasePeriodMaximumFundingOfCollaborativeAgreement" xlink:type="locator" xlink:label="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentForManufacturingOfEntityProducts" xlink:type="locator" xlink:label="cers_PaymentForManufacturingOfEntityProducts" />
    <link:loc xlink:href="cers-20200331.xsd#cers_PaymentsForManufacturingAndDevelopmentCost" xlink:type="locator" xlink:label="cers_PaymentsForManufacturingAndDevelopmentCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndDevelopmentPaymentLiability" xlink:type="locator" xlink:label="cers_ManufacturingAndDevelopmentPaymentLiability" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsLineItems" xlink:type="locator" xlink:label="cers_LicensesAgreementsLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_CerusCorporationMember" xlink:type="locator" xlink:label="cers_CerusCorporationMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:type="locator" xlink:label="us-gaap_ProjectMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="locator" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_FreseniusKabiAGMember" xlink:type="locator" xlink:label="cers_FreseniusKabiAGMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingAndSupplyAgreementsMember" xlink:type="locator" xlink:label="cers_ManufacturingAndSupplyAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_LicensesAgreementsTable" xlink:type="locator" xlink:label="cers_LicensesAgreementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="cers_LicensesAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cers_ManufacturingAndSupplyAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cers_FreseniusKabiAGMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cers_CerusCorporationMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsTable" xlink:to="cers_LicensesAgreementsLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_ManufacturingAndDevelopmentPaymentLiability" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_PaymentsForManufacturingAndDevelopmentCost" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_PaymentForManufacturingOfEntityProducts" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_BasePeriodMaximumFundingOfCollaborativeAgreement" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_BasePeriodAdditionalFundingOfCollaborativeAgreement" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_OptionPeriodMaximumFundingOfCollaborativeAgreement" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_CoInvestmentForCollaborativeAgreement" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_AdditionalCoInvestmentForCollaborativeAgreement" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="cers_CoInvestmentForCollaborativeAgreementIncurred" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_LicensesAgreementsLineItems" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail">
    <link:loc xlink:href="cers-20200331.xsd#cers_ManufacturingEfficiencyAssets" xlink:type="locator" xlink:label="cers_ManufacturingEfficiencyAssets" />
    <link:loc xlink:href="cers-20200331.xsd#cers_UnamortizedDeferredCostForDevelopmentActivities" xlink:type="locator" xlink:label="cers_UnamortizedDeferredCostForDevelopmentActivities" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:type="locator" xlink:label="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" />
    <link:loc xlink:href="cers-20200331.xsd#cers_DevelopmentAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cers_DevelopmentAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DevelopmentAndLicenseAgreementsAbstract" xlink:to="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable" xlink:to="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_UnamortizedDeferredCostForDevelopmentActivities" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems" xlink:to="cers_ManufacturingEfficiencyAssets" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail" xlink:href="cers-20200331.xsd#Role_DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsAndNotesReceivableNet" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AccrualForManufacturingOfEntityProducts" xlink:type="locator" xlink:label="cers_AccrualForManufacturingOfEntityProducts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="cers_AccrualForManufacturingOfEntityProducts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_AccountsAndNotesReceivableNet" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail" xlink:href="cers-20200331.xsd#Role_DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:loc xlink:href="cers-20200331.xsd#cers_AmericanRedCrossMember" xlink:type="locator" xlink:label="cers_AmericanRedCrossMember" />
    <link:loc xlink:href="cers-20200331.xsd#cers_EtablissementFrancaisDuSangMember" xlink:type="locator" xlink:label="cers_EtablissementFrancaisDuSangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_MajorCustomersAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cers_EtablissementFrancaisDuSangMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cers_AmericanRedCrossMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800239456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800207536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables) - 2008 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Activity Under Equity Incentive Plans Related to Stock Options</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.74</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.51</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,621</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Activity Under Equity Incentive Plans Related to RSUs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,098</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,029</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,578</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Includes shares issuable under performance-based restricted stock unit awards.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814093312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>Customer </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of payment of customer invoice contract</a></td>
<td class="text">The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized, that were included in deferred product revenue</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation', window );">Application of an optional exemption not to disclose the value of unsatisfied performance obligations</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers', window );">Number of major customers representing outstanding trade receivables | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_WorkInProcessInventoryLifePeriod', window );">Protracted length of inventory</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash purchases of capital expenditures</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization intangible assets</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment charges acquired intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ProductWarrantyTerm', window );">Period of warranty</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty claim liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PaymentOfCustomerInvoiceContractPeriod', window );">Payment of customer invoice contract period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_InventoryLifeFinishedGoodsPeriod', window );">Shelf lives of inventory</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PaymentOfCustomerInvoiceContractPeriod', window );">Payment of customer invoice contract period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_InventoryLifeFinishedGoodsPeriod', window );">Shelf lives of inventory</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers whose outstanding trade receivables by a single customer accounts for 10 percent or more of an entity's trade receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_InventoryLifeFinishedGoodsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory life finished goods period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_InventoryLifeFinishedGoodsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_PaymentOfCustomerInvoiceContractPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of customer invoice contract period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_PaymentOfCustomerInvoiceContractPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ProductWarrantyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product warranty term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ProductWarrantyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_WorkInProcessInventoryLifePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Work in process inventory life, period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_WorkInProcessInventoryLifePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether optional exemption was applied not to disclose amount of transaction price allocated to and explanation of expected timing of revenue recognition for remaining performance obligation, when contract has expected duration of one year or less or right to consideration corresponds directly to performance completed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130558-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813074496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (16,466)<span></span>
</td>
<td class="num">$ (18,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,754<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_NonCashOperatingLeaseCost', window );">Non-cash operating lease cost</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of available-for-sale securities</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,283)<span></span>
</td>
<td class="num">(5,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,226)<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,308)<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities', window );">Accrued liabilities and other non-current liabilities</a></td>
<td class="num">(4,356)<span></span>
</td>
<td class="num">(4,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability', window );">Manufacturing and development obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred product revenue</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,802)<span></span>
</td>
<td class="num">(22,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(3,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(68,520)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities and sale of investments</a></td>
<td class="nump">18,787<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(50,185)<span></span>
</td>
<td class="nump">13,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from equity incentives</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offerings</a></td>
<td class="nump">67,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Net payment on revolving line of credit</a></td>
<td class="num">(204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,010)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">68,684<span></span>
</td>
<td class="nump">9,133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,303)<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">37,421<span></span>
</td>
<td class="nump">31,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">$ 36,118<span></span>
</td>
<td class="nump">$ 31,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued liabilities and other non-current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in manufacturing and development payment liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_NonCashOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_NonCashOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800236096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cers_CerusEuropeBVMember', window );">Cerus Europe B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cers_CerusEuropeBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cers_CerusEuropeBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804601648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,679<span></span>
</td>
<td class="nump">$ 34,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">99,426<span></span>
</td>
<td class="nump">50,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">18,165<span></span>
</td>
<td class="nump">16,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,684<span></span>
</td>
<td class="nump">19,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">6,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">178,319<span></span>
</td>
<td class="nump">128,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,654<span></span>
</td>
<td class="nump">14,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">14,080<span></span>
</td>
<td class="nump">14,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,473<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">215,363<span></span>
</td>
<td class="nump">165,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,185<span></span>
</td>
<td class="nump">22,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">17,198<span></span>
</td>
<td class="nump">20,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Debt &#8211; current</a></td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">5,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred product revenue &#8211; current</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,089<span></span>
</td>
<td class="nump">50,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Debt &#8211; non-current</a></td>
<td class="nump">39,458<span></span>
</td>
<td class="nump">39,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; non-current</a></td>
<td class="nump">18,005<span></span>
</td>
<td class="nump">18,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">102,955<span></span>
</td>
<td class="nump">108,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">978,944<span></span>
</td>
<td class="nump">906,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(866,577)<span></span>
</td>
<td class="num">(850,111)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">112,408<span></span>
</td>
<td class="nump">57,052<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 215,363<span></span>
</td>
<td class="nump">$ 165,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795368080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,695,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,867,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cers_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,866,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cers_CantorFitzgeraldCoMember', window );">Cantor Fitzgerald &amp; Co | Amendment No. 3 | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_MaximumAmountAvailableUnderOffering', window );">Maximum common stock offering price</a></td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PercentageOfProceedsPayableAsCompensationToUnderwriter', window );">Percentage of proceeds payable as compensation to underwriter</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_CommonStockSharesUnsoldValue', window );">Unsold shares of common stock, value</a></td>
<td class="nump">$ 31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_CommonStockSharesAvailableForSaleValue', window );">Common stock registered for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_CommonStockSharesAvailableForSaleValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, shares available for sale, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_CommonStockSharesAvailableForSaleValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_CommonStockSharesUnsoldValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares unsold value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_CommonStockSharesUnsoldValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_MaximumAmountAvailableUnderOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount available under ATM offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_MaximumAmountAvailableUnderOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_PercentageOfProceedsPayableAsCompensationToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds payable as compensation to underwriter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_PercentageOfProceedsPayableAsCompensationToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_StockholdersEquityNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_StockholdersEquityNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cers_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cers_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cers_CantorFitzgeraldCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cers_CantorFitzgeraldCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cers_SalesAmendmentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cers_SalesAmendmentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cers_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cers_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001564590-20-021342-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-021342-xbrl.zip
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M$&\X$X4A\&82IU3AP8\OP2.*2^8_.O]LY4[\5_? CREG!F#SERYN $'U7%Y
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M7<4HCE!LG0 4D%E;5;VI9_#=JKX[H3:_RJ83/MO/M&>JUI062%AVG0P4G-F
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MO.D)Q<?2Y_EE[UZP^?GF%W(C'UR\X5GG5^JFKZ=L(7$NSR-P8:ZZ*$#V\]K
MF]2\D.M'364YM5+=</GSIS\D8_X;0M#VV4NNU2]:QTU >CL]:P\])C@]<X.]
MR0:_A6>W..':R9.EBV:N1*M]L#Q5+LHY%*?J3CEJ:_/HCF]_XF;X'5_UXS[9
MT?4J[H,=7;H328O,'^7=KO/QD.:X7=J7YI#L%IO;OO_M3\C""??_#-SK0C/?
MYK#LF@/78C*_>HYN4L<Y32T)L-9Q!W9)R4C%?3((A)R.TF6(D&&*7-PGRQW=
M=%<C.,@S[_/,FF.T\UG\)B:QXT]?2GRSRZ9?-L.VXRWA49[UN#:JJX_7;4R(
M[0CFLIN6V$WP'#^TRA[&+QBWIHB/98M[&:_\YC]U=FMV6V*RX5H\6OJL.V()
M8"JFJBL&C\3R4_S\8MXG3E-LS2'\W(BNK4]6)%+E@_)Q;9248.@^?NC>F5##
MF(L)^<# %P%TOX#(]O#T,79N-MN5-4?5AOS93VI.CKB?5,^K4+;%/DQ[9NL&
MD8.BCB4N3#8E/_E_ LROQ5XGTW3/U'T4[Q]$MPF1_\36)R%A6%,GQ$^L$FD@
M0_&%ON<*T\)LS'O"4>7%'S2JZNR)G5_/>K?7JZ4J36^J66YPP=D7J5XIM9J-
M4K.\R.6?/_P7/UO+F>N+'<U(5_T,,$<DK%C+AXSL]AR:#)).49W35_M_KRQX
MK+I:DKSZ!-+NK0'V.&V7:&PI-,:)O<SI?:+GCS95?IPK8S;&2\7XJ;PR;?IT
MDD,?ISAY^'XESU,4P(L6(,M;C3]1(=\O8)^?,06)58O2WL2O;DRZPM']OJX>
M<6X&/VI_O>GR4J2=_NVH>SN*]!2)90/V/T,-)ADAFLI;OV@=+0B4!N1W[<'(
MG_@>V3F?N5F_J!P6UY&J%]6W$W$N!<[ AMDX0<V&Z]YM^[;3:]\0YO(QZ^8;
M[DU\LO@:6;\3PP2-O_WK&?-.MT:#ZA?UHPE5VLY'K/WV8VK907O'ATO^ 4^V
M3IXV3-_QY"E60/VT=C0=D>^Y=!JDH%^<UI+*:RSI*EZ[6<TDP\$*F=A\;?VW
MWJC[_4%Z6%C6!]&M[#OW+O8X'7>]"!2*ZC1^$OP'SU0\37>I]G%A@)6--=Q/
M/@5)<,(^AR5%)=W$SDJFHT32OM8DV2.J1^>=DTOASD2RQC:U+AJY-DULE7/5
MO1UVKQ[8JV'_IG?%+-/5P]?V#3-5W8?A;]WN7D:J8_$Q\GT-]LKAU;%%GM-7
MQ6"VBY+AA%)FM43<3_J\;BDI<L6OJ"HZ X<_DEJ9,7#O;'ON6S\!C1H:-31J
MAQNUI=?UT+_K#MJCP^U:R!.SQJ0_H_Y7EQ9NQ!Z)SL^)T4WQ,V'TT,1EV\3)
M:.+0Q,$Q<9W^][M!-VD3QS,+;#IAU_$3N#>6@Z:N@*:N4@13E[H!$KL#P7M^
MBR#IHO*/MR8IO%\ UBKU.__ZK7]SU1TDL)9<-4@BN65B&>QK3I!.0KI_>;K[
MFH1A0DOP#O;5(EB" CD].;(Y2T^H/?SMX3IQ3TAQ)N3:L'ZB!U1 NU=#NW<"
MNU?D3</;_J@[?!CU'S88N/ENXC[U-2V7/;QKD0T&;MT.8V:,%.XJ;IVT.N8H
MO,U1D#%'X4V.@OSPO7W;_A;X35>]8>=^..SU;Q_8NS?_&?:&>[E1WQ53>1)6
M9)'G?Z4[JN>WQ.9>4-M4C%='%_[4TOAPZ^0?I.+7#*CC&6_CZVB5\F&5_-1A
M-$MALU1!L_3&+%4>_GW?OAWUV)*N]WN7_W$S?\UMU$U_>+^'6?HW/T6I,P>'
M1["YA6%O&/._N8$R+,?CQY7:CY;GSLOG#G3G!UJ=?%B="EJ=B-6IHM5Y8W6J
M?+TU&O1OA@]W@WZG>W4_Z.X9OG9MIHC"QMS9EDHU;E;0B!3)B&!J_\Y/=M!1
MD:,)5P9R_5,^,]4[)7%LI8TTCDN1_NBW[B#]LU(I6U<\[H0V$9)-3-N=/O7Y
MI_=.DH+PJ*6'F^ZW]HWO3G>O>K??]O&G;^B38OB.M&C @)YT7CSIO3-G"V _
MVFA UAB0]L.@-_S7PW6[,^KOE4O&PW?D6E%=RT:[@78CMW;CU'N:F3 ;\L/]
M[:#[K3<<=0<\-:Q]TQT^=/]]WQO]YV'8[=P/>OL<!;HW0RVDAXKA%S8+<DY#
M'=9XV._>$0U- Z<%+4].+$\#-Q!2W[;,A.6I/%QUK]OW-Z/AP_U=_Y99F]M>
M?S W.KV]]A.NZ%@1F1#W,]ZVCIJZ98?L#=H6M"UYM2VGWIS,A&VI/GSOW7:9
M-W/=97[,/!%BOSW*[^P?YL.,*7-=0JD/:$O0EN35EM30ED1M2>V!>26A/:P]
M3$A?E%'OF7YM:/8I&@\T'GDU'G4T'E'C47_H_N]OO:^]O0I%=5\F^J..YTMR
M8RVV5GC:N6QGRS].F(G=]O0@WFL#?K?#PT>=^#02<Y9&:MC[=ML>[;DR6GYI
MDX5Z^VWQ,&@]XEF/=5LY&]M2O3O6E:$=4H*]8+<,215V_UC.Q4&=9E+(SA1=
M@7B&YD,O5'1X97G'/R6]2[*^VONB_\!\,OQYX+;#MT-Q>Q(DVH= *E_(C76V
M<J.IW+E75%K( 6G<PMWZ91[;MI(0')4CS7:\A]_'"@H]V5J<>ZD>RW<7,R%X
M:J?FB=N-*< N*&LZ]^S(%-DPCCN6/5Y<1L*7D> RXE^6GZGY\D$WB3NQ/$<Q
M->?CL7JO9;@9SAN7_5%1?SS9%ELW\%^S[,N_78O_?5ZI]L)'\Z;6RT4CW/%-
ME'M9?2M2\:7AMRP\))Q4N6A \_OW::=\PLF6CK 0#IZY+/X7FM?FB:-;<2,?
MIYQ^YMA%0J<QS&J,Z,1!*,6%Y/M*D3"(VO!N/"(W6$"U2!>M8T3GT"BA4=H
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M)Q=T.+F)+Y2E2-?J;PDZ( -#,=W(P,C R,"','"DUMT.#'S(L?MZK50#E-.
M#)R11(="'S  &D?&<P6I;K/P245O!BA.49<&H0(*%:8OPH !<_:14! G))3,
M0X6$DI%SZ*%8D,JFE=I)!(/"L_MH&=J!.,4%Y:;7_MJ[Z8UZW2%IWUZ1X:C?
M^==O_9NK[F#X/Z3[[_O>Z#_@ H&XHL33.P6%8<=#>X@$*D1!8,#U($I_86%
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M0;$@>!D"P4O2RHG)@XY9%\8#X.=PD/<+S/NQU 1-'IJ\S.H@/]Z )J^ )J]
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M;DK[XV^6I8G*9;Z?Z0PM0WNOGNC! 9YFJ<+3(8"7+L.*[>E;"B18.%@@P>8
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M5"(F=6.7^\6#H9D,B1_DL1:*/J#BA,49LX,5EAH  0,R"C(*XH2,D@.LD%%
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M*>5X^MML&GAVE&(DX.9F9=!WBJZQQTK= $,ZC0@#&3B&NC 6 )H!;EW4WCE
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MDL?CYU+EH@$;AXXRTUW%(/1E1DU-=ST;>YT#4 88TUYXFP0"!CQ'&"O"'6E
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M3[1DD[Z/?0QDO.@^S&M*E+.9G5]1CG"J]*"V>B**/#]"'&$^GX)KK_NN8*#
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M+OI6FC%,"D78#U.NE"77BE9W\*<;)G\Z:RW'PE1Q8JWI*E.R_U0/7CLX%J"
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MHZ$(HGO%43>2"1MRZ9N7CC( 1T7UE!:HT<<9Z[0PX+S<,0]OA9I'+)*HEG\
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MW__5O/X/?/L&,9!Q\A6-KPJVX)>/_*<_22?%P,II.NN%WH18O6>_-1O.DBP
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MRB8;<U$FQ%933PA+"&L!GPAA3Y-O>QPC:=MS2<!JG"V<(^GW"$EM$SFZ)(!
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M/\! 3QO4[],H? -O]''H0XC-)S\4.TO-03 >)K&U-7:Z*S"^;(T7@;Y5B%C
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MU]ZMM<&ER]6O\49I,H&GA.!?3OTT(YHFRAW/\$VQ& HI08'@[R<^N+OP_YJ
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MYV2>W@!_=;VW'.)MG,[4L8.3:!8BSCR(V1 #;\I@TZX+<Q#/#33[1TN-Y83
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MSOV-_%O8E:E.(@6 5]@($;N4J0S/SD?*YD_U:CN69GFAZ8US2<#)DI"D1IX
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M([5%#)-XLLC#H+VI?3I[="\\$,V[F'I6*/2&^5YC-B_>FX)E,4":Q5]!8@1
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MUM:'147&*F&J4[GP-OB)HT]*ST\)TFWNZ-Z"H3%D@,%+\H111G,R5P3V06!
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M,QUH$T$U3\ZKU_U35I&&SO67FT%D&6" 6F33,O";!BJRGL7;L^E$EJ]]H.J
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M':%!A:45L1B%9 7"7\:84BZP?!9FB6A #CSH ^98N93P@+WT?8W@AR&BHAB
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MOE%.>,+?'7:/S"_@R,R=12(BQ=^<?WE[[ODW(-RH]W9M84FO(17%OP>J(<,
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MW@DN\!ZH8-8FYP#[I?_2OLZ )$@462=Y0UNL$EH%,'OI@;2U"P%G/R$J]G5
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M:#'WIP_'-(X7Z;/GOK[J,CH:^FU>G!WBT5_ZMBM6NW#K]^YOI[AVL/D_#G;
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MEDORT^D[YT6WME>#MDC7I2NZ7I? "F+BB22EER4VL2KHNI'8_9LY,V5R#RO
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MWJV\\4 +%P6UK,7%B1BRQ#(+0V!!(SQ&@T^)1&$U=ZZ)PBH*JWD+*S*",+D
M,#>I-@FDKF-E8')EF+A3"BP$#*HCF2$0I%'#*F@M\S.E%5NTPZ6)$FONK!,E
M5I18\Y98W$"G4%CHJ&/\D;Q86I2*%<HYWF=O:4.1S'Q);9D="4+3:I?/0HMC
M]ZMN\6A4+=B8F<46D05$$3=W7HLB+HJX>8NXL%QT@()D;/6KAYCCVNH NA!-
MR]YM''Q;FB/1A!S6_+/ PM^BT)HQ]T2A%876ER.TI"Q3BH$9>7DI@U:=,17*
MI;VA&1\\$$)/+3A'5YXWGV*\H+'&]B"'&#L>40=@.D6UAQ[P":OFAMW16=#;
M<@#_9Q_FA#M/N,;YVUA>%Q5&5!A181Q2&(<!D@N'VL=%)KYIT?9?M&DXG$,K
MYAVR8'3!Y\XE43A%X31_X82Y*FQC56A^X8'N@R9&W^VIN5[N.B(C*J\%Z82=
M]"PA,PNM7\Z8VOOZ #XF2J^YLU&47E%ZS5MZ9:,>][RNZEC<-G\21\D2)<N\
M)4N8$$4ZH5AB5L@HTS#&N'OZP_/7P4=M>SN;2T$IR1 ;0B*&_%!N^99AIPQ,
MVN32YZ])VD&9BH"%ZM=:N1EF":0'78%TS)OJ%*CQ125M]3(GC(]6YD5Y*\W"
MGMAE ]2RM3N;CK9%03MWCH^"-@K:>0O:Y1I]#'DR&*4UR*"$(_&:@?R-\F?N
MC!#E3Y0_\Y8_!\%^';BW@.W3O_I,!ET+')&%OA+CS$& XWE_];G@IS+YY!5L
MJKSG7["Y:'',Z$5_??KJZ9O4CB3CH>P"F=]9^'O%<M_'/!K;;E$@SITSHT",
M G'> E%@]7FL)<^*&@QB;&H2#9O609K#?2W82^1ZF  ASN4M4S=FZ7P-O-9&
M)X'6I0F2F[:.V4/'NKICQ4YD"2=89WY11O#J@A#@<,HHSRM7CQD()*ZXF?_@
MGO*>$NHQM"4]Z0C=;@(8*B.[D[_@.S\-CNL5P/@+ #YB#W_YZ95(^7^@OX16
MJR]X+<:N!9']QYO7:;1ROZC;%85Z%.KS%NH677NIHPT@D4-@@$ 6-A*O5!G:
M>EQ-%VU<[,;@TK6+=<IX',!0[L45,7ZH:#LW"XSK_5@>(X*IP<L X'%99L5F
M$&-=]!TC6/*\1(Z6 FX;]8. Y P2S;EA=.0T'& KZUEDIW9Z8'8J,5PM$E1<
M6BY9)+.>]%/O9/*KDS=1"L_].D0I'*7PO*6PQ#H91#HH%R^S<ZU4KLMBN1N@
MU/LO[$T)%WGFF_,P*?[40#AS[8Z=>A2\R X+BITP7P)?17$6Q=F\Q5D LG<Q
M5CCFA&8K<H/=B')![W>0_AXV5.;-P%3LBJXG@Y7'!?((&>-@20.9)L,#/EYK
MS1>!<SW16I,M2 %\I!Z:4:O,16.B!)/=L$&/T:A%M4+D@V<6R%-0=L!V>2\H
M\/0%^FJ#LQ!4=_0$M1BN@]$,&?#R4S?R\9RC19@\@+$-['SPJK:9C@[/,'H]
ME_$3:X!P<"%JZ-GP9^Q08@>;CS&2&XS!W+8U:4E3B:/"(Q&9%P?:E99G9X U
MY%F8<YT*I,L +R],R?B3'8\&-[^1HS/ O_^U-ZVX-EQF*Q.-4/_/\R)X2OO/
M;BC(PMBI56@%.)>1(#+!!W/\FLZ.=:O+P4+P7:6 G\#L7!OIC HF;O" &QX[
M*..P4C=; IW_]*QS-_C,/I,_K6^300^RW'>D;*K!O"TZ^KXJK4LHTT+LZKD4
M9=N@0RM8?6$G[E6X"B [!LN<LD>H2[6(Q'P6RB0K4 T4'2T5+BX?KCB2(J+<
MZNW,@A3)'W"KS-18TW?))5P,2W*VV2[)LPV95U<=;3=[4?)V;5J1QH<;](BW
MZ_.@XVTT&#&8*7J!4%E>81#A9^D"O.$S(!Y>^PR(ZYCGN6^]7,<JWA[F3#LC
MQN(5B[VS&8Y>"<V9WVM,SH<E7P05C6ZTW.9*0V<T%S/^MF /BDC'8$ RCAJ9
M>-FZ";:B=:UV_R K,PU-@S#VJ7/M4BFL7$G9Y':]:PN251@G]<Z0+MX6%798
MFBP?-_EMF^(LZT0.;_L%<6;2DCR$%,MV-3X<5$0M:IZA'7Q65FI'/,O@ZY\G
MAD8.IFNQ&&_-^!3L1*$+!J"]QY:O&_\0G;BN<$475Y/Z2+,RMPYQPG!V;7[L
MF!WU]ZRFCI-G?DC]Q#QH.YEH.)8I&%'D\'79*+&P2!NZ,>U:K4\[8@A['4R6
MK ?CFA8FG,,H:U3%6@0#LG28H8Y:T#)=,8/<H@=#VS=%-]:*AZ[/#;1.;/'+
M8'J<W$<W' I R3RP39(08(>REKEBS@IPD[SV_L(WL@V/-6>>D^G,_%XR.HR3
M3Z-/:;%.$[(&BAGE;;IZ-L0U5%=(^N4\V\G= R:A&,+C=A:1-'DOTS/MYK$!
M?L7@I6S>3S%JX)KHI=P_ 1E4+HO0F7H[>^A6INGXQJ)S[[8Y'S<A,@A7#H;#
M(?M=DO1;\B#D4^*ABH7>U&J=@N39=@,'1GW]Y$1]7T;C9U>+8Z43<]B<3[;C
M";!6KO"P6M"4Y[NZN6*8/,8[D&)4HZ*!CH)<*1)BIESIU%RBVR]]);DF*7P8
MI[N&M&Q)+G=D?ATG3W4:L5^M^'4=[6S;#::Q!OFLK182J/H"#MQ9D<.CEHZG
M0;? 8&PKJ;1^(Q=H3$=]-0YF 3(;/SW>"V@-S-1MN!XYXF"0(D;S@J=TZ7FR
M8T3,S,^B9B^>I=1@^FS6\I%EZFC95XP&M'H6\ ZY/<BVZUD=JO?' 'GLJ(+9
M@XFI]/[PD27&%1MYL;\'V)8L'3VQ&-((F*GP,<&\T1Z1^#]ERV4MDZ092F1#
M)]]+F)Y.M@1JGPZ"I8\U/'U.OBIDDO$W/'[USV[^WT('^7D-RV-,1[N9F(#H
M99T;96JG7XMG9P]K;\SF!0\C MJ&DR;;FI[X,%E9YA?B^:'4$S2[\*8OUS58
M"[?5S;.<N/-6!G(*.7=C &7\KQS]P>-- XEFYZ4BU4W7YB:JRP.V55Z;5N-#
M#*S-UF99:N"&+-AU?<I2V88"Z'->$5V$Z%V'C[3LYA[(5!8;IN +-K17AF&_
M0$NV=G9Z)\&]@&-94BS"Z^':H>ST:EQV70F=UU%9;(O\R%0,?DG?/RL:TLN#
MTH*U@17?D75[PD?PW'](>4^L9?VM->(6!4]W'8T1G]['8 L92Q@_T=RO'>;$
MNB=N02W<6<TO3'XXPO!IG8^,4<PMXQ8=VEL@ &P,CU00$=J_M!V^%>+9#GO'
M56WZC43@#IS<!UQI>R#2!,?"8W";P\!H-3!V+7NQY6&+/]S:TTN2VTT"QB1C
M-^E]GU:3_.:8C2?:.WY'%YTYPL7D^A2=]7TA)PLA)EB8-Q0^II3'8P+1DFO2
M-R:_B-/R>GS#,4N83I8LXJ7[03^%,"L?6+\L#?!HE@4]_.<UQJJSM-F0]ZR<
MH=]<9ZW?!H)XOXC-B9)0;_,%:DK%23![-HCH<SAO*_"-;@N"+#'>0#J22$.9
MHZOS@F8BIA">T^@(SWG+]IKD69=97/"!J>)FT$\OXLW)ZS='3^O_.[K'6_[I
M^>LW*7GJB(?7#>E#?W/.C27!SG27?:E38=S(J6^U;J][]WUY2_(GMOSXGVKB
MX=7./?XS1P=(6Y+&XAFY50VT,X3,DVR#7(^@=F2+6NZF&(4_G+Q^=L(Q6;(B
M=A.+M$(_6"%]URT].X6CTTTO&8<F<@K9#D01!@8+]U:<(USOQ9HF2[(6!E>R
MJWOOX013@T5LV^=PSF)A@K"RFWP-D\L)>V8DC[2<F\Y:8H8=0_]Z\QM/J[?I
MF2"@\"OZ152!NJ/AD$ZH&\G*D"61.=IJ&B23=^'&6Z$OX7/[F8R#'^*,KM1'
MT"B"O7XPX20N17)OS=_>-_*&U7DL#V2K;-%Y/>&7S)%C<1;$N!J[C-Y,4%-6
MK6">;62S8'N9)H@#,M=H 2P._.NT-ML[$1?<C3WS+GF#&=L#)+] 3."Y[Q,5
M-\Q M%E,G42/NDN]&*.-LSB']-H/J _BYW>^IP^>%5U3:\B:+_+EOG16)_HE
M4M4%"4FI;9(PX;DIRZ,0!I@OGMXRI(:Y]D"RG'NQ4>@QJ*CJZLMG8/1S5702
M)N0YXJXUS*5&A^L3D>".];(G8%]KR5  8VE#Q"+"D1.8X_YQ=:TAQ[93N]!%
M#B?,O*K6^81B88PB/Y^4FN.]6)VOBX=$@^*72H @=,>;&LA4G_^^0*1_WKTL
MEP"^-Q(V8%IPP.[ 9EB(DUA?9DRE@;UA WZ!\(;^XV)D?*\LSG !-+"C0C0O
MR%+D-I,@(&.?-)A..>!4^!(:3%;^ '^SIL\G_@B3@$-BKDU&?;^!0I>Z;!?V
M]&;56]% )(Y<CO[  ;F4B6XLO6 /NF*[6:X75_/9G8HTV Q"H346 1O:_]J&
M_":7)L_RA4@!OV&75^:V^K+?.1O('B)]ZK32H+YJ()Z5+2J#\@AQ2C9;N UD
MP]\PG?5B%9 PB#F&85MFD^5:(LRN28VMUB (_YZTT]2YZSE+?#QW;6\XYD'D
MHECY4H8S :$G"\W8<"TWCY%A-72X@Z@+48]+H\(4!CV?%DXO:9JZ<3D%X9&+
MVH%;7A-=4+I$6NI$ZF0A"'^KHMEX:S3PH4<&65X@FH:[V'5-L>@[&^,[' I*
M1X& QJQP9>4,MGVS)/^1ESX0&@/KNQ5#U3\'8J&O.*8[('C8B-CV'(DPOA@:
M.^?>P'.C54K&:.+X#.=W:G.MC6$4'#I];-#Y=7+_R?Q%PW>(!.03K"SADXZN
M0LG=,V0HL%=E;=#6LTX [0-/4][)8X7;GBU[(A>L4YO"";= 3U@A%$P;N>'U
M*H\^:[W*->[TT@6VGW@=8@X$S;,>: J1N)+L<!N:R"0[&MX2,1PXWH?@@@W>
MB<QU.3G!-)B*%#+ @EZLL844%I]J=VT9I)OXP2ZE%B8R0W^6+>EJIS*]=4ZP
M7\+*F'*4_?".+0>[,J=@5;W:HE:/<3K(JKEU2'K-BDSD<WQ_72X"T=LX8NGM
MU>XBF5)(<FV03(5\PBIMGD_C9QP[TG %7CY:RT4&PT\D86JM,47U:M':  .?
MSDHDM+.%;?'E4-2I[S.&1.,$FC,G71C&[,&>Z?<E9X@?!N7-@][MZ6J 5$0]
MPJN!O3EN.MRB@!<&MR[%\077AJ[I'88X<,IZQ"99^;.M^;X@-]?$3*>FEYR<
MW2\,V',44-+@BH3T_<LBEVH T:=:NFEC/N*SOQ\GQ)9$^6S=^!/':&7/N)";
MM526<+JYX*] %[KRA+%-2LLJ2\,UX!+^'6[!JF(.-&IMC%5Z/+1'%N=?M,$Z
M)*&J=<M6*2X,BP*]95S.3;\_SYIQ%IM<$U!7C!)F.=HI9VW%HUF8[IPKR'6E
M(]#U0<&7R\(0;_9-%8A 88ZBFDARR0U*N71 '5N52X=YS:ZT;Z5T2R>WM:8L
MY5SM]$H6T<$I95B[--(2#ZVZ<ZF2;O2PG1GESI'K(Z3:R*9D)G+U&DUS3]05
M\2O-:L4VC64!NO0"'W$>5*'YF&O"<4;^N@CSB[8@XH97M]!Z29BE&O\Y3IZY
M!Z4.Z\%-$O8Q=;=N6^] VI:WVV_XJ[IFFX.WIT^2A*[H4NOMVG<L8DSGI:#&
M\DG.D:L/>U8--]"LIK=>D)>@4S@U:,G;KEDHLO ]'Y967U3F/):U4M4LE:,S
M,3*2F:UG(&"G[YN]H+:8"691*-EQDV!8!$-C.."&FA3&"'%H*"PX\5@.7>(=
M$KP05DL=K^D@;7$2?Q/WHB6[!XT-EK9#'!;5@.\*"!#^7L'NJDY2FW)8TJ$5
M01;+J>13IR0MME*Q.XMUKCQ+AR@HP^VQ43,^40[:X[)S\X0]2BG;H!-;%UM7
M8N>DH*U.L\]*%H@(XVY]4%7T[#V?GRY.0; UQFGB?>0%4:^^3)D81,S'19^?
MVLZ'J<+"(;89D^X4%F"EL+;""?0:;AO6$F2Q V!4$7,RNW'U3\7,I8-&71M-
MDPN4CX8_V13_A9BWS17+,:RK0'"O%R >Y>R1:4&$(LHVN]2%*FDG72G-0DU-
M)N$9,PIVK8Y]N,&\:(F;-",MZMN']FN$=IT),-+U^X<KEU-.(JC@QDNK(!R%
M,D?^-VF7 @B6DF.QE=J"]2;I:S[>X^3Y&3*G*,,(,) &U$;SDJU9<U;GA>JA
M\VN<*K%D'2HH3_(;YQ/J48:&YB&KTENO;]A=&9;'VR+F=W Y.%\*75A)X9EQ
MA8TXFY;DH*F"V+<&?[DD@A\*T2N%OBY!B.2_^D2N["#E&)RF*@L(57#!./2D
M!O9PN1.UX@5D!*I&3245=2A'KU<KM@)0JV,/V(+WV?I+5AT9+*-\<)!#D_\'
M/NFLV?D6!;68K-]E?LOH]PL[9\-6VB<EL5@KDC0T++G\K;$= HN=.(<M[&_Z
MP7X)YTL&#/L+((2%"^ ^"EM/S>D+9"Q +LD&!YT(!Z^'2!W?@BD<CC-X9\PV
M_)(44.?U>94&$06?G@V%(D81<Y 7%5>CF6Q[7A0O?R1O@@GN$\Y72'K;+DKG
MY<6BW.O@(1-;Y-HMN>+2-V(:!J)QJKXR+*C<*_RU/P_2+TZ0C.3T*.-RJ+O!
M10X&TB.H.*YMG?/ (^ X@JTSUL@-PMX7%H?ZWCK7H@DSE)?FD#$9X7*T&0'1
MQ)8N]WA;Y!? 8M(-[.3")??OWGL$+\^RE+C?6X%!I[- %,F-DAT<2]#6R&)'
M_\J%![LM$@I<\<5%'JXU"%<]2*L.SWE-Q@9.T$L&-ADY$./<YF.!=WCN!=6>
MCSZHR!X&%Y  M\A)^UBE5V7;\"8)B*D0C$F4:K?GWJD&!Q>T:!S(L82]PBZU
MX%9-(F?!S>/22*/R#\&;9ELW[A!<F6>X66\ZX" VR,U*?D#P5EMKF?C#$YH!
M,E^3,(44:S?F./G+Z-PF[KC4./+U&:X$"Z7CVAG2VVR/X%]J8L-'<&4Z;;\@
M <?U-SZ5.GP65ZM?=.07<TO@M&O7BSQ-S:T!8WJ*>>#_D?GET_*(-\(EH)?E
M_ \DF7N](IY:7.PCN6 -@1T@FDUK39QD(D$&VVNC73.G!6X,G[$'P7GO,?AF
MNX2,X%+# U_M';M&25H3[-U&'FR\%!>B;_<CJ5Q%; U"6Q\<I!*Y#9[^_6X_
M[G?#/)JWOK#*PGH>;B:<&C[&Q%O1<H.6JD#9D[BLCF3VF.3GG-7M%.?>Z#'8
M<.*-L,B56,M J*KV';C/-N*\[U+ *[,1_(&''!8*RR%PL?2F1OERSJX R3J3
MJ@Z!16M(-@Z6 KNQVOE2ES ?"FYLB3,8+(\3(RXHS59O7K#'L0X\:AM>;?"!
M7LOE$;X.HD^C+$!(O_ULL0O$CI!"IFB)H_M=<^)&=@7^=4)G@=TGK^F13YN:
M>]"T-E*:V$K6P1TJGT^1F)'DR-"[W)MK%T)PG/89\7IGC';,5:='I*0WKI^J
M00!10S&!<K5&?M!'.[%8J) -"0*I&ZA(C(K:Y0S0*7E!$H-Y.4P(G7*[DR>]
MI1$I!],US@\("<+'P"P20+CT71%B-@3-6""5Y="#749[(E>MJOU]BD$VL7].
M,/':!J06AP4!7AV4\SM7NI>9"/F2\_>VE\#SHG4$U2F6X$!;UN=0=J!6A\*N
M87Q,=))C.XUOH989\5OEN?UC<.4.''\G$I6UG*3S<LA$RK9%SGJ6XV8V%NTL
MI"PWO_;:SDUZ> 4S:_IM3B.AD9K]RKV.9&FC;X<EQSZ(E_G&T:% :</J*PG)
M9$MMGX6#R3?X#<+U?,IDJS])75:/>_31#[,J(+A/^R)G=9G7RUXJC+5_[@?7
M%?$:J<FG&OEYP_2$0\C"2M3+4W^UG]L:S8U+?+T-&NG>6 ^-#O!YM>97<X%Z
MMC*=I -.1L&S5\X[P0N#AQUK)Q^S_=Y&?)LLI-\-K^;X.E9S?-YU[*FT(!XS
MBMNS%[U5G%U7A>"G5TQ<09OR9"^X'5ET,TOQ_#"S]3!A9K:F-S-;CX5709RD
M+,-Z'M=RGJ*T';]OI!N:7XZ(_88>N6Y]X2X4BK O??A8%4(8WSW/BDX!R>1Y
M#GC,Y='(*EXR[$,!R&A;;4!2I])N8W;C:-%;6QDE,>9!MER4^\Q.^H!%BFKE
M>2W4&HA[;H)-+&1%-PB 2O>8;[_RUE)05NGE'7PL'K0XB(MJ0:?4#@3(8Q,4
M#JHG$I2RU*N+N,CQP[D98O*$4RC\LV'I[W6239>=LIDEN&K6&/1;QRY;%$!Y
M^XQUP" K$L5Y%.>?0IR',^0#^<LX2<W2AXZSDOY628FWFB6XF3Y@?] BT:Y(
M<LRS2JI$;9WF?BVE:3H->^P!>'GF1\%]&XMH+E[/2=G6Y S/;%4B?AT$V!)S
MB;CG!^*O'5?[C).\3KZ/TXPNV3^,/@3 7S,[!ZU-G=NJ<-<YG&-11OF.\_E;
M5-Z9+9D5)<N9F2U, D:L\ADGB%=1T,>Z711=[ZW_VPCTA"V2((/J9W08-E7R
MO$</EI8?)_^3T9+3!,] O?@HM1"",;DL/QEBH4D=!+&M)Y/J<)Q! ).Q&M",
M",NSM/7M!0?\;.>$O-[CSDB2NIH(Q\KL-HZYR8;2041<ZX[WB@DXW4;;_@LK
MTUV:_,@U7E+9]+PZ+>F__%#W 12CM])R4'D#VU9LX'$;LDCQQVR0I.$T1:B#
MCQ:[HT$*?9&1S):<L$2N\1 N52EK9'=M7D;KV#FF6S+NV$3R)G -7V5]F3Q?
M-R5LAQ<">ZFH,J^>OSA.7BYL\;#D7?PC7.S.%EU+ 7U00\XOD>6-:LBLNF"?
M,1M$\-7#!,%1CNPZ<#C4C%*18TP.Y8,=#4CB]()-60E-.:LI!9__#M;$&W_^
M0OH'@B;7[04/]C@X3$\)EVMMGVE(T-3-H&*Y@3M"+WSZ/$$YHSLX[2A9H/"%
MVQH[J3/1S(6;6+^I\W )8X1IN]:P2,@FI(>XH[8)E):S0J[:#G/M&6$>&L<Z
M/(6T. T[,8\\HDM8A;(*4XM[M19XFEP*SU,N\?E7FW=^;39]I97WP5P$>OG_
MD >(^J][*4+CWZ3V8=Y@ =*HA>UQ_5#B\E6^$.00%P3%],SJ/YV<:*_,JFC:
MSG5D:/,7B1'KVO;C?DW)Z @&OF5>*6Z!V40/MM7U_9:I>&Y*5E(<H0%V4UV=
M@O\<);@40G"&%"EHB.HBG=HN%QHD-?<.2:LJI*' +H>WJ1LKD.#3.06"=.7O
M-ST>'P^.JO7E2ZBA._C>J\Q<&/CW*D<=),U$:U;([]I>#!6A6.F2$7)-ZKZM
M@YO[D1SGNZ.?F>BQ&W(RH)ERX83)=0[JXZ1+1,Y&3V3H5:&-J^,\$ 24EDX.
M#.V)M#(7*IUI&!KGW1B'/U>,BF&G8H3!<=GVG'VH%U^1X3?GH,&L[)%<\^3.
M!@W% V+;-R!XA)R^/*MHIFIP92@"@* [_)/_)X$:%Z/7\*)%/,$KD2CKAB4\
M@B 7T(DK@Z7JV/CD_9%M80] (C4B-;E+@6"5>-+$UG#G9;D'=RB%/;[YJU[\
MP@80OHK22,3>]L)0LF?=JHX5[-5>FMA5LK<KN8ZZW 'W5AQYL!G?FJLP>1'<
M(2\7U#/'#6TV(!GP/SW1DQ3-8XZ>,KEMQ1:DIJL_4/R$YS^^$4;GB<#$^SW7
M<M2-*\[4P8F^4C,8NH@.%5$:[KE2Q:T#AE<7/''T&&Z>*7)C-<Z"(6Y1DP$!
M<5YS41B2UWQ_SFL73,+'=1<,32(/@)KC,C*3+=<B#T4=\J#B K_#E\QO$-]:
M@(;,-<M1J[+OW[U_=_\8L^%!3IWC]$FIJ0@D\HHEE/,LL.+!27W\,[#@?_@8
MFI]9,)%*8+M:];]%P [ZB]OWXKJ'R#Y*0U;IK.(UX:Y2S1E94@UA2R&#_FS;
M_.Q?C\G.C78_67"W%IK; <AHIY[]LXWYM$9%RXXG]:"1J>I\^8(G6PAHC\-N
M]YJ<M?)?"VVEME,JA5I?XZ.HAZN>8_WV/6Y9\##.,(JH$U +-J^<0N+W!F5"
M=NJT?0P7>FI;M4\NX*]%)7TV U5EW1C:GG4IW=E?<A8#&.B5%[O!D]Y?#JS?
MQ150.UFJ/\(R9=ZPGMD$?08S7H+91GM7"A,6 4Z]RLYJ12IF-.6)0_4-VT$-
M"_U^SYBR<6QOE/EN>E1M33#1"';3=8-H09GPC:]1R23PZ#)<K3$<BK"&9O@(
MB]/7L#M0=J09I<"'MJW3DX97VPNU0.Q5YDAD >2#.$;"!KXR0(774)1?6H"G
M!\Q[K(HO@5T6RQ>/!CA8AD1CW0+@VEV\O&FV2!-MJ?+R6GP3J?)SCTC=Y<<J
MP^O4MQ=/C2<GND"LAUW3@$)2/W;SS(H 4-6$EJT[O(([![<*[\Y_TN8N"UA$
MEQV*B"C1.8&[\VS.48L^:/D2:\T+80UDH:UTJX [6A+'V/C!%#?M'J3UX A\
MN;J-PF!EJ5N?0Z-@"M+]+S::917'ZN6PG&[03=RJ7Q$^8^7V1*:1O@/?T>%8
M$Y@C(Q>S,<OZM(+!.B[M-06O)6BMY"W!!<K>Z:@1.^-$ P>)13O*1&QG?(#V
M=ND8"Y<]]@!<[1AHRR)3#7"JK,!DV-^^@]OH,N7VF8%+MFP*+O*[@1=$X\G8
M.?\3 48?+=9&UG84(&2,Y<$TD!!>6;M##* 7%% \-Q!="BY8]H*45@V;Z=CW
M%&);Q# N=M39!:V+?HOE/K%:*!$.#THH2%K'C)OQ(=/;]0?&=JBK27_?+H"=
M_BRH]6 [5D&!6P9*YE()#J"N^% 9J+;9V/"KZX?EV1[[KV)F%RO7"'SZ6$8=
M((QL];2O['L-&6F]JTG. A1K7[=[G/S@BT.FJ<T!E':_GV^\+%OA8BQ,SH8#
M&GP:+)PLXKX;!%VMBM-> XT*8F #2=QSZ2*(HCE#' ]$W">#JX+FX?.BDR%6
ME<E< -.N;_J O<?7/F#O=E>\O@G$I&^Y9F29C4VY2/F^K\\?= "0Y%#$@4T0
M8;9YLBE8'@NGX/\F;CC>!XL @>+A1+93.U7-BJ<)T116&P1P5/6P\4< IP(Q
MEX<>>C( 4F+95%UDGDKX*\3?FG[LA4_9"WUOC&'3OB9?29)&TV31$#(CNAHW
MX"IC!T<CO@KA'7K:-@3%0_W2$2(*V?=-O]5*T3'<Q=@GW$=CXYKH15LS2"=<
M!DRYL5-*>?F#9O(@2\;>C$W!=!YLU!<UZ>-\RG7/%W' &;*$=FD4\Q6-I^U@
M1&UK'7WZ"'+8UB4*]C^SE/O<2@!\]-%""/I&>L&_D,I0QASU]:)A<]Y@"*"O
M0]O+X#"U+7R-!1SMN\PE.S+Q(H=7'>,'ZOJ=5D,+%]%375YT^C)^\H#U=0Q2
M_=FPP['LQL$L-\"Q9-RM*[H+<Y^4^K.U^=@LUDFQ&5AP502C&89I/QMYDA"V
MR^X3N="NW9)!O13@F=#@LPD=AD!33)Q!LJ415]2UH"M..)PZB8F'0\Z%&#IN
M!KR/?R@&WML0L3%(%MA6TJ#DP$K3L)FQKG!A^<'/S-(UDCV4Q38C.5SLE?ED
MC8P)I^>=UTV9#X8!2>ROX\DG1PC: *QJV>QJ.#4%\E?$::]^.A'!X1J [0R7
MZ04S2IA42)BR=4.J].V21_?8@H"5<SW1^M&04"UCG0YA1&@AJ)!W"FSB\RU;
M)TB&^2!^.!LVM  DER:1M*QD_[Z0N4-[HR'<K$%VR09_'?@,00I8L;]&QE0]
M1*K8QT62 %RM7I9Q45SM91*U.?!B>8ZK ENV7K6^Q_ *4^UZ$")^;3#5XQ8Q
M# &[<7(A&<D9!W:<G%@44!W3HN -C-V%7)$>K!^LTEU\*X0U'79#8+<,>\EM
MH[F 0]K@/E-2KU=P\3G:.<02T3ODUCJ2MMQJBDDWIAU/"K&1)V8JE=7XLXJ"
M\$%D,2'(9'MO-%GA1O+"B3TGI[C= EPB3 78P,6@_(=O -OWX:L=QK=@;AR0
M>@JMP3BTV[YIL;CQ_5[5EY )'*! F,]LD*\R%CB'-E\L&.'$XBE+SF+0F+'H
M"\S(E"HHK5\+=BV8FI*H*A6HV!ZZ@U"AO[H,^P!+Z-P('($M$7-0!N*Q?,!F
M!\TV>X_%K#B@MX:0)JAEU(F<]BYRPB#XE2MVX'F;S!L;HR5)^G$>*@H@M7']
MQA[=X>ME;C;L^\GO_!2WBO!3[#?8J1N#J(I$JFVNR 5>Z#5%+L@EU0"[SCHP
MEV(G5IL^I9*.UQ1>WA3B@GO2D,]H:H=LHEB2$H^M3FL.%(71.8S)<[]0*.3?
M#=TLG%Z98"ZN[?)^+W8S7T,^3N=;3]9RNCK$2>34O2(YCZUQD9"UIVAAD5E!
MT(]7'OKAQL4, J!# DK=UJ3F'Y0@^S*D$4%9H;K.7E>0&IS<N S3Z?#WO)?-
MDM:"!3GDF]#$D[7@#UI'P-242L!<7'$W4\;?3;%2605D.K_:@QS"75K9S]N!
MPI44J^(3O%,[>:,5+G.'P8%M=R HEV756PI4)!9-M\N-N942HT;5F.L5(6X-
M0.F<RO0FXVE9+]PHB2DG;]AK)/+ TK]S,00N<4".E9.,"'N0L4-RK2C=V(DR
M6[X3A$Z'.SQ^%$-7^6"4&.-[4S-%'OA!._)ZN)N\G-'\$C=U;S6L+IM\L^6F
MUR8W;W@=K\U3\^K%<!8S!EJ3F./-\8@.GBLHRW*^1[?F;$7/-V.%A^H*1IP:
M!+; .)71$A@A:/!6_Z;@*Z'%BL 3[,/1&UH7OW)[UX"5<C7S.?ULR+85\]T#
MP*B%"2EB\CW"\R0!9!QTL"C/CPE3=/ZQ-R_KM8=*F89(LSJU6R! 5-X7X\G.
M886-:E9V@UUX+P!]\^#[HU]ZK-KCY*_^KC=(TVP&CILC%]$3I85 IV1,>5CU
M7+505X,U3:U QFZRG+PXJZLNA%#Q$R*!74?TYD0G(@7%HPZ\-,B'RRQYBW'J
M. 8#*"STL2U##Z"@;U*\YTU63HQ@%/R[ +@IF*$4]-ZL#D#9#4&=748BB.L@
M+1H"A \0E9R8]8!!(UBN$QX3X@9SVOE7 64]\:P2A5_#+" ]]DO,TNM&!>MN
M,L+0''7:VHK+- QZ6WFZK0%ZLN11%:T7$M*W0CM%[4/7D9)%"9 PH[77V&CD
M;(V%S0IQMW-);W,YR ;]*D"$;&S;%Q_0>=%*LU4[Q+6RLSO0>N, PE(_&,$5
M)-*GV]7.YG*"B5E[\)"+$D.L)-NA4%4" [?-=B&2X:%@\; 9@'P*@6UC+U5<
MK\,#O@=KKG&E2#JF"6=S$'=:K:2%[BHMM8$VW*.S-2@521KI[Y')==K4Y[]'
M/LQ>D;YU,;F).:TCG^$IV+,ZE^N.XMG*"Y$WG6"4$GV?OG@S"(]"UE0.IT\?
M&]Y^N(RL(/U%&<B U+J&9,;7K=9?U<2WIQPZ4L14$NJI\W.GVU>"2#!:@F!T
MCX-16FR)>[DJ@22J7U4][E_'65F%=G<:/L=LZV: A&9WQ-C7 ?XZOH.#V.^>
M:4RP4 ?=;:]=S>8TO&;+I@(I,K!;[,,E3*M0A;J679"U=DI38DM6P-E!.SSJ
M3Y''<W*$>% /GOMOU'<[&C-F'4Y1]$?'Y<4#U$"1QN?D3:XE8T5KW'^.E##!
MN\^;[)Q]AM16\=I1XM;7G?IDQ9%5;ES>2!S?LZ$+90M/D_/]S\JVK3T__N=Q
M&K2.,3DK;N;X7_HYKS=V(C1__)_'_WOL?]$8#N3D/=MZ(E#.:NE4LM%[@ K]
M5G3!(OB-MD!9(3[WZ,;JH/(K=@24>ERG&1PR)VK#L[(?/DIL19MQ5@B:R9ZO
M<>#UAI?9?!/+;*Z[8UY\5%3$9J@1A!&$(4[9!O?V0#Z W:@E4/CY.HGR L:Z
MM3'K9F9U ;%NXCWX*BH(9[:LUQCLDLUL454ZLP6IH3,P^F:VQ'1NG,7Y0;+A
MZ+\_%7F._IE,@$+40YW9>I$/R][94J.O.-/F[4^8/2@]..<*_**TSJMU&V:V
M&9>U(H.V3 .K=Q!%@C;IFT7&[0BT0Q$&:?*V)P*)#?7/=UQEF-J-DF?=;LFG
MX))SHV95-9BWEJ%HD;Z CB"?QK)QNQ4ILTK+ .EW[.IDR%ZWG;X?;HF-8CFS
ML J:\WUJ9V:GSIUF(W!YL56Q9-D=3AG.OW>?6*KXZ(E4[9_!!,A=Q4KHP1V.
MB(9O&3W?2BW;9.B"-_NI)$^?D=]8HEMACUJV(;VC#9S2"RM?%"J%>3:9"-<0
M,6'YJ[;:S/#NP&^9V9)25Q0E@. S6]Z+T.G7B3?:8-M7R- ;> 2H%+ 2%BFE
MPN6(M&[)0K,'.<*9;50%WLQ6->B]Y6"P]$B[TMF:<]P8H*2077+V-JPU''D6
M#B5W<-AA,CD-@KD^A.N1MY)L0=IA;E=H;D23EN+!R H_JFI:B ?.'X8*(>O*
M8!!P#A%Y.ZM]EB^$=1'I/16?Y.[ZL&%N0O9/R'?^&L+2_N,,?R;J/!WHH3!?
M,8C;B!IT!88C+<A(TR0M,$[<QCL=/SM3Y9"6NV!>NYL+"% JKH)#.^B99+?W
M>HYO*([)<%C-VZ;?;,>I+00@(+DM+*S$I.E)JQ4CUED+36:EH%:A4["VIUF5
MY5D:Q "?KHGOPH"QHY.MA][67'2@ WB1597*I4,O1)"\Z=IPY,P6X5< 0B!W
M+(*ZU6R2!'YM>4]0XV8?SU%R7HOFE2VKA5DTAW->X:2YB*TE3M%$>P.P/FW]
M1Y*\/C?V@%$UHB_R9R!?H*W30;@KAR"F[?KA=?C9@EQ4E+KB6O1EZ3 <3GT/
MLF@'JFPF0*UN&%\/LPSCE*4(1GA$9)8T/';9CNITZ..6,<.:.,\,^T5#7&K)
M]9\R_2077)0B[ =F0*W)8J?<E 5$CP6J2;FBAT1TI77D*^WG8A5OBV13Q=@,
M^$1*SH8-#3>J&.+EH-%W-&!O,+7N@K8]Q<AC==8SGI9#]&F#V640?TA9$V-P
M(ULF>#^<B@LR_BQ\O.3@:N%585T[ <W;*R7T<!L_/7OMRGSW:A=\!6Q0&,N]
M:UH@?T&SN&WG"&#F C!\'B$F?+ZS"9X#,\\E-^Q'9;%MX: I TB@$#$G!.S;
MVY/K.YJ<J9994W0GS3A2BJZ9>I9:4^67#EO4TS&4\,:;Q4$EZ4W+<(^NAXPE
MAON-!J: *IH9D[_M-[ ?O!G<?%><U@VP?(?7A$%;[91COBHZ"_D 4X7%8HS
MNW.7*_C&HL[YBDE%;5C;AC4B"G=$!W-J22N5.H-6SP1IV-/V6Z5T7IQ96@N9
M2[/JZ.3H3](3MN :Q_^^<_>.5#1N.2GL?MZ"J?1G?8Y\XPBF=K9MS;?V']]A
M?=V:*$U,(6]H^/_9 J9W$[O56_<8^?##XT</__C=^;KHS!'>#2XX;[+MG=]=
MJ/5Q>2UD\O\<<?E_CMG\SO<RIQ<T^*^ONORZ3^&RZ_YLV<C/OA*>L?;U=X%;
M<X N7S;;7=K+O_-](/_^X_\]>K)W-/1_#?X/0H+^2W(DBI,H3J(XB>)D4IRH
MP1E%R=QI&D5)%"7S%B4#B)XH4.9.V2A0HD"9MT!AB($H2[X HD99$F7)O&6)
M@G!$43)WFD91$D7)O$7)"/$ABI2YTS:*E"A2YBU2''XG5]!$B3)WTD:)$B7*
MW"6*.5(DGF5I,AF9AO(M+8B*,F;NQ(XR)LJ8><L8:?//PN'V15U%R3)W$D?)
M$B7+O"4+VOGL8!J5,/6R9]CX*&*^!%I'$1-%S+Q%###>Z1T,UH;A!2UW%& "
MO<G1!A5ES-R)'65,E#'SEC$VK N@51-"0Z*'N\F3=\9L=:A$E#I?"/FCU(E2
M9^92!Y-<RJROEFL 79V9@FZQC-G(I\>\1*DS=_)'J1.ESKRESJ]]!O,FBI*Y
MTS2*DBA*YBU*& B]*]I@!-"FCG'?+X'*4;A$X3)OX6)C,H(!9X?VTC]9N.#G
M*&!F3.DH8** F;> &<SN.KZ<,+FIXUR>Q'$NUXK:&^*L)1LZ2#=USJ&C^3(+
MQKIG!$=6BH#@RY8[BT+(W\[RM4X:5W<_^'IC3NF_L-D'0  Z;4]&RAWIZ"H'
MC<N9#YX=[Z:VVLDC/$B:@2,QA<&#ZAV"_M/)3OCNAA\23%?O6R,C<,/9-1ZI
M,'4;Q",P,N'*"V LQP#H,!U.X!X>">,>YF935X)?R_.MLFY_("3HD2HZK,6U
MLQ.1"X[I\GN#P8\A]-P"XTZ-3B_5I]*F 8'HQF"-#@HE?3+O5BG#6(\,#HE5
MNCG@T].Z6Q[JS!!\:8+)8 *!RQ!^NRT. Z./LW>H&DRJGL>!T?-W)FL$GG(\
M.\!4C+ (R-$ ]5E'0_-$8ZR1AQ;6BH_*T*.K%>!V><HBX$V!,(L/9H/ETO?+
M@J1LJS/R@H'W/ 9[B:_PZ*,.J)>CH7!XCVU0)UIGQ:8-O\YHEFW'*(5+BWR+
M,2*\3T;@5"0ODP_I[E!!Z9&\ [UA0*C$K\_JLA<(6#OE7!%%Q>K<\=/LH'7&
MA05DZY:64"PP_%G&H05+S6BC6YVO!W1/1UL^(C<-4D98*@>$F)7,S>%L<C?]
MO7&OD=W1JK==L>'6.8BOOI4U"T@F,36)LJH;3ZO^A2Y-FUO484"[F\;",N9F
M552\$!S(N6!RTJTJNIZG9@]?!$CYX<'9"Z6<.GB5T-C=%":VI;1%UAV^/TO.
M"GZ1FS_/;V2)INO )W$H&0;;":#J: 8'_5[@OM>D!DPPRYZO J:O6Q8@F7%@
MZ?X5N,QT+UDU^-DPAY\I-.8IKT6EAVWLP!7W-2O],0C1R7 9C(!&:_IGS]$;
M!VRK&,"K8+AH,/^][1='EC/VWN%G 'J87.9WR#L&K-[QJF56J,Q\R?)Z:XGB
MO\6B3D!F!Y\ YPE<K'"B:L'!$%.&7'>/FI %0SX)AAM"C?@YIG;0A!=#@*%5
M&@9D<:,,\#OH>>&Y+!Q7J3WM $V5*;Y6=0:?F7B27"^>%D2'+ZMG76=WH#Q.
MY,&JLRUD" FS\%F#2Z2C7'ZD3YFJ()OB9$-O;R'@"J@H'AV@?,'J0(_N+%AZ
M+8K__2_3WT-JRFO?FJ;?U,G;AMC'OC)@1'HA_&8\H=UD)'UY->=^@JI7S3P?
MDF2;POXZ31W(-F+:C#'3W?"(T:%A$XY-CBS2\X'E8PE]:Y&@ Y$ZIJQ8*(H<
MG\E<\EW=B]7 <@CKM'#%N4,Z%M%NT8Z5&X^3-YC(FQ?MLC';K!JPV\:039-;
MKK?G.%B+#FSP<Y\Q/IT'>O#NA[#'7J\OC#<?,+IY9&GQ$? V&)X\HQ6" 7NI
M^.5?BN:29R^RZIT V:LDH <2$7F\AZS%ZSEZ,\D6T<G]AKZ5LKF@X,).;@28
M^RW#0:\\\J^V4@GH,S%PWP[AHD<"P1FS@*2V(-+"2WB"##>&D<'6.*V;AP<X
M"C&U&:H=OS-M-V$A6-'<N<-F.TD_A"-#A6-QVMM!N_*7PN(-,_ ^S#U16/;9
M5H2$#^7!OYCB[%&T95,PY^PR[:CK/6VNA-!9P0% LY*&SY^>D8MM#*50BS<"
M#9F=946IFFMD%YR;H:T8ZA.\,/BF& 48#:9;=!=R9F-69C<C3..C0-@&]KE,
M\@U/$V(L/&DEX^1L[YGMC?BZV@FS%%4PY@ &#0\D&G,R'($$4PSJ2F]-P0JT
M41<A%4SY2GJYI;;F ED0P-R#)P,#T^N9O1%3P62&Z8%)GWP&C!SWU<<G3)#O
M"L1Z&KK3K[RC?;5M3H<6YQ,X>CK$%F&I.1AX-Q2A.EL/G@(/6X?4U-'5PMPZ
MJ4&?!E;"GT//C!1M8<[LC) V9$H$53HV3%7]J3G!5J-(=9D!L^6Y".3MJ-DK
MS]3*UI6;@LZF0%[S:]]5)-S).V7H>S^;X91OBP0X#-V3$=8*SVY<KDW>0P&0
M.V%=\_&Y:9B#(P4:Y<C8"=(!)7*)!_-R-*J !03QCKTPAQL;P15U?,MW:?#E
M!J8+Q[W<G"R(2&^(N2WQ5X./D:;=N$!2W6XUYN,_7W0RS6Q_G86ZO#9$=580
MPR[JK,G):Y<Q2;SMM<E*S.PB+=H1_7AF,VG?SIC1_D2$97:-^.?!-0UWOVSZ
M@DUG'<S #HZP<+&%Z(,'L']L.JJ(7VNGVPQHBN@$*7BB6F4X)#/X"-:!;>5B
M"]0\CB,0Z=E2Q2=;_72GZ9^;F@0FF&WX'CYF8AX9*H>U-'3+RL'LHQ2S)AHB
M&X9^V?%<,L:ARLB3H,<0R\F$'#_6!VM@K[FQ]A.V3,Y?I?ZE'9FC'NC(J PT
MJ_4B]S1LFK0(]V1NN-V:B 91/;W+E89$7YO<O.&S>6V>FE<O=$2,08Z4+DT)
M+=GR_#WQF:QN$Q^*&)B>PG1;\12HE4X=&LP_"2Q3L$,%;\M:F_9Y_%K_JN K
MH1:%^6&:L_$;F-,VAN24V[0.; Q.SAZ4#\-9NF)K0FF-H;D!1CQV"?-"6C'?
M1V-'\ J1$?2AW5'6':UY1A.6ZV<4\AA2R^DZ\=#:SG8)=@%!2. @V91[^::!
M^<\*^@]'[,#_SL*GQ<%YPTOY">3\[4=2!^_1"30BV=FWV]#6&YG&$E@?(]%,
M#\:NA]+*$5@83*4)[1Q36'2R'\_?]0?+;PQ.E]S4IM_:Z2W,W?[6B:%/KP$3
ML&.WIIN!O9GVT)5T7S+$A>M?>X2CK3K3N*PH#5/]?_;>O4ERX[H2_RH5LG^[
M=@2Z-4,];(F_5<3P)=$V+2Z',O]&%5#=\%0!):#0S=*GW[SG/O)F JCND3QD
ML56.#2UGIAM(Y./F?9Q[3A_B8A::8112,-6<$<\_29;U4 Y'K_%&>6!91WR?
M:OFE9L\_R,:<7WRX'^F9W69#KI\S3VY7)[)JX5;L&ZR<Q.73NRR,($EY!1\H
MO#0*U]0/W>X!\]K76Z0(L#.0+N."1/5@<LQ\D#E9C;0:EE/4=WE^281Q6G[!
MJ_Y[K.Y(C-'I<(=XDB5SQ/V@XS)(_XRKL:KV8>8$A%FFQ*J_XMV*;F1J@B5O
MJT.'4(:U7?6BRC.^J*10P2SN30R0"C04&05O)!S',%XROOB1,$'\>^L:7U$?
M$4F7XFL5HM<V<8?*X+AEYQ[+'_.R/"%)Y'Z[^E9++$B*DL#E8+XA7;S1-^00
M>+H.E()T6EW>RN?[T4E^A9.TKWLL%'M_'%1I]80_0-U-N$>2=\.B0A)4[BPN
M!+TPK:O/IYN.JVYB&<1%SR=8LB-_'LFXMV5P(AZ+U("8,Y!N%4G'YUG>_/GD
MLS?=..Q.ZG=-L_8^?SGL>=CA:#2<UN$Z55CQ,.W!],A_;DYA5>KP*LH(A?]7
MAF,TT#-@=+YOZ#+9G=A1P'K#9VO8*= <F-?OI7QGMVFB8AZ?8AHH2@1;$OG6
M464NT\R!C\JJL%>'6A_+%HI"$3H[FC/E)\2OE@JC";U_C9S7+Q;$WGA%Z'H-
MD]-"FR^8Z=(>5ZB_A1\LS%G0:Y8O.3Z&P;Z1W_/G$1JGA98K$ST[<;_#\6O$
M.L1QD[V:1E.E>L/K<F@&%U/Y0N&N+BO6F[UC/=1!/(W[.G6S+6Z;[LM$_+2G
M-\*KHS796_ );[N1JH@JI'))9]NT40F49\H%5?J ,-4UXF0]172,M=#9UX=:
MO0[*__4V,@J5HYU"B!P&<,80O0!PSB]?_:#@G"L:YW=:!+=4RWSV7VIAN<1@
M(N696+GS^IJ2"L%1"S\I^S^6#VB%TW0.;I="BY:]I7=F/,C;,'N<FESAMJ%X
M=C>*.BE_)?L$$\<"OFYJ(CB32N!_"ESH\(=_P:L'#>'*_+;C$;,S_*R7B+RX
MVH+"$ V)L96?.M0]K2I5ZWKWDA (E'OY$<K:L$RY\P.31W66?PMF3] ^G7L.
MAY/J+[U0"6^-MJ.OL2<_\1@\@@U5&T]^YB,TJLZ$A1'L:)4</BA[)GS?RKWP
M.'F7_&3KDULSK]9H=>$R#W?X>'=/F0X'J4H$2<WW>G.$&TQW:Y& R7AK+(#(
M/,!&73TW3 L.W51%CS!.F2\6BF:N3.',.9<#3B%2/1LC<K4WZN0B/,PLT+,M
MEP!3Z.Z]&T/4@21JG"N*^L)'37$\,^E3/LTQ>M-C9G&? SH!_=6PY"NM+GXB
MDS'FB>A8.7XNW.'S/V*$P=(1RFI<DWN=R[1SCAX6$1]%28XC)=/T[",5-&M-
MOW%_>5>W&T +Z11F!6I*]L-=8H\=GU&&60Z_PYKKG&<S+*%$X>RP;7K$S913
MK=MZVQR'(JV6F_L-H[Y7[)C@/ELR/B\M2OMRBTWH5G$F/@['I$;60\_&#'K2
M"P;C0@OW03!((K"=_":*?%6>:# 0CYHY,3]<M8[&+IXZ;S;")Z*Z0V7:M-??
MMG3XYZE'E!3U?O:[,-2'YMAW<AG%5,  .6[!?@#S9@K;FE?CG3K[:KZ31=-<
M##'7+^A/K6!0(@+2D(3;V2E1"(]?M0F_P4DP%_Q2#T&Q>@/J%I2!Y_H D28T
M\MJ(W(EIZ112M#3XN=6UH<A.JI96^W;U.>5)^+N'-.&>[5.[#!0+E&\)-O9-
M2[F\.@'2JJ'2L%-_8_30V;(*?TN6<SNVE1@PC?.6PVV:.EJ*O4FQZS@G-B:)
M&SD838""X5$>C3+(.N["TI52I<3U0*M SB*FI0A'N[V9R62H201T,6(#[>_7
M82?01<28!@-.A17YX[FK.W@%!"S,0$,G3F?KO,[/R.WJ]X;?QC5VYNJ$,:Z1
M1_5([Y@V1D9R<'!F@GFAN.1/@<MANIWDGZCR]F'G)$FG9[D+="]RHB+!6>*6
MLBLL)BYC7L"%_/:;!7WTKC;R1[F32BX4:K@0(?#)A_!W<!8@V/SP@PA'I/ZR
MJ^^:86?A2UE)K93_IMR8I_.6 -* JW_TZO5OHN5MAF$D]U*R$^;2*%MEL4)_
MU*N//Z&4$[R3;ZA,_VDPN>&HK-["8;M3W_,3;/-/(QKO\X&<GF:XY[U!<_NM
M Q*_K?L'(-[".G[>WN/5-+2WL8WCC<?FA/GZVNP9O= ]K,!(7W\LFQ7!%I7D
M!0-C0Z(.CITU7>#@GJ+1XR4;W/$)1J-F$S>9'2[+[W9SN->P+:AY)1Y0GINW
M;/@3"!?RW&U$8LJ&HY])[8:6!^<'(X=TSVG$/W2/E)3V.?H351;+AWH!$C[Y
M& D&^*1+EPQ_59(SPY!P=W:'NM<V$W9&]?<]X$KS@TV?'2@-N DV6;;($M)C
MQO"O.SWX:M'$'<%K>?Q% O97*XV2&5^6]QU9'OCNK1P96>R9?3"=WO6);\6V
M4AL)YZT&IJP]WONFECOB2Q,D8+'ZJNS#*'_QN@B'[Z/7MZNW]S!+W#%#U;#Y
M7&@T0ISB)DZ!Z89XU@:3U#!>&Z'<4L"P!<@NPTEQ)PR7.WDXR]IRG69:P^=B
M#W9:U^97W_K,X9M..KN?$6*[VV7M-5A? 5_8]%=2+>*)YTG_<IL.=A.,:8.]
M1FTN8?>D6T=;2V0MS(+CYDJ ]>HUQH6P)'C8\Y1XEIT7'C.&G0QD+I?)J"\
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M^$J%#_2KA.6&YQ1*>O/#M8'1N#E+1+]'UQ_Y;=C96!.8 ?A^7/U.F'I=5'M
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M4+% 8#_G&6ZPX>*_&ML-7<\3!%AJ=#0/?+2=2E%0='O"A=&!#*5 B(;9C=9
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MVD2"<C3]?'Q*"@[-M)N&PDO'33?QHHXE,A1$J9^D[,4IFOE"H+7]N/2#BFR
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MU8')L(>$P'"P41:K$DPOH"N$N W1MF&H<1404CKBX6-OZTPC*OA=M9.&)8I
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M=W<]"=S=R%Q]@?\+0\8VE=P!"Y>X[1=[)AHPX)F\9U(^+H1#MIYV\])7*#'
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ME$23AKE;G@KN99G+LB_(>_LO)#'O#7XF;'#FT<4/4\VY&5R?C%16I"$\)3Z
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MIMB/W!')7!0+]EY!NC\;?XLT/#*';@MS^:[F:\%</B#6:"_?U(S9>!#:$B(
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MDO%7"W3!6^%J@:X6Z+(M$%PDAOC"JD@?(^ MW',] ?XE#E#XP:L%NN"M<+5
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M!/8DG<IY;T>43?DD]4I1*J*BGEZ:!O*+<+&$$'FH/9UK>IJ0G+5+T/^86D?
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M!G&KV@H-%RCEL3DF.6GV'$<.0AZX@5C*/]2'-1SC9O?BK8_A1E7 +3\U_*4
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M-IQ\O\/&,%V]-"G-*TQ'U]YZ6\-%%D9^LC7S#8H4% R\5V2OST4[YT0DZ0G
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M5JT,=(1;*591GQS>(/,AJW(X>:TQ@[P6R@[UPMXU+4L'Q*U?]CWY(]9/9E5
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M!'2FGW5YP.%!3A1MPM<.6$GH%@?4$/_J5EAV/>:XW)%DP)15?O'-8",9JF[
MBL[!544GUJ\"_+<]G;0&C/,BIX!EKB$&R\6J$EWB[U@+LA>H4! 65=?#2*#[
MG<DP0Z77> QIX(8-5=Q:R3N@1JQQR\CP442K_P"6L2O$,OB&(&FO9"'4M&?L
MOMBVLI /,<<!V1>U\O"FB.V#A5%0TC*BQP RL<8X&WX>BI;$N.0^EFBPJ'H+
M#N->T6% UZR.&$W8/1QU0?5(W_!^^?N?E>[]"S[I35$XO]75IT3X1]2WH3PY
MW,3?Q:3I@==QY!#JASSGI"2.'.T$-6]8^<T*JDZ(LF]@?OCP&UB5,?.!1+J]
M@T'5@DZ84@H-=XBY>K'6NS8??^)W),DPK*0"%6K=5$4&*CV4TG_)3ZXX*I!$
M0T<(YO>TIE.=@C<_Q7X38#KC;YGW/?UT[D,8=[ G'HF2?GA#!M;=@:.<R_UG
M1>///\R![CV"DW,'U#OPY_U'^@Z$3X1>J13'S5L 6A82 0?EO*9!V<>(M=TA
M*;R)!?G;=%K?L#?$SJ(/H\$U"OQH'%UD*/P+H=7:Q1W6M#HN=1715;V?2L"-
M-_EK4C6Z4)YQ.N2X1L5RO]C%5Y4B&.:(I[4*F@?:G:@\QM*?-N/1_R:<U^@G
M:A(&D>*-:-^<4@I"F+*0;NZ\;LH<\@H^<G 5,=W!OT[]9U@5(AZ:@34:3X7\
MQC-A@NH109&3QIR]S.A?]]3_6#,+P\$>H78(GHCI.-69QM  J/V$PXH >K7J
MD5-L%2Z $X[<<+A],U5X,ZQK2G"M6O<L8@-T!LH+1&E1G6 @GFU8B8.4Z5H<
M",QRX-M#VX1XPYK<:V#V1<)8G&/B D/2*V_FIH8M$Q&=3$8$)Y%_C@&EII%_
MHLR)#$W;99N,03XLGXRT[C-TA?4="_]?*&(<^^ G2X%HSUMMN/*KE8]ELMWD
M,7 K$)C?+U0?0/,BK?(8YLI9HB8CSNH5<NA#Z 7F>]QUQ_Q)/_5G3G?DCS\W
MH-5 ZX<@HR#BELM!JMUKYF%A F3I(5,WQ)LD(=;SGB7^N<Y2'I9-E$UK_,$X
MB@9Q1+PNON"6MS2)7>^P* NM2F6I)N(S_BTMM*5LP %9('VESPK(=V3'7K]@
MR;V>:Z+#+C:[B,)BXYM8>VAR+>LW:TBF*-6<31GD81-OFG:;,H?KH?'23SQ8
M<I,FQLX?2'[DN/Z/83LC=&\MG/U8"$:>YBO.AKYRT-0.6[5C& :U[7/N^PP5
M$Q7X-];+B;?BM".=-C%2?18UQ(_RV$00-FU"8I?+UJOF/4HY?\8,NTZ!)0YX
MOR? V0+B#CXV+RE/S*<1&R#QZ1063H$_-(:6+C]5.FS#):=X07Y42 T1DYSW
M^WKV@6<M9'"U)=74+K'(V[:0*V/F.FIO-:F\D<JO*#:QFDC_D+UBMB$#Y&<*
MYS8;:V#E,2 WPZJA-';ORGV6"%M4\5ZW7X^!B=UO>F]]I<(]Y)5<9&_HF(2G
M6A 7[+0@A']%/+QU?)&4=9#]KO0;>@?^7U-YPJ"@]7&<9\W/],1=B=\ULZ\D
M9-:%V#P6S3PW"$WABS#D##V5TH;$5IL,4F:XFN!!M'\A*O[/,'UBAFVXSY%D
MEY7[Y-A:H1\U,O1"TG9G:X@XB4 ?#.K@BC"(-5Y;2MR,1$,9T=OG;@:NHEP&
M:$+ZA-U94,&0O!0'<!P6!'\KU4-%Y,EZ#.KKB&XW[1QXS#$E;SY(&N7=O.=*
M2T&KRGS4>5ZQV%<P7#6KIR_#U)G$99O-4+M^@@%K#V.-_AZ3Q6#B.LY9BT9U
M[%88P?I@Q>H/9[0=9X5]'TI;ZYK%^&ED1A?.?TXQ&\F77IE,0GD+ER!S31E.
MMM=]HY &]]+$A],Y)-:!\XSFWB\+DF\G709]%9NVQE_7$C6.EFDN8V0>\O+:
M3/FDSL'[Q,P#\-5AM!:<1PI8U;/$HJ"W3Y+WEJJ@[9=3%%2OD<[TVX6,4TFU
M-9L#BE/[6 %IL:L:?P)Q;T[8\?KINI*]* Y S3TE=[CK73BH,DJIIU<^8,$A
M/"E9D *56W8(/BL<0_"QZY3LZ-@%4Z1YT5AI>J@=A-+F\7-?N>MC"7&@+,9_
MA,JD7T_(YFU6##W=.)%RZ&')2"B\ZHC8B6F=+B%/9H4BV'W18Y!')F]HO4)0
M!$XC;$NUY@ ,<[IA6WR$DUUSLAGO34XVX2Z1+7HY5WL(EQ%&8:%U5S35Q.MO
MYM ; WR+!!'H/YUPG'5O;^\@:G^" *&2]/&5C52" V%@Q)HE&H3G8DBAX4>[
M;M<0Q7R+]42<UVPK"CVN[]=5%+*"<3,1!&WV(=7,&$UP]O9)WR@%S9X5;-!2
M$$"02\(?"4?*4 :+ZIA1I5HG+QV;,]B<^FPX2R./%M=J(WS9&MHD'PS%<EJ
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M Z>,5-YK#^1\P7.! R^<?WWO:_P8@8J)'*0PU?:=7H8RE;HP[P]["8J=TO?
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M/7.&@X1S#$5YHC%J Q7^5J$UHK<IN P!'")4&7P=& 1XZ."47_0/_VNFA"9
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MRZ4W8X;I7 (B.R/!"\T6-1AKYE^"AT_-Q;3P#2W2Q& C?"(LO E4@UK/#LT
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M9L18AR9\3KO.BB;?@5L#Z8<_?AV<"71V&*"#-('RG07H'D&:<%M6Y<58>J%
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MONAH&:Q:!X:8(WS;KDO)%VX1)!0M@[_-$3/+VCF%XU$QE'H75#TLTE[L6XA
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MBO(:#Y9:SQ\X?+J!]V++TV(X0IJ?^QY4XRBV)';' QP5,D*I7L5N>#%%L/<
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M32S&,*GS"YQ\T)KU__C_4$L#!!0    ( ("+I5#$B3<-9!0  )#F   1
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M9DOFGU/7XEOS55F+SS%8I%AEHF3"UEV+;VU2Q2:CYQW1; BF&86A92?B'9N
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M:.;0.WK>49=1OORW^%DH&DV+5:H:[86U>/3Z7>#)Y\X&@LF!>Z?B:D7$5IS
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M<:6R2E]3$_?S!%S;D"W^Z?]02P,$%     @ @(NE4+\AMWSP$   >0T! !4
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MJT<1!1I&>>4H*+<H&!&A86BWM\J+][])0:EAY):-,C\G( *M8?B6#3I*WX@
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MO_ # L5W&T@J:!W[_X-]^;X@NUC?;)R?V<B;.V$R^(+_\\!T_O(_4$L#!!0
M   ( ("+I5#VM[1%GRH  /#Z @ 5    8V5R<RTR,#(P,#,S,5]D968N>&UL
M[5W=<]LXDG^_JOL??-F7V[IS_)7,)*F=W9)M.>M:Q?))=F;W:8HF(8D;BM
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M=T#H.E%.1^X.8:UCQSFE1^P7=&V0#B5H_7C)J=QC>:O\&F ;N:LXE)$P3>]
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MWH=)%4:"L9GMP56RSS,KC,-D,]OC&V\?9E8, LVFE?M\552.<.N3/P,/UBO
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MOLSP,WVP0L4+) GJ8R/%P(&7$'X@2"(0TG_ BK,?_J*&(]92YR(P0S6X"$O
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M9N9T!_E=,C?[M]/L\#D\=ZF?MFQ>P2:NV>;M=)NV\V[63NRE5#;Z_VGMU$N
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M\)MNUHZFP;/3%DX+<X<1H]#QAR$$%FX 6I%3]/FJ0N><Y4@AWL''X+-I.=(
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MBFP3TW!02XEQ*;4G;Z&86E+'RD<+OH5:37OU4P@!2BE *4;/VLCT_N?Y87=
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MR8FL= J)>.F8)UYK@#\VU_SRL!8^S=D#QA]4 A2/V->MH"[#Y'?#R<Q/@LR
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M-"\22%%W<O6C#%X9 Z*HPP)[PARDC+L/]S[4P,3J:O4?N,8Q?'/**1BS>DC
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MQD,I#W<H]>LL.\#HXD"]_XZ]X,O9W<)/[%>6YHT7F#[AVA9*'9SD0&=V"IJ
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MP<Q#J"%FUP@(0>%5'-[!7\351.KQ>O:#OY"K"NWDD [^8JXH')@C.O@+NJ(
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M;EKAJD6$FA:IHA?B.JX5;'(<@75,.1$Y&\_RZ6#7;OC7 @66YUQ"&WF5$Y#
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M-+YLVWFN[?DM&U>O])F*CZ^R6U8\:A:FKQ5Z%KL@&]HTXDN]#"_[,F1L,X?
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MQXGM^'0]2-Q06(^@KYG31VOJPF+Q^)2:[9;K'?#]7!OYZ@C*$VZ':4?W=UF
M0^#YVE#NWJ.#ON!17?1B78#35_BZ,-P/.>15 <LZXTMBM"N,71+P5%&^+$Q+
M_;[QZ:^A9^L-$=[9]L:/6Q&S/T@E>\.(]B"]6Y!A#2%*&2?3-[;FT07RT=P%
MQ1Z5DI *2,RH<;0.KXIU,8C51*3XNF2S.XT"O$87OP%#(@N_K0] (]OI)<C^
ML,"O'QWD)C-+_V-_0NF/_ICZ(=41XI&.A]^TP-0M6EA>,HIH5&/A9ZI6DW#0
M80T!'0&$!:/+1 =6DNG<-A 1$M=.A^DQ>F++&9=L'M/#[:H4#2Y2=*;'V94>
M![CJ3#(]EDYX$PE8$:8'<8E;8UC %N1H*5= 13XQ;?>9*_2*/+R.+X/T3N7:
M3.K)(D!)F)6Z.T[S@7IP[VD@A)9T/!NYKTP5D%OL+YY1L+K$?FR(D%GP$.!%
M8,$2$44IRMU(\$WL5V#07>/@$GMT=,QJW;UR3.F&C-A.$K^KP*A*<<[G66@T
M8=[!=-O#72W>DIPF_J?$/WUGO;FK:'4=Q?4'69)-([9E2$O)P-QMR3!\=E4)
M(46[H12*YP%.6(K_U-])%^B=Y4=SJK_BY@RS>6)C4DWF1%2G";,M3*\)MV2?
M/#US<B<0RRF#,BQ$4DO2L$>-1#^>6ZX_[I#%3ME$0Z\CD(] D*#4?%0@EN)Z
MZUHOKD=G7GA"0#2EN$[-$\+M$[@CLI*&O!_R$@=KG%2UE7%%%GPNI]5<:NP[
MKFUY$^?5\FWD/%)#DEXMEKL3,HG"96SL YF5IJ\E53O _T!V""_6L/>A#EXO
MK;4;6I[[5YI).YM_\]<!?D7. W, !*&+R/3-]B)JYU_3V]]DA>G/_HI7R,4F
M_9U-;+$RUJ'9Z:T,KR7)/7HAZ)\176+3UU@=@HOF%!/H@'>63"515:.<2$<R
M0-=>*0D=_.^?G^PFC",_?+1"!%],(M2ZD$IN:551Z4H*Z.(JIR%UGE['?A@W
M(O])+9?)5^!I6?+U^,ZHX9UQWQI]BM9K;\.M/N!4BI+3L4^N7=\-T2V]%S@W
M?FCY"_?%0Q-"$&7#^@<.+CV+$+D*.V#2'<M[L>%L054%B*RB^PKLJ;OT>SVE
MT.(Z+P\6-?2> \LG=/6SV"F9Y^YZ6IV_>0N+B^LF9Q#OWG5+&TON,].?Q9OH
M-#%,B_6TZ:_K3<]&##SG!_$N+[#)!6);S"M6(Q_;8FAD0FUL2\E-R/0Z,-"C
MLOSVNKNE/AN'E+ /H :MPQUGIGX&>'XJ$"OR5_$B,V8V+H7NR5)WY>Z6_-$X
MH$1=OM58'6S(<S-5O;B3OQROPRUHIK$.W8*MO%;M;M^?C0-9QTLC+GU#Y>54
MS+1XJ]^<<=/G<@Z?F=I2+!B^("JBQ4S^7@ CJAKK8UDRI'XT<PD)1P25N78J
MXY,X>F;6;H.@!PQ(X]"I*Y%VK-"!(Q4Y>&:6^)0%KSXN-4/NIT$9S>7(P0.1
M,PA_-O/QI0&$@'!TCN)X=$AG)G 01ST(R4K)</NBO-+A<>(&SD#B"(Y*4";_
MC.,WJC]HUN$6N[-3#;[WOF3D/D6KE15L9O.' *TMUWF\BM_KZ:_N6'S3^=RU
M7>3;F_BOVTC95<%)_W-Z&TG9.!1SCZQXXDX-%:D O6^^E7@[$;V))9N)7<.H
MELMC:%--YS(WJ3"O8+I2W.=)DYR;-YU7.J%QW;,$H4/]5">$+'D=P8FYD>%1
M^P4?:^/YDIV2=.Z;L%Y(0X<$%Y;'G-A/2X3"6\8G*P8 CC&NHM*5%-#8X7(:
M[>]D6 RQ#&E)&:HK20#"AF'TNK4$H6+C!O,RB,CB!GL!BVS0H408UZJY&K2&
M%CDL<+AAD8/8],C@!GB5 '5F<*!9,VW6R X?1'!MPSL0EKVP<7 -]G(I K?F
MYLZCW30<R+US>DU6+ "7/%@;MOGIKZ8_X"Y#%I25Q<^WZO9JQ,L1.;[DY-11
M0\B.P[$)9>D>ARC'T#V"U0ZJ)B17(\ZV@\CRE%6<$J8W9KLJ-][ V:["D\7-
M7S,?(&40%-R5'#H--H6V@_ )+>+PIHB$>$6-!=_YBMA[UWKIVKFBHNKJLJH;
ML ='F@)A-&C/I-OB;#Y;(_8N["]2MD$^U0HB6BH;):,]HC6["/@+&<U?3J-S
M?54K'A::":WJO6\ZZLE=^"Z]OEC\5Y^75IBJ=>2PTQ$'B#4:>D8LX,EF;"_0
M;/Z,Z=4I/20?J97J1ZA-W=8BH\>C$]L 04=E0.PS1I*TAT>7_,DY.X/HHFHZ
M.C1J8AK^[CHH!3&IP)#.Q:&_0$ H89)R-QQ*@ZV71^1<!IA :T25?2[%RS2D
M=J%+2'QUO:8&IFVYY"IZLOP%D"T!2A*K@01A;B70/^VO OJC/UBAC=E\9X[$
MWXMK"+3%\\Y@PD6ERK[48KE8'KM+Q/LAU5IL)TC4QJPFI*4NZK[6ND"^O5Q9
MP9_P0(-Z6MU(M,GX )=MK:6E1:)TB1]P U]QM:0ZF2&Y\IF59#I::3(E-"O)
M:-%G]A(YD8>VSJ7<<;^MC;55LA>;[$*SO:,(A\<H'6Z\H6J]H2J9,]/#:=K8
M3UA03PPERD9$YU9A5E@BQ?!(&Y'S%@-LA*%$W.C;QWM&I>GU_,"F>B5Z^Y<,
MTXO_@:]N6/C&:7H(4TL[N\P987H1P1KW#:[U*9E>-5#,)X?%'8>F%PN$ 5;F
M .8HF7T"M&2@"#O]AU)C$/JP4F6N[+P*<0 [C4!)_X;]X\4BZ-__/U!+ P04
M    " " BZ50\.:%@58%  "+/0  $@   &-E<G,M97@Q,#%?,38Y+FAT;>U;
M77/:.!1][\S^!]5-.MT9XR\, 4(RDQ":MAN2;,JVNT\=85] K9 \LH"POWXE
MVR0T(21-TFU+Q /8NI*E>W1TCZZ-F\\/3EK=?T[;Z$VW<X1._]H_>MM"5LEU
M/Y9;KGO0/<@-H>/YJ"LP2XDDG&'JNNUC"UE#*9.&ZTZG4V=:=K@8N-TS=RA'
M-'0IYRDXL8RMW=^>-759]@LXUK^22 KJ( *1EN#<]_Q/?K7NJ&K*Z,ZM37=>
M_WFIA(X/48NS"0@) DTJCN<$3KF&2B5=H<?CF?I]UDQ0*F<4=BP)Y[*$*1FP
MAB"#H=S>Q]&7@>!C%I<B3KEHO'B=?;9'6 P(*_6XE'S4\!(Y+Y$\R4ZS2Q$6
M Y,-;W.[SYDL34%?M-'C--XN+N=EG]R<DG^AX>O&V6D?CPB=-;ID!"DZABDZ
MXR/,BJIZO W&Q0C3O"NID>ZK E7*(*\UP8)@U3\J*EJ[38P8'BE/VW^_>;O_
MMOO)]\JJU,4K+.WS(>D1B7S/\9MNLKL<KT@Y"N*>@/G!3XM8X/EUA%F, B_P
M4/L<HK$D$T G_3Y13%3T&B7 4JPYCO:$NN8 1LJ%] I4CP1,Q0G"S0="48!:
MN/@@=+I#0-$B JH%DJH0+H#B.5"I.D M$.-40282+O+Z @98Q(0-%,9LC"GJ
MX110BJGJ2HU< R\5'"!1CS/5-@&AF88'RC@% 0BGJD]*^31M/ KB-ZW=E=RZ
MP-[:?<EZ:;*=#R4F$_4M<8^"&KZ(0>Q8GH4BH#1-<*2\OCA/<!S/S[,%M6/E
M*\J:NY-?0+M"<9)"8WZPC:8DED/5OQJJI?L3^BN>M\NM8=6I:+,*E/$2L^\[
M8765/72"^BI[V:G[J^VU<,'NYH,L1CHI/,YGQ$+SM@5H\YE*.24Q\IU*(M&<
M^];BC%]=.#=.-(6^S,Z_GFI=<"WL7,YP[7O&F6,5?#5K+@%\+%2N!^E;%\#/
M"Y,.Q\V>0.[N7A8O7K[PJYY2G13RTO<Z<LQT5.#]6\7J%\:A@T4T1/[_S)A?
M<F5=4J:;*0G$!6FTH.2&5PE6B!"6B?SO!M2[@!IX9AV:=7@ORBQ;A[K1W.\E
MNU2U<\B:-EUMW'TE.>H!*I;M.A-,H>8O1J3E.R?EAZ+9_F'KY.CD;,=Z<;#7
M;K\N6U>)I]V]ZR[JP6#]F(SD(Z&4X!'J..A0 ##5QQ5Z/)I_V0B)5%,0/=#C
M;_#O5$!*]$BRW*@U)-"_GI7>$HX>AR??)SK]-*GM1K7BV6H,!LN'8UFM;!H8
M'X.26Q5#R>]!R16JNC[2^ =,5(IS4 CC6JGBAU,;O28,LP@6=#$O(9C>31>?
M$/LW0J]NE\M5 T@!2'B;0CTA+#;"H&[7O+(!9"DYOBD#6Q_U."/1$(L8O7/0
M/K#/JE.&UDI#<LWH0$RBNRK&ZOE>\U61A8EJO68@NK^J/&ET-L(PM+?*6P:B
MARO/^NC,$1X+T/OXCJ/_*8#3H:T.#YPUU)KW$5&#(4IH3()R/3;X=N6VV/"$
M #$)RE?DJ-CUBDE03(*R> ^(3. +>H=G6.!U>^J3Z\5) OIO<VQ@LI,[Q(AR
M:->\BH'H1H@JGLE.5A%HJV8'M5MND3YIB+XFT)/(3EI#,4M5\$?'#NH PR)>
M0YTY@L'E';#L><HA,"4]5"5D8Y8"-1NOR^<H@1V:YR@F35E*#K]J5X+  &+2
ME(40BP6GJ,.Y@+62CO? "!?H@](,=/$G-1N=P6!,L>1BAO;Z?4Q$_E+/GV,U
M.CE#9G=U<_@H5[?L,#"WQ\WSE?L2J.:I#,80Z-L4R<U>V%-E^>M[/^Q]0@WN
MXON$3;=X8;GI%J]&_P=02P,$%     @ @(NE4!]SHV;7"@  #U@  !(   !C
M97)S+65X,3 R7S$W,"YH=&WM7.MOVS@2_[[ _0]<;W=A WZ[;5+;#9"F::^'
M-@W2] [W:4%+M,TM)6HIRJ[OK[\9DI(E/^*TB?-PG ].+,GDS&_>G''ZO[[]
M?'+YW_-3\L_+3Q_)^=<W'S^<D%*MT?A/YZ31>'OYUMYX7F^VR*6B8<PUER$5
MC<;I68F4QEI'W49C.IW6IYVZ5*/&Y45CK /QO"&DC%G=UW[IZ!^_]/&:^<VH
MC[\UUX+!'QY3<8U];S7;?[8.FG5X#&XVTKO]1OK\K[4:.7M/3F0X84HS128O
MZLUZN]XY)+4:/C"0_@Q^_]*/2*QG@KTN:?9=UZC@H["K^&BL>P%5(Q[6!E)K
M&72;479%R\B\'<I0UZ8,'^X.I/#MA9C_CW5;[?3^D 9<S+J7/& Q.6-3<B$#
M&KI'<>=N*%5 1<_LKQ&S(5R JR&S3TVHXC3479)_D(<^@VO-WWNEH]/O8S[@
MFK2 PWXC.KH14PNK;^;!L(N?+!W]$0[BJ+>>! \69>KQ 'O"5!*#$JE(*HJ*
M?'/65L%[]YR6CHX#!D3XA(8^N6"QIAK>G,FP=AI$0LX8(V^Y8IZ6"O@/(A;&
M!@!R+@7W9KN#P^EP"%SR">N2?]$PH6I&6E72;K:NL*3'QF,JZ\&L*$MX$W"M
M&?#^C@V49;YCN'^^0]Q'D9(3R_X;295/Y#!3[CC/^O.=8WTN^%6<'T>*"])Z
M9=@^($^&[T]4>6/2-FP?/C6N#Y#M=G,[;-\H42CN^#+=PE+U5Q)K/IS=9;:R
ML*6CR\CP"BH.ZB]?_?[#,G?ZXF1YLXA&0<P!"P:0]8(&Z#%;H0ZDC-?_^.VP
MW6[V^KA2"L :]37$< W(>+"'6;#?P%M'9I%6KX+K+R5,I/S3>YBU%O>8CB7A
M,3"K"16Q)#%3$QZ."(TADR$LS5TR4B!]H>$,WW,-CPR'7'!(=8!_AC#%2895
ME="?QR/%=8E<+@2!6PP2#",)+Q]_8Z8)B%./"0_A+O"UC-_-\C04,RS[TWRE
MV5Z1*Z"9X++X"Y3,:I>1A,>J1A11!)^C \'JMVU>]^I@0T@0!3FA\;@ ]LZY
MD$O05&J9]9#9-5H[8$).T1PC.D-A$RV),:M4)1>4H8IZSO[&9>$%RW(Q@TN@
MU$* FNNXFJT$#U)_0D./$3]1:.%H/4.N8DTZ3>+368Q&;79S:^%GIF,.%_!1
MIX[6 J7G):IN_;U]_3 $<\\LYR\)5,P]914U>\" :T#Y9$PYP!(N^%+P*[E;
MX&DUFL+<[3JOXVS>IMEQ<8T%("TZR!!@#OB#AR,:!.V6UF-T<&FU@L"ZQ2PH
M@$BV'Q7@,Z@B,T9!!&;)N1 ($PS!3I^^MIP-D@-&()NN*>.&!D G0!%:<2#B
M\-:X,I;?<(&>*==61/.%:" 3H"BBW#?.9<[62MEF<L/$GOLL+DB\G.H0!@E!
M=8I=JC9T:"_EUD$),="UV 8$MU*E:KRN8J-$ /7#1.3UUM(<6Z)10LPL7"?D
M2NL!:YF &P>FDPC> JTH#.<F?3XAQG&\+@DVU"6XI TK ZE\IEZ7FB7B,2'B
MB'I@$]G[B/I^^C[U0O8C-4\*0:.8==,_>B  7X\A"3)''+"#PA>?3-S.X)%*
MZ2+V4>N/ '_-:K@UNI2IHE%IM[S><GB\'SI:=1=P42GZ#>TORV=;P-\:%]=,
MQ-LF$;\Z+RG&W0NF*0^9ZBYB!"\*7]!>X#>8TJV"U'I1[QS>JWK2>@$G1ROZ
MB6[GI<%Q9:CJDF<.JI<'U1?-*PJ_QPK,8",PQY@#F"B:JX=36)Z_J#936/8.
M>.^ 2T?MO0,N.N#LH-BFO.2+2[7>,;;WPYO]\''B<YT_;7_6?FE]3@;=;D&T
MV2/G('(H&*36M2>>M7).>I>0\C8BE2I)_C'! !95<U&H6VO6VRL5[TP&/ 0P
M\8 ,*IGT7(F1]W+"5&C*ZP+*S26UW$?$?40L'77V$7%=1/QDCWS*L''-V%]E
M'QXW9.-+X;#5>>KA<%W<.UP/3([E/ 2YAMV]L;QLRJ6C5K]!C\PY%XYUJ92+
MB(Y8;: 8_58SYV==*J9T%O<6(L(NJ4.?DI &P,N?QZ<?/G_]2&-]@4T>Q?QS
M0.,-@F'NM#'ZTP<3!+SZJEQDA3;_:-JQS63X7F>+_DZXGNU^JXA9/J_5/1C!
MJN;T&Q7>YOS7ZWFVF\U#XA#]$.*0 K9!S@5DNS?K9>,2"QW.0JL(#X]B+;UO
M1$9(7ISQ$"4J3N!/['N9/JMKNJ:\8DJ U"=:JEEQ#=<&P9;.=Z8\'F,[!'.&
M"%")QU0QURB#I=$)IAF]X_(=5N&?J/H&*/^;BH0YRDF9QL1G0Q[..S'(7R7]
MO(%=S- T+>[8^D!Q6>+L)WRT5?B X=,V02@!WQS@1>RJ!%(QVU31#.!O-2NF
MMQ.3H9+!\A)+<#J%H5.J_.O#&5"?$0I@!J F'A6F>4BHYT%987Q*UEE"6EU_
M;+X,LI'B8>&7B3970L9LWPF;=EBWV)EEP"9U7-0SBCF8%5N ZTO6PA'L[?"/
M[4C3A)JE'20>!,S'<0:X!-J#!,GY% ,DH^'(=%)/0+>5%)MTI$KB9/ 7\QP!
M\_X8?K!UT,OF"' ]'B82U,>ENAO53X^53$9NX *[FON.UP-PW@\ELVBM2BSN
MD9Y]M;NR ??>QH.SM-)-BUORN1@WS,1!.H+EG =Q:WQB#!-#XYV_8- 9PQ9,
MN8$L##8_'\F+6RS$].KB:$INK,+X\57-L^I2WF)&$\"QR"G&T((CKZ;S"/@4
MU=;7@8@Y7 .ZNJ3,*]C_SPV>8.3%IQ"Y*MR'!\;@0@<,PBI=.<1GPI0F@D'5
M0/24"4B"RJUV!6)RJ,?Q/ [D!;(PD%'$R01&V)I7,F8]Z^#3P;HYO?F(,T<A
M8Z'[=(XYRK1"KGET2PNI7S;@$B:I=$V^%\^'%@LY698&HO8\.S#GX%5BE,K.
M^AJM,0HBJ/>M]L4#BX+5)I@6FDFDXO9F,UB 89)D G42I_-5%,HSJ$!!E@ A
M\80T=V**ZRVFIZNI39F#_$6!890[D!H&-D\%7#%DVR&<E:D+?M#8F57<FZ7U
MQXZ73K/VEL[(.9*_Y!*RC!'P3X2Q!B<62%=,#>++:9C2%C*4D\8A5+ B!Z19
MPHX-Y6'&% V7<RFUG4,"S,K?*[GQ)AJ&4,6H&+]^X.RTD#ECDEF>5=R-!:A"
MT-8%6]Z<PBWG;EENMN E4@Z0H!XZB=T[F"L/?L"(4?2@1!@$K*23D&OK^F\P
MY7SQY>NJ\=JM.(A5)G%[-I O4QW!.64T%@+,[IAA[,N8?1DSGQO9ES&/J(RQ
M)0QQ&*TJ819=R-HR8<M50GIRM684_9'5$%=SL['"V"!C\N0:KM=N)W5L.^F>
M*I=739P^W5;ELMW4YJ[2^\?=X6W?4W=WGWD<;4I_'UAB4B4/C*"%XN"!4;?P
M[=*'0M85I=,#H_0'CCBRY&&WDH3KG'1 *H8%NL-@:\%^?PJQ/X78GT+L9W7O
MK.S_$'+-T[J_OC*XOX'Z8V0<#6J\5-W?WIF?GGO7-#^PUL(QP4H;YFX_)I@=
M&W'&;@O<,O8>^7!>TF;_SV)%HZ2:<T;+=W-?.ZY4B]]H_H$#B:<WHGQ/%7"K
MU=YF";QOWMUZ=6]&F!0#;CH5)TSWQ?[\?ZW(&=:*Z;E]0^ZVT]3K=>+652!W
MW9"[TNKOX-@JG^T6]/F!:/*6<^*MY#FW\6_.'LNI7B?[WD:_X?YI;K_A_CWO
M_P%02P,$%     @ @(NE4*?A>P.D"0  <$$  !$   !C97)S+65X,3 S7S<V
M+FAT;>U<:7/:2!/^OE7O?^AE:U/[IK@$=@ZP785!MEESN$!.:FMK:VN0!IA$
MTB@S(S#Y]=LS$I<A\=IK.\%./@"26M,]/4\_W7,X!S\WNG7GCPL;SIQV"RXN
MCUO-.F1RA<+[<KU0:#B-Y,%>OFB!(T@HF6(\)'ZA8'<RD!DK%54*A>ETFI^6
M\UR,"DZO,%:!OU?P.9<T[RDO<_2_GP[T/?--B:>_%5,^Q1\N%3)'KZQB^>_7
MK_(HA<\*\X<'A;GXS[D<=$ZASL,)%8H*F.SGB_E2OOP&<CDM,.#>#+]_.HA
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M4Z"ZO:%1(A8X^5_H=4D\'&8\EVK6&\@<''L#4_;>Y%Q7HJ1(3QN;<Q4;]V3
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M*,A\ XL\'RE@(V,%V%>-3@.K*>4*GDH]7EX77(C%]<)@L4HK-4KQPD%_\67
M9E+X"9H +1)ZL/1'L&G5,]JSL6@DBAZW3XZ?#V83Z:%%79,!9I87C?L_H)=;
MG\\3/I!3*E_H_H1Z=-NG"=UZ33, Z28V'\97L?)74_GSWK^T(TY[-N%38!:G
M/LQ X%R7COU1<L*TFF-Y8:QG1K.WV'AD6K?3^IV9C)V!+1U"W:((IV5EL+00
M_K'TAUP#/]%K:M_Y%GVGM]>^\S-WZ#'H&_F<?<))HT",H1E=J'(<8; );3Q+
ML3+'U87K.2NUMR7@H+F''%<^<B;.<KQ"913+>(I%EIE<>N9-E-L0T)""<]S.
M223GGP#[76O389E 9;!+1;:A/D@@E38M<Q336!TU02]B./?3"7,E_5G5GX&%
MJA$:0"Z=PG .'1%=S$]P@*Z -"A([1:HFA$X3(SPT"BC^;H9:C#48+BNQ]&W
M"09@F=3H>N3%*U=K(A50'&_;M?M2DTIA8<7OJ2H%MHGNO.97342!I&6Z0&\D
MD!!@E%J1HG)2=Z-KA)$(B6"3)$J% H@'@SX<NG-!GY2["<N4F;D%.RR,I2-C
M><:I,.J-6C;7$. 6RFQH6U.@IL!U/8[WF@+#:R[SXME/O>Z/ U?Y>95;TG)J
MLDSBY8$[#/YTR;B%X+GHB9(< )5BX,@9I)M0#1++,9J@B(*NA72I,J[$>A1G
M6*.B"Q?6I""PV+$#]%@!B(#HEA=7Z83K,; WN(1_+!6X*K8_XJWNR0$<QDMJ
MI'LB8E%43]*6A8X0H9X8K?AK;(F^3EH]K,MLL\L,NZ2QWV0/2E#2TJ]YLB,S
M_84>N6)PNQ/71/U?Z<$/]YFHY^!05<1)R%4^3[TFI5$I+]W]JU ^,P+D5M53
MS)!,:;$!#'"FTH6P":5 AW9H<W 5<*T';184#R"L4J05PII50$<W)09?J(LS
M2@KN@Z(C)X5$.]$ 9$SD0ABIJ:7247(5%A$7,K$09!D'J)#'H(XJ%1P)G):*
M4VR(PPI*K)(TK!%3OO5,%;^-@ 0Q?,/Z(.IP;5>F?8W77<'KZ!O"Z[T#O0W*
MWC]$O#=L$=!3*8BAW!D=.,,=\I>VL0BLW(H%Y!"[DH^DDGY.B>NV;@GY@8<!
M=9'6UT37ML%"\'U5#:@H;8&H=2'13E/$5E @;(B-06/^K)"X> <*0CF)E-I'
MJB+R98%1;\W579GO-5=WA:OI7G/U L=1AMB.H -9!JF74\2%V[*UMMPGN$>L
M&B^W[[8%C&)%C#-=W-,;F=+?KL%]HFF^E ;:L,P^O_//1HNMT+ R0+0$G152
MXS4)=V2&UB3<%1**O2;A>83,)JSH6+3:'@QWMA+Q 7$E)>4F34M+2%K+@+>T
MFAOGL9S>Q<*V7(H-5>\_L(-;JF3(5HSX;DA7BJ=(O'"B2X>]NESJ=1BUFG"W
MW"Z@6#&P&$0(HH,]J@!WSI3\!*HZWKTAW_QB$]7\K>FSJ<=)?2"S[4 FO"(E
M%NQJKH(:BK'6^;&*;X@ #\B@-[8(E]KQ4DAOK%LFK:$ F\QSZ3W '1'DR&!:
M3/>%1/U"(P=(&0S8' 6$^$G67: 1_B@EJA\P6.HT' 0?UF<LNS)YZQ!M5R"Y
MWV<L;Y1BM!TGD8%TVDHGN*D$)%:5<"[/.F; /U$&&;?#0@X9-O+"NVN+=TD>
MQ,'J6"*>?V^)@[C B@Z68="MS*RV_[ *@@^YTHQIK,,<UI4YVAL'' 93A9];
MW[JI0Z1=FI<U_W:%?_M]"/(&,]',8I#51!I!" V19^$-V I\S9C(23TU:@J4
MS6D^KE[DM54T"7FAS!SP[FQB8OS(KV$5,?A54MWVW8!:/H5'_7PJVJ5WP_\"
M]AY#NFJ"Q%\]-;Z8>W$L*X!&\9,_/1]42BU&&\[66:?]XTF!2P9-&#K@UG[0
M>)"%JDL"?;B^;C(J>$*G/,?)V6>_\3D[:;)>I]>Y@Y37#=;=&7O=#?GMC_NX
M<[?ZSSKAWSX]ZL0E-WZJ%M^<6S-;$GWEW@[SI ]V^YS\KZCT^46@^Q7F(2FU
M[Y/P^@2LI]X33[T]FEE_DRFP#Q9325*GR=Z&H">F:V<3"5E50F'0^[A3=^.7
MR/_?XS_X$%\5P>%M#/1PP]$>'>^MVR!F2^M&:,6B1\_<Z@?]ITGU'P?\!U!+
M P04    " " BZ50 Z,HBF0%  #%%@  $    &-E<G,M97@S,C%?-RYH=&WM
M6&US&C<0_IZ9_H<-F63L&;CC ,<I.)Y),4X\C5]BDWKZJ2/N=)Q:(5TE'9C^
M^N[J#@R8M$G<-ATG_F!.TFI?'NVN=G7P^.B\/_SY8@!OAJ=OX>+]#V]/^E!K
MA.%UNQ^&1\.C<J$3-",8&J:L<$(K)L-P<%:#6N9<W@W#V6P6S-J!-N-P>!EF
M;B([H=3:\B!Q2>WPNT<'-.=_.4OHUPDG.7[$W-@&OVFWHE_V R3"I7"Q=A N
MJ!\W&G#V&OI:3;EQW,!T+V@&K:#] AH-(ACI9(Z_CPYRL&XN^<N:XS>NP:08
MJZX1X\SU)LR,A6J,M'-ZTFWFRQFG<S_T.X1*N'+=YM->JI5KS#CM[8ZT3,H)
M*_[@W8C(_3!E$R'GW:&8< MG? :7>L)414J*=)4V$R9+YHX 3'$"9Q4OJ:;,
M"(82H2*L'0YN,C$2[MF3Z'FSUVX%T4&8'VZW+$9=N5DU)&KEVTS]O]C6'UP.
M3XY/^J^&)^=G'[;KU\(ZD<X_T;!.L-=Y^LFF5#!4*M[+NHO"V *GP&EP&0?#
M?R^$X1-4#BQW@ Q<!D+!92$Y1&W6B#H[HUW0J2>_XG%A,+Y0Q\%-G#$UYO J
M=K0<?=_NU(%98,@LX4D==FC'LR<O6JUF;Y7:3T6]76 J(8X4KJ4K1>V])O'J
M9RRG&'K>IM&0@@VB%PLEWBOA..YTS*$>?9UPV,'5]\%5T ^ ..U[3KMUN!92
M"C:!TP!>&\X50EKW//J9X"G:@/8X,>5PGJ8" ]T+YZ8@MB;7AI%N:X;T]21G
M:KYFPX]\BH@=53)6!1P+Q50LF%P5X)=+-G7(N.&C.> 2N1.N,5=?',Z(6U=M
M$ 9^4WHF>3+FW0?GE5$ PUM0"-MHOV?A7<$HE<HY7'(\#,1"P3'NJ9REV7A'
M_NJARKD1.@'O>7#*3)Q5R2FJ0ZO9:GI,9YF(,R07E@X9@1)Q>< XP9QC<8:;
M&;GV1GI;\X ++TK$E5(+3ZA#6DA4-48C) 7(3+AL,\8L'>>&R^^PW?(335E?
MVMM)%DNEUZQ&49U<[\%Y0JOT!*&(LCR<&"F94'@T&&2$PL8!0,H$^4ANN"6(
MZT3'I 3<CY08>[B0(["VC,QT&9/(.?'%@H]BI"ID>4(:W<D+MQOQ&CPXP$_.
MX/ID>#:XNH+K-X/+P?EQB5*!^AF+AB'N&<,,2;=#F8C0!1/K$Q?&%%M"M(?N
MGK Y#4_9O R[3;P^J\(I@2$L:X?/U,CFO9)K(J;@L7]9\_53#><<&^%=,=(&
MM7]9:]8PL4II<Q8+-5Z.<Y8DBW&E6+FC$6LI66YY=_'1PS!.7-;MH#*>OZ%_
M"4PKP:4E-5CP*:E9X72OTF)AK-52)- ,]O=R!T^:_L^S_'APJJ'DJ?/C=;26
M$Z4_$M67=*S0AMNNWS*?T0%B%9T<4BUM/@]70N5K W4+H/>!\@$C=8'I7)!F
M/K=_J-S;N3 "[X*<R=(O[U#L;H%W 5A6:AOYQ/2E(-_(D)LGL)HQ[QMP7W$B
M6Z_PO^6P^^"YCN6W]+45I)\P^< RA]6K1I*O)+.[K>5M,KN[>#>/A;Y4PCDL
MH_ZU$NTC"N7/$?1?G\:06L9XK65D<>Q; NKTJ/JEOA1\2[IL-(7#GD+2(T6=
M.DRE'20<V\ $6Q!LY&\;Q)57%3K?99>'3<=$6+MH4"H>R']$'5)<O5 @I]$<
M):58D).+"$5EN9J3%*QRMS]I^/)^4_CM2TY[_25'WR']N]<?V)EE'/<8[,(2
M>LE C#GQ8:FK!">H^J)W6**';;0P5;]&US"NDRECKK CDRM6DQ$2-2@8*K'6
M(MH"L2]M_T?:C[]\9/3N&.6;%VWUV'L05H_*?P)02P$"% ,4    " " BZ50
M3Q&'XL6J @"^YB( %0              @ $     8V5R<RTQ,'%?,C R,# S
M,S$N:'1M4$L! A0#%     @ @(NE4,2)-PUD%   D.8  !$
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M &-E<G,M,C R,# S,S%?<')E+GAM;%!+ 0(4 Q0    ( ("+I5#PYH6!5@4
M (L]   2              "  0FR P!C97)S+65X,3 Q7S$V.2YH=&U02P$"
M% ,4    " " BZ50'W.C9M<*   /6   $@              @ &/MP, 8V5R
M<RUE>#$P,E\Q-S N:'1M4$L! A0#%     @ @(NE4*?A>P.D"0  <$$  !$
M             ( !EL(# &-E<G,M97@Q,#-?-S8N:'1M4$L! A0#%     @
M@(NE4%W&,G+Y!P  AD   !               ( !:<P# &-E<G,M97@S,3%?
M."YH=&U02P$"% ,4    " " BZ503*9GQ@4(  "I0   $
M@ &0U , 8V5R<RUE>#,Q,E\V+FAT;5!+ 0(4 Q0    ( ("+I5 #HRB*9 4
M ,46   0              "  </< P!C97)S+65X,S(Q7S<N:'1M4$L%!@
0   ,  P !P,  %7B P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814058752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>USD ($) </div>
<div>Tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, face amount</a></td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_NumberOfEqualTranches', window );">Number of loan tranches | Tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Two Thousand Nineteen Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt instrument floating interest rate percentage</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentInterestOnlyPaymentsDate', window );">Interest-only payments date</a></td>
<td class="text">Mar.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod', window );">Principal plus declining interest payments</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_InterestOnlyPaymentPeriod', window );">Interest only payment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_TrailingNetRevenueTarget', window );">Trailing net revenue target period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, face amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Tranche 2 | Two Thousand Nineteen Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentAvailableAmountUponCondition', window );">Loan and security agreement available upon revenue achievement</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Tranche 3 | Two Thousand Nineteen Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentAvailableAmountUponCondition', window );">Loan and security agreement available upon revenue achievement</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_OxfordTermLoanAgreementMember', window );">Prior Loan Agreement | 2017 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_RepaymentsPrincipalAndInterestAggregateAmount', window );">Repayments principal and interest aggregate amount</a></td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtPrepaymentFee', window );">Prepayment fees in aggregate amount</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_OxfordTermLoanAgreementMember', window );">Prior Loan Agreement | Interest Expense | 2017 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss recorded</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, face amount</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentAvailableAmountUponCondition', window );">Loan and security agreement available upon revenue achievement</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt instrument floating interest rate percentage</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Loan Credit Agreement | Two Thousand Nineteen Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtInstrumentAvailableAmountUponCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, available amount upon condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtInstrumentAvailableAmountUponCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtInstrumentInterestOnlyPaymentsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest only payments date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtInstrumentInterestOnlyPaymentsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument principal and declining interest payments additional period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_InterestOnlyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest only payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_InterestOnlyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_NumberOfEqualTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_NumberOfEqualTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_RepaymentsPrincipalAndInterestAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments principal and interest aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_RepaymentsPrincipalAndInterestAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_TrailingNetRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trailing net revenue target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_TrailingNetRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cers_TwoThousandNineteenTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cers_TwoThousandNineteenTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cers_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cers_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cers_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cers_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cers_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cers_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cers_OxfordTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cers_OxfordTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cers_TwoThousandSeventeenTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cers_TwoThousandSeventeenTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6669433840">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_AccrualForManufacturingOfEntityProducts', window );">Payables to Fresenius</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,262<span></span>
</td>
<td class="nump">$ 8,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Receivables from Fresenius</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 1,796<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in &#8220;Accounts Payable&#8221; and &#8220;Accrued Liabilities&#8221; in the Company's condensed consolidated balance sheets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in &#8220;Other current assets&#8221; in the Company's condensed consolidated balance sheets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_AccrualForManufacturingOfEntityProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrual for manufacturing of entity products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_AccrualForManufacturingOfEntityProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813035872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Less: debt-current</a></td>
<td class="num">$ (4,813)<span></span>
</td>
<td class="num">$ (5,017)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Debt-non-current</a></td>
<td class="nump">39,458<span></span>
</td>
<td class="nump">39,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt, Principal</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt, Unamortized Discount</a></td>
<td class="num">(542)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Total debt</a></td>
<td class="nump">39,458<span></span>
</td>
<td class="nump">39,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentCarryingNonCurrent', window );">Debt - non-current, Principal</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DebtInstrumentUnamortizedNoncurrent', window );">Debt - non-current, Unamortized Discount</a></td>
<td class="num">(542)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Debt-non-current</a></td>
<td class="nump">$ 39,458<span></span>
</td>
<td class="nump">$ 39,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtInstrumentCarryingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-current portion carrying value of the debt instrument before deducting unamortized discounts (if any).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtInstrumentCarryingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DebtInstrumentUnamortizedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-current portion of the unamortized discounts on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DebtInstrumentUnamortizedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805005360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Available-for-sale securities in unrealized net loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Gross realized gains from the sale or maturity of available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Gross realized losses from the sale or maturity of available-for-sale investments</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Gross realized gains from the sale or maturity of available-for-sale investments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804636224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of anti-dilutive potential shares</a></td>
<td class="nump">22,145<span></span>
</td>
<td class="nump">19,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of anti-dilutive potential shares</a></td>
<td class="nump">17,361<span></span>
</td>
<td class="nump">17,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of anti-dilutive potential shares</a></td>
<td class="nump">4,743<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cers_EmployeeStockPurchasePlanRightsMember', window );">Employee Stock Purchase Plan Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of anti-dilutive potential shares</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cers_EmployeeStockPurchasePlanRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cers_EmployeeStockPurchasePlanRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797119312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Stockholders&#8217; Equity</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Public Offering of Common Stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued and sold 16,866,667 shares of common stock, par value $0.001 per share, at $3.75 per share in an underwritten public offering. The total proceeds from this offering were approximately $62.7 million, net of the underwriting discount and other issuance costs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales Agreement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 4, 2017, the Company entered into Amendment No. 3 to the Controlled Equity Offering <sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup> Sales Agreement with Cantor Fitzgerald &amp; Co. (as amended on August 4, 2017, the &#8220;Amended Cantor Agreement&#8221;). The Amended Cantor Agreement became effective on January 8, 2018, and provided for the issuance and sale of shares of the Company&#8217;s common stock having an aggregate offering price of up to $70.0 million through Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), which amount included the $31.4 million of unsold shares of common stock available for sale immediately prior to the effectiveness of the Amended Cantor Agreement. Under the Amended Cantor Agreement, Cantor also acts as the Company&#8217;s sales agent and receives compensation based on an aggregate of 2% of the gross proceeds on the sale price per share of its common stock. The issuance and sale of these shares by the Company pursuant to the Amended Cantor Agreement are deemed an &#8220;at-the-market&#8221; offering and are registered under the Securities Act of 1933, as amended.&#160;During the three months ended March&#160;31, 2020, 1.0 million shares of the Company&#8217;s common stock were sold under the Amended Cantor Agreement for net proceeds of $4.4 million.&#160;At March&#160;31, 2020, the Company had approximately $9.6 million of common stock available to be sold under the Amended Cantor Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800331232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Customer and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Customer and Geographic Information</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Segment, Customer and Geographic Information</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to operate in only one segment, blood safety. The Company&#8217;s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company&#8217;s operations in the U.S. are responsible for the R&amp;D and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had the following significant customers that accounted for more than 10% of the Company&#8217;s total product revenue, during the three months ended March&#160;31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#201;tablissement Fran&#231;ais du Sang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Red Cross</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160; Represents an amount less than 10% of product revenue.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6680452528">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Development and License Agreements - Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems', window );"><strong>Deferred Costs Capitalized Prepaid And Other Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_UnamortizedDeferredCostForDevelopmentActivities', window );">Prepaid R&amp;D asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems', window );"><strong>Deferred Costs Capitalized Prepaid And Other Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_UnamortizedDeferredCostForDevelopmentActivities', window );">Prepaid R&amp;D asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ManufacturingEfficiencyAssets', window );">Manufacturing efficiency asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 1,349<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in &#8220;Prepaid and other current assets&#8221; in the Company's condensed consolidated balance sheets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in &#8220;Prepaid and other assets&#8221; in the Company's condensed consolidated balance sheets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred costs capitalized prepaid and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ManufacturingEfficiencyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing efficiency assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ManufacturingEfficiencyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_UnamortizedDeferredCostForDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized deferred cost for development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_UnamortizedDeferredCostForDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814322032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values on Financial Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">$ 110,159<span></span>
</td>
<td class="nump">$ 59,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">United States government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">22,865<span></span>
</td>
<td class="nump">15,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">United States government agency securities | Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">22,865<span></span>
</td>
<td class="nump">15,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">76,561<span></span>
</td>
<td class="nump">35,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">10,733<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">99,426<span></span>
</td>
<td class="nump">50,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | United States government agency securities | Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">22,865<span></span>
</td>
<td class="nump">15,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total financial assets</a></td>
<td class="nump">$ 76,561<span></span>
</td>
<td class="nump">$ 35,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813382960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Available-for-Sale Securities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 110,282,000<span></span>
</td>
<td class="nump">$ 59,478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">364,000<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(487,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">110,159,000<span></span>
</td>
<td class="nump">59,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,733,000<span></span>
</td>
<td class="nump">8,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,733,000<span></span>
</td>
<td class="nump">8,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">United States government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,591,000<span></span>
</td>
<td class="nump">15,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">274,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,865,000<span></span>
</td>
<td class="nump">15,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,958,000<span></span>
</td>
<td class="nump">35,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(487,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 76,561,000<span></span>
</td>
<td class="nump">$ 35,171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804949024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail) - Term Loan Credit Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022, Principal</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023, Principal</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024, Principal</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total, Principal</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear', window );">2020 (remainder), Interest and Fees</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo', window );">2021, Interest and Fees</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree', window );">2022, Interest and Fees</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour', window );">2023, Interest and Fees</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive', window );">2024, Interest and Fees</a></td>
<td class="nump">1,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees', window );">Total, Interest and Fees</a></td>
<td class="nump">10,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear', window );">2020 (remainder), Total</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo', window );">2021, Total</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree', window );">2022, Total</a></td>
<td class="nump">17,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour', window );">2023, Total</a></td>
<td class="nump">21,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive', window );">2024, Total</a></td>
<td class="nump">6,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest', window );">Total</a></td>
<td class="nump">$ 50,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees in remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees in year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees in year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of interest and fees in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cers_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803092464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="text-align:justify;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Commitments and Contingencies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early.&#160;The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company&#8217;s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases is as follows<span style="font-family:Arial;"> </span>(dollars in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Month Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payments for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/></p>

<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum non-cancelable payments under</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leases as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as follows (in thousands):</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,927</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,053</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,616</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2020 and 2019, the Company recorded operating lease expenses of $0.8 million and $0.5 million, respectively. As of March&#160;31, 2020, the Company had no leases that have not yet commenced. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Purchase Commitments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6591997856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DevelopmentAndLicenseAgreementsAbstract', window );"><strong>Development And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DevelopmentAndLicenseAgreementsTextBlock', window );">Development and License Agreements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Development and License Agreements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Fresenius</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fresenius Kabi AG (&#8220;Fresenius&#8221;) manufactures and supplies the platelet and plasma systems to the Company under a supply agreement (the &#8220;Supply Agreement&#8221;). Fresenius is obligated to sell, and the Company is obligated to purchase, finished disposable kits for the Company&#8217;s platelet and plasma systems and the Company&#8217;s red blood cell system product candidate (the &#8220;RBC Sets&#8221;). The Supply Agreement permits the Company to purchase platelet and plasma systems and RBC Sets from third parties to the extent necessary to maintain supply qualifications with such third parties or where local or regional manufacturing is needed to obtain product registrations or sales. Pricing terms per unit are initially fixed and decline at specified annual production levels, and are subject to certain adjustments after the initial pricing term. Under the Supply Agreement, the Company maintains the amounts due from the components sold to Fresenius as a current asset on its accompanying condensed consolidated balance sheets until such time as the Company purchases finished disposable kits using those components. The Supply Agreement also required the Company to make certain payments totaling &#8364;8.6 million (&#8220;Manufacturing and Development Payments&#8221;) to Fresenius. Because these payments represented unconditional payment obligations, the Company recognized its liability for these payments at their net present value at discount rate of 9.72% based on the Company&#8217;s effective borrowing rate at that time. The Manufacturing and Development Payments liability was accreted through interest expense based on the estimated timing of its ultimate settlement.&#160;In 2016, the Company paid &#8364;3.1 million to Fresenius.&#160;In August 2019, the Company paid the remaining &#8364;5.5 million to Fresenius.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Supply Agreement also required the Company to make payments to support certain projects Fresenius has and will perform on behalf of the Company related to certain R&amp;D activities and manufacturing efficiency activities for which certain assets have been established in the Company&#8217;s condensed consolidated balance sheets. The manufacturing efficiency asset is expensed on a straight-line basis over the life of the Supply Agreement.&#160;The prepaid asset related to amounts paid up front for the R&amp;D activities to be conducted by Fresenius on behalf of the Company is expensed over the period which such activities occur. The following table summarizes the amounts of prepaid R&amp;D asset and manufacturing efficiency asset at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&amp;D asset &#8211; current <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&amp;D asset &#8211; non-current <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,094</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing efficiency asset <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Prepaid and other current assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Prepaid and other assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the Supply Agreement extends through July 1, 2025 (the &#8220;Initial Term&#8221;) and is automatically renewed thereafter for additional two year terms (each, a &#8220;Renewal Term&#8221;), subject to termination by either party upon (i) two years written notice prior to the expiration of the Initial Term or (ii) one year written notice prior to the expiration of any Renewal Term. Under the Supply Agreement, the Company has the right, but not the obligation, to purchase certain assets and assume certain liabilities from Fresenius.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments to Fresenius of $8.1 million and $7.8 million relating to the manufacturing of the Company&#8217;s products during the three months ended March&#160;31, 2020 and 2019, respectively. The following table summarizes the amounts of the Company&#8217;s payables to and receivables from Fresenius at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payables to Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables from Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,631</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,796</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Accounts Payable&#8221; and &#8220;Accrued Liabilities&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Other current assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreement with BARDA</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company entered into an agreement with BARDA to support the Company&#8217;s development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells.</p>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement with BARDA and its subsequent modifications include a base period (the &#8220;Base Period&#8221;) and options (each, an &#8220;Option Period&#8221;). As of March&#160;31, 2020, the agreement included committed funding&#160;of up to $103.2 million for clinical development of the INTERCEPT Blood System for red blood cells (the &#8220;red blood cell system&#8221;). In April 2020, BARDA committed an additional $13.8 million raising the committed funding to up to $116.9 million, and the potential for the exercise by BARDA of subsequent Option Periods that, if exercised by BARDA and completed, would bring the total funding opportunity to $213.9 million&#160;through December 31, 2021. If exercised by BARDA, subsequent Option Periods would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of emerging pathogens, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. The Company is responsible for co-investment of $5.0 million and would be responsible for an additional $9.6 million, if certain Option Periods are exercised. Through March&#160;31, 2020, the Company has incurred approximately $1.2 million related to the co-investment. BARDA will make periodic assessments of the Company&#8217;s progress and the continuation of the agreement is based on the Company&#8217;s success in completing the required tasks under the Base Period and each exercised Option Period. BARDA has rights under certain contract clauses to terminate the agreement, including the ability to terminate the agreement for convenience at any time.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020 and December&#160;31, 2019, $5.0 million and $4.2 million, respectively, of billed and unbilled amounts were included in accounts receivable on the Company&#8217;s condensed consolidated balance sheets related to BARDA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DevelopmentAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DevelopmentAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DevelopmentAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DevelopmentAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>cers-10q_20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cers="http://www.cerus.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cers-20200331.xsd" xlink:type="simple"/>
    <context id="C_0001020214_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_20200421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <instant>2020-04-21</instant>
        </period>
    </context>
    <context id="C_0001020214_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cers:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cers:EmployeeStockPurchasePlanRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cers:EmployeeStockPurchasePlanRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheOneMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_20190329_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandSeventeenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:OxfordTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheTwoMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheThreeMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cers:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cers:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329_20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cers:TwoThousandNineteenTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-08</startDate>
            <endDate>2018-01-08</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cers:CantorFitzgeraldCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cers:SalesAmendmentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cers:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cers:PerformanceUnitsAndCashBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cers:PerformanceUnitsAndCashBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20190605_20190605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-05</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cers:TwoThousandEightEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusEuropeBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusEuropeBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20160101_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20190801_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cers:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:FreseniusKabiAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cers:CerusCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cers:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:EtablissementFrancaisDuSangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:EtablissementFrancaisDuSangMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:AmericanRedCrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001020214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cers:AmericanRedCrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_cersCustomer">
        <measure>cers:Customer</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_cersSegment">
        <measure>cers:Segment</measure>
    </unit>
    <unit id="U_cersTranche">
        <measure>cers:Tranche</measure>
    </unit>
    <unit id="U_cersPeriod">
        <measure>cers:Period</measure>
    </unit>
    <unit id="U_iso4217EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001020214_20200101_20200331" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001020214_20200101_20200331" id="F_000003_2">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001020214_20200101_20200331" id="F_000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001020214_20200101_20200331" id="F_000007">0001020214</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001020214_20200101_20200331" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="C_0001020214_20200101_20200331" id="F_000009">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityCurrentReportingStatus contextRef="C_0001020214_20200101_20200331" id="F_000013">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001020214_20200101_20200331" id="F_000019">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:RevenuePracticalExpedientRemainingPerformanceObligation contextRef="C_0001020214_20200101_20200331" id="F_000288">true</us-gaap:RevenuePracticalExpedientRemainingPerformanceObligation>
    <dei:DocumentFiscalYearFocus contextRef="C_0001020214_20200101_20200331" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <cers:ProductWarrantyTerm contextRef="C_0001020214_20200101_20200331" id="F_000318">P1Y</cers:ProductWarrantyTerm>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001020214_20200331"
      id="F_000076"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001020214_20191231"
      id="F_000077"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001020214_20200101_20200331" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001020214_20200101_20200331" id="F_000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001020214_20200101_20200331" id="F_000002">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001020214_20200101_20200331" id="F_000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001020214_20200101_20200331" id="F_000020">000-21937</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001020214_20200101_20200331" id="F_000006">CERUS CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001020214_20200101_20200331" id="F_000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001020214_20200101_20200331" id="F_000021">68-0262011</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001020214_20200101_20200331" id="F_000023">1220 Concord Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001020214_20200101_20200331" id="F_000024">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001020214_20200101_20200331" id="F_000025">Concord</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001020214_20200101_20200331" id="F_000026">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001020214_20200101_20200331" id="F_000027">94520</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001020214_20200101_20200331" id="F_000028">925</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001020214_20200101_20200331" id="F_000029">288-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001020214_20200101_20200331" id="F_000015">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001020214_20200101_20200331" id="F_000005">CERS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001020214_20200101_20200331" id="F_000016">NASDAQ</dei:SecurityExchangeName>
    <dei:EntitySmallBusiness contextRef="C_0001020214_20200101_20200331" id="F_000010">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001020214_20200101_20200331" id="F_000011">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001020214_20200101_20200331" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001020214_20200421"
      decimals="INF"
      id="F_000012"
      unitRef="U_xbrlishares">163987805</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">33679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">34986000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">99426000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">50732000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">18165000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">16882000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">21684000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">19490000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">5365000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">6018000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">178319000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">128108000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">14654000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">14898000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">1316000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1316000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">14080000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">14122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">82000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">132000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2439000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">2435000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">4473000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">4524000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">215363000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">165535000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">20185000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">22185000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">17198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">20951000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">4813000</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">5017000</us-gaap:SecuredDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">1751000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">1613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">1142000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">570000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">45089000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">50336000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">39458000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">39414000</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">18005000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">18406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">403000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">327000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">102955000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">108483000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">164000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">144000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">978944000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">906905000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">-123000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">114000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">-866577000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">-850111000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">112408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">57052000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">215363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">165535000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">18611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">17504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">8320000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">8432000</us-gaap:CostOfGoodsAndServicesSold>
    <cers:GrossProfitOnProductRevenue
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">10291000</cers:GrossProfitOnProductRevenue>
    <cers:GrossProfitOnProductRevenue
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">9072000</cers:GrossProfitOnProductRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20200101_20200331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">6030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapGovernmentContractMember_20190101_20190331"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">4461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">15810000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">13440000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">15913000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">16161000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">31723000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">29601000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-15402000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-16068000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">-223000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-162000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpense
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">935000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">2924000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">151000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">422000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-1007000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">-2664000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">-16409000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-18732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">57000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">60000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-16466000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-18792000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001020214_20200101_20200331"
      decimals="2"
      id="F_000120"
      unitRef="U_iso4217USD_xbrlishares">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001020214_20190101_20190331"
      decimals="2"
      id="F_000121"
      unitRef="U_iso4217USD_xbrlishares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000122"
      unitRef="U_xbrlishares">157405000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000123"
      unitRef="U_xbrlishares">137108000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-16466000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-18792000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-237000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">211000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-16703000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-18581000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_xbrlishares">144291000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">906905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-850111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">57052000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000136"
      unitRef="U_xbrlishares">17867000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">67094000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">67112000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000140"
      unitRef="U_xbrlishares">1803000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">2000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">1191000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">1193000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">3754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">3754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-237000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-237000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-16466000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-16466000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000150"
      unitRef="U_xbrlishares">163961000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">978944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-866577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">112408000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000156"
      unitRef="U_xbrlishares">136853000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">863531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">-778867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20181231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">84519000</us-gaap:StockholdersEquity>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331"
      decimals="-3"
      id="F_000162"
      unitRef="U_xbrlishares">965000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20190331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">2000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">682000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">684000</cers:IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20190331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">2878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">2878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20190331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">211000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">211000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20190331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-18792000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-18792000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331"
      decimals="-3"
      id="F_000172"
      unitRef="U_xbrlishares">137818000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">867091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-797659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001020214_20190331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">69500000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-16466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-18792000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">706000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">376000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">3754000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">2878000</us-gaap:ShareBasedCompensation>
    <cers:NonCashOperatingLeaseCost
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">-300000</cers:NonCashOperatingLeaseCost>
    <cers:NonCashOperatingLeaseCost
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-353000</cers:NonCashOperatingLeaseCost>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-267000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <cers:NonCashInterestExpense
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">119000</cers:NonCashInterestExpense>
    <cers:NonCashInterestExpense
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">197000</cers:NonCashInterestExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">1283000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">5004000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">2226000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">2286000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">-1119000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-2165000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-2308000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">2597000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-4356000</cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities>
    <cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-4809000</cers:IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities>
    <cers:IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-118000</cers:IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">572000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">265000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-19802000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-22178000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">452000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">3315000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">68520000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">1000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">18787000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">17500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-50185000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">13185000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">1193000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">710000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">67695000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">204000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">39433000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">31010000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">68684000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">9133000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-1303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">37421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001020214_20181231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">31587000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">36118000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001020214_20190331"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">31727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000226">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 1. Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation and Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (together with Cerus Corporation, hereinafter &#x201c;Cerus&#x201d; or the &#x201c;Company&#x201d;) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three months ended March&#160;31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future periods.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, which were included in the Company&#x2019;s 2019 Annual Report on Form 10-K, filed with the SEC on February 21, 2020. The accompanying condensed consolidated balance sheet as of December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements as of that date&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (&#x201c;SSP&#x201d;) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (&#x201c;platelet and plasma systems&#x201d; or &#x201c;disposable kits&#x201d;), UVA illumination devices (&#x201c;illuminators&#x201d;), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company&#x2019;s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis, and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company estimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company receives reimbursement under its U.S. government contract &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;)&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;that supports research and development of defined projects. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See &#x201c;Note 1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and License A&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;greements&#x2014;Agreement with BARDA&#x201d;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contract generally provides for reimbursement of approved costs incurred under the terms of the contract. Revenue related to the cost reimbursement provisions under the Company&#x2019;s U.S. government contract are recognized as the qualified direct and indirect costs on the projects are incurred. The Company invoices under its U.S. government contract using the provisional rates in the government contract and thus is subject to future audits at the discretion of government. These audits could result in an adjustment to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;government contract &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;revenue previously reported, which &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; potentially could be significant. The Company believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. Costs incurred related to services performed under the contract are included as a component of research and development or selling, general and administrative expenses in the Company&#x2019;s &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated statements of operations. The Company&#x2019;s use of estimates in recording accrued liabilities for government contract activities (see &#x201c;Use of Estimates&#x201d; above) affects the revenue recorded from development funding and under the government contract. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Disaggregation of Product Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe, Middle East and Africa&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;North America&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice. Accounts receivable are recorded when the Company&#x2019;s right to the consideration are estimated to be unconditional. The Company had no contract assets at March&#160;31, 2020 and December&#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities mainly consist of deferred product revenue related to maintenance services, unshipped products, and uninstalled illuminators. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the service period. The increase in the deferred product revenue balance for the three months ended March&#160;31, 2020 is primarily driven by performance obligations not satisfied but invoiced as of March&#160;31, 2020, offset by $0.3 million of revenue recognized that were included in the deferred product revenue balance as of December&#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company&#x2019;s U.S. government contract. Research and development expenses include salaries and related expenses for scientific and regulatory personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&amp;amp;D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s use of estimates in recording accrued liabilities for R&amp;amp;D activities (see &#x201c;Use of Estimates&#x201d; above) affects the amounts of R&amp;amp;D expenses recorded from development funding and under its U.S. government contract. Actual results may differ from those estimates under different assumptions or conditions.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities were recorded in &#x201c;Unrealized gains (losses) on available-for-sale investments, net of taxes&#x201d; on the Company&#x2019;s condensed consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale&#160;investments, if any, were recorded in &#x201c;Other income, net&#x201d; on the Company&#x2019;s condensed consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in &#x201c;Other income, net&#x201d; on the Company&#x2019;s condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2020,&#160;the Company&#x2019;s &#x201c;Restricted cash&#x201d; primarily consisted of a&#160;letter of credit relating to the lease of the Company&#x2019;s office building. As of March&#160;31, 2020 and December&#160;31, 2019, the Company also had certain non-U.S. dollar denominated deposits recorded as &#x201c;Restricted cash&#x201d; in compliance with certain foreign contractual requirements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Company&#x2019;s investment policy, substantially all of the Company&#x2019;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#x2019;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#160;31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#x2019;s cash equivalents and short-term investments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had three customers that accounted for more than 10% of the Company&#x2019;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. These customers cumulatively represented approximately 58% and 56% of the Company&#x2019;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At March&#160;31, 2020 and December&#160;31, 2019, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, illuminators, and certain replacement parts for the illuminators. Platelet and plasma systems&#x2019; disposable kits generally have 18 to 24 month shelf lives from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time before being sold to, and ultimately incorporated and assembled by Fresenius Kabi Deutschland GmbH or Fresenius, Inc. (with their affiliates, &#x201c;Fresenius&#x201d;) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be sold to Fresenius for &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;production &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;within the next twelve month&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and evaluates its &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company&#x2019;s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its work-in-process and finished units to meet the Company&#x2019;s forecasted demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;one year&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. At &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company classified its work-in-process inventory as a current asset on its &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated balance sheets based on its evaluation that the work-in-process inventory would be sold to Fresenius for finished disposable kit production within each respective subsequent twelve-month period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in &#x201c;Cost of product revenue&#x201d; on the Company&#x2019;s condensed consolidated statements of operations. At March&#160;31, 2020 and December&#160;31, 2019, the Company had $0.2 million and $0.1 million, respectively, recorded for potential obsolete, expiring or unsalable product.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the three months ended March&#160;31, 2020 and 2019, the Company had non-cash purchases of capital expenditures of $0.2 million and $2.9 million, respectively.&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and Intangible Assets, net&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratable amortization over the original estimated useful life of ten years. Accumulated amortization of intangible assets as of March&#160;31, 2020 and December&#160;31, 2019, was $1.9 million and $1.9 million, respectively. Goodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August&#160;31 of each fiscal year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit&#x2019;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company&#x2019;s one reporting unit.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company performs an impairment test on its intangible assets if certain events or changes in circumstances occur which indicate that the carrying amounts of its intangible assets may not be recoverable. If the intangible assets are not recoverable, an impairment loss would be recognized by the Company based on the excess amount of the carrying value of the intangible assets over its fair value. During the three months ended March&#160;31, 2020 and 2019, there were no impairment charges recognized related to the acquired intangible assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Remeasurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&#x2019;s foreign subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company&#x2019;s condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock-based awards issued to non-employees, the Company recognizes stock-based compensation expense for the grant date fair value of the vested portion of the awards in its condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 8 for further information regarding the Company&#x2019;s stock-based compensation expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company&#x2019;s U.S. federal tax returns for years 1999 through 2018, California tax returns for years through 2018, and Netherlands tax returns for years 2015 through 2018 remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the three months ended March&#160;31, 2020 and 2019, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of anti-dilutive potential shares:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s condensed consolidated balance sheets. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have finance leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Guarantee and Indemnification Arrangements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#x2019;s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company&#x2019;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generally provides for a &lt;span style="-sec-ix-hidden:F_000318"&gt;one-year&lt;/span&gt; warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March&#160;31, 2020 and December&#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company&#x2019;s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company&#x2019;s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 2 for further information regarding the Company&#x2019;s valuation of financial instruments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326):&lt;/span&gt; &lt;span style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments,&lt;/span&gt; which requires measurement and recognition of expected credit losses for financial assets held. The standard is effective for annual periods beginning after December 15, 2019, and interim periods thereafter, with early application permitted. The Company adopted the new accounting standard on January 1, 2020, using the modified retrospective transition method. The adoption of this ASU had no material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000237">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation and Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (together with Cerus Corporation, hereinafter &#x201c;Cerus&#x201d; or the &#x201c;Company&#x201d;) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three months ended March&#160;31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future periods.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, which were included in the Company&#x2019;s 2019 Annual Report on Form 10-K, filed with the SEC on February 21, 2020. The accompanying condensed consolidated balance sheet as of December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements as of that date&lt;span style="font-style:italic;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001020214_20200101_20200331" id="F_000238">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (&#x201c;SSP&#x201d;) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000239">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (&#x201c;platelet and plasma systems&#x201d; or &#x201c;disposable kits&#x201d;), UVA illumination devices (&#x201c;illuminators&#x201d;), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company&#x2019;s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis, and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company estimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company receives reimbursement under its U.S. government contract &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;)&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;that supports research and development of defined projects. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See &#x201c;Note 1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and License A&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;greements&#x2014;Agreement with BARDA&#x201d;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contract generally provides for reimbursement of approved costs incurred under the terms of the contract. Revenue related to the cost reimbursement provisions under the Company&#x2019;s U.S. government contract are recognized as the qualified direct and indirect costs on the projects are incurred. The Company invoices under its U.S. government contract using the provisional rates in the government contract and thus is subject to future audits at the discretion of government. These audits could result in an adjustment to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;government contract &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;revenue previously reported, which &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; potentially could be significant. The Company believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. Costs incurred related to services performed under the contract are included as a component of research and development or selling, general and administrative expenses in the Company&#x2019;s &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated statements of operations. The Company&#x2019;s use of estimates in recording accrued liabilities for government contract activities (see &#x201c;Use of Estimates&#x201d; above) affects the revenue recorded from development funding and under the government contract. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Disaggregation of Product Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe, Middle East and Africa&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;North America&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice. Accounts receivable are recorded when the Company&#x2019;s right to the consideration are estimated to be unconditional. The Company had no contract assets at March&#160;31, 2020 and December&#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities mainly consist of deferred product revenue related to maintenance services, unshipped products, and uninstalled illuminators. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the service period. The increase in the deferred product revenue balance for the three months ended March&#160;31, 2020 is primarily driven by performance obligations not satisfied but invoiced as of March&#160;31, 2020, offset by $0.3 million of revenue recognized that were included in the deferred product revenue balance as of December&#160;31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000257">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe, Middle East and Africa&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;North America&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20200101_20200331"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">12220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20190101_20190331"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">12653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20200101_20200331"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">6077000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_srtNorthAmericaMember_20190101_20190331"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">4551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20200101_20200331"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">314000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersOtherMember_20190101_20190331"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">18611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20190101_20190331"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">17504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="C_0001020214_20200101_20200331" id="F_000282">The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <cers:PaymentOfCustomerInvoiceContractPeriod
      contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331"
      id="F_000283">P30D</cers:PaymentOfCustomerInvoiceContractPeriod>
    <cers:PaymentOfCustomerInvoiceContractPeriod
      contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331"
      id="F_000284">P60D</cers:PaymentOfCustomerInvoiceContractPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001020214_20200101_20200331"
      decimals="-5"
      id="F_000287"
      unitRef="U_iso4217USD">300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001020214_20200101_20200331" id="F_000240">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company&#x2019;s U.S. government contract. Research and development expenses include salaries and related expenses for scientific and regulatory personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&amp;amp;D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s use of estimates in recording accrued liabilities for R&amp;amp;D activities (see &#x201c;Use of Estimates&#x201d; above) affects the amounts of R&amp;amp;D expenses recorded from development funding and under its U.S. government contract. Actual results may differ from those estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000241">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cers:AvailableForSaleSecuritiesPolicy contextRef="C_0001020214_20200101_20200331" id="F_000242">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities were recorded in &#x201c;Unrealized gains (losses) on available-for-sale investments, net of taxes&#x201d; on the Company&#x2019;s condensed consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale&#160;investments, if any, were recorded in &#x201c;Other income, net&#x201d; on the Company&#x2019;s condensed consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in &#x201c;Other income, net&#x201d; on the Company&#x2019;s condensed consolidated statements of operations.&lt;/p&gt;</cers:AvailableForSaleSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001020214_20200101_20200331" id="F_000243">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2020,&#160;the Company&#x2019;s &#x201c;Restricted cash&#x201d; primarily consisted of a&#160;letter of credit relating to the lease of the Company&#x2019;s office building. As of March&#160;31, 2020 and December&#160;31, 2019, the Company also had certain non-U.S. dollar denominated deposits recorded as &#x201c;Restricted cash&#x201d; in compliance with certain foreign contractual requirements.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001020214_20200101_20200331" id="F_000244">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Company&#x2019;s investment policy, substantially all of the Company&#x2019;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#x2019;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#160;31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#x2019;s cash equivalents and short-term investments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had three customers that accounted for more than 10% of the Company&#x2019;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. These customers cumulatively represented approximately 58% and 56% of the Company&#x2019;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
      contextRef="C_0001020214_20191231"
      decimals="INF"
      id="F_000290"
      unitRef="U_cersCustomer">3</cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers>
    <cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
      contextRef="C_0001020214_20200331"
      decimals="INF"
      id="F_000289"
      unitRef="U_cersCustomer">3</cers:CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331"
      decimals="2"
      id="F_000291"
      unitRef="U_xbrlipure">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000292"
      unitRef="U_xbrlipure">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000245">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At March&#160;31, 2020 and December&#160;31, 2019, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, illuminators, and certain replacement parts for the illuminators. Platelet and plasma systems&#x2019; disposable kits generally have 18 to 24 month shelf lives from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time before being sold to, and ultimately incorporated and assembled by Fresenius Kabi Deutschland GmbH or Fresenius, Inc. (with their affiliates, &#x201c;Fresenius&#x201d;) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be sold to Fresenius for &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;production &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;within the next twelve month&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and evaluates its &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company&#x2019;s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its work-in-process and finished units to meet the Company&#x2019;s forecasted demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;one year&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. At &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company classified its work-in-process inventory as a current asset on its &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated balance sheets based on its evaluation that the work-in-process inventory would be sold to Fresenius for finished disposable kit production within each respective subsequent twelve-month period&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in &#x201c;Cost of product revenue&#x201d; on the Company&#x2019;s condensed consolidated statements of operations. At March&#160;31, 2020 and December&#160;31, 2019, the Company had $0.2 million and $0.1 million, respectively, recorded for potential obsolete, expiring or unsalable product.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <cers:InventoryLifeFinishedGoodsPeriod
      contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331"
      id="F_000293">P18M</cers:InventoryLifeFinishedGoodsPeriod>
    <cers:InventoryLifeFinishedGoodsPeriod
      contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331"
      id="F_000294">P24M</cers:InventoryLifeFinishedGoodsPeriod>
    <cers:WorkInProcessInventoryLifePeriod contextRef="C_0001020214_20200101_20200331" id="F_000295">P1Y</cers:WorkInProcessInventoryLifePeriod>
    <us-gaap:InventoryValuationReserves
      contextRef="C_0001020214_20200331"
      decimals="-5"
      id="F_000296"
      unitRef="U_iso4217USD">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_0001020214_20191231"
      decimals="-5"
      id="F_000297"
      unitRef="U_iso4217USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000246">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the three months ended March&#160;31, 2020 and 2019, the Company had non-cash purchases of capital expenditures of $0.2 million and $2.9 million, respectively.&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_20200101_20200331"
      id="F_000298">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331"
      id="F_000299">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001020214_20200101_20200331"
      decimals="-5"
      id="F_000300"
      unitRef="U_iso4217USD">200000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001020214_20190101_20190331"
      decimals="-5"
      id="F_000301"
      unitRef="U_iso4217USD">2900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000247">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and Intangible Assets, net&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratable amortization over the original estimated useful life of ten years. Accumulated amortization of intangible assets as of March&#160;31, 2020 and December&#160;31, 2019, was $1.9 million and $1.9 million, respectively. Goodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August&#160;31 of each fiscal year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit&#x2019;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company&#x2019;s one reporting unit.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company performs an impairment test on its intangible assets if certain events or changes in circumstances occur which indicate that the carrying amounts of its intangible assets may not be recoverable. If the intangible assets are not recoverable, an impairment loss would be recognized by the Company based on the excess amount of the carrying value of the intangible assets over its fair value. During the three months ended March&#160;31, 2020 and 2019, there were no impairment charges recognized related to the acquired intangible assets.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="C_0001020214_20200101_20200331" id="F_000304">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001020214_20200331"
      decimals="-5"
      id="F_000302"
      unitRef="U_iso4217USD">1900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001020214_20191231"
      decimals="-5"
      id="F_000303"
      unitRef="U_iso4217USD">1900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0001020214_20200101_20200331"
      decimals="INF"
      id="F_000305"
      unitRef="U_cersSegment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0001020214_20200101_20200331"
      decimals="INF"
      id="F_000306"
      unitRef="U_cersSegment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0001020214_20200101_20200331"
      decimals="INF"
      id="F_000307"
      unitRef="U_cersSegment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0001020214_20200101_20200331"
      decimals="INF"
      id="F_000308"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0001020214_20190101_20190331"
      decimals="INF"
      id="F_000309"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000248">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000249">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Remeasurement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&#x2019;s foreign subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company&#x2019;s condensed consolidated statements of operations.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001020214_20200101_20200331" id="F_000250">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For stock-based awards issued to non-employees, the Company recognizes stock-based compensation expense for the grant date fair value of the vested portion of the awards in its condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 8 for further information regarding the Company&#x2019;s stock-based compensation expenses.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000251">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company&#x2019;s U.S. federal tax returns for years 1999 through 2018, California tax returns for years through 2018, and Netherlands tax returns for years 2015 through 2018 remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000252">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the three months ended March&#160;31, 2020 and 2019, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of anti-dilutive potential shares:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000258">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three&#160;Months&#160;Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of anti-dilutive potential shares:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331"
      decimals="-3"
      id="F_000310"
      unitRef="U_xbrlishares">17361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20190331"
      decimals="-3"
      id="F_000311"
      unitRef="U_xbrlishares">17648000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331"
      decimals="-3"
      id="F_000312"
      unitRef="U_xbrlishares">4743000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20190331"
      decimals="-3"
      id="F_000313"
      unitRef="U_xbrlishares">2247000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20200101_20200331"
      decimals="-3"
      id="F_000314"
      unitRef="U_xbrlishares">41000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cersEmployeeStockPurchasePlanRightsMember_20190101_20190331"
      decimals="-3"
      id="F_000315"
      unitRef="U_xbrlishares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000316"
      unitRef="U_xbrlishares">22145000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001020214_20190101_20190331"
      decimals="-3"
      id="F_000317"
      unitRef="U_xbrlishares">19902000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000253">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s condensed consolidated balance sheets. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have finance leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term. &lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="C_0001020214_20200101_20200331" id="F_000254">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Guarantee and Indemnification Arrangements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#x2019;s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company&#x2019;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generally provides for a &lt;span style="-sec-ix-hidden:F_000318"&gt;one-year&lt;/span&gt; warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March&#160;31, 2020 and December&#160;31, 2019.&lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="C_0001020214_20200331"
      decimals="INF"
      id="F_000319"
      unitRef="U_iso4217USD">0</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="C_0001020214_20191231"
      decimals="INF"
      id="F_000320"
      unitRef="U_iso4217USD">0</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001020214_20200101_20200331" id="F_000255">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company&#x2019;s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company&#x2019;s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 2 for further information regarding the Company&#x2019;s valuation of financial instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000256">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326):&lt;/span&gt; &lt;span style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments,&lt;/span&gt; which requires measurement and recognition of expected credit losses for financial assets held. The standard is effective for annual periods beginning after December 15, 2019, and interim periods thereafter, with early application permitted. The Company adopted the new accounting standard on January 1, 2020, using the modified retrospective transition method. The adoption of this ASU had no material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000227">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2. Available-for-sale Securities and Fair Value on Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale Securities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of available-for-sale securities at March&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,282&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of available-for-sale securities at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following by contractual maturity (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;One year or less&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Greater than one year and less than five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,811&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,282&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 Months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 Months or Greater&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2019, the Company did not have any available-for-sale securities in an unrealized net loss position.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company typically invests in highly-rated securities, and its investment policy limits the amount of credit exposure to any one issuer. The policy generally requires investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for expected credit loss, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, and any changes thereto, changes in market interest rates, and the Company&#x2019;s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment&#x2019;s cost basis. The Company also regularly reviews its investments in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three months ended March&#160;31, 2020 and 2019, the Company did not recognize any credit losses. The Company has no current requirement or intent to sell the securities in an unrealized loss position. The Company expects to recover up to (or beyond) the initial cost of investment for securities held. The Company recorded gross realized gains of less than $0.1 million and gross realized losses of $0.3 million during the three months ended March&#160;31, 2020. The Company did not record any gross realized gains or losses from the sale or maturity of available-for-sale investments during the three months ended March&#160;31, 2019. &lt;/p&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Disclosures&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses certain assumptions that market participants would use to determine the fair value of an asset or liability in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Times New Roman;"&gt;Level 1: Quoted prices in active markets for identical instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Times New Roman;"&gt;Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"&gt;&lt;span style="font-family:Times New Roman;"&gt;Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To estimate the fair value of Level 2 debt securities as of March&#160;31, 2020, the Company&#x2019;s primary pricing service relies on inputs from multiple industry-recognized pricing sources to determine the price for each investment. Corporate debt and U.S. government agency securities are systematically priced by this service as of the close of business each business day. If the primary pricing service does not price a specific asset a secondary pricing service is utilized.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets and liabilities were determined using the following inputs at March&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;classification&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets and liabilities were determined using the following inputs at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;classification&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,732&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have any transfers among fair value measurement levels during the three months ended March&#160;31, 2020. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000259">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of available-for-sale securities at March&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,282&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of available-for-sale securities at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">10733000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">10733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">22591000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">274000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">22865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">76958000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">487000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">76561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">110282000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">364000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">487000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">110159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">8860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">8860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">15545000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">15561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">35073000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">35171000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">59478000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">114000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">59592000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000260">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following by contractual maturity (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;One year or less&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Greater than one year and less than five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,811&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,282&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">54471000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">54565000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">43822000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">43907000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">55811000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">55594000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">15656000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">15685000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">110282000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">110159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">59478000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">59592000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000261">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 Months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 Months or Greater&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&#160;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">55318000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">487000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">55318000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">487000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0001020214_20191231"
      decimals="INF"
      id="F_000365"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_20200331"
      decimals="INF"
      id="F_000366"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001020214_20190331"
      decimals="INF"
      id="F_000367"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains
      contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_20200101_20200331"
      decimals="INF"
      id="F_000368"
      unitRef="U_iso4217USD">100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="C_0001020214_20200101_20200331"
      decimals="-5"
      id="F_000370"
      unitRef="U_iso4217USD">300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains
      contextRef="C_0001020214_20190101_20190331"
      decimals="INF"
      id="F_000369"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses
      contextRef="C_0001020214_20190101_20190331"
      decimals="INF"
      id="F_000371"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000262">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets and liabilities were determined using the following inputs at March&#160;31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;classification&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,733&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets and liabilities were determined using the following inputs at December&#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;classification&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,732&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">10733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20200331"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">10733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">22865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">22865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">76561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">76561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">110159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20200331"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">10733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20200331"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">99426000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">8860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">8860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">15561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">15561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">35171000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">35171000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">59592000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">8860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001020214_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">50732000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InventoryDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000228">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 3. Inventories&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000263">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,490&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">5668000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">5160000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">16016000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">14330000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">21684000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">19490000</us-gaap:InventoryNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000229">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4. Accrued Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and related costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000264">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and related costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">8660000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">12703000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">4039000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">3489000</us-gaap:AccruedProfessionalFeesCurrent>
    <cers:AccruedDevelopmentCostsCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">1369000</cers:AccruedDevelopmentCostsCurrent>
    <cers:AccruedDevelopmentCostsCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">1468000</cers:AccruedDevelopmentCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">3130000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">3291000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">17198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">20951000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000230">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5. Debt&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt at March&#160;31, 2020, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized Discount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Credit Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: debt &#x2013; current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt &#x2013; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt at December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized Discount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: debt &#x2013; current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt &#x2013; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal, interest and fee payments on Term Loan Credit Agreement at March&#160;31, 2020, are expected to be as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 (remainder)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Loan Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 29, 2019 (the &#x201c;Closing Date&#x201d;), the Company entered into a Credit, Security and Guaranty Agreement (Term Loan) (the &#x201c;Term Loan Credit Agreement&#x201d;) with MidCap Financial Trust (&#x201c;MidCap&#x201d;) to borrow up to $70 million in three tranches (collectively &#x201c;2019 Term Loan&#x201d;), with a maturity date of March 1, 2024. The first advance of $40.0 million (&#x201c;Tranche 1&#x201d;) was drawn by the Company on March 29, 2019, with the proceeds used in part to repay in full the outstanding term loans and fees under a prior loan agreement. The Company repaid principal and interest in an aggregate amount equal to approximately $31.2&#160;million and prepayment fees in an aggregate amount equal to approximately $0.6&#160;million, and terminated all obligations under the prior loan agreement. As a result, the Company recorded a loss of $2.1 million on the extinguishment of the prior loan agreement in &#x201c;Interest expense&#x201d; on the Company's condensed consolidated statements of operations. The second advance of $15.0&#160;million (&#x201c;Tranche 2&#x201d;) will be available to the Company from January&#160;1, 2020 through December&#160;31, 2020, subject to the Company&#x2019;s satisfaction of certain conditions described &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in the Term Loan Credit Agreement, and (ii)&#160;the third advance of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.0&#160;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million (&#x201c;Tranche 3&#x201d;) will be available to the Company starting April&#160;1, 2020, through March&#160;31, 2021, subject to the Company&#x2019;s satisfaction of certain other conditions described in the Term Loan Credit Agreement. The&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; borrowings under the&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2019 Term Loan bears interest at the sum of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a fixed percentage spread and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;greater of (i) &lt;/span&gt;1.80&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% or (ii)&#160;one month LIBOR. The effective interest rate on the Term Loan at &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;was approximately &lt;/span&gt;7.50&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%. All three tranches require interest only payments through &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1, 2022&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, followed by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24 months&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of payments with interest and equal payment of principal. The interest only payment period can be extended for &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 months&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; upon achievement of a specified trailing &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;twelve month&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; net revenue target. Prepayments of the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 T&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;erm &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;L&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;oan under the Term Loan Credit Agreement, in whole or in part, will be subject to early termination fees which decline each year until the fourth anniversary&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of the applicable funding date&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, at which time there is no early termination fee. Upon the final payment, the Company must also pay an exit fee &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;calculated based on &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a percentage &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of the aggregate principal amount of all tranches advanced to the Company&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also entered into a Credit, Security and Guaranty Agreement (Revolving Loan) (the &#x201c;Revolving Loan Credit Agreement&#x201d;) with MidCap on March 29, 2019, to initially borrow up to $5.0 million. The amount borrowed under the Revolving Loan Credit Agreement can be increased, upon request by the Company by up to an additional $15.0 million, subject to agent and lender approval and the satisfaction of certain conditions. The Revolving Loan Credit Agreement has a maturity date of March 1, 2024. Amounts drawn under the Revolving Loan Credit Agreement bear interest at the sum of a fixed percentage spread and the greater of (i) 1.80% or (ii) one month LIBOR. There are also fractional fees based on the amounts either drawn or undrawn. If the Revolving Loan Credit Agreement is terminated before maturity or the funding obligation is permanently reduced, there are termination fees which decline each anniversary until the third anniversary, at which time there is no termination fee. As of March&#160;31, 2020 and December&#160;31, 2019, the Company had borrowed $4.8 million and $5.0 million, respectively, under the Revolving Loan Credit Agreement, which is included in &#x201c;Debt &#x2013; current&#x201d; in the Company&#x2019;s condensed consolidated balance sheets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Term Loan Credit Agreement and Revolving Loan Credit Agreement contain certain financial and non-financial covenants, with which the Company was in compliance at March&#160;31, 2020. Additionally, both agreements are secured by substantially all of the Company&#x2019;s assets, with some exclusions.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000265">
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt at March&#160;31, 2020, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized Discount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Credit Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: debt &#x2013; current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt &#x2013; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt at December&#160;31, 2019, consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized Discount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: debt &#x2013; current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt &#x2013; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">542000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SecuredDebt
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">39458000</us-gaap:SecuredDebt>
    <cers:DebtInstrumentCarryingNonCurrent
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">40000000</cers:DebtInstrumentCarryingNonCurrent>
    <cers:DebtInstrumentUnamortizedNoncurrent
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">542000</cers:DebtInstrumentUnamortizedNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">39458000</us-gaap:SecuredLongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">586000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SecuredDebt
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">39414000</us-gaap:SecuredDebt>
    <cers:DebtInstrumentCarryingNonCurrent
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">40000000</cers:DebtInstrumentCarryingNonCurrent>
    <cers:DebtInstrumentUnamortizedNoncurrent
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">586000</cers:DebtInstrumentUnamortizedNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">39414000</us-gaap:SecuredLongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000266">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal, interest and fee payments on Term Loan Credit Agreement at March&#160;31, 2020, are expected to be as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 (remainder)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">2291000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">2291000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">3042000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">3042000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">2660000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">17660000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">1203000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">21203000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">5000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">1264000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">6264000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFees
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">10460000</cers:LongTermDebtMaturitiesRepaymentsOfInterestAndFees>
    <cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">50460000</cers:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329"
      decimals="INF"
      id="F_000434"
      unitRef="U_iso4217USD">70000000</us-gaap:DebtInstrumentFaceAmount>
    <cers:NumberOfEqualTranches
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      decimals="INF"
      id="F_000435"
      unitRef="U_cersTranche">3</cers:NumberOfEqualTranches>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      id="F_000437">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheOneMember_20190329"
      decimals="-5"
      id="F_000436"
      unitRef="U_iso4217USD">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <cers:RepaymentsPrincipalAndInterestAggregateAmount
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">31200000</cers:RepaymentsPrincipalAndInterestAggregateAmount>
    <cers:DebtPrepaymentFee
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_20190329_20190329"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">600000</cers:DebtPrepaymentFee>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandSeventeenTermLoanMember_us-gaapDebtInstrumentAxis_cersOxfordTermLoanAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapInterestExpenseMember_20190329_20190329"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">2100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cers:DebtInstrumentAvailableAmountUponCondition
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheTwoMember_20190329"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">15000000.0</cers:DebtInstrumentAvailableAmountUponCondition>
    <cers:DebtInstrumentAvailableAmountUponCondition
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_us-gaapLongtermDebtTypeAxis_cersTrancheThreeMember_20190329"
      decimals="-5"
      id="F_000442"
      unitRef="U_iso4217USD">15000000.0</cers:DebtInstrumentAvailableAmountUponCondition>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329"
      decimals="4"
      id="F_000443"
      unitRef="U_xbrlipure">0.0180</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331"
      decimals="4"
      id="F_000444"
      unitRef="U_xbrlipure">0.0750</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <cers:DebtInstrumentInterestOnlyPaymentsDate
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      id="F_000445">2022-03-01</cers:DebtInstrumentInterestOnlyPaymentsDate>
    <cers:DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      id="F_000446">P24M</cers:DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod>
    <cers:InterestOnlyPaymentPeriod
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      id="F_000447">P12M</cers:InterestOnlyPaymentPeriod>
    <cers:TrailingNetRevenueTarget
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329_20190329"
      id="F_000448">P12M</cers:TrailingNetRevenueTarget>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329"
      decimals="INF"
      id="F_000449"
      unitRef="U_iso4217USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <cers:DebtInstrumentAvailableAmountUponCondition
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329"
      decimals="-5"
      id="F_000452"
      unitRef="U_iso4217USD">15000000.0</cers:DebtInstrumentAvailableAmountUponCondition>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001020214_us-gaapCreditFacilityAxis_cersTwoThousandNineteenTermLoanMember_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329_20190329"
      id="F_000453">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20190329"
      decimals="4"
      id="F_000454"
      unitRef="U_xbrlipure">0.0180</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20200331"
      decimals="-5"
      id="F_000450"
      unitRef="U_iso4217USD">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001020214_us-gaapDebtInstrumentAxis_us-gaapRevolvingCreditFacilityMember_20191231"
      decimals="-5"
      id="F_000451"
      unitRef="U_iso4217USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000231">
&lt;p style="text-align:justify;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6. Commitments and Contingencies&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early.&#160;The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company&#x2019;s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases is as follows&lt;span style="font-family:Arial;"&gt; &lt;/span&gt;(dollars in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Month Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash payments for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum non-cancelable payments under&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; operating&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; leases as of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;were&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 (remainder)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,927&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,616&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three months ended March&#160;31, 2020 and 2019, the Company recorded operating lease expenses of $0.8 million and $0.5 million, respectively. As of March&#160;31, 2020, the Company had no leases that have not yet commenced. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Purchase Commitments&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cers:MinimumTermOfNonCancelableOperatingLeases contextRef="C_0001020214_20200101_20200331" id="F_000455">P1Y</cers:MinimumTermOfNonCancelableOperatingLeases>
    <cers:ExpirationOfNonCancelableOperatingLeasesMaximumYear contextRef="C_0001020214_20200101_20200331" id="F_000456">2030</cers:ExpirationOfNonCancelableOperatingLeasesMaximumYear>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000267">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases is as follows&lt;span style="font-family:Arial;"&gt; &lt;/span&gt;(dollars in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Month Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash payments for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">964000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001020214_20200101_20200331"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">265000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001020214_20200331" id="F_000459">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001020214_20200331"
      decimals="3"
      id="F_000460"
      unitRef="U_xbrlipure">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000268">
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum non-cancelable payments under&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; operating&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; leases as of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;were&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 (remainder)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,927&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,788&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,711&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,053&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,616&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">2443000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">3450000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">2927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">2788000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">2711000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">16053000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">30372000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">10616000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">19756000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001020214_20200101_20200331"
      decimals="-5"
      id="F_000470"
      unitRef="U_iso4217USD">800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001020214_20190101_20190331"
      decimals="-5"
      id="F_000471"
      unitRef="U_iso4217USD">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription contextRef="C_0001020214_20200101_20200331" id="F_000472">the Company had no leases that have not yet commenced.</us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000232">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7. Stockholders&#x2019; Equity&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Public Offering of Common Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020, the Company issued and sold 16,866,667 shares of common stock, par value $0.001 per share, at $3.75 per share in an underwritten public offering. The total proceeds from this offering were approximately $62.7 million, net of the underwriting discount and other issuance costs.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 4, 2017, the Company entered into Amendment No. 3 to the Controlled Equity Offering &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;SM&lt;/sup&gt; Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (as amended on August 4, 2017, the &#x201c;Amended Cantor Agreement&#x201d;). The Amended Cantor Agreement became effective on January 8, 2018, and provided for the issuance and sale of shares of the Company&#x2019;s common stock having an aggregate offering price of up to $70.0 million through Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), which amount included the $31.4 million of unsold shares of common stock available for sale immediately prior to the effectiveness of the Amended Cantor Agreement. Under the Amended Cantor Agreement, Cantor also acts as the Company&#x2019;s sales agent and receives compensation based on an aggregate of 2% of the gross proceeds on the sale price per share of its common stock. The issuance and sale of these shares by the Company pursuant to the Amended Cantor Agreement are deemed an &#x201c;at-the-market&#x201d; offering and are registered under the Securities Act of 1933, as amended.&#160;During the three months ended March&#160;31, 2020, 1.0 million shares of the Company&#x2019;s common stock were sold under the Amended Cantor Agreement for net proceeds of $4.4 million.&#160;At March&#160;31, 2020, the Company had approximately $9.6 million of common stock available to be sold under the Amended Cantor Agreement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131"
      decimals="INF"
      id="F_000473"
      unitRef="U_xbrlishares">16866667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131"
      decimals="INF"
      id="F_000474"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200131"
      decimals="INF"
      id="F_000475"
      unitRef="U_iso4217USD_xbrlishares">3.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200101_20200131"
      decimals="-5"
      id="F_000476"
      unitRef="U_iso4217USD">62700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cers:MaximumAmountAvailableUnderOffering
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108"
      decimals="INF"
      id="F_000477"
      unitRef="U_iso4217USD">70000000.0</cers:MaximumAmountAvailableUnderOffering>
    <cers:CommonStockSharesUnsoldValue
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">31400000</cers:CommonStockSharesUnsoldValue>
    <cers:PercentageOfProceedsPayableAsCompensationToUnderwriter
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20180108_20180108"
      decimals="2"
      id="F_000478"
      unitRef="U_xbrlipure">0.02</cers:PercentageOfProceedsPayableAsCompensationToUnderwriter>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000480"
      unitRef="U_xbrlishares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000481"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cers:CommonStockSharesAvailableForSaleValue
      contextRef="C_0001020214_srtCounterpartyNameAxis_cersCantorFitzgeraldCoMember_us-gaapSubsidiarySaleOfStockAxis_cersSalesAmendmentThreeMember_us-gaapTypeOfArrangementAxis_cersSalesAgreementMember_20200331"
      decimals="-5"
      id="F_000482"
      unitRef="U_iso4217USD">9600000</cers:CommonStockSharesAvailableForSaleValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000233">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8. Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Plans&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains an Employee Stock Purchase Plan (the &#x201c;Purchase Plan&#x201d;), which is intended to qualify as an employee stock purchase plan within the meaning of Section&#160;423(b) of the Internal Revenue Code. Under the Purchase Plan, the Company&#x2019;s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. Under the Purchase Plan eligible employee participants may purchase shares of common stock of the Company at a purchase price equal to 85% of the lower of the fair market value per share on the start date of the offering period or the fair market value per share on the purchase date. The Purchase Plan consists of a fixed offering period of 12 months with two purchase periods within each offering period. At March&#160;31, 2020, the Company had 0.4 million shares available for future issuance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2008 Equity Incentive Plan and Inducement Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors. The Company currently grants equity awards from one plan, the 2008 Equity Incentive Plan and its subsequent amendments (collectively, the &#x201c;Amended 2008 Plan&#x201d;). The Amended 2008 Plan allows for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units (&#x201c;RSUs&#x201d;), stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. On June 5, 2019, the Company&#x2019;s stockholders approved an &lt;/p&gt;

&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;amendment and restatement of the 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance under the 2008 Plan by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,800,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option a&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;wards under the Amended 2008 Plan generally have a maximum term of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10 years&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; from the date of the award. The Amended 2008 Plan generally requires options to be granted at &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of the fair market value of the Company&#x2019;s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;four years&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. RSUs are measured based on the fair market value of the underlying stock on the date of grant&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. RSUs granted by the Company to employees&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; generally vest over&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;three to four years&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance-based stock or cash awards granted under the Amended 2008 Plan are limited to either &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;500,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock or $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million per recipient per calendar year.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;40,000&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;performance-based stock &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;awards&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;were outstanding. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At March&#160;31, 2020, the Company had an aggregate of approximately 28.1 million shares of its common stock subject to outstanding options or unvested RSUs, or remaining available for future issuance under the Amended 2008 Plan, of which approximately 18.6&#160;million shares and 5.6 million shares were subject to outstanding options and unvested RSUs, respectively, and approximately 3.9&#160;million shares were available for future issuance under the Amended 2008 Plan. The Company&#x2019;s policy is to issue new shares of common stock upon the exercise of options or vesting of RSUs.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,098&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Includes shares issuable under performance-based restricted stock unit awards.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Assumptions for Stock-based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan rights. The Black-Scholes option pricing model is affected by the Company&#x2019;s stock price, as well as assumptions regarding a number of complex and subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company&#x2019;s expected stock price volatility, the risk-free interest rate and expected dividends. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331"
      decimals="2"
      id="F_000483"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331"
      id="F_000484">P12M</cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm>
    <cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331"
      decimals="INF"
      id="F_000485"
      unitRef="U_cersPeriod">2</cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200331"
      decimals="INF"
      id="F_000486"
      unitRef="U_xbrlishares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20190605_20190605"
      decimals="INF"
      id="F_000495"
      unitRef="U_xbrlishares">11800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000487">P10Y</cers:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="INF"
      id="F_000488"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000489">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001020214_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000490">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001020214_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000491">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="INF"
      id="F_000492"
      unitRef="U_xbrlishares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="C_0001020214_us-gaapAwardTypeAxis_cersPerformanceUnitsAndCashBasedAwardsMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-5"
      id="F_000493"
      unitRef="U_iso4217USD">1000000.0</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <cers:PerformanceBasedStockOptionsOutstanding
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="INF"
      id="F_000494"
      unitRef="U_xbrlishares">40000</cers:PerformanceBasedStockOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-5"
      id="F_000496"
      unitRef="U_xbrlishares">28100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-5"
      id="F_000497"
      unitRef="U_xbrlishares">18600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-5"
      id="F_000498"
      unitRef="U_xbrlishares">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-5"
      id="F_000499"
      unitRef="U_xbrlishares">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000269">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231"
      decimals="-3"
      id="F_000500"
      unitRef="U_xbrlishares">16830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231"
      decimals="2"
      id="F_000505"
      unitRef="U_iso4217USD_xbrlishares">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000501"
      unitRef="U_xbrlishares">2034000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000506"
      unitRef="U_iso4217USD_xbrlishares">5.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000502"
      unitRef="U_xbrlishares">196000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000507"
      unitRef="U_iso4217USD_xbrlishares">3.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000503"
      unitRef="U_xbrlishares">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000508"
      unitRef="U_iso4217USD_xbrlishares">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-3"
      id="F_000504"
      unitRef="U_xbrlishares">18621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="2"
      id="F_000509"
      unitRef="U_iso4217USD_xbrlishares">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      id="F_000270">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,098&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Includes shares issuable under performance-based restricted stock unit awards.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231"
      decimals="-3"
      id="F_000510"
      unitRef="U_xbrlishares">4098000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231"
      decimals="2"
      id="F_000515"
      unitRef="U_iso4217USD_xbrlishares">5.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000511"
      unitRef="U_xbrlishares">3029000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000516"
      unitRef="U_iso4217USD_xbrlishares">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000512"
      unitRef="U_xbrlishares">1514000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000517"
      unitRef="U_iso4217USD_xbrlishares">5.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="-3"
      id="F_000513"
      unitRef="U_xbrlishares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331"
      decimals="2"
      id="F_000518"
      unitRef="U_iso4217USD_xbrlishares">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="-3"
      id="F_000514"
      unitRef="U_xbrlishares">5578000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200331"
      decimals="2"
      id="F_000519"
      unitRef="U_iso4217USD_xbrlishares">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000234">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9. Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded income tax expense of $0.1 million for both the three months ended March&#160;31, 2020 and 2019, primarily related to the operating profit of the Company&#x2019;s Cerus Europe B.V. subsidiary. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20200101_20200331"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20190101_20190331"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <cers:DevelopmentAndLicenseAgreementsTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000235">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10. Development and License Agreements &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreements with Fresenius&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fresenius Kabi AG (&#x201c;Fresenius&#x201d;) manufactures and supplies the platelet and plasma systems to the Company under a supply agreement (the &#x201c;Supply Agreement&#x201d;). Fresenius is obligated to sell, and the Company is obligated to purchase, finished disposable kits for the Company&#x2019;s platelet and plasma systems and the Company&#x2019;s red blood cell system product candidate (the &#x201c;RBC Sets&#x201d;). The Supply Agreement permits the Company to purchase platelet and plasma systems and RBC Sets from third parties to the extent necessary to maintain supply qualifications with such third parties or where local or regional manufacturing is needed to obtain product registrations or sales. Pricing terms per unit are initially fixed and decline at specified annual production levels, and are subject to certain adjustments after the initial pricing term. Under the Supply Agreement, the Company maintains the amounts due from the components sold to Fresenius as a current asset on its accompanying condensed consolidated balance sheets until such time as the Company purchases finished disposable kits using those components. The Supply Agreement also required the Company to make certain payments totaling &#x20ac;8.6 million (&#x201c;Manufacturing and Development Payments&#x201d;) to Fresenius. Because these payments represented unconditional payment obligations, the Company recognized its liability for these payments at their net present value at discount rate of 9.72% based on the Company&#x2019;s effective borrowing rate at that time. The Manufacturing and Development Payments liability was accreted through interest expense based on the estimated timing of its ultimate settlement.&#160;In 2016, the Company paid &#x20ac;3.1 million to Fresenius.&#160;In August 2019, the Company paid the remaining &#x20ac;5.5 million to Fresenius.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Supply Agreement also required the Company to make payments to support certain projects Fresenius has and will perform on behalf of the Company related to certain R&amp;amp;D activities and manufacturing efficiency activities for which certain assets have been established in the Company&#x2019;s condensed consolidated balance sheets. The manufacturing efficiency asset is expensed on a straight-line basis over the life of the Supply Agreement.&#160;The prepaid asset related to amounts paid up front for the R&amp;amp;D activities to be conducted by Fresenius on behalf of the Company is expensed over the period which such activities occur. The following table summarizes the amounts of prepaid R&amp;amp;D asset and manufacturing efficiency asset at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid R&amp;amp;D asset &#x2013; current &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid R&amp;amp;D asset &#x2013; non-current &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing efficiency asset &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Prepaid and other current assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Prepaid and other assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial term of the Supply Agreement extends through July 1, 2025 (the &#x201c;Initial Term&#x201d;) and is automatically renewed thereafter for additional two year terms (each, a &#x201c;Renewal Term&#x201d;), subject to termination by either party upon (i) two years written notice prior to the expiration of the Initial Term or (ii) one year written notice prior to the expiration of any Renewal Term. Under the Supply Agreement, the Company has the right, but not the obligation, to purchase certain assets and assume certain liabilities from Fresenius.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made payments to Fresenius of $8.1 million and $7.8 million relating to the manufacturing of the Company&#x2019;s products during the three months ended March&#160;31, 2020 and 2019, respectively. The following table summarizes the amounts of the Company&#x2019;s payables to and receivables from Fresenius at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payables to Fresenius &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivables from Fresenius &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,631&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,796&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Accounts Payable&#x201d; and &#x201c;Accrued Liabilities&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Other current assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement with BARDA&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Company entered into an agreement with BARDA to support the Company&#x2019;s development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The agreement with BARDA and its subsequent modifications include a base period (the &#x201c;Base Period&#x201d;) and options (each, an &#x201c;Option Period&#x201d;). As of March&#160;31, 2020, the agreement included committed funding&#160;of up to $103.2 million for clinical development of the INTERCEPT Blood System for red blood cells (the &#x201c;red blood cell system&#x201d;). In April 2020, BARDA committed an additional $13.8 million raising the committed funding to up to $116.9 million, and the potential for the exercise by BARDA of subsequent Option Periods that, if exercised by BARDA and completed, would bring the total funding opportunity to $213.9 million&#160;through December 31, 2021. If exercised by BARDA, subsequent Option Periods would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of emerging pathogens, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. The Company is responsible for co-investment of $5.0 million and would be responsible for an additional $9.6 million, if certain Option Periods are exercised. Through March&#160;31, 2020, the Company has incurred approximately $1.2 million related to the co-investment. BARDA will make periodic assessments of the Company&#x2019;s progress and the continuation of the agreement is based on the Company&#x2019;s success in completing the required tasks under the Base Period and each exercised Option Period. BARDA has rights under certain contract clauses to terminate the agreement, including the ability to terminate the agreement for convenience at any time.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2020 and December&#160;31, 2019, $5.0 million and $4.2 million, respectively, of billed and unbilled amounts were included in accounts receivable on the Company&#x2019;s condensed consolidated balance sheets related to BARDA.&lt;/p&gt;</cers:DevelopmentAndLicenseAgreementsTextBlock>
    <cers:ManufacturingAndDevelopmentPaymentLiability
      contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20200101_20200331"
      decimals="-5"
      id="F_000522"
      unitRef="U_iso4217EUR">8600000</cers:ManufacturingAndDevelopmentPaymentLiability>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20161231"
      decimals="2"
      id="F_000523"
      unitRef="U_xbrlipure">9.72</us-gaap:AlternativeInvestmentMeasurementInput>
    <cers:PaymentsForManufacturingAndDevelopmentCost
      contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20160101_20161231"
      decimals="-5"
      id="F_000524"
      unitRef="U_iso4217EUR">3100000</cers:PaymentsForManufacturingAndDevelopmentCost>
    <cers:PaymentsForManufacturingAndDevelopmentCost
      contextRef="C_0001020214_deiLegalEntityAxis_cersFreseniusKabiAGMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_cersManufacturingAndSupplyAgreementsMember_20190801_20190831"
      decimals="-5"
      id="F_000525"
      unitRef="U_iso4217EUR">5500000</cers:PaymentsForManufacturingAndDevelopmentCost>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000271">The following table summarizes the amounts of prepaid R&amp;amp;D asset and manufacturing efficiency asset at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid R&amp;amp;D asset &#x2013; current &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid R&amp;amp;D asset &#x2013; non-current &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing efficiency asset &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Prepaid and other current assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Prepaid and other assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <cers:UnamortizedDeferredCostForDevelopmentActivities
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">42000</cers:UnamortizedDeferredCostForDevelopmentActivities>
    <cers:UnamortizedDeferredCostForDevelopmentActivities
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">54000</cers:UnamortizedDeferredCostForDevelopmentActivities>
    <cers:UnamortizedDeferredCostForDevelopmentActivities
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">2105000</cers:UnamortizedDeferredCostForDevelopmentActivities>
    <cers:UnamortizedDeferredCostForDevelopmentActivities
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">2094000</cers:UnamortizedDeferredCostForDevelopmentActivities>
    <cers:ManufacturingEfficiencyAssets
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20200331"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">1288000</cers:ManufacturingEfficiencyAssets>
    <cers:ManufacturingEfficiencyAssets
      contextRef="C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_20191231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">1349000</cers:ManufacturingEfficiencyAssets>
    <cers:PaymentForManufacturingOfEntityProducts
      contextRef="C_0001020214_20200101_20200331"
      decimals="-5"
      id="F_000532"
      unitRef="U_iso4217USD">8100000</cers:PaymentForManufacturingOfEntityProducts>
    <cers:PaymentForManufacturingOfEntityProducts
      contextRef="C_0001020214_20190101_20190331"
      decimals="-5"
      id="F_000533"
      unitRef="U_iso4217USD">7800000</cers:PaymentForManufacturingOfEntityProducts>
    <cers:SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000272">The following table summarizes the amounts of the Company&#x2019;s payables to and receivables from Fresenius at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payables to Fresenius &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivables from Fresenius &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,631&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,796&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Accounts Payable&#x201d; and &#x201c;Accrued Liabilities&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in &#x201c;Other current assets&#x201d; in the Company's condensed consolidated balance sheets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cers:SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock>
    <cers:AccrualForManufacturingOfEntityProducts
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">8262000</cers:AccrualForManufacturingOfEntityProducts>
    <cers:AccrualForManufacturingOfEntityProducts
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">8470000</cers:AccrualForManufacturingOfEntityProducts>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="C_0001020214_20200331"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">1631000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="C_0001020214_20191231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">1796000</us-gaap:AccountsAndNotesReceivableNet>
    <cers:BasePeriodMaximumFundingOfCollaborativeAgreement
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331"
      decimals="INF"
      id="F_000538"
      unitRef="U_iso4217USD">103200000</cers:BasePeriodMaximumFundingOfCollaborativeAgreement>
    <cers:BasePeriodAdditionalFundingOfCollaborativeAgreement
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430"
      decimals="-5"
      id="F_000539"
      unitRef="U_iso4217USD">13800000</cers:BasePeriodAdditionalFundingOfCollaborativeAgreement>
    <cers:BasePeriodMaximumFundingOfCollaborativeAgreement
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200430"
      decimals="INF"
      id="F_000540"
      unitRef="U_iso4217USD">116900000</cers:BasePeriodMaximumFundingOfCollaborativeAgreement>
    <cers:OptionPeriodMaximumFundingOfCollaborativeAgreement
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331"
      decimals="INF"
      id="F_000541"
      unitRef="U_iso4217USD">213900000</cers:OptionPeriodMaximumFundingOfCollaborativeAgreement>
    <cers:CoInvestmentForCollaborativeAgreement
      contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331"
      decimals="INF"
      id="F_000542"
      unitRef="U_iso4217USD">5000000.0</cers:CoInvestmentForCollaborativeAgreement>
    <cers:AdditionalCoInvestmentForCollaborativeAgreement
      contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331"
      decimals="INF"
      id="F_000543"
      unitRef="U_iso4217USD">9600000</cers:AdditionalCoInvestmentForCollaborativeAgreement>
    <cers:CoInvestmentForCollaborativeAgreementIncurred
      contextRef="C_0001020214_deiLegalEntityAxis_cersCerusCorporationMember_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200101_20200331"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">1200000</cers:CoInvestmentForCollaborativeAgreementIncurred>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20200331"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_0001020214_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cersBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_20191231"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">4200000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000236">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 11. Segment, Customer and Geographic Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continues to operate in only one segment, blood safety. The Company&#x2019;s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company&#x2019;s operations in the U.S. are responsible for the R&amp;amp;D and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had the following significant customers that accounted for more than 10% of the Company&#x2019;s total product revenue, during the three months ended March&#160;31, 2020 and 2019:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#xc9;tablissement Fran&#xe7;ais du Sang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;American Red Cross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&#160;&#160; Represents an amount less than 10% of product revenue.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001020214_20200101_20200331"
      decimals="INF"
      id="F_000547"
      unitRef="U_cersSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="C_0001020214_20200101_20200331" id="F_000273">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had the following significant customers that accounted for more than 10% of the Company&#x2019;s total product revenue, during the three months ended March&#160;31, 2020 and 2019:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#xc9;tablissement Fran&#xe7;ais du Sang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;American Red Cross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&#160;&#160; Represents an amount less than 10% of product revenue.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331"
      decimals="2"
      id="F_000548"
      unitRef="U_xbrlipure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331"
      decimals="2"
      id="F_000549"
      unitRef="U_xbrlipure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331"
      decimals="2"
      id="F_000550"
      unitRef="U_xbrlipure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001020214_srtMajorCustomersAxis_cersAmericanRedCrossMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20190331"
      decimals="2"
      id="F_000551"
      unitRef="U_xbrlipure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000516"
          xlink:label="F_000516"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000517"
          xlink:label="F_000517"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000511"
          xlink:label="F_000511"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000512"
          xlink:label="F_000512"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000513"
          xlink:label="F_000513"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000518"
          xlink:label="F_000518"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes shares issuable under performance-based restricted stock unit awards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000516"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000517"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000511"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000512"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000513"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000518"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000527"
          xlink:label="F_000527"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000526"
          xlink:label="F_000526"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in &#x201c;Prepaid and other current assets&#x201d; in the Company's condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000527"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000526"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000529"
          xlink:label="F_000529"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000528"
          xlink:label="F_000528"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000530"
          xlink:label="F_000530"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000531"
          xlink:label="F_000531"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in &#x201c;Prepaid and other assets&#x201d; in the Company's condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000529"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000528"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000530"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000531"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000534"
          xlink:label="F_000534"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000535"
          xlink:label="F_000535"
          xlink:type="locator"/>
        <link:footnote id="FNT_000003" xlink:label="FNT_000003" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in &#x201c;Accounts Payable&#x201d; and &#x201c;Accrued Liabilities&#x201d; in the Company's condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000534"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000535"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000536"
          xlink:label="F_000536"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000537"
          xlink:label="F_000537"
          xlink:type="locator"/>
        <link:footnote id="FNT_000004" xlink:label="FNT_000004" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in &#x201c;Other current assets&#x201d; in the Company's condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000536"
          xlink:to="FNT_000004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000537"
          xlink:to="FNT_000004"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813065952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail) - Product - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total product revenue</a></td>
<td class="nump">$ 18,611<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total product revenue</a></td>
<td class="nump">12,220<span></span>
</td>
<td class="nump">12,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total product revenue</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">4,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total product revenue</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cers_EuropeMiddleEastAndAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cers_EuropeMiddleEastAndAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cers_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cers_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6681560704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Securities and Fair Value on Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,958</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,282</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,073</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Available-for-Sale Debt Securities by Original Contractual Maturity</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following by contractual maturity (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One year or less</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,565</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,907</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greater than one year and less than five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,811</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,282</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Available-for-Sale Marketable Securities in Unrealized Position</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 Months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months or Greater</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Values of Financial Assets and Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,426</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,732</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793711488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases is as follows<span style="font-family:Arial;"> </span>(dollars in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Month Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash payments for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Non-Cancelable Lease Payments Under Operating Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/></p>

<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum non-cancelable payments under</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leases as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as follows (in thousands):</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,927</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,711</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,053</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,616</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL*N-W9G_['Q15 V\.M?R"]02P,$%     @ ?8NE4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M3, 6PO$G'FWI=QC A#J,</R)1UOZ&R; 9($-DW#^B6<[\UL,84(MAC< XAM
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M$8_;VX[<[:1O+M-N8W;?\ES_!U!+ P04    " !]BZ50TY[3"G(#  "E#@
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MUH?C+9[M/&:SX<VP_""V?N/J)U!+ P04    " !]BZ50<"'D&K,!  #2 P
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MRZ;^-]8&0"F[&QRA#C_88BAH0CS>XME-8S89P?;S#V++-RY_ E!+ P04
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M4V%OVR 0_2N('U 2QVO3R+;4=*HV:9.B3NL^$_MLHP+G H[;?U_ KN=MUKX
M=]Q[]^XXL@'-LVT!''E54MN<MLYU!\9LV8+B]@H[T/ZF1J.X\Z9IF.T,\"J"
ME&3)9G/-%!>:%EGTG4R18>^DT' RQ/9*<?-V!(E#3K?TP_$HFM8%!RNRCC?P
M ]S/[F2\Q6:62BC05J F!NJ<WFT/QS3$QX G 8-=G$FHY(SX'(RO54XW01!(
M*%U@X'Z[P#U(&8B\C)>)D\XI W!Y_F!_B+7[6L[<PCW*7Z)R;4[WE%10\UZZ
M1QR^P%3/)TJFXK_!!:0/#TI\CA*EC2LI>^M032Q>BN*OXRYTW(?Q)KV>8.N
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M=_YLAE$<#*?;\9>1Z:OG_P!02P,$%     @ ?8NE4&-\SMC& 0  -P0  !D
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MEU-SG5?#876CU:D>?(-F^E[] U!+ P04    " !]BZ50S8_5*4X"  "7!P
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M5U%OFS 0_BN(]Q5LL($JB;2FFC9IDZI-VYYIXB2H@!DX2??O9QL7!?M<L9>
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M8Q"*<2ZWD97.UD62(LWR6^",4PIR2@%.B<5IQ)";2 E-74(N#*'42X> = A
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M<.9<@7:,7G1IM7XEYH#!69ENKOMBO"O'0/%^>@;0_!95?P%02P,$%     @
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M ;X!$X,P,0 S<V &37(V332+$P=Y!:IP#,,D($QR#9/?J$T*&J2/UR8##3*
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MM]_.^E@K6?0NNBE%^M8=L[(]GKLG,?5A.(#W ?P2P)/) .H#Z'\ FPP(^H#
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M![T7\US.@>+#\N2@]=TK_@)02P,$%     @ ?8NE4"S(O=8C @  E@8  !D
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M"E#P@I("%(QA2@92,H!"%I1L1<$)BA]<?PYB<@ 3+C#Y^OI1F!(8@Q%<<@@
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M]*S,,-%CT;64;J)XV[=+;^C9^3]02P,$%     @ ?8NE4#M!G<.H @  M D
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MG"NFZXUG>B3/^@HU="IV5*:9Z[;H[A%=1_&VOR-%PT5M\P]02P,$%     @
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MGMOW;P^2C<MH0^M\+?\!4$L#!!0    ( 'V+I5!>*=BD0 ,  .X-   9
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M"B.OT]KU=AUG_2O-30AG0K@0=.S_$:*9$+T18EO\E)DM]1-1I,P%'Y&8?M9
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MS]61:7BK&/GK7Y-:]Q7;&D&'"+D;PBUDDHWI7.Y7,R0*H5%KY<RU1"[%1D,
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MA.2Y?X9$KS^2,_/<_#6R?XV?QTR(E/:>C[J?V%D;C'=8CA]A7KR*9HDV)N+
M8FS^V6U7Z&A.[,:!&=G\DRU>(;UXIBT[V?/S=#(Z47/]KZ'&_1;G_V<(TEB[
MNZW>WTZ.8O(.+.!/)D<QAP?6\;WD*&95-]4I4N4H(,9.6]CC?+"/TY)"5Y]+
M#.F4D6Y''_OTQGYV9OWW]S#J/]IX'^0>QO5.3T[(OIT.8?W]K,Z]X4DZ&)[T
MAI-T/#8E0PLW!_AL-$Q/SM"E 2.=G ]:/E?!&KUU7"%\Y2,CE)KD LN:XOM8
M<6[/ND[Z2:1I^UN ROG'K[,9B!=>F:F:?80/)+(_.9'JK:>#L?T.]F<!^\/A
M[*;T9F^2#L;GO7$Z.7,]Z&)NW.@P'9^<PW\GL*\?/,27B>^$)H:PG^-T=&X=
M6.V5XQJPPW.D#A :SZ?#<"M> FN(_?:( S+%$NCX!0E[[1(03]^4C\:N"[S2
MI>Y[*2D2A&M_1C;VM@+I7QS,MLHZFN@'Z6" FW,TG8S(RSH&(I^>D0_B1V:,
MQ*6&/QE#5<LO;/[_4K],F?CD@QW=F#7Y-EIM$^>>E<&XK$L#DV,GB%NFCO4Y
M.[$#'TY^N_7QN['S2/UXQT6N,?IETKW),8J+U!S?4=?Y/]$GR?>'7FBUQF_T
MT%[G<*XD-H1$;H[RF^>U[\0?T=$T_X=7U<V:#H!,^+_P8(0W-Z[/B#@)AK*<
M8)C,:(R'%A\,TQ%PEI'\;S":]*;F]Y-)[X3^RT-2:PW"X<3<Q_B'O_D-EBKA
MA1N=&V$-R=#D>(7#C]3S$GB=B3$)$JK3JLS9])+)QJ0&I\)N1@'F/ZC].K)[
M^=SKL'N+;8@+N8G>%?/+;*UP,Y]K3%)G0F+XL?T$=Y\PK&(3?G8ZL!;7PM13
M1!%DAHEZCTS5!K)52(NT-'9T;BUH-)DSG9JB [RH3(P3T0LID7$VO\LDX]>S
MR:#O!F+&_IG'D0S=C#$#6YW=EV%^HRK</,^)5G'J*U/S%4V,;!Y?4V@'QX'C
MJUZ-#)PB(W?E")KBGQE;W>BA0^&W:MYEQ5RYXAC/;PO0D2W6N*9;2;3\XA[/
MQL,@<^F:ALZF^MSZ!PYN;] _<;DWR7%E(ECF'.>JJAZ[JO7Q25\T! I&&U$[
M]01GTF5O!6[S2+D";"(=]!YN048S>+BNOA*7<=ER(+G_XZF6__6)11'9PN'1
MYW"Z@SY'ZD2RSZX;#8Z6IO_(RBW:3XST9H*D@WL-67<0[-+*>T%%JS-;&\#5
MV[!Q,_.\F=7%=6ZSRW0S%J:%HZ)X+@I%4?NKD.Q<AO'ARP#KSS#1"]CH9:*L
M>+P2W@TV?/(R<'3 TQ:#2<$"_O5!\#D@3#2K&W5?2WS*=L5Q+(OB*X>=( J5
M@GC7:+&U#F.3W0)>/H*5_P'=$K0'B"G@3/YOW[SX\(D'Q &J%,NK'="&\MVH
MVDH"9^+U6<$/F$!A&?)]4_'*=H$%<E2);6^7N/D1-,\2!9LH34$:AI&;+SFE
M@A8?F$499J;!"^(GB@W!Y,87&S='XHF?9S@R'5,:$$FC8UJW]DR&S'.6)J]
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M" ;DD)(2QFN_.Q;4U,@%O,G.^Z>C'WPC4DN@LJ$& 4(ED_J)N-&\/X>MFYH
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MNJY4&VBE1YP^S5KPHPYY;<*85PK'[)$"_B__#/_[B8W?#=]6KVN$U(_&PY]
MBH?NDZNLO.F-IC_T1N<_]# *'V<,C'>>7&+=DMX0?AZ.?^C]+V3&[-EI&"Y.
M+AU7:D4F'TRQ?2VXHHDZ,;2NH(H01Q3UCLQ?SUM);CDGSY(ACY?VFC(WYPNV
MLB\2B0&-7C)/:H0U5>VBW)89R N<A#9Z<;H4%2KSF\,P2=I\1G*8/-%F#$;U
M91:61O >1QL0YLG>0%ISJYDT00,F#(%,F":A)+YE\]8Q^S"/'.&RIDS?Y8B
M=C'Y>$.0PVQFHEITZ6I5HZ4Q)9L?LS;.<T->@=I),/6<+D/.]J@+Z=J==!!Q
M>)ZO-\[EXZ?XADD(L1,VF9B[<<3^?''QT<Y_(?61ZF+E50!VH@1QTVV-B%X+
MSJ^WR[S1:E4A1>O);NK7H'UEHLHI,I>R%-NA7+VZ5 8(6@&8L,3,8"(%+MAE
M[CZ7@"0<X**J-B75X[8R-RBN.%,18%EGCFX(60O(;KN&"[J2@CEE=F,2]R'
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M2F95W/(SJ056&&>4NF^$F;5E&.OID$#W)<Q0LJ8TG/4S=V,T2J >@KNQE)0
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ML;Z7AVHXF?JU@>]>1YXZIZ9SU2J9ERPN9EA-;%Q^P( MRU!0"#A>8:@\D,M
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M,CP]=-^FY^GD](QV9^*-'1Y,S_=P#CK0+W% BGV 7/#!A!Q>JOR'[UAM?SB
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M(=FE'NIWOH=T]V@I+LB<B--*3TY(T$F',$T_)R4(X^D !/+A)!V/C9FG<'.
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M<<0VPEB7-_=N:U9"B4I\A;+=LSO]]*<VXJM6CLN\,%K*]JSF0'L2WL%^*WD
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MWL)B><%E<6]8LSFN467#9NYX4TLYP;([M="\_3*CN<;IDY?W_P)02P,$%
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MG5'6_I@VNFI_2O)BS.9C/NO_&[!X U!+ 0(4 Q0    ( 'V+I5 ?(\\#P
M !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M 'V+I5 GZ(<.@@   +$    0              "  >D   !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ ?8NE4#GSAN_O    *P(  !$
M ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?8NE4)E<G",0
M!@  G"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !]BZ50U+PV1$$#  "=#P  &               @ 'X"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?8NE4&WOC/=.
M!   _A0  !@              ( !;PP  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( 'V+I5#3GM,*<@,  *4.   8              "
M ?,0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !]BZ50
M%;V7;Q<"  #"!0  &               @ &;%   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ ?8NE4 X#R1&Y P  6!   !@
M     ( !Z!8  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M 'V+I5!OEXG/*00  !43   8              "  =<:  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !]BZ50LI\R^+,!  #2 P  &
M            @ $V'P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ ?8NE4' AY!JS 0  T@,  !@              ( !'R$  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'V+I5#S9+TKM@$  - #
M   8              "  0@C  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !]BZ50B$*>7[4!  #2 P  &0              @ 'T)
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'V+I5"S%'JK
MM $  -(#   9              "  > F  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ ?8NE4!;_HV^T 0  T@,  !D
M ( !RR@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !]
MBZ50!K<N'[4!  #2 P  &0              @ &V*@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'V+I5#,'[H\M $  -(#   9
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M970Q."YX;6Q02P$"% ,4    " !]BZ505)+*=L4!   W!   &0
M    @ %$-P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M 'V+I5 S@T\VX@$   $%   9              "  4 Y  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ ?8NE4+#OR^*Y 0  T0,  !D
M             ( !63L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !]BZ50_6<:UKD!  #2 P  &0              @ %)/0  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'V+I5"3.@.3R $
M #<$   9              "  3D_  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ ?8NE4-3!DXW% 0  -P0  !D              ( !
M.$$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !]BZ50
MYX,J++L!  #V P  &0              @ $T0P  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( 'V+I5!C?,[8Q@$  #<$   9
M      "  29%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ ?8NE4'+1W"^X 0  T@,  !D              ( !(T<  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !]BZ50D9\-[E("  ":!P
M&0              @ $220  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( 'V+I5# )(PC6P,  (D/   9              "  9M+  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ?8NE4,V/U2E.
M @  EP<  !D              ( !+4\  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !]BZ500 Z433$#   8#@  &0
M@ &R40  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'V+
MI5!?\>M<+P(  )<&   9              "  1I5  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ ?8NE4(@9X*7Z 0  T 4  !D
M         ( !@%<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " !]BZ50#Z^&$3D"  #P!@  &0              @ &Q60  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'V+I5 C,_9,[@(  )(-
M   9              "  2%<  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ ?8NE4$^2U^GF 0  [ 0  !D              ( !1E\
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !]BZ50A9A*
MH1,"   !!@  &0              @ %C80  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( 'V+I5#A-7UB4@(  #H(   9
M  "  :UC  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M?8NE4,)@JR>B @  \ D  !D              ( !-F8  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !]BZ50S[MFS$H#   R$   &0
M            @ $/:0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( 'V+I5 .P<>)! (  )$%   9              "  9!L  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ?8NE4 D^G:CI 0
M P4  !D              ( !RVX  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !]BZ50+,B]UB,"  "6!@  &0              @ 'K
M<   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( 'V+I5!0
M;V+QHP(  "L*   9              "  45S  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ ?8NE4"B)O\L5 P  2PX  !D
M     ( !'W8  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M" !]BZ50*R<MH5\"  "_!P  &0              @ %K>0  >&PO=V]R:W-H
M965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( 'V+I5 [09W#J (  +0)   9
M              "  0%\  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L!
M A0#%     @ ?8NE4,) 3/'^ 0  :P4  !D              ( !X'X  'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !]BZ507BG8I$ #
M  #N#0  &0              @ $5@0  >&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;%!+ 0(4 Q0    ( 'V+I5#'B&Z55@(  +@'   9              "
M 8R$  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ?8NE
M4-.4:B4B @  0 8  !D              ( !&8<  'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !]BZ50>8?,L;P!  #2 P  &0
M        @ %RB0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( 'V+I5 +V]!U P(  *X%   9              "  66+  !X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ ?8NE4'JPGK/\>0  [.L!
M !0              ( !GXT  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ ?8NE4$C4\FYB @  @ P   T              ( !S0<! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !]BZ50C) %[( $  !V(P  #P
M    @ %:"@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ?8NE4!HKVS'N
M 0  5"   !H              ( !!P\! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ ?8NE4(RC=%'1 0  (R   !,
M ( !+1$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #X /@#D$   +Q,!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813806688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 05, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>Period </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Stock-based compensation, option to be granted at percentage of fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm', window );">Employee Stock Purchase Plan, offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod', window );">Number of purchase periods within each offering period | Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate number of shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Stock-based compensation, option to be granted at percentage of fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate number of shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Stock-based compensation, award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PerformanceBasedStockOptionsOutstanding', window );">Performance-based stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares of common stock authorized for issuance</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options and other stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,621,000<span></span>
</td>
<td class="nump">16,830,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,578,000<span></span>
</td>
<td class="nump">4,098,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan | Performance-based Stock or Cash Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Employee Stock Purchase Plan, authorized shares for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Stock option plan granted on cash award | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan | Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember', window );">2008 Equity Incentive Plan | Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_PerformanceBasedStockOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance-based stock options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_PerformanceBasedStockOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award employee stock purchase plan offering term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cers_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cers_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cers_PerformanceUnitsAndCashBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cers_PerformanceUnitsAndCashBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800299488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_MinimumTermOfNonCancelableOperatingLeases', window );">Minimum term of non-cancellable operating leases</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear', window );">Expiration of non-cancellable operating leases maximum year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription', window );">Operating lease not yet commenced</a></td>
<td class="text">the Company had no leases that have not yet commenced.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest period of expiration of non-cancelable operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_MinimumTermOfNonCancelableOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum term of non-cancelable operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_MinimumTermOfNonCancelableOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease that has not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800241328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1. Summary of Significant Accounting Policies</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation and Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (together with Cerus Corporation, hereinafter &#8220;Cerus&#8221; or the &#8220;Company&#8221;) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three months ended March&#160;31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, which were included in the Company&#8217;s 2019 Annual Report on Form 10-K, filed with the SEC on February 21, 2020. The accompanying condensed consolidated balance sheet as of December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements as of that date<span style="font-style:italic;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (&#8220;SSP&#8221;) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (&#8220;platelet and plasma systems&#8221; or &#8220;disposable kits&#8221;), UVA illumination devices (&#8220;illuminators&#8221;), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company&#8217;s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis, and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company estimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.</p>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives reimbursement under its U.S. government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that supports research and development of defined projects. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Note 1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and License A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greements&#8212;Agreement with BARDA&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract generally provides for reimbursement of approved costs incurred under the terms of the contract. Revenue related to the cost reimbursement provisions under the Company&#8217;s U.S. government contract are recognized as the qualified direct and indirect costs on the projects are incurred. The Company invoices under its U.S. government contract using the provisional rates in the government contract and thus is subject to future audits at the discretion of government. These audits could result in an adjustment to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue previously reported, which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> potentially could be significant. The Company believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. Costs incurred related to services performed under the contract are included as a component of research and development or selling, general and administrative expenses in the Company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations. The Company&#8217;s use of estimates in recording accrued liabilities for government contract activities (see &#8220;Use of Estimates&#8221; above) affects the revenue recorded from development funding and under the government contract. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disaggregation of Product Revenue</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe, Middle East and Africa</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">North America</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice. Accounts receivable are recorded when the Company&#8217;s right to the consideration are estimated to be unconditional. The Company had no contract assets at March&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities mainly consist of deferred product revenue related to maintenance services, unshipped products, and uninstalled illuminators. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the service period. The increase in the deferred product revenue balance for the three months ended March&#160;31, 2020 is primarily driven by performance obligations not satisfied but invoiced as of March&#160;31, 2020, offset by $0.3 million of revenue recognized that were included in the deferred product revenue balance as of December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (&#8220;R&amp;D&#8221;) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company&#8217;s U.S. government contract. Research and development expenses include salaries and related expenses for scientific and regulatory personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&amp;D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s use of estimates in recording accrued liabilities for R&amp;D activities (see &#8220;Use of Estimates&#8221; above) affects the amounts of R&amp;D expenses recorded from development funding and under its U.S. government contract. Actual results may differ from those estimates under different assumptions or conditions.</p>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities were recorded in &#8220;Unrealized gains (losses) on available-for-sale investments, net of taxes&#8221; on the Company&#8217;s condensed consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale&#160;investments, if any, were recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020,&#160;the Company&#8217;s &#8220;Restricted cash&#8221; primarily consisted of a&#160;letter of credit relating to the lease of the Company&#8217;s office building. As of March&#160;31, 2020 and December&#160;31, 2019, the Company also had certain non-U.S. dollar denominated deposits recorded as &#8220;Restricted cash&#8221; in compliance with certain foreign contractual requirements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s investment policy, substantially all of the Company&#8217;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#8217;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#160;31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#8217;s cash equivalents and short-term investments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had three customers that accounted for more than 10% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. These customers cumulatively represented approximately 58% and 56% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020 and December&#160;31, 2019, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, illuminators, and certain replacement parts for the illuminators. Platelet and plasma systems&#8217; disposable kits generally have 18 to 24 month shelf lives from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time before being sold to, and ultimately incorporated and assembled by Fresenius Kabi Deutschland GmbH or Fresenius, Inc. (with their affiliates, &#8220;Fresenius&#8221;) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be sold to Fresenius for </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within the next twelve month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and evaluates its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company&#8217;s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its work-in-process and finished units to meet the Company&#8217;s forecasted demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company classified its work-in-process inventory as a current asset on its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets based on its evaluation that the work-in-process inventory would be sold to Fresenius for finished disposable kit production within each respective subsequent twelve-month period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in &#8220;Cost of product revenue&#8221; on the Company&#8217;s condensed consolidated statements of operations. At March&#160;31, 2020 and December&#160;31, 2019, the Company had $0.2 million and $0.1 million, respectively, recorded for potential obsolete, expiring or unsalable product.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the three months ended March&#160;31, 2020 and 2019, the Company had non-cash purchases of capital expenditures of $0.2 million and $2.9 million, respectively.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratable amortization over the original estimated useful life of ten years. Accumulated amortization of intangible assets as of March&#160;31, 2020 and December&#160;31, 2019, was $1.9 million and $1.9 million, respectively. Goodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August&#160;31 of each fiscal year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit&#8217;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company&#8217;s one reporting unit.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an impairment test on its intangible assets if certain events or changes in circumstances occur which indicate that the carrying amounts of its intangible assets may not be recoverable. If the intangible assets are not recoverable, an impairment loss would be recognized by the Company based on the excess amount of the carrying value of the intangible assets over its fair value. During the three months ended March&#160;31, 2020 and 2019, there were no impairment charges recognized related to the acquired intangible assets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Remeasurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s foreign subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company&#8217;s condensed consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to non-employees, the Company recognizes stock-based compensation expense for the grant date fair value of the vested portion of the awards in its condensed consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 8 for further information regarding the Company&#8217;s stock-based compensation expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company&#8217;s U.S. federal tax returns for years 1999 through 2018, California tax returns for years through 2018, and Netherlands tax returns for years 2015 through 2018 remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the three months ended March&#160;31, 2020 and 2019, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of anti-dilutive potential shares:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,648</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,247</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>

<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s condensed consolidated balance sheets. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have finance leases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#8217;s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company&#8217;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a <span style="-sec-ix-hidden:F_000318">one-year</span> warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company&#8217;s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company&#8217;s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 for further information regarding the Company&#8217;s valuation of financial instruments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):</span> <span style="font-style:italic;">Measurement of Credit Losses on Financial Instruments,</span> which requires measurement and recognition of expected credit losses for financial assets held. The standard is effective for annual periods beginning after December 15, 2019, and interim periods thereafter, with early application permitted. The Company adopted the new accounting standard on January 1, 2020, using the modified retrospective transition method. The adoption of this ASU had no material impact on the Company&#8217;s condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813538448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development and License Agreements - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PaymentForManufacturingOfEntityProducts', window );">Payments made relating to the manufacturing of the products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_BasePeriodMaximumFundingOfCollaborativeAgreement', window );">Committed fund receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_OptionPeriodMaximumFundingOfCollaborativeAgreement', window );">Committed fund receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Accounts receivable of billed and unbilled amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | BARDA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_BasePeriodMaximumFundingOfCollaborativeAgreement', window );">Committed fund receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_BasePeriodAdditionalFundingOfCollaborativeAgreement', window );">Additional committed fund receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cers_CerusCorporationMember', window );">Cerus Corporation | BARDA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_CoInvestmentForCollaborativeAgreement', window );">Co-investment by the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_AdditionalCoInvestmentForCollaborativeAgreement', window );">Additional co-investment by the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_CoInvestmentForCollaborativeAgreementIncurred', window );">Co-investment incurred by the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cers_ManufacturingAndSupplyAgreementsMember', window );">Manufacturing and Supply Agreement | Fresenius</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_ManufacturingAndDevelopmentPaymentLiability', window );">Payments made based on the successful achievement of production volumes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_PaymentsForManufacturingAndDevelopmentCost', window );">Manufacturing and development payments | &#8364;</a></td>
<td class="nump">&#8364; 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cers_ManufacturingAndSupplyAgreementsMember', window );">Manufacturing and Supply Agreement | Fresenius | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_LicensesAgreementsLineItems', window );"><strong>Licenses Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Manufacturing and development obligations, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_AdditionalCoInvestmentForCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional co-investment for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_AdditionalCoInvestmentForCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_BasePeriodAdditionalFundingOfCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base period additional funding of collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_BasePeriodAdditionalFundingOfCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_BasePeriodMaximumFundingOfCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base period maximum funding of collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_BasePeriodMaximumFundingOfCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_CoInvestmentForCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-investment for collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_CoInvestmentForCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_CoInvestmentForCollaborativeAgreementIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co investment for collaborative agreement incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_CoInvestmentForCollaborativeAgreementIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_LicensesAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_LicensesAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_ManufacturingAndDevelopmentPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and development payment liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_ManufacturingAndDevelopmentPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_OptionPeriodMaximumFundingOfCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option period maximum funding of collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_OptionPeriodMaximumFundingOfCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_PaymentForManufacturingOfEntityProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for manufacturing of entity products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_PaymentForManufacturingOfEntityProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_PaymentsForManufacturingAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for manufacturing and development cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_PaymentsForManufacturingAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cers_CerusCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cers_CerusCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cers_ManufacturingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cers_ManufacturingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cers_FreseniusKabiAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cers_FreseniusKabiAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804582608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 8,320<span></span>
</td>
<td class="nump">$ 8,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_GrossProfitOnProductRevenue', window );">Gross profit</a></td>
<td class="nump">10,291<span></span>
</td>
<td class="nump">9,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">15,810<span></span>
</td>
<td class="nump">13,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">15,913<span></span>
</td>
<td class="nump">16,161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,723<span></span>
</td>
<td class="nump">29,601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,402)<span></span>
</td>
<td class="num">(16,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expense, net</a></td>
<td class="num">(1,007)<span></span>
</td>
<td class="num">(2,664)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(16,409)<span></span>
</td>
<td class="num">(18,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,466)<span></span>
</td>
<td class="num">$ (18,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares used for calculating net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">157,405<span></span>
</td>
<td class="nump">137,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 18,611<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 6,030<span></span>
</td>
<td class="nump">$ 4,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_GrossProfitOnProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross profit on product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_GrossProfitOnProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803114016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Customer and Geographic Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803092464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Accrued Liabilities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and related costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,703</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803091664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Stock-Based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Plans</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains an Employee Stock Purchase Plan (the &#8220;Purchase Plan&#8221;), which is intended to qualify as an employee stock purchase plan within the meaning of Section&#160;423(b) of the Internal Revenue Code. Under the Purchase Plan, the Company&#8217;s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. Under the Purchase Plan eligible employee participants may purchase shares of common stock of the Company at a purchase price equal to 85% of the lower of the fair market value per share on the start date of the offering period or the fair market value per share on the purchase date. The Purchase Plan consists of a fixed offering period of 12 months with two purchase periods within each offering period. At March&#160;31, 2020, the Company had 0.4 million shares available for future issuance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2008 Equity Incentive Plan and Inducement Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors. The Company currently grants equity awards from one plan, the 2008 Equity Incentive Plan and its subsequent amendments (collectively, the &#8220;Amended 2008 Plan&#8221;). The Amended 2008 Plan allows for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units (&#8220;RSUs&#8221;), stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. On June 5, 2019, the Company&#8217;s stockholders approved an </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amendment and restatement of the 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance under the 2008 Plan by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,800,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wards under the Amended 2008 Plan generally have a maximum term of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from the date of the award. The Amended 2008 Plan generally requires options to be granted at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the fair market value of the Company&#8217;s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. RSUs are measured based on the fair market value of the underlying stock on the date of grant</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. RSUs granted by the Company to employees</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> generally vest over</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three to four years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based stock or cash awards granted under the Amended 2008 Plan are limited to either </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock or $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million per recipient per calendar year.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span>40,000<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance-based stock </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were outstanding. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020, the Company had an aggregate of approximately 28.1 million shares of its common stock subject to outstanding options or unvested RSUs, or remaining available for future issuance under the Amended 2008 Plan, of which approximately 18.6&#160;million shares and 5.6 million shares were subject to outstanding options and unvested RSUs, respectively, and approximately 3.9&#160;million shares were available for future issuance under the Amended 2008 Plan. The Company&#8217;s policy is to issue new shares of common stock upon the exercise of options or vesting of RSUs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,830</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.74</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.51</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,621</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unvested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,098</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,029</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at March&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,578</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Includes shares issuable under performance-based restricted stock unit awards.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Valuation Assumptions for Stock-based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan rights. The Black-Scholes option pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding a number of complex and subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company&#8217;s expected stock price volatility, the risk-free interest rate and expected dividends. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cers-10q_20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "cers-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cers-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cers-10q_20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cers-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cers-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cers-20200331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 479,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 3,
    "http://www.cerus.com/20200331": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 9,
    "total": 13
   },
   "keyCustom": 60,
   "keyStandard": 304,
   "memberCustom": 24,
   "memberStandard": 26,
   "nsprefix": "cers",
   "nsuri": "http://www.cerus.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Accrued Liabilities",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Debt",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Stockholders' Equity",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Stock-Based Compensation",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Income Taxes",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cers:DevelopmentAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Development and License Agreements",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements",
     "shortName": "Development and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cers:DevelopmentAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Segment, Customer and Geographic Information",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation",
     "shortName": "Segment, Customer and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables",
     "shortName": "Available-for-sale Securities and Fair Value on Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Inventories (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Debt (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Development and License Agreements (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables",
     "shortName": "Development and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Segment, Customer and Geographic Information (Tables)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables",
     "shortName": "Segment, Customer and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_srtProductOrServiceAxis_us-gaapProductMember_srtStatementGeographicalAxis_cersEuropeMiddleEastAndAfricaMember_20200101_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail",
     "shortName": "Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Available-for-Sale Securities (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail",
     "shortName": "Summary of Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Available-for-Sale Debt Securities by Original Contractual Maturity (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail",
     "shortName": "Available-for-Sale Debt Securities by Original Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Available-for-Sale Marketable Securities in Unrealized Position (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
     "shortName": "Available-for-Sale Marketable Securities in Unrealized Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20190101_20190331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGains",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Fair Values on Financial Assets and Liabilities (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
     "shortName": "Fair Values on Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Inventories (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail",
     "shortName": "Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Accrued Liabilities (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail",
     "shortName": "Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredDebtCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Debt (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
     "shortName": "Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail",
     "shortName": "Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Debt - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
     "shortName": "Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapDebtInstrumentAxis_cersTermLoanCreditAgreementMember_20190329",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cers:MinimumTermOfNonCancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cers:MinimumTermOfNonCancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail",
     "shortName": "Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail",
     "shortName": "Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cersUnderwrittenPublicOfferingMember_20200101_20200131",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersEmployeeStockPurchasePlanMember_20200101_20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Activity Under Equity Incentive Plans Related to Stock Options (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail",
     "shortName": "Activity Under Equity Incentive Plans Related to Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Activity Under Equity Incentive Plans Related to RSUs (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
     "shortName": "Activity Under Equity Incentive Plans Related to RSUs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_cersTwoThousandEightEquityIncentivePlanMember_20200101_20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_deiLegalEntityAxis_cersCerusEuropeBVMember_20200101_20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cers:PaymentForManufacturingOfEntityProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Development and License Agreements - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Development and License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cers:PaymentForManufacturingOfEntityProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cers:UnamortizedDeferredCostForDevelopmentActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Development and License Agreements - Summary of Prepaid R&D Asset and Manufacturing Efficiency Asset (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail",
     "shortName": "Development and License Agreements - Summary of Prepaid R&D Asset and Manufacturing Efficiency Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cers:UnamortizedDeferredCostForDevelopmentActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cers:AccrualForManufacturingOfEntityProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail",
     "shortName": "Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cers:DevelopmentAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cers:AccrualForManufacturingOfEntityProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cersSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Segment, Customer and Geographic Information - Additional Information (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail",
     "shortName": "Segment, Customer and Geographic Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cersSegment",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail)",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
     "shortName": "Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_srtMajorCustomersAxis_cersEtablissementFrancaisDuSangMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueProductLineMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments",
     "shortName": "Available-for-sale Securities and Fair Value on Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Inventories",
     "role": "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cers-10q_20200331.htm",
      "contextRef": "C_0001020214_20200101_20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "cers_AccrualForManufacturingOfEntityProducts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrual for manufacturing of entity products.",
        "label": "Accrual For Manufacturing Of Entity Products",
        "terseLabel": "Payables to Fresenius"
       }
      }
     },
     "localname": "AccrualForManufacturingOfEntityProducts",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_AccruedDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued development costs, current.",
        "label": "Accrued Development Costs Current",
        "terseLabel": "Accrued development costs"
       }
      }
     },
     "localname": "AccruedDevelopmentCostsCurrent",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_AdditionalCoInvestmentForCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional co-investment for collaborative agreement.",
        "label": "Additional Co Investment For Collaborative Agreement",
        "terseLabel": "Additional co-investment by the company"
       }
      }
     },
     "localname": "AdditionalCoInvestmentForCollaborativeAgreement",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_AmericanRedCrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "American red cross.",
        "label": "American Red Cross [Member]",
        "terseLabel": "American Red Cross"
       }
      }
     },
     "localname": "AmericanRedCrossMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_AvailableForSaleSecuritiesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available for sale securities policy.",
        "label": "Available For Sale Securities Policy",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesPolicy",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cers_BasePeriodAdditionalFundingOfCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Base period additional funding of collaborative agreement.",
        "label": "Base Period Additional Funding Of Collaborative Agreement",
        "terseLabel": "Additional committed fund receivable"
       }
      }
     },
     "localname": "BasePeriodAdditionalFundingOfCollaborativeAgreement",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_BasePeriodMaximumFundingOfCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Base period maximum funding of collaborative agreement.",
        "label": "Base Period Maximum Funding Of Collaborative Agreement",
        "terseLabel": "Committed fund receivable"
       }
      }
     },
     "localname": "BasePeriodMaximumFundingOfCollaborativeAgreement",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biomedical advanced research and development authority.",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA Agreement"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_CantorFitzgeraldCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cantor fitzgerald &amp; co.",
        "label": "Cantor Fitzgerald Co [Member]",
        "terseLabel": "Cantor Fitzgerald &amp; Co"
       }
      }
     },
     "localname": "CantorFitzgeraldCoMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_CerusCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cerus corporation.",
        "label": "Cerus Corporation [Member]",
        "terseLabel": "Cerus Corporation"
       }
      }
     },
     "localname": "CerusCorporationMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_CerusEuropeBVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cerus Europe B. V.",
        "label": "Cerus Europe B V [Member]",
        "terseLabel": "Cerus Europe B.V."
       }
      }
     },
     "localname": "CerusEuropeBVMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_CoInvestmentForCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co-investment for collaborative agreement.",
        "label": "Co Investment For Collaborative Agreement",
        "terseLabel": "Co-investment by the company"
       }
      }
     },
     "localname": "CoInvestmentForCollaborativeAgreement",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_CoInvestmentForCollaborativeAgreementIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co investment for collaborative agreement incurred.",
        "label": "Co Investment For Collaborative Agreement Incurred",
        "terseLabel": "Co-investment incurred by the company"
       }
      }
     },
     "localname": "CoInvestmentForCollaborativeAgreementIncurred",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_CommonStockSharesAvailableForSaleValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock, shares available for sale, value.",
        "label": "Common Stock Shares Available For Sale Value",
        "terseLabel": "Common stock registered for sale"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForSaleValue",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_CommonStockSharesUnsoldValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock shares unsold value.",
        "label": "Common Stock Shares Unsold Value",
        "terseLabel": "Unsold shares of common stock, value"
       }
      }
     },
     "localname": "CommonStockSharesUnsoldValue",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of customers whose outstanding trade receivables by a single customer accounts for 10 percent or more of an entity's trade receivable.",
        "label": "Cumulative Outstanding Trade Receivables Number Of Major Customers",
        "terseLabel": "Number of major customers representing outstanding trade receivables"
       }
      }
     },
     "localname": "CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cers_DebtInstrumentAvailableAmountUponCondition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument, available amount upon condition.",
        "label": "Debt Instrument Available Amount Upon Condition",
        "terseLabel": "Loan and security agreement available upon revenue achievement"
       }
      }
     },
     "localname": "DebtInstrumentAvailableAmountUponCondition",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DebtInstrumentCarryingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_SecuredDebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current portion carrying value of the debt instrument before deducting unamortized discounts (if any).",
        "label": "Debt Instrument Carrying Current",
        "negatedLabel": "Less: debt - current, Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingCurrent",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DebtInstrumentCarryingNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_SecuredLongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-current portion carrying value of the debt instrument before deducting unamortized discounts (if any).",
        "label": "Debt Instrument Carrying Non Current",
        "terseLabel": "Debt - non-current, Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingNonCurrent",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DebtInstrumentInterestOnlyPaymentsDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument interest only payments date.",
        "label": "Debt Instrument Interest Only Payments Date",
        "terseLabel": "Interest-only payments date"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentsDate",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "cers_DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument principal and declining interest payments additional period.",
        "label": "Debt Instrument Principal And Declining Interest Payments Additional Period",
        "terseLabel": "Principal plus declining interest payments"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAndDecliningInterestPaymentsAdditionalPeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_DebtInstrumentUnamortizedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_SecuredDebtCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current portion of the unamortized discounts on the debt instrument.",
        "label": "Debt Instrument Unamortized Current",
        "terseLabel": "Less: debt - current, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedCurrent",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DebtInstrumentUnamortizedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_SecuredLongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-current portion of the unamortized discounts on the debt instrument.",
        "label": "Debt Instrument Unamortized Noncurrent",
        "negatedLabel": "Debt - non-current, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedNoncurrent",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DebtPrepaymentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt prepayment fee.",
        "label": "Debt Prepayment Fee",
        "terseLabel": "Prepayment fees in aggregate amount"
       }
      }
     },
     "localname": "DebtPrepaymentFee",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred costs capitalized prepaid and other assets.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets [Line Items]",
        "terseLabel": "Deferred Costs Capitalized Prepaid And Other Assets [Line Items]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsLineItems",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_DeferredCostsCapitalizedPrepaidAndOtherAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred costs capitalized prepaid and other assets.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets [Table]",
        "terseLabel": "Deferred Costs Capitalized Prepaid And Other Assets [Table]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsTable",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_DevelopmentAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and license agreements.",
        "label": "Development And License Agreements [Abstract]"
       }
      }
     },
     "localname": "DevelopmentAndLicenseAgreementsAbstract",
     "nsuri": "http://www.cerus.com/20200331",
     "xbrltype": "stringItemType"
    },
    "cers_DevelopmentAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and license agreements.",
        "label": "Development And License Agreements [Text Block]",
        "terseLabel": "Development and License Agreements"
       }
      }
     },
     "localname": "DevelopmentAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cers_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_EmployeeStockPurchasePlanRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan rights.",
        "label": "Employee Stock Purchase Plan Rights [Member]",
        "terseLabel": "Employee Stock Purchase Plan Rights"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanRightsMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_EtablissementFrancaisDuSangMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Etablissement Francais du Sang.",
        "label": "Etablissement Francais Du Sang [Member]",
        "terseLabel": "Etablissement Francais du Sang"
       }
      }
     },
     "localname": "EtablissementFrancaisDuSangMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_EuropeMiddleEastAndAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Europe, middle east and africa.",
        "label": "Europe Middle East And Africa [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EuropeMiddleEastAndAfricaMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_ExpirationOfNonCancelableOperatingLeasesMaximumYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Latest period of expiration of non-cancelable operating lease.",
        "label": "Expiration Of Non Cancelable Operating Leases Maximum Year",
        "terseLabel": "Expiration of non-cancellable operating leases maximum year"
       }
      }
     },
     "localname": "ExpirationOfNonCancelableOperatingLeasesMaximumYear",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "cers_FreseniusKabiAGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fresenius Kabi AG.",
        "label": "Fresenius Kabi A G [Member]",
        "terseLabel": "Fresenius"
       }
      }
     },
     "localname": "FreseniusKabiAGMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_GrossProfitOnProductRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross profit on product revenue.",
        "label": "Gross Profit On Product Revenue",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfitOnProductRevenue",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in accrued liabilities and other non-current liabilities.",
        "label": "Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities",
        "terseLabel": "Accrued liabilities and other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in manufacturing and development payment liability.",
        "label": "Increase Decrease In Manufacturing And Development Payment Liability",
        "terseLabel": "Manufacturing and development obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_InterestOnlyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest only payment period.",
        "label": "Interest Only Payment Period",
        "terseLabel": "Interest only payment period"
       }
      }
     },
     "localname": "InterestOnlyPaymentPeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_InventoryLifeFinishedGoodsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory life finished goods period.",
        "label": "Inventory Life Finished Goods Period",
        "terseLabel": "Shelf lives of inventory"
       }
      }
     },
     "localname": "InventoryLifeFinishedGoodsPeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases shares.",
        "label": "Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Shares",
        "terseLabel": "Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases value.",
        "label": "Issuance Of Common Stock From Exercise Of Stock Options Or Warrants And Vesting Of Restricted Stock Units And Employee Stock Purchase Plans Purchases Value",
        "terseLabel": "Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LicensesAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licenses agreements.",
        "label": "Licenses Agreements [Line Items]",
        "terseLabel": "Licenses Agreements [Line Items]"
       }
      }
     },
     "localname": "LicensesAgreementsLineItems",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_LicensesAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licenses Agreements [Table]",
        "label": "Licenses Agreements [Table]",
        "terseLabel": "Licenses Agreements [Table]"
       }
      }
     },
     "localname": "LicensesAgreementsTable",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees",
        "totalLabel": "Total, Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10060.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees in remainder of fiscal year.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees In Remainder Of Fiscal Year",
        "terseLabel": "2020 (remainder), Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInRemainderOfFiscalYear",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10100.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees in year five.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees In Year Five",
        "terseLabel": "2024, Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFive",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10090.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees in year four.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees In Year Four",
        "terseLabel": "2023, Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearFour",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10080.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees in year three.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees In Year Three",
        "terseLabel": "2022, Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearThree",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10070.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfInterestAndFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of interest and fees in year two.",
        "label": "Long Term Debt Maturities Repayments Of Interest And Fees In Year Two",
        "terseLabel": "2021, Interest and Fees"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterestAndFeesInYearTwo",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10010.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in remainder of fiscal year.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Remainder Of Fiscal Year",
        "terseLabel": "2020 (remainder), Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInRemainderOfFiscalYear",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10050.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year five.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Five",
        "terseLabel": "2024, Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10040.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year four.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Four",
        "terseLabel": "2023, Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10030.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year three.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Three",
        "terseLabel": "2022, Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10020.0,
       "parentTag": "cers_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year two.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Two",
        "terseLabel": "2021, Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_ManufacturingAndDevelopmentPaymentLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing and development payment liability.",
        "label": "Manufacturing And Development Payment Liability",
        "terseLabel": "Payments made based on the successful achievement of production volumes"
       }
      }
     },
     "localname": "ManufacturingAndDevelopmentPaymentLiability",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_ManufacturingAndSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing and supply agreements.",
        "label": "Manufacturing And Supply Agreements [Member]",
        "terseLabel": "Manufacturing and Supply Agreement"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_ManufacturingEfficiencyAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing efficiency assets.",
        "label": "Manufacturing Efficiency Assets",
        "terseLabel": "Manufacturing efficiency asset"
       }
      }
     },
     "localname": "ManufacturingEfficiencyAssets",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_MaximumAmountAvailableUnderOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount available under ATM offering.",
        "label": "Maximum Amount Available Under Offering",
        "terseLabel": "Maximum common stock offering price"
       }
      }
     },
     "localname": "MaximumAmountAvailableUnderOffering",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_MinimumTermOfNonCancelableOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum term of non-cancelable operating lease.",
        "label": "Minimum Term Of Non Cancelable Operating Leases",
        "terseLabel": "Minimum term of non-cancellable operating leases"
       }
      }
     },
     "localname": "MinimumTermOfNonCancelableOperatingLeases",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_NonCashOperatingLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cash operating lease cost.",
        "label": "Non Cash Operating Lease Cost",
        "negatedLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCost",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_NumberOfEqualTranches": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equal tranches.",
        "label": "Number Of Equal Tranches",
        "terseLabel": "Number of loan tranches"
       }
      }
     },
     "localname": "NumberOfEqualTranches",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cers_OptionPeriodMaximumFundingOfCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Option period maximum funding of collaborative agreement.",
        "label": "Option Period Maximum Funding Of Collaborative Agreement",
        "terseLabel": "Committed fund receivable"
       }
      }
     },
     "localname": "OptionPeriodMaximumFundingOfCollaborativeAgreement",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_OxfordTermLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oxford term loan agreement.",
        "label": "Oxford Term Loan Agreement [Member]",
        "verboseLabel": "Prior Loan Agreement"
       }
      }
     },
     "localname": "OxfordTermLoanAgreementMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_PaymentForManufacturingOfEntityProducts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment for manufacturing of entity products.",
        "label": "Payment For Manufacturing Of Entity Products",
        "terseLabel": "Payments made relating to the manufacturing of the products"
       }
      }
     },
     "localname": "PaymentForManufacturingOfEntityProducts",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_PaymentOfCustomerInvoiceContractPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of customer invoice contract period.",
        "label": "Payment Of Customer Invoice Contract Period",
        "terseLabel": "Payment of customer invoice contract period"
       }
      }
     },
     "localname": "PaymentOfCustomerInvoiceContractPeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_PaymentsForManufacturingAndDevelopmentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for manufacturing and development cost.",
        "label": "Payments For Manufacturing And Development Cost",
        "terseLabel": "Manufacturing and development payments"
       }
      }
     },
     "localname": "PaymentsForManufacturingAndDevelopmentCost",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_PercentageOfProceedsPayableAsCompensationToUnderwriter": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of proceeds payable as compensation to underwriter.",
        "label": "Percentage Of Proceeds Payable As Compensation To Underwriter",
        "terseLabel": "Percentage of proceeds payable as compensation to underwriter"
       }
      }
     },
     "localname": "PercentageOfProceedsPayableAsCompensationToUnderwriter",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cers_PerformanceBasedStockOptionsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance-based stock options outstanding.",
        "label": "Performance Based Stock Options Outstanding",
        "terseLabel": "Performance-based stock options, outstanding"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionsOutstanding",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cers_PerformanceUnitsAndCashBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance units and cash-based awards.",
        "label": "Performance Units And Cash Based Awards [Member]",
        "terseLabel": "Performance-based Stock or Cash Awards"
       }
      }
     },
     "localname": "PerformanceUnitsAndCashBasedAwardsMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_ProductWarrantyTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product warranty term.",
        "label": "Product Warranty Term",
        "terseLabel": "Period of warranty"
       }
      }
     },
     "localname": "ProductWarrantyTerm",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_RepaymentsPrincipalAndInterestAggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments principal and interest aggregate amount.",
        "label": "Repayments Principal And Interest Aggregate Amount",
        "terseLabel": "Repayments principal and interest aggregate amount"
       }
      }
     },
     "localname": "RepaymentsPrincipalAndInterestAggregateAmount",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_SalesAmendmentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales amendment three.",
        "label": "Sales Amendment Three [Member]",
        "terseLabel": "Amendment No. 3"
       }
      }
     },
     "localname": "SalesAmendmentThreeMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award employee stock purchase plan offering term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Employee Stock Purchase Plan Offering Term",
        "terseLabel": "Employee Stock Purchase Plan, offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Purchase Period",
        "terseLabel": "Number of purchase periods within each offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cers_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Term",
        "terseLabel": "Stock-based compensation, award term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_StockholdersEquityNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders equity note.",
        "label": "Stockholders Equity Note [Line Items]",
        "terseLabel": "Stockholders Equity Note [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityNoteLineItems",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_StockholdersEquityNoteTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders equity note.",
        "label": "Stockholders Equity Note [Table]",
        "terseLabel": "Stockholders Equity Note [Table]"
       }
      }
     },
     "localname": "StockholdersEquityNoteTable",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of amounts payable and receivable under agreement.",
        "label": "Summary Of Amounts Payable And Receivable Under Agreement Table [Text Block]",
        "terseLabel": "Summary of Amounts Payable and Amounts Receivable from Fresenius"
       }
      }
     },
     "localname": "SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cers_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cers_TermLoanCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term loan credit agreement.",
        "label": "Term Loan Credit Agreement [Member]",
        "terseLabel": "Term Loan Credit Agreement"
       }
      }
     },
     "localname": "TermLoanCreditAgreementMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TrailingNetRevenueTarget": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trailing net revenue target.",
        "label": "Trailing Net Revenue Target",
        "terseLabel": "Trailing net revenue target period"
       }
      }
     },
     "localname": "TrailingNetRevenueTarget",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cers_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche 1"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche three.",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche 3"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche two.",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche 2"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TwoThousandEightEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand eight equity incentive plan.",
        "label": "Two Thousand Eight Equity Incentive Plan [Member]",
        "terseLabel": "2008 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEightEquityIncentivePlanMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TwoThousandNineteenTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand nineteen term loan.",
        "label": "Two Thousand Nineteen Term Loan [Member]",
        "terseLabel": "Two Thousand Nineteen Term Loan"
       }
      }
     },
     "localname": "TwoThousandNineteenTermLoanMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_TwoThousandSeventeenTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand seventeen term loan.",
        "label": "Two Thousand Seventeen Term Loan [Member]",
        "terseLabel": "2017 Term Loans"
       }
      }
     },
     "localname": "TwoThousandSeventeenTermLoanMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_UnamortizedDeferredCostForDevelopmentActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unamortized deferred cost for development activities.",
        "label": "Unamortized Deferred Cost For Development Activities",
        "terseLabel": "Prepaid R&amp;D asset"
       }
      }
     },
     "localname": "UnamortizedDeferredCostForDevelopmentActivities",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cers_UncategorizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Uncategorized [Abstract]",
        "label": "Uncategorized [Abstract]"
       }
      }
     },
     "localname": "UncategorizedAbstract",
     "nsuri": "http://www.cerus.com/20200331",
     "xbrltype": "stringItemType"
    },
    "cers_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cers_WorkInProcessInventoryLifePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Work in process inventory life, period.",
        "label": "Work In Process Inventory Life Period",
        "terseLabel": "Protracted length of inventory"
       }
      }
     },
     "localname": "WorkInProcessInventoryLifePeriod",
     "nsuri": "http://www.cerus.com/20200331",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r126",
      "r210",
      "r215",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r124",
      "r210",
      "r213",
      "r345",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r125",
      "r210",
      "r214",
      "r347",
      "r355",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "auth_ref": [
      "r19",
      "r128",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts And Notes Receivable Net",
        "terseLabel": "Receivables from Fresenius"
       }
      }
     },
     "localname": "AccountsAndNotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r19",
      "r128",
      "r129",
      "r211"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite Lived Intangible Assets Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r223",
      "r225",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment Measurement Input",
        "terseLabel": "Manufacturing and development obligations, discount rate"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Weighted average number of anti-dilutive potential shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r122",
      "r321",
      "r336"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r50"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r134",
      "r152"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost",
        "terseLabel": "Greater than one year and less than five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r139",
      "r141",
      "r331"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Fair Value",
        "terseLabel": "Greater than one year and less than five years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Available For Sale Securities Debt Maturities Within One Year Amortized Cost",
        "terseLabel": "One year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r139",
      "r140",
      "r330"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "One year or less, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r131",
      "r135",
      "r152"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Total available-for-sale securities fair value",
        "verboseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r133",
      "r152"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Gross Realized Gains",
        "terseLabel": "Gross realized gains from the sale or maturity of available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGains",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Gross Realized Losses",
        "terseLabel": "Gross realized losses from the sale or maturity of available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r226",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Non-cash purchases of capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]",
        "terseLabel": "Project"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r32",
      "r86"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r87",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r87",
      "r92",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r86",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r287"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r185",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Aggregate number of shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued and sold"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r282",
      "r283",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r282",
      "r283",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r114",
      "r115",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r260",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation and Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r204",
      "r206",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r204",
      "r205",
      "r211"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred product revenue \u2013 current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized, that were included in deferred product revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r222",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10140.0,
       "parentTag": "cers_GrossProfitOnProductRevenue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r322",
      "r323",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r192",
      "r323",
      "r334"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_SecuredDebt",
       "weight": 1.0
      },
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "Total debt, Principal",
        "totalLabel": "Total, Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Term loan, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r40",
      "r193",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r41",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r96",
      "r198",
      "r199",
      "r200",
      "r201",
      "r290",
      "r291",
      "r293",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r290",
      "r293"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_SecuredDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument Unamortized Discount",
        "negatedLabel": "Total debt, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r136",
      "r152",
      "r158",
      "r159"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "terseLabel": "Allowance for Credit Loss",
        "verboseLabel": "Credit losses recognized"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r145",
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r145",
      "r156"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss",
        "terseLabel": "12 Months or Longer, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r145",
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months",
        "terseLabel": "Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r145",
      "r156"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss",
        "terseLabel": "Less than 12 Months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Gain Loss",
        "negatedLabel": "Loss on sale of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r142",
      "r153",
      "r161"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position",
        "terseLabel": "Available-for-sale securities in unrealized net loss position",
        "totalLabel": "Total, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r143",
      "r154"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r120"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation Of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Summary of Product Revenue by Geographical Locations of Customers"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation and related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Employee Service Share Based Compensation Cash Flow Effect Cash Used To Settle Awards",
        "terseLabel": "Stock option plan granted on cash award"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Wide Revenue Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r278",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Fair Values of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r273",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Available-for-sale Securities and Fair Value on Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r273",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r273",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r273",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r92",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r155",
      "r157",
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "terseLabel": "Accumulated amortization intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r172",
      "r174",
      "r177",
      "r178",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r172",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r284",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Before Tax",
        "terseLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r286",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r84",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "terseLabel": "Extinguishment loss recorded"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r171",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Policy [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentContractMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Formal agreement with government or its agency.",
        "label": "Government Contract [Member]",
        "terseLabel": "Government Contract"
       }
      }
     },
     "localname": "GovernmentContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "auth_ref": [
      "r92",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.",
        "label": "Guarantees Indemnifications And Warranties Policies",
        "terseLabel": "Guarantee and Indemnification Arrangements"
       }
      }
     },
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r84",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment Of Intangible Assets Finitelived",
        "verboseLabel": "Impairment charges acquired intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r180",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r101",
      "r319",
      "r327",
      "r344"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r121",
      "r255"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r92",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred product revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r119",
      "r289",
      "r292",
      "r329"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r167"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory Finished Goods Net Of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r48",
      "r163"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r49",
      "r92",
      "r106",
      "r164",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r48",
      "r99",
      "r163",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r167"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory Work In Process Net Of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Available-for-Sale Debt Securities by Original Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]",
        "terseLabel": "Fair value of financial assets and liabilities"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases Of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2020 (remainder)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of lessor's operating lease that has not yet commenced.",
        "label": "Lessor Operating Lease Lease Not Yet Commenced Description",
        "terseLabel": "Operating lease not yet commenced"
       }
      }
     },
     "localname": "LessorOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r324",
      "r340"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r98",
      "r190"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five",
        "terseLabel": "2024, Principal"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r98",
      "r190"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2023, Principal"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r98",
      "r190"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2022, Principal"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r98",
      "r190"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2021, Principal"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year",
        "terseLabel": "2020 (remainder), Principal"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long Term Debt Percentage Bearing Variable Interest Rate",
        "terseLabel": "Debt instrument floating interest rate percentage"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r58",
      "r61",
      "r68",
      "r85",
      "r104",
      "r328",
      "r343"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total non-operating expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Non-operating expense, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number Of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities \u2013 non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash payments for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r303",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r302",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r65",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized (losses) gains on available-for-sale investments, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r226",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds from public offerings",
        "verboseLabel": "Net proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r77",
      "r245"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options",
        "terseLabel": "Net proceeds from equity incentives"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r132"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities",
        "terseLabel": "Proceeds from maturities and sale of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r38",
      "r187",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual Classified Current",
        "terseLabel": "Warranty claim liability"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r58",
      "r61",
      "r80",
      "r122",
      "r123",
      "r259",
      "r261",
      "r262",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Member]",
        "terseLabel": "Project"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r181",
      "r341"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r92",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful life of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.",
        "label": "Receivables Long Term Contracts Or Programs",
        "terseLabel": "Accounts receivable of billed and unbilled amounts"
       }
      }
     },
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r79",
      "r97"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments Of Lines Of Credit",
        "negatedLabel": "Net payment on revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r92",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r86",
      "r91",
      "r356"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r202",
      "r339"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10130.0,
       "parentTag": "cers_GrossProfitOnProductRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue Performance Obligation Description Of Payment Terms",
        "terseLabel": "Description of payment of customer invoice contract"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether optional exemption was applied not to disclose amount of transaction price allocated to and explanation of expected timing of revenue recognition for remaining performance obligation, when contract has expected duration of one year or less or right to consideration corresponds directly to performance completed.",
        "label": "Revenue Practical Expedient Remaining Performance Obligation",
        "terseLabel": "Application of an optional exemption not to disclose the value of unsatisfied performance obligations"
       }
      }
     },
     "localname": "RevenuePracticalExpedientRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Loan Credit Agreement"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Common stock, sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Sales Revenue Product Line [Member]",
        "terseLabel": "Sales Revenue, Goods, Net"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Anti-Dilutive Effect of Common Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule Of Debt Table [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r226",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]",
        "terseLabel": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]",
        "terseLabel": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Future Minimum Non-Cancelable Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]",
        "terseLabel": "Customer that Accounted for More Than Ten Percent of Total Product Revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r226",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Activity Under Equity Incentive Plans Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r231",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Activity Under Equity Incentive Plans Related to Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule Of Unrealized Loss On Investments Table [Text Block]",
        "terseLabel": "Available-for-Sale Marketable Securities in Unrealized Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r16",
      "r323",
      "r338"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredDebtCurrent": {
     "auth_ref": [
      "r14",
      "r322",
      "r337"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt Current",
        "negatedTotalLabel": "Less: debt-current",
        "terseLabel": "Debt \u2013 current"
       }
      }
     },
     "localname": "SecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long Term Debt",
        "terseLabel": "Debt \u2013 non-current",
        "totalLabel": "Debt-non-current"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Customer and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70",
      "r162"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Stock-based compensation, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Forfeited, Number of Restricted Stock Units Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Granted, Number of Restricted Stock Units Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Restricted Stock Units Unvested, Ending Balance",
        "periodStartLabel": "Number of Restricted Stock Units Unvested, Beginning Balance",
        "terseLabel": "Number of unvested Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward",
        "terseLabel": "Activity under the Company's equity incentive plans related to restricted stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Vested, Number of Restricted Stock Units Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Increase in shares of common stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Employee Stock Purchase Plan, authorized shares for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Forfeited/canceled, Number of Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Granted, Number of Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options Outstanding, Beginning Balance",
        "terseLabel": "Outstanding options and other stock based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Activity under the Company's equity incentive plans related to stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r224",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Forfeited/canceled, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r92",
      "r226",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Stock-based compensation, option to be granted at percentage of fair value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short Term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r197",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock from public offering, net of offering costs (in shares)",
        "verboseLabel": "Common stock, number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r197",
      "r202",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Exercised, Number of Options Outstanding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r197",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock from public offerings, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r130"
     ],
     "calculation": {
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue Extensible List",
        "terseLabel": "Product revenue:"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "United States government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail",
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Weighted average shares used for calculating net loss per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130554-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130558-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r361": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r362": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r363": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r364": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812990144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation and Basis of Presentation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (together with Cerus Corporation, hereinafter &#8220;Cerus&#8221; or the &#8220;Company&#8221;) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three months ended March&#160;31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020, or for any future periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, which were included in the Company&#8217;s 2019 Annual Report on Form 10-K, filed with the SEC on February 21, 2020. The accompanying condensed consolidated balance sheet as of December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements as of that date<span style="font-style:italic;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the nature and timing of satisfaction of performance obligations, the timing when the customer obtains control of products or services, the standalone selling price (&#8220;SSP&#8221;) of performance obligations, variable consideration, accounts receivable, inventory reserves, fair values of investments, the allowance for credit losses, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, accrued liabilities, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (&#8220;platelet and plasma systems&#8221; or &#8220;disposable kits&#8221;), UVA illumination devices (&#8220;illuminators&#8221;), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company&#8217;s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis, and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company estimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.</p>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company receives reimbursement under its U.S. government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that supports research and development of defined projects. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Note 1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and License A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greements&#8212;Agreement with BARDA&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contract generally provides for reimbursement of approved costs incurred under the terms of the contract. Revenue related to the cost reimbursement provisions under the Company&#8217;s U.S. government contract are recognized as the qualified direct and indirect costs on the projects are incurred. The Company invoices under its U.S. government contract using the provisional rates in the government contract and thus is subject to future audits at the discretion of government. These audits could result in an adjustment to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government contract </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue previously reported, which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> potentially could be significant. The Company believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. Costs incurred related to services performed under the contract are included as a component of research and development or selling, general and administrative expenses in the Company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated statements of operations. The Company&#8217;s use of estimates in recording accrued liabilities for government contract activities (see &#8220;Use of Estimates&#8221; above) affects the revenue recorded from development funding and under the government contract. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disaggregation of Product Revenue</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe, Middle East and Africa</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">North America</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invoices its customers based upon the terms in the contracts, which generally requires payment 30 to 60 days from the date of invoice. Accounts receivable are recorded when the Company&#8217;s right to the consideration are estimated to be unconditional. The Company had no contract assets at March&#160;31, 2020 and December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities mainly consist of deferred product revenue related to maintenance services, unshipped products, and uninstalled illuminators. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the service period. The increase in the deferred product revenue balance for the three months ended March&#160;31, 2020 is primarily driven by performance obligations not satisfied but invoiced as of March&#160;31, 2020, offset by $0.3 million of revenue recognized that were included in the deferred product revenue balance as of December&#160;31, 2019.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (&#8220;R&amp;D&#8221;) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company&#8217;s U.S. government contract. Research and development expenses include salaries and related expenses for scientific and regulatory personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&amp;D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s use of estimates in recording accrued liabilities for R&amp;D activities (see &#8220;Use of Estimates&#8221; above) affects the amounts of R&amp;D expenses recorded from development funding and under its U.S. government contract. Actual results may differ from those estimates under different assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_AvailableForSaleSecuritiesPolicy', window );">Investments</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities were recorded in &#8220;Unrealized gains (losses) on available-for-sale investments, net of taxes&#8221; on the Company&#8217;s condensed consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale&#160;investments, if any, were recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in &#8220;Other income, net&#8221; on the Company&#8217;s condensed consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2020,&#160;the Company&#8217;s &#8220;Restricted cash&#8221; primarily consisted of a&#160;letter of credit relating to the lease of the Company&#8217;s office building. As of March&#160;31, 2020 and December&#160;31, 2019, the Company also had certain non-U.S. dollar denominated deposits recorded as &#8220;Restricted cash&#8221; in compliance with certain foreign contractual requirements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s investment policy, substantially all of the Company&#8217;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#8217;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#160;31, 2020, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#8217;s cash equivalents and short-term investments.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had three customers that accounted for more than 10% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. These customers cumulatively represented approximately 58% and 56% of the Company&#8217;s outstanding trade receivables at March&#160;31, 2020 and December&#160;31, 2019, respectively. To date, the Company has not experienced collection difficulties from these customers.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2020 and December&#160;31, 2019, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, illuminators, and certain replacement parts for the illuminators. Platelet and plasma systems&#8217; disposable kits generally have 18 to 24 month shelf lives from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time before being sold to, and ultimately incorporated and assembled by Fresenius Kabi Deutschland GmbH or Fresenius, Inc. (with their affiliates, &#8220;Fresenius&#8221;) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be sold to Fresenius for </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within the next twelve month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and evaluates its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company&#8217;s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its work-in-process and finished units to meet the Company&#8217;s forecasted demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company classified its work-in-process inventory as a current asset on its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets based on its evaluation that the work-in-process inventory would be sold to Fresenius for finished disposable kit production within each respective subsequent twelve-month period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in &#8220;Cost of product revenue&#8221; on the Company&#8217;s condensed consolidated statements of operations. At March&#160;31, 2020 and December&#160;31, 2019, the Company had $0.2 million and $0.1 million, respectively, recorded for potential obsolete, expiring or unsalable product.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the three months ended March&#160;31, 2020 and 2019, the Company had non-cash purchases of capital expenditures of $0.2 million and $2.9 million, respectively.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets, net</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratable amortization over the original estimated useful life of ten years. Accumulated amortization of intangible assets as of March&#160;31, 2020 and December&#160;31, 2019, was $1.9 million and $1.9 million, respectively. Goodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August&#160;31 of each fiscal year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit&#8217;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company&#8217;s one reporting unit.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an impairment test on its intangible assets if certain events or changes in circumstances occur which indicate that the carrying amounts of its intangible assets may not be recoverable. If the intangible assets are not recoverable, an impairment loss would be recognized by the Company based on the excess amount of the carrying value of the intangible assets over its fair value. During the three months ended March&#160;31, 2020 and 2019, there were no impairment charges recognized related to the acquired intangible assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Remeasurement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s foreign subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company&#8217;s condensed consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards issued to non-employees, the Company recognizes stock-based compensation expense for the grant date fair value of the vested portion of the awards in its condensed consolidated statements of operations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 8 for further information regarding the Company&#8217;s stock-based compensation expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company&#8217;s U.S. federal tax returns for years 1999 through 2018, California tax returns for years through 2018, and Netherlands tax returns for years 2015 through 2018 remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the three months ended March&#160;31, 2020 and 2019, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of anti-dilutive potential shares:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,648</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,247</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>

<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s condensed consolidated balance sheets. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have finance leases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantee and Indemnification Arrangements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#8217;s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company&#8217;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a <span style="-sec-ix-hidden:F_000318">one-year</span> warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at March&#160;31, 2020 and December&#160;31, 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company&#8217;s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company&#8217;s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 for further information regarding the Company&#8217;s valuation of financial instruments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):</span> <span style="font-style:italic;">Measurement of Credit Losses on Financial Instruments,</span> which requires measurement and recognition of expected credit losses for financial assets held. The standard is effective for annual periods beginning after December 15, 2019, and interim periods thereafter, with early application permitted. The Company adopted the new accounting standard on January 1, 2020, using the modified retrospective transition method. The adoption of this ASU had no material impact on the Company&#8217;s condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_AvailableForSaleSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_AvailableForSaleSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805079792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related costs</a></td>
<td class="nump">$ 8,660<span></span>
</td>
<td class="nump">$ 12,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_AccruedDevelopmentCostsCurrent', window );">Accrued development costs</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">3,130<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 17,198<span></span>
</td>
<td class="nump">$ 20,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_AccruedDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued development costs, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_AccruedDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812938640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Marketable Securities in Unrealized Position (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 55,318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Loss</a></td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Fair Value</a></td>
<td class="nump">55,318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Unrealized Loss</a></td>
<td class="nump">$ 487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6658931664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and related costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,703</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803138704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_DevelopmentAndLicenseAgreementsAbstract', window );"><strong>Development And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset</a></td>
<td class="text">The following table summarizes the amounts of prepaid R&amp;D asset and manufacturing efficiency asset at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&amp;D asset &#8211; current <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid R&amp;D asset &#8211; non-current <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,094</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing efficiency asset <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Prepaid and other current assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Prepaid and other assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock', window );">Summary of Amounts Payable and Amounts Receivable from Fresenius</a></td>
<td class="text">The following table summarizes the amounts of the Company&#8217;s payables to and receivables from Fresenius at March&#160;31, 2020 and December&#160;31, 2019 (in thousands).
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payables to Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables from Fresenius <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,631</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,796</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Accounts Payable&#8221; and &#8220;Accrued Liabilities&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in &#8220;Other current assets&#8221; in the Company's condensed consolidated balance sheets.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_DevelopmentAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_DevelopmentAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of amounts payable and receivable under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_SummaryOfAmountsPayableAndReceivableUnderAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6591997856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3. Inventories</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,490</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800489552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Activity Under Equity Incentive Plans Related to RSUs (Detail) - 2008 Equity Incentive Plan - Restricted Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Activity under the Company's equity incentive plans related to restricted stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units Unvested, Beginning Balance | shares</a></td>
<td class="nump">4,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Number of Restricted Stock Units Unvested | shares</a></td>
<td class="nump">3,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Number of Restricted Stock Units Unvested | shares</a></td>
<td class="num">(1,514)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Number of Restricted Stock Units Unvested | shares</a></td>
<td class="num">(35)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units Unvested, Ending Balance | shares</a></td>
<td class="nump">5,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">5.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">6.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes shares issuable under performance-based restricted stock unit awards.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804967696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (remainder)</a></td>
<td class="nump">$ 2,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">2,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">2,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">30,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">10,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 19,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812810480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 84,519<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 863,531<span></span>
</td>
<td class="num">$ (281)<span></span>
</td>
<td class="num">$ (778,867)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue', window );">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares', window );">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,792)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">69,500<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">867,091<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(797,659)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">57,052<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">906,905<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(850,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offerings, net of offering costs</a></td>
<td class="nump">67,112<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">67,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue', window );">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares', window );">Issuance of common stock from exercise of stock options, vesting of restricted stock units, and ESPP purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,466)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 112,408<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 978,944<span></span>
</td>
<td class="num">$ (123)<span></span>
</td>
<td class="num">$ (866,577)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from exercise of stock options or warrants and vesting of restricted stock units and employee stock purchase plans purchases value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cers_IssuanceOfCommonStockFromExerciseOfStockOptionsOrWarrantsAndVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlansPurchasesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cers_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812859008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CERS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CERUS CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001020214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,987,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-21937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0262011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1220 Concord Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Concord<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">288-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800322736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Debt</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at March&#160;31, 2020, consisted of the following (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Credit Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal, interest and fee payments on Term Loan Credit Agreement at March&#160;31, 2020, are expected to be as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803209152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Customer and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Customer that Accounted for More Than Ten Percent of Total Product Revenue</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had the following significant customers that accounted for more than 10% of the Company&#8217;s total product revenue, during the three months ended March&#160;31, 2020 and 2019:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#201;tablissement Fran&#231;ais du Sang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Red Cross</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160; Represents an amount less than 10% of product revenue.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813246064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,466)<span></span>
</td>
<td class="num">$ (18,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available-for-sale investments, net of taxes</a></td>
<td class="num">(237)<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,703)<span></span>
</td>
<td class="num">$ (18,581)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800246560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Securities and Fair Value on Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Available-for-sale Securities and Fair Value on Financial Instruments</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. Available-for-sale Securities and Fair Value on Financial Instruments</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Available-for-sale Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,958</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.82%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,282</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of available-for-sale securities at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,073</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities at March&#160;31, 2020 and December&#160;31, 2019, consisted of the following by contractual maturity (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One year or less</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,565</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,907</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greater than one year and less than five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,811</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,282</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.34%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 Months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months or Greater</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized&#160;Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company did not have any available-for-sale securities in an unrealized net loss position.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically invests in highly-rated securities, and its investment policy limits the amount of credit exposure to any one issuer. The policy generally requires investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for expected credit loss, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, and any changes thereto, changes in market interest rates, and the Company&#8217;s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment&#8217;s cost basis. The Company also regularly reviews its investments in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the three months ended March&#160;31, 2020 and 2019, the Company did not recognize any credit losses. The Company has no current requirement or intent to sell the securities in an unrealized loss position. The Company expects to recover up to (or beyond) the initial cost of investment for securities held. The Company recorded gross realized gains of less than $0.1 million and gross realized losses of $0.3 million during the three months ended March&#160;31, 2020. The Company did not record any gross realized gains or losses from the sale or maturity of available-for-sale investments during the three months ended March&#160;31, 2019. </p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value Disclosures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses certain assumptions that market participants would use to determine the fair value of an asset or liability in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 1: Quoted prices in active markets for identical instruments</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the fair value of Level 2 debt securities as of March&#160;31, 2020, the Company&#8217;s primary pricing service relies on inputs from multiple industry-recognized pricing sources to determine the price for each investment. Corporate debt and U.S. government agency securities are systematically priced by this service as of the close of business each business day. If the primary pricing service does not price a specific asset a secondary pricing service is utilized.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at March&#160;31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,733</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,426</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets and liabilities were determined using the following inputs at December&#160;31, 2019 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">classification</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,561</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,732</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any transfers among fair value measurement levels during the three months ended March&#160;31, 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801551456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Activity Under Equity Incentive Plans Related to Stock Options (Detail) - 2008 Equity Incentive Plan<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Activity under the Company's equity incentive plans related to stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning Balance | shares</a></td>
<td class="nump">16,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Number of Options Outstanding | shares</a></td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Number of Options Outstanding | shares</a></td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/canceled, Number of Options Outstanding | shares</a></td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending Balance | shares</a></td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">5.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">3.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/canceled, Weighted Average Exercise Price per Share | $ / shares</a></td>
<td class="nump">5.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 4.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cers_TwoThousandEightEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794092320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating leases</a></td>
<td class="nump">$ 964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804647648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail) - Customer Concentration Risk - Sales Revenue, Goods, Net<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Etablissement Francais du Sang</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">American Red Cross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cers_EtablissementFrancaisDuSangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cers_EtablissementFrancaisDuSangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cers_AmericanRedCrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cers_AmericanRedCrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments</Role>
      <ShortName>Available-for-sale Securities and Fair Value on Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Development and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements</Role>
      <ShortName>Development and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Segment, Customer and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation</Role>
      <ShortName>Segment, Customer and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsTables</Role>
      <ShortName>Available-for-sale Securities and Fair Value on Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureInventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Development and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsTables</Role>
      <ShortName>Development and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Segment, Customer and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationTables</Role>
      <ShortName>Segment, Customer and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfProductRevenueByGeographicalLocationsOfCustomersDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Product Revenue by Geographical Locations of Customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosurePotentialSharesExcludedFromCalculationOfWeightedAverageNumberOfSharesOutstandingUsedForCalculationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Potential Shares, Excluded from Calculation of Weighted Average Number of Shares Outstanding used for Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSummaryOfAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Summary of Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Available-for-Sale Debt Securities by Original Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleDebtSecuritiesByOriginalContractualMaturityDetail</Role>
      <ShortName>Available-for-Sale Debt Securities by Original Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Available-for-Sale Marketable Securities in Unrealized Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleMarketableSecuritiesInUnrealizedPositionDetail</Role>
      <ShortName>Available-for-Sale Marketable Securities in Unrealized Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAvailableForSaleSecuritiesAndFairValueOnFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Available-for-sale Securities and Fair Value on Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Values on Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureFairValuesOnFinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Fair Values on Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesDetail</Role>
      <ShortName>Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureInventoriesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesDetail</Role>
      <ShortName>Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtDetail</Role>
      <ShortName>Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtExpectedPrincipalInterestAndFeePaymentsOnTermLoanCreditAgreementDetail</Role>
      <ShortName>Debt - Expected Principal, Interest and Fee Payments on Term Loan Credit Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDebtAdditionalInformationDetail</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalCashFlowInformationRelatedToOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Supplemental Cash Flow Information Related to Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumNonCancelableLeasePaymentsUnderOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments Under Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Activity Under Equity Incentive Plans Related to Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToStockOptionsDetail</Role>
      <ShortName>Activity Under Equity Incentive Plans Related to Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Activity Under Equity Incentive Plans Related to RSUs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureActivityUnderEquityIncentivePlansRelatedToRsusDetail</Role>
      <ShortName>Activity Under Equity Incentive Plans Related to RSUs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Development and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Development and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Development and License Agreements - Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfPrepaidRDAssetAndManufacturingEfficiencyAssetDetail</Role>
      <ShortName>Development and License Agreements - Summary of Prepaid R&amp;D Asset and Manufacturing Efficiency Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureDevelopmentAndLicenseAgreementsSummaryOfAmountsPayableAndAmountsReceivableFromFreseniusDetail</Role>
      <ShortName>Development and License Agreements - Summary of Amounts Payable and Amounts Receivable from Fresenius (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Segment, Customer and Geographic Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationAdditionalInformationDetail</Role>
      <ShortName>Segment, Customer and Geographic Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cers-10q_20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerus.com/20200331/taxonomy/role/DisclosureSegmentCustomerAndGeographicInformationSignificantCustomerThatAccountedForMoreThanTenPercentageOfTotalProductRevenueDetail</Role>
      <ShortName>Segment, Customer and Geographic Information - Significant Customer that Accounted for More than Ten Percentage of Total Product Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cers-10q_20200331.htm">cers-10q_20200331.htm</File>
    <File>cers-20200331.xsd</File>
    <File>cers-20200331_cal.xml</File>
    <File>cers-20200331_def.xml</File>
    <File>cers-20200331_lab.xml</File>
    <File>cers-20200331_pre.xml</File>
    <File>cers-ex101_169.htm</File>
    <File>cers-ex102_170.htm</File>
    <File>cers-ex103_76.htm</File>
    <File>cers-ex311_8.htm</File>
    <File>cers-ex312_6.htm</File>
    <File>cers-ex321_7.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800354288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Product Revenue by Geographical Locations of Customers</a></td>
<td class="text">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue by geographical locations of customers during the three months ended March&#160;31, 2020 and 2019, were as follows (in thousands):</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe, Middle East and Africa</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">North America</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.8%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,611</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Effect of Common Shares</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the three months ended March&#160;31, 2020 and 2019 (shares in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;Months&#160;Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of anti-dilutive potential shares:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,648</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,247</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>

<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803076368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Debt</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at March&#160;31, 2020, consisted of the following (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Credit Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt at December&#160;31, 2019, consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unamortized Discount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt &#8211; current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt &#8211; non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal, interest and fee payments on Term Loan Credit Agreement at March&#160;31, 2020, are expected to be as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (remainder)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Loan Agreements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 29, 2019 (the &#8220;Closing Date&#8221;), the Company entered into a Credit, Security and Guaranty Agreement (Term Loan) (the &#8220;Term Loan Credit Agreement&#8221;) with MidCap Financial Trust (&#8220;MidCap&#8221;) to borrow up to $70 million in three tranches (collectively &#8220;2019 Term Loan&#8221;), with a maturity date of March 1, 2024. The first advance of $40.0 million (&#8220;Tranche 1&#8221;) was drawn by the Company on March 29, 2019, with the proceeds used in part to repay in full the outstanding term loans and fees under a prior loan agreement. The Company repaid principal and interest in an aggregate amount equal to approximately $31.2&#160;million and prepayment fees in an aggregate amount equal to approximately $0.6&#160;million, and terminated all obligations under the prior loan agreement. As a result, the Company recorded a loss of $2.1 million on the extinguishment of the prior loan agreement in &#8220;Interest expense&#8221; on the Company's condensed consolidated statements of operations. The second advance of $15.0&#160;million (&#8220;Tranche 2&#8221;) will be available to the Company from January&#160;1, 2020 through December&#160;31, 2020, subject to the Company&#8217;s satisfaction of certain conditions described </p>

<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the Term Loan Credit Agreement, and (ii)&#160;the third advance of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.0&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million (&#8220;Tranche 3&#8221;) will be available to the Company starting April&#160;1, 2020, through March&#160;31, 2021, subject to the Company&#8217;s satisfaction of certain other conditions described in the Term Loan Credit Agreement. The</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> borrowings under the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019 Term Loan bears interest at the sum of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a fixed percentage spread and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greater of (i) </span>1.80<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% or (ii)&#160;one month LIBOR. The effective interest rate on the Term Loan at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was approximately </span>7.50<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%. All three tranches require interest only payments through </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1, 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, followed by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of payments with interest and equal payment of principal. The interest only payment period can be extended for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon achievement of a specified trailing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">twelve month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> net revenue target. Prepayments of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erm </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oan under the Term Loan Credit Agreement, in whole or in part, will be subject to early termination fees which decline each year until the fourth anniversary</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the applicable funding date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, at which time there is no early termination fee. Upon the final payment, the Company must also pay an exit fee </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculated based on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a percentage </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the aggregate principal amount of all tranches advanced to the Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also entered into a Credit, Security and Guaranty Agreement (Revolving Loan) (the &#8220;Revolving Loan Credit Agreement&#8221;) with MidCap on March 29, 2019, to initially borrow up to $5.0 million. The amount borrowed under the Revolving Loan Credit Agreement can be increased, upon request by the Company by up to an additional $15.0 million, subject to agent and lender approval and the satisfaction of certain conditions. The Revolving Loan Credit Agreement has a maturity date of March 1, 2024. Amounts drawn under the Revolving Loan Credit Agreement bear interest at the sum of a fixed percentage spread and the greater of (i) 1.80% or (ii) one month LIBOR. There are also fractional fees based on the amounts either drawn or undrawn. If the Revolving Loan Credit Agreement is terminated before maturity or the funding obligation is permanently reduced, there are termination fees which decline each anniversary until the third anniversary, at which time there is no termination fee. As of March&#160;31, 2020 and December&#160;31, 2019, the Company had borrowed $4.8 million and $5.0 million, respectively, under the Revolving Loan Credit Agreement, which is included in &#8220;Debt &#8211; current&#8221; in the Company&#8217;s condensed consolidated balance sheets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Credit Agreement and Revolving Loan Credit Agreement contain certain financial and non-financial covenants, with which the Company was in compliance at March&#160;31, 2020. Additionally, both agreements are secured by substantially all of the Company&#8217;s assets, with some exclusions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803101376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded income tax expense of $0.1 million for both the three months ended March&#160;31, 2020 and 2019, primarily related to the operating profit of the Company&#8217;s Cerus Europe B.V. subsidiary. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794730096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">$ 5,668<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">16,016<span></span>
</td>
<td class="nump">14,330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 21,684<span></span>
</td>
<td class="nump">$ 19,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794702608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities by Original Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">One year or less, amortized cost</a></td>
<td class="nump">$ 54,471<span></span>
</td>
<td class="nump">$ 43,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Greater than one year and less than five years, amortized cost</a></td>
<td class="nump">55,811<span></span>
</td>
<td class="nump">15,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">110,282<span></span>
</td>
<td class="nump">59,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One year or less, fair value</a></td>
<td class="nump">54,565<span></span>
</td>
<td class="nump">43,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Greater than one year and less than five years, fair value</a></td>
<td class="nump">55,594<span></span>
</td>
<td class="nump">15,685<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities fair value</a></td>
<td class="nump">$ 110,159<span></span>
</td>
<td class="nump">$ 59,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
